FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Palacios, R
   Patino, EG
   Piorelli, RD
   Conde, MTRP
   Batista, AP
   Zeng, G
   Xin, QQ
   Kallas, EG
   Flores, J
   Ockenhouse, CF
   Gast, C
AF Palacios, Ricardo
   Patino, Elizabeth Gonzalez
   de Oliveira Piorelli, Roberta
   Conde, Monica Tilli Reis Pessoa
   Batista, Ana Paula
   Zeng, Gang
   Xin, Qianqian
   Kallas, Esper G.
   Flores, Jorge
   Ockenhouse, Christian F.
   Gast, Christopher
TI Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to
   Evaluate the Efficacy and Safety of treating Healthcare Professionals
   with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
   - PROFISCOV: A structured summary of a study protocol for a randomised
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Inactivated Vaccines;
   Phase III Clinical Trial; COVID-19 Vaccine; Brazil
AB Objectives: To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19.To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).
   Trial design: This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac.The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older).
   The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.
   Participants: Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.
   Intervention and comparator: Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 mu g/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant.Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solutionThe schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.
   Main outcomes: The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample.The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.
   Randomisation: There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.
   Blinding (masking): This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.
   Numbers to be randomised (sample size): The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.
   Trial Status: Protocol version 2.0 - 24-Aug-2020. Recruitment started on July 21(st), 2020. The recruitment is expected to conclude in October 2020.
   Trial registration: ClinicalTrials.gov Identifier: NCT0445659. Registry on 2 July 2020
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Palacios, Ricardo; Patino, Elizabeth Gonzalez; de Oliveira Piorelli, Roberta; Conde, Monica Tilli Reis Pessoa; Batista, Ana Paula] Inst Butantan, Ctr Clin Trials & Pharmacovigilance, Sao Paulo, Brazil.
   [Zeng, Gang; Xin, Qianqian] Sinovac Life Sci, Beijing, Peoples R China.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Flores, Jorge; Ockenhouse, Christian F.] PATH US, Washington, DC USA.
   [Gast, Christopher] PATH, Seattle, WA USA.
RP Palacios, R (corresponding author), Inst Butantan, Ctr Clin Trials & Pharmacovigilance, Sao Paulo, Brazil.
EM ricardo.palacios@butantan.gov.br
RI Palacios, Ricardo/B-7248-2018
OI Palacios, Ricardo/0000-0002-1410-8579
FU Fundacao Butantan; Sao Paulo Research Foundation - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2020/10127-1]
FX This study is financed by Fundacao Butantan and The Sao Paulo Research
   Foundation - FAPESP (Grant 2020/10127-1).; Fundacao Butantan supports
   the activities of Instituto Butantan as trial sponsor. Instituto
   Butantan is leading the design, analysis, interpretation of data and
   manuscript writing.
NR 0
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD OCT 15
PY 2020
VL 21
IS 1
AR 853
DI 10.1186/s13063-020-04775-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OG1KB
UT WOS:000581650900001
PM 33059771
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hallak, J
   Teixeira, TA
   Bernardes, FS
   Carneiro, F
   Duarte, SAS
   Pariz, JR
   Esteves, SC
   Kallas, E
   Saldiva, PHN
AF Hallak, Jorge
   Teixeira, Thiago A.
   Bernardes, Felipe S.
   Carneiro, Felipe
   Duarte, Sergio A. S.
   Pariz, Juliana R.
   Esteves, Sandro C.
   Kallas, Esper
   Saldiva, Paulo H. N.
TI SARS-CoV-2 and its relationship with the genitourinary tract:
   Implications for male reproductive health in the context of COVID-19
   pandemic
SO ANDROLOGY
LA English
DT Review; Early Access
DE angiotensin-converting enzyme 2; COVID-19; kidney; SARS-CoV-2; semen;
   sperm; testis
ID ANGIOTENSIN-CONVERTING ENZYME; SEMEN QUALITY; NITRIC-OXIDE; CORONAVIRUS;
   RECEPTOR; ACE2; PATHOGENESIS; INFERTILITY; TESTIS; VIRUS
AB Background The current outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, named coronavirus disease 19 (COVID-19), is not the first well-known spillover of an animal originated virus to infect humans. However, one of the few to make such a fast jump in a powerful evolutionary shortcut. The incredible pattern of aggressiveness worldwide since the beginning of the outbreak is that up to 20% of those infected need hospitalization and 5% evolve to critical conditions, not limited to respiratory-related issues, but rather to systemic involvement. Objective This study aims to summarize the current knowledge about the effects of SARS-CoV-2 infection on the male genitourinary tract. Materials and methods A narrative review was carried out to identify articles on the SARS-CoV-2 infection on the male genitourinary system. Results Considerations were made about the molecular characteristics of SARS-CoV-2 and immune response to coronavirus. We discussed the influence of the virus on the urinary system, potential mechanisms of COVID-19- related acute kidney injury (AKI), and the role of cytokine release syndrome on the renal pathophysiology of the disease. In the male reproductive tract, it was discussed the testis' vulnerability to SARS-CoV-2 invasion and the possible adverse effects on its function and the seminal findings of COVID-19. Discussion and conclusion During the COVID-19 pandemic, an international coordinated scientific effort must arise to understand the role of the urogenital system in the SARS-CoV-2 infection in the clinical setting.
C1 [Hallak, Jorge; Teixeira, Thiago A.; Bernardes, Felipe S.; Carneiro, Felipe; Duarte, Sergio A. S.; Pariz, Juliana R.] Androscience, Sci & Innovat Ctr Androl, Sao Paulo, Brazil.
   [Hallak, Jorge; Teixeira, Thiago A.; Bernardes, Felipe S.; Carneiro, Felipe; Duarte, Sergio A. S.; Pariz, Juliana R.] Androscience, High Complex Clin & Androl Res Lab, Sao Paulo, Brazil.
   [Hallak, Jorge; Teixeira, Thiago A.; Bernardes, Felipe S.; Duarte, Sergio A. S.; Pariz, Juliana R.] Univ Sao Paulo, Div Urol, Sao Paulo, Brazil.
   [Hallak, Jorge; Saldiva, Paulo H. N.] Univ Sao Paulo, Dept Pathol, Reprod Toxicol Unit, Sao Paulo, Brazil.
   [Teixeira, Thiago A.; Bernardes, Felipe S.; Carneiro, Felipe; Pariz, Juliana R.; Saldiva, Paulo H. N.] Univ Sao Paulo, Inst Adv Studies, Mens Hlth Study Grp, Sao Paulo, Brazil.
   [Teixeira, Thiago A.] Univ Fed Amapa, Sch Med, Div Urol, Amapa, Brazil.
   [Carneiro, Felipe] Univ Sao Paulo, Dept Radiol, Sao Paulo, Brazil.
   [Esteves, Sandro C.] Univ Campinas UNICAMP, Dept Surg, Div Urol, Campinas, Brazil.
   [Esteves, Sandro C.] Androfert, Androl & Human Reprod Clin, Campinas, Brazil.
   [Esteves, Sandro C.] Aarhus Univ, Fac Hlth, Aarhus, Denmark.
   [Kallas, Esper] Univ Sao Paulo, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
RP Hallak, J (corresponding author), Androscience, Sci & Innovat Ctr Androl, Sao Paulo, Brazil.; Hallak, J (corresponding author), Androscience, High Complex Clin & Androl Res Lab, Sao Paulo, Brazil.
EM hallakj@androscience.com.br
RI Esteves, Sandro/G-4416-2012; Pariz, Juliana/M-2292-2013; Hallak,
   Jorge/D-6697-2012
OI Esteves, Sandro/0000-0002-1313-9680; Teixeira,
   Thiago/0000-0002-6598-2442; Carneiro, Felipe/0000-0001-5767-5867; Pariz,
   Juliana/0000-0002-9194-5266; Hallak, Jorge/0000-0002-6452-0502; Kallas,
   Esper/0000-0003-2026-6925
FU Androscience, Science and Innovation Center in Andrology and
   High-Complex Clinical and Research Andrology Laboratory
FX Androscience, Science and Innovation Center in Andrology and
   High-Complex Clinical and Research Andrology Laboratory.
CR Aitken RJ, 2020, ANDROLOGY, P1
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Ben Addi A, 2008, EUR J IMMUNOL, V38, P1610, DOI 10.1002/eji.200737781
   Bronimann S, 2020, CURR OPIN UROL, V30, P735, DOI 10.1097/MOU.0000000000000808
   Bwire GM, 2020, J MED VIROL, DOI 10.1002/jmv.26349
   Carlsen E, 2003, HUM REPROD, V18, P2089, DOI 10.1093/humrep/deg412
   Chan VW, 2020, WORLD J UROL, V27, P1
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Deng YY, 2020, CHINESE MED J-PEKING, V133, P1129, DOI 10.1097/CM9.0000000000000783
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Diao B., 2020, DIAGNOSIS ACUTE RESP
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Douglas GC, 2004, ENDOCRINOLOGY, V145, P4703, DOI 10.1210/en.2004-0443
   Duarte-Neto AN, 2020, HISTOPATHOLOGY, V77, P186, DOI 10.1111/his.14160
   Eisenberg ML, 2014, HUM REPROD, V29, P1567, DOI 10.1093/humrep/deu106
   Fan C, 2020, ACE2 EXPRESSION KIDN
   Fijak M, 2018, HUM REPROD UPDATE, V24, P416, DOI 10.1093/humupd/dmy009
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guy JL, 2005, BBA-PROTEINS PROTEOM, V1751, P2, DOI 10.1016/j.bbapap.2004.10.010
   Gwathmey TM, 2010, HYPERTENSION, V55, P166, DOI 10.1161/HYPERTENSIONAHA.109.141622
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hedger MP, 2011, J ANDROL, V32, P625, DOI 10.2164/jandrol.111.012989
   Hoffmann M, 2020, CELL, V181, P271, DOI [10.1016/j.cell.2020.02.052, 10.1007/978-3-030-58342-2_15]
   Holtmann N, 2020, FERTIL STERIL, V114, P233, DOI 10.1016/j.fertnstert.2020.05.028
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Husain-Syed F, 2016, AM J RESP CRIT CARE, V194, P402, DOI 10.1164/rccm.201602-0420CP
   Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016
   Jung A, 2007, ANDROLOGIA, V39, P203, DOI 10.1111/j.1439-0272.2007.00794.x
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li DG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8292
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Ma L, 2020, J MED VIROL, DOI 10.1002/jmv.26259
   Pan F, FERTILITY STERILITY
   Pan PP, 2013, INT J MOL SCI, V14, P21071, DOI 10.3390/ijms141021071
   Reis AB, 2010, J MOL HISTOL, V41, P75, DOI 10.1007/s10735-010-9264-8
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Salam AP, 2017, EMERG INFECT DIS, V23, P1922, DOI 10.3201/eid2311.171049
   Satie AP, 2011, J BIOL CHEM, V286, P23280, DOI 10.1074/jbc.M111.229120
   Song Ci, 2020, Biol Reprod, V103, P4, DOI 10.1093/biolre/ioaa050
   Stanley CP, 2019, NATURE, V566, P548, DOI 10.1038/s41586-019-0947-3
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Valdivia A, 2020, REPRODUCTION, V159, P241, DOI 10.1530/REP-19-0274
   Ventimiglia E, 2015, FERTIL STERIL, V104, P48, DOI 10.1016/j.fertnstert.2015.04.020
   Vinson GP, 1996, REGUL PEPTIDES, V67, P131, DOI 10.1016/S0167-0115(96)00118-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040920
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZS, 2020, J UROLOGY, V204, P7, DOI 10.1097/JU.0000000000001068
   Xu J, 2006, BIOL REPROD, V74, P410, DOI 10.1095/biolreprod.105.044776
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang M, EUROPEAN UROLOGY FOC
   Ye MH, 2006, J AM SOC NEPHROL, V17, P3067, DOI 10.1681/ASN.2006050423
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 63
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
DI 10.1111/andr.12896
EA SEP 2020
PG 7
WC Andrology
SC Endocrinology & Metabolism
GA NU5YK
UT WOS:000573717800001
PM 32869939
OA Bronze
DA 2020-11-26
ER

PT J
AU Costa, NDX
   Ribeiro, G
   Alemany, AAD
   Belotti, L
   Schalch, AS
   Cavalcante, MF
   Ribeiro, S
   Veras, MM
   Kallas, EG
   Saldiva, PHN
   Dolhnikoff, M
   da Silva, LFF
AF Xavier Costa, Natalia de Souza
   Ribeiro Junior, Gabriel
   dos Santos Alemany, Adair Aparecida
   Belotti, Luciano
   Schalch, Alexandre Santos
   Cavalcante, Marcela Frota
   Ribeiro, Susan
   Veras, Mariana Matera
   Kallas, Esper Georges
   Nascimento Saldiva, Paulo Hilario
   Dolhnikoff, Marisa
   Ferraz da Silva, Luiz Fernando
TI Air pollution impairs recovery and tissue remodeling in a murine model
   of acute lung injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; PM2.5 MASS CONCENTRATIONS;
   BACTERIAL-ENDOTOXIN; PARTICULATE MATTER; ALVEOLAR MACROPHAGES; TGF-BETA;
   INFLAMMATION; LIPOPOLYSACCHARIDE; RESPONSES; ULTRAFINE
AB Evidence regarding the impact of air pollution on acute respiratory distress syndrome (ARDS) is limited, and most studies focus on ARDS onset. Our study aimed to evaluate whether exposure to fine particulate matter interferes with lung recovery and remodeling in a murine model of acute lung injury. Forty-eight mice received nebulized LPS or the vehicle (controls). Blood, BALF, lungs and spleen were collected after 5 weeks of exposure to either PM2.5 (PM and LPS+PM group) or filtered air (control and LPS5w groups). Inflammatory cells and cytokines were assessed in the blood, BALF, lungs and spleen. Stereological analyses and remodeling assessments were performed by histology. The LPS+PM group showed increased BALF leukocytes, characterized by increased macrophages, increased IL-1 beta and IL-6 levels, anemia and thrombocytopenia. Moreover, we also observed septal thickening, decreased alveolar air space total volume and, septa surface density. Finally, regarding tissue remodeling, we observed elastosis of the lung parenchyma, and unlike in the LPS5w group, we did not observe fibrosis in the LPS+PM group. In conclusion, the delayed inflammation resolution due to subchronic exposure to PM2.5 could be influenced by low systemic and local lymphocyte counts, which lead to impaired lung injury recovery and tissue remodeling.
C1 [Xavier Costa, Natalia de Souza; Ribeiro Junior, Gabriel; dos Santos Alemany, Adair Aparecida; Belotti, Luciano; Schalch, Alexandre Santos; Veras, Mariana Matera; Nascimento Saldiva, Paulo Hilario; Dolhnikoff, Marisa; Ferraz da Silva, Luiz Fernando] Univ Sao Paulo, Fac Med, Dept Patol, Lab Poluicao Atmosfer Expt LIM05, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
   [Cavalcante, Marcela Frota] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, SP, Brazil.
   [Ribeiro, Susan; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Lab Imunol Clin & Alergia LIM60, Sao Paulo, SP, Brazil.
   [Ribeiro, Susan] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
RP Costa, NDX (corresponding author), Univ Sao Paulo, Fac Med, Dept Patol, Lab Poluicao Atmosfer Expt LIM05, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM nataliasxcosta@usp.br
FU FundacAo de Amparo a Pesquisa do Estado de SAo PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2008/57717-6, 2012/23334-9];
   Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [573813/2008-6, 479679/2012-6]
FX The authors would like to thank FundacAo de Amparo a Pesquisa do Estado
   de SAo Paulo (Grant Numbers #2008/57717-6 and #2012/23334-9) and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Grant
   Numbers #573813/2008-6 and #479679/2012-6) for financial support. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872
   Anderson JO, 2012, J MED TOXICOL, V8, P166, DOI 10.1007/s13181-011-0203-1
   Andrade MD, 2012, AIR QUAL ATMOS HLTH, V5, P79, DOI 10.1007/s11869-010-0104-5
   Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140303762
   Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868
   Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   CETESB, 2017, QUALIDADE AR ESTADO
   D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498
   Dancer RCA, 2011, EUR RESPIR J, V38, P1461, DOI 10.1183/09031936.00024711
   de Miranda RM, 2012, AIR QUAL ATMOS HLTH, V5, P63, DOI 10.1007/s11869-010-0124-1
   Duru Nadire, 2016, World J Biol Chem, V7, P231
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW
   FRIEDRICH MJ, 2019, JAMA-J AM MED ASSOC, V321, P1041, DOI DOI 10.1001/JAMA.2019.1934
   Hamon A, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0516-9
   Honda T, 2017, ENVIRON INT, V101, P125, DOI 10.1016/j.envint.2017.01.017
   Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
   Huang XF, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1264913
   Inoue H, 2009, EXP TOXICOL PATHOL, V61, P51, DOI 10.1016/j.etp.2007.10.001
   Inoue KI, 2007, TOXICOLOGY, V238, P99, DOI 10.1016/j.tox.2007.05.022
   Inoue KI, 2006, ENVIRON HEALTH PERSP, V114, P1325, DOI 10.1289/ehp.8903
   Li Tao, 2018, Chronic Dis Transl Med, V4, P176, DOI 10.1016/j.cdtm.2018.07.002
   Lin HL, 2018, J EXPO SCI ENV EPID, V28, P392, DOI 10.1038/s41370-018-0034-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marshall R, 1998, THORAX, V53, P815, DOI 10.1136/thx.53.10.815
   Lopes TDM, 2018, ENVIRON POLLUT, V241, P511, DOI 10.1016/j.envpol.2018.05.055
   Meyerholz DK, 2018, VET PATHOL, V55, P42, DOI 10.1177/0300985817726117
   Miyata R, 2011, TOXICOL APPL PHARM, V257, P209, DOI 10.1016/j.taap.2011.09.007
   Nikolic M, 2008, POL J ENVIRON STUD, V17, P267
   Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476
   Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382
   Reilly JP, 2019, AM J RESP CRIT CARE, V199, P62, DOI 10.1164/rccm.201803-0435OC
   Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227
   Roberts ES, 2003, INHAL TOXICOL, V15, P1327, DOI 10.1080/08958370390241795
   Shoenfelt J, 2009, J LEUKOCYTE BIOL, V86, P303, DOI 10.1189/jlb.1008587
   Simao RR, 2016, ACTA CIR BRAS, V31, P278, DOI 10.1590/S0102-865020160040000009
   SIOUTAS C, 1995, ENVIRON HEALTH PERSP, V103, P172, DOI 10.2307/3432274
   Takano H, 2002, AM J RESP CRIT CARE, V165, P1329, DOI 10.1164/rccm.2108122
   Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5
   Weibel ER, 1979, STEREOLOGICAL METHOD, P415
   Williams MA, 2007, BIOMARK INSIGHTS, V2, P226
   World Health Organization Occupational and Environmental Health Team, 2006, WHO AIR QUALITY GUID
   Costa NDX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185474
   Xing YF, 2016, J THORAC DIS, V8, pE69, DOI 10.3978/j.issn.2072-1439.2016.01.19
   Yanagisawa R, 2004, EXP BIOL MED, V229, P1081
   Yanagisawa R, 2003, THORAX, V58, P605, DOI 10.1136/thorax.58.7.605
   Akinaga LMY, 2009, TOXICOL PATHOL, V37, P306, DOI 10.1177/0192623309332994
   Yoshizaki K, 2016, ENVIRON POLLUT, V213, P359, DOI 10.1016/j.envpol.2016.02.044
NR 50
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 17
PY 2020
VL 10
IS 1
AR 15314
DI 10.1038/s41598-020-72130-3
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU6NF
UT WOS:000573758500058
PM 32943719
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Wendel, S
   Kutner, JM
   Machado, R
   Fontao-Wendel, R
   Bub, C
   Fachini, R
   Yokoyama, A
   Candelaria, G
   Sakashita, A
   Achkar, R
   Hamerschlak, N
   Scuracchio, P
   Amaral, M
   Dal Ben, M
   Araujo, D
   Soares, C
   Camargo, A
   Kallas, E
   Durigon, E
   Reis, LF
   Rizzo, LV
AF Wendel, Silvano
   Kutner, Jose Mauro
   Machado, Rafael
   Fontao-Wendel, Rita
   Bub, Carolina
   Fachini, Roberta
   Yokoyama, Ana
   Candelaria, Gabriela
   Sakashita, Araci
   Achkar, Ruth
   Hamerschlak, Nelson
   Scuracchio, Patricia
   Amaral, Marcelo
   Dal Ben, Mirian
   Araujo, Danielle
   Soares, Camila
   Camargo, Anamaria
   Kallas, Esper
   Durigon, Edison
   Reis, Luiz Fernando
   Rizzo, Luiz Vicente
TI Screening forSARS-CoV-2 antibodies in convalescent plasma in Brazil:
   Preliminary lessons from a voluntary convalescent donor program
SO TRANSFUSION
LA English
DT Article; Early Access
DE convalescent plasma therapy; COVID-19; passive immune therapy;
   SARS-COV-2; coronavirus
ID NEUTRALIZING ANTIBODIES; CORONAVIRUS; INFECTION; IMMUNOTHERAPY;
   SARS-COV-2; PROTECTION; COVID-19; OBESITY; DISEASE; BLOOD
AB Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. Methods and Materials Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for >= 14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. Results Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT-PCR was negative on swab (77.0%) or blood (88.4%;P= .46). Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT-PCR -ve with neutralizing antibody >= 160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P< .05), probably denoting a "golden period" for CCP collection (<= 28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. Conclusions RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
C1 [Wendel, Silvano; Fontao-Wendel, Rita; Fachini, Roberta; Candelaria, Gabriela; Achkar, Ruth; Scuracchio, Patricia; Amaral, Marcelo] Hosp Sirio Libanes Blood Bank, Rua Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.
   [Kutner, Jose Mauro; Bub, Carolina; Yokoyama, Ana; Sakashita, Araci; Hamerschlak, Nelson] Hosp Israelita Albert Einstein Blood Bank, Sao Paulo, Brazil.
   [Machado, Rafael; Araujo, Danielle; Soares, Camila; Durigon, Edison] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   [Dal Ben, Mirian; Camargo, Anamaria; Reis, Luiz Fernando] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Rizzo, Luiz Vicente] Albert Einstein Jewish Inst Educ & Res, Sao Paulo, Brazil.
   [Kallas, Esper] Univ Sao Paulo, Sch Med, Infectious Dis Dept, Sao Paulo, Brazil.
RP Wendel, S (corresponding author), Hosp Sirio Libanes Blood Bank, Rua Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.
EM snwendel@terra.com.br
RI Bub, Carolina/N-8010-2018
OI Bub, Carolina/0000-0001-5103-4970
FU Fundacao de. Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/23680-0, 2017/24769-2];
   Coordenacao de Aperfeicoamento de Pessoal de. Nivel Superior -
   CAPESCAPES [88 887.131387/2016-00]; Fundacao de Amparo a Pesquisa do
   Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2016/20045-7, 2020/06409-1]
FX C.P.S. is funded by Grant 2018/23680-0 (Fundacao de. Amparo a Pesquisa
   do Estado de Sao Paulo); D.B.A. by Grant 88 887.131387/2016-00
   (Coordenacao de Aperfeicoamento de Pessoal de. Nivel Superior - CAPES),
   R.R.G.M. by Grant 2017/24769-2 (Fundacao de. Amparo a Pesquisa do Estado
   de Sao Paulo) and E.L.D. by Grants 2016/20045-7 and 2020/06409-1
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo). All other
   authors have no conflict of interest.
CR Almeida FJ, 2020, PEDIATR INFECT DIS J, V39, pE161, DOI 10.1097/INF.0000000000002737
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Araujo DB, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760200342
   Barone P, 2020, TRANSFUSION, V60, P1123, DOI 10.1111/trf.15843
   Bloch Evan M, 2020, Vox Sang, DOI 10.1111/vox.12970
   Blutt SE, 2012, MUCOSAL IMMUNOL, V5, P712, DOI 10.1038/mi.2012.51
   Brazilian Ministry of Health, 192020SEIGSTCODIRE1A
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Caussy C, 2020, LANCET DIABETES ENDO, V8, P562, DOI [10.1016/S2213-8587(20)30160-0, 10.1016/S2213-8587(20)30160-1]
   Cervia C, 2020, BIORXIV, DOI [10.1101/2020.05.21.108308, DOI 10.1101/2020.05.21.108308]
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dzik Sunny, 2020, Transfus Med Rev, V34, P141, DOI 10.1016/j.tmrv.2020.04.002
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Epstein J, 2020, VOX SANG, DOI 10.1111/vox.12964
   Epstein J, 2020, VOX SANG, V115, P485, DOI 10.1111/vox.12939
   European Commission Directorate-General For Health And Food Safety, EU PROGR COVID 19 CO
   Gallup JL, 2019, STATA J, V19, P598, DOI 10.1177/1536867X19874236
   Gniadek TJ, 2020, TRANSFUSION, V60, P1643, DOI 10.1111/trf.15871
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Keil SD, 2020, VOX SANG, V115, P495, DOI 10.1111/vox.12937
   Knudson CM, 2020, TRANSFUSION, V60, P1332, DOI 10.1111/trf.15842
   Kwon SY, 2020, VOX SANG, DOI 10.1111/vox.12925
   Lanteri MC, 2020, TRANSFUSION, V60, P1319, DOI 10.1111/trf.15807
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li N, 2020, J MED VIROL, V92, P2286, DOI 10.1002/jmv.25952
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Liu STH, 2020, CONVALESCENT PLASMA, P2236, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Liu WD, 2020, J INFECTION, V81, P329, DOI 10.1016/j.jinf.2020.03.063
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Luchsinger Larry L, 2020, medRxiv, DOI 10.1101/2020.06.08.20124792
   Luke TC, 2010, CRIT CARE MED, V38, pE66, DOI 10.1097/CCM.0b013e3181d44c1e
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   McGuire LW, 1919, J AMER MED ASSOC, V72, P709, DOI 10.1001/jama.1919.02610100017007
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298
   Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
   Oliveira DBL, 2016, NEW ENGL J MED, V375, P1202, DOI 10.1056/NEJMc1607583
   Park WH, 1932, J AMER MED ASSOC, V99, P1050, DOI 10.1001/jama.1932.02740650008003
   Park WH, 1926, J AMER MED ASSOC, V87, P556, DOI 10.1001/jama.1926.02680080022009
   RAMBAR AC, 1946, AM J DIS CHILD, V71, P1
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Sahr F, 2017, J INFECTION, V74, P302, DOI 10.1016/j.jinf.2016.11.009
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   STINEBAUGH BJ, 1966, AM J MED, V40, P217, DOI 10.1016/0002-9343(66)90103-3
   Tan CW, 2020, NAT RES
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   U.S. Food and Drug Administration, 2020, REC INV COVID 19 CON
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Walsh EE, 2004, J INFECT DIS, V190, P373, DOI 10.1086/421524
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, LAB TEST COR DIS 201, P1
   Wong HK, 2020, VOX SANG, V115, P545, DOI 10.1111/vox.12927
   World Health Organization, NAM COR DIS COVID 19
   World Health Organization (WHO), 2020, 2020WHO2019NCOVCLINI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]
   Wu F, 2020, NEUTRALIZING ANTIBOD, V2020, P30, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yan HM, 2002, J VIROL, V76, P10972, DOI 10.1128/JVI.76.21.10972-10979.2002
   Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
   Zhang Q, 2020, SARS COV 2 NEUTRALIZ
   Zhao J, 2020, CLIN INFECT DIS, V344, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080743
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
NR 80
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
DI 10.1111/trf.16065
EA SEP 2020
PG 14
WC Hematology
SC Hematology
GA NP1JH
UT WOS:000569937100001
PM 32935877
OA Other Gold
DA 2020-11-26
ER

PT J
AU Cerqueira, NB
   Vasconcelos, R
   Hojilla, JC
   Kallas, EG
   Avelino-Silva, VI
AF Cerqueira, Natalia Barros
   Vasconcelos, Ricardo
   Hojilla, J. Carlo
   Kallas, Esper Georges
   Avelino-Silva, Vivian, I
TI Attitudes and Knowledge About Human Immunodeficiency Virus Pre-Exposure
   Prophylaxis Among Brazilian Infectious Disease Physicians
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article; Early Access
DE health knowledge; attitudes; practice; pre-exposure prophylaxis;
   implementation science; HIV infections
ID HEALTH-CARE PROVIDERS; HIV; PREP; AWARENESS; PRESCRIPTION; STIGMA; MEN;
   SEX
AB The objective was to describe levels and predictors of knowledge, attitudes, and willingness to prescribe pre-exposure prophylaxis (PrEP) among Brazilian Infectious Disease (ID) Physicians. The design was a cross-sectional study. We collected information on demographics and attitudes/knowledge about PrEP using an anonymous electronic survey. Willingness to prescribe PrEP, fear of adherence issues, and concerns about risk compensation were addressed in three case vignettes that varied by a single characteristic (i.e., by gender identity, drug use, and socioeconomic status) randomly assigned to physicians. Three hundred seventy ID physicians responded to the survey. Although most identified as informed/well informed about PrEP (75%) and believed PrEP availability to be necessary (38%), concerns with adherence (49%), side effects (38%), risk compensation (28%), and increase in sexually transmitted infection incidence (38%) were raised. We found no statistically significant differences in willingness to prescribe PrEP and concerns around risk compensation across the three case vignettes. ID physicians who declared having a religion reported more concerns about risk compensation compared to those self-identified as atheists (72% vs. 46%,p < .001). Most Brazilian ID physicians reported a positive attitude toward PrEP. Patients' gender identity, drug use, and socioeconomic status were not associated with willingness to prescribe PrEP. However, ID physicians who declared having a religion were more frequently concerned about risk compensation among PrEP users, suggesting that personal beliefs can influence PrEP implementation.
C1 [Cerqueira, Natalia Barros; Vasconcelos, Ricardo; Kallas, Esper Georges; Avelino-Silva, Vivian, I] Univ Sao Paulo, Dept Infect & Parasit Dis, Sch Med, Sao Paulo, Brazil.
   [Hojilla, J. Carlo; Avelino-Silva, Vivian, I] Univ Calif San Francisco, Dept Psychiat, Weill Inst Neurosci, San Francisco, CA USA.
   [Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
RP Cerqueira, NB (corresponding author), Lab Invest Med 60, Av Dr Arnaldo 455,Sala 3205, BR-01246903 Sao Paulo, SP, Brazil.
EM natalia.b.cerqueira@gmail.com
CR Adams LM, 2016, AIDS CARE, V28, P1154, DOI 10.1080/09540121.2016.1153595
   Blackstock OJ, 2017, J GEN INTERN MED, V32, P62, DOI 10.1007/s11606-016-3903-z
   Blumenthal J, 2015, AIDS BEHAV, V19, P802, DOI 10.1007/s10461-015-0996-z
   Calabrese SK, 2019, AIDS PATIENT CARE ST, V33, P79, DOI 10.1089/apc.2018.0166
   Calabrese SK, 2014, AIDS BEHAV, V18, P226, DOI 10.1007/s10461-013-0675-x
   Chariyalertsak S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024295
   Desai M, 2016, HIV MED, V17, P133, DOI 10.1111/hiv.12285
   Goodman-Meza D, 2019, AIDS CARE, V31, P1228, DOI 10.1080/09540121.2019.1595523
   Grinsztejn B, 2018, LANCET HIV, V4, P1
   Grov C, 2019, AIDS BEHAV, V23, P1277, DOI 10.1007/s10461-018-2309-9
   Hojilla JC, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25103
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Krakower D, 2012, CURR OPIN HIV AIDS, V7, P593, DOI 10.1097/COH.0b013e3283590446
   McGowan CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018462
   Mimiaga MJ, 2014, AIDS CARE, V26, P684, DOI 10.1080/09540121.2013.845289
   Ministerio da Saude: Secretaria de Vigilancia em Saude, 2018, B EP HIV AIDS 2018
   Ministerio da Saude: Secretaria de Vigilancia em Saude . Departamento de IST Aids e Hepatites Virais, 2017, PROT CLIN DIR TER PR
   Mullins TLK, 2017, AIDS PATIENT CARE ST, V31, P504, DOI 10.1089/apc.2017.0147
   Nunn AC, 2017, PLOS ONE, V12, pe0173057
   Page K, 2017, LANCET HIV, V4, pE52, DOI 10.1016/S2352-3018(16)30208-9
   Petroll AE, 2017, AIDS BEHAV, V21, P1256, DOI 10.1007/s10461-016-1625-1
   Petroll AE, 2011, SEX TRANSM DIS, V38, P63, DOI 10.1097/OLQ.0b013e3181ebd50f
   Puro V, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-217
   Reyniers T, 2018, SEX HEALTH, V15, P606, DOI 10.1071/SH18072
   Seidman D, 2016, CONTRACEPTION, V93, P463, DOI 10.1016/j.contraception.2015.12.018
   Sharma M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105283
   Silverman T, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10020166
   Tripathi A, 2012, SOUTH MED J, V105, P199, DOI 10.1097/SMJ.0b013e31824f1a1b
   UNAIDS, 2018, UNAIDS DAT 2018
   Varas-Diaz N., 2014, Journal of the International Association of Providers of AIDS Care, V13, P305, DOI 10.1177/2325957412472935
   Varas-Diaz N, 2010, GLOB PUBLIC HEALTH, V5, P295, DOI 10.1080/17441690903436581
   Westergaard RP, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-10
   Woolf-King SE, 2013, J URBAN HEALTH, V90, P948, DOI 10.1007/s11524-013-9820-0
NR 33
TC 0
Z9 0
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
DI 10.1089/aid.2019.0281
EA AUG 2020
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MW3LE
UT WOS:000556942100001
PM 32657136
DA 2020-11-26
ER

PT J
AU Grinsztejn, B
   Donnell, D
   Clement, M
   Hanscom, B
   Cottle, L
   Coelho, L
   Cabello, R
   Chariyalestak, S
   Dunne, E
   Frank, I
   Gaur, A
   Gonzalez, P
   Ha, TV
   Hinojosa, J
   Kallas, E
   Kelley, C
   Losso, M
   Madruga, JV
   Middelkoop, K
   Phanuphak, N
   Gallardo, J
   Santos, B
   Sued, O
   Huanami, JV
   Hucks-Ortiz, C
   Cardozo, N
   Monteiro, L
   Promjantuek, K
   Mvula, X
   Jones, D
   Eshleman, S
   Blanchette, C
   Lucas, J
   Scott, H
   Fields, S
   Gomez-Feliciano, K
   Jennings, A
   Rooney, J
   Spreen, W
   Margolis, D
   Rinehart, A
   Adeyeye, A
   Cohen, M
   McCauley, M
   Landovitz, R
   Vela, C
AF Grinsztejn, B.
   Donnell, D.
   Clement, M.
   Hanscom, B.
   Cottle, L.
   Coelho, L.
   Cabello, R.
   Chariyalestak, S.
   Dunne, E.
   Frank, I.
   Gaur, A.
   Gonzalez, P.
   Ha, T. V.
   Hinojosa, J.
   Kallas, E.
   Kelley, C.
   Losso, M.
   Madruga, J. Valdez
   Middelkoop, K.
   Phanuphak, N.
   Gallardo, J.
   Santos, B.
   Sued, O.
   Huanami, J. Valencia
   Hucks-Ortiz, C.
   Cardozo, N.
   Monteiro, L.
   Promjantuek, K.
   Mvula, X.
   Jones, D.
   Eshleman, S.
   Blanchette, C.
   Lucas, J.
   Scott, H.
   Fields, S.
   Gomez-Feliciano, K.
   Jennings, A.
   Rooney, J.
   Spreen, W.
   Margolis, D.
   Rinehart, A.
   Adeyeye, A.
   Cohen, M.
   McCauley, M.
   Landovitz, R.
   Vela, C.
CA HPTN 083 Study Team
TI HPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP)
   containing long-acting injectable cabotegravir (CAB-LA) is maintained
   across regions and key populations
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.] Inst Nacl Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Donnell, D.; Hanscom, B.; Cottle, L.] Fred Hutchinson Canc Inst, Seattle, WA USA.
   [Clement, M.] Louisiana State Univ, Baton Rouge, LA 70803 USA.
   [Coelho, L.] Inst Pesquisa Clin Evandro Changas Fiocruz, Rio De Janeiro, Brazil.
   [Cabello, R.] Via Libre Clin Res Ctr, Lima, Peru.
   [Chariyalestak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Dunne, E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Dunne, E.] Silom Clin, Bangkok, Thailand.
   [Frank, I.] Univ Penn, Philadelphia, PA 19104 USA.
   [Gaur, A.; Jones, D.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Gonzalez, P.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Ha, T. V.] Hlth Ctr Pho Yen, Pho Yen, Vietnam.
   [Hinojosa, J.; Vela, C.] Asociaci Civil Selva Amazon, Iquitos, Peru.
   [Kallas, E.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Kelley, C.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Losso, M.] Hosp Gen Agudos JM Ramos Mejia, Buenos Aires, DF, Argentina.
   [Madruga, J. Valdez] Sao Paulo DST AIDS CRS, Sao Paulo, Brazil.
   [Middelkoop, K.] Groote Schuur Hosp, Cape Town, South Africa.
   [Phanuphak, N.; Promjantuek, K.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Gallardo, J.] CITBM CRS, Lima, Peru.
   [Santos, B.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Sued, O.; Cardozo, N.] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Huanami, J. Valencia] Barranco CRS, Lima, Peru.
   [Hucks-Ortiz, C.] JWCH Inst, Los Angeles, CA USA.
   [Monteiro, L.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Mvula, X.] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa.
   [Eshleman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Blanchette, C.; Lucas, J.; Gomez-Feliciano, K.; Jennings, A.; McCauley, M.] FHI 360, Durham, NC USA.
   [Scott, H.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Fields, S.] New York Inst Technol, Old Westbury, NY 11568 USA.
   [Rooney, J.] Gilead Sci, Foster City, CA USA.
   [Spreen, W.; Margolis, D.; Rinehart, A.] ViiV Healthcare, Durham, NC USA.
   [Adeyeye, A.] NIAID, Div AIDS, NIH, Clin Prevent Res Branch, Rockville, MD USA.
   [Cohen, M.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.
   [Landovitz, R.] Univ Calif Los Angeles, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
NR 0
TC 1
Z9 1
U1 2
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OACLB0101
BP 174
EP 175
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900334
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Landovitz, RJ
   Donnell, D
   Clement, M
   Hanscom, B
   Cottle, L
   Coelho, L
   Cabello, R
   Chariyalestak, S
   Dunne, E
   Frank, I
   Gallardo, J
   Gaur, A
   Gonzalez, P
   Ha, V
   Hinojosa, J
   Kallas, E
   Kelley, C
   Losso, M
   Madruga, JV
   Middelkoop, K
   Phanuphak, N
   Santos, B
   Sued, O
   Huanami, JV
   Overton, ET
   Swaminathan, S
   del Rio, C
   Gulick, R
   Richardson, P
   Sullivan, P
   Piwowar-Manning, E
   Marzinke, M
   Marrazzo, J
   Daar, E
   Asmelash, A
   Anderson, P
   Eshleman, S
   Blanchette, C
   Lucas, J
   Psaros, C
   Safren, S
   Sugarman, J
   Scott, H
   Eron, J
   Fields, S
   Gomez-Feliciano, K
   Jennings, A
   Shin, K
   Rooney, J
   Spreen, W
   Margolis, D
   Rinehart, A
   Adeyeye, A
   Cohen, M
   McCauley, M
   Grinsztejn, B
AF Landovitz, R. J.
   Donnell, D.
   Clement, M.
   Hanscom, B.
   Cottle, L.
   Coelho, L.
   Cabello, R.
   Chariyalestak, S.
   Dunne, E.
   Frank, I.
   Gallardo, J.
   Gaur, A.
   Gonzalez, P.
   Ha, V.
   Hinojosa, J.
   Kallas, E.
   Kelley, C.
   Losso, M.
   Valdez Madruga, J.
   Middelkoop, K.
   Phanuphak, N.
   Santos, B.
   Sued, O.
   Valencia Huanami, J.
   Overton, E. T.
   Swaminathan, S.
   Rio, C. del
   Gulick, R.
   Richardson, P.
   Sullivan, P.
   Piwowar-Manning, E.
   Marzinke, M.
   Marrazzo, J.
   Daar, E.
   Asmelash, A.
   Anderson, P.
   Eshleman, S.
   Blanchette, C.
   Lucas, J.
   Psaros, C.
   Safren, S.
   Sugarman, J.
   Scott, H.
   Eron, J.
   Fields, S.
   Gomez-Feliciano, K.
   Jennings, A.
   Shin, K.
   Rooney, J.
   Spreen, W.
   Margolis, D.
   Rinehart, A.
   Adeyeye, A.
   Cohen, M.
   McCauley, M.
   Grinsztejn, B.
CA HPTN 083 Study Team
TI HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing
   long-acting injectable cabotegravir (CAB-LA) is safe and highly
   effective for cisgender men and transgender women who have sex with men
   (MSM,TGW)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Landovitz, R. J.] Univ Calif Los Angeles, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA USA.
   [Donnell, D.; Hanscom, B.; Cottle, L.] Fred Hutchinson Canc Inst, Seattle, WA USA.
   [Clement, M.] Louisiana State Univ, Baton Rouge, LA 70803 USA.
   [Coelho, L.; Grinsztejn, B.] Inst Pesquisa Clin Evandro Changas Fiocruz, Rio De Janeiro, Brazil.
   [Cabello, R.] Via Libre Clin Res Ctr, Lima, Peru.
   [Chariyalestak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand.
   [Dunne, E.] Ctr Dis Control & Prevent, Silom Clin Bangkok Thailand, Atlanta, GA USA.
   [Frank, I.] Univ Penn, Philadelphia, PA 19104 USA.
   [Gallardo, J.] CITBM CRS, Lima, Peru.
   [Gaur, A.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Gonzalez, P.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Ha, V.] Yen Hoa Clin, Hanoi, Vietnam.
   [Hinojosa, J.] Asociaci Civil Selva Amazon, Iquitos, Peru.
   [Kallas, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kelley, C.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Losso, M.] Hosp Gen Agudos JM Ramos Mejia, Buenos Aires, DF, Argentina.
   [Valdez Madruga, J.] Sao Paulo DST AIDS CRS, Sao Paulo, Brazil.
   [Middelkoop, K.] Groote Schuur Hosp, Cape Town, South Africa.
   [Phanuphak, N.] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand.
   [Santos, B.] Hosp Nossa Senhora Conceicao, Porto Alegre, RS, Brazil.
   [Sued, O.] Fundac Huesped, Buenos Aires, DF, Argentina.
   [Valencia Huanami, J.] Barranco CRS, Lima, Peru.
   [Overton, E. T.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Swaminathan, S.] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Rio, C. del] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Gulick, R.] Cornell Univ, Div Infect Dis, Weill Med Coll, New York, NY USA.
   [Richardson, P.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Sullivan, P.; Piwowar-Manning, E.; Marzinke, M.] Johns Hopkins Univ, Baltimore, MD USA.
   [Marrazzo, J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Daar, E.] Harbor UCLA Med Ctr, Lundquist Inst, Los Angeles, CA USA.
   [Asmelash, A.; Blanchette, C.; Lucas, J.; Gomez-Feliciano, K.; Jennings, A.; McCauley, M.] FHI 360, Washington, DC USA.
   [Anderson, P.] Univ Colorado, Anschutz Campus, Aurora, CO USA.
   [Eshleman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Psaros, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Safren, S.] Univ Miami, Miami, FL USA.
   [Sugarman, J.] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA.
   [Scott, H.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Eron, J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA.
   [Fields, S.] New York Inst Technol, Old Westbury, NY 11568 USA.
   [Shin, K.] Pharmaceut Affairs Branch, Div AIDS, Rockville, MD USA.
   [Rooney, J.] Gilead Sci, Foster City, CA USA.
   [Spreen, W.; Margolis, D.; Rinehart, A.] ViiV Healthcare, Durham, NC USA.
   [Adeyeye, A.] NIAID, Div AIDS, NIH, Clin Prevent Res Branch, Rockville, MD USA.
   [Cohen, M.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA OAXLB0101
BP 183
EP 183
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900349
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Precioso, AR
   Palacios, R
   Thome, B
   Braga, PE
   Vanni, T
   Campos, LMA
   Ferrari, L
   Mondini, G
   Salomao, MD
   da Silva, A
   Espinola, HM
   Santos, JD
   Santos, CLS
   Timenetsky, MDST
   Miraglia, JL
   Gallina, NMF
   Weiskopf, D
   Sette, A
   Goulart, R
   Salles, RT
   Maestri, A
   Sallum, AME
   Farhat, SCL
   Sakita, NK
   Ferreira, JCOA
   Silveira, CGT
   Costa, PR
   Raw, I
   Whitehead, SS
   Durbin, AP
   Kalil, J
AF Kallas, Esper G.
   Precioso, Alexander Roberto
   Palacios, Ricardo
   Thome, Beatriz
   Braga, Patricia Emilia
   Vanni, Tazio
   Campos, Lucia M. A.
   Ferrari, Lilian
   Mondini, Gabriella
   Salomao, Maria da Graca
   da Silva, Anderson
   Espinola, Heloisa M.
   Santos, Joane do Prado
   Santos, Cecilia L. S.
   Timenetsky, Maria do Carmo S. T.
   Miraglia, Joao Luiz
   Gallina, Neuza M. F.
   Weiskopf, Daniela
   Sette, Alessandro
   Goulart, Raphaella
   Salles, Rafael Tavares
   Maestri, Alvino
   Sallum, Adriana Maluf Elias
   Farhat, Sylvia Costa Lima
   Sakita, Neusa K.
   Ferreira, Juliana C. O. A.
   Silveira, Cassia G. T.
   Costa, Priscilla R.
   Raw, Isaias
   Whitehead, Stephen S.
   Durbin, Anna P.
   Kalil, Jorge
TI Safety and immunogenicity of the tetravalent, live-attenuated dengue
   vaccine Butantan-DV in adults in Brazil: a two-step, double-blind,
   randomised placebo-controlled phase 2 trial
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID T-CELL RESPONSES; VIRUS SEROTYPES; CANDIDATE; NAIVE; CHILDREN; HEALTHY
AB Background The Butantan Institute has manufactured a lyophilised tetravalent live-attenuated dengue vaccine Butantan-DV, which is analogous to the US National Institutes of Health (NIH) TV003 admixture. We aimed to assess the safety and immunogenicity of Butantan-DV.
   Methods We did a two-step, double-blind, randomised placebo-controlled phase 2 trial at two clinical sites in Sao Paulo, Brazil. We recruited healthy volunteers aged 18-59 years; pregnant women, individuals with a history of neurological, heart, lung, liver or kidney disease, diabetes, cancer, or autoimmune diseases, and individuals with HIV or hepatitis C were excluded. Step A was designed as a small bridge-study between Butantan-DV and TV003 in DENV-naive participants. In step A, we planned to randomly assign 50 dengue virus (DENV)-naive individuals to receive two doses of Butantan-DV, TV003, or placebo, given 6 months apart. In step B, we planned to randomly assign 250 participants (DENV-naive and DENV-exposed) to receive one dose of Butantan-DV or placebo. Participants were randomly assigned, by computer-generated block randomisation (block sizes of five); participants in step A were randomly assigned (2:2:1) to receive Butantan-DV, TV003, or placebo and participants in step B were randomly assigned (4:1) to receive Butantan-DV or placebo. Participants and study staff were unaware of treatment allocation. The primary safety outcome was the frequency of solicited and unsolicited local and systemic adverse reactions within 21 days of the first vaccination, analysed by intention to treat. The primary immunogenicity outcome was seroconversion rates of the DENV-1-4 serotypes measured 91 days after the first vaccination, analysed in the per-protocol population, which included all participants in step A, and all participants included in step B who completed all study visits with serology sample collection. This trial is registered with ClinicalTrials. gov, NCT01696422.
   Findings Between Nov 5, 2013, and Sept 21, 2015, 300 individuals were enrolled and randomly assigned: 155 (52%) DENV-naive participants and 145 (48%) DENV-exposed participants. Of the 155 DENV-naive participants, 97 (63%) received Butantan-DV, 17 (11%) received TV003, and 41 (27%) received placebo. Of the 145 DENV-exposed participants, 113 (78%) received Butantan-DV, three (2%) received TV003, and 29 (20%) received placebo. Butantan-DV and TV003 were both immunogenic, well-tolerated, and no serious adverse reactions were observed. In step A, rash was the most frequent adverse event (16 [845] of 19 participants in the Butantan-DV group and 13 [76%] of 17 participants in the TV003 group). Viraemia was similar between the Butantan-DV and TV003 groups. Of the 85 DENV-naive participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis and thus were included in the per-protocol analysis population, 74 (87%) achieved seroconversion to DENV-1, 78 (92%) to DENV-2, 65 (76%) to DENV-3, and 76 (89%) to DENV-4. Of the 101 DENV-exposed participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis, 82 (81%) achieved seroconversion to DENV-1, 79 (78%) to DENV-2, 83 (82%) to DENV-3, and 78 (77%) to DENV-4.
   Interpretation Butantan-DV and TV003 were safe and induced robust, balanced neutralising antibody responses against the four DENV serotypes. Efficacy evaluation of the Butantan-DV vaccine is ongoing. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Precioso, Alexander Roberto; Campos, Lucia M. A.; Sallum, Adriana Maluf Elias; Farhat, Sylvia Costa Lima; Sakita, Neusa K.; Ferreira, Juliana C. O. A.] Univ Sao Paulo, Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Ferrari, Lilian; Goulart, Raphaella; Salles, Rafael Tavares; Maestri, Alvino; Silveira, Cassia G. T.; Costa, Priscilla R.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Precioso, Alexander Roberto; Palacios, Ricardo; Braga, Patricia Emilia; Vanni, Tazio; Mondini, Gabriella; Salomao, Maria da Graca; da Silva, Anderson; Espinola, Heloisa M.; Santos, Joane do Prado; Miraglia, Joao Luiz; Gallina, Neuza M. F.; Raw, Isaias] Inst Butantan, Div Clin Trials & Pharmacovigilance, BR-05503900 Sao Paulo, Brazil.
   [Thome, Beatriz] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil.
   [Santos, Cecilia L. S.; Timenetsky, Maria do Carmo S. T.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, San Diego, CA USA.
   [Whitehead, Stephen S.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Durbin, Anna P.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA.
RP Precioso, AR (corresponding author), Inst Butantan, Div Clin Trials & Pharmacovigilance, BR-05503900 Sao Paulo, Brazil.
EM alexander.precioso@butantan.gov.br
RI thome, beatriz/B-7337-2018; Precioso, Alexander/A-9712-2013; Palacios,
   Ricardo/B-7248-2018; Salomao, Maria da Graca/L-1349-2014
OI thome, beatriz/0000-0002-3941-3756; Caires de Oliveira Achili Ferreira,
   Juliana/0000-0002-9249-2318; Precioso, Alexander/0000-0001-8657-9292;
   Palacios, Ricardo/0000-0002-1410-8579; Miraglia, Joao
   Luiz/0000-0002-4788-6254; Salomao, Maria da Graca/0000-0001-8066-6774
FU Intramural Research Program US NIH National Institute of Allergy and
   Infectious Diseases; Brazilian National Bank for Economic and Social
   Development; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Fundacao Butantan
FX Intramural Research Program US NIH National Institute of Allergy and
   Infectious Diseases, Brazilian National Bank for Economic and Social
   Development, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, and
   Fundacao Butantan.
CR Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179
   Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10
   Buddhari D, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003230
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Durbin Anna P, 2016, J Infect Dis, V214, P832, DOI 10.1093/infdis/jiw067
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   European Medicines Agency, 1995, ICH TOP E2A CLIN SAF
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   Halstead SB, 2009, ANN NY ACAD SCI, V1171, pE48, DOI 10.1111/j.1749-6632.2009.05052.x
   Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Mahoney RT, 2012, VACCINE, V30, P4892, DOI 10.1016/j.vaccine.2012.02.064
   Nivarthi UK, 2017, J VIROL, V91, DOI 10.1128/JVI.02041-16
   Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328
   Precioso AR, 2015, VACCINE, V33, P7121, DOI 10.1016/j.vaccine.2015.09.105
   Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8
   Sirivichayakul C, 2016, J INFECT DIS, V213, P1562, DOI 10.1093/infdis/jiv762
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   The Uppsala Monitoring Centre, US WHO UMC SYST STAN
   U.S. Department of Health and Human Services, COMMON TERMINOLOGY C
   U.S. Department of Health and Human Services. Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND TOX GRAD SC
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whitehead SS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005584
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
NR 33
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2020
VL 20
IS 7
BP 839
EP 850
DI 10.1016/S1473-3099(20)30023-2
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA ME3PZ
UT WOS:000544572300041
PM 32220283
DA 2020-11-26
ER

PT J
AU Perrotta, AR
   Borrelli, GM
   Martins, CO
   Kallas, EG
   Sanabani, SS
   Griffith, LG
   Alm, EJ
   Abrao, MS
AF Perrotta, Allison R.
   Borrelli, Giuliano M.
   Martins, Carlo O.
   Kallas, Esper G.
   Sanabani, Sabri S.
   Griffith, Linda G.
   Alm, Eric J.
   Abrao, Mauricio S.
TI The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in
   Endometriosis: a Pilot Study
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE Endometriosis; Pathogenesis; Microbiome; Vaginal microbiome; Diagnosis
ID IMMUNE-RESPONSE; PATHOGENESIS; BIOMARKERS; WOMEN
AB Endometriosis remains a challenge to understand and to diagnose. This is an observational cross-sectional pilot study to characterize the gut and vaginal microbiome profiles among endometriosis patients and control subjects without the disease and to explore their potential use as a less-invasive diagnostic tool for endometriosis. Overall, 59 women were included, n = 35 with endometriosis and n = 24 controls. Rectal and vaginal samples were collected in two different periods of the menstrual cycle from all subjects. Gut and vaginal microbiomes from patients with different rASRM (revised American Society for Reproductive Medicine) endometriosis stages and controls were analyzed. Illumina sequencing libraries were constructed using a two-step 16S rRNA gene PCR amplicon approach. Correlations of 16S rRNA gene amplicon data with clinical metadata were conducted using a random forest-based machine-learning classification analysis. Distribution of vaginal CSTs (community state types) significantly differed between follicular and menstrual phases of the menstrual cycle (p = 0.021, Fisher's exact test). Vaginal and rectal microbiome profiles and their association to severity of endometriosis (according to rASRM stages) were evaluated. Classification models built with machine-learning methods on the microbiota composition during follicular and menstrual phases of the cycle were built, and it was possible to accurately predict rASRM stages 1-2 verses rASRM stages 3-4 endometriosis. The feature contributing the most to this prediction was an OTU (operational taxonomic unit) from the genus Anaerococcus. Gut and vaginal microbiomes of women with endometriosis have been investigated. Our findings suggest for the first time that vaginal microbiome may predict stage of disease when endometriosis is present.
C1 [Perrotta, Allison R.; Alm, Eric J.] MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Borrelli, Giuliano M.; Martins, Carlo O.; Abrao, Mauricio S.] Univ Sao Paulo, Gynecol Div, Fac Med, Endometriosis Sect,Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Fac Med, Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil.
   [Sanabani, Sabri S.] Univ Sao Paulo, Trop Med Inst Sao Paulo, Lab Dermatol & Immunodeficiency, Dept Dermatol, Sao Paulo, Brazil.
   [Griffith, Linda G.; Alm, Eric J.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Griffith, Linda G.] MIT, Mech Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Griffith, Linda G.] MIT, Ctr Gynephathol Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Alm, Eric J.] MIT, Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Alm, Eric J.] MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Abrao, Mauricio S.] BP Beneficencia Portuguesa Sao Paulo, Gynecol Div, Sao Paulo, SP, Brazil.
RP Perrotta, AR; Alm, EJ (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Borrelli, GM; Abrao, MS (corresponding author), Univ Sao Paulo, Gynecol Div, Fac Med, Endometriosis Sect,Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil.; Alm, EJ (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Alm, EJ (corresponding author), MIT, Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Alm, EJ (corresponding author), MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Abrao, MS (corresponding author), BP Beneficencia Portuguesa Sao Paulo, Gynecol Div, Sao Paulo, SP, Brazil.
RI Sanabani, Sabri Saeed/F-5600-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; de Oliveira Martins,
   Carlo/0000-0003-1287-8884
FU National Institute of Environmental Health Sciences of the NIH
   [P30-ES002109]; Brazilian Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Massachusetts Institute of Technology (MIT)/Brazil
   Seed Fund [CNPq-MIT 457125/2012-8]
FX Library preparation and sequencing efforts through the MIT BioMicro
   Center were funded by the National Institute of Environmental Health
   Sciences of the NIH under award P30-ES002109.; This study was funded by
   grants from the Brazilian Council for Scientific and Technological
   Development (CNPq). Specifically, the Massachusetts Institute of
   Technology (MIT)/Brazil Seed Fund (Process number: CNPq-MIT
   457125/2012-8)..
CR Abrao MS, 2007, HUM REPROD, V22, P3092, DOI 10.1093/humrep/dem187
   Anahtar MN, 2015, IMMUNITY, V42, P965, DOI 10.1016/j.immuni.2015.04.019
   Beste MT, 2014, SCI TRANSL MED, V6, p222ra16
   Borrelli GM, 2014, HUM REPROD, V29, P253, DOI 10.1093/humrep/det401
   Brooks J. Paul, 2017, Microbial Ecology in Health and Disease, V28, P1303265, DOI 10.1080/16512235.2017.1303265
   Burney RO, 2012, FERTIL STERIL, V98, P511, DOI 10.1016/j.fertnstert.2012.06.029
   Campos GB, 2018, FERTIL STERIL, V109, P549, DOI 10.1016/j.fertnstert.2017.11.009
   Chen C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00901-0
   Christodoulakos G, 2007, EUR J CONTRACEP REPR, V12, P194, DOI 10.1080/13625180701387266
   Clemente JC, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5145
   David LA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-7-r89
   Dorien FO, 2018, BEST PRACT RES CL OB, V50, P72, DOI 10.1016/j.bpobgyn.2018.04.001
   Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
   Eslami S, 2016, APMIS, V124, P697, DOI 10.1111/apm.12556
   Farage Miranda, 2006, Archives of Gynecology and Obstetrics, V273, P195, DOI 10.1007/s00404-005-0079-x
   Gajer P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003605
   Kiely CJ, 2018, GUT MICROBES, V9, P477, DOI 10.1080/19490976.2018.1448742
   Kvaskoff M, 2015, HUM REPROD UPDATE, V21, P500, DOI 10.1093/humupd/dmv013
   Lagana AS, 2017, MED HYPOTHESES, V103, P10, DOI 10.1016/j.mehy.2017.03.032
   Laschke MW, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.036
   Maybin JA, 2015, HUM REPROD UPDATE, V21, P748, DOI 10.1093/humupd/dmv038
   Narayanan V, 2014, CANCER PREV RES, V7, P1108, DOI 10.1158/1940-6207.CAPR-14-0273
   Nisenblat V, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012281
   Nunn Kenetta L., 2016, Yale Journal of Biology and Medicine, V89, P331
   Opazo MC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00432
   Papa E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039242
   Peterson CT, 2015, CLIN EXP IMMUNOL, V179, P363, DOI 10.1111/cei.12474
   Podgaec S, 2007, HUM REPROD, V22, P1373, DOI 10.1093/humrep/del516
   Podgaec S, 2012, AM J REPROD IMMUNOL, V68, P301, DOI 10.1111/j.1600-0897.2012.01173.x
   Preheim SP, 2013, APPL ENVIRON MICROB, V79, P6593, DOI 10.1128/AEM.00342-13
   Quast C, 2012, NUCLEIC ACIDS RES, DOI DOI 10.1093/NAR/GKS1219
   Quigley EMM, 2017, NAT REV GASTRO HEPAT, V14, P315, DOI 10.1038/nrgastro.2017.29
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Rogers GB, 2010, MOL DIAGN THER, V14, P343, DOI 10.2165/11587680-000000000-00000
   Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-4
   Santulli P, 2018, BEST PRACT RES CLIN, VS1521-6934, p[ii, 30028]
   Senturk LM, 1999, J REPROD IMMUNOL, V43, P67, DOI 10.1016/S0165-0378(98)00079-5
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07
   Yuan M, 2018, HUM REPROD, V33, P607, DOI 10.1093/humrep/dex372
   Zhou X, 2010, FEMS IMMUNOL MED MIC, V58, P169, DOI 10.1111/j.1574-695X.2009.00618.x
NR 40
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD APR
PY 2020
VL 27
IS 4
BP 1064
EP 1073
DI 10.1007/s43032-019-00113-5
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA LC6HO
UT WOS:000525432900014
PM 32046455
OA Green Published
DA 2020-11-26
ER

PT J
AU Tenore, SD
   Avelino-Silva, VI
   Costa, PR
   Franco, LM
   Sabino, EC
   Kalil, J
   Cerqueira, NB
   Nakagawa, Z
   Kallas, EG
AF Tenore, Simone de Barros
   Avelino-Silva, Vivian Iida
   Costa, Priscilla Ramos
   Franco, Lucas M.
   Sabino, Ester Cerdeira
   Kalil, Jorge
   Cerqueira, Natalia Barros
   Nakagawa, Zelinda
   Kallas, Esper Georges
TI Immune effects ofLactobacillus caseiShirota in treated HIV-infected
   patients with poor CD4+T-cell recovery
SO AIDS
LA English
DT Article
DE Lactobacillus caseiShirota; CD4+; HIV; immune discordant;
   Lactobacillusspp; probiotic; recovery
ID ACTIVE ANTIRETROVIRAL THERAPY; MICROBIAL TRANSLOCATION; DOUBLE-BLIND;
   PROBIOTIC YOGURT; CELL RECOVERY; INDIVIDUALS; ACTIVATION; MICRONUTRIENT;
   RESTORATION; SUPPRESSION
AB Background: HIV infection leads to depletion of intestinal CD4+ T cells, mucosal barrier dysfunction, increased gut permeability and microbial translocation even among patients on suppressive ART. Previous studies suggest probiotics may help restore intestinal function. Methods: In this double-blind, placebo-controlled pilot study, we enrolled HIV-infected patients on suppressive ART with poor CD4+ recovery to address the effect of daily oral use ofLactobacillus caseiShirota (LcS) on CD4+ T-cell count and CD4+/CD8+ ratio at 6 and 12 weeks after treatment initiation; immune activation and intestinal microbiome composition were addressed as secondary outcomes. Results: From January 2015 to July 2016, 48 patients were randomized (1 : 1) to active intervention or placebo. Groups had comparable demographic and clinical characteristics; only CD4+ T-cell nadir was statistically different between groups. All participants were virologically suppressed under ART. At week 6, the increment in CD4+ T-cell count was 17 cells/mu l [interquartile range (IQR) -33 to 74] in the active intervention arm and 4 cells/mu l (IQR -43 to 51) in the placebo arm (P = 0.291); at week 12, the change in CD4+ T-cell count was 8 cells//mu l (IQR -30 to 70) in the active arm and 10 cells//mu l (IQR -50 to 33) among participants allocated to placebo (P = 0.495). Median change in CD4+/CD8+ ratio at week 6 compared with baseline was 0 (IQR -0.04 to 0.05) in the active intervention arm and -0.01 in the placebo arm (IQR -0.06 to 0.03;P = 0.671). At week 12, the change in CD4+/CD8+ ratio was higher in the active product group compared with placebo (respectively 0.07 and 0.01), but this difference failed to reach statistical significance (P = 0.171). We found no significant effects of LcS on immune activation markers, CD4+ and CD8+ subpopulations, sCD14 levels or NK cells at week 12. Finally, we found no statistically significant differences between groups in the change of enteric microbiome at week 12. Conclusion: In this pilot study, we found no statistically significant effect of LcS probiotic on CD4+ T-cell counts, CD4+/CD8+ ratio, immune activation or intestinal microbiome among HIV-infected patients on suppressive ART with poor CD4+ recovery.
C1 [Tenore, Simone de Barros; Avelino-Silva, Vivian Iida; Sabino, Ester Cerdeira; Kallas, Esper Georges] Univ Sao Paulo, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Costa, Priscilla Ramos; Kalil, Jorge; Cerqueira, Natalia Barros; Nakagawa, Zelinda; Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Franco, Lucas M.; Sabino, Ester Cerdeira] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Sao Paulo, SP, Brazil.
EM esper.kallas@usp.br
RI Avelino-Silva, Vivian/L-2640-2013
OI Avelino-Silva, Vivian/0000-0002-6660-3088
CR Avelino-Silva VI, 2016, JAIDS-J ACQ IMM DEF, V71, P189, DOI 10.1097/QAI.0000000000000845
   Avelino-Silva VI, 2011, AGEING RES REV, V10, P163, DOI 10.1016/j.arr.2010.10.004
   Bandera A, 2018, CURR OPIN HIV AIDS, V13, P73, DOI [10.1097/coh.0000000000000429, 10.1097/COH.0000000000000429]
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   d'Ettorre G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137200
   Falster K, 2009, JAIDS-J ACQ IMM DEF, V50, P307, DOI 10.1097/QAI.0b013e3181945ed4
   Gootenberg DB, 2017, CURR OPIN INFECT DIS, V30, P31, DOI 10.1097/QCO.0000000000000341
   Heiser Carla R, 2004, J Int Assoc Physicians AIDS Care (Chic), V3, P121, DOI 10.1177/154510970400300403
   Hemsworth JC, 2012, GUT MICROBES, V3, P414, DOI 10.4161/gmic.21248
   Hummelen R, 2011, NUTRIENTS, V3, P897, DOI 10.3390/nu3100897
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Irvine SL, 2010, J CLIN GASTROENTEROL, V44, pE201, DOI 10.1097/MCG.0b013e3181d8fba8
   Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476
   Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484
   Kim CJ, 2014, JAIDS-J ACQ IMM DEF, V67, P514, DOI 10.1097/QAI.0000000000000359
   Lozupone CA, 2014, GUT MICROBES, V5, P562, DOI 10.4161/gmic.32132
   Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746
   Muller GC, 2015, CELL IMMUNOL, V296, P149, DOI 10.1016/j.cellimm.2015.05.006
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pontes Rose Meire Albuquerque, 2004, Arq. Gastroenterol., V41, P137, DOI 10.1590/S0004-28032004000200014
   Ribeiro ABDTM, 2017, EUR J MICROBIOL IMMU, V7, P158, DOI 10.1556/1886.2017.00016
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075
   Stiksrud B, 2015, JAIDS-J ACQ IMM DEF, V70, P329, DOI 10.1097/QAI.0000000000000784
   Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002
   Trois L, 2008, J TROP PEDIATRICS, V54, P19, DOI 10.1093/tropej/fmm066
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Villar-Garcia J, 2015, JAIDS-J ACQ IMM DEF, V68, P256, DOI 10.1097/QAI.0000000000000468
   Yang OO, 2014, AIDS RES HUM RETROV, V30, P988, DOI [10.1089/aid.2014.0181, 10.1089/AID.2014.0181]
   Zevin AS, 2016, CURR OPIN HIV AIDS, V11, P182, DOI 10.1097/COH.0000000000000234
NR 31
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 1
PY 2020
VL 34
IS 3
BP 381
EP 389
DI 10.1097/QAD.0000000000002420
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ME8JF
UT WOS:000544898400005
PM 31714353
DA 2020-11-26
ER

PT J
AU Leda, AR
   Hunter, J
   de Oliveira, UC
   de Azevedo, IJ
   Kallas, EG
   Sucupira, MCA
   Diaz, RS
AF Leda, Ana Rachel
   Hunter, James
   de Oliveira, Ursula Castro
   de Azevedo, Inacio Junqueira
   Kallas, Esper G.
   Araripe Sucupira, Maria Cecilia
   Diaz, Ricardo Sobhie
TI HIV-1 genetic diversity and divergence and its correlation with disease
   progression among antiretroviral naive recently infected individuals
SO VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EVOLUTION; SUBTYPE; NEUTRALIZATION;
   TRANSMISSION; ESCAPE; TIME; RECOMBINATION; BOTTLENECK; SELECTION
AB HIV-1 genetic diversity evolution was deeply characterized during the first year of infection among recently-infected patients using deep sequencing technology and correlated with disease progression surrogate markers. RNA and DNA samples from twenty-five individuals (13 female) encoding the protease and reverse transcriptase regions of the poi gene, and the V3 region of the env gene were evaluated at recent infection and during established infection. Infection by a unique HIV-1 strain was inferred in 70.1% of the individuals, with no differences between genders. Infections by multiple strains were associated with higher viral loads and faster CD4(+) T cell declines. Either low or high levels of viral loads accompanied low levels of genetic diversity and lower selective pressure. With massive sequence data from 3 distinct genomic HIV-1 regions from plasma and PBMCs over time, we propose a model for HIV-1 genetic diversity, which correlates to basal viral loads of patients.
C1 [Leda, Ana Rachel; Hunter, James; Araripe Sucupira, Maria Cecilia; Diaz, Ricardo Sobhie] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [de Oliveira, Ursula Castro; de Azevedo, Inacio Junqueira] Butantan Inst, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, Sao Paulo, Brazil.
EM rsdiaz@catg.com.br
RI Junqueira-de-Azevedo, Inacio L. M./H-5239-2011; Center of Toxins,
   Immune-response/J-5731-2015
OI Junqueira-de-Azevedo, Inacio L. M./0000-0003-4491-0180; Leda,
   Ana/0000-0003-0276-0487
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/12156-0,
   2011/50238-8]
FX We thank Will Fischer for useful discussions on deep sequencing analysis
   and for pearl scripts kindly provided. This work was financially
   supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), research grant #2011/12156-0 to RSD and PhD scholarship
   #2011/50238-8 to ARL.
CR Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08
   Sucupira MCA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030292
   Arif MS, 2017, J VIROL, V91, DOI [10.1128/jvi.00793-17, 10.1128/JVI.00793-17]
   Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519
   Bunnik EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002106
   Carlson JM, 2014, SCIENCE, V345, DOI 10.1126/science.1254031
   Chawla A, 2007, J CLIN MICROBIOL, V45, P415, DOI 10.1128/JCM.01879-06
   Cicala C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S2
   Cotton LA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004295
   de Mendoza C, 2007, J ANTIMICROB CHEMOTH, V59, P698, DOI 10.1093/jac/dkm012
   Deng WJ, 2010, BIOTECHNIQUES, V48, P405, DOI 10.2144/000113370
   Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137
   DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995
   Diaz RS, 1996, AIDS RES HUM RETROV, V12, P1291, DOI 10.1089/aid.1996.12.1291
   Diaz RS, 1997, AIDS, V11, P415, DOI 10.1097/00002030-199704000-00003
   Eshleman SH, 2007, AIDS, V21, P1165, DOI 10.1097/QAD.0b013e32810fd72e
   Fenton-May AE, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-146
   Frange P, 2010, J CLIN MICROBIOL, V48, P3487, DOI 10.1128/JCM.00704-10
   Frost SDW, 2005, P NATL ACAD SCI USA, V102, P18514, DOI 10.1073/pnas.0504658102
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   Geffin R, 2003, VIROLOGY, V310, P207, DOI 10.1016/S0042-6822(03)00137-5
   Giorgi EE, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-532
   Haaland RE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000274
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Huang W, 2009, AIDS RES HUM RETROV, V25, P795, DOI 10.1089/aid.2008.0252
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375
   Komninakis S.V., 2012, J CLIN, V50, P2132
   Korber B, 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Lee WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090581
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890
   Long EM, 2000, NAT MED, V6, P71
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Masharsky AE, 2010, J INFECT DIS, V201, P1697, DOI 10.1086/652702
   NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   Ping LH, 2013, J VIROL, V87, P7218, DOI 10.1128/JVI.03577-12
   Powers KA, 2008, LANCET INFECT DIS, V8, P553, DOI 10.1016/S1473-3099(08)70156-7
   PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924
   Quinlan AR, 2008, NAT METHODS, V5, P179, DOI 10.1038/NMETH.1172
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Ross HA, 2002, J VIROL, V76, P11715, DOI 10.1128/JVI.76.22.11715-11720.2002
   Russell ES, 2011, J VIROL, V85, P8253, DOI 10.1128/JVI.00197-11
   Sagar M, 2004, J VIROL, V78, P7279, DOI 10.1128/JVI.78.13.7279-7283.2004
   Sagar M, 2003, J VIROL, V77, P12921, DOI 10.1128/JVI.77.23.12921-12926.2003
   Sagar M, 2009, J INFECT DIS, V199, P580, DOI 10.1086/596557
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Williamson S, 2003, MOL BIOL EVOL, V20, P1318, DOI 10.1093/molbev/msg144
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
   Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002
NR 65
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB
PY 2020
VL 541
BP 13
EP 24
DI 10.1016/j.virol.2019.11.006
PG 12
WC Virology
SC Virology
GA KM5ZX
UT WOS:000514219400002
PM 31826842
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Grunenberg, NA
   Yu, CC
   Manso, B
   Pantaleo, G
   Casapia, M
   Baden, LR
   Valencia, J
   Sobieszczyk, M
   Tieu, HV
   Allen, M
   Hural, J
   Graham, BS
   Kublin, J
   Gilbert, PB
   Corey, L
   Goepfert, PA
   McElrath, MJ
   Johnson, RP
   Huang, YD
   Frahm, N
AF Kallas, Esper G.
   Grunenberg, Nicole A.
   Yu, Chenchen
   Manso, Bryce
   Pantaleo, Giuseppe
   Casapia, Martin
   Baden, Lindsey R.
   Valencia, Javier
   Sobieszczyk, Magdalena
   Hong Van Tieu
   Allen, Mary
   Hural, John
   Graham, Barney S.
   Kublin, James
   Gilbert, Peter B.
   Corey, Lawrence
   Goepfert, Paul A.
   McElrath, M. Juliana
   Johnson, R. Paul
   Huang, Yunda
   Frahm, Nicole
TI Antigenic competition in CD4(+) T cell responses in a randomized,
   multicenter, double-blind clinical HIV vaccine trial
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HIGHLY PATHOGENIC SIV; NEUTRALIZING ANTIBODIES; PROTEINS; IMMUNITY;
   MODELS; COMPLEXES; STEP
AB T cell responses have been implicated in reduced risk of HIV acquisition in uninfected persons and control of viral replication in HIV-infected individuals. HIV Gag-specific T cells have been predominantly associated with post-infection control, whereas Env antigens are the target for protective antibodies; therefore, inclusion of both antigens is common in HIV vaccine design. However, inclusion of multiple antigens may provoke antigenic competition, reducing the potential effectiveness of the vaccine. HVTN 084 was a randomized, multicenter, double-blind phase 1 trial to investigate whether adding Env to a Gag/Pol vaccine decreases the magnitude or breadth of Gag/ Pol-specific T cell responses. Fifty volunteers each received one intramuscular injection of 1 x 10(10) particle units (PU) of rAd5 Gag/Pol and EnvA/B/C (3:1:1:1 mixture) or 5 x 10(9) PU of rAd5 Gag/Pol. CD4(+) T cell responses to Gag/ Pol measured 4 weeks after vaccination by cytokine expression were significantly higher in the group vaccinated without Env, whereas CD8(+) T cell responses did not differ significantly between the two groups. Mapping of individual epitopes revealed greater breadth of the Gag/Pol-specific T cell response in the absence of Env compared to Env coimmunization. Addition of an Env component to a Gag/Pol vaccine led to reduced Gag/Pol CD4(+) T cell response rate and magnitude as well as reduced epitope breadth, confirming the presence of antigenic competition. Therefore, T cell-based vaccine strategies should aim at choosing a minimalist set of antigens to reduce interference of individual vaccine components with the induction of the maximally achievable immune response.
C1 [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, SP, Brazil.
   [Grunenberg, Nicole A.; Yu, Chenchen; Manso, Bryce; Hural, John; Kublin, James; Gilbert, Peter B.; Corey, Lawrence; McElrath, M. Juliana; Huang, Yunda; Frahm, Nicole] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.
   [Pantaleo, Giuseppe] Lausanne Univ Hosp CHUV, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland.
   [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos 16002, Peru.
   [Baden, Lindsey R.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Valencia, Javier] Asociac Civil Impacta Salud & Educ, Lima 15063, Peru.
   [Sobieszczyk, Magdalena] Columbia Univ Coll Phys & Surg, Dept Med, Div Infect Dis, New York, NY 10025 USA.
   [Hong Van Tieu] New York Blood Ctr, Lab Infect Dis Prevent, New York, NY 10065 USA.
   [Allen, Mary] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA.
   [Graham, Barney S.] NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.
   [Goepfert, Paul A.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
   [Goepfert, Paul A.] Univ Alabama Birmingham, Dept Med, Dept Surg, Div Gastroenterol, Birmingham, AL 35294 USA.
   [McElrath, M. Juliana; Frahm, Nicole] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [McElrath, M. Juliana] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [McElrath, M. Juliana] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Johnson, R. Paul] Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
RP Frahm, N (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.; Frahm, N (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
EM nicole.frahm@gatesmri.org
RI Corey, Lawrence/AAE-1796-2020
OI Corey, Lawrence/0000-0002-2179-2436; Manso, Bryce/0000-0002-4860-4888;
   Grunenberg, Nicole/0000-0003-2565-3879; Kallas,
   Esper/0000-0003-2026-6925
FU National Institute of Allergy and Infectious Diseases (NIAID) U.S.
   Public Health Service [UM1 AI068614, UM1 AI068635, UM1 AI068618, UM1
   AI069481, UM1 AI069412, UM1 AI069438, UM1 AI069420, UM1 AI069470, P51
   OD011132]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [UM1AI068635, UM1AI069438, UM1AI068618, UM1AI068614,
   UM1AI069481, UM1AI069481, UM1AI069412, UM1AI069438, UM1AI069412,
   UM1AI068618, UM1AI069412, UM1AI068635, UM1AI068614, UM1AI068635,
   UM1AI068635, UM1AI068618, UM1AI069470, UM1AI069470, UM1AI069438,
   UM1AI069470, UM1AI069438, UM1AI068635, UM1AI069412, UM1AI068618,
   UM1AI068614, UM1AI068618, UM1AI068635, UM1AI069412, UM1AI069481,
   UM1AI069470, UM1AI068618, UM1AI069481, UM1AI068618, UM1AI069470,
   UM1AI068614] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR,
   NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P51OD011132,
   P51OD011132, P51OD011132, P51OD011132, P51OD011132, P51OD011132,
   P51OD011132, P51OD011132, P51OD011132, P51OD011132, P51OD011132] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID) U.S. Public Health Service grants UM1
   AI068614 (LOC: HIV Vaccine Trials Network), UM1 AI068635 (SDMC: HIV
   Vaccine Trials Network), UM1 AI068618 (LC: HIV Vaccine Trials Network),
   UM1 AI069481 (Seattle-Lausanne-Kampala Clinical Trials Unit: Centre
   Hospitalier Universitaire Vaudois Clinical Research Site), UM1 AI069412
   (Harvard/Boston/Providence Clinical Trials Unit: Brigham and Women's
   Hospital Clinical Research Site), UM1 AI069438 [IMPACTA Peru Clinical
   Trials Unit: Asociacion Civil Impacta Salud y Educacion (IMPACTA) and
   Asociacion Civil Selva Amazonica (ACSA) Clinical Research Sites], UM1
   AI069420 (Sao Paulo Clinical Trials Unit: Centro de Referencia e
   Treinamento DST/AIDS Clinical Research Site), UM1 AI069470 (Columbia
   Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit:
   College of Physicians and Surgeons and New York Blood Center Clinical
   Research Sites), and P51 OD011132 (Yerkes NPRC Base Grant). The opinions
   expressed in this article are those of the authors and do not
   necessarily represent the official views of the NIAID or the NIH.
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]
   Blobel NJ, 2017, J IMMUNOL, V198
   Bockl K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034723
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Chirmule N, 1996, MICROBIOL REV, V60, P386, DOI 10.1128/MMBR.60.2.386-406.1996
   Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736
   Churchyard GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021225
   De Rosa SC, 2012, CYTOM PART A, V81A, P1019, DOI 10.1002/cyto.a.22218
   Finak G, 2014, BIOSTATISTICS, V15, P87, DOI 10.1093/biostatistics/kxt024
   Frahm N, 2012, J CLIN INVEST, V122, P359, DOI 10.1172/JCI60202
   Grufman P, 1999, EUR J IMMUNOL, V29, P2197, DOI 10.1002/(SICI)1521-4141(199907)29:07<2197::AID-IMMU2197>3.0.CO;2-B
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hayball JD, 2004, IMMUNOL CELL BIOL, V82, P103, DOI 10.1046/j.0818-9641.2004.01233.x
   Hertz T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003404
   Horton H, 2007, J IMMUNOL METHODS, V323, P39, DOI 10.1016/j.jim.2007.03.002
   Hu HT, 2008, J IMMUNOL, V180, P5593, DOI 10.4049/jimmunol.180.8.5593
   Janes H, 2013, J INFECT DIS, V208, P1231, DOI 10.1093/infdis/jit322
   Janes HE, 2017, J INFECT DIS, V215, P1376, DOI 10.1093/infdis/jix086
   Kedl RM, 2003, CURR OPIN IMMUNOL, V15, P120, DOI 10.1016/S0952-7915(02)00009-2
   Kedl RM, 2000, J EXP MED, V192, P1105, DOI 10.1084/jem.192.8.1105
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516
   Lachenbruch PA, 2001, STAT MED, V20, P1215, DOI 10.1002/sim.790
   Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Mothe B, 2018, ADV EXP MED BIOL, V1075, P31, DOI 10.1007/978-981-13-0484-2_2
   Papasavvas E, 2015, IMMUNOLOGY, V145, P380, DOI 10.1111/imm.12452
   Peiperl L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013579
   Radebe M, 2015, AIDS, V29, P23, DOI 10.1097/QAD.0000000000000508
   RADOVICH J, 1967, SCIENCE, V158, P512, DOI 10.1126/science.158.3800.512
   SCHECHTE.I, 1965, BIOCHIM BIOPHYS ACTA, V104, P303, DOI 10.1016/0304-4165(65)90254-0
   Smith A, 2000, IMMUNITY, V13, P783, DOI 10.1016/S1074-7613(00)00076-5
   Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175
   Taussig M J, 1973, Curr Top Microbiol Immunol, V60, P125
   Valentin A, 2015, HUM VACC IMMUNOTHER, V11, P2005, DOI 10.1080/21645515.2015.1016671
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   WEIGLE WO, 1967, J IMMUNOL, V99, P392
   Williamson AL, 2016, EXPERT REV VACCINES, V15, P585, DOI 10.1586/14760584.2016.1129904
   Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730
NR 43
TC 5
Z9 5
U1 0
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD NOV 20
PY 2019
VL 11
IS 519
AR eaaw1673
DI 10.1126/scitranslmed.aaw1673
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA JP0PV
UT WOS:000497975000003
PM 31748227
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Zanella, LGFABD
   Moreira, CHV
AF Kallas, E. G.
   Zanella, D'Elia L. G. F. A. B.
   Moreira, C. H., V
TI Predictors of mortality in patients with yellow fever: an observational
   cohort study (vol 19, pg 750, 2019)
SO LANCET INFECTIOUS DISEASES
LA English
DT Correction
CR Kallas EG, 2019, LANCET INFECT DIS, V19, P750, DOI 10.1016/S1473-3099(19)30125-2
NR 1
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2019
VL 19
IS 11
BP E370
EP E370
DI 10.1016/S1473-3099(19)30496-7
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA JH4KT
UT WOS:000492738200002
OA Bronze
DA 2020-11-26
ER

PT J
AU Grebe, E
   Facente, SN
   Bingham, J
   Pilcher, CD
   Powrie, A
   Gerber, J
   Priede, G
   Chibawara, T
   Busch, MP
   Murphy, G
   Kassanjee, R
   Welte, A
   Welte, A
   Sempa, J
   Matten, D
   Brand, H
   Chibawara, T
   Murphy, G
   Hall, J
   Mckinney, E
   Busch, MP
   Grebe, E
   Facente, S
   Hampton, D
   Keating, S
   Lebedeva, M
   Pilcher, CD
   Marson, K
   Kassanjee, R
   Laeyendecker, O
   Quinn, T
   Burns, D
   Little, S
   Sands, A
   Hallett, T
   Owen, SM
   Parekh, B
   Sexton, C
   Price, M
   Kamali, A
   Loeb, L
   Martin, J
   Deeks, SG
   Hoh, R
   Bartolomei, Z
   Cerqueira, N
   Santos, B
   Zabtoski, K
   Lira, RDA
   Sperhacke, RD
   Motta, LR
   Paganella, M
   Kallas, E
   Tomiyama, H
   Tomiyama, C
   Costa, P
   Nunes, MA
   Reis, G
   Sauer, MM
   Cerqueira, N
   Nakagawa, Z
   Ferrari, L
   Amaral, AP
   Milani, K
   Karim, SSA
   Karim, QA
   Ndungu, T
   Majola, N
   Samsunder, N
   Naniche, D
   Mandomando, I
   Macete, EV
   Sanchez, J
   Lama, J
   Duerr, A
   Capobianchi, MR
   Suligoi, B
   Stramer, S
   Williamson, P
   Vermeulen, M
   Sabino, E
AF Grebe, Eduard
   Facente, Shelley N.
   Bingham, Jeremy
   Pilcher, Christopher D.
   Powrie, Andrew
   Gerber, Jarryd
   Priede, Gareth
   Chibawara, Trust
   Busch, Michael P.
   Murphy, Gary
   Kassanjee, Reshma
   Welte, Alex
   Welte, Alex
   Sempa, Joseph
   Matten, David
   Brand, Hilmarie
   Chibawara, Trust
   Murphy, Gary
   Hall, Jake
   Mckinney, Elaine
   Busch, Michael P.
   Grebe, Eduard
   Facente, Shelley
   Hampton, Dylan
   Keating, Sheila
   Lebedeva, Mila
   Pilcher, Christopher D.
   Marson, Kara
   Kassanjee, Reshma
   Laeyendecker, Oliver
   Quinn, Thomas
   Burns, David
   Little, Susan
   Sands, Anita
   Hallett, Tim
   Owen, Sherry Michele
   Parekh, Bharat
   Sexton, Connie
   Price, Matthew
   Kamali, Anatoli
   Loeb, Lisa
   Martin, Jeffrey
   Deeks, Steven G.
   Hoh, Rebecca
   Bartolomei, Zelinda
   Cerqueira, Natalia
   Santos, Breno
   Zabtoski, Kellin
   Alves Lira, Rita de Cassia
   Sperhacke, Rosa Dea
   Motta, Leonardo R.
   Paganella, Machline
   Kallas, Esper
   Tomiyama, Helena
   Tomiyama, Claudia
   Costa, Priscilla
   Nunes, Maria A.
   Reis, Gisele
   Sauer, Mariana M.
   Cerqueira, Natalia
   Nakagawa, Zelinda
   Ferrari, Lilian
   Amaral, Ana P.
   Milani, Karine
   Karim, Salim S. Abdool
   Karim, Quarraisha Abdool
   Ndungu, Thumbi
   Majola, Nelisile
   Samsunder, Natasha
   Naniche, Denise
   Mandomando, Inacio
   Macete, Eusebio V.
   Sanchez, Jorge
   Lama, Javier
   Duerr, Ann
   Capobianchi, Maria R.
   Suligoi, Barbara
   Stramer, Susan
   Williamson, Phillip
   Vermeulen, Marion
   Sabino, Ester
CA Consortium Evaluation Performance
TI Interpreting HIV diagnostic histories into infection time estimates:
   analytical framework and online tool
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Infection dating; Infection duration; Infection timing;
   Diagnostics; Diagnostic assays
ID SEROCONVERSION; PERFORMANCE; SPECIMENS
AB Background It is frequently of epidemiological and/or clinical interest to estimate the date of HIV infection or time-since-infection of individuals. Yet, for over 15 years, the only widely-referenced infection dating algorithm that utilises diagnostic testing data to estimate time-since-infection has been the 'Fiebig staging' system. This defines a number of stages of early HIV infection through various standard combinations of contemporaneous discordant diagnostic results using tests of different sensitivity. To develop a new, more nuanced infection dating algorithm, we generalised the Fiebig approach to accommodate positive and negative diagnostic results generated on the same or different dates, and arbitrary current or future tests - as long as the test sensitivity is known. For this purpose, test sensitivity is the probability of a positive result as a function of time since infection. Methods The present work outlines the analytical framework for infection date estimation using subject-level diagnostic testing histories, and data on test sensitivity. We introduce a publicly-available online HIV infection dating tool that implements this estimation method, bringing together 1) curatorship of HIV test performance data, and 2) infection date estimation functionality, to calculate plausible intervals within which infection likely became detectable for each individual. The midpoints of these intervals are interpreted as infection time 'point estimates' and referred to as Estimated Dates of Detectable Infection (EDDIs). The tool is designed for easy bulk processing of information (as may be appropriate for research studies) but can also be used for individual patients (such as in clinical practice). Results In many settings, including most research studies, detailed diagnostic testing data are routinely recorded, and can provide reasonably precise estimates of the timing of HIV infection. We present a simple logic to the interpretation of diagnostic testing histories into infection time estimates, either as a point estimate (EDDI) or an interval (earliest plausible to latest plausible dates of detectable infection), along with a publicly-accessible online tool that supports wide application of this logic. Conclusions This tool, available at , is readily updatable as test technology evolves, given the simple architecture of the system and its nature as an open source project.
C1 [Grebe, Eduard; Facente, Shelley N.; Busch, Michael P.; Busch, Michael P.; Grebe, Eduard; Facente, Shelley; Hampton, Dylan; Keating, Sheila; Lebedeva, Mila] Vitalant Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
   [Grebe, Eduard; Bingham, Jeremy; Chibawara, Trust; Kassanjee, Reshma; Welte, Alex] Stellenbosch Univ, DST NRF Ctr Excellence Epidemiol Modelling & Anal, 19 Jonkershoek Ave, ZA-7925 Stellenbosch, South Africa.
   [Grebe, Eduard; Facente, Shelley N.; Pilcher, Christopher D.; Busch, Michael P.] Univ Calif San Francisco, 1001 Potrero Ave,Room 5H22, San Francisco, CA 94110 USA.
   [Facente, Shelley N.] Facente Consulting, Richmond, CA USA.
   [Powrie, Andrew; Gerber, Jarryd; Priede, Gareth] Implicit Design, Block B,North Bldg Black River Pk,2 Fir St, ZA-7925 Cape Town, South Africa.
   [Murphy, Gary; Hall, Jake; Mckinney, Elaine] Publ Hlth England, 61 Colindale Ave, London NW9 5EQ, England.
   [Kassanjee, Reshma] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa.
   [Welte, Alex; Sempa, Joseph; Matten, David; Brand, Hilmarie; Chibawara, Trust] Stellenbosch Univ, South African Ctr Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Pilcher, Christopher D.; Marson, Kara] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Kassanjee, Reshma] Univ Cape Town, Cape Town, South Africa.
   [Laeyendecker, Oliver; Quinn, Thomas; Burns, David] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Little, Susan] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Sands, Anita] WHO, Geneva, Switzerland.
   [Hallett, Tim] Imperial Coll London, London, England.
   [Owen, Sherry Michele; Parekh, Bharat; Sexton, Connie] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Price, Matthew; Kamali, Anatoli] Int AIDS Vaccine Initiat, New York, NY USA.
   [Loeb, Lisa] Univ Calif San Francisco, Opt Study, San Francisco, CA 94143 USA.
   [Martin, Jeffrey; Deeks, Steven G.; Hoh, Rebecca] Univ Calif San Francisco, SCOPE Study, San Francisco, CA 94143 USA.
   [Bartolomei, Zelinda; Cerqueira, Natalia] Univ Sao Paulo, AMPLIAR Cohort, Sao Paulo, Brazil.
   [Santos, Breno; Zabtoski, Kellin; Alves Lira, Rita de Cassia] Grp Hosp Conceicao, AMPLIAR Cohort, Porto Alegre, RS, Brazil.
   [Sperhacke, Rosa Dea; Motta, Leonardo R.; Paganella, Machline] Univ Caxias Do Sul, AMPLIAR Cohort, Caxias Do Sul, RS, Brazil.
   [Kallas, Esper; Tomiyama, Helena; Tomiyama, Claudia; Costa, Priscilla; Nunes, Maria A.; Reis, Gisele; Sauer, Mariana M.; Cerqueira, Natalia; Nakagawa, Zelinda; Ferrari, Lilian; Amaral, Ana P.; Milani, Karine] Univ Sao Paulo, Sao Paulo Cohort, Sao Paulo, Brazil.
   [Karim, Salim S. Abdool; Karim, Quarraisha Abdool; Ndungu, Thumbi; Majola, Nelisile; Samsunder, Natasha] Univ Kwazulu Natal, CAPRISA, Durban, South Africa.
   [Naniche, Denise] Barcelona Ctr Int Hlth Res, GAMA Study, Barcelona, Spain.
   [Mandomando, Inacio; Macete, Eusebio V.] Fundacao Manhica, GAMA Study, Manhica, Mozambique.
   [Sanchez, Jorge; Lama, Javier] Asociac Civil Impacta Salud & Educ IMPACTA, SABES Cohort, Lima, Peru.
   [Duerr, Ann] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Capobianchi, Maria R.] Natl Inst Infect Dis L Spallanzani, Rome, Italy.
   [Suligoi, Barbara] Ist Super Sanita, Rome, Italy.
   [Stramer, Susan] Amer Red Cross, Washington, DC 20006 USA.
   [Williamson, Phillip] Vitalant Res Inst, Creat Testing Solut, San Francisco, CA USA.
   [Vermeulen, Marion] South African Natl Blood Serv, Pretoria, South Africa.
   [Sabino, Ester] Hemoctr Sao Paolo, Sao Paulo, Brazil.
RP Grebe, E (corresponding author), Vitalant Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.; Grebe, E (corresponding author), Stellenbosch Univ, DST NRF Ctr Excellence Epidemiol Modelling & Anal, 19 Jonkershoek Ave, ZA-7925 Stellenbosch, South Africa.
EM EGrebe@vitalant.org
RI SULIGOI, BARBARA/O-6490-2019; Facente, Shelley/M-1147-2019; Mandomando,
   Inacio/ABD-8007-2020
OI Mandomando, Inacio/0000-0002-1078-2187; Loeb Stanga,
   Lisa/0000-0001-7471-5381; Grebe, Eduard/0000-0001-7046-7245
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1017716, OPP1062806, OPP1115799]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R34 MH096606]; South African
   Department of Science and Technology; National Research Foundation;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01 AI071713, R01 HD074511, P30
   AI027763, R24 AI067039, U01 AI043638, P01 AI074621, R24 AI106039]; HIV
   Prevention Trials Network (HPTN) - NIAID of the NIH, DHHS [UM1 AI068613,
   R01 AI095068]; National Institutes of Child Health and Human Development
   (NICH/HD) of the NIH, DHHS [UM1 AI068613, R01 AI095068]; National
   Institute on Drug Abuse of the NIH, DHHS [UM1 AI068613, R01 AI095068];
   National Institute of Mental Health of the NIH, DHHS [UM1 AI068613, R01
   AI095068]; Office of AIDS Research, of the NIH, DHHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [UM1 AI068613, R01 AI095068]; Sao Paulo City Health Department
   [2004-0.168.922-7]; IAVI; USAIDUnited States Agency for International
   Development (USAID)
FX CEPHIA was supported by grants from the Bill and Melinda Gates
   Foundation (OPP1017716, OPP1062806 and OPP1115799). Additional support
   for analysis was provided by a grant from the US National Institutes of
   Health (R34 MH096606) and by the South African Department of Science and
   Technology and the National Research Foundation. Specimen and data
   collection were funded in part by grants from the NIH (P01 AI071713, R01
   HD074511, P30 AI027763, R24 AI067039, U01 AI043638, P01 AI074621 and R24
   AI106039); the HIV Prevention Trials Network (HPTN) sponsored by the
   NIAID, National Institutes of Child Health and Human Development
   (NICH/HD), National Institute on Drug Abuse, National Institute of
   Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1
   AI068613 and R01 AI095068); the California HIV-1 Research Program
   (RN07-SD-702); Brazilian Program for STD and AIDS, Ministry of Health
   (914/BRA/3014-UNESCO); and the Sao Paulo City Health Department
   (2004-0.168.922-7). Matthew Price and selected samples from
   IAVI-supported cohorts are funded by IAVI with the generous support of
   USAID and other donors; a full list of IAVI donors is available at
   www.iavi.org.The funders had no role in study design, data collection,
   analysis or interpretation.
CR Ananworanich J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-56
   Delaney KP, 2017, CLIN INFECT DIS, V64, P53, DOI 10.1093/cid/ciw666
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Grebe E, 2017, JAIDS-J ACQ IMM DEF, V76, P547, DOI [10.1097/qai.0000000000001537, 10.1097/QAI.0000000000001537]
   Hologic I, 2015, 501623 ROCH MOL DIAL
   Kassanjee R, 2014, CHARACTERISATION APP
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Keating SM, 2016, JAIDS-J ACQ IMM DEF, V73, P581, DOI 10.1097/QAI.0000000000001146
   Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038
   Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
   Murphy G, 2017, EPIDEMIOL INFECT, V145, P925, DOI 10.1017/S0950268816002910
   Owen SM, 2008, J CLIN MICROBIOL, V46, P1588, DOI 10.1128/JCM.02196-07
   Owen SM, 2015, AACC ANN M BIOR IND
   Perry KR, 2008, TRANSFUSION MED, V18, P228, DOI 10.1111/j.1365-3148.2008.00874.x
   Pilcher CD, 2019, AIDS, V33, P1231, DOI [10.1097/QAD.0000000000002190, 10.1097/qad.0000000000002190]
   Roche Molecular Diagnostics GmbH, COBAS AMPLICOR HIV 1
NR 16
TC 4
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 26
PY 2019
VL 19
IS 1
AR 894
DI 10.1186/s12879-019-4543-9
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA JH6MV
UT WOS:000492883800002
PM 31655566
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Marins, LMS
   Torres, TS
   Leite, ID
   Moreira, RI
   Luz, PM
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Liu, AY
   Anderson, PL
   Grinsztejn, B
   Veloso, VG
AF Marins, Luana M. S.
   Torres, Thiago S.
   Leite, Iuri da C.
   Moreira, Ronaldo I.
   Luz, Paula M.
   Hoagland, Brenda
   Kallas, Esper G.
   Madruga, Jose Valdez
   Liu, Albert Y.
   Anderson, Peter L.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
TI Performance of HIV pre-exposure prophylaxis indirect adherence measures
   among men who have sex with men and transgender women: Results from the
   PrEP Brasil Study
SO PLOS ONE
LA English
DT Article
ID SERODISCORDANT COUPLES; CLINICAL-TRIAL; PREVENTION; INFECTION;
   CONCORDANCE; SYSTEM; RISK
AB Introduction
   Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence. We examined the concordance between indirect adherence measures and protective drug levels among participants retained through 48 weeks in the PrEP Brasil Study.
   Methods
   PrEP Brasil was a prospective, multicenter, open-label demonstration project evaluating PrEP provision for men who have sex with men (MSM) and transgender women (TGW) at higher risk for HIV infection within the setting of Brazilian Public Health System. Three indirect adherence measures were obtained at week 48: medication possession ratio (MPR), pill count and self-report (30-days recall). Tenofovir diphosphate (TFV-DP) concentration in Dried Blood Spot (DBS) was measured at week 48. Areas under (AUC) the receiver operating characteristics (ROC) curve were used to evaluate the concordance between achieving protective drug levels (TFV-DP >= 700fmol/punch) and the indirect adherence measures. Youden's index and distance to corner were used to determine the optimal cutoff points for each indirect adherence measure. We calculated sensitivity, specificity, negative (NPV) and positive (PPV) predictive values for the found cutoff points. Finally, Delong test was used to compare AUCs.
   Results and discussion
   From April, 2014 to July, 2016, 450 participants initiated PrEP, 375(83.3%) were retained through 48 weeks. Of these, 74% (277/375) had TFV-DP >= 700fmol/punch. All adherence measures discriminated between participants with and without protective drug levels (AUC>0.5). High indirect adherence measure was predictive of protective drug levels (PPV>0.8) while low indirect adherence measure was not predictive of lack of protective drug levels (NPV<0.5). No significant differences were found between the adherence methods (p = 0.44).
   Conclusions
   Low-burden measurements such as MPR and self-report can be used to predict PrEP adherence in a public health context in Brazil for MSM and TGW retained through 48 weeks.
C1 [Marins, Luana M. S.; Torres, Thiago S.; Moreira, Ronaldo I.; Luz, Paula M.; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Leite, Iuri da C.] Escola Nacl Saude Publ ENSP Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Escola Med, Sao Paulo, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Anderson, Peter L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
RP Marins, LMS (corresponding author), Inst Nacl Infectol Evandro Chagas INI Fiocruz, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
EM luana.marins@ini.fiocruz.br
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X; Marins,
   Luana/0000-0003-0045-6764; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health (Brasilia, Brazil) [01/2013 BRA/K57];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [402004/2012-4, 454931/2014-0]; Secretaria de Vigilancia em Saude
   (SVS) [281/2013]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/110.261/2014]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/51743-0]; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Secretaria de Vigilancia Sanitaria; Gilead SciencesGilead Sciences;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476]
   Funding Source: NIH RePORTER
FX This study was sponsored by the Brazilian Ministry of Health (Brasilia,
   Brazil; #01/2013 BRA/K57), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; #402004/2012-4, #454931/2014-0),
   Secretaria de Vigilancia em Saude (SVS; #281/2013), Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ;
   #E-26/110.261/2014), and Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP; #2012/51743-0). BG and PML are funded by the CNPq and
   FAPERJ. EGK is funded by FAPESP. Gilead Sciences donated the study drug
   and covered costs related to drug concentration assessment but had no
   role in study design, collection, analysis and interpretation of data,
   writing of the manuscript, or the decision to submit the manuscript for
   publication.; The authors would like to thank the following: the study
   participants; the PrEP Brasil Study Team; and the University of Colorado
   Antiviral Pharmacology Laboratory. The authors also acknowledge the
   support of our funders: CNPq; Secretaria de Vigilancia Sanitaria;
   FAPERJ; FAPESP; and Gilead Sciences.
CR Abaasa A, 2018, AIDS BEHAV, V22, P1165, DOI 10.1007/s10461-017-1951-y
   Agot K, 2015, AIDS BEHAV, V19, P743, DOI 10.1007/s10461-014-0859-z
   Amico KR, 2016, AIDS BEHAV, V20, P1535, DOI 10.1007/s10461-016-1360-7
   Amico KR, 2014, JAIDS-J ACQ IMM DEF, V66, P530, DOI 10.1097/QAI.0000000000000216
   Amico KR, 2012, CURR OPIN HIV AIDS, V7, P542, DOI 10.1097/COH.0b013e3283582d4a
   Anderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2018, J Int AIDS Soc, V21 Suppl 6, pe25148, DOI 10.1002/jia2.25148
   [Anonymous], SIST CONTR LOG MED S
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baker Z, 2018, AIDS BEHAV, V22, P1174, DOI 10.1007/s10461-017-1958-4
   Baxi SM, 2015, JAIDS-J ACQ IMM DEF, V68, P13, DOI 10.1097/QAI.0000000000000386
   Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66
   Castillo-Mancilla JR, 2018, CURR HIV-AIDS REP, V15, P49, DOI 10.1007/s11904-018-0377-0
   Castillo-Mancilla JR, 2012, AIDS RES HUM RETROV
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158
   D'Alessandro A, 2010, BLOOD TRANSFUS-ITALY, V8, P82, DOI 10.2450/2009.0122-09
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Food and Drug Administration, 2012, TRUV PREP FACT SHEET
   Galea JT, 2018, LANCET HIV, V5, pE110, DOI 10.1016/S2352-3018(18)30011-0
   Grangeiro A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009021
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Haberer JE, 2016, CURR OPIN HIV AIDS, V11, P10, DOI 10.1097/COH.0000000000000220
   Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
   Haberer JE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001511
   Hajian-Tilaki K, 2018, STAT METHODS MED RES, V27, P2374, DOI 10.1177/0962280216680383
   Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Kabore Lassane, 2015, J Int Assoc Provid AIDS Care, V14, P156, DOI 10.1177/2325957414557263
   Kebaabetswe PM, 2015, AIDS BEHAV, V19, P758, DOI 10.1007/s10461-014-0891-z
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Luz PM, 2018, MEDICINE, V97, pS75, DOI [10.1097/MD.0000000000010602, 10.1097/md.0000000000010602]
   Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Montgomery MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157742
   Musinguzi N, 2016, AIDS, V30, P1121, DOI 10.1097/QAD.0000000000001024
   PAHO/ WHO, BRAZ IN IMPL PREP PR
   PrEP-O ESTADO DE IMPLEMENTACAO DA PREP NO BRASIL, 2019, B VAC ANT HIV AIDS, V32
   Psaros C, 2014, JAIDS-J ACQ IMM DEF, V66, P522, DOI 10.1097/QAI.0000000000000212
   Seifert SM, 2015, CLIN INFECT DIS, V60, P804, DOI 10.1093/cid/ciu916
   Spinner CD, 2016, INFECTION, V44, P151, DOI 10.1007/s15010-015-0850-2
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Torres T. S., 2018, AIDS 2018
   Torres TS, 2019, JMIR PUBLIC HLTH SUR
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   WHO, 2017, BRAZ BEG PREP ROLL O
   Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7
   World Health Organization, 2014, CONS PREEXP PROPH PR
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 55
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2019
VL 14
IS 8
AR e0221281
DI 10.1371/journal.pone.0221281
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IW5OC
UT WOS:000485026800040
PM 31430318
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hanajiri, R
   Sani, GM
   Hanley, PJ
   Silveira, CG
   Kallas, EG
   Keller, MD
   Bollard, CM
AF Hanajiri, Ryo
   Sani, Gelina M.
   Hanley, Patrick J.
   Silveira, Cassia G.
   Kallas, Esper G.
   Keller, Michael D.
   Bollard, Catherine M.
TI Generation of Zika virus - specific T cells from seropositive and
   virus-naive donors for potential use as an autologous or "off-the-shelf"
   immunotherapeutic
SO CYTOTHERAPY
LA English
DT Article
DE cord blood; epitope mapping; Good Manufacturing Practice; immunotherapy;
   T lymphocytes; Zika virus
ID GUILLAIN-BARRE-SYNDROME; STEM-CELL; VIRAL-INFECTIONS; BK VIRUS; TARGET;
   BLOOD; ADENOVIRUS; CMV; EBV; LYMPHOCYTES
AB Background: Zika virus (ZIKV) infection can cause severe birth defects in newborns with no effective currently available treatment. Adoptive transfer of virus-specific T cells has proven to be safe and effective for the prevention or treatment of many viral infections, and could represent a novel treatment approach for patients with ZIKV infection. However, extending this strategy to the ZIKV setting has been hampered by limited data on immunogenic T-cell antigens within ZIKV. Hence, we have generated ZIKV-specific T cells and characterized the cellular immune responses against ZIKV antigens. Methods: T-cell products were generated from peripheral blood of ZIKV-exposed donors, ZIKV-naive adult donors and umbilical cord blood by stimulation with pentadecamer (15mer) overlapping peptide libraries spanning four ZIKV polyproteins (C, M, E and NS1) using a Good Manufacturing Practice compliant protocol. Results: We successfully generated T cells targeting ZIKV antigens with clinically relevant numbers. The ex vivo-expanded T cells comprised both CD4(+) and CD8(+) T cells that were able to produce Th1-polarized effector cytokines and kill ZIKV-infected HLA-matched monocytes, confirming functionality of this unique T-cell product as a potential "off-the-shelf" therapeutic. Epitope mapping using peptide arrays identified several novel HLA class I and class II restricted epitopes within NS1 antigen, which is essential for viral replication and immune evasion. Discussion: Our findings demonstrate that it is feasible to generate potent ZIKV-specific T cells from a variety of cell sources including virus naive donors for future clinical use in an "off-the-shelf" setting.
C1 [Hanajiri, Ryo; Sani, Gelina M.; Hanley, Patrick J.; Keller, Michael D.; Bollard, Catherine M.] Childrens Natl Hlth Syst, Ctr Canc & Immunol Res, 111 Michigan Ave NW, Washington, DC 20010 USA.
   [Hanley, Patrick J.; Keller, Michael D.; Bollard, Catherine M.] George Washington Univ, Washington, DC USA.
   [Silveira, Cassia G.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Keller, Michael D.] Childrens Natl Hlth Syst, Div Allergy & Immunol, Washington, DC USA.
   [Bollard, Catherine M.] Childrens Natl Hlth Syst, Div Blood & Marrow Transplantat, Washington, DC USA.
RP Bollard, CM (corresponding author), Childrens Natl Hlth Syst, Ctr Canc & Immunol Res, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM cbollard@childrensnational.org
FU Be The Match; American Society for Blood and Marrow Transplantation (Amy
   Strelzer Manasevit Award); National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [K23-HL136783-01]; Jeffrey Modell Foundation; Board of Visitors of
   the Children's National Health System; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA148600,
   P01CA148600, P01CA148600, P01CA148600, P01CA148600, P01CA148600,
   P01CA148600, P01CA148600, P01CA148600, P01CA148600, P01CA148600,
   P01CA148600, P01CA148600, P01CA148600, P01CA148600, P01CA148600,
   P01CA148600, P01CA148600, P01CA148600, P01CA148600, P01CA148600,
   P01CA148600, P01CA148600, P01CA148600, P01CA148600, P01CA148600] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [K23HL136783, K23HL136783, K23HL136783] Funding Source: NIH RePORTER
FX This work was supported by grants from Be The Match and the American
   Society for Blood and Marrow Transplantation (Amy Strelzer Manasevit
   Award to P.J.H.), the National Institutes of Health (K23-HL136783-01 to
   M. D. K.), the Jeffrey Modell Foundation and the Board of Visitors of
   the Children's National Health System.
CR Bailey MJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07008-0
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Bollard CM, 2016, BLOOD, V127, P3331, DOI 10.1182/blood-2016-01-628982
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dave H, 2017, MOL THER-METH CLIN D, V5, P13, DOI 10.1016/j.omtm.2017.02.001
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Fontes-Garfias CR, 2017, CELL REP, V21, P1180, DOI 10.1016/j.celrep.2017.10.016
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Gerdemann U, 2013, MOL THER, V21, P2113, DOI 10.1038/mt.2013.151
   Goldszmid RS, 2014, CELL HOST MICROBE, V15, P295, DOI 10.1016/j.chom.2014.02.003
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   GRIFONI A, 2017, J VIROL, V91, DOI DOI 10.1128/JVI.01469-17
   Hanley PJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2546
   Hanley PJ, 2009, BLOOD, V114, P1958, DOI 10.1182/blood-2009-03-213256
   Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237
   Hilgenfeld R, 2016, EMBO J, V35, P2631, DOI 10.15252/embj.201695871
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z
   Jurado KA, 2017, NAT MICROBIOL, V2, P1460, DOI 10.1038/s41564-017-0049-7
   Jurado KA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88461
   Lai LL, 2018, CLIN INFECT DIS, V66, P1, DOI 10.1093/cid/cix732
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475
   Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324
   Li AZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05276-4
   Lima NS, 2017, TRENDS IMMUNOL, V38, P594, DOI 10.1016/j.it.2017.05.004
   Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Muftuoglu M, 2018, NEW ENGL J MED, V379, P1443, DOI 10.1056/NEJMoa1801540
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Neuenhahn M, 2017, LEUKEMIA, V31, P2161, DOI 10.1038/leu.2017.16
   Ngo MC, 2014, J IMMUNOTHER, V37, P193, DOI 10.1097/CJI.0000000000000014
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825
   Paquin-Proulx Dominic, 2017, Pathog Immun, V2, P274, DOI 10.20411/pai.v2i2.188
   Pardy RD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006184
   Patel S, 2018, MOL THER, V26, P1435, DOI 10.1016/j.ymthe.2018.04.009
   Patel S, 2016, BIOL BLOOD MARROW TR, V22, P536, DOI 10.1016/j.bbmt.2015.12.007
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y
   Poland GA, 2018, LANCET INFECT DIS, V18, pE211, DOI 10.1016/S1473-3099(18)30063-X
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Rana J, 2018, J VIROL, V92, DOI 10.1128/JVI.01174-18
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   Ricciardi MJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006000
   Saa P, 2018, NEW ENGL J MED, V378, P1778, DOI 10.1056/NEJMoa1714977
   Shuaib W, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.02.027
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sutrave G, 2017, CYTOTHERAPY, V19, P1284, DOI 10.1016/j.jcyt.2017.07.012
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/JCO.2017.73.0655, 10.1200/jco.2017.73.0655]
   Weber G, 2013, LEUKEMIA, V27, P1538, DOI 10.1038/leu.2013.66
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Whitmire JK, 2011, VIROLOGY, V411, P216, DOI 10.1016/j.virol.2010.12.015
   Winkler CW, 2017, J IMMUNOL, V198, P3526, DOI 10.4049/jimmunol.1601949
   Xu X, 2016, PLOS CURR, V8, DOI [10.1371/ecurrents.outbreaks.9aa2e1fb61b0f632-f58a098773008c4b, DOI 10.1371/ECURRENTS.OUTBREAKS.9AA2E1FB61B0F632-F58A098773008C4B]
NR 64
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465-3249
EI 1477-2566
J9 CYTOTHERAPY
JI Cytotherapy
PD AUG
PY 2019
VL 21
IS 8
BP 840
EP 855
DI 10.1016/j.jcyt.2019.06.008
PG 16
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA IX6HK
UT WOS:000485783700005
PM 31279695
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Sempa, JB
   Welte, A
   Busch, MP
   Hall, J
   Hampton, D
   Facente, SN
   Keating, SM
   Marson, K
   Parkin, N
   Pilcher, CD
   Murphy, G
   Grebe, E
   Semp, J
   Matten, D
   Brand, H
   Chibawara, T
   Mckinney, E
   Facente, S
   Keating, S
   Lebedeva, M
   Kassanjee, R
   Laeyendecker, O
   Quinn, T
   Burns, D
   Little, S
   Sands, A
   Hallett, T
   Owen, SM
   Parekh, B
   Sexton, C
   Price, M
   Kamali, A
   Loeb, L
   Martin, J
   Deeks, SG
   Hoh, R
   Bartolomei, Z
   Cerqueira, N
   Santos, B
   Zabtoski, K
   Lira, RDA
   Sperhacke, RD
   Motta, LR
   Paganella, M
   Kallas, E
   Tomiyama, H
   Tomiyama, C
   Costa, P
   Nunes, MA
   Reis, G
   Sauer, MM
   Nakagawa, Z
   Ferrari, L
   Amaral, AP
   Milani, K
   Karim, SSA
   Karim, QA
   Ndungu, T
   Majola, N
   Samsunder, N
   Naniche, D
   Mandomando, I
   Macete, EV
   Sanchez, J
   Lama, J
   Duerr, A
   Capobianchi, MR
   Suligoi, B
   Stramer, S
   Williamson, P
   Vermeulen, M
   Sabino, E
AF Sempa, Joseph B.
   Welte, Alex
   Busch, Michael P.
   Hall, Jake
   Hampton, Dylan
   Facente, Shelley N.
   Keating, Sheila M.
   Marson, Kara
   Parkin, Neil
   Pilcher, Christopher D.
   Murphy, Gary
   Grebe, Eduard
   Semp, Joseph
   Matten, David
   Brand, Hilmarie
   Chibawara, Trust
   Mckinney, Elaine
   Facente, Shelley
   Keating, Sheila
   Lebedeva, Mila
   Kassanjee, Reshma
   Laeyendecker, Oliver
   Quinn, Thomas
   Burns, David
   Little, Susan
   Sands, Anita
   Hallett, Tim
   Owen, Sherry Michele
   Parekh, Bharat
   Sexton, Connie
   Price, Matthew
   Kamali, Anatoli
   Loeb, Lisa
   Martin, Jeffrey
   Deeks, Steven G.
   Hoh, Rebecca
   Bartolomei, Zelinda
   Cerqueira, Natalia
   Santos, Breno
   Zabtoski, Kellin
   Alves Lira, Rita de Cassia
   Sperhacke, Rosa Dea
   Motta, Leonardo R.
   Paganella, Machline
   Kallas, Esper
   Tomiyama, Helena
   Tomiyama, Claudia
   Costa, Priscilla
   Nunes, Maria A.
   Reis, Gisele
   Sauer, Mariana M.
   Nakagawa, Zelinda
   Ferrari, Lilian
   Amaral, Ana P.
   Milani, Karine
   Karim, Salim S. Abdool
   Karim, Quarraisha Abdool
   Ndungu, Thumbi
   Majola, Nelisile
   Samsunder, Natasha
   Naniche, Denise
   Mandomando, Inacio
   Macete, Eusebio, V
   Sanchez, Jorge
   Lama, Javier
   Duerr, Ann
   Capobianchi, Maria R.
   Suligoi, Barbara
   Stramer, Susan
   Williamson, Phillip
   Vermeulen, Marion
   Sabino, Ester
CA Consortium Evaluation Performance
TI Performance comparison of the Maxim and Sedia Limiting Antigen Avidity
   assays for HIV incidence surveillance
SO PLOS ONE
LA English
DT Article
ID INFECTION
AB Background
   Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting 'recent' HIV infection in cross-sectional incidence estimation. This study assesses and compares the performance of the two assays for incidence surveillance.
   Methods
   We ran both assays on a panel of 2,500 well-characterized HIV-1-infected specimens. We analysed concordance of assay results, assessed reproducibility using repeat testing and estimated mean durations of recent infection (MDRIs) and false-recent rates (FRRs) for a range of normalized optical density (ODn) thresholds, alone and in combination with viral load thresholds. We defined three hypothetical surveillance scenarios, similar to the Kenyan and South African epidemics, and a concentrated epidemic. These scenarios allowed us to evaluate the precision of incidence estimates obtained by means of various recent infection testing algorithms (RITAs) based on each of the two assays.
   Results
   The Maxim assay produced lower ODn values than the Sedia assay on average, largely as a result of higher calibrator readings (mean OD of 0.749 vs. 0.643), with correlation of normalized readings lower (R-2 = 0.908 vs. R-2 = 0.938). Reproducibility on blinded control specimens was slightly better for Maxim. The MDRI of a Maxim-based algorithm at the 'standard' threshold (ODn <= 1.5 & VL > 1,000) was 201 days (95% CI: 180,223) and for Sedia 171 (152,191). The difference Differences in MDRI were estimated at 32.7 (22.9,42.8) and 30.9 days (21.7,40.7) for the two algorithms, respectively. Commensurately, the Maxim algorithm had a higher FRR in treatment-naive subjects (1.7% vs. 1.1%). The two assays produced similar precision of incidence estimates in the three surveillance scenarios.
   Conclusions
   Differences between the assays can be primarily attributed to the calibrators supplied by the manufacturers. Performance for surveillance was extremely similar, although different thresholds were optimal (i.e. produced the lowest variance of incidence estimates) and at any given ODn threshold, different estimates of MDRI and FRR were obtained. The two assays cannot be treated as interchangeable: assay and algorithm-specific performance characteristic estimates must be used for survey planning and incidence estimation.
C1 [Sempa, Joseph B.; Welte, Alex; Grebe, Eduard] Stellenbosch Univ, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Busch, Michael P.; Hampton, Dylan; Facente, Shelley N.; Keating, Sheila M.; Grebe, Eduard] Vitalant Res Inst, San Francisco, CA 94118 USA.
   [Busch, Michael P.; Facente, Shelley N.; Keating, Sheila M.; Marson, Kara; Pilcher, Christopher D.; Grebe, Eduard] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Hall, Jake; Murphy, Gary; Mckinney, Elaine] Publ Hlth England, London, England.
   [Facente, Shelley N.] Facente Consulting, Richmond, CA USA.
   [Parkin, Neil] Data First Consulting, Belmont, MA USA.
   [Sempa, Joseph B.; Welte, Alex; Matten, David; Brand, Hilmarie; Chibawara, Trust] Stellenbosch Univ, South African Ctr Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Busch, Michael P.; Hampton, Dylan; Grebe, Eduard; Facente, Shelley; Keating, Sheila; Lebedeva, Mila] Vitalant Res Inst, Blood Syst Res Inst, San Francisco, CA USA.
   [Kassanjee, Reshma] Univ Cape Town, ZA-7700 Rondebosch, South Africa.
   [Laeyendecker, Oliver; Quinn, Thomas; Burns, David] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Little, Susan] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Sands, Anita] WHO, Geneva, Switzerland.
   [Hallett, Tim] Imperial Coll London, London, England.
   [Owen, Sherry Michele; Parekh, Bharat; Sexton, Connie] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Price, Matthew; Kamali, Anatoli] Int AIDS Vaccine Initiat, New York, NY USA.
   [Loeb, Lisa] Univ Calif San Francisco, Opt Study, San Francisco, CA 94143 USA.
   [Martin, Jeffrey; Deeks, Steven G.; Hoh, Rebecca] Univ Calif San Francisco, SCOPE Study, San Francisco, CA 94143 USA.
   [Bartolomei, Zelinda; Cerqueira, Natalia] Univ Sao Paulo, AMPLIAR Cohort, Sao Paulo, Brazil.
   [Santos, Breno; Zabtoski, Kellin; Alves Lira, Rita de Cassia] Grp Hosp Conceicao, AMPLIAR Cohort, Cristo Redentor, Brazil.
   [Sperhacke, Rosa Dea; Motta, Leonardo R.; Paganella, Machline] Univ Caxias Do Sul, AMPLIAR Cohort, Caxias Do Sul, RS, Brazil.
   [Cerqueira, Natalia; Kallas, Esper; Tomiyama, Helena; Tomiyama, Claudia; Costa, Priscilla; Nunes, Maria A.; Reis, Gisele; Sauer, Mariana M.; Nakagawa, Zelinda; Ferrari, Lilian; Amaral, Ana P.; Milani, Karine] Univ Sao Paulo, Sao Paulo Cohort, Sao Paulo, Brazil.
   [Karim, Salim S. Abdool; Karim, Quarraisha Abdool; Ndungu, Thumbi; Majola, Nelisile; Samsunder, Natasha] Univ Kwazulu Natal, CAPRISA, Durban, South Africa.
   [Naniche, Denise] Barcelona Ctr Int Hlth Res, GAMA Study, Barcelona, Spain.
   [Mandomando, Inacio; Macete, Eusebio, V] Fundacao Manhica, SABES Cohort, Manhica, Mozambique.
   [Sanchez, Jorge; Lama, Javier] Asociac Civil Impacta Salud & Educ IMPACTA, SABES Cohort, Lima, Peru.
   [Duerr, Ann] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Capobianchi, Maria R.] Natl Inst Infect Dis L Spallanzani, Rome, Italy.
   [Suligoi, Barbara] Ist Super Sanita, Rome, Italy.
   [Stramer, Susan] Amer Red Cross, Washington, DC 20006 USA.
   [Williamson, Phillip] Vitalant Res Inst, Creat Testing Solut, San Francisco, CA USA.
   [Vermeulen, Marion] South African Natl Blood Serv, Pinetown, South Africa.
   [Sabino, Ester] Hemoctr Sao Paolo, Sao Paulo, Brazil.
RP Grebe, E (corresponding author), Stellenbosch Univ, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa.; Grebe, E (corresponding author), Vitalant Res Inst, San Francisco, CA 94118 USA.; Grebe, E (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Murphy, G (corresponding author), Publ Hlth England, London, England.
EM Gary.Murphy@phe.gov.uk; EGrebe@vitalant.org
RI SULIGOI, BARBARA/O-6490-2019; Facente, Shelley/M-1147-2019; Little,
   Susan/AAA-6116-2019; Karim, Salim Abdool/AAE-7118-2019; Mandomando,
   Inacio/ABD-8007-2020; Sabino, Ester Cerdeira/F-7750-2010
OI Mandomando, Inacio/0000-0002-1078-2187; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Keating, Sheila/0000-0002-8324-3694;
   Grebe, Eduard/0000-0001-7046-7245; Loeb Stanga,
   Lisa/0000-0001-7471-5381; Deeks, Steven/0000-0001-6371-747X; Bukulu
   Sempa, Joseph/0000-0003-1062-0417
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1115799, OPP1062806, OPP1017716]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R34 MH096606]; South African
   Department of Science and Technology; National Research Foundation;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01 AI071713, R01 HD074511, P30
   AI027763, R24 AI067039, U01 AI043638, P01 AI074621, R24 AI106039]; HIV
   Prevention Trials Network (HPTN) - NIAID; National Institute on Drug
   AbuseUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA); Office of AIDS Research, of the NIH, DHHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [UM1 AI068613, R01 AI095068]; California HIV-1 Research Program
   [RN07-SD-702]; Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO]; Sao Paulo City Health Department
   [2004-0.168.922-7]; IAVI; USAIDUnited States Agency for International
   Development (USAID); National Institutes of Child Health and Human
   Development (NICH/HD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD);
   National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH); EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [R01HD074511] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, UM1AI068613, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, R24AI067039, UM1AI068613, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, R24AI106039,
   P30AI027763, R24AI106039, UM1AI068613, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, R01AI095068, UM1AI068613, P30AI027763, P30AI027763,
   R01AI095068, P30AI027763, P30AI027763, R01AI095068, R24AI106039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, R24AI106039, P30AI027763, R24AI067039] Funding
   Source: NIH RePORTER
FX The Consortium for the Evaluation and Performance of HIV Incidence
   Assays (CEPHIA) was supported by grants from the Bill and Melinda Gates
   Foundation (OPP1017716 to G.M., OPP1062806 to C.D.P. and OPP1115799).
   Additional support for analysis was provided by a grant from the US
   National Institutes of Health (R34 MH096606 to C.D.P.) and by the South
   African Department of Science and Technology and the National Research
   Foundation. Specimen and data collection were funded in part by grants
   from the NIH (P01 AI071713, R01 HD074511, P30 AI027763, R24 AI067039,
   U01 AI043638, P01 AI074621 and R24 AI106039); the HIV Prevention Trials
   Network (HPTN) sponsored by the NIAID, National Institutes of Child
   Health and Human Development (NICH/HD), National Institute on Drug
   Abuse, National Institute of Mental Health, and Office of AIDS Research,
   of the NIH, DHHS (UM1 AI068613 and R01 AI095068); the California HIV-1
   Research Program (RN07-SD-702); Brazilian Program for STD and AIDS,
   Ministry of Health (914/BRA/3014-UNESCO); and the Sao Paulo City Health
   Department (2004-0.168.922-7). Selected samples from International AIDS
   Vaccine Initiative (IAVI)-supported cohorts were funded by IAVI with the
   generous support of USAID and other donors; a full list of IAVI donors
   is available at www.iavi.org.S.N.F.is affiliated to Facente Consulting.
   Facente Consulting provided support in the form of salary for author S.
   N. F. but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific role of this author is articulated in the `
   author contributions' section. N. P. is Executive Director of Data First
   Consulting, Inc., which received salary support for this project from
   the Bill and Melinda Gates Foundation through grant OPP1115799 to FIND
   (Geneva, Switzerland). The funder did not have any additional role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific role of this author is
   articulated in the ` author contributions' section. The funders provided
   support in the form of salaries for authors J. B. S., A. W., M. P. B.,
   J. H., D. H., S. M. K., K. M., C. D. P., G. M. and E. G. but did not
   have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
CR BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Duke Human Vaccine Institute, 2019, EQAPOL LIM ANT LAG A
   Duong YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114947
   Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
   Gao ZY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161183
   Grebe E, 2018, BIORXIV
   Grebe E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203638
   Grebe E, 2017, JAIDS-J ACQ IMM DEF, V76, P547, DOI [10.1097/qai.0000000000001537, 10.1097/QAI.0000000000001537]
   Human Sciences Research Council (HSRC), 2018, 5 S AFR NAT HIV PREV
   Kassanjee R, 2016, AIDS, V30, P2361, DOI 10.1097/QAD.0000000000001209
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/aid.2013.0113, 10.1089/AID.2013.0113]
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Mahiane GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044377
   Maxim Biomedical, 2013, MAXIM BIOMEDICAL MAX
   McDougal JS, 2006, AIDS RES HUM RETROV, V22, P945, DOI 10.1089/aid.2006.22.945
   McWalter TA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007368
   Ministry of Health of Malawi, 2018, MAL POP BAS HIV IMP
   Ministry of Health Zambia, 2019, ZAMB POP BAS HIV IMP
   Murphy G, 2017, EPIDEMIOL INFECT, V145, P925, DOI 10.1017/S0950268816002910
   Schlusser KE, 2017, AIDS RES HUM RETROV, V33, P555, DOI 10.1089/aid.2016.0245
   Schlusser KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172283
   Sedia Biosciences Corporation, 2016, SED HIV 1 LAG AV EIA
   WHO, 2017, HIV DRUG RES REP 201
NR 25
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2019
VL 14
IS 7
AR e0220345
DI 10.1371/journal.pone.0220345
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IW4WC
UT WOS:000484979500030
PM 31348809
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Zanella, LGFABD
   Moreira, CHV
   Buccheri, R
   Diniz, GBF
   Castineiras, ACP
   Costa, PR
   Dias, JZC
   Marmorato, MP
   Song, ATW
   Maestri, A
   Borges, IC
   Joelsons, D
   Cerqueira, NB
   Souza, NCSE
   Claro, IM
   Sabino, EC
   Levi, JE
   Avelino-Silva, VI
   Ho, YL
AF Kallas, Esper G.
   D'Elia Zanella, Luiz Gonzaga F. A. B.
   Moreira, Carlos Henrique, V
   Buccheri, Renata
   Diniz, Gabriela B. F.
   Castineiras, Anna Carla P.
   Costa, Priscilla R.
   Dias, Juliana Z. C.
   Marmorato, Mariana P.
   Song, Alice T. W.
   Maestri, Alvino
   Borges, Igor C.
   Joelsons, Daniel
   Cerqueira, Natalia B.
   Santiago e Souza, Nathalia C.
   Claro, Ingra Morales
   Sabino, Ester C.
   Levi, Jose Eduardo
   Avelino-Silva, Vivian, I
   Ho, Yeh-Li
TI Predictors of mortality in patients with yellow fever: an observational
   cohort study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS OUTBREAK; ZIKA VIRUS; PCR; RESURGENCE; SPREAD; ANGOLA
AB Background Yellow fever virus infection results in death in around 30% of symptomatic individuals. The aim of this study was to identify predictors of death measured at hospital admission in a cohort of patients admitted to hospital during the 2018 outbreak of yellow fever in the outskirts of Sao Paulo city, Brazil.
   Methods In this observational cohort study, we enrolled patients with yellow fever virus from two hospitals in Sao Paolo-the Hospital das Clinicas, University of Sao Paulo and the Infectious Diseases Institute "Emilio Ribas". Patients older than 18 years admitted to hospital with fever or myalgia, headache, arthralgia, oedema, rash, or conjunctivitis were consecutively screened for inclusion in the present study. Consenting patients were included if they had travelled to geographical areas in which yellow fever virus cases had been previously confirmed. Yellow fever infection was confirmed by real-time PCR in blood collected at admission or tissues at autopsy. We sequenced the complete genomes of yellow fever virus from infected individuals and evaluated demographic, clinical, and laboratory findings at admission and investigated whether any of these measurements correlated with patient outcome (death).
   Findings Between Jan 11, 2018, and May 10, 2018, 118 patients with suspected yellow fever were admitted to Hospital das Clinicas, and 113 patients with suspected yellow fever were admitted to Infectious Diseases Institute "Emilio Ribas". 95 patients with suspected yellow fever were included in the study, and 136 patients were excluded. Three (3%) of 95 patients with suspected yellow fever who were included in the study were excluded because they received a different diagnosis, and 16 patients with undetectable yellow fever virus RNA were excluded. Therefore, 76 patients with confirmed yellow fever virus infection, based on detectable yellow fever virus RNA in blood (74 patients) or yellow fever virus confirmed only at the autopsy report (two patients), were included in our analysis. 27 (36%) of 76 patients died during the 60 day period after hospital admission. We generated 14 complete yellow fever virus genomes from the first 15 viral load-detectable samples. The genomes belonged to a single monophyletic clade of the South America I genotype, sub-genotype E. Older age, male sex, higher leukocyte and neutrophil counts, higher alanine aminotransferase, aspartate transaminase (AST), bilirubin, and creatinine, prolonged prothrombin time, and higher yellow fever virus RNA plasma viral load were associated with higher mortality. In a multivariate regression model, older age, elevated neutrophil count, increased AST, and higher viral load remained independently associated with death. All 11 (100%) patients with neutrophil counts of 4000 cells per mL or greater and viral loads of 5.1 log(10) copies/mL or greater died (95% CI 72-100), compared with only three (11%) of 27 (95% CI 2-29) among patients with neutrophil counts of less than 4000 cells per mL and viral loads of less than 5.1 log(10) copies/mL.
   Interpretation We identified clinical and laboratory predictors of mortality at hospital admission that could aid in the care of patients with yellow fever virus. Identification of these prognostic markers in patients could help clinicians prioritise admission to the intensive care unit, as patients often deteriorate rapidly. Moreover, resource allocation could be improved to prioritise key laboratory examinations that might be more useful in determining whether a patient could have a better outcome. Our findings support the important role of the virus in disease pathogenesis, suggesting that an effective antiviral could alter the clinical course for patients with the most severe forms of yellow fever.
C1 [Kallas, Esper G.; D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Costa, Priscilla R.; Dias, Juliana Z. C.; Marmorato, Mariana P.; Song, Alice T. W.; Maestri, Alvino; Borges, Igor C.; Joelsons, Daniel; Cerqueira, Natalia B.; Claro, Ingra Morales; Sabino, Ester C.; Avelino-Silva, Vivian, I; Ho, Yeh-Li] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Buccheri, Renata; Diniz, Gabriela B. F.; Castineiras, Anna Carla P.] Infect Dis Inst Emilio Ribas, Sao Paulo, Brazil.
   [Santiago e Souza, Nathalia C.; Levi, Jose Eduardo] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Marmorato, Mariana/V-5375-2018; Avelino-Silva, Vivian I/L-2640-2013;
   Castineiras, Anna/AAB-6754-2019; Sabino, Ester Cerdeira/F-7750-2010;
   Borges, Igor Carmo/AAG-8531-2019
OI Marmorato, Mariana/0000-0002-0644-0862; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Castineiras, Anna/0000-0003-2503-9414; Sabino,
   Ester Cerdeira/0000-0003-2623-5126; Carmo Borges,
   Igor/0000-0003-2749-0313; Kallas, Esper/0000-0003-2026-6925; Moreira,
   Carlos Henrique Valente/0000-0002-4187-5482; Barros D'Elia Zanella, Luiz
   Gonzaga Francisco de Assis/0000-0002-3166-5633
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX Sao Paulo Research Foundation (FAPESP).
CR Aguiar BS, 2018, INT J INFECT DIS, V70, P20, DOI 10.1016/j.ijid.2018.02.007
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P442
   Bae HG, 2003, J VIROL METHODS, V110, P185, DOI 10.1016/S0166-0934(03)00129-0
   BEEUWKES Henry, 1936, Transactions of the Royal Society of Tropical Medicine and Hygiene, V30, P61, DOI 10.1016/S0035-9203(36)90014-7
   Blake LE, 2014, MBIO, V5, DOI 10.1128/mBio.01253-14
   de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Engelmann F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003295
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Fernandes-Monteiro AG, 2015, HUM VACC IMMUNOTHER, V11, P1865, DOI 10.4161/21645515.2014.990854
   Fischer C, 2017, EMERG INFECT DIS, V23, P1867, DOI 10.3201/eid2311.171131
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   Grobbelaar AA, 2016, EMERG INFECT DIS, V22, P1854, DOI 10.3201/eid2210.160818
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Hughes HR, 2018, EMERG INFECT DIS, V24, P1598, DOI 10.3201/eid2408.180588
   Julander JG, 2014, ANTIVIR RES, V103, P32, DOI 10.1016/j.antiviral.2013.12.011
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Massad E, 2018, EPIDEMIOL INFECT, V146, P1219, DOI [10.1017/S0950268818001334, 10.1017/s0950268818001334]
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   Nunes PCG, 2018, VIRUSES, V10, pE236
   Plotkin SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay130
   Quaresma JAS, 2013, REV MED VIROL, V23, P305, DOI 10.1002/rmv.1752
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rowe EK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002777
   Secretary of Health State of Sao Paulo, 2018, B EP FEBR AM
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Song ATW, 2019, HEPATOLOGY, V69, P1349, DOI 10.1002/hep.30273
   ter Meulen J, 2004, J INFECT DIS, V190, P1821, DOI 10.1086/425016
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Wilder-Smith A, 2017, J TRAVEL MED, V24, P1
NR 35
TC 13
Z9 13
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2019
VL 19
IS 7
BP 750
EP 758
DI 10.1016/S1473-3099(19)30125-2
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA IF1DQ
UT WOS:000472818900035
PM 31104909
DA 2020-11-26
ER

PT J
AU Pilcher, CD
   Porco, TC
   Facente, SN
   Grebe, E
   Delaney, KP
   Masciotra, S
   Kassanjee, R
   Busch, MP
   Murphy, G
   Owen, SM
   Welte, A
   Matten, D
   Brand, H
   Chibawara, T
   McKinney, E
   Hall, J
   Busch, M
   Keating, S
   Lebedeva, M
   Hampton, D
   Pilcher, C
   Facente, S
   Marson, K
   Laeyendecker, O
   Quinn, T
   Burns, D
   Little, S
   Sands, A
   Hallett, T
   Owen, SM
   Parekh, B
   Sexton, C
   Price, M
   Kamali, A
   Loeb, L
   Martin, J
   Deeks, SG
   Hoh, R
   Bartolomei, Z
   Cerqueira, N
   Santos, B
   Zabtoski, K
   Lira, RDA
   Sperhacke, RD
   Motta, LR
   Paganella, M
   Kallas, E
   Tomiyama, H
   Tomiyama, C
   Costa, P
   Nunes, MA
   Reis, G
   Sauer, MM
   Nakagawa, Z
   Ferrari, L
   Amaral, AP
   Milani, K
   Karim, SSA
   Karim, QA
   Ndungu, T
   Majola, N
   Samsunder, N
   Naniche, D
   Mandomando, I
   Macete, EV
   Sanchez, J
   Lama, J
   Duerr, A
   Capobianchi, MR
   Suligoi, B
   Stramer, S
   Williamson, P
   Vermeulen, M
   Sabino, E
AF Pilcher, Christopher D.
   Porco, Travis C.
   Facente, Shelley N.
   Grebe, Eduard
   Delaney, Kevin P.
   Masciotra, Silvina
   Kassanjee, Reshma
   Busch, Michael P.
   Murphy, Gary
   Owen, S. Michele
   Welte, Alex
   Matten, David
   Brand, Hilmarie
   Chibawara, Trust
   McKinney, Elaine
   Hall, Jake
   Busch, Michael
   Keating, Sheila
   Lebedeva, Mila
   Hampton, Dylan
   Pilcher, Christopher
   Facente, Shelley
   Marson, Kara
   Laeyendecker, Oliver
   Quinn, Thomas
   Burns, David
   Little, Susan
   Sands, Anita
   Hallett, Tim
   Owen, Sherry Michele
   Parekh, Bharat
   Sexton, Connie
   Price, Matthew
   Kamali, Anatoli
   Loeb, Lisa
   Martin, Jeffrey
   Deeks, Steven G.
   Hoh, Rebecca
   Bartolomei, Zelinda
   Cerqueira, Natalia
   Santos, Breno
   Zabtoski, Kellin
   Alves Lira, Rita de Cassia
   Sperhacke, Rosa Dea
   Motta, Leonardo R.
   Paganella, Machline
   Kallas, Esper
   Tomiyama, Helena
   Tomiyama, Claudia
   Costa, Priscilla
   Nunes, Maria A.
   Reis, Gisele
   Sauer, Mariana M.
   Nakagawa, Zelinda
   Ferrari, Lilian
   Amaral, Ana P.
   Milani, Karine
   Karim, Salim S. Abdool
   Karim, Quarraisha Abdool
   Ndungu, Thumbi
   Majola, Nelisile
   Samsunder, Natasha
   Naniche, Denise
   Mandomando, Inicio
   Macete, Eusebio, V
   Sanchez, Jorge
   Lama, Javier
   Duerr, Ann
   Capobianchi, Maria R.
   Suligoi, Barbara
   Stramer, Susan
   Williamson, Phillip
   Vermeulen, Marion
   Sabino, Ester
CA Consortium Evaluation Performance
TI A generalizable method for estimating duration of HIV infections using
   clinical testing history and HIV test results
SO AIDS
LA English
DT Article
DE duration of infection; HIV disease staging; HIV infection dating; HIV
   staging; HIV testing
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; INITIATION;
   SEROCONVERSION; DIAGNOSIS; SERVICES; OUTCOMES; ADULTS
AB Objective: To determine the precision of new and established methods for estimating duration of HIV infection.
   Design: A retrospective analysis of HIV testing results from serial samples in commercially available panels, taking advantage of extensive testing previously conducted on 53 seroconverters.
   Methods: We initially investigated four methods for estimating infection timing: method 1, 'Fiebig stages' based on test results from a single specimen; method 2, an updated '4th gen' method similar to Fiebig stages but using antigen/antibody tests in place of the p24 antigen test; method 3, modeling of 'viral ramp-up' dynamics using quantitative HIV-1 viral load data from antibody-negative specimens; and method 4, using detailed clinical testing history to define a plausible interval and best estimate of infection time. We then investigated a 'two-step method' using data from both methods 3 and 4, allowing for test results to have come from specimens collected on different days.
   Results: Fiebig and '4th gen' staging method estimates of time since detectable viremia had similar and modest correlation with observed data. Correlation of estimates from both new methods (3 and 4), and from a combination of these two ('two-step method') was markedly improved and variability significantly reduced when compared with Fiebig estimates on the same specimens.
   Conclusion: The new 'two-step' method more accurately estimates timing of infection and is intended to be generalizable to more situations in clinical medicine, research, and surveillance than previous methods. An online tool is now available that enables researchers/clinicians to input data related to method 4, and generate estimated dates of detectable infection. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Pilcher, Christopher D.; Porco, Travis C.; Facente, Shelley N.; Facente, Shelley; Marson, Kara] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Facente, Shelley N.; Grebe, Eduard; Busch, Michael P.; Busch, Michael; Keating, Sheila; Lebedeva, Mila; Hampton, Dylan] Vitalant Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
   [Facente, Shelley N.] Facente Consulting, Richmond, CA USA.
   [Grebe, Eduard; Kassanjee, Reshma; Welte, Alex] Stellenbosch Univ, South African DST NRF Ctr Excellence Epidemiol Mo, Stellenbosch, South Africa.
   [Delaney, Kevin P.; Masciotra, Silvina; Owen, S. Michele; Owen, Sherry Michele; Parekh, Bharat; Sexton, Connie] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Kassanjee, Reshma] Univ Cape Town, Dept Stat Sci, Rondebosch, South Africa.
   [Murphy, Gary; McKinney, Elaine; Hall, Jake] Publ Hlth England, London, England.
   [Grebe, Eduard; Kassanjee, Reshma; Welte, Alex; Matten, David; Brand, Hilmarie; Chibawara, Trust] South African Ctr Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Laeyendecker, Oliver; Quinn, Thomas; Burns, David] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Pilcher, Christopher; Little, Susan] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Sands, Anita] WHO, Geneva, Switzerland.
   [Hallett, Tim] Imperial Coll London, London, England.
   [Price, Matthew; Kamali, Anatoli] Int AIDS Vaccine Initiat, New York, NY USA.
   [Loeb, Lisa] Univ Calif San Francisco, Opt Study, San Francisco, CA 94143 USA.
   [Martin, Jeffrey; Deeks, Steven G.; Hoh, Rebecca] Univ Calif San Francisco, SCOPE Study, San Francisco, CA 94143 USA.
   [Bartolomei, Zelinda] Univ Sao Paulo, AMPLIAR Cohort, Sao Paulo, Brazil.
   [Santos, Breno; Zabtoski, Kellin; Alves Lira, Rita de Cassia] Grp Hosp Conceicao, AMPLIAR Cohort, Porto Alegre, RS, Brazil.
   [Sperhacke, Rosa Dea; Motta, Leonardo R.; Paganella, Machline] Univ Caxias do Sul, AMPLIAR Cohort, Caxias Do Sul, RS, Brazil.
   [Cerqueira, Natalia; Kallas, Esper; Tomiyama, Helena; Tomiyama, Claudia; Costa, Priscilla; Nunes, Maria A.; Reis, Gisele; Sauer, Mariana M.; Nakagawa, Zelinda; Ferrari, Lilian; Amaral, Ana P.; Milani, Karine] Univ Sao Paulo, Sao Paulo Cohort, Sao Paulo, Brazil.
   [Karim, Salim S. Abdool; Karim, Quarraisha Abdool; Ndungu, Thumbi; Majola, Nelisile; Samsunder, Natasha] Univ Kwazulu Natal, CAPRISA, Durban, South Africa.
   [Naniche, Denise] Barcelona Ctr Int Hlth Res, GAMA Study, Barcelona, Spain.
   [Mandomando, Inicio; Macete, Eusebio, V] Fundacao Manhica, GAMA Study, Manhica, Mozambique.
   [Sanchez, Jorge; Lama, Javier] Asociac Civil Impacta Salud & Educ IMPACTA, SABES Cohort, Manhica, Mozambique.
   [Duerr, Ann] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Capobianchi, Maria R.] Natl Inst Infect Dis L Spallanzani, Rome, Italy.
   [Suligoi, Barbara] Ist Super Sanita, Rome, Italy.
   [Stramer, Susan] Amer Red Cross, Washington, DC 20006 USA.
   [Williamson, Phillip] Creat Testing Solut, Blood Syst Res Inst, Tempe, AZ USA.
   [Vermeulen, Marion] South African Natl Blood Serv, Kimberley, South Africa.
   [Sabino, Ester] Hemoctr Sao Paolo, Sao Paulo, Brazil.
RP Facente, SN (corresponding author), Vitalant Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
EM sfacente@vitalant.org
RI SULIGOI, BARBARA/O-6490-2019; Facente, Shelley/M-1147-2019; Little,
   Susan/AAA-6116-2019; Karim, Salim Abdool/AAE-7118-2019; Sabino, Ester
   Cerdeira/F-7750-2010
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Grebe,
   Eduard/0000-0001-7046-7245
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1017716, OPP1062806, OPP1115799]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R34 MH096606]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH
   RePORTER
FX The Consortium for the Evaluation and Performance of HIV Incidence
   Assays (CEPHIA) constitutes: AlexWelte, Eduard Grebe, Reshma Kassanjee,
   David Matten, Hilmarie Brand, Trust Chibawara (South African Centre for
   Epidemiological Modelling and Analysis); Gary Murphy, Elaine McKinney,
   Jake Hall (Public Health England); Michael Busch, Sheila Keating, Mila
   Lebedeva, Dylan Hampton (Vitalant Research Institute); Christopher
   Pilcher, Shelley Facente, Kara Marson; (University of California, San
   Francisco); Oliver Laeyendecker, Thomas Quinn, David Burns (National
   Institutes of Health); Susan Little (University of California, San
   Diego); Anita Sands (World Health Organization); Tim Hallett (Imperial
   College London); Sherry Michele Owen, Bharat Parekh, Connie Sexton
   (Centers for Disease Control and Prevention); Matthew Price, Anatoli
   Kamali (International AIDS Vaccine Initiative); Lisa Loeb (The Options
   Study - University of California, San Francisco); Jeffrey Martin, Steven
   G Deeks, Rebecca Hoh (The SCOPE Study - University of California, San
   Francisco); Zelinda Bartolomei, Natalia Cerqueira (The AMPLIAR Cohort -
   University of Sao Paulo); Breno Santos, Kellin Zabtoski, Rita de Cassia
   Alves Lira (The AMPLIAR Cohort - Grupo Hospital Conceicao); Rosa Dea
   Sperhacke, Leonardo R Motta, Machline Paganella (The AMPLIAR Cohort -
   Universidade Caxias Do Sul); Esper Kallas, Helena Tomiyama, Claudia
   Tomiyama, Priscilla Costa, Maria A Nunes, Gisele Reis, Mariana M Sauer,
   Natalia Cerqueira, Zelinda Nakagawa, Lilian Ferrari, Ana P Amaral,
   Karine Milani (The Sao Paulo Cohort - University of Sao Paulo, Brazil);
   Salim S Abdool Karim, Quarraisha Abdool Karim, Thumbi Ndungu, Nelisile
   Majola, Natasha Samsunder (CAPRISA, University of Kwazulu-Natal); Denise
   Naniche (The GAMA Study - Barcelona Centre for International Health
   Research); Inacio Mandomando, Eusebio V Macete (The GAMA Study -
   Fundacao Manhica); Jorge Sanchez, Javier Lama (SABES Cohort Asociacion
   Civil Impacta Salud y Educacion (IMPACTA)); Ann Duerr (The Fred
   Hutchinson Cancer Research Center); Maria R. Capobianchi (National
   Institute for Infectious Diseases 'L. Spallanzani', Rome); Barbara
   Suligoi (Istituto Superiore di Sanita, Rome); Susan Stramer (American
   Red Cross); Phillip Williamson (Creative Testing Solutions/Blood Systems
   Research Institute); Marion Vermeulen (South African National Blood
   Service); and Ester Sabino (Hemocentro do Sao Paolo). CEPHIA was
   supported by grants from the Bill and Melinda Gates Foundation
   (OPP1017716, OPP1062806 and OPP1115799). Additional support for analysis
   was provided by a grant from the US National Institutes of Health (R34
   MH096606).
CR Ananworanich J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-56
   Cohen MS, 2010, J INFECT DIS, V202, pS270, DOI 10.1086/655651
   Cohen SE, 2019, LANCET HIV, V6, pE43, DOI 10.1016/S2352-3018(18)30288-1
   da Motta LR, 2013, J VIROL METHODS, V194, P132, DOI 10.1016/j.jviromet.2013.08.016
   Delaney KP, 2017, SEX TRANSM DIS, V44, P747, DOI 10.1097/OLQ.0000000000000736
   Delaney KP, 2017, CLIN INFECT DIS, V64, P53, DOI 10.1093/cid/ciw666
   Donnell D, 2017, AIDS, V31, P2007, DOI [10.1097/qad.0000000000001577, 10.1097/QAD.0000000000001577]
   Eller L, 2013, C RETR OPP INF CROI
   Fidler S, 2013, NEW ENGL J MED, V368, P207, DOI 10.1056/NEJMoa1110039
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Grebe E., 2018, BIORXIV, DOI [10.1101/323808, DOI 10.1101/323808]
   Green N, 2017, AIDS, V31, P287, DOI 10.1097/QAD.0000000000001308
   Grinsztejn B, 2014, LANCET INFECT DIS, V14, P281, DOI 10.1016/S1473-3099(13)70692-3
   Henrich TJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002417
   Herout S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152910
   Kuhar DT, 2013, INFECT CONT HOSP EP, V34, P875, DOI 10.1086/672271
   Li JZ, 2016, AIDS, V30, P343, DOI 10.1097/QAD.0000000000000953
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Masciotra S, 2013, J CLIN VIROL, V58, pE54, DOI 10.1016/j.jcv.2013.07.002
   Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
   Moyer VA, 2013, ANN INTERN MED, V159, P349, DOI 10.7326/0003-4819-159-5-201309030-00672
   Murphy G, 2017, EPIDEMIOL INFECT, V145, P925, DOI 10.1017/S0950268816002910
   Owen SM, 2008, J CLIN MICROBIOL, V46, P1588, DOI 10.1128/JCM.02196-07
   Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission, 2018, REC US ANT DRUGS TRA
   Perry KR, 2008, TRANSFUSION MED, V18, P228, DOI 10.1111/j.1365-3148.2008.00874.x
   Pilcher CD, 2017, JAIDS-J ACQ IMM DEF, V74, P44, DOI 10.1097/QAI.0000000000001134
   Priddy FH, 2007, JAIDS-J ACQ IMM DEF, V44, P196, DOI 10.1097/01.qai.0000254323.86897.36
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rutstein SE, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21579
   Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809
   UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2011, US ASS REC INF EST H
NR 31
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2019
VL 33
IS 7
BP 1231
EP 1240
DI 10.1097/QAD.0000000000002190
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA IQ4CS
UT WOS:000480699300013
PM 30870196
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Delatorre, E
   de Abreu, FVS
   Ribeiro, IP
   Gomez, MM
   dos Santos, AAC
   Ferreira-de-Brito, A
   Neves, MSAS
   Bonelly, I
   de Miranda, RM
   Furtado, ND
   Raphael, LMS
   da Silva, LDF
   de Castro, MG
   Ramos, DG
   Romano, APM
   Kallas, EG
   Vicente, ACP
   Bello, G
   Lourenco-de-Oliveira, R
   Bonaldo, MC
AF Delatorre, Edson
   Santos de Abreu, Filipe Vieira
   Ribeiro, Ieda Pereira
   Gomez, Mariela Martinez
   Cunha dos Santos, Alexandre Araujo
   Ferreira-de-Brito, Anielly
   Alberto Santos Neves, Maycon Sebastiao
   Bonelly, Iule
   de Miranda, Rafaella Moraes
   Furtado, Nathalia Dias
   Souza Raphael, Lidiane Menezes
   Fernandes da Silva, Lucileis de Fatima
   de Castro, Marcia Goncalves
   Ramos, Daniel Garkauskas
   Martins Romano, Alessandro Pecego
   Kallas, Esper Georges
   Paulo Vicente, Ana Carolina
   Bello, Gonzalo
   Lourenco-de-Oliveira, Ricardo
   Bonaldo, Myrna Cristina
TI Distinct YFV Lineages Co-circulated in the Central-Western and
   Southeastern Brazilian Regions From 2015 to 2018
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE yellow fever virus; Brazilian outbreak; lineages; amino acid changes;
   phylogeography
ID YELLOW-FEVER; VIRUS; EVOLUTIONARY; PERFORMANCE
AB The current outbreak of yellow fever virus (YFV) that is afflicting Brazil since the end of 2016 probably originated from a re-introduction of YFV from endemic areas into the non-endemic Southeastern Brazil. However, the lack of genomic sequences from endemic regions hinders the tracking of YFV's dissemination routes. We assessed the origin and spread of the ongoing YFV Brazilian outbreak analyzing a new set of YFV strains infecting humans, non-human primates (NHPs) and mosquitoes sampled across five Brazilian states from endemic and non-endemic regions between 2015 and 2018. We found two YFV sub-clade 1E lineages circulating in NHP from Goias state (GO), resulting from independent viral introductions into the Araguaia tributary river basin: while one strain from 2017 clustered intermingled with Venezuelan YFV strains from 2000, the other YFV strains sampled in 2015 and 2017 clustered with sequences of the current YFV outbreak in the Brazilian Southeastern region (named YFV2015-2018 lineage), displaying the same molecular signature associated to the current YFV outbreak. After its introduction in GO at around mid-2014, the YFV2015-2018 lineage followed two paths of dissemination outside GO, originating two major YFV sub-lineages: (1) the YFVMG/ES/RJ sub-lineage spread sequentially from the eastern area of Minas Gerais state to Espirito Santo and then to Rio de Janeiro states, following the Southeast Atlantic basin; (2) the YFVMG/SP sub-lineage spread from the southwestern area of Minas Gerais to the metropolitan region of Sao Paulo state, following the Parana basin. These results indicate the ongoing YFV outbreak in Southeastern Brazil originated from a dissemination event from GO almost 2 years before its recognition at the end of 2016. From GO this lineage was introduced in Minas Gerais state at least two times, originating two sub-lineages that followed different routes toward densely populated areas. The spread of YFV outside endemic regions for at least 4 years stresses the imperative importance of the continuous monitoring of YFV to aid decision-making for effective control policies aiming the increase of vaccination coverage to avoid the YFV transmission in densely populated urban centers.
C1 [Delatorre, Edson; Paulo Vicente, Ana Carolina] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microorganismos, Rio De Janeiro, Brazil.
   [Santos de Abreu, Filipe Vieira; Ferreira-de-Brito, Anielly; Alberto Santos Neves, Maycon Sebastiao; Bonelly, Iule; de Miranda, Rafaella Moraes; de Castro, Marcia Goncalves; Lourenco-de-Oliveira, Ricardo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, Rio De Janeiro, Brazil.
   [Santos de Abreu, Filipe Vieira] Inst Fed Norte Minas Gerais, Salinas, Brazil.
   [Ribeiro, Ieda Pereira; Gomez, Mariela Martinez; Cunha dos Santos, Alexandre Araujo; Furtado, Nathalia Dias; Souza Raphael, Lidiane Menezes; Bonaldo, Myrna Cristina] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Rio De Janeiro, Brazil.
   [Gomez, Mariela Martinez] Inst Invest Biol Clemente Estable, Div Biol Mol & Genet, Dept Biol & Mol, Montevideo, Uruguay.
   [Fernandes da Silva, Lucileis de Fatima] Secretaria Saude Goias, Lab Cent Saude Publ Dr Giovanni Cysneiros, Goiania, Go, Brazil.
   [Ramos, Daniel Garkauskas; Martins Romano, Alessandro Pecego] Minist Saude, Coordenacao Geral Vigilancia Doencas Transmissive, Dept Vigilancia Doencas Transmissiveis, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Dept Mol Infecciosas, Hosp Clin HCFMUSR, Fac Med, Sao Paulo, Brazil.
   [Bello, Gonzalo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
RP Delatorre, E (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microorganismos, Rio De Janeiro, Brazil.
EM edsonod@ioc.fiocruz.br
RI Delatorre, Edson/J-8330-2015
OI Delatorre, Edson/0000-0002-5746-0820; Ribeiro, Ivonizete
   Pires/0000-0003-0737-5430; Garkauskas Ramos, Daniel/0000-0002-7404-2209
FU "Programa Nacional de Pos-Doutorado (PNPD)" by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) [001];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; Conselho Nacional Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq) [309577/2013-6, 312446/2018-7]; Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   [E-26/203.064/2016]; Institut Pasteur, Transversal Research Program
   (PTR) [528]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [COFECUB 799-14, AUXPE 1731/2014]; CNPq fellowship for
   Productivity in Technological Development and Innovative Extension
   [309471/2016-8]; Preventing and Combating the Zika Virus, MCTIC/FNDCT -
   CNPq/MEC-CAPES/MS-Decit [426767/2018-7, 88881.130684/2016-01];
   INOVA-Fiocruz [VPPIS-004-FIO18]
FX ED was financed by a Postdoctoral fellowship from the "Programa Nacional
   de Pos-Doutorado (PNPD)" by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior -Brazil (CAPES) -Finance Code 001. MG and IR
   received a Postdoctoral fellowship from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) Finance
   Code 001. RL-d-O is funded by grants from Conselho Nacional
   Desenvolvimento Cientifico e Tecnologico (CNPq) (Grant Nos.
   309577/2013-6 and 312446/2018-7), Fundacao Carlos Chagas Filho de Amparo
   a Pesquisa do Estado do Rio de Janeiro (Grant E-26/203.064/2016),
   Institut Pasteur, Transversal Research Program (PTR Grant No. 528) and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Grant No.
   COFECUB 799-14, AUXPE 1731/2014). MB is a recipient of CNPq fellowship
   for Productivity in Technological Development and Innovative Extension
   (Grant 309471/2016-8) and is funded by grants from Preventing and
   Combating the Zika Virus, MCTIC/FNDCT - CNPq/MEC-CAPES/MS-Decit. (Grants
   426767/2018-7 and 88881.130684/2016-01) and INOVA-Fiocruz (Grant
   VPPIS-004-FIO18).
CR Agencia Nacional de Aguas [ANA], 2019, DIV HIDR BRAS
   Alencar J, 2018, J AM MOSQUITO CONTR, V34, P85, DOI 10.2987/18-6739.1
   Ayres DL, 2012, SYST BIOL, V61, P170, DOI 10.1093/sysbio/syr100
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Carrington CVF, 2013, INFECT GENET EVOL, V13, P198, DOI 10.1016/j.meegid.2012.08.015
   CAUSEY OR, 1950, AM J TROP MED, V30, P301
   Vasconcelos PFD, 2010, REV SAUDE PUBL, V44, P1144, DOI 10.1590/S0034-89102010005000046
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
   de Souza RP, 2010, J MED VIROL, V82, P175, DOI 10.1002/jmv.21606
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Faria NR, 2018, SCIENCE, V361, P894, DOI 10.1126/science.aat7115
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Fioravanti C, 2018, ALARME MACACOS
   Frost SDW, 2015, EPIDEMICS-NETH, V10, P88, DOI 10.1016/j.epidem.2014.09.001
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hamrick PN, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005897
   Jung L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129789
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Mir D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07873-7
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Nunes MRT, 2012, J VIROL, V86, P13263, DOI 10.1128/JVI.00565-12
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180278
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, P1, DOI 10.1590/0074-02760170361
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   de Abreu FVS, 2019, EMERG MICROBES INFEC, V8, P218, DOI 10.1080/22221751.2019.1568180
   Secretaria de Vigilancia em Saude, 2015, REEM FEBR AM SILV BR
   Secretaria de Vigilancia em Saude, 2017, EM EP FEBR AM BRAS P
   Secretaria de Vigilancia em Saude, 2019, MON PER SAZ FEBR AM
   Secretaria de Vigilancia em Saude, 2014, EP PRIM NAO HUM PNH
NR 41
TC 8
Z9 8
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD MAY 24
PY 2019
VL 10
AR 1079
DI 10.3389/fmicb.2019.01079
PG 12
WC Microbiology
SC Microbiology
GA HZ5RT
UT WOS:000468911000001
PM 31178835
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU de Sousa, FTG
   Manuli, ER
   Zanella, LG
   Ho, YL
   Netto, LC
   Marmorato, MP
   Dias, JZ
   Thomazella, MV
   Correia, CA
   Silveira, CG
   Costa, PR
   Pereira, GM
   Ferreira, MS
   Romano, CM
   Kallas, EG
   Harris, E
   Sabino, EC
AF de Sousa, Francielle Tramontini Gomes
   Manuli, Erika R.
   Zanella, Luiz G.
   Ho, Yeh-Li
   Netto, Lucas Chaves
   Marmorato, Mariana P.
   Dias, Juliana Z.
   Thomazella, Mateus V.
   Correia, Carolina A.
   Silveira, Cassia G.
   Costa, Priscilla R.
   Pereira, Geovana M.
   Ferreira, Midia S.
   Romano, Camila M.
   Kallas, Esper G.
   Harris, Eva
   Sabino, Ester C.
TI SYNDECAN-1 AS A BIOMARKER OF SEVERITY IN ACUTE YELLOW FEVER
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 20-24, 2019
CL National Harbor, MD
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Bavarian Nord, GSK, Takeda, Integrum Sci, Celgene, Vulcan, Plos Neglected Trop Dis, Elsevier
C1 [de Sousa, Francielle Tramontini Gomes; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Manuli, Erika R.; Romano, Camila M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Lab Med Invest, Fac Med, Sao Paulo, Brazil.
   [Zanella, Luiz G.; Ho, Yeh-Li; Netto, Lucas Chaves; Marmorato, Mariana P.; Dias, Juliana Z.; Thomazella, Mateus V.; Correia, Carolina A.; Silveira, Cassia G.; Costa, Priscilla R.; Pereira, Geovana M.; Ferreira, Midia S.; Kallas, Esper G.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Dept Infect & Parasit Dis, Inst Trop Med, Fac Med, Sao Paulo, Brazil.
RI Romano, Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 101
SU 5
MA 662
BP 203
EP 204
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KC7PF
UT WOS:000507364503016
DA 2020-11-26
ER

PT J
AU Grifoni, A
   Costa-Ramos, P
   Pham, J
   Tian, Y
   Rosales, SL
   Seumois, G
   Sidney, J
   de Silva, AD
   Premkumar, L
   Collins, MH
   Stone, M
   Norris, PJ
   Romero, CME
   Durbin, A
   Ricciardi, MJ
   Ledgerwood, JE
   de Silva, AM
   Busch, M
   Peters, B
   Vijayanand, P
   Harris, E
   Falconar, AK
   Kallas, E
   Weiskopf, D
   Sette, A
AF Grifoni, Alba
   Costa-Ramos, Priscilla
   Pham, John
   Tian, Yuan
   Rosales, Sandy L.
   Seumois, Gregory
   Sidney, John
   de Silva, Aruna D.
   Premkumar, Lakshmanane
   Collins, Matthew H.
   Stone, Mars
   Norris, Phillip J.
   Romero, Claudia M. E.
   Durbin, Anna
   Ricciardi, Michael J.
   Ledgerwood, Julie E.
   de Silva, Aravinda M.
   Busch, Michael
   Peters, Bjoern
   Vijayanand, Pandurangan
   Harris, Eva
   Falconar, Andrew K.
   Kallas, Esper
   Weiskopf, Daniela
   Sette, Alessandro
TI Cutting Edge: Transcriptional Profiling Reveals Multifunctional and
   Cytotoxic Antiviral Responses of Zika Virus-Specific CD8(+) T Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID DENGUE; INFECTION
AB Zika virus (ZIKV) constitutes an increasing public health problem. Previous studies have shown that CD8(+) T cells play an important role in ZIKV-specific protective immunity. We have previously defined antigenic targets of the ZIKV-specific CD8(+) T cell response in humans. In this study, we characterized the quality and phenotypes of these responses by a combined use of flow cytometry and transcriptomic methods, using PBMCs from donors deriving from different geographical locations collected in the convalescent phase of infection. We show that ZIKV-specific CD8(+) T cells are characterized by a polyfunctional IFN-gamma signature with upregulation of TNF-alpha, TNF receptors, and related activation markers, such as CD69, as well as a cytotoxic signature characterized by strong upregulation of GZMB and CRTAM. The signature is stable and not influenced by previous dengue virus exposure, geographical location, or time of sample collection postinfection. To our knowledge, this work elucidates the first in-depth characterization of human CD8(+) T cells responding to ZIKV infection.
C1 [Grifoni, Alba; Pham, John; Tian, Yuan; Rosales, Sandy L.; Seumois, Gregory; Sidney, John; de Silva, Aruna D.; Peters, Bjoern; Vijayanand, Pandurangan; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [Costa-Ramos, Priscilla; Kallas, Esper] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo 08, Sri Lanka.
   [Premkumar, Lakshmanane; Collins, Matthew H.; de Silva, Aravinda M.] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27516 USA.
   [Collins, Matthew H.] Emory Univ, Dept Med, Sch Med, Hope Clin,Emory Vaccine Ctr,Div Infect Dis, Decatur, GA 30317 USA.
   [Stone, Mars; Norris, Phillip J.; Busch, Michael] Blood Syst Res Inst, San Francisco, CA 94118 USA.
   [Romero, Claudia M. E.; Falconar, Andrew K.] Univ Norte, Barranquilla 1569, Colombia.
   [Durbin, Anna] Univ Vermont, Sch Med, Burlington, VT 05405 USA.
   [Ricciardi, Michael J.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33146 USA.
   [Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Peters, Bjoern; Sette, Alessandro] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vacdnol, Berkeley, CA 94720 USA.
   [de Silva, Aruna D.] Kotelawala Def Univ, Dept Paraclin Sci, Ratmalana, Sri Lanka.
RP Sette, A (corresponding author), 9420 Athena Circle, La Jolla, CA 92037 USA.
EM alex@lji.org
OI Seumois, Gregory/0000-0002-8164-6852; , Alba/0000-0002-2209-5966
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [HHSN272200900042C, HHSN27220140045C, U19 AI118626-01,
   HHSN268201100001I, S10OD016262]; Zika Preparedness Latin American
   Network from the European Union's Horizon 2020 research and innovation
   program [734584]; Shared Instrumentation Grant Program [S10 RR027366];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [S10OD016262]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [S10RR027366] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI118626, U19AI118626, P01AI106695, P01AI106695, U19AI118626,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, U19AI118626,
   U19AI118626, U19AI118626, P01AI106695, P01AI106695, U19AI118626,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, U19AI118626,
   P01AI106695, U19AI118626, U19AI118626, U19AI118626, U19AI118626,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, U19AI118626, U19AI118626,
   U19AI118626, P01AI106695, U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, U19AI118626, P01AI106695,
   P01AI106695, U19AI118626, P01AI106695, U19AI118626, U19AI118626,
   P01AI106695, P01AI106695, U19AI118626, U19AI118626, P01AI106695,
   P01AI106695, P01AI106695, U19AI118626, U19AI118626, U19AI118626,
   P01AI106695, U19AI118626, U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626] Funding Source: NIH RePORTER; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [S10OD016262] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) Contracts
   HHSN272200900042C and HHSN27220140045C, and Grants U19 AI118626-01 to
   A.S., HHSN268201100001I to M.B., and S10OD016262 to P.V. Further support
   was provided by the Zika Preparedness Latin American Network, which has
   received funding from the European Union's Horizon 2020 research and
   innovation program under Grant Agreement 734584. Blood donor samples
   from Puerto Rico and Florida were collected as part of the National
   Heart, Lung, and Blood Institute Recipient Epidemiology and Donor
   Evaluation Study-III. The La Jolla Institute for Allergy and
   Immunology's FACSAria II cell sorter was acquired through Shared
   Instrumentation Grant Program S10 RR027366. The Illumina HiSeq 2500
   Sequencer was purchased through NIH S10OD016262.
CR Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]
   Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237
   Hinz D, 2016, CLIN EXP ALLERGY, V46, P705, DOI 10.1111/cea.12692
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01196
   Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003
   Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4
   Lum FM, 2018, J INFECT DIS, V218, P814, DOI 10.1093/infdis/jiy225
   Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0
   Miao TZ, 2017, J EXP MED, V214, P1787, DOI 10.1084/jem.20160553
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Rosales SL, 2018, METHODS MOL BIOL, V1799, P275, DOI 10.1007/978-1-4939-7896-0_21
   Schuster M, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-23
   Takeuchi A, 2009, J IMMUNOL, V183, P4220, DOI 10.4049/jimmunol.0901248
   Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5
   Trifilo MJ, 2003, J VIROL, V77, P4004, DOI 10.1128/JVI.77.7.4004-4014.2003
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Yoshimori M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112564
NR 27
TC 18
Z9 18
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2018
VL 201
IS 12
BP 3487
EP 3491
DI 10.4049/jimmunol.1801090
PG 5
WC Immunology
SC Immunology
GA HD6EF
UT WOS:000452626700002
PM 30413672
OA Green Published, Green Accepted, Bronze
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Kallas, EG
AF Avelino-Silva, Vivian I.
   Kallas, Esper G.
TI Untold stories of the Zika virus epidemic in Brazil
SO REVIEWS IN MEDICAL VIROLOGY
LA English
DT Review
DE congenital Zika syndrome; Guillain-Barre syndrome; microcephaly;
   outbreak; Zika virus
ID GUILLAIN-BARRE-SYNDROME; FDA-APPROVED DRUG; AEDES-AEGYPTI; SEXUAL
   TRANSMISSION; DENGUE VIRUS; CULEX-QUINQUEFASCIATUS; BORNE TRANSMISSION;
   ANTIVIRAL ACTIVITY; CROSS-REACTIVITY; BIRTH-DEFECTS
AB The Zika virus infection outbreak in Brazil in 2014 to 2015 resulted in the identification of previously unknown consequences of the disease, including the notorious microcephaly among many defects in fetuses born to women infected during pregnancy. A number of individuals were involved in this remarkable discovery, from the detection of viral circulation in the country to the studies on the causal link with congenital abnormalities and the provision of awareness and social support to families affected by the disease. In this article, we review the background to this experience, describing aspects of the epidemiology, medical research, and scientific response to the Zika virus outbreak in Brazil.
C1 [Avelino-Silva, Vivian I.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Kallas,
   Esper/0000-0003-2026-6925
CR Abrao EP, 2016, VECTOR-BORNE ZOONOT, V16, P124, DOI 10.1089/vbz.2015.1804
   Acosta LJ, 2016, HUFFINGTON POST
   Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Malta JMAS, 2017, EPIDEMIOL SERV SAUDE, V26, P9, DOI [10.5123/S1679-49742017000100002, 10.5123/s1679-49742017000100002]
   [Anonymous], MON CAS OB FEBR AM B
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Avelino-Silva A.C, 2017, 53 C SOC BRAS MED TR
   Avelino-Silva VI, 2016, LANCET, V387, P2599, DOI 10.1016/S0140-6736(16)30843-1
   Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Besnard M., 2014, EURO SURVEILL, V19
   Blitvich BJ, 2015, VIRUSES-BASEL, V7, P1927, DOI 10.3390/v7041927
   Brasil Ministerio da Saude, PORT N 1 813 11 NOV
   Brasil Ministerio da Saude, 2015, PROT VIG RESP OC MIC
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Ferreira MLB, 2017, AM J TROP MED HYG, V97, P1405, DOI 10.4269/ajtmh.17-0106
   Brito MB, 2016, REV BRAS GINECOL OBS, V38, P583, DOI 10.1055/s-0036-1593411
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Carrington CVF, 2013, INFECT GENET EVOL, V13, P198, DOI 10.1016/j.meegid.2012.08.015
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Darney BG, 2017, OBSTET GYNECOL, V129, P638, DOI [10.1097/AOG.0000000000001914, 10.1097/aog.0000000000001914]
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Oliveira WK, 2017, NEW ENGL J MED, V376, P1591, DOI 10.1056/NEJMc1608612
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   Diaz-Quijano FA, 2017, ANN EPIDEMIOL, V27, P616, DOI 10.1016/j.annepidem.2017.08.009
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Diniz D, 2017, J FAM PLAN REPROD H, V43, P80, DOI 10.1136/jfprhc-2016-101678
   Diniz D, 2016, DEV WORLD BIOETH, V16, P62, DOI 10.1111/dewb.12119
   Dodson BL, 2017, PEERJ, V5, DOI 10.7717/peerj.3096
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Dyer O, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i383
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   FENTON TR, 2013, BMC PEDIATR, V13
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Ferreira AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09797-8
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franca RFO, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004760
   Frank C, 2016, EUROPEAN COMMUNICABL, V2016, P21, DOI DOI 10.2807/1560-7917
   Freour T., 2016, EURO SURVEILL, V21
   Goertz GP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005654
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Kallas EG, 2016, JAMA PEDIATR, V170, P633, DOI 10.1001/jamapediatrics.2016.0857
   Kam YW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92428
   Kenney JL, 2017, AM J TROP MED HYG, V96, P1235, DOI 10.4269/ajtmh.16-0865
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   Leite RD, 2015, EMERG INFECT DIS, V21, P1681, DOI 10.3201/eid2109.150391
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Liu ZZ, 2017, EMERG INFECT DIS, V23, P1085, DOI 10.3201/eid2307.161528
   Liuzzi G, 2016, NEW MICROBIOL, V39, P83
   Magnani DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8184
   Magnani DM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005655
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI DOI 10.1136/BMJ
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mehrjardi MZ, 2017, JPN J RADIOL, V35, P341, DOI 10.1007/s11604-017-0641-z
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Ministerio da Saude . Secretaria de Vigilancia em Saude, 2018, B EP, V11
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2016, JAMA PEDIAT
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EURO SURVEILL, V19
   Muturi EJ, 2017, TROP MED INT HEALTH, V22, P399, DOI 10.1111/tmi.12846
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Partlow J, 2016, WASHINGTON POST
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Paz-Bailey G., 2017, N ENGL J MED
   Pires de Mello CP, 2017, ANTIMICROB AGENTS CH, V62
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Quintero-Gil DC, 2014, J INFECT DEV COUNTR, V8, P876, DOI 10.3855/jidc.3978
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Rossetto EV, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759017, 10.1590/s1678-9946201759017]
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   SACRAMENTO CQ, 2017, SCI REP UK, V7
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Shiryaev SA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15467-6
   Silva AA, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0589
   Silveira M., 2015, NAO ENGRAVIDEM AGORA
   Snyder B, 2018, J MED VIROL, V90, P8, DOI 10.1002/jmv.24932
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tebas P, 2017, N ENGL J MED
   Terradas G, 2017, CURR OPIN INSECT SCI, V22, P37, DOI 10.1016/j.cois.2017.05.005
   Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Venturi G, 2016, EURO SURVEILL, V21
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
   Vinhaes ES, 2017, CLIN INFECT DIS, V64, P675, DOI 10.1093/cid/ciw770
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Xu L, 2017, P NATL ACAD SCI USA, V114, P113, DOI 10.1073/pnas.1618558114
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 131
TC 2
Z9 2
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1052-9276
EI 1099-1654
J9 REV MED VIROL
JI Rev. Med. Virol.
PD NOV
PY 2018
VL 28
IS 6
AR e2000
DI 10.1002/rmv.2000
PG 9
WC Virology
SC Virology
GA HA2NV
UT WOS:000450076600006
PM 30074287
OA Bronze
DA 2020-11-26
ER

PT J
AU Eisenberg, AL
   Patel, EU
   Packman, ZR
   Fernandez, RE
   Piwowar-Manning, E
   Hamilton, EL
   MacPhail, C
   Hughes, J
   Pettifor, A
   Kallas, EG
   Busch, MP
   Murphy, G
   Quinn, TC
   Eshleman, SH
   Laeyendecker, O
AF Eisenberg, Anna L.
   Patel, Eshan U.
   Packman, Zoe R.
   Fernandez, Reinaldo E.
   Piwowar-Manning, Estelle
   Hamilton, Erica L.
   MacPhail, Catherine
   Hughes, James
   Pettifor, Audrey
   Kallas, Esper G.
   Busch, Michael P.
   Murphy, Gary
   Quinn, Thomas C.
   Eshleman, Susan H.
   Laeyendecker, Oliver
CA HPTN 068
   CEPHIA
TI Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV
   Incidence Testing
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE dried blood spot; incidence testing; sample storage
ID ASSAYS
AB The limiting antigen (LAg)-avidity assay is a serologic assay used for cross-sectional HIV incidence testing. We compared the results obtained with the LAg-avidity assay using dried blood spot (DBS) samples stored at room temperature (18 degrees C-25 degrees C) or stored frozen at -80 degrees C with results obtained from matched plasma samples. Matched DBS and plasma samples (306 paired samples) were collected in the HIV Prevention Trials Network (HPTN) 068 trial in South Africa (2012-2014). The DBS were stored at room temperature before testing. Matched DBS and plasma samples (100 paired samples) from the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) were collected in 2016 and were stored at -80 degrees C. All DBS testing was performed in 2017. Differences in normalized optical density (ODn) were compared between matched DBS and plasma samples. For DBS samples stored at room temperature (HPTN 068), the average difference in ODn values for plasma versus DBS was 1.49 (95% confidence intervals [CI]: 1.36-1.62). In contrast, when DBS samples were stored at -80 degrees C (CEPHIA), the average difference in ODn values for plasma versus DBS was -0.22 (95% CI: -0.32 to -0.13). DBS samples stored at room temperature should not be used for cross-sectional HIV incidence testing with the LAg-avidity assay.
C1 [Eisenberg, Anna L.; Quinn, Thomas C.; Laeyendecker, Oliver] NIAID, Div Intramural Res, NIH, 855 North Wolfe St,Rangos Bldg,Room 538A, Baltimore, MD 21205 USA.
   [Patel, Eshan U.; Packman, Zoe R.; Fernandez, Reinaldo E.; Piwowar-Manning, Estelle; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Hamilton, Erica L.] FHI 360, Sci Facilitat Dept, Durham, NC USA.
   [MacPhail, Catherine] Univ Wollongong, Sch Hlth & Soc, Wollongong, NSW, Australia.
   [Hughes, James] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Hughes, James] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Pettifor, Audrey] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Pettifor, Audrey] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA.
   [Pettifor, Audrey] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Med Res Council,Wits Rural Publ Hlth & Hlth Trans, Johannesburg, South Africa.
   [Pettifor, Audrey] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
   [Busch, Michael P.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
   [Murphy, Gary] Publ Hlth England, London, England.
RP Laeyendecker, O (corresponding author), NIAID, Div Intramural Res, NIH, 855 North Wolfe St,Rangos Bldg,Room 538A, Baltimore, MD 21205 USA.
EM olaeyen1@jhmi.edu
OI Patel, Eshan/0000-0003-2174-5004; Keating, Sheila/0000-0002-8324-3694;
   Kallas, Esper/0000-0003-2026-6925
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [T32
   5T32A1007001, R01 MH110186]; National Institute of Allergy and
   Infectious Diseases of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1 AI068619, UM1A1068617, UM1AI068613]; National Institute on Drug
   Abuse of the National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [UM1 AI068619, UM1A1068617,
   UM1AI068613]; NIMH R01United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH087118]; Carolina Population Center and
   its NIH Center grant [P2C HD050924]; Division of Intramural Research,
   NIAID, NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation [OPP1017716]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P01
   AI071713, R01 HD074511, P30 AI027763, R24 AI067039]; Brazilian Ministry
   of Health, Brazilian Program for STD and AIDS [914/BRA/3014-UNESCO]; Sao
   Paulo City Health Department [2004-0.168.922-7]; National Institute of
   Mental Health of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [UM1 AI068619,
   UM1A1068617, UM1AI068613];  [2R01 A1095068-05];  [R34MH096606]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [P2CHD050924,
   P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924,
   P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924,
   P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924, P2CHD050924,
   P2CHD050924, P2CHD050924, P2CHD050924, R01HD074511, P2CHD050924,
   P2CHD050924, P2CHD050924, P2CHD050924] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   P30AI027763, UM1AI068617, UM1AI069423, P30AI027763, P30AI027763,
   P30AI027763, UM1AI068617, UM1AI069424, R24AI067039, UM1AI068619,
   P30AI027763, P30AI027763, R24AI067039, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, P30AI027763, UM1AI069423,
   UM1AI068619, P30AI027763, R01AI095068, P30AI027763, P30AI027763,
   R01AI095068, UM1AI068619, UM1AI068613, P30AI027763, UM1AI069424,
   T32AI007001, ZIAAI000361, UM1AI069423, ZIAAI000361, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI068613, UM1AI068617,
   UM1AI068613, P30AI027763, UM1AI068613, UM1AI068617, UM1AI069423,
   T32AI007001, UM1AI068613, UM1AI069424, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI068613, UM1AI068619, R24AI067039,
   UM1AI068613, UM1AI069424, P30AI027763, UM1AI068613, UM1AI068613,
   P30AI027763, UM1AI068613, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, T32AI007001, R24AI067039, UM1AI068613,
   P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01MH110186, R01MH110186, R01MH110186, R01MH110186, R01MH110186]
   Funding Source: NIH RePORTER
FX This study was funded by T32 5T32A1007001, R01 MH110186 from the
   National Institutes of Health (NIH) and by award numbers UM1 AI068619
   (HPTN Leadership and Operations Center), UM1A1068617 (HPTN Statistical
   and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)
   from the National Institute of Allergy and Infectious Diseases, the
   National Institute of Mental Health, and the National Institute on Drug
   Abuse of the National Institutes of Health. This work was also supported
   by NIMH R01 (R01MH087118) and the Carolina Population Center and its NIH
   Center grant (P2C HD050924). Additional support was provided by 2R01
   A1095068-05 (Eshleman), R34MH096606 (Pilcher), and the Division of
   Intramural Research, NIAID, NIH. Funding for this project was also
   provided by the Bill and Melinda Gates Foundation (grant OPP1017716).
   The AMPLIAR and Options Cohorts received funding from the NIH (grants
   P01 AI071713 and R01 HD074511). The SCOPE study also received funding
   from the NIH (grants P30 AI027763 and R24 AI067039). The Sao Paulo
   Cohort acknowledges funding by the Brazilian Ministry of Health,
   Brazilian Program for STD and AIDS (grant 914/BRA/3014-UNESCO) and the
   Sao Paulo City Health Department (grant 2004-0.168.922-7). The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Aitken SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131541
   Brookmeyer R, 2010, EPIDEMIOL REV, V32, P26, DOI 10.1093/epirev/mxq002
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   CLSI, 2013, BLOOD COLL FILT PAP
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Laeyendecker O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068349
   Longosz AF, 2014, AIDS, V28, P1227, DOI 10.1097/QAD.0000000000000221
   Mei JV, 2001, J NUTR, V131, p1631S
   Pettifor A, 2016, LANCET GLOB HEALTH, V4, pE978, DOI [10.1016/S2214-109X(16)30253-4, 10.1016/s2214-109x(16)30253-4]
   Schlusser KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172283
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2018
VL 34
IS 12
BP 1013
EP 1016
DI 10.1089/aid.2018.0138
EA OCT 2018
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA HE2BG
UT WOS:000447589400001
PM 30215267
OA Green Published
DA 2020-11-26
ER

PT J
AU Veloso, VG
   Torres, TS
   Moreira, RI
   Leite, IC
   Kallas, EG
   Cerqueira, NB
   Madruga, JV
   Goulart, SP
   Fernandes, NM
   Santos, TA
   Freitas, JS
   Monteiro, L
   Lacerda, MV
   Alencastro, P
   Marins, LMS
   Nazer, S
   Cardoso, SW
   Luz, PM
   Hoagland, B
   Grinsztejn, B
AF Veloso, Valdilea G.
   Torres, Thiago Silva
   Moreira, Ronaldo I.
   Leite, Iuri C.
   Kallas, Esper G.
   Cerqueira, Natalia B.
   Madruga, Jose V.
   Goulart, Silvia P.
   Fernandes, Nilo M.
   Santos, Tony A.
   Freitas, Josias S.
   Monteiro, Laylla
   Lacerda, Marcus V.
   Alencastro, Paulo
   Marins, Luana M. S.
   Nazer, Sandro
   Cardoso, Sandra Wagner
   Luz, Paula Mendes
   Hoagland, Brenda
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI Retention and Persistance on PrEP for MSM and TGW: 96-week Results of
   the PrEP Brazil Demonstration Study
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Veloso, Valdilea G.; Torres, Thiago Silva; Moreira, Ronaldo I.; Leite, Iuri C.; Fernandes, Nilo M.; Santos, Tony A.; Freitas, Josias S.; Monteiro, Laylla; Marins, Luana M. S.; Nazer, Sandro; Cardoso, Sandra Wagner; Luz, Paula Mendes; Hoagland, Brenda; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia B.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Madruga, Jose V.; Goulart, Silvia P.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Lacerda, Marcus V.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Alencastro, Paulo] Hosp Sanat Partenon, Porto Alegre, RS, Brazil.
RI TORRES, THIAGO SILVA/D-6548-2014
OI TORRES, THIAGO SILVA/0000-0002-2557-601X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P25.18
BP 373
EP 373
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600692
DA 2020-11-26
ER

PT J
AU Cerqueira, N
   Vasconcelos, R
   Hojilla, C
   Kallas, E
   Avelino-Silva, V
AF Cerqueira, Natalia
   Vasconcelos, Ricardo
   Hojilla, Carlo
   Kallas, Esper
   Avelino-Silva, Vivian
TI Attitudes and Knowledge About HIV PrEP Among Infectious Diseases
   Physicians in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Cerqueira, Natalia; Vasconcelos, Ricardo; Kallas, Esper; Avelino-Silva, Vivian] Univ Sao Paulo, Sao Paulo, Brazil.
   [Hojilla, Carlo] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Avelino-Silva, Vivian] Hosp Sirio Libanes, Sao Paulo, Brazil.
RI Avelino-Silva, Vivian I/L-2640-2013; Vasconcelos, Ricardo/AAL-4634-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Vasconcelos,
   Ricardo/0000-0002-9753-0563
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P14.47
BP 275
EP 275
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600502
DA 2020-11-26
ER

PT J
AU Apps, R
   Bachtel, N
   Umviligihozo, G
   Pickering, S
   Mota, T
   Liang, H
   Del Prete, G
   Chatterjee, P
   Lee, G
   Thomas, R
   Brockman, M
   Neil, S
   Carrington, M
   Bwana, B
   Bangsberg, D
   Martin, J
   Kallas, E
   Donini, C
   Cerqueira, N
   O'Doherty, U
   Hahn, B
   Jones, B
   Brumme, Z
   Nixon, D
AF Apps, Richard
   Bachtel, Nathaniel
   Umviligihozo, Gisele
   Pickering, Suzanne
   Mota, Talia
   Liang, Hua
   Del Prete, Gregory
   Chatterjee, Pramita
   Lee, Guinevere
   Thomas, Rasmi
   Brockman, Mark
   Neil, Stuart
   Carrington, Mary
   Bwana, Bosco
   Bangsberg, David
   Martin, Jeffrey
   Kallas, Esper
   Donini, Camila
   Cerqueira, Natalia
   O'Doherty, Una
   Hahn, Beatrice
   Jones, Brad
   Brumme, Zabrina
   Nixon, Douglas
TI HLA-C DOWNREGULATION BY HIV ADAPTS TO HOST HLA GENOTYPE
SO HUMAN IMMUNOLOGY
LA English
DT Meeting Abstract
CT 44th Annual Meeting of the
   American-Society-for-Histocompatibility-and-Immunogenetics
CY OCT 01-05, 2018
CL Baltimore, MD
SP Amer Soc Histocompatibil & Immunogenet
C1 [Apps, Richard; Bachtel, Nathaniel; Mota, Talia; Liang, Hua; Jones, Brad; Nixon, Douglas] George Washington Univ, Washington, DC USA.
   [Umviligihozo, Gisele; Brockman, Mark; Brumme, Zabrina] Simon Fraser Univ, Burnaby, BC, Canada.
   [Pickering, Suzanne; Neil, Stuart] Kings Coll London, Sch Med, London, England.
   [Del Prete, Gregory; Chatterjee, Pramita; Carrington, Mary] Frederick Natl Lab, Frederick, MD USA.
   [Lee, Guinevere] Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA.
   [Thomas, Rasmi] Henry M Jackson Fdn, Bethesda, MD USA.
   [Thomas, Rasmi] US Mil HIV Res Program, Silver Spring, MD USA.
   [Bwana, Bosco; Bangsberg, David] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Bangsberg, David] Portland State Univ, Sch Publ Hlth, Portland, OR 97207 USA.
   [Martin, Jeffrey] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Kallas, Esper; Donini, Camila; Cerqueira, Natalia] Univ Sao Paulo, Sao Paulo, Brazil.
   [O'Doherty, Una; Hahn, Beatrice] Univ Penn, Philadelphia, PA 19104 USA.
   [Brumme, Zabrina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
RI Thomas, Rasmi/AAI-4921-2020; Lee, Guinevere Q./D-4436-2017
OI Lee, Guinevere Q./0000-0002-9412-886X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD OCT
PY 2018
VL 79
SU 1
MA OR21
BP 28
EP 28
DI 10.1016/j.humimm.2018.07.026
PG 1
WC Immunology
SC Immunology
GA GT8IZ
UT WOS:000444782200022
DA 2020-11-26
ER

PT J
AU Bechtel, ND
   Umviligihozo, G
   Pickering, S
   Mota, TM
   Liang, H
   Del Prete, GQ
   Chatterjee, P
   Lee, GQ
   Thomas, R
   Brockman, MA
   Neil, S
   Carrington, M
   Bwana, B
   Bangsberg, DR
   Martin, JN
   Kallas, EG
   Donini, CS
   Cerqueira, NB
   O'Doherty, UT
   Hahn, BH
   Jones, RB
   Brumme, ZL
   Nixon, DF
   Apps, R
AF Bechtel, Nathaniel D.
   Umviligihozo, Gisele
   Pickering, Suzanne
   Mota, Talia M.
   Liang, Hua
   Del Prete, Gregory Q.
   Chatterjee, Pramita
   Lee, Guinevere Q.
   Thomas, Rasmi
   Brockman, Mark A.
   Neil, Stuart
   Carrington, Mary
   Bwana, Bosco
   Bangsberg, David R.
   Martin, Jeffrey N.
   Kallas, Esper G.
   Donini, Camila S.
   Cerqueira, Natalia B.
   O'Doherty, Una T.
   Hahn, Beatrice H.
   Jones, R. Brad
   Brumme, Zabrina L.
   Nixon, Douglas F.
   Apps, Richard
TI HLA-C downregulation by HIV-1 adapts to host HLA genotype
SO PLOS PATHOGENS
LA English
DT Article
ID T-CELL-ACTIVATION; CLASS-I MOLECULES; COMPLEX CLASS-I; SURFACE
   EXPRESSION; IMMUNE CONTROL; NEF PROTEIN; IMPACT; VIREMIA; DETERMINANTS;
   ASSOCIATION
AB HIV-1 can downregulate HLA-C on infected cells, using the viral protein Vpu, and the magnitude of this downregulation varies widely between primary HIV-1 variants. The selection pressures that result in viral downregulation of HLA-C in some individuals, but preservation of surface HLA-C in others are not clear. To better understand viral immune evasion targeting HLA-C, we have characterized HLA-C downregulation by a range of primary HIV-1 viruses. 128 replication competent viral isolates from 19 individuals with effective anti-retroviral therapy, show that a substantial minority of individuals harbor latent reservoir virus which strongly downregulates HLA-C. Untreated infections display no change in HLA-C downregulation during the first 6 months of infection, but variation between viral quasispecies can be detected in chronic infection. Vpu molecules cloned from plasma of 195 treatment naive individuals in chronic infection demonstrate that downregulation of HLA-C adapts to host HLA genotype. HLA-C alleles differ in the pressure they exert for downregulation, and individuals with higher levels of HLA-C expression favor greater viral downregulation of HLA-C. Studies of primary and mutant molecules identify 5 residues in the transmembrane region of Vpu, and 4 residues in the transmembrane domain of HLA-C, which determine interactions between Vpu and HLA. The observed adaptation of Vpu-mediated downregulation to host genotype indicates that HLA-C alleles differ in likelihood of mediating a CTL response that is subverted by viral downregulation, and that preservation of HLA-C expression is favored in the absence of these responses. Finding that latent reservoir viruses can downregulate HLA-C could have implications for HIV-1 cure therapy approaches in some individuals.
C1 [Bechtel, Nathaniel D.; Mota, Talia M.; Nixon, Douglas F.; Apps, Richard] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
   [Umviligihozo, Gisele; Brockman, Mark A.; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada.
   [Pickering, Suzanne; Neil, Stuart] Kings Coll London, Sch Med, Guys Hosp, Dept Infect Dis, London, England.
   [Liang, Hua] George Washington Univ, Dept Stat & Biostat, Washington, DC USA.
   [Del Prete, Gregory Q.] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD USA.
   [Chatterjee, Pramita; Carrington, Mary] Frederick Natl Lab Canc Res, Canc & Inflammat Program, HLA Immunogenet Sect, Basic Sci Program, Frederick, MD USA.
   [Lee, Guinevere Q.; Carrington, Mary] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
   [Thomas, Rasmi] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA.
   [Thomas, Rasmi] Henry M Jackson Fdn, Bethesda, MD USA.
   [Brockman, Mark A.; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
   [Bwana, Bosco; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Bangsberg, David R.] Portland State Univ, Sch Publ Hlth, Oregon Hlth & Sci Univ, Portland, OR 97207 USA.
   [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Kallas, Esper G.; Donini, Camila S.; Cerqueira, Natalia B.] Univ Sao Paulo, Sao Paulo, Brazil.
   [O'Doherty, Una T.; Hahn, Beatrice H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [O'Doherty, Una T.; Hahn, Beatrice H.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Mota, Talia M.; Jones, R. Brad; Nixon, Douglas F.] Weill Cornell Med Coll, Div Infect Dis, Dept Med, New York, NY USA.
   [Apps, Richard] NIH, Trans NIH Ctr Human Immunol Autoimmun & Inflammat, Bldg 10, Bethesda, MD 20892 USA.
RP Apps, R (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
EM richard.apps@nih.gov
RI Nixon, Douglas/AAU-5734-2020; Thomas, Rasmi/AAI-4921-2020; Bachtel,
   Nathaniel/P-8637-2019; Lee, Guinevere Q./D-4436-2017; Brockman,
   Mark/D-1669-2016
OI Nixon, Douglas/0000-0002-2801-1786; Bachtel,
   Nathaniel/0000-0002-2631-2243; Lee, Guinevere Q./0000-0002-9412-886X;
   Neil, Stuart/0000-0003-3306-5831; Pickering,
   Suzanne/0000-0002-2747-9029; Kallas, Esper/0000-0003-2026-6925;
   Brockman, Mark/0000-0001-6432-1426; Mota, Talia/0000-0002-8925-0158; ,
   Hua/0000-0001-8772-5984
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI126617]; National
   Institute on Drug AbuseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA); National Institute of Mental HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH); National Institute
   of Neurological Disorders and StrokeUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS); District of
   Columbia Center for AIDS Research, an NIH - NIAID [AI117970]; District
   of Columbia Center for AIDS Research, an NIH - NCIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [AI117970]; District of Columbia Center for AIDS Research, an NIH
   - NICHD [AI117970]; District of Columbia Center for AIDS Research, an
   NIH - NHLBI [AI117970]; District of Columbia Center for AIDS Research,
   an NIH - NIDA [AI117970]; District of Columbia Center for AIDS Research,
   an NIH - NIMH [AI117970]; Frederick National Laboratory for Cancer
   Research; National Cancer Institute, National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI)
   [HHSN261200800001E]; Intramural Research Program of the NIH, Frederick
   National Lab, Center for Cancer Research; Wellcome TrustWellcome Trust
   [WT098049AIA]; MRC UKMedical Research Council UK (MRC) [G0801937];
   Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [PJT-148621]; Michael Smith Foundation for Health
   ResearchMichael Smith Foundation for Health Research; District of
   Columbia Center for AIDS Research, an NIH - NIA [AI117970]; District of
   Columbia Center for AIDS Research, an NIH - FIC [AI117970]; District of
   Columbia Center for AIDS Research, an NIH - NIGMS [AI117970]; District
   of Columbia Center for AIDS Research, an NIH - NIDDK [AI117970];
   District of Columbia Center for AIDS Research, an NIH - OAR [AI117970];
   Canada Research Chair in Viral Pathogenesis and Immunity; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIABC010792, ZIABC010792, ZIABC010792, ZIABC010792]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI120011, R01AI120011,
   UM1AI126617, R01AI120011, R01AI120011, UM1AI126617, UM1AI126617,
   UM1AI126617, UM1AI126617, R01AI120011] Funding Source: NIH RePORTER
FX Research reported in this publication was supported by 1) the National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of Health under award number UM1AI126617 (the Martin Delaney BELIEVE
   collaboratory), with co-funding support from the National Institute on
   Drug Abuse, the National Institute of Mental Health, and the National
   Institute of Neurological Disorders and Stroke; 2) a 2017 award from the
   District of Columbia Center for AIDS Research, an NIH funded program
   (AI117970), which is supported by the following NIH Co-Funding and
   Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA,
   NIMH, NIA, FIC, NIGMS, NIDDK, and OAR; 3) federal funds from the
   Frederick National Laboratory for Cancer Research, and the National
   Cancer Institute, National Institutes of Health, under Contract No.
   HHSN261200800001E; 4) the Intramural Research Program of the NIH,
   Frederick National Lab, Center for Cancer Research; 5) a Wellcome Trust
   Senior Research Fellowship (WT098049AIA) and an MRC UK project grant
   (G0801937); 6) a project grant from the Canadian Institutes of Health
   Research (PJT-148621), Canada Research Chair in Viral Pathogenesis and
   Immunity, and Scholar Award from the Michael Smith Foundation for Health
   Research. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the funders, nor
   does mention of trade names, commercial products, or organizations imply
   endorsement by the U.S. Government. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Apps R, 2016, CELL HOST MICROBE, V19, P686, DOI 10.1016/j.chom.2016.04.005
   Apps R, 2015, J IMMUNOL, V194, P3594, DOI 10.4049/jimmunol.1403234
   Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685
   Baba M, 2000, AIDS RES HUM RETROV, V16, P935, DOI 10.1089/08892220050058344
   Bartha I, 2013, ELIFE, V2, DOI 10.7554/eLife.01123
   Blais ME, 2012, J IMMUNOL, V188, P4663, DOI 10.4049/jimmunol.1103472
   Bongiovanni M, 2006, J ANTIMICROB CHEMOTH, V58, P502, DOI 10.1093/jac/dkl268
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4
   Brockman MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00506
   Carlson JM, 2016, NAT MED, V22, P606, DOI 10.1038/nm.4100
   Carlson JM, 2012, J VIROL, V86, P5230, DOI 10.1128/JVI.06728-11
   Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346
   Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   Davis ZB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005421
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Ende Z., 2018, J VIROL
   Fadda L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002805
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Fenton-May AE, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-146
   Fogli M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000101
   Foster TL, 2016, CELL HOST MICROBE, V20, P429, DOI 10.1016/j.chom.2016.08.006
   Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365
   Herschhorn A, 2010, J IMMUNOL, V185, P7623, DOI 10.4049/jimmunol.1001561
   Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214
   Hirayasu K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002565
   Honda K, 2011, EUR J IMMUNOL, V41, P97, DOI 10.1002/eji.201040841
   Honeyborne I, 2010, J VIROL, V84, P11279, DOI 10.1128/JVI.01144-10
   Hosmane NN, 2017, J EXP MED, V214, P959, DOI 10.1084/jem.20170193
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Iyer SS, 2017, P NATL ACAD SCI USA, V114, pE590, DOI 10.1073/pnas.1620144114
   Jones RB, 2016, J CLIN INVEST, V126, P455, DOI 10.1172/JCI80566
   KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0
   Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Korner C, 2017, CELL HOST MICROBE, V22, P111, DOI 10.1016/j.chom.2017.06.008
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Kueck T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002609
   Laird GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003398
   Lin ZS, 2016, CELL REP, V17, P2210, DOI 10.1016/j.celrep.2016.10.075
   Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12
   Makadzange AT, 2010, EUR J IMMUNOL, V40, P1036, DOI 10.1002/eji.200939634
   Mann JK, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-100
   Martins MAR, 2019, J SOLUTION CHEM, V48, P962, DOI 10.1007/s10953-018-0793-1
   Nattermann J, 2005, ANTIVIR THER, V10, P95
   Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Nou E, 2009, J VIROL, V83, P6941, DOI 10.1128/JVI.00306-09
   Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570
   Parolini F., 2017, J VIROL JVI
   Parrish NF, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002686
   Patterson S, 2015, INT J EPIDEMIOL, V44, P58, DOI 10.1093/ije/dyu046
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Pickering S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003895
   R Development Core Team, 2017, R LANG ENV STAT COMP
   Rahimi A, 2017, J VIROL METHODS, V240, P32, DOI 10.1016/j.jviromet.2016.11.004
   Robinson J, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006862
   Romani B, 2017, SCI REP-UK, V7, DOI 10.1038/srep44894
   Sauter D, 2015, CELL REP, V10, P586, DOI 10.1016/j.celrep.2014.12.047
   Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338
   Shah AH, 2010, CELL HOST MICROBE, V8, P397, DOI 10.1016/j.chom.2010.10.008
   Specht A, 2010, J VIROL, V84, P7300, DOI 10.1128/JVI.00619-10
   Stoll A, 2015, J IMMUNOL METHODS, V418, P9, DOI 10.1016/j.jim.2015.01.005
   Swigut T, 2004, J VIROL, V78, P13335, DOI 10.1128/JVI.78.23.13335-13344.2004
   Thammavongsa V, 2009, IMMUNOGENETICS, V61, P703, DOI 10.1007/s00251-009-0399-2
   Thomas R, 2009, NAT GENET, V41, P1290, DOI 10.1038/ng.486
   Tremblay-McLean A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100295
   WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992
   Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996
   Zhang H, 2015, BBA-BIOMEMBRANES, V1848, P3007, DOI 10.1016/j.bbamem.2015.09.008
NR 72
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2018
VL 14
IS 9
AR e1007257
DI 10.1371/journal.ppat.1007257
PG 25
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA GY9OA
UT WOS:000448975900017
PM 30180214
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Luna, E
   Romano, C
   Araujo, E
   Felix, AC
   Nakasone, O
   Campos, S
   Fernandes, L
   Levi, JE
   Santiago, N
   Fernandes, J
   Fragoso, D
   Kallas, E
   Pannuti, C
AF Luna, E.
   Romano, C.
   Araujo, E.
   Felix, A. C.
   Nakasone, O.
   Campos, S.
   Fernandes, L.
   Levi, J. E.
   Santiago, N.
   Fernandes, J.
   Fragoso, D.
   Kallas, E.
   Pannuti, C.
TI Low prevalence after the first Zika virus epidemic wave in Southeastern
   Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Luna, E.; Romano, C.; Felix, A. C.; Campos, S.; Levi, J. E.; Santiago, N.; Kallas, E.; Pannuti, C.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Araujo, E.; Nakasone, O.; Fernandes, L.; Fernandes, J.; Fragoso, D.] Hosp Ana Costa, Santos, Brazil.
RI Luna, Expedito J A/B-7948-2012
OI Luna, Expedito J A/0000-0002-1145-9672; Campos,
   Sergio/0000-0002-1048-8332
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2016/16069-8]
FX Grant FAPESP no. 2016/16069-8
NR 0
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2018
VL 73
SU S
MA SADI 12.00
BP 17
EP 17
DI 10.1016/j.ijid.2018.04.3464
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA GO8MP
UT WOS:000440345100030
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Marins, LMS
   Torres, TS
   Leite, IC
   Moreira, RI
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Anderson, PL
   Liu, AY
   Grinsztejn, B
   Veloso, V
AF Marins, L. M. S.
   Torres, T. S.
   Costa Leite, I.
   Moreira, R. I.
   Hoagland, B.
   Kallas, E. G.
   Madruga, J. V.
   Anderson, P. L.
   Liu, A. Y.
   Grinsztejn, B.
   Veloso, V.
CA PrEP Brasil Study Team
TI Comparison of measures of adherence to HIV pre-exposure prophylaxis
   (PrEP) among men who have sex with men (MSM) and transgender women
   (TGW): results from the PrEP Brasil study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Marins, L. M. S.; Torres, T. S.; Moreira, R. I.; Hoagland, B.; Grinsztejn, B.; Veloso, V.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Costa Leite, I.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Madruga, J. V.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Anderson, P. L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Denver, CO 80202 USA.
   [Liu, A. Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2018
VL 21
SU 6
SI SI
MA TUAC0303
BP 16
EP 17
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GO4RZ
UT WOS:000440002700032
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Costa, PR
   Silveira, CGT
   Marmorato, MP
   Cerqueira, NB
   Sutton, MS
   O'Connor, SL
   Carvalho, KI
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Costa, Priscilla R.
   Terrassani Silveira, Cassia G.
   Marmorato, Mariana P.
   Cerqueira, Natalia B.
   Sutton, Matthew S.
   O'Connor, Shelby L.
   Carvalho, Karina I.
   Nixon, Douglas F.
   Kallas, Esper G.
TI Latent Mycobacterium tuberculosis Infection Is Associated With a Higher
   Frequency of Mucosal-Associated Invariant T and Invariant Natural Killer
   T Cells.
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE mucosal-associated invariant T cells; invariant natural killer T cells;
   Mycobacterium tuberculosis; HIV-1; CCR6
ID CD1D-RESTRICTED NKT CELLS; ANTIRETROVIRAL THERAPY; HIV-1 INFECTION; MAIT
   CELLS; ACTIVATION; HETEROGENEITY; INDIVIDUALS; METABOLITES; RESPONSES;
   CD4(+)
AB Increasing drug resistance and the lack of an effective vaccine are the main factors contributing to Mycobacterium tuberculosis (Mtb) being a major cause of death globally. Despite intensive research efforts, it is not well understood why some individuals control Mtb infection and some others develop active disease. HIV-1 infection is associated with an increased incidence of active tuberculosis, even in virally suppressed individuals. Mucosal-associated invariant T (MAIT) and invariant natural killer T (iNKT) cells are innate T cells that can recognize Mtb-infected cells. Contradicting results regarding the frequency of MAIT cells in latent Mtb infection have been reported. In this confirmatory study, we investigated the frequency, phenotype, and IFN gamma production of MAIT and iNKT cells in subjects with latent or active Mtb infection. We found that the frequency of both cell types was increased in subjects with latent Mtb infection compared with uninfected individuals or subjects with active infection. We found no change in the expression of HLA-DR, PD-1, and CCR6, as well as the production of IFN. by MAIT and iNKT cells, among subjects with latent Mtb infection or uninfected controls. The proportion of CD4-CD8+ MAIT cells in individuals with latent Mtb infection was, however, increased. HIV-1 infection was associated with a loss of MAIT and iNKT cells, and the residual cells had elevated expression of the exhaustion marker PD-1. Altogether, the results suggest a role for MAIT and iNKT cells in immunity against Mtb and show a deleterious impact of HIV-1 infection on those cells.
C1 [Paquin-Proulx, Dominic; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Costa, Priscilla R.; Terrassani Silveira, Cassia G.; Marmorato, Mariana P.; Cerqueira, Natalia B.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Sutton, Matthew S.; O'Connor, Shelby L.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Carvalho, Karina I.] Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM dpaquin_proulx@gwu.edu
RI Carvalho, Karina IL/J-6789-2012; Marmorato, Mariana/V-5375-2018; Nixon,
   Douglas/AAU-5734-2020
OI Carvalho, Karina IL/0000-0002-7763-8139; Marmorato,
   Mariana/0000-0002-0644-0862; Nixon, Douglas/0000-0002-2801-1786; Paquin
   Proulx, Dominic/0000-0003-1407-3414
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI52731];  [R21 AI127127]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052731, R21AI127127, R01AI052731, R01AI052731, R01AI052731,
   R01AI052731, R01AI052731, R21AI127127] Funding Source: NIH RePORTER
FX This work was supported in part by NIAID (R01 AI52731) to DN and in part
   by R21 AI127127 to SO.
CR Azakami K, 2009, BLOOD, V114, P3208, DOI 10.1182/blood-2009-02-203042
   Canaday DH, 2001, J IMMUNOL, V167, P2734, DOI 10.4049/jimmunol.167.5.2734
   Chancellor A, 2017, TUBERCULOSIS, V105, P86, DOI 10.1016/j.tube.2017.04.011
   Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   Dias J, 2017, P NATL ACAD SCI USA, V114, pE5434, DOI 10.1073/pnas.1705759114
   Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1
   Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021
   Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407
   Greene JM, 2017, MUCOSAL IMMUNOL, V10, P802, DOI 10.1038/mi.2016.91
   Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034156
   Huang SX, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00594
   Huang SX, 2009, P NATL ACAD SCI USA, V106, P8290, DOI 10.1073/pnas.0903196106
   Jiang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32320
   Kee SJ, 2012, INFECT IMMUN, V80, P2100, DOI 10.1128/IAI.06018-11
   Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Kurioka A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01031
   Kwon YS, 2015, TUBERCULOSIS, V95, P267, DOI 10.1016/j.tube.2015.03.004
   Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3
   Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408
   Moll M, 2006, BLOOD, V107, P3081, DOI 10.1182/blood-2005-09-3636
   Montoya CJ, 2008, CLIN IMMUNOL, V127, P1, DOI 10.1016/j.clim.2007.12.006
   Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712
   Paquin-Proulx D, 2017, MUCOSAL IMMUNOL, V10, P69, DOI 10.1038/mi.2016.34
   Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345
   Grassi MFR, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1428-z
   Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239
   Saeidi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124659
   Sakai S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005667
   Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545
   Serbina NV, 2001, J IMMUNOL, V167, P6991, DOI 10.4049/jimmunol.167.12.6991
   Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567
   Sortino O, 2018, AIDS, V32, P825, DOI [10.1097/qad.0000000000001760, 10.1097/QAD.0000000000001760]
   Wong EB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083474
   Yang QT, 2015, SCI REP-UK, V5, DOI 10.1038/srep17918
NR 43
TC 15
Z9 15
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 19
PY 2018
VL 9
AR 1394
DI 10.3389/fimmu.2018.01394
PG 9
WC Immunology
SC Immunology
GA GJ9LS
UT WOS:000435723800001
PM 29971068
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Brunialti, MKC
   Cerqueira, N
   Maestri, A
   Chaves, L
   Levi, JE
   Pannuti, CS
   Kallas, EG
   Burattini, MN
   Salomao, R
AF Brunialti, Milena K. C.
   Cerqueira, Natalia
   Maestri, Alvino
   Chaves, Lucas
   Levi, Jose E.
   Pannuti, Claudio S.
   Kallas, Esper G.
   Burattini, Marcelo N.
   Salomao, Reinaldo
TI TOLL-LIKE RECEPTOR SIGNALING PATHWAY IS DIFFERENTIALLY MODULATED IN
   PATIENTS WITH DENGUE WITHOUT WARNING SIGNS AND DENGUE WITH WARNING SIGNS
SO SHOCK
LA English
DT Meeting Abstract
CT 41st Annual Conference on Shock
CY JUN 09-12, 2018
CL Scottsdale, AZ
SP Shock Soc
C1 [Brunialti, Milena K. C.; Burattini, Marcelo N.; Salomao, Reinaldo] Univ Fed Sao Paulo, Hosp Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil.
   [Cerqueira, Natalia; Maestri, Alvino; Chaves, Lucas; Kallas, Esper G.] Univ Sao Paulo, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Levi, Jose E.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2018
VL 49
IS 6
SU 1
MA P120
BP 90
EP 91
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GQ0XL
UT WOS:000441343800190
DA 2020-11-26
ER

PT J
AU Carvalho, KI
   Watanabe, CM
   Kallas, EG
AF Carvalho, Karina I.
   Watanabe, Caroline Mitika
   Kallas, Esper G.
TI Challenger Treats Zika Virus
SO CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES
LA English
DT Article
DE Flavivirus; Zika virus; Pregnancy; Treatment
AB Purpose of review Arthropod-borne viruses (arboviruses) are zoonotic, and the common vectors are ticks and hematophagous mosquitoes. Currently, dengue, chikungunya, yellow fever, West Nile, and Japanese encephalitis virus infections have been causing worldwide concerns. In 2015, a large outbreak was documented with another mosquito-borne flavivirus, the Zika virus (ZIKV), and ravaging South and Central Americas and the Caribbean. ZIKV was declaring a public health emergency, because of the clinical evidence neurological complications. Recent findings The flavivirus infection is difficult to differentiate only with clinical manifestation. It has been reported 2366 cases of microcephaly or congenital defects associated with ZIKV in Brazil, and the mechanism or processes that lead to these neurological complications are still under investigation. No antivirals are available to treat ZIKV infection, leading to no option to prevent the fetal infection during pregnancy which could avoid the congenital Zika syndrome. In this review, we will describe the drugs that are being tested in vitro and in animal models against ZIKV. We reviewed several publications that test the compounds for the treatment of ZIKV disease. We conclude that some of these compounds testing in vitro and in vivo have shown a therapeutic possibilities to consider and to be test in pregnancy and in individuals with high risk of infection.
C1 [Carvalho, Karina I.; Watanabe, Caroline Mitika] Hosp Israelita Albert Einstein, Ave Albert Einstein,627 Bloco A 2ss, BR-05652000 Morumbi, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
RP Carvalho, KI (corresponding author), Hosp Israelita Albert Einstein, Ave Albert Einstein,627 Bloco A 2ss, BR-05652000 Morumbi, Brazil.
EM karina.ladislau@einstein.br
CR Abrams RPM, 2017, NEUROTHERAPEUTICS, V14, P1027, DOI 10.1007/s13311-017-0575-2
   Adams J, 1999, CANCER RES, V59, P2615
   Adibi JJ, 2016, LANCET, V387, P1587, DOI 10.1016/S0140-6736(16)00650-4
   [Anonymous], 1995, PARASITIC DIS
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Borges MC, 2013, MEM I OSWALDO CRUZ, V108, P596, DOI 10.1590/S0074-02762013000500010
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   CALNE DB, 1974, BMJ-BRIT MED J, V4, P442, DOI 10.1136/bmj.4.5942.442
   Calvet GA, 2016, CURR OPIN INFECT DIS, V29, P459, DOI 10.1097/QCO.0000000000000301
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   CDC, 2017, MALARIA
   Chan JFW, 2017, ANTIVIR RES, V141, P29, DOI 10.1016/j.antiviral.2017.02.002
   CHEN LL, 1987, J BACTERIOL, V169, P2373, DOI 10.1128/jb.169.6.2373-2379.1987
   Choy MM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004058
   Diamond MS, 2002, VIROLOGY, V304, P211, DOI 10.1006/viro.2002.1685
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DRUG F-USF, 2017, FDA APPR 2 HEP C DRU
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   ELIOPOULOS GM, 1986, ANTIMICROB AGENTS CH, V30, P532, DOI 10.1128/AAC.30.4.532
   Enfissi A, 2016, LANCET, V387, P227, DOI 10.1016/S0140-6736(16)00003-9
   Fang JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078425
   FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515
   Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x
   Ginther OJ, 2012, THERIOGENOLOGY, V78, P1969, DOI 10.1016/j.theriogenology.2012.08.003
   Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/mmbr.00055-16, 10.1128/MMBR.00055-16]
   Henss L, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0607-2
   Hoglen NC, 2004, J PHARMACOL EXP THER, V309, P634, DOI 10.1124/jpet.103.062034
   Iwamoto K, 2007, BIOPHYS J, V93, P1608, DOI 10.1529/biophysj.106.101584
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Johansen LM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5597
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Kang S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003084
   Kato F, 2016, ANTIVIR RES, V131, P141, DOI 10.1016/j.antiviral.2016.04.014
   KIRBY WMM, 1956, ARCH INTERN MED, V98, P1, DOI 10.1001/archinte.1956.00250250007001
   Koe BK, 1983, J PHARMACOL EXP THER, V226, P686
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   LIEBERT M, 1983, TRANSPLANTATION, V36, P200, DOI 10.1097/00007890-198308000-00019
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   MOLANDER CW, 1964, J BACTERIOL, V88, P591, DOI 10.1128/JB.88.3.591-594.1964
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Ng CY, 2007, ANTIVIR RES, V76, P222, DOI 10.1016/j.antiviral.2007.06.007
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Organization W-WH, 2017, IVERMECTIN
   Perachon S, 1999, EUR J PHARMACOL, V366, P293, DOI 10.1016/S0014-2999(98)00896-6
   PERERA DR, 1970, AM J TROP MED HYG, V19, P610, DOI 10.4269/ajtmh.1970.19.610
   Qing M, 2009, ANTIMICROB AGENTS CH, V53, P3226, DOI 10.1128/AAC.00189-09
   Rausch K, 2017, CELL REP, V18, P804, DOI 10.1016/j.celrep.2016.12.068
   Richard AS, 2015, P NATL ACAD SCI USA, V112, P14682, DOI 10.1073/pnas.1508095112
   Rieckmann KH, 1974, B WORLD HEALTH ORGAN, V51, P375
   Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Solomon T, 2016, LANCET INFECT DIS, V16, P402, DOI 10.1016/S1473-3099(16)00125-0
   Sun YH, 2002, MICROBIOL-SGM, V148, P361, DOI 10.1099/00221287-148-2-361
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Takhampunya R, 2006, J GEN VIROL, V87, P1947, DOI 10.1099/vir.0.81655-0
   Tan CW, 2017, ANTIVIR RES, V143, P186, DOI 10.1016/j.antiviral.2017.04.017
   THORNER MO, 1974, BRIT MED J, V2, P419, DOI 10.1136/bmj.2.5916.419
   Varghese FS, 2016, ANTIVIR RES, V126, P117, DOI 10.1016/j.antiviral.2015.12.012
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   WHO, 1995, MODEL
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Wu T, 2014, EPSTEIN BARR VIRUS, V107, P95, DOI [10.1016/j.antiviral.2014.05.003, DOI 10.1016/J.ANTIVIRAL.2014.05.003]
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yuan SF, 2017, ANTIVIR RES, V145, P33, DOI 10.1016/j.antiviral.2017.07.007
   Zhang Y, 1999, METABOLISM, V48, P1033, DOI 10.1016/S0026-0495(99)90202-0
NR 70
TC 0
Z9 0
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 1534-6250
J9 CURR TREAT OPT INFEC
JI Curr. Treat. Option Infect. Dis
PD JUN
PY 2018
VL 10
IS 2
BP 217
EP 228
DI 10.1007/s40506-018-0160-1
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA VJ0QL
UT WOS:000526795800008
DA 2020-11-26
ER

PT J
AU Leal, FE
   Menezes, SM
   Costa, EAS
   Brailey, PM
   Gama, L
   Segurado, AC
   Kallas, EG
   Nixon, DF
   Dierckx, T
   Khouri, R
   Vercauteren, J
   Galvao-Castro, B
   Raposo, RAS
   Van Weyenbergh, J
AF Leal, Fabio E.
   Menezes, Soraya Maria
   Costa, Emanuela A. S.
   Brailey, Phillip M.
   Gama, Lucio
   Segurado, Aluisio C.
   Kallas, Esper G.
   Nixon, Douglas F.
   Dierckx, Tim
   Khouri, Ricardo
   Vercauteren, Jurgen
   Galvao-Castro, Bernardo
   Saraiva Raposo, Rui Andre
   Van Weyenbergh, Johan
TI Comprehensive Antiretroviral Restriction Factor Profiling Reveals the
   Evolutionary Imprint of the ex Vivo and in Vivo IFN-beta Response in
   HTLV-1-Associated Neuroinflammation
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE HTLV-1; HIV; retrovirus; evolution; interferon; neuroinflammation;
   multiple sclerosis; transcriptomics
ID MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; CLASS-II TRANSACTIVATOR;
   LYMPHOTROPIC VIRUS TYPE-1; HIV-1 INFECTION; EXPRESSION PROFILE; ELITE
   CONTROLLERS; CELLS; ACTIVATION; THERAPY; TARGETS
AB HTLV-1-Associated Myelopathy (HAM/TSP) is a progressive neuroinflammatory disorder for which no disease-modifying treatment exists. Modest clinical benefit from type I interferons (IFN-alpha/beta) in HAM/TSP contrasts with its recently identified IFN-inducible gene signature. In addition, IFN-alpha treatment in vivo decreases proviral load and immune activation in HAM/TSP, whereas IFN-beta therapy decreases tax mRNA and lymphoproliferation. We hypothesize this "IFN paradox" in HAM/TSP might be explained by both cell type-and gene-specific effects of type I IFN in HTLV-1-associated pathogenesis. Therefore, we analyzed ex vivo transcriptomes of CD4+ T cells, PBMCs and whole blood in healthy controls, HTLV-1-infected individuals, and HAM/TSP patients. First, we used a targeted approach, simultaneously quantifying HTLV-1 mRNA (HBZ, Tax), proviral load and 42 host genes with known antiretroviral (anti -HIV) activity in purified CD4(+) T cells. This revealed two major clusters ("antiviral/protective" vs. "proviral/deleterious'), as evidenced by significant negative (TRIM5/TRIM22/BST2) vs. positive correlation (ISG15/PAF1/CDKN1A) with HTLV-1 viral markers and clinical status. Surprisingly, we found a significant inversion of antiretroviral activity of host restriction factors, as evidenced by opposite correlation to in vivo HIV -1 vs. HTLV-1 RNA levels. The anti-HTLV-1 effect of antiviral cluster genes was significantly correlated to their adaptive chimp/human evolution score, for both Tax mRNA and PVL. Six genes of the proposed antiviral cluster underwent lentivirus-driven purifying selection during primate evolution (TRIM5/TRIM22/BST2/APOBEC3F-G-H), underscoring the cross-retroviral evolutionary imprint. Secondly, we examined the genome-wide type I IFN response in HAM/TSP patients, following short-term ex vivo culture of PBMCs with either IFN-alpha or IFNI,. Microarray analysis evidenced 12 antiretroviral genes (including TRIM5(x/TRIM22/BST2) were significantly up-regulated by IFN-alpha, but not IFN-alpha, in HAM/TSP. This was paralleled by a significant decrease in lymphoproliferation by IFN-beta but not IFN(x treatment. Finally, using published ex vivo whole blood transcriptomic data of independent cohorts, we validated the significant positive correlation between TRIM5, TRIM22, and BST2 in HTLV-1-infected individuals and HAM/TSP patients, which was independent of the HAM/TSP disease signature. In conclusion, our results provide ex vivo mechanistic evidence for the observed immunovirological effect of in vivo IFNtreatment in HAM/TSP, reconcile an apparent IFN paradox in HTLV-1 research and identify biomarkers/targets for a precision medicine approach.
C1 [Leal, Fabio E.; Brailey, Phillip M.; Nixon, Douglas F.; Saraiva Raposo, Rui Andre] Inst Nacl Canc INCA, Oncovirol Program, Rio De Janeiro, Brazil.
   [Leal, Fabio E.] George Washington Univ, Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Menezes, Soraya Maria; Dierckx, Tim; Khouri, Ricardo; Vercauteren, Jurgen; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Costa, Emanuela A. S.; Segurado, Aluisio C.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Gama, Lucio] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
   [Khouri, Ricardo] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Galvao-Castro, Bernardo] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
RP Leal, FE (corresponding author), Inst Nacl Canc INCA, Oncovirol Program, Rio De Janeiro, Brazil.; Leal, FE (corresponding author), George Washington Univ, Microbiol Immunol & Trop Med, Washington, DC 20052 USA.; Van Weyenbergh, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
EM fabio.leal@inca.gov.br; johan.vanweyenbergh@kuleuven.be
RI Segurado, Aluisio C/K-2229-2012; Van Weyenbergh, Johan/Q-3829-2019;
   Vercauteren, Jurgen/P-7676-2019; Khouri, Ricardo/M-3184-2018; Nixon,
   Douglas/AAU-5734-2020; Van Weyenbergh, Johan/B-4187-2009
OI Segurado, Aluisio C/0000-0002-6311-8036; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Vercauteren, Jurgen/0000-0003-0698-4736;
   Khouri, Ricardo/0000-0001-5664-4436; Nixon, Douglas/0000-0002-2801-1786;
   Van Weyenbergh, Johan/0000-0003-3234-8426; Dierckx,
   Tim/0000-0002-1969-7974
FU CNPq (Pronex, PVE); KU Leuven (Vaast Leysen Leerstoel voor
   Infectieziekten in Ontwikkelingslanden); FWOFWO [G0D6817N]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30AI087714,
   P30AI117970]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/EGK, 2010/05845-0/EGK/DFN]; CNPq/CAPESNational Council for
   Scientific and Technological Development (CNPq)CAPES [056/2012];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI087714,
   P30AI117970, P30AI117970, P30AI117970, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI117970, P30AI087714, P30AI117970,
   P30AI087714, P30AI087714, P30AI117970, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI087714, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI087714,
   P30AI087714, P30AI117970, P30AI087714, P30AI087714, P30AI117970,
   P30AI087714, P30AI117970, P30AI087714, P30AI087714, P30AI117970,
   P30AI117970, P30AI087714, P30AI117970, P30AI087714, P30AI117970,
   P30AI087714, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI087714, P30AI117970, P30AI087714, P30AI087714, P30AI117970,
   P30AI117970, P30AI087714, P30AI087714, P30AI087714] Funding Source: NIH
   RePORTER
FX This work was supported by CNPq (Pronex, PVE), KU Leuven (Vaast Leysen
   Leerstoel voor Infectieziekten in Ontwikkelingslanden) and FWO (grant
   G0D6817N). This work was partially supported by the National Institutes
   of Health grant to the District of Columbia Center for AIDS Research,
   (P30AI087714 and P30AI117970), Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (04/15856-9/EGK and 2010/05845-0/EGK/DFN), CNPq/CAPES
   056/2012 (DFN).
CR Abdel-Mohsen M, 2015, AIDS, V29, P411, DOI 10.1097/QAD.0000000000000572
   Abdel-Mohsen M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-106
   Bangham CRM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.12
   Baratella M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005285
   Cachat A, 2013, J VIROL, V87, P13386, DOI 10.1128/JVI.02758-13
   Costa DT, 2012, CASE REP NEUROL MED, DOI 10.1155/2012/958786
   Viana GMD, 2014, REV INST MED TROP SP, V56, P443, DOI 10.1590/S0036-46652014000500013
   Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
   Dierckx T, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2016.126
   dos Santos PF, 2018, J IMMUNOL, V200, P1434, DOI 10.4049/jimmunol.1701120
   Farberov L, 2015, J CELL SCI, V128, P1607, DOI 10.1242/jcs.167817
   Forlani G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00564
   Forlani G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0853-5
   Foster TL, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01853
   Gallo RC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01800
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6
   Kinpara S, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-52
   Lascano J, 2016, J VIROL, V90, P308, DOI 10.1128/JVI.02496-15
   Leng J, 2014, CELL HOST MICROBE, V15, P717, DOI 10.1016/j.chom.2014.05.011
   Liu L, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-94
   LU HT, 1995, J EXP MED, V182, P1517, DOI 10.1084/jem.182.5.1517
   McLaren PJ, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0165-5
   Menezes SM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-18
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Moens B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001729
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Nexo BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074063
   Nozuma S, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0350-9
   Oh U, 2005, ANN NEUROL, V57, P526, DOI 10.1002/ana.20429
   Ortiz M, 2009, MOL BIOL EVOL, V26, P2865, DOI 10.1093/molbev/msp197
   OSAME M, 1986, LANCET, V1, P1031
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   Raposo RAS, 2014, J VIROL, V88, P11624, DOI 10.1128/JVI.01771-14
   Raposo RAS, 2013, J LEUKOCYTE BIOL, V94, P1051, DOI 10.1189/jlb.0313150
   Raposo RAS, 2013, J VIROL, V87, P11924, DOI 10.1128/JVI.02128-13
   Rotger M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000781
   Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19
   Sawada L, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006597
   Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Singh R, 2014, J VIROL, V88, P4291, DOI 10.1128/JVI.03603-13
   Tagaya Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01425
   Tattermusch S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002480
   Telenti Amalio, 2005, Infection Genetics and Evolution, V5, P327, DOI 10.1016/j.meegid.2004.11.001
   Tosi G, 2011, J VIROL, V85, P10719, DOI 10.1128/JVI.00813-11
NR 46
TC 3
Z9 4
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD MAY 22
PY 2018
VL 9
AR 985
DI 10.3389/fmicb.2018.00985
PG 12
WC Microbiology
SC Microbiology
GA GG4NM
UT WOS:000432673400001
PM 29872426
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Grifoni, A
   Pham, J
   Peters, B
   De-Oliveira-Pinto, ML
   de Silva, A
   Durbin, A
   Diehl, SA
   Harris, E
   Crowe, J
   Busch, M
   Vivanco-Cid, H
   Graham, BS
   Turtle, L
   Kallas, E
   Watkins, D
   Weiskopf, D
   Sette, A
AF Grifoni, Alba
   Pham, John
   Peters, Bjorn
   de-Oliveira-Pinto, Maria Luzia
   de Silva, Aravinda
   Durbin, Anna
   Diehl, Sean A.
   Harris, Eva
   Crowe, James
   Busch, Micheal
   Vivanco-Cid, Hector
   Graham, Barney S.
   Turtle, Lance
   Kallas, Esper
   Watkins, David
   Weiskopf, Daniela
   Sette, Alessandro
TI ZIKV-specific CD8 T cell immunity in humans is affected by DENV
   pre-exposure
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Immunologists (AAI)
CY MAY 04-08, 2018
CL Austin, TX
SP Amer Assoc Immunologists
C1 [Grifoni, Alba; Pham, John; Peters, Bjorn; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [de-Oliveira-Pinto, Maria Luzia] Oswaldo Cruz Fndn FIOCRUZ, Rio De Janeiro, Brazil.
   [de Silva, Aravinda] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Durbin, Anna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Diehl, Sean A.] Univ Vermont, Burlington, VT 05405 USA.
   [Harris, Eva] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Crowe, James] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Busch, Micheal] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Inst Invest Med Biol, Mexico City, DF, Mexico.
   [Graham, Barney S.] NIAID, NIH, North Bethesda, MD USA.
   [Turtle, Lance] Univ Liverpool, Liverpool, Merseyside, England.
   [Kallas, Esper] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Watkins, David] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
RI Graham, Barney S./AAC-5898-2019; Crowe, James E./B-5549-2009; Diehl,
   Sean/AAE-2779-2020
OI Graham, Barney S./0000-0001-8112-0853; Crowe, James
   E./0000-0002-0049-1079; Diehl, Sean/0000-0001-9700-235X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2018
VL 200
IS 1
SU S
MA 61.8
PG 3
WC Immunology
SC Immunology
GA HN1WM
UT WOS:000459977704180
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Rogers, TF
   Maness, NJ
   Grubaugh, ND
   Beutler, N
   Bailey, VK
   Gonzalez-Nieto, L
   Gutman, MJ
   Pedreno-Lopez, N
   Kwal, JM
   Ricciardi, MJ
   Myers, TA
   Julander, JG
   Bohm, RP
   Gilbert, MH
   Schiro, F
   Aye, PP
   Blair, RV
   Martins, MA
   Falkenstein, KP
   Kaur, A
   Curry, CL
   Kallas, EG
   Desrosiers, RC
   Goldschmidt-Clermont, PJ
   Whitehead, SS
   Andersen, KG
   Bonaldo, MC
   Lackner, AA
   Panganiban, AT
   Burton, DR
   Watkins, DI
AF Magnani, Diogo M.
   Rogers, Thomas F.
   Maness, Nicholas J.
   Grubaugh, Nathan D.
   Beutler, Nathan
   Bailey, Varian K.
   Gonzalez-Nieto, Lucas
   Gutman, Martin J.
   Pedreno-Lopez, Nuria
   Kwal, Jaclyn M.
   Ricciardi, Michael J.
   Myers, Tereance A.
   Julander, Justin G.
   Bohm, Rudolf P.
   Gilbert, Margaret H.
   Schiro, Faith
   Aye, Pyone P.
   Blair, Robert V.
   Martins, Mauricio A.
   Falkenstein, Kathrine P.
   Kaur, Amitinder
   Curry, Christine L.
   Kallas, Esper G.
   Desrosiers, Ronald C.
   Goldschmidt-Clermont, Pascal J.
   Whitehead, Stephen S.
   Andersen, Kristian G.
   Bonaldo, Myrna C.
   Lackner, Andrew A.
   Panganiban, Antonito T.
   Burton, Dennis R.
   Watkins, David I.
TI Fetal demise and failed antibody therapy during Zika virus infection of
   pregnant macaques
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NONHUMAN PRIMATE; DENGUE VIRUSES; BIRTH-DEFECTS; UNITED-STATES; SEQUENCE
   DATA; MODEL; BRAZIL; EXPOSURE; JANUARY; MALARIA
AB Zika virus (ZIKV) infection of pregnant women is associated with pathologic complications of fetal development. Here, we infect pregnant rhesus macaques (Macaca mulatta) with a minimally passaged ZIKV isolate from Rio de Janeiro, where a high rate of fetal development complications was observed. The infection of pregnant macaques with this virus results in maternal viremia, virus crossing into the amniotic fluid (AF), and in utero fetal deaths. We also treated three additional ZIKV-infected pregnant macaques with a cocktail of ZIKV-neutralizing human monoclonal antibodies (nmAbs) at peak viremia. While the nmAbs can be effective in clearing the virus from the maternal sera of treated monkeys, it is not sufficient to clear ZIKV from AF. Our report suggests that ZIKV from Brazil causes fetal demise in non-human primates (NHPs) without additional mutations or confounding co-factors. Treatment with a neutralizing anti-ZIKV nmAb cocktail is insufficient to fully stop vertical transmission.
C1 [Magnani, Diogo M.; Bailey, Varian K.; Gonzalez-Nieto, Lucas; Gutman, Martin J.; Pedreno-Lopez, Nuria; Kwal, Jaclyn M.; Ricciardi, Michael J.; Martins, Mauricio A.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, 1951 NW 7th Ave,Room 2340, Miami, FL 33136 USA.
   [Rogers, Thomas F.; Grubaugh, Nathan D.; Beutler, Nathan; Andersen, Kristian G.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, 3215 Merryfield Row Immunol 308, San Diego, CA 92121 USA.
   [Maness, Nicholas J.; Myers, Tereance A.; Bohm, Rudolf P.; Gilbert, Margaret H.; Schiro, Faith; Aye, Pyone P.; Blair, Robert V.; Falkenstein, Kathrine P.; Kaur, Amitinder; Lackner, Andrew A.; Panganiban, Antonito T.] Tulane Natl Primate Res Ctr, 18703 Three Rivers Rd, Covington, LA 70433 USA.
   [Julander, Justin G.] Utah State Univ, Inst Antiviral Res, 5600 Old Main Hill, Logan, UT 84322 USA.
   [Curry, Christine L.] Univ Miami, Leonard M Miller Sch Med, Dept Obstet & Gynecol, CRB 11th Floor, Miami, FL 33136 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
   [Goldschmidt-Clermont, Pascal J.] Univ Miami, Dept Med, Leonard M Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL USA.
   [Whitehead, Stephen S.] NIAID, NIH, Lab Infect Dis, Bldg 33,Room 3W10A,33 North Dr,MSC 3210, Bethesda, MD 20892 USA.
   [Andersen, Kristian G.] Scripps Translat Sci Inst, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Andersen, Kristian G.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Bonaldo, Myrna C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Ave Brasil,4365 Manguinhos, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Burton, Dennis R.] Harvard Med Sch, Ragon Inst, 400 Technol Sq, Boston, MA 02139 USA.
RP Watkins, DI (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Pathol, 1951 NW 7th Ave,Room 2340, Miami, FL 33136 USA.; Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, 3215 Merryfield Row Immunol 308, San Diego, CA 92121 USA.; Burton, DR (corresponding author), Harvard Med Sch, Ragon Inst, 400 Technol Sq, Boston, MA 02139 USA.
EM burton@scripps.edu; dwatkins@med.miami.edu
RI Martins, Mauricio/AAU-9226-2020; amsalu, ribka/G-8780-2019; Whitehead,
   Stephen/AAG-2787-2019
OI Martins, Mauricio/0000-0001-8336-216X; Kallas,
   Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406; Grubaugh,
   Nathan/0000-0003-2031-1933; Beutler, Nathan/0000-0003-3240-9524
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1152818]; National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [4P01AI094420-05]; Wallace H. Coulter Center for Translational
   Research at the University of Miami; Miami Clinical and Translational
   Science Institute (CTSI); Jacobson Jewish Community Foundation; Clarence
   Wolf Jr & Alma B Wolf Foundation; National Institute of Allergy and
   Infectious Diseases, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P51
   OD011104, P30AI073961]; Defense Advanced Research Projects Agency
   (DARPA) Autonomous Diagnostics to Enable Prevention and Therapeutics:
   Prophylactic Options to Environmental and Contagious Threats
   (ADEPT-PROTECT) programUnited States Department of DefenseDefense
   Advanced Research Projects Agency (DARPA) [W31P4Q-13-1-0011]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI073961, T32AI007244, T32AI007244, P30AI073961, ZIAAI000891,
   P30AI073961, P30AI073961, T32AI007244, T32AI007244, T32AI007244,
   P30AI073961, P30AI073961, P01AI094420, P30AI073961, P01AI094420,
   P30AI073961, P01AI094420, P01AI094420, T32AI007244, P30AI073961,
   P01AI094420, P30AI073961, P01AI094420, T32AI007244, P30AI073961,
   P30AI073961, T32AI007244, P30AI073961, R21AI137690, T32AI007244,
   ZIAAI000891, P01AI094420, P01AI094420, P30AI073961, P30AI073961,
   P01AI094420, P30AI073961, P01AI094420, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, ZIAAI000891, T32AI007244,
   P30AI073961, P30AI073961, P01AI094420, T32AI007244, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, T32AI007244, P30AI073961,
   P30AI073961, P01AI094420, P30AI073961, T32AI007244, T32AI007244,
   ZIAAI000891, P30AI073961, T32AI007244, P30AI073961, P30AI073961,
   T32AI007244, P30AI073961, P30AI073961, P01AI094420, P30AI073961,
   ZIAAI000891, P30AI073961, P01AI094420, P30AI073961, T32AI007244,
   P30AI073961, P30AI073961, T32AI007244, P01AI094420, ZIAAI000891,
   ZIAAI000891, P30AI073961, P30AI073961, P30AI073961, T32AI007244,
   P30AI073961, P30AI073961, P30AI073961, T32AI007244, P30AI073961,
   P01AI094420, T32AI007244, P30AI073961, P01AI094420, T32AI007244,
   P30AI073961, P30AI073961, T32AI007244, P30AI073961, P30AI073961,
   T32AI007244, T32AI007244, R21AI137690, P30AI073961, T32AI007244,
   P30AI073961, T32AI007244, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, P01AI094420, ZIAAI000891, P30AI073961, T32AI007244,
   P30AI073961, T32AI007244, T32AI007244, P30AI073961, P30AI073961,
   P30AI073961, T32AI007244, P01AI094420, T32AI007244, P01AI094420,
   P01AI094420, P30AI073961, ZIAAI000891, P30AI073961, P01AI094420,
   P30AI073961, P30AI073961, ZIAAI000891, T32AI007244, P30AI073961,
   P30AI073961, T32AI007244, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, P01AI094420, ZIAAI000891, T32AI007244,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, T32AI007244, P01AI094420, P30AI073961, P01AI094420,
   P30AI073961, P01AI094420, P01AI094420, P01AI094420, P30AI073961,
   T32AI007244, P30AI073961] Funding Source: NIH RePORTER; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, T32OD011124, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104, P51OD011104, P51OD011104, P51OD011104, P51OD011104,
   P51OD011104] Funding Source: NIH RePORTER
FX This work was supported by the Bill and Melinda Gates Foundation
   (OPP1152818), the National Institutes of Health (NIH) grant
   4P01AI094420-05, the Wallace H. Coulter Center for Translational
   Research at the University of Miami, the Miami Clinical and
   Translational Science Institute (CTSI), the Jacobson Jewish Community
   Foundation and Clarence Wolf Jr & Alma B Wolf Foundation, and the
   Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, NIH. This work was in part supported by NIH grant
   P51 OD011104 to the TNPRC, the NIH grant P30AI073961 to the Miami Center
   for AIDS Research, as well as the Defense Advanced Research Projects
   Agency (DARPA) Autonomous Diagnostics to Enable Prevention and
   Therapeutics: Prophylactic Options to Environmental and Contagious
   Threats (ADEPT-PROTECT) program (W31P4Q-13-1-0011). The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aliota MT, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006964
   Barry PA, 2006, ILAR J, V47, P49, DOI 10.1093/ilar.47.1.49
   Bialas KM, 2015, P NATL ACAD SCI USA, V112, P13645, DOI 10.1073/pnas.1511526112
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Butler D, 2016, NATURE, V535, P475, DOI 10.1038/nature.2016.20309
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Carter AM, 2007, PLACENTA, V28, pS41, DOI 10.1016/j.placenta.2006.11.002
   Davison BB, 1998, AM J TROP MED HYG, V59, P189, DOI 10.4269/ajtmh.1998.59.189
   Davison BB, 2000, AM J TROP MED HYG, V63, P158, DOI 10.4269/ajtmh.2000.63.158
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   DeSesso JM, 2012, CRIT REV TOXICOL, V42, P185, DOI 10.3109/10408444.2011.653487
   Dudley DM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02222-8
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Hirsch AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02499-9
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Magnani DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8184
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mohr EL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190617
   Nguyen SM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006378
   Oduyebo T, 2017, MMWR-MORBID MORTAL W, V66, P781, DOI 10.15585/mmwr.mm6629e1
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rath T, 2015, CRIT REV BIOTECHNOL, V35, P235, DOI 10.3109/07388551.2013.834293
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Santiago GA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002311
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Styer LM, 2007, PLOS PATHOG, V3, P1262, DOI 10.1371/journal.ppat.0030132
   Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193
NR 35
TC 29
Z9 29
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR 24
PY 2018
VL 9
AR 1624
DI 10.1038/s41467-018-04056-4
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GD7EU
UT WOS:000430674000013
PM 29691387
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU De Boni, RB
   Machado, IK
   De Vasconcellos, MTL
   Hoagland, B
   Kallas, EG
   Madruga, JV
   Fernandes, NM
   Cerqueira, NB
   Moreira, RI
   Goulart, SP
   Veloso, VG
   Grinsztejn, B
   Luz, PM
AF De Boni, Raquel B.
   Machado, Iona K.
   De Vasconcellos, Mauricio T. L.
   Hoagland, Brenda
   Kallas, Esper G.
   Madruga, Jose Valdez
   Fernandes, Nilo M.
   Cerqueira, Natalia B.
   Moreira, Ronaldo I.
   Goulart, Silvia P.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Luz, Paula M.
TI Syndemics among individuals enrolled in the PrEP Brasil Study
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE HIV infection; Pre-exposure prophylaxis; MSM; Transgender; Binge
   drinking; Polysubstance use
ID COST-EFFECTIVENESS ANALYSIS; PSYCHOSOCIAL HEALTH-PROBLEMS; PREEXPOSURE
   PROPHYLAXIS; HIV RISK; TRANSGENDER WOMEN; SEXUAL COMPULSIVITY; SENSATION
   SEEKING; ANAL INTERCOURSE; BISEXUAL MEN; SAMPLE
AB Background: Concurrent psychosocial problems may synergistically increase the risk of HIV infection (syndemics), representing a challenge for prevention. We aimed to evaluate the prevalence and associated factors of syndemics among men who have sex with men (MSM) and transgender women (TGW) enrolled in the Brazilian pre-exposure prophylaxis demonstration study (PrEP Brasil Study).
   Methods: Secondary cross-sectional analysis of the PrEP Brasil Study was performed. Of 450 HIV-seronegative MSM/TGW enrolled in the PrEP Brasil Study- conducted at Rio de Janeiro and Sao Paulo, Brazil- 421 participants with complete data were included in the present analysis. Syndemics was defined as occurrence of 2 of the following conditions: polysubstance (2) use, binge drinking, positive depression screen, compulsive sexual behavior, and intimate partner violence (IPV).
   Results: The prevalence of recent polysubstance use was 22.8%, binge drinking 51.1%, positive depression screening 5.2%, compulsive sexual behavior 7.1%, and IPV 7.3%. Syndemics prevalence was 24.2%, and associated factors were younger age (adjusted Odds Ratio (aOR) 0.95, 95% Confidence Interval (95% CI) 0.92-0.98 per year increase), TGW vs. MSM (aOR 3.09, 95% CI: 1.2-8.0), some college education or more vs. less than college (aOR 2.49, 95% CI: 1.31-4.75), and multiple male sexual partners in prior 3 months (aOR 1.69, 95% CI: 0.92-3.14).
   Conclusion: Given the high prevalence of syndemics, particularly of polysubstance use and binge drinking, PrEP delivery offers an opportunity to diagnose and intervene in mental and social well-being.
C1 [De Boni, Raquel B.; Hoagland, Brenda; Fernandes, Nilo M.; Moreira, Ronaldo I.; Veloso, Valdilea G.; Grinsztejn, Beatriz; Luz, Paula M.] Fiocruz MS, Natl Inst Infectol Evandro Chagas, Lapclin STD AIDS, Ave Brasil 4-365, Rio De Janeiro, Brazil.
   [Machado, Iona K.] Columbia Coll Phys & Surg, 630 W 168 St, New York, NY USA.
   [De Vasconcellos, Mauricio T. L.] IBGE, Natl Sch Stat Sci, Rua Andre Cavalcanti,106 Ctr, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia B.; Goulart, Silvia P.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Madruga, Jose Valdez] Ctr Referencia & Treinamento DST AIDS, 81 Vila Mariana, Sao Paulo, Brazil.
RP De Boni, RB (corresponding author), Fiocruz MS, Natl Inst Infectol Evandro Chagas, Lapclin STD AIDS, Ave Brasil 4350, BR-21040360 Rio De Janeiro, Brazil.
EM raqueldeboni@gmail.com; raqueldeboni@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Kallas,
   Esper/0000-0003-2026-6925; Luz, Paula/0000-0001-9746-719X
FU Brazilian Ministry of Health [01/2013 BRA/650 K57]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [476333/2013-0,
   402004/2012-4, 454931/2014-0, 476024/2013-7]; SVS [281/2013];
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E- 26/110.261/2014, 2012/51743]; National
   Council of Technological and Scientific DevelopmentNational Council for
   Scientific and Technological Development (CNPq); Research Funding Agency
   the State of Rio de Janeiro; Sao Paulo State Funding Agency; Gilead
   SciencesGilead Sciences
FX The authors acknowledge funding from the Brazilian Ministry of Health
   (#01/2013 BRA/650 K57), CNPq ((#476333/2013-0, #402004/2012-4, #
   454931/2014-0, # 476024/2013-7) SVS (#281/2013), FAPERJ (#E-
   26/110.261/2014) and FAPESP (< gn4 > #2012/51743- </gn4 > 0). PML and BG
   acknowledge funding from the National Council of Technological and
   Scientific Development and the Research Funding Agency the State of Rio
   de Janeiro. EGK acknowledges funding from the Sao Paulo State Funding
   Agency. Gilead Sciences donated the study drug and covered the costs
   related to drug level assessment in the PrEP Brasil Study.
CR Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Biello K. B., 2016, AIDS CARE, V121, P1
   Biello KB, 2014, AIDS BEHAV, V18, P1264, DOI 10.1007/s10461-013-0632-8
   Blashill AJ, 2015, AIDS BEHAV, V19, P981, DOI 10.1007/s10461-014-0925-6
   Caceres CF, 2015, J INT AIDS SOC, V18
   CDC, 2014, PREEXP PROPH PREV HI
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Defechereux PA, 2016, AIDS BEHAV, V20, P1478, DOI 10.1007/s10461-015-1082-2
   Drabo EF, 2016, CLIN INFECT DIS, V63, P1495, DOI 10.1093/cid/ciw578
   Dyer TP, 2012, J URBAN HEALTH, V89, P697, DOI 10.1007/s11524-012-9674-x
   Ferlatte O, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1961-5
   Ferlatte O, 2014, AIDS BEHAV, V18, P1256, DOI 10.1007/s10461-013-0639-1
   Friedman MR, 2015, AIDS, V29, P1087, DOI 10.1097/QAD.0000000000000657
   Gonzalez-Guarda RM, 2011, PUBLIC HEALTH NURS, V28, P366, DOI 10.1111/j.1525-1446.2010.00928.x
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Guadamuz TE, 2014, AIDS BEHAV, V18, P2089, DOI 10.1007/s10461-014-0826-8
   Halkitis PN, 2015, AIDS BEHAV, V19, P970, DOI 10.1007/s10461-014-0892-y
   Halkitis PN, 2013, AM PSYCHOL, V68, P261, DOI 10.1037/a0032746
   Henrique Iara Ferraz Silva, 2004, Rev. Assoc. Med. Bras., V50, P199, DOI 10.1590/S0104-42302004000200039
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Institute for Health and Metrics Evaluation (IHME), 2016, GLOB BURD DIS COUNTR
   KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1
   KALICHMAN SC, 1995, J PERS ASSESS, V65, P586, DOI 10.1207/s15327752jpa6503_16
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Liu A, 2014, JAIDS-J ACQ IMM DEF, V67, P528, DOI 10.1097/QAI.0000000000000351
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Martinez O, 2016, DRUG ALCOHOL DEPEN, V166, P258, DOI 10.1016/j.drugalcdep.2016.06.033
   Mayer KH, 2012, SEX TRANSM DIS, V39, P1, DOI 10.1097/OLQ.0b013e31823b1922
   Mimiaga MJ, 2015, ARCH SEX BEHAV, V44, P1869, DOI 10.1007/s10508-015-0488-2
   Mimiaga MJ, 2015, JAIDS-J ACQ IMM DEF, V68, P329, DOI 10.1097/QAI.0000000000000475
   NIAAA, 2004, NIAAA COUNC APPR DEF, V3
   Nichols BE, 2016, LANCET INFECT DIS, V16, P1423, DOI 10.1016/S1473-3099(16)30311-5
   Operario D, 2010, JAIDS-J ACQ IMM DEF, V55, pS91, DOI 10.1097/QAI.0b013e3181fbc9ec
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Parsons JT, 2012, AM J PUBLIC HEALTH, V102, P156, DOI 10.2105/AJPH.2011.300284
   Rocha GM, 2013, AIDS BEHAV, V17, P1288, DOI 10.1007/s10461-012-0398-4
   Santos GM, 2014, SEX TRANSM INFECT, V90, P250, DOI 10.1136/sextrans-2013-051318
   Scanavino MD, 2016, ARCH SEX BEHAV, V45, P207, DOI 10.1007/s10508-014-0356-5
   Schneider K, 2014, CLIN INFECT DIS, V58, P1027, DOI 10.1093/cid/cit946
   SINGER M, 1994, SOC SCI MED, V39, P931, DOI 10.1016/0277-9536(94)90205-4
   Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X
   Stall R, 2003, AM J PUBLIC HEALTH, V93, P939, DOI 10.2105/AJPH.93.6.939
   Tsai AC, 2017, LANCET, V389, P978, DOI 10.1016/S0140-6736(17)30403-8
   Tsai AC, 2016, AIDS BEHAV, V20, P423, DOI 10.1007/s10461-015-1260-2
   United Nations Office on Drugs and Crime, 2016, WORLD DRUG REP
   Wang Y, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2132-8
   Wei CY, 2012, DRUG ALCOHOL DEPEN, V120, P246, DOI 10.1016/j.drugalcdep.2011.07.016
   Wu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032312
NR 51
TC 6
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2018
VL 185
BP 168
EP 172
DI 10.1016/j.drugalcdep.2017.12.016
PG 5
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA GD8TD
UT WOS:000430784100021
PM 29454927
DA 2020-11-26
ER

PT J
AU Grinsztejn, B
   Hoagland, B
   Moreira, RI
   Kallas, EG
   Madruga, JV
   Goulart, S
   Leite, IC
   Freitas, L
   Martins, LMS
   Torres, TS
   Vasconcelos, R
   De Boni, RB
   Anderson, PL
   Liu, A
   Luz, PM
   Veloso, VG
AF Grinsztejn, Beatriz
   Hoagland, Brenda
   Moreira, Ronaldo I.
   Kallas, Esper G.
   Madruga, Jose V.
   Goulart, Silvia
   Leite, Iuri C.
   Freitas, Lucilene
   Martins, Luana M. S.
   Torres, Thiago S.
   Vasconcelos, Ricardo
   De Boni, Raquel B.
   Anderson, Peter L.
   Liu, Albert
   Luz, Paula M.
   Veloso, Valdilea G.
CA PrEP Brasil Study Team
TI Retention, engagement, and adherence to pre-exposure prophylaxis for men
   who have sex with men and transgender women in PrEP Brasil: 48 week
   results of a demonstration study
SO LANCET HIV
LA English
DT Article
ID DRIED BLOOD SPOTS; TENOFOVIR-DIPHOSPHATE; HIV-INFECTION; EMTRICITABINE;
   VALIDITY; RISK
AB Background PrEP Brasil was a demonstration study to assess feasibility of daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost to men who have sex with men (MSM) and transgender women at high risk for HIV within the Brazilian public health system. We report week 48 pre-exposure prophylaxis (PrEP) retention, engagement, and adherence, trends in sexual behaviour, and incidence of HIV and sexually transmitted infections in this study cohort.
   Methods PrEP Brasil was a 48 week, open-label, demonstration study that assessed PrEP delivery at three referral centres for HIV prevention and care in Rio de Janeiro, Brazil (Fundacao Oswaldo Cruz), and Sao Paulo, Brazil (Universidade de Sao Paulo and Centro de Referencia e Treinamento em DST e AIDS). Eligible participants were MSM and transgender women who were HIV negative, aged at least 18 years, resident in Rio de Janeiro or Sao Paulo, and reported one or more sexual risk criteria in the previous 12 months (eg, condomless anal sex with two or more partners, two or more episodes of anal sex with an HIV-infected partner, or history of sexually transmitted infection [STI] diagnosis). Participants were seen at weeks 4, 12, 24, 36, and 48 for PrEP provision, clinical and laboratory evaluation, and HIV testing. Computer-assisted self-interviews were also done at study visits 12, 24, 36, and 48, and assessed sexual behaviour and drug use. PrEP retention was defined by attendance at the week 48 visit, PrEP engagement was an ordinal five-level variable combining presence at the study visit and drug concentrations, and PrEP adherence was evaluated by measuring tenofovir diphosphate concentrations in dried blood spots. Logistic regression models were used to quantify the association of variables with high adherence (>= 4 doses per week). The study is registered with ClinicalTrials. gov, number NCT01989611.
   Findings Between April 1, 2014, and July 8, 2016, 450 participants initiated PrEP, 375 (83%) of whom were retained until week 48. At week 48, 277 (74%) of 375 participants had protective drug concentrations consistent with at least four doses per week: 183 (82%) of 222 participants from Sao Paulo compared with 94 (63%) of 150 participants from Rio de Janeiro (adjusted odds ratio 1.88, 95% CI 1.06-3.34); 119 (80%) of 148 participants who reported sex with HIV-infected partners compared with 158 (70%) of 227 participants who did not (1.78, 1.03-3.08); 67 (87%) of 77 participants who used stimulants compared with 210 (71%) of 298 participants who did not (2.23, 1.02-4.92); and 232 (80%) of 289 participants who had protective concentrations of tenofovir disphosphate at week 4 compared with 42 (54%) of 78 participants who did not (3.28, 1.85-5.80). Overall, receptive anal sex with the last three partners increased from 45% at enrolment to 49% at week 48 (p=0.17), and the mean number of sexual partners in the previous 3 months decreased from 11.4 (SD 28.94) at enrolment to 8.3 (19.55) at week 48 (p<0.0013). Two individuals seroconverted during follow-up (HIV incidence 0.51 per 100 person-years, 95% CI 0.13-2.06); both of these patients had undetectable tenofovir concentrations at seroconversion.
   Interpretation Our results support the effectiveness and feasibility of PrEP in a real-world setting. Offering PrEP at public health-care clinics in a middle-income setting can retain high numbers of participants and achieve high levels of adherence without risk compensation in the investigated populations.
C1 [Grinsztejn, Beatriz; Hoagland, Brenda; Moreira, Ronaldo I.; Freitas, Lucilene; Martins, Luana M. S.; Torres, Thiago S.; De Boni, Raquel B.; Luz, Paula M.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-22461 Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Vasconcelos, Ricardo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Madruga, Jose V.; Goulart, Silvia] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Leite, Iuri C.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Anderson, Peter L.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO USA.
   [Liu, Albert] Bridge HIV, San Francisco Dept Publ Hlth, San Francisco, CA USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-22461 Rio De Janeiro, Brazil.
EM beatriz.grinsztejn@gmail.com
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Vasconcelos,
   Ricardo/AAL-4634-2020; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Vasconcelos,
   Ricardo/0000-0002-9753-0563; TORRES, THIAGO SILVA/0000-0002-2557-601X;
   Moreira, Carlos Henrique Valente/0000-0002-4187-5482; Luz,
   Paula/0000-0001-9746-719X; Kallas, Esper/0000-0003-2026-6925; PRADO,
   GLADYS/0000-0001-8833-3368
FU Brazilian Ministry of Health; Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Secretaria de Vigilancia em Saude;
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Brazilian Ministry of Health, Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Secretaria de Vigilancia em Saude, Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro,
   and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo.
CR Allison P. D., 2012, LOGISTIC REGRESSION
   Anderson P, 2017, C RETR OPP INF 2017
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Barbosa A, 2009, CAD SAUDE PUBLICA, V25, P727, DOI 10.1590/S0102-311X2009000400003
   Brasil. Ministerio da Saude (MS), 2016, B EP HIV AIDS
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Curran K, 2013, AIDS BEHAV, V17, P2977, DOI 10.1007/s10461-013-0510-4
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Division of AIDS National Institute of Allergy and Infectious Diseases, 2004, DIVISION AIDS TABLE
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2017, LANCET HIV, V4, pE169, DOI 10.1016/S2352-3018(17)30015-2
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
   Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6
   Liu A, 2017, ADHERENCE 2017
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Luz PM, 2016, 21 INT AIDS C DURB S
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Tangmunkongvorakul A, 2013, AIDS CARE, V25, P961, DOI 10.1080/09540121.2012.748871
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 29
TC 37
Z9 37
U1 2
U2 17
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD MAR
PY 2018
VL 5
IS 3
BP E136
EP E145
DI 10.1016/S2352-3018(18)30008-0
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FZ2PK
UT WOS:000427422000009
PM 29467098
DA 2020-11-26
ER

PT J
AU Grifoni, A
   ORourke, PH
   de Silva, AD
   Costa, PR
   Durbin, A
   Diehl, SA
   Cerpas, C
   Balmaseda, A
   Kallas, EG
   Harris, E
   Sette, A
   Weiskopf, D
AF Grifoni, Alba
   ORourke, Patrick
   de Silva, Aruna
   Costa, Priscilla
   Durbin, Anna
   Diehl, Sean
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kallas, Esper
   Harris, Eva
   Sette, Alessandro
   Weiskopf, Daniela
TI FLAVIVIRUS INDUCED T CELL CROSS-REACTIVITY
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 67th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTHM)
CY OCT 28-NOV 01, 2018
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Takeda Pharmaceut Int AG, Novartis Social Business, Celgene Corp, Techlab Inc, Indiana Univ, Sch Med, B EI Resources, Sanofi Pasteur, Welcome, PLOS, Elsevier
C1 [Grifoni, Alba; ORourke, Patrick; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [de Silva, Aruna] Kotelawala Def Univ, Ratmalana, Sri Lanka.
   [Costa, Priscilla; Kallas, Esper] Univ Sao Paulo, Sao Paulo, Brazil.
   [Durbin, Anna] Johns Hopkins Univ, Baltimore, MD USA.
   [Diehl, Sean] Univ Vermont, Burlington, VT USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Natl Virol Lab, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RI Diehl, Sean/AAE-2779-2020
OI Diehl, Sean/0000-0001-9700-235X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2018
VL 99
IS 4
SU S
MA 725
BP 227
EP 228
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA HP0WF
UT WOS:000461386603059
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Avelino-Silva, VI
   Santos, BAN
   Barsotti, NS
   Siroma, F
   Ramos, JF
   Tonacio, AC
   Song, A
   Maestri, A
   Cerqueira, NB
   Felix, AC
   Levi, JE
   Greenspun, BC
   Rougvie, MD
   Rosenberg, MG
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Avelino-Silva, Vivian I.
   Santos, Bianca A. N.
   Barsotti, Nathalia Silveira
   Siroma, Fabiana
   Ramos, Jessica Fernandes
   Tonacio, Adriana Coracini
   Song, Alice
   Maestri, Alvino
   Cerqueira, Natalia Barros
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Greenspun, Benjamin C.
   Rougvie, Miguel de Mulder
   Rosenberg, Michael G.
   Nixon, Douglas F.
   Kallas, Esper G.
TI MAIT cells are activated in acute Dengue virus infection and after in
   vitro Zika virus infection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INVARIANT T-CELLS; TRANSMISSION; POPULATION; IMMUNITY
AB Dengue virus (DENV) and Zika virus (ZIKV) are members of the Flaviviridae and are pre-dominantly transmitted via mosquito bites. Both viruses are responsible for a growing number of infections in tropical and subtropical regions. DENV infection can cause lethargy with severe morbidity and dengue shock syndrome leading to death in some cases. ZIKV is now linked with Guillain-Barre A syndrome and fetal malformations including microcephaly and developmental disorders (congenital Zika syndrome). The protective and pathogenic roles played by the immune response in these infections is unknown. Mucosal-associated invariant T (MAIT) cells are a population of innate T cells with potent anti-bacterial activity. MAIT cells have also been postulated to play a role in the immune response to viral infections. In this study, we evaluated MAIT cell frequency, phenotype, and function in samples from subjects with acute and convalescent DENV infection. We found that in acute DENV infection, MAIT cells had elevated co-expression of the activation markers CD38 and HLA-DR and had a poor IFN gamma response following bacterial stimulation. Furthermore, we found that MAIT cells can produce IFN gamma in response to in vitro infection with ZIKV. This MAIT cell response was independent of MR1, but dependent on IL-12 and IL-18. Our results suggest that MAIT cells may play an important role in the immune response to Flavivirus infections.
C1 [Paquin-Proulx, Dominic; Greenspun, Benjamin C.; Rougvie, Miguel de Mulder; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Avelino-Silva, Vivian I.; Santos, Bianca A. N.; Barsotti, Nathalia Silveira; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice; Maestri, Alvino; Cerqueira, Natalia Barros; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Siroma, Fabiana; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Rosenberg, Michael G.] Jacobi Med Ctr, Pediat Infect Dis Dept, Bronx, NY USA.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM dpaquin_proulx@gwu.edu
RI de Mulder Rougvie, Miguel/AAG-6224-2020; Nixon, Douglas/AAU-5734-2020;
   Song, Alice Tung Wan/F-2494-2014; Avelino-Silva, Vivian I/L-2640-2013
OI de Mulder Rougvie, Miguel/0000-0002-8026-7076; Nixon,
   Douglas/0000-0002-2801-1786; Song, Alice Tung Wan/0000-0001-6992-9326;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Silveira Barsotti,
   Nathalia/0000-0003-3513-5258; Paquin Proulx,
   Dominic/0000-0003-1407-3414; Kallas, Esper/0000-0003-2026-6925
FU District of Columbia Center for AIDS Research, an NIH [AI117970]; GWU
   SMHS Office of International Medicine Programs
FX This research was funded in part by a pilot award, and facilities and
   services, from the District of Columbia Center for AIDS Research, an NIH
   funded program (AI117970), and from the GWU SMHS Office of International
   Medicine Programs. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Dias J, 2017, P NATL ACAD SCI US
   Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR
   Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449
   Gold MC, 2014, J EXP MED, V211, P1601, DOI 10.1084/jem.20140507
   Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447
   Joao Esau Custodio, 2017, Pediatr Infect Dis J, V36, P500, DOI 10.1097/INF.0000000000001482
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072
   Leeansyah E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4143
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134
   Li J, 2016, AUSTRALAS J DERMATOL
   Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Pal T, 2014, J CLIN VIROL, V61, P365, DOI 10.1016/j.jcv.2014.09.003
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Paquin-Proulx D, 2017, IMMUNOHORIZON, V1, P141
   Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345
   Penot P, 2017, EURO SURVEILL, V22
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Salou M, 2017, CURR OPIN IMMUNOL, V48, P7, DOI 10.1016/j.coi.2017.07.009
   Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218
   Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2898, DOI 10.1038/jid.2014.261
   Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
NR 40
TC 17
Z9 17
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2018
VL 12
IS 1
AR e0006154
DI 10.1371/journal.pntd.0006154
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FU7HJ
UT WOS:000424022700027
PM 29357366
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hoagland, B
   Moreira, RI
   De Boni, RB
   Kallas, EG
   Madruga, JV
   Vasconcelos, R
   Goulart, S
   Torres, TS
   Marins, LMS
   Anderson, PL
   Luz, PM
   Leite, ID
   Liu, AY
   Veloso, VG
   Grinsztejn, B
AF Hoagland, Brenda
   Moreira, Ronaldo I.
   De Boni, Raquel B.
   Kallas, Esper G.
   Madruga, Jose Valdez
   Vasconcelos, Ricardo
   Goulart, Silvia
   Torres, Thiago S.
   Marins, Luana M. S.
   Anderson, Peter L.
   Luz, Paula M.
   Leite, Iuri da Costa
   Liu, Albert Y.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI High pre-exposure prophylaxis uptake and early adherence among men who
   have sex with men and trans-gender women at risk for HIV Infection: the
   PrEP Brasil demonstration project (vol 20, 21472, 2017)
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Correction
RI Vasconcelos, Ricardo/AAL-4634-2020
OI Vasconcelos, Ricardo/0000-0002-9753-0563
CR Hoagland B, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21472
NR 1
TC 0
Z9 0
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JAN
PY 2018
VL 21
AR e25069
DI 10.1002/jia2.25069
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FU4FO
UT WOS:000423809100012
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Grebe, E
   Welte, A
   Hall, J
   Keating, SM
   Facente, SN
   Marson, K
   Martin, JN
   Little, SJ
   Price, MA
   Kallas, EG
   Busch, MP
   Pilcher, CD
   Murphy, G
AF Grebe, Eduard
   Welte, Alex
   Hall, Jake
   Keating, Sheila M.
   Facente, Shelley N.
   Marson, Kara
   Martin, Jeffrey N.
   Little, Susan J.
   Price, Matthew A.
   Kallas, Esper G.
   Busch, Michael P.
   Pilcher, Christopher D.
   Murphy, Gary
CA Consortium Evaluation Performance
TI Infection Staging and Incidence Surveillance Applications of High
   Dynamic Range Diagnostic Immuno-Assay Platforms
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE infection timing; infection staging; incidence; recent infection;
   diagnostic assays; staging assays
ID POPULATION INCIDENCE; HIV-INFECTION; ASSAYS
AB Background: Custom HIV staging assays, including the Sedia HIV-1 Limiting Antigen (LAg) Avidity EIA and avidity modifications of the Ortho VITROS anti-HIV-1+2 and Abbott ARCHITECT HIV Ag/Ab Combo assays, are used to identify "recent" infections in clinical settings and for cross-sectional HIV incidence estimation. However, the high dynamic range of chemiluminescent platforms allows differentiating recent and long-standing infection on signal intensity, and this raises the prospect of using unmodified diagnostic assays for infection timing and surveillance applications.
   Methods: We tested a panel of 2500 well-characterized specimens with estimable duration of HIV infection with the 3 assays and the unmodified ARCHITECT. Regression models were used to estimate mean durations of recent infection (MDRIs), context-specific false-recent rates (FRRs) and correlation between diagnostic signal intensity and LAg measurements. Hypothetical epidemiological scenarios were constructed to evaluate utility in surveillance applications.
   Results: Over a range of MDRIs (reflecting recency discrimination thresholds), a diluted ARCHITECT-based RITA produced lower FRRs than the VITROS platform (FRR approximate to 0.5% and 1.5%, respectively at MDRI approximate to 200 days), and the unmodified diagnostic ARCHITECT produces incidence estimates with comparable precision to LAg (relative SE approximate to 17.5% and 15%, respectively at MDRI approximate to 200 days). ARCHITECT S/CO measurements were highly correlated with LAg optical density measurements (r = 0.80), and values below 200 are strongly predictive of LAg recency and duration of infection less than 1 year.
   Conclusions: Low quantitative measurements from the unmodified ARCHITECT obviate the need for additional recency testing, and its use is feasible in clinical staging and incidence surveillance applications.
C1 [Grebe, Eduard; Welte, Alex] Stellenbosch Univ, SACEMA, Stellenbosch, South Africa.
   [Hall, Jake; Murphy, Gary] Publ Hlth England, Natl Infect Serv, London, England.
   [Keating, Sheila M.; Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
   [Keating, Sheila M.; Facente, Shelley N.; Marson, Kara; Martin, Jeffrey N.; Price, Matthew A.; Busch, Michael P.; Pilcher, Christopher D.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   [Little, Susan J.] Univ Calif San Diego, Dept Med, Div Infect Dis, San Diego, CA 92103 USA.
   [Price, Matthew A.] IAVI, Dept Med Affairs, New York, NY USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Grebe, E (corresponding author), Stellenbosch Univ, SACEMA, Private Bag X1, ZA-7602 Matieland, South Africa.
EM eduardgrebe@sun.ac.za
RI Little, Susan/AAA-6116-2019; Facente, Shelley/M-1147-2019
OI Kallas, Esper/0000-0003-2026-6925; Loeb Stanga,
   Lisa/0000-0001-7471-5381; Facente, Shelley N./0000-0002-7266-352X;
   Grebe, Eduard/0000-0001-7046-7245
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1017716, OPP1062806, OPP1115799]; US National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R34 MH096606]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [P01 AI071713, R01 HD074511, P30 AI027763, R24 AI067039, U01
   AI043638, P01 AI074621, R24 AI106039]; California HIV-1 Research Program
   [RN07-SD-702]; Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO]; Sao Paulo City Health Department
   [2004-0.168.922-7]; AbbottAbbott Laboratories; Ortho Clinical
   Diagnostics; Sedia Biosciences Corporation; IAVI; USAIDUnited States
   Agency for International Development (USAID); EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01HD074511, R01HD074511, R01HD074511,
   R01HD074511, R01HD074511] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, U01AI043638, U01AI043638, P30AI027763,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, R24AI067039,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P01AI071713, P01AI071713, P30AI027763, P30AI027763, P01AI071713,
   R24AI106039, P30AI027763, P30AI027763, U01AI043638, U01AI043638,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, P30AI027763,
   P01AI074621, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P01AI071713, P01AI071713, P01AI074621, P30AI027763, P01AI074621,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI074621,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI074621,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, U01AI043638,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   P01AI071713, R24AI067039, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI074621, R24AI106039, P30AI027763, P01AI071713,
   P01AI074621, P01AI071713, R24AI106039, P01AI071713, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, P01AI071713, R24AI106039,
   P30AI027763, P30AI027763, P01AI074621, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, U01AI043638, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, P01AI074621, P30AI027763, P30AI027763,
   P01AI074621, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI074621, P30AI027763, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P01AI074621, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P01AI074621, P30AI027763, R24AI067039,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, R24AI067039,
   P30AI027763, P01AI074621, U01AI043638, R24AI106039, P30AI027763,
   P01AI074621, P30AI027763, P30AI027763, P30AI027763, R24AI106039,
   U01AI043638, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI043638, P30AI027763,
   U01AI043638, P01AI071713, P01AI071713, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, U01AI043638, P01AI074621, P30AI027763,
   P01AI074621, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, U01AI043638,
   R24AI067039, P01AI071713, P01AI074621, R24AI067039, U01AI043638,
   P30AI027763, P30AI027763, P30AI027763, R24AI106039, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, R24AI106039, U01AI043638,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI074621,
   P01AI074621, P30AI027763, P01AI071713, P01AI071713, P01AI071713,
   P30AI027763, P01AI074621, P30AI027763, P30AI027763, R24AI106039,
   P01AI071713, P01AI074621, P30AI027763, R24AI067039, P01AI071713,
   P30AI027763, P01AI074621, P01AI071713] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R34MH096606, R34MH096606,
   R01MH100974, R01MH100974, R01MH100974, R34MH096606, R01MH100974,
   R01MH100974] Funding Source: NIH RePORTER
FX All authors, as members or collaborators of the Consortium for the
   Evaluation and Performance of HIV Incidence Assays (CEPHIA), were
   supported by grants from the Bill and Melinda Gates Foundation
   (OPP1017716, OPP1062806 and OPP1115799). Additional support for analysis
   was provided by a grant from the US National Institutes of Health (R34
   MH096606), and specimen and data collection were funded in part by
   additional grants from the NIH (P01 AI071713, R01 HD074511, P30
   AI027763, R24 AI067039, U01 AI043638, P01 AI074621, and R24 AI106039);
   California HIV-1 Research Program (RN07-SD-702); Brazilian Program for
   STD and AIDS, Ministry of Health (914/BRA/3014-UNESCO); and Sao Paulo
   City Health Department (2004-0.168.922-7). S.M.K and M.P.B. receive
   ongoing grant support from Abbott, Ortho Clinical Diagnostics, and Sedia
   Biosciences Corporation for the evaluation of their respective assays.
   M.A.P. and selected samples from IAVI-supported cohorts are funded by
   IAVI with the generous support of USAID and other donors; a full list of
   IAVI donors is available at www.iavi.org.
CR BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Chawla A, 2007, J CLIN MICROBIOL, V45, P415, DOI 10.1128/JCM.01879-06
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Grebe E, 2016, CROSS SECTIONALLY ES
   Guy R, 2009, LANCET INFECT DIS, V9, P747, DOI 10.1016/S1473-3099(09)70300-7
   Kassanjee R., 2014, THESIS
   Kassanjee R, 2016, AIDS, V30, P2361, DOI 10.1097/QAD.0000000000001209
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/aid.2013.0113, 10.1089/AID.2013.0113]
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Keating SM, 2016, JAIDS-J ACQ IMM DEF, V73, P581, DOI 10.1097/QAI.0000000000001146
   Laeyendecker O, 2013, J INFECT DIS, V207, P232, DOI 10.1093/infdis/jis659
   Laeyendecker O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025899
   Mahiane GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044377
   Mastro Timothy D, 2010, J HIV AIDS Surveill Epidemiol, V2, P1
   McDougal JS, 2006, AIDS RES HUM RETROV, V22, P945, DOI 10.1089/aid.2006.22.945
   McWalter TA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007368
   Morrison C, 2017, ASSAYS MEASURE HIV I
   Murphy G, 2017, EPIDEMIOL INFECT, V145, P925, DOI 10.1017/S0950268816002910
   Suligoi B, 2011, J CLIN MICROBIOL, V49, P2610, DOI 10.1128/JCM.02115-10
   Welte A, 2016, INCTOOLS INCIDENCE E
NR 22
TC 7
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 15
PY 2017
VL 76
IS 5
BP 547
EP 555
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FT6TU
UT WOS:000423287500017
PM 28914669
DA 2020-11-26
ER

PT J
AU Ricciardi, MJ
   Magnani, DM
   Grifoni, A
   Kwon, YC
   Gutman, MJ
   Grubaugh, ND
   Gangavarapu, K
   Sharkey, M
   Silveira, CGT
   Bailey, VK
   Pedreno-Lopez, N
   Gonzalez-Nieto, L
   Maxwell, HS
   Domingues, A
   Martins, MA
   Pham, J
   Weiskopf, D
   Altman, J
   Kallas, EG
   Andersen, KG
   Stevenson, M
   Lichtenberger, P
   Choe, H
   Whitehead, SS
   Sette, A
   Watkins, DI
AF Ricciardi, Michael J.
   Magnani, Diogo M.
   Grifoni, Alba
   Kwon, Young-Chan
   Gutman, Martin J.
   Grubaugh, Nathan D.
   Gangavarapu, Karthik
   Sharkey, Mark
   Silveira, Cassia G. T.
   Bailey, Varian K.
   Pedreno-Lopez, Nuria
   Gonzalez-Nieto, Lucas
   Maxwell, Helen S.
   Domingues, Aline
   Martins, Mauricio A.
   Pham, John
   Weiskopf, Daniela
   Altman, John
   Kallas, Esper G.
   Andersen, Kristian G.
   Stevenson, Mario
   Lichtenberger, Paola
   Choe, Hyeryun
   Whitehead, Stephen S.
   Sette, Alessandro
   Watkins, David I.
TI Ontogeny of the B- and T-cell response in a primary Zika virus infection
   of a dengue-naive individual during the 2016 outbreak in Miami, FL
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CROSS-REACTIVITY; STRUCTURAL BASIS; ENHANCEMENT; TRANSMISSION;
   NEUTRALIZATION; RHESUS; REPLICATION; EMERGENCE; MODEL
AB Zika virus (ZIKV) is a mosquito-borne flavivirus of significant public health concern. In the summer of 2016, ZIKV was first detected in the contiguous United States. Here we present one of the first cases of a locally acquired ZIKV infection in a dengue-naive individual. We collected blood from a female with a maculopapular rash at day (D) 5 and D7 post onset of symptoms (POS) and we continued weekly blood draws out to D148 POS. To establish the ontogeny of the immune response against ZIKV, lymphocytes and plasma were analyzed in a longitudinal fashion. The plasmablast response peaked at D7 POS (19.6% of CD19(+) B-cells) and was undetectable by D15 POS. ZIKV-specific IgM was present at D5 POS, peaked between D15 and D21 POS, and subsequently decreased. The ZIKV-specific IgG response, however, was not detected until D15 POS and continued to increase after that. Interestingly, even though the patient had never been infected with dengue virus (DENV), cross-reactive IgM and IgG binding against each of the four DENV serotypes could be detected. The highest plasma neutralization activity against ZIKV peaked between D15 and D21 POS, and even though DENV binding antibodies were present in the plasma of the patient, there was neither neutralization nor antibody dependent enhancement (ADE) of DENV. Interestingly, ADE against ZIKV arose at D48 POS and continued until the end of the study. CD4(+) and CD8(+) T-cells recognized ZIKV-NS2A and ZIKV-E, respectively. The tetramer positive CD8(+) T-cell response peaked at D21 POS with elevated levels persisting for months. In summary, this is the first study to establish the timing of the ontogeny of the immune response against ZIKV.
C1 [Ricciardi, Michael J.; Magnani, Diogo M.; Gutman, Martin J.; Bailey, Varian K.; Pedreno-Lopez, Nuria; Gonzalez-Nieto, Lucas; Maxwell, Helen S.; Domingues, Aline; Martins, Mauricio A.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Grifoni, Alba; Pham, John; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA.
   [Kwon, Young-Chan; Choe, Hyeryun] Scripps Res Inst, Dept Immunol & Microbial Sci, Jupiter, FL USA.
   [Grubaugh, Nathan D.; Gangavarapu, Karthik; Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Sharkey, Mark; Stevenson, Mario; Lichtenberger, Paola] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Altman, John] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Altman, John] Emory Univ, Emory Vaccine Res Ctr, Atlanta, GA 30322 USA.
   [Whitehead, Stephen S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Ricciardi, MJ (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
EM mricciardi@med.miami.edu
RI Martins, Mauricio/AAU-9226-2020; Whitehead, Stephen/AAG-2787-2019
OI Martins, Mauricio/0000-0001-8336-216X; Magnani,
   Diogo/0000-0002-1773-2406; , Alba/0000-0002-2209-5966; Kallas,
   Esper/0000-0003-2026-6925; Weiskopf, Daniela/0000-0003-2968-7371;
   Grubaugh, Nathan/0000-0003-2031-1933
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [1P01AI094420-05]; University of Miami Clinical Translational Research
   Institute (CTSI); U.S, National Institutes for HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [HHSN27220140045C, 1P01AI106695-01A1, U19AI118626-01]; EUEuropean
   Union (EU) [734584]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR000460, UL1TR000460, UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI118626, T32AI007244, U19AI118626, ZIAAI000987, U19AI118626,
   U19AI118626, U19AI118626, U19AI118626, T32AI007244, T32AI007244,
   T32AI007244, ZIAAI000987, T32AI007244, U19AI118626, T32AI007244,
   T32AI007244, U19AI118626, T32AI007244, T32AI007244, ZIAAI000987,
   U19AI118626, T32AI007244, U19AI118626, ZIAAI000987, ZIAAI000987,
   U19AI118626, ZIAAI000987, T32AI007244, U19AI118626, U19AI118626,
   U19AI118626, T32AI007244, T32AI007244, U19AI118626, T32AI007244,
   ZIAAI000987, U19AI118626, T32AI007244, U19AI118626, T32AI007244,
   T32AI007244, U19AI118626, T32AI007244, U19AI118626, U19AI118626,
   T32AI007244, U19AI118626, U19AI118626, T32AI007244, U19AI118626,
   U19AI118626, T32AI007244, T32AI007244, U19AI118626, U19AI118626,
   T32AI007244, U19AI118626, U19AI118626, T32AI007244, U19AI118626,
   T32AI007244, U19AI118626, T32AI007244, T32AI007244, U19AI118626,
   U19AI118626, T32AI007244, T32AI007244, U19AI118626, T32AI007244,
   U19AI118626, U19AI118626, ZIAAI000987, U19AI118626, T32AI007244,
   ZIAAI000987, ZIAAI000987, T32AI007244, T32AI007244, U19AI118626,
   U19AI118626, U19AI118626, T32AI007244, T32AI007244, U19AI118626,
   U19AI118626, U19AI118626, T32AI007244, T32AI007244] Funding Source: NIH
   RePORTER
FX This work was supported by a grant from the U.S. National Institutes of
   Health supplement to 1P01AI094420-05 awarded to D.I.W., and an internal
   grant from the University of Miami Clinical Translational Research
   Institute (CTSI) [http://www.miamictsi.org]. Additional support was
   provided by the U.S, National Institutes for Health grants
   HHSN27220140045C, 1P01AI106695-01A1, U19AI118626-01, and the EU-grant
   734584 to A.S. The views expressed are those of the authors and not
   necessarily those of the funding bodies. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   [Anonymous], 2016, FLOR INV LINKS 4 REC
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bierlaire D, 2017, TRANSFUSION
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Camacho E, 2016, EMERG INFECT DIS, V22, P927, DOI 10.3201/eid2205.160023
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Case Counts in the US, 2016, THE CENTERS FOR DISE
   Coffey LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171148
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Fields BN, 1990, FIELDS VIROLOGY
   Friberg H, 2011, SCI REP-UK, V1, DOI 10.1038/srep00051
   Grifoni A, J VIROL IN PRESS
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   HALSTEAD SB, 1976, P SOC EXP BIOL MED, V151, P136, DOI 10.3181/00379727-151-39160
   HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huerta-Cepas J, 2016, MOL BIOL EVOL, V33, P1635, DOI 10.1093/molbev/msw046
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Krow-Lucal ER, 2017, EMERG INFECT DIS, V23
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   MCCRAE AWR, 1982, T ROY SOC TROP MED H, V76, P552, DOI 10.1016/0035-9203(82)90161-4
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Monaghan AJ, 2016, PLOS CURR, P8
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   MORLAN HB, 1965, AM J TROP MED HYG, V14, P892, DOI 10.4269/ajtmh.1965.14.892
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Paz-Bailey G., 2017, N ENGL J MED
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Sikka V, 2016, J GLOB INFECT DIS, V8, P3, DOI 10.4103/0974-777X.176140
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898
   Vasilakis N, 2017, CURR OPIN VIROL, V22, P30, DOI 10.1016/j.coviro.2016.11.007
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
   YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
NR 82
TC 22
Z9 22
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2017
VL 11
IS 12
AR e0006000
DI 10.1371/journal.pntd.0006000
PG 23
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FR5LR
UT WOS:000419108500004
PM 29267278
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Grifoni, A
   Pham, J
   Sidney, J
   O'Rourke, PH
   Paul, S
   Peters, B
   Martini, SR
   de Silva, AD
   Ricciardi, MJ
   Magnani, DM
   Silveira, CGT
   Maestri, A
   Costa, PR
   de-Oliveira-Pinto, LM
   de Azeredo, EL
   Damasco, PV
   Phillips, E
   Mallal, S
   de Silva, AM
   Collins, M
   Durbin, A
   Diehl, SA
   Cerpas, C
   Balmaseda, A
   Kuan, G
   Coloma, J
   Harris, E
   Crowe, JE
   Stone, M
   Norris, PJ
   Busch, M
   Vivanco-Cid, H
   Cox, J
   Graham, BS
   Ledgerwood, JE
   Turtle, L
   Solomon, T
   Kallas, EG
   Watkins, DI
   Weiskopf, D
   Sette, A
AF Grifoni, Alba
   Pham, John
   Sidney, John
   O'Rourke, Patrick H.
   Paul, Sinu
   Peters, Bjoern
   Martini, Sheridan R.
   de Silva, Aruna D.
   Ricciardi, Michael J.
   Magnani, Diogo M.
   Silveira, Cassia G. T.
   Maestri, Alvino
   Costa, Priscilla R.
   de-Oliveira-Pinto, Luzia Maria
   de Azeredo, Elzinandes Leal
   Damasco, Paulo Vieira
   Phillips, Elizabeth
   Mallal, Simon
   de Silva, Aravinda M.
   Collins, Matthew
   Durbin, Anna
   Diehl, Sean A.
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kuan, Guillermina
   Coloma, Josefina
   Harris, Eva
   Crowe, James E., Jr.
   Stone, Mars
   Norris, Phillip J.
   Busch, Michael
   Vivanco-Cid, Hector
   Cox, Josephine
   Graham, Barney S.
   Ledgerwood, Julie E.
   Turtle, Lance
   Solomon, Tom
   Kallas, Esper G.
   Watkins, David I.
   Weiskopf, Daniela
   Sette, Alessandro
TI Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in
   Humans
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE ZIKV; DENV; T cells; heterologous immunity; cross-reactivity;
   immunodominance
ID ORIGINAL ANTIGENIC SIN; COMPREHENSIVE ANALYSIS; HETEROLOGOUS IMMUNITY;
   CROSS-REACTIVITY; PROTECTIVE ROLE; RESPONSES; INFECTION; VACCINE;
   ANTIBODIES; CD4(+)
AB While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.
   IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.
C1 [Grifoni, Alba; Pham, John; Sidney, John; O'Rourke, Patrick H.; Paul, Sinu; Peters, Bjoern; Martini, Sheridan R.; Weiskopf, Daniela; Sette, Alessandro] Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Ricciardi, Michael J.; Magnani, Diogo M.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [de-Oliveira-Pinto, Luzia Maria; de Azeredo, Elzinandes Leal] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Fed Univ State Rio Janeiro UNIRIO, Rio De Janeiro, Brazil.
   [Phillips, Elizabeth; Mallal, Simon] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [de Silva, Aravinda M.; Collins, Matthew] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Durbin, Anna] Johns Hopkins Univ Bloomberg, Sch Publ Hlth, Baltimore, MD USA.
   [Diehl, Sean A.] Univ Vermont, Sch Med, Burlington, VT 05405 USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Kuan, Guillermina] Minist Hlth, Hlth Ctr Socrates Flores Vivas, Managua, Nicaragua.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA.
   [Stone, Mars; Norris, Phillip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Inst Invest Med Biolog, Veracruz, Mexico.
   [Cox, Josephine; Graham, Barney S.; Ledgerwood, Julie E.] NIH, Vaccine Res Ctr, NIAID, Bldg 10, Bethesda, MD 20892 USA.
   [Turtle, Lance] Univ Liverpool, Inst Infect & Global Hlth, Ctr Global Vaccine Res, Liverpool, Merseyside, England.
   [Turtle, Lance; Solomon, Tom] Univ Liverpool, NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool, Merseyside, England.
   [Turtle, Lance] Royal Liverpool Univ Hosp, Trop & Infect Dis Unit, Liverpool, Merseyside, England.
   [Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Phillips, Elizabeth; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia.
RP Sette, A (corresponding author), Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
EM alex@lji.org
RI Crowe, James E./B-5549-2009; Graham, Barney S./AAC-5898-2019;
   /AAD-2097-2020; Diehl, Sean/AAE-2779-2020; desilva,
   Aravinda/ABE-6260-2020
OI Crowe, James E./0000-0002-0049-1079; Graham, Barney
   S./0000-0001-8112-0853; Diehl, Sean/0000-0001-9700-235X; desilva,
   Aravinda/0000-0003-3317-5950; Turtle, Lance/0000-0002-0778-1693;
   Solomon, Tom/0000-0001-7266-6547; Weiskopf, Daniela/0000-0003-2968-7371;
   Cox, Josephine/0000-0003-1301-7373; Magnani, Diogo/0000-0002-1773-2406;
   Kallas, Esper/0000-0003-2026-6925; , Alba/0000-0002-2209-5966
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900042C,
   HHSN27220140045C, U19 AI118626-01, HHSN268201100001I, 1P01AI106695-01A1,
   RO1 AI127828]; ZikaPLAN - European Union [734584]; BMGF [457
   OPP1104710]; University of Miami Clinical and Translational Research
   Institute; Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras
   de la CienciaConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [2015-02-1192]; Ciencia Basica SEP-CONACyT [256235]; Fosiss-CONACyT
   [233697]; Medical Research CouncilMedical Research Council UK (MRC)
   [G116/194, MC_PC_15096] Funding Source: researchfish; National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [RP-PG-0108-10048, EME/12/205/28, 12/205/28, CL-2013-07-005,
   NF-SI-0514-10177] Funding Source: researchfish; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI118626, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, U19AI118626,
   P01AI106695, U19AI118626, P01AI106695, U19AI118626, U19AI118626,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, U19AI118626,
   P01AI106695, ZIAAI005047, P01AI106695, P01AI106695, P01AI106695,
   R01AI127828, P01AI106695, R01AI127828, U19AI118626, U19AI118626,
   P01AI106695, U19AI118626, P01AI106695, U19AI118626, U19AI118626,
   P01AI106695, U19AI118626, U19AI118626, U19AI118626, ZIAAI005047,
   P01AI106695, U19AI118626, ZIAAI005047, R01AI127828, P01AI106695,
   U19AI118626, U19AI118626, ZIAAI005037, P01AI106695, P01AI106695,
   P01AI106695, U19AI118626, P01AI106695, ZIAAI005037, P01AI106695,
   P01AI106695, P01AI106695, ZIAAI005047, U19AI118626, U19AI118626,
   P01AI106695, U19AI118626, P01AI106695, P01AI106695, U19AI118626,
   ZIAAI005037, ZIAAI005047, P01AI106695, ZIAAI005047, ZIAAI005037,
   P01AI106695, P01AI106695, ZIAAI005037, ZIAAI005047, U19AI118626,
   P01AI106695, ZIAAI005037, ZIAAI005037, ZIAAI005047, P01AI106695,
   P01AI106695, P01AI106695, U19AI118626, P01AI106695, R01AI127828,
   P01AI106695, P01AI106695, ZIAAI005047, U19AI118626, U19AI118626,
   U19AI118626, ZIAAI005037, ZIAAI005047, U19AI118626, ZIAAI005037,
   P01AI106695, P01AI106695, ZIAAI005037, P01AI106695, ZIAAI005037,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, P01AI106695, ZIAAI005047] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305] Funding Source: NIH
   RePORTER
FX This work was supported by National Institutes of Health contracts and
   grants HHSN272200900042C, HHSN27220140045C, and U19 AI118626-01 to A.S.,
   HHSN268201100001I to BSRI, 1P01AI106695-01A1 to E.H., and RO1 AI127828
   to J.E.C. Further support was provided by ZikaPLAN, which has received
   funding from the European Union's Horizon 2020 research and innovation
   program under grant agreement no. 734584, to A.S., by BMGF grant 457
   OPP1104710 to A.P.D., an internal grant from the University of Miami
   Clinical and Translational Research Institute to D.I.W., and grants from
   Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras de la
   Ciencia 2015-02-1192, Ciencia Basica SEP-CONACyT 256235, and
   Fosiss-CONACyT 233697 to H.V.-C.
CR Ahmed R, 2011, IMMUNOL CELL BIOL, V89, P340, DOI 10.1038/icb.2010.155
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Domingues RB, 2008, J NEUROL SCI, V267, P36, DOI 10.1016/j.jns.2007.09.040
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2008, J INFECT DIS, V197, P1296, DOI 10.1086/586898
   Ledgerwood JE, 2010, VACCINE, V29, P304, DOI 10.1016/j.vaccine.2010.10.037
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862
   Sharma S, 2014, J LEUKOCYTE BIOL, V95, P405, DOI 10.1189/jlb.0713386
   Sikka V, 2016, J GLOB INFECT DIS, V8, P3, DOI 10.4103/0974-777X.176140
   Sips GJ, 2012, REV MED VIROL, V22, P69, DOI 10.1002/rmv.712
   Soares CN, 2010, INT J INFECT DIS, V14, pE150, DOI 10.1016/j.ijid.2009.03.016
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Waggoner JJ, 2016, J CLIN VIROL, V78, P57, DOI 10.1016/j.jcv.2016.01.007
   Waggoner JJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002116
   Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14
   Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   World Health Organization, 2017, ZIK VIR MICR GUILL B
   Xu X, 2016, PLOS CURR, V8
   Yun SI, 2017, J MICROBIOL, V55, P204, DOI 10.1007/s12275-017-7063-6
   Zehn D, 2010, J IMMUNOL, V184, P6320, DOI 10.4049/jimmunol.1000149
NR 55
TC 53
Z9 53
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2017
VL 91
IS 24
AR e01469-17
DI 10.1128/JVI.01469-17
PG 19
WC Virology
SC Virology
GA FO1TT
UT WOS:000416548700018
PM 28978707
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Ricciardi, MJ
   Gonzalez-Nieto, L
   Pedreno-Lopez, N
   Bailey, VK
   Gutman, MJ
   Maxwell, HS
   Domingues, A
   Costa, PR
   Ferrari, L
   Goulart, R
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Kalil, J
   Timenetsky, MD
   Wrammert, J
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Ricciardi, Michael J.
   Gonzalez-Nieto, Lucas
   Pedreno-Lopez, Nuria
   Bailey, Varian K.
   Gutman, Martin J.
   Maxwell, Helen S.
   Domingues, Aline
   Costa, Priscilla R.
   Ferrari, Lilian
   Goulart, Raphaella
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Kalil, Jorge
   Timenetsky, Maria do Carmo
   Wrammert, Jens
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI Potent Plasmablast-Derived Antibodies Elicited by the National
   Institutes of Health Dengue Vaccine
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE B cell; Butantan-DV; TV003; dengue; monoclonal antibodies; plasmablast;
   vaccines
ID MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; B-CELLS; NEUTRALIZING
   ANTIBODIES; DISEASE SEVERITY; HIGHLY POTENT; EFFICACY; ENHANCEMENT;
   RECOMBINANT; RESPONSES
AB Exposure to dengue virus (DENV) is thought to elicit lifelong immunity, mediated by DENV-neutralizing antibodies (nAbs). However, Abs generated by primary infections confer serotype-specific protection, and immunity against other serotypes develops only after subsequent infections. Accordingly, the induction of these nAb responses acquired after serial DENV infections has been a long-sought-after goal for vaccination. Nonetheless, it is still unclear if tetravalent vaccines can elicit or recall nAbs. In this study, we have characterized the responses from a volunteer who had been previously exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, developed by the NIH and Butantan Institute. Eleven days after vaccination, we observed an similar to 70-fold expansion of the plasmablast population. We generated 21 monoclonal Abs (MAbs) from singly sorted plasmablasts. These MAbs were the result of clonal expansions and had significant levels of somatic hypermutation (SHM). Nineteen MAbs (90.5%) neutralized at least one DENV serotype at concentrations of 1 mu g/ml or less; 6 of the 21 MAbs neutralized three or more serotypes. Despite the tetravalent composition of the vaccine, we observed a neutralization bias in the induced repertoire: DENV3 was targeted by 18 of the 19 neutralizing MAbs (nMAbs). Furthermore, the P3D05 nMAb neutralized DENV3 with extraordinary potency (concentration to achieve half-maximal neutralization [Neut(50)] = 0.03 mu g/ml). Thus, the Butantan-DV vaccine engendered a mature, antigen-selected B cell repertoire. Our results suggest that preexisting responses elicited by a previous DENV3 infection were recalled by immunization.
   IMPORTANCE The dengue epidemic presents a global public health challenge that causes widespread economic burden and remains largely unchecked by existing control strategies. Successful control of the dengue epidemic will require effective prophylactic and therapeutic interventions. Several vaccine clinical efficacy trials are approaching completion, and the chances that one or more live attenuated tetravalent vaccines (LATVs) will be introduced worldwide is higher than ever. While it is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers are associated with protection, the Ab repertoire induced by LATVs remain uncharacterized. Here, we describe the isolation of potent (Neut(50) < 0.1 mu g/ml) nAbs from a DENV-seropositive volunteer immunized with the tetravalent vaccine Butantan-DV, which is currently in phase III trials.
C1 [Magnani, Diogo M.; Ricciardi, Michael J.; Gonzalez-Nieto, Lucas; Pedreno-Lopez, Nuria; Bailey, Varian K.; Gutman, Martin J.; Maxwell, Helen S.; Domingues, Aline; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Costa, Priscilla R.; Ferrari, Lilian; Goulart, Raphaella; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Univ, Sao Paulo, Brazil.
   [Timenetsky, Maria do Carmo] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Wrammert, Jens] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA.
   [Whitehead, Stephen S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA.
   [Burton, Dennis R.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.; Kallas, EG (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
EM esper.kalias@urp.br; dwatkins@med.miami.edu
RI Whitehead, Stephen/AAG-2787-2019; KALIL, JORGE/C-8029-2012; Martins,
   Mauricio/AAU-9226-2020
OI KALIL, JORGE/0000-0001-8415-4274; Martins, Mauricio/0000-0001-8336-216X;
   Kallas, Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406
FU Wallace H. Coulter Center for Translational Research, Miami, FL;
   Brazilian Development Bank (BNDES); Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases (NIAID, NIH);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [ZIAAI000987, ZIAAI000987, ZIAAI000987, ZIAAI000987, ZIAAI000987,
   ZIAAI000987, ZIAAI000987, ZIAAI000987, R01AI098446, R01AI098446,
   ZIAAI000987, R01AI098446, R01AI098446, R01AI098446, R01AI098446,
   ZIAAI000987, R01AI098446, ZIAAI000987] Funding Source: NIH RePORTER
FX This work was supported by funding from the Wallace H. Coulter Center
   for Translational Research, Miami, FL, the Brazilian Development Bank
   (BNDES), and the Intramural Research Program of the National Institute
   of Allergy and Infectious Diseases (NIAID, NIH).
CR Acosta EG, 2016, EXPERT REV VACCINES, V15, P467, DOI 10.1586/14760584.2016.1121814
   Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brien James D, 2013, Curr Protoc Microbiol, V31, DOI 10.1002/9780471729259.mc15d03s31
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Deng YQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016059
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Fibriansah G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7341
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Friberg H, 2012, VIRAL IMMUNOL, V25, P348, DOI 10.1089/vim.2012.0010
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halliley JL, 2010, VACCINE, V28, P3582, DOI 10.1016/j.vaccine.2010.02.088
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Halstead SB, 2013, VACCINE, V31, P4501, DOI 10.1016/j.vaccine.2013.06.079
   Halstead SB, 2012, LANCET, V380, P1535, DOI 10.1016/S0140-6736(12)61510-4
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109
   Nishiura H, 2007, J INFECT DIS, V195, P1007, DOI 10.1086/511825
   Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328
   Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Smith DP, 2013, MBIO, V4, DOI 10.1128/mBio.00133-12
   Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119
   Smith SA, 2012, J VIROL, V86, P2665, DOI 10.1128/JVI.06335-11
   Srikiatkhachorn A, 2016, EXPERT REV VACCINES, V15, P455, DOI 10.1586/14760584.2016.1116949
   Swaminathan S, 2013, LANCET INFECT DIS, V13, P191, DOI 10.1016/S1473-3099(13)70028-8
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032
   Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727
   Wilder-Smith A, 2016, EXPERT REV VACCINES, V15, P437, DOI 10.1586/14760584.2016.1143366
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
NR 48
TC 8
Z9 9
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2017
VL 91
IS 22
AR e00867-17
DI 10.1128/JVI.00867-17
PG 12
WC Virology
SC Virology
GA FL1WP
UT WOS:000414005400009
PM 28878078
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Grifoni, A
   Angelo, MA
   Lopez, B
   O'Rourke, PH
   Sidney, J
   Cerpas, C
   Balmaseda, A
   Silveira, CGT
   Maestri, A
   Costa, PR
   Durbin, AP
   Diehl, SA
   Phillips, E
   Mallal, S
   De Silva, AD
   Nchinda, G
   Nkenfou, C
   Collins, MH
   de Silva, AM
   Lim, MQ
   Macary, PA
   Tatullo, F
   Solomon, T
   Satchidanandam, V
   Desai, A
   Ravi, V
   Coloma, J
   Turtle, L
   Rivino, L
   Kallas, EG
   Peters, B
   Harris, E
   Sette, A
   Weiskopf, D
AF Grifoni, Alba
   Angelo, Michael A.
   Lopez, Benjamin
   O'Rourke, Patrick H.
   Sidney, John
   Cerpas, Cristhiam
   Balmaseda, Angel
   Silveira, Cassia G. T.
   Maestri, Alvino
   Costa, Priscilla R.
   Durbin, Anna P.
   Diehl, Sean A.
   Phillips, Elizabeth
   Mallal, Simon
   De Silva, Aruna D.
   Nchinda, Godwin
   Nkenfou, Celine
   Collins, Matthew H.
   de Silva, Aravinda M.
   Lim, Mei Qiu
   Macary, Paul A.
   Tatullo, Filippo
   Solomon, Tom
   Satchidanandam, Vijaya
   Desai, Anita
   Ravi, Vasanthapram
   Coloma, Josefina
   Turtle, Lance
   Rivino, Laura
   Kallas, Esper G.
   Peters, Bjoern
   Harris, Eva
   Sette, Alessandro
   Weiskopf, Daniela
TI Global Assessment of Dengue Virus-Specific CD4(+) T Cell Responses in
   Dengue-Endemic Areas
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE dengue virus; CD4(+) T cells; HLA; epitope; adaptive immunity
ID BINDING REPERTOIRES; IMMUNITY; SHARE; NS3
AB Background: Dengue is a major public health problem worldwide. Assessment of adaptive immunity is important to understanding immunopathology and to define correlates of protection against dengue virus (DENV). To enable global assessment of CD4(+) T cell responses, we mapped HLA-DRB1-restricted DENV-specific CD4(+) T cell epitopes in individuals previously exposed to DENV in the general population of the dengue-endemic region of Managua, Nicaragua.
   Methods: HLA class II epitopes in the population of Managua were identified by an in vitro IFN gamma ELISPOT assay. CD4(+) T cells purified by magnetic bead negative selection were stimulated with HLA-matched epitope pools in the presence of autologous antigen-presenting cells, followed by pool deconvolution to identify specific epitopes. The epitopes identified in this study were combined with those previously identified in the DENV endemic region of Sri Lanka, to generate a "megapool" (MP) consisting of 180 peptides specifically designed to achieve balanced HLA and DENV serotype coverage. The DENV CD4MP(180) was validated by intracellular cytokine staining assays.
   Results: We detected responses directed against a total of 431 epitopes, representing all 4 DENV serotypes, restricted by 15 different HLA-DRB1 alleles. The responses were associated with a similar pattern of protein immunodominance, overall higher magnitude of responses, as compared to what was observed previously in the Sri Lanka region. Based on these epitope mapping studies, we designed a DENV CD4 MP180 with higher and more consistent coverage, which allowed the detection of CD4(+) T cell DENV responses ex vivo in various cohorts of DENV exposed donors worldwide, including donors from Nicaragua, Brazil, Singapore, Sri Lanka, and U.S. domestic flavivirus-naive subjects immunized with Tetravalent Dengue Live-Attenuated Vaccine (TV005). This broad reactivity reflects that the 21 HLA-DRB1 alleles analyzed in this and previous studies account for more than 80% of alleles present with a phenotypic frequency >= 5% worldwide, corresponding to 92% phenotypic coverage of the general population (i.e., 92% of individuals express at least one of these alleles).
   Conclusion: The DENV CD4 MP180 can be utilized to measure ex vivo responses to DENV irrespective of geographical location.
C1 [Grifoni, Alba; Angelo, Michael A.; Lopez, Benjamin; O'Rourke, Patrick H.; Sidney, John; De Silva, Aruna D.; Peters, Bjoern; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Salud, Ctr Nacl Diagnost & Referencia, Lab Nacl Virol, Managua, Nicaragua.
   [Silveira, Cassia G. T.; Maestri, Alvino; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Durbin, Anna P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Diehl, Sean A.] Univ Vermont, Larner Coll Med, Vaccine Testing Ctr, Dept Med, Burlington, VT USA.
   [Phillips, Elizabeth; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia.
   [Phillips, Elizabeth; Mallal, Simon] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [De Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Nchinda, Godwin; Nkenfou, Celine] Chantal BIYA Int Reference Ctr Res Prevent & Mana, Yaounde, Cameroon.
   [Collins, Matthew H.; de Silva, Aravinda M.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   [Lim, Mei Qiu] Duke NUS Med Sch, Emerging Infect Dis Programme, Singapore, Singapore.
   [Macary, Paul A.] Natl Univ Singapore, Life Sci Inst, Dept Microbiol & Immunol, Immunol Programme, Singapore, Singapore.
   [Tatullo, Filippo; Solomon, Tom; Turtle, Lance] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Solomon, Tom; Turtle, Lance] Univ Liverpool, Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Satchidanandam, Vijaya] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore, Karnataka, India.
   [Desai, Anita; Ravi, Vasanthapram] Natl Inst Mental Hlth & Neurosci NIMHANS, Neurovirol, Bangalore, Karnataka, India.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [De Silva, Aruna D.] Kotelawala Def Univ, Dept Paraclin Sci, Fac Med, Ratmalana, Sri Lanka.
RP Weiskopf, D (corresponding author), La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
EM daniela@lji.org
RI Diehl, Sean/AAE-2779-2020
OI Diehl, Sean/0000-0001-9700-235X; Turtle, Lance/0000-0002-0778-1693;
   Kallas, Esper/0000-0003-2026-6925; Rivino, Laura/0000-0001-6213-9794;
   Weiskopf, Daniela/0000-0003-2968-7371; Solomon, Tom/0000-0001-7266-6547
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900042C,
   HHSN27220140045C, 1P01AI106695]; BMGF [457 OPP1104710]; Singapore
   National Medical Research CouncilNational Medical Research Council,
   Singapore [CBRG-NIG R-913-301-289-213]; Wellcome TrustWellcome Trust
   [205228/Z/16/Z]; National Institute of Health Research Health Protection
   Unit (NIHR HPRU) in Emerging and Zoonotic Infections; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305] Funding Source: NIH RePORTER; Medical Research
   CouncilMedical Research Council UK (MRC) [G116/194, MC_PC_15096] Funding
   Source: researchfish; National Institute for Health ResearchNational
   Institute for Health Research (NIHR) [12/205/28, RP-PG-0108-10048,
   NF-SI-0514-10177, EME/12/205/28, CL-2013-07-005] Funding Source:
   researchfish
FX This work was supported by National Institutes of Health contracts Nr.
   HHSN272200900042C and HHSN27220140045C to AS, 1P01AI106695 to EH, and
   the BMGF grant 457 OPP1104710 to APD. The Singapore work was funded by
   the Cooperative Basic Research Grant-New Investigator Grant (CBRG-NIG
   R-913-301-289-213) of the Singapore National Medical Research Council to
   ER. LT is supported by a Wellcome Trust clinical research career
   development fellowship, grant number 205228/Z/16/Z. TS is supported by
   the National Institute of Health Research Health Protection Unit (NIHR
   HPRU) in Emerging and Zoonotic Infections. The views expressed arc those
   of the authors and not necessarily those of the NHS, the NIHR, the
   Department of Health, or Public Health England.
CR Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Antunes RDS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169086
   Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760
   Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Cucunawangsih, 2017, Virology (Auckl), V8, p1178122X17695836, DOI 10.1177/1178122X17695836
   Faria NRD, 2016, T ROY SOC TROP MED H, V110, P228, DOI 10.1093/trstmh/trw013
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Goncalves AJS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004277
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2017, J VIROL, V91, DOI 10.1128/JVI.02133-16
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Hinz D, 2016, CLIN EXP ALLERGY, V46, P705, DOI 10.1111/cea.12692
   Imrie A, 2007, J VIROL, V81, P10081, DOI 10.1128/JVI.00330-07
   Khetarpal N, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6803098
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Low SL, 2015, AM J TROP MED HYG, V93, P40, DOI 10.4269/ajtmh.14-0671
   Ma CS, 2014, IMMUNOL CELL BIOL, V92, P64, DOI 10.1038/icb.2013.55
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Meyer D, 2007, IMMUNOBIOLOGY HUMAN, VI, P653
   Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Muema DM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175570
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Piazza P, 2014, CLIN EXP IMMUNOL, V177, P696, DOI 10.1111/cei.12373
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Rivino L, 2016, EXPERT REV VACCINES, V15, P443, DOI 10.1586/14760584.2016.1116948
   Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Sidney J, 1996, HUM IMMUNOL, V45, P79, DOI 10.1016/0198-8859(95)00173-5
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655
   Singla M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004497
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Turtle L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005263
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
NR 50
TC 28
Z9 28
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 13
PY 2017
VL 8
AR 1309
DI 10.3389/fimmu.2017.01309
PG 13
WC Immunology
SC Immunology
GA FJ6LI
UT WOS:000412868900001
PM 29081779
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Ricciardi, MJ
   Bailey, VK
   Gutman, MJ
   Pedreno-Lopez, N
   Silveira, CGT
   Maxwell, HS
   Domingues, A
   Gonzalez-Nieto, L
   Su, Q
   Newman, RM
   Pack, M
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Rakasz, EG
   Allen, TM
   Whitehead, SS
   Burton, DR
   Gao, GP
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Ricciardi, Michael J.
   Bailey, Varian K.
   Gutman, Martin J.
   Pedreno-Lopez, Nuria
   Silveira, Cassia G. T.
   Maxwell, Helen S.
   Domingues, Aline
   Gonzalez-Nieto, Lucas
   Su, Qin
   Newman, Ruchi M.
   Pack, Melissa
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Rakasz, Eva G.
   Allen, Todd M.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Gao, Guangping
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in
   Rhesus Monkeys
SO MOLECULAR THERAPY
LA English
DT Article
ID 4 SEROTYPES; EPITOPE DETERMINANTS; FC-RECEPTOR; INFECTION; PROTECTION;
   ENHANCEMENT; DISEASE; BINDING; HUMANS; POTENT
AB Development of vaccines against mosquito-borne Flaviviruses is complicated by the occurrence of antibody-dependent enhancement (ADE), which can increase disease severity. Long-term delivery of neutralizing antibodies (nAbs) has the potential to effectively block infection and represents an alternative to vaccination. The risk of ADE may be avoided by using prophylactic nAbs harboring amino acid mutations L234A and L235A (LALA) in the immunoglobulin G (IgG) constant region. Here, we used recombinant adeno-associated viruses (rAAVs) to deliver the anti-dengue virus 3 (DENV3) nAb P3D05. While the administration of rAAV-P3D05-rhesus immunoglobulin GI (rhIgGl)-LALA to rhesus macaques engendered DENV3-neutralizing activity in serum, it did not prevent infection. The emergence of viremia following DENV3 challenge was delayed by 3-6 days in the rAAV-treated group, and replicating virus contained the envelope mutation K64R. This neutralization-resistant variant was also confirmed by virus outgrowth experiments in vitro. By delivering P3D05 with unmutated Fc sequences, we further demonstrated that DENV3 also evaded wild-type nAb prophylaxis, and serum viral loads appeared to be higher in the presence of low levels of unmutated P3D05-rhIgGl. Our study shows that a vectored approach for long-term delivery of nAbs with the LALA mutations is promising, but prophylaxis using a single nAb is likely insufficient at preventing DENV infection and replication.
C1 [Magnani, Diogo M.; Ricciardi, Michael J.; Bailey, Varian K.; Gutman, Martin J.; Pedreno-Lopez, Nuria; Maxwell, Helen S.; Domingues, Aline; Gonzalez-Nieto, Lucas; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-246903 Sao Paulo, Brazil.
   [Su, Qin; Gao, Guangping] Univ Massachusetts, Horae Gene Therapy Ctr, Med Sch, Worcester, MA 01605 USA.
   [Su, Qin; Gao, Guangping] Univ Massachusetts, Dept Microbiol & Physiol Syst, Med Sch, Worcester, MA 01655 USA.
   [Newman, Ruchi M.; Pack, Melissa; Allen, Todd M.; Burton, Dennis R.] MGH MIT & Harvard, Ragon Inst, Cambridge, MA 02139 USA.
   [Rakasz, Eva G.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Miller Sch Med, 1951 NW 7th Ave,LSTP Room 2340, Miami, FL 33136 USA.
EM dwatkins@med.miami.edu
RI Rakasz, Eva G/H-9197-2019; Allen, Todd/F-5473-2011; Martins,
   Mauricio/AAU-9226-2020; Whitehead, Stephen/AAG-2787-2019
OI Allen, Todd/0000-0002-6609-1318; Martins, Mauricio/0000-0001-8336-216X;
   Magnani, Diogo/0000-0002-1773-2406; Kallas, Esper/0000-0003-2026-6925
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05, P51OD011106]; Wallace
   H. Coulter Center for Translational Research at the University of Miami;
   Miami Clinical and Translational Science Institute (CTSI); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI094420, P01AI094420, R01AI098446, ZIAAI000891, P01AI094420,
   P01AI094420, R01AI098446, ZIAAI000891, P01AI094420, ZIAAI000891,
   P01AI094420, ZIAAI000891, ZIAAI000891, P01AI094420, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, P01AI094420, P01AI094420, P01AI094420,
   P01AI094420, R01AI098446, P01AI094420, P01AI094420, P01AI094420,
   P01AI094420, P01AI094420, ZIAAI000891, R01AI098446, R01AI098446,
   P01AI094420, P01AI094420, ZIAAI000891, P01AI094420, P01AI094420,
   P01AI094420, P01AI094420, P01AI094420, R01AI098446, R01AI098446,
   R01AI098446, P01AI094420, P01AI094420, P01AI094420, P01AI094420,
   P01AI094420] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR,
   NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106] Funding Source: NIH RePORTER
FX This work was supported by NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami,
   and the Miami Clinical and Translational Science Institute (CTSI). This
   work was in part supported by NIH grant P51OD011106 to the WNPRC at the
   University of Wisconsin-Madison. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. We would like to thank Kim Weisgrau,
   Jessica Furlott, Nicholas Pornplun, and Logan Vosler for technical
   support and Eric Peterson, Kristin Crosno, and Wendy Newton for
   providing care of the rhesus macaques used in this experiment. We also
   thank the veterinary and animal care staff for their contribution to
   this study.
CR Acosta EG, 2016, EXPERT REV VACCINES, V15, P467, DOI 10.1586/14760584.2016.1121814
   Barrett ADT, 2016, NEW ENGL J MED, V375, P301, DOI 10.1056/NEJMp1606997
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Byers Anthony M, 2015, Open Forum Infect Dis, V2, pofv172, DOI 10.1093/ofid/ofv172
   Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268
   Caskey M, 2016, NEW ENGL J MED, V375, P2019, DOI 10.1056/NEJMp1613362
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Diamond MS, 2008, IMMUNOL REV, V225, P212, DOI 10.1111/j.1600-065X.2008.00676.x
   Diamond MS, 2009, ANTIVIR RES, V83, P214, DOI 10.1016/j.antiviral.2009.05.006
   Dornemann J, 2017, J INFECT DIS, V215, P171, DOI 10.1093/infdis/jiw493
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Fuchs SP, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.68
   Fuchs SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158009
   Fuchs SP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005090
   Furuyama W, 2016, SCI REP-UK, V6, DOI 10.1038/srep20514
   Gao G., 2012, MOL CLONING, V2, P1209
   Goncalvez AP, 2007, P NATL ACAD SCI USA, V104, P9422, DOI 10.1073/pnas.0703498104
   Goncalvez AP, 2004, J VIROL, V78, P12919, DOI 10.1128/JVI.78.23.12919-12928.2004
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   Haque A, 2015, ANTIMICROB AGENTS CH, V59, P5892, DOI 10.1128/AAC.01105-15
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Institute for Laboratory Animal Research (U.S.) National Academies Press (U.S.), 2011, GUIDE CARE USE LAB A, pxxv
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967
   Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612
   Lai CJ, 2007, J VIROL, V81, P12766, DOI 10.1128/JVI.01420-07
   Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692
   Mores CN, 2014, J INFECT DIS, V209, P571, DOI 10.1093/infdis/jiu110
   NIAID National Institute of Allergy and Infectious Diseases, 2016, EV SAF EFF VRC01 ANT
   Priyamvada L, 2016, J VIROL, V90, P5574, DOI 10.1128/JVI.03203-15
   Qiu XG, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9875
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Ramadhany R, 2015, ANTIVIR RES, V124, P61, DOI 10.1016/j.antiviral.2015.10.012
   Roehrig JT, 2001, ANN NY ACAD SCI, V951, P286
   Santiago GA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002311
   Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929
   Simmons M, 2016, AM J TROP MED HYG, V95, P1148, DOI 10.4269/ajtmh.16-0319
   Sirivichayakul C, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-48
   Smith DP, 2013, MBIO, V4, DOI 10.1128/mBio.00133-12
   Smith DR, 2017, CRIT REV MICROBIOL, V43, P405, DOI [10.1080/1040841x.2016.1230974, 10.1080/1040841X.2016.1230974]
   Styer LM, 2007, PLOS PATHOG, V3, P1262, DOI 10.1371/journal.ppat.0030132
   Tam CC, 2016, LANCET, V388, P1374, DOI 10.1016/S0140-6736(16)31645-2
   Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625
   Timiryasova TM, 2013, AM J TROP MED HYG, V88, P962, DOI 10.4269/ajtmh.12-0461
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128
   Williams KL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003157
   Xu MH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-016-0003-3
   Yang X, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-674
   Yang X, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-475
   Zompi S, 2012, VIRUSES-BASEL, V4, P62, DOI 10.3390/v4010062
NR 57
TC 1
Z9 1
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD OCT 4
PY 2017
VL 25
IS 10
BP 2323
EP 2331
DI 10.1016/j.ymthe.2017.06.020
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA FJ7VQ
UT WOS:000412968200015
PM 28750738
OA Other Gold, Green Published
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Rogers, TF
   Beutler, N
   Ricciardi, MJ
   Bailey, VK
   Gonzalez-Nieto, L
   Briney, B
   Sok, D
   Le, K
   Strubel, A
   Gutman, MJ
   Pedreno-Lopez, N
   Grubaugh, ND
   Silveira, CGT
   Maxwell, HS
   Domingues, A
   Martins, MA
   Lee, DE
   Okwuazi, EE
   Jean, S
   Strobert, EA
   Chahroudi, A
   Silvestri, G
   Vanderford, TH
   Kallas, EG
   Desrosiers, RC
   Bonaldo, MC
   Whitehead, SS
   Burton, DR
   Watkins, DI
AF Magnani, Diogo M.
   Rogers, Thomas F.
   Beutler, Nathan
   Ricciardi, Michael J.
   Bailey, Varian K.
   Gonzalez-Nieto, Lucas
   Briney, Bryan
   Sok, Devin
   Le, Khoa
   Strubel, Alexander
   Gutman, Martin J.
   Pedreno-Lopez, Nuria
   Grubaugh, Nathan D.
   Silveira, Cassia G. T.
   Maxwell, Helen S.
   Domingues, Aline
   Martins, Mauricio A.
   Lee, David E.
   Okwuazi, Erica E.
   Jean, Sherrie
   Strobert, Elizabeth A.
   Chahroudi, Ann
   Silvestri, Guido
   Vanderford, Thomas H.
   Kallas, Esper G.
   Desrosiers, Ronald C.
   Bonaldo, Myrna C.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Watkins, David I.
TI Neutralizing human monoclonal antibodies prevent Zika virus infection in
   macaques
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID DENGUE VIRUS; DEPENDENT ENHANCEMENT; STRUCTURAL BASIS; RHESUS-MONKEYS;
   PROTECTION; VACCINE; DISEASE; BINDING
AB Therapies to prevent maternal Zika virus (ZIKV) infection and its subsequent fetal developmental complications are urgently required. We isolated three potent ZIKV-neutralizing monoclonal antibodies (nmAbs) from the plasma-blasts of a ZIKV-infected patient-SMZAb1, SMZAb2, and SMZAb5-directed against two different domains of the virus. We engineered these nmAbs with Fc LALA mutations that abrogate Fc gamma receptor binding, thus eliminating potential therapy-mediated antibody-dependent enhancement. We administered a cocktail of these three nmAbs to nonhuman primates 1 day before challenge with ZIKV and demonstrated that the nmAbs completely prevented viremia in serum after challenge. Given that numerous antibodies have exceptional safety profiles in humans, the cocktail described here could be rapidly developed to protect uninfected pregnant women and their fetuses.
C1 [Magnani, Diogo M.; Ricciardi, Michael J.; Bailey, Varian K.; Gonzalez-Nieto, Lucas; Gutman, Martin J.; Pedreno-Lopez, Nuria; Maxwell, Helen S.; Domingues, Aline; Martins, Mauricio A.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Leonard M Miller Sch Med, Miami, FL 33136 USA.
   [Rogers, Thomas F.; Beutler, Nathan; Briney, Bryan; Sok, Devin; Le, Khoa; Strubel, Alexander; Grubaugh, Nathan D.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Rogers, Thomas F.; Beutler, Nathan; Briney, Bryan; Sok, Devin; Le, Khoa; Strubel, Alexander; Grubaugh, Nathan D.; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA.
   [Silveira, Cassia G. T.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Lee, David E.; Okwuazi, Erica E.; Jean, Sherrie; Strobert, Elizabeth A.; Chahroudi, Ann; Silvestri, Guido; Vanderford, Thomas H.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
   [Chahroudi, Ann] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
   [Bonaldo, Myrna C.] Fiocruz MS, Lab Biol Mol Flavivirus, Inst Oswaldo Cruz, BR-21040360 Rio De Janeiro, Brazil.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Leonard M Miller Sch Med, Miami, FL 33136 USA.; Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.; Burton, DR (corresponding author), Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA.; Burton, DR (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
EM burton@scripps.edu; dwatkins@med.miami.edu
RI Whitehead, Stephen/AAG-2787-2019; amsalu, ribka/G-8780-2019; Martins,
   Mauricio/AAU-9226-2020
OI Martins, Mauricio/0000-0001-8336-216X; Beutler,
   Nathan/0000-0003-3240-9524; Kallas, Esper/0000-0003-2026-6925; Grubaugh,
   Nathan/0000-0003-2031-1933; Magnani, Diogo/0000-0002-1773-2406; Strubel,
   Alexander/0000-0002-8175-962X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05, P30AI073961, P51
   OD011132]; Wallace H. Coulter Center for Translational Research at the
   University of Miami; Miami Clinical and Translational Science Institute
   (CTSI); National Institute of Allergy and Infectious Diseases, NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); Defense Advanced Research Projects Agency (DARPA)
   Autonomous Diagnostics to Enable Prevention and Therapeutics:
   Prophylactic Options to Environmental and Contagious Threats
   (ADEPT-PROTECT) program [W31P4Q-13-1-0011]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI073961,
   P01AI094420, P30AI073961, P01AI094420, P30AI073961, P30AI073961,
   P01AI094420, T32AI007244, P01AI094420, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P01AI094420,
   P30AI073961, P30AI073961, T32AI007244, T32AI007244, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, P01AI094420, T32AI007244, T32AI007244, P01AI094420,
   ZIAAI000891, P01AI094420, ZIAAI000891, P01AI094420, P30AI073961,
   P30AI073961, T32AI007244, T32AI007244, P30AI073961, P30AI073961,
   T32AI007244, P30AI073961, P30AI073961, T32AI007244, T32AI007244,
   P01AI094420, T32AI007244, P30AI073961, P30AI073961, P30AI073961,
   P01AI094420, P30AI073961, P30AI073961, P30AI073961, P01AI094420,
   P30AI073961, T32AI007244, ZIAAI000891, P30AI073961, T32AI007244,
   ZIAAI000891, ZIAAI000891, P30AI073961, P30AI073961, ZIAAI000891,
   P30AI073961, P30AI073961, P01AI094420, ZIAAI000891, P30AI073961,
   P30AI073961, P01AI094420, P30AI073961, P30AI073961, P01AI094420,
   P30AI073961, P01AI094420, T32AI007244, T32AI007244, P30AI073961,
   P01AI094420, P01AI094420, ZIAAI000891, P30AI073961, T32AI007244,
   ZIAAI000891, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   T32AI007244, P30AI073961, P30AI073961, T32AI007244, T32AI007244,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   P01AI094420, T32AI007244, P30AI073961, T32AI007244, P30AI073961,
   P30AI073961, P30AI073961, P01AI094420, T32AI007244, P01AI094420,
   T32AI007244, P30AI073961, P30AI073961, P30AI073961, P01AI094420,
   P30AI073961, P30AI073961, P01AI094420, T32AI007244, T32AI007244,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P01AI094420,
   P01AI094420, P30AI073961, T32AI007244, T32AI007244, P30AI073961,
   P30AI073961, P30AI073961, P01AI094420, P30AI073961, T32AI007244,
   P30AI073961, P30AI073961, T32AI007244, ZIAAI000891, P30AI073961,
   P30AI073961, P30AI073961, T32AI007244, P30AI073961, P30AI073961,
   T32AI007244, P30AI073961, P01AI094420, T32AI007244, P30AI073961,
   T32AI007244, T32AI007244, T32AI007244, T32AI007244, P30AI073961,
   P30AI073961, P01AI094420, ZIAAI000891, P30AI073961] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [P51OD011132, P51OD011132, P51OD011132, P51OD011132,
   P51OD011132, P51OD011132, P51OD011132, P51OD011132, P51OD011132,
   P51OD011132, P51OD011132, P51OD011132, P51OD011132, P51OD011132,
   P51OD011132, P51OD011132, P51OD011132, P51OD011132, P51OD011132,
   P51OD011132] Funding Source: NIH RePORTER
FX This work was supported by NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami,
   the Miami Clinical and Translational Science Institute (CTSI), and the
   Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, NIH. This research was also supported in part by
   the Defense Advanced Research Projects Agency (DARPA) Autonomous
   Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options
   to Environmental and Contagious Threats (ADEPT-PROTECT) program
   (W31P4Q-13-1-0011), as well as NIH grant P30AI073961 to the Miami Center
   for AIDS Research and grant P51 OD011132 to the YNPRC. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH. The funders had no role in
   study design, data collection, and analysis, decision to publish, or
   preparation of the manuscript.
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brien James D, 2013, Curr Protoc Microbiol, V31, DOI 10.1002/9780471729259.mc15d03s31
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Fuss I.J., 2009, CURR PROTOC IMMUNOL
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Juckstock J, 2015, PHARMACOLOGY, V95, P209, DOI 10.1159/000381626
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Lai CJ, 2007, J VIROL, V81, P12766, DOI 10.1128/JVI.01420-07
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Magnani D. M., 2017, MOL THER
   Marston HD, 2016, NEW ENGL J MED, V375, P1209, DOI 10.1056/NEJMp1607762
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Robbie GJ, 2013, ANTIMICROB AGENTS CH, V57, P6147, DOI 10.1128/AAC.01285-13
   Rogers TF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan6809
   Santiago GA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002311
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7
   Styer LM, 2007, PLOS PATHOG, V3, P1262, DOI 10.1371/journal.ppat.0030132
   Sukupolvi-Petty S, 2010, J VIROL, V84, P9227, DOI 10.1128/JVI.01087-10
   Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128
   World Health Organization Fifth Meeting of the Emergency Committee under the International Health Regulations, 2005, 5 M EM COMM INT HLTH
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
NR 35
TC 48
Z9 48
U1 0
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD OCT 4
PY 2017
VL 9
IS 410
AR eaan8184
DI 10.1126/scitranslmed.aan8184
PG 7
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA FI7HJ
UT WOS:000412167400005
PM 28978754
OA Green Accepted, Bronze
DA 2020-11-26
ER

PT J
AU Arif, MS
   Hunter, J
   Leda, AR
   Zukurov, JPL
   Samer, S
   Camargo, M
   Galinskas, J
   Kallas, EG
   Komninakis, SV
   Janini, LM
   Sucupira, MC
   Diaz, RS
AF Arif, Muhammad Shoaib
   Hunter, James
   Leda, Ana Rachel
   Lopes Zukurov, Jean Paulo
   Samer, Sadia
   Camargo, Michelle
   Galinskas, Juliana
   Kallas, Esper Georges
   Komninakis, Shirley Vasconcelos
   Janini, Luiz Mario
   Sucupira, Maria Cecilia
   Diaz, Ricardo Sobhie
TI Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after
   Recent Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE coreceptor; disease progression; tropism switch
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE;
   ANTIRETROVIRAL THERAPY; TYPE-1 INFECTION; GENOTYPIC TOOLS; DENDRITIC
   CELLS; HIV-1 TROPISM; V3 REGION; USAGE; CCR5
AB HIV-1 entry into target cells influences several aspects of HIV-1 pathogenesis, including viral tropism, HIV-1 transmission and disease progression, and response to entry inhibitors. The evolution from CCR5- to CXCR4-using strains in a given human host is still unpredictable. Here we analyzed timing and predictors for coreceptor evolution among recently HIV-1-infected individuals. Proviral DNA was longitudinally evaluated in 66 individuals using Geno2pheno[coreceptor]. Demographics, viral load, CD4(+) and CD8(+) T cell counts, CCR5.32 polymorphisms, GB virus C (GBV-C) coinfection, and HLA profiles were also evaluated. Ultradeep sequencing was performed on initial samples from 11 selected individuals. A tropism switch from CCR5-to CXCR4-using strains was identified in 9/49 (18.4%) individuals. Only a low baseline false-positive rate (FPR) was found to be a significant tropism switch predictor. No minor CXCR4-using variants were identified in initial samples of 4 of 5 R5/non-R5 switchers. Logistic regression analysis showed that patients with an FPR of similar to 40.6% at baseline presented a stable FPR over time whereas lower FPRs tend to progressively decay, leading to emergence of CXCR4-using strains, with a mean evolution time of 27.29 months (range, 8.90 to 64.62). An FPR threshold above 40.6% determined by logistic regression analysis may make it unnecessary to further determine tropism for prediction of disease progression related to emergence of X4 strains or use of CCR5 antagonists. The detection of variants with intermediate FPRs and progressive FPR decay over time not only strengthens the power of Geno2pheno in predicting HIV tropism but also indirectly confirms a continuous evolution from earlier R5 variants toward CXCR4-using strains.
   IMPORTANCE The introduction of CCR5 antagonists in the antiretroviral arsenal has sparked interest in coreceptors utilized by HIV-1. Despite concentrated efforts, viral and human host features predicting tropism switch are still poorly understood. Limited longitudinal data are available to assess the influence that these factors have on predicting tropism switch and disease progression. The present study describes longitudinal tropism evolution in a group of recently HIV-infected individuals to determine the prevalence and potential correlates of tropism switch. We demonstrated here that a low baseline FPR determined by the Geno2pheno[coreceptor] algorithm can predict tropism evolution from CCR5 to CXCR4 coreceptor use.
C1 [Arif, Muhammad Shoaib; Hunter, James; Leda, Ana Rachel; Samer, Sadia; Camargo, Michelle; Galinskas, Juliana; Komninakis, Shirley Vasconcelos; Sucupira, Maria Cecilia; Diaz, Ricardo Sobhie] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Lopes Zukurov, Jean Paulo; Janini, Luiz Mario] Univ Fed Sao Paulo, Div Microbiol, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Dept Internal Med, Sao Paulo, Brazil.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
EM rsdiaz@catg.com.br
RI Arif, Muhammad Shoaib/O-2717-2019; Komninakis, Shirley V/B-2915-2010;
   Araripe Sucupira, Maria Cecilia/K-1931-2012
OI Arif, Muhammad Shoaib/0000-0001-7129-3312; Komninakis, Shirley
   V/0000-0001-7784-3418; Leda, Ana/0000-0003-0276-0487; Kallas,
   Esper/0000-0003-2026-6925; Janini, Luiz Mario/0000-0002-6186-6284;
   Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/17334-3]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of EducationCAPES
FX This work was supported by the Sao Paulo Research Foundation (FAPESP)
   (2011/17334-3). M.S.A. received a PhD fellowship from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of Education.
CR Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8
   Sucupira MCA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030292
   Berkowitz RD, 2000, AIDS RES HUM RETROV, V16, P1039, DOI 10.1089/08892220050075291
   Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925
   BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994
   Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519
   Bunnik EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002106
   Casas P, 2016, FUNMODELING LEARNING
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621
   CORNELISSEN M, 1995, J VIROL, V69, P1810, DOI 10.1128/JVI.69.3.1810-1818.1995
   de Lima-Stein ML, 2014, AIDS RES HUM RETROV, V30, P867, DOI [10.1089/aid.2013.0241, 10.1089/AID.2013.0241]
   de Mendoza C, 2008, JAIDS-J ACQ IMM DEF, V48, P241, DOI 10.1097/QAI.0b013e3181734f0e
   de Mendoza C, 2007, J ANTIMICROB CHEMOTH, V59, P698, DOI 10.1093/jac/dkm012
   DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992
   Delobel P, 2007, J CLIN MICROBIOL, V45, P1572, DOI 10.1128/JCM.02090-06
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Diaz RS, 1997, AIDS, V11, P415, DOI 10.1097/00002030-199704000-00003
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Eshleman SH, 2007, AIDS, V21, P1165, DOI 10.1097/QAD.0b013e32810fd72e
   FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992
   Frange P, 2010, J CLIN MICROBIOL, V48, P3487, DOI 10.1128/JCM.00704-10
   Frange P, 2009, J ANTIMICROB CHEMOTH, V64, P135, DOI 10.1093/jac/dkp151
   Gareth J., 2013, INTRO STAT LEARNING
   Gorry Paul R, 2011, Curr HIV/AIDS Rep, V8, P45, DOI 10.1007/s11904-010-0069-x
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Harouse JM, 2003, P NATL ACAD SCI USA, V100, P10977, DOI 10.1073/pnas.1933268100
   Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171
   Hastie T, 2009, ELEMENTS STAT LEARNI
   Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255
   Hedskog C, 2013, AIDS RES HUM RETROV, V29, P1237, DOI [10.1089/aid.2012.0349, 10.1089/AID.2012.0349]
   Huang W, 2009, AIDS RES HUM RETROV, V25, P795, DOI 10.1089/aid.2008.0252
   Jensen MA, 2003, J VIROL, V77, P13376, DOI 10.1128/JVI.77.24.13376-13388.2003
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Komninakis SV, 2012, J CLIN MICROBIOL, V50, P2132, DOI 10.1128/JCM.00393-12
   KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004
   Kuhn M., 2016, CARET CLASSIFICATION
   Labrosse B, 2003, J VIROL, V77, P1610, DOI 10.1128/JVI.77.2.1610-1613.2003
   Lavigne S, 2014, AIDS RES HUM RETROV, V30, P147, DOI [10.1089/aid.2012.0261, 10.1089/AID.2012.0261]
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Lee WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090581
   Lehmann C, 2006, J CLIN VIROL, V37, P300, DOI 10.1016/j.jcv.2006.08.008
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Low AJ, 2007, AIDS, V21, pF19, DOI 10.1097/QAD.0b013e3282ef81ea
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mortier V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080259
   Pessoa R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093374
   Pion M, 2007, J INVEST DERMATOL, V127, P319, DOI 10.1038/sj.jid.5700518
   Poon AFY, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002753
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Poveda E, 2007, AIDS, V21, P1487, DOI 10.1097/QAD.0b013e32826fb741
   Poveda E, 2012, AIDS REV, V14, P208
   Poveda E, 2009, J ANTIMICROB CHEMOTH, V63, P1006, DOI 10.1093/jac/dkp063
   PRATT RD, 1995, J INFECT DIS, V172, P851, DOI 10.1093/infdis/172.3.851
   Quinlan AR, 2008, NAT METHODS, V5, P179, DOI 10.1038/NMETH.1172
   R Core Team, 2015, R LANG ENV STAT COMP
   Raymond S, 2008, AIDS, V22, pF11, DOI 10.1097/QAD.0b013e32830ebcd4
   Regoes RR, 2005, TRENDS MICROBIOL, V13, P269, DOI 10.1016/j.tim.2005.04.005
   RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968
   Rieder P, 2011, CLIN INFECT DIS, V53, P1271, DOI 10.1093/cid/cir725
   Salemi M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000950
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992
   Schwarze-Zander C, 2010, ANTIVIR THER, V15, P745, DOI 10.3851/IMP1602
   Seclen E, 2010, J ANTIMICROB CHEMOTH, V65, P1486, DOI 10.1093/jac/dkq137
   Sierra-Enguita R, 2014, AIDS, V28, P1603, DOI 10.1097/QAD.0000000000000269
   Silva WP, 2006, VIROLOGY, V354, P35, DOI 10.1016/j.virol.2006.04.039
   Soriano V, 2009, AIDS, V23, P2377, DOI 10.1097/QAD.0b013e328332d32d
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   Svicher V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053603
   Swenson LC, 2011, CLIN INFECT DIS, V53, P732, DOI 10.1093/cid/cir493
   Swenson LC, 2011, J INFECT DIS, V203, P237, DOI 10.1093/infdis/jiq030
   Swofford DL, 2002, PAUP PHYLOGENETIC AN
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tilton JC, 2010, ANTIVIR RES, V85, P91, DOI 10.1016/j.antiviral.2009.07.022
   VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560
   Wodarz D, 1998, P ROY SOC B-BIOL SCI, V265, P2149, DOI 10.1098/rspb.1998.0552
   Wodarz D, 1999, J THEOR BIOL, V196, P101, DOI 10.1006/jtbi.1998.0816
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Yamamoto T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000279
   ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453
NR 80
TC 4
Z9 4
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2017
VL 91
IS 19
AR e00793-17
DI 10.1128/JVI.00793-17
PG 21
WC Virology
SC Virology
GA FG4TX
UT WOS:000410261600017
PM 28659473
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Costa, NDX
   Ribeiro, G
   Alemany, AAD
   Belotti, L
   Zati, DH
   Cavalcante, MF
   Veras, MM
   Ribeiro, S
   Kallas, EG
   Saldiva, PHN
   Dolhnikott, M
   da Silva, LFF
AF Xavier Costa, Natalia de Souza
   Ribeiro Junior, Gabriel
   dos Santos Alemany, Adair Aparecida
   Belotti, Luciano
   Zati, Douglas Hidalgo
   Cavalcante, Marcela Frota
   Veras, Mariana Matera
   Ribeiro, Susan
   Kallas, Esper Georges
   Nascimento Saldiva, Paulo Hilario
   Dolhnikott, Marisa
   Ferraz da Silva, Luiz Fernando
TI Early and late pulmonary effects of nebulized LPS in mice: An acute lung
   injury model
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; FLUID CLEARANCE; ANIMAL-MODELS;
   PATHOGENESIS; INFLAMMATION; RECRUITMENT; EXPRESSION; MORTALITY;
   ENDOTOXIN; FIBROSIS
AB Background and objective
   Acute respiratory distress syndrome (ARDS) has a high mortality rate of 35 - 46% depending on its severity. Animal models are crucial to better understand the pathophysiology of diseases, including ARDS. This study presents a feasible animal model of acute lung injury (ALI) using nebulized lipopolysaccharide (LPS) in a non-invasive approach, focusing on its short and long-term effects.
   Methods
   Mice received nebulized LPS or vehicle only (control group). Blood, BALF and lung tissue were collected 24 hours (LPS 24h) or 5 weeks (LPS 5w) after the nebulized LPS-induced lung injury. Inflammatory cytokines were assessed in the blood serum, BALF and lung tissue. Stereological analyses and remodeling changes were assessed by histology and immunohistochemistry at the specified time points.
   Results
   The LPS 24h group showed increased pro-inflammatory cytokine levels, intense cell influx, increased total septal volume, septal thickening and decreased surface density of the alveolar septa. The LPS 5w group showed persistent lung inflammation, septal thickening, increased total lung volume, accentuated collagen deposition, especially of collagen type I, and decreased MMP-2 protein expression.
   Conclusion
   We present a feasible, reproducible and non-invasive nebulized-LPS animal model that allows the assessment of both the acute and late phases of acute lung injury. The presence of lung remodeling with collagen deposition after 5 weeks makes it useful to study the pathophysiology, complications, and possible therapeutic intervention studies that aim to understand and reduce pulmonary fibrosis in the late phases of ALI.
C1 [Xavier Costa, Natalia de Souza; Ribeiro Junior, Gabriel; dos Santos Alemany, Adair Aparecida; Belotti, Luciano; Zati, Douglas Hidalgo; Veras, Mariana Matera; Nascimento Saldiva, Paulo Hilario; Dolhnikott, Marisa; Ferraz da Silva, Luiz Fernando] Univ Sao Paulo, Sch Med, Lab Expt Air Pollut LIM05, Sao Paulo, SP, Brazil.
   [Cavalcante, Marcela Frota] Univ Sao Paulo, Sch Pharmaceut Sci, Biochem Lab, Sao Paulo, SP, Brazil.
   [Ribeiro, Susan; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, SP, Brazil.
   [Ribeiro, Susan] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
RP Costa, NDX (corresponding author), Univ Sao Paulo, Sch Med, Lab Expt Air Pollut LIM05, Sao Paulo, SP, Brazil.
EM nataliasxcosta@usp.br
RI Silva, Luiz/D-2760-2012; Costa, Natalia Souza Xavier/ABB-1285-2020;
   Veras, Mariana M/D-8575-2012; Santos, Adair/C-5565-2013
OI Silva, Luiz/0000-0002-0181-6357; Veras, Mariana M/0000-0002-8363-4329;
   Kallas, Esper/0000-0003-2026-6925; de Souza Xavier Costa,
   Natalia/0000-0002-7848-2092; Dolhnikoff, Marisa/0000-0002-9073-9989;
   Santos, Adair/0000-0002-6435-4698
CR AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872
   Armstrong L, 1999, AM J RESP CRIT CARE, V160, P1910, DOI 10.1164/ajrccm.160.6.9811084
   Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Brass DM, 2008, AM J RESP CELL MOL, V39, P584, DOI 10.1165/rcmb.2007-0448OC
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71
   Chu SY, 2011, INT IMMUNOPHARMACOL, V11, P1780, DOI 10.1016/j.intimp.2011.06.010
   D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498
   Dushianthan A, 2011, POSTGRAD MED J, V87, P612, DOI 10.1136/pgmj.2011.118398
   Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1034/j.1399-3003.2000.15a16.x
   Garibaldi BT, 2013, AM J RESP CELL MOL, V48, P35, DOI 10.1165/rcmb.2012-0198OC
   Ghorani V, 2017, TOB INDUC DIS, V15, DOI 10.1186/s12971-017-0130-2
   Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
   Grattendick K, 2002, AM J RESP CELL MOL, V26, P716, DOI 10.1165/ajrcmb.26.6.4723
   Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
   Hu R, 2013, FRONT BIOSCI-LANDMRK, V18, P1244, DOI 10.2741/4176
   JUNQUEIRA LCU, 1978, ARCH HISTOL JAPON, V41, P267, DOI 10.1679/aohc1950.41.267
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marshall R, 1998, THORAX, V53, P815, DOI 10.1136/thx.53.10.815
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Mock JR, 2014, MUCOSAL IMMUNOL, V7, P1440, DOI 10.1038/mi.2014.33
   Moore BB, 2013, AM J RESP CELL MOL, V49, P167, DOI 10.1165/rcmb.2013-0094TR
   Mouratis MA, 2011, CURR OPIN PULM MED, V17, P355, DOI 10.1097/MCP.0b013e328349ac2b
   Muhlfeld C, 2013, AM J PHYSIOL-LUNG C, V305, P1205, DOI 10.1152/ajplung.00427.2012
   Nijland R, 2014, MAR DRUGS, V12, P4260, DOI 10.3390/md12074260
   Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701
   Roos AB, 2014, JOVE-J VIS EXP, V94, P51470
   Sartori C, 2002, EUR RESPIR J, V20, P1299, DOI 10.1183/09031936.02.00401602
   Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365-2613.2007.00566.x
   Villar J, 2014, CURR OPIN CRIT CARE, V20, P3, DOI 10.1097/MCC.0000000000000057
   Walkin L, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-18
   Ware LB, 1999, AM J RESP CRIT CARE, V159, pA694
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Weigert C., 1898, Z ALLG PATHOL, V9, P289
   WHEELDON EB, 1992, LAB ANIM, V26, P29, DOI 10.1258/002367792780809020
   Yoshida T, 2014, RESP PHYSIOL NEUROBI, V191, P75, DOI 10.1016/j.resp.2013.11.008
NR 42
TC 20
Z9 21
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 27
PY 2017
VL 12
IS 9
AR e0185474
DI 10.1371/journal.pone.0185474
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FI4WR
UT WOS:000411980300071
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Vieira, VA
   Avelino-Silva, VI
   Cerqueira, NB
   Costa, DA
   Costa, PR
   Vasconcelos, RP
   Madruga, VR
   Moreira, RI
   Hoagland, B
   Veloso, VG
   Grinsztejn, B
   Kallas, EG
AF Vieira, Vinicius A.
   Avelino-Silva, Vivian I.
   Cerqueira, Natalia B.
   Costa, Dayane A.
   Costa, Priscilla R.
   Vasconcelos, Ricardo P.
   Madruga, Valdez R.
   Moreira, Ronaldo I.
   Hoagland, Brenda
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Kallas, Esper G.
CA PrEP Brasil Study Team
TI Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae
   infections are associated with systemic CD8(+) T-cell activation
SO AIDS
LA English
DT Article
DE cellular immunity; Chlamydia trachomatis; HIV; immune activation;
   Neisseria gonorrhoeae; preexposure prophylaxis; T lymphocyte
ID HIV PREEXPOSURE PROPHYLAXIS; SEXUALLY-TRANSMITTED INFECTIONS; IMMUNE
   ACTIVATION; HIGH-RISK; TRANSGENDER WOMEN; RECTAL GONORRHEA;
   GENITAL-TRACT; UNITED-STATES; MEN; SEX
AB Background: Oral preexposure prophylaxis (PrEP) has been established as a pivotal strategy in HIV prevention. However, bacterial sexually transmitted infections (STIs), such as Chlamydia trachomatis and Neisseria gonorrhoeae, are also highly prevalent. Although the presence of STI-related mucosal lesions is a known risk factor for HIV acquisition, the potential increase in risk associated with asymptomatic STIs is not completely understood. Recent data demonstrated higher T-cell activation is a risk factor for sexually acquired HIV-1 infection. We examined the effect of asymptomatic C. trachomatis and N. gonorrhoeae anorectal infection on systemic immune activation, potentially increasing the risk of HIV acquisition.
   Methods: We analyzed samples from participants of PrEP Brasil, a demonstration study of daily oral emtricitabine/tenofovir disoproxil fumarate HIV PrEP among healthy MSM, for T-cell activation by flow cytometry. We included 34 asymptomatic participants with anorectal swab for C. trachomatis and/or N. gonorrhoeae infection, whereas negative for other STIs, and 35 controls.
   Results: We found a higher frequency of human leukocyte antigen DR(+)CD3(+)CD8(+)T cells (1.5 vs. 0.9%, P<0.005) and with memory phenotype in the group with asymptomatic C. trachomatis and/or N. gonorrhoeae infection. Exhaustion and senescence markers were also significant higher in this group. No difference was observed in the soluble CD14 levels.
   Conclusion: Our findings suggest asymptomatic anorectal C. trachomatis and/or N. gonorrhoeae increase systemic immune activation, potentially increasing the risk of HIV acquisition. Regular screening and treatment of asymptomatic STIs should be explored as adjuvant tools for HIV prevention. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Vieira, Vinicius A.; Cerqueira, Natalia B.; Costa, Dayane A.; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Vasconcelos, Ricardo P.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Inst Ensino & Pesquisa, Sao Paulo, SP, Brazil.
   [Madruga, Valdez R.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, SP, Brazil.
   [Moreira, Ronaldo I.; Hoagland, Brenda; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM esper.kallas@usp.br
RI Vasconcelos, Ricardo/AAL-4634-2020; Avelino-Silva, Vivian I/L-2640-2013
OI Vasconcelos, Ricardo/0000-0002-9753-0563; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health [01/2013 BRA/K57]; National Counsel of
   Technological and Scientific Development - CNPqNational Council for
   Scientific and Technological Development (CNPq) [402004/2012-4,
   454931/2014-0]; SVS [281/2013]; Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [E-26/110.261/2014];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/51743-0];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES
FX The current work and PrEP Brasil study was supported by the Brazilian
   Ministry of Health (#01/2013 BRA/K57), National Counsel of Technological
   and Scientific Development - CNPq (#402004/2012-4, #454931/2014-0) SVS
   (#281/2013), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJ (#E-26/110.261/2014) and Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP (#2012/51743-0). Gilead Sciences donated the study
   drug and covered the costs related to drug level assessment. D.A.C.'s
   scholarship was funded by FAPESP; P.R.C.'s scholarship was funded by
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES.
CR Avelino-Silva VI, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005219
   Baker J, 2009, AIDS PATIENT CARE ST, V23, P585, DOI 10.1089/apc.2008.0277
   Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Bernstein KT, 2010, JAIDS-J ACQ IMM DEF, V53, P537, DOI 10.1097/QAI.0b013e3181c3ef29
   Blumenthal Jill, 2014, Virtual Mentor, V16, P909, DOI 10.1001/virtualmentor.2014.16.11.stas1-1411
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801
   Centers for Disease Control and Prevention, SEX TRANSM DIS SURV
   Cohen MS, 1998, LANCET, V351, P5
   Cohen Myron S, 2004, Top HIV Med, V12, P104
   CRAIB KJP, 1995, GENITOURIN MED, V71, P150, DOI 10.1136/sti.71.3.150
   Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   HAHN T, 1989, CLIN IMMUNOL IMMUNOP, V50, P53, DOI 10.1016/0090-1229(89)90221-3
   Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kahle EM, 2015, J INFECT DIS, V211, P1451, DOI 10.1093/infdis/jiu621
   Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117
   Kuebler PJ, 2016, J INFECT DIS, V213, P569, DOI 10.1093/infdis/jiv425
   Lee HSW, 2008, J IMMUNOL, V180, P6827, DOI 10.4049/jimmunol.180.10.6827
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298
   Masson L, 2014, SEX TRANSM INFECT, V90, P580, DOI 10.1136/sextrans-2014-051601
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733
   Pathela P, 2015, CLIN INFECT DIS, V61, P281, DOI 10.1093/cid/civ289
   Pathela P, 2013, CLIN INFECT DIS, V57, P1203, DOI 10.1093/cid/cit437
   Pattacini L, 2016, JAIDS-J ACQ IMM DEF, V72, P119, DOI 10.1097/QAI.0000000000000919
   Reddy BS, 2004, CLIN EXP IMMUNOL, V137, P552, DOI 10.1111/j.1365-2249.2004.02564.x
   Redgrove KA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00534
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Scott HM, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0089-8
   Sheth PM, 2008, J INFECT DIS, V197, P1394, DOI 10.1086/587697
   Solomon MM, 2014, CLIN INFECT DIS, V59, P1020, DOI 10.1093/cid/ciu450
   Tao GY, 2016, CLIN INFECT DIS, V63, P1325, DOI 10.1093/cid/ciw594
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
NR 45
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 24
PY 2017
VL 31
IS 15
BP 2069
EP 2076
DI 10.1097/QAD.0000000000001580
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FG8ZM
UT WOS:000410727600004
PM 28692536
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Vieira, VA
   Sauer, MM
   Tomiyama, HI
   Kalil, J
   Kallas, EG
AF Tarosso, Leandro F.
   Vieira, Vinicius A.
   Sauer, Mariana M.
   Tomiyama, Helena I.
   Kalil, Jorge
   Kallas, Esper G.
TI Conserved HIV-1 Gag p24 Epitopes Elicit Cellular Immune Responses That
   Impact Disease Outcome
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE antigen processing and presentation; Gag; immune response; T cells
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; VIRAL LOAD;
   HIV-1-SPECIFIC CD4(+); FUNCTIONAL PROFILE; ESCAPE MUTATIONS; INFECTION;
   VACCINE; NONPROGRESSORS; REPLICATION
AB Although the breadth of the human immunodeficiency virus type 1 (HIV-1)-specific cellular immune response and its impact on the control of viral replication have already been addressed, reported data have proven controversial. We hypothesize that the nature of targeted epitopes, rather than the simple breadth or magnitude of responses, correlates with disease outcome. In this study, we explore the occurrence of patterns of Gag p24 recognition among untreated HIV-1-infected patients by identifying the epitopes that compose such patterns and how they distinctly associate with disease progression. Utilizing enzyme-linked immunospot (ELISPOT) interferon gamma (IFN-gamma), we screened cellular responses of 27 HIV-1-infected subjects against 15-mer peptides encompassing the whole Gag p24 protein. Obtained data were used to develop a clustering analysis that allowed definition of two groups of individuals with totally distinct patterns of recognition. Although targeted Gag p24 peptides were completely different between the two groups, the breadth and magnitude of the responses were not. Interestingly, viral control and preservation of CD4(+) T cells were increased in one group. In addition, we compared genetic conservation of amino acid sequences of the recognized peptides, as well as of the human leucocyte antigen class I (HLA-I)-restricted epitopes within them. Subjects presenting higher control of HIV-1 replication targeted more conserved epitopes, and higher genetic variation was present mainly in anchor residues for HLA-I molecules. We strengthen the existing evidence from cases of HIV-1 infection in humans that, cellular immune responses targeting conserved epitopes, rather than the magnitude and breadth of responses, associate with a better control of viral replication and maintenance of peripheral CD4(+) T cell counts.
C1 [Tarosso, Leandro F.; Vieira, Vinicius A.; Sauer, Mariana M.; Tomiyama, Helena I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Tarosso, Leandro F.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Ribeirao Preto, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274; Kallas, Esper/0000-0003-2026-6925
FU Ministry of HealthMinistry of Health - Turkey [914/BRA/3014]; Sao Paulo
   City Health Department [2004-0.168.922-7]; FAPESP (Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo)Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2010/51609-7, 04/15856-9]
FX The authors are especially grateful to Amelia Raj, Laurel Stewart, and
   David O'Connor for their critical reading of our article and suggestions
   for writing improvements. We also thank Douglas Nixon, Raphael R
   Almeida, and Maria Teresa Giret for valuable discussion on the presented
   data. The authors were supported and granted by Brazilian Program for
   STD and AIDS-Ministry of Health Grant 914/BRA/3014 and the Sao Paulo
   City Health Department Grant 2004-0.168.922-7 (to E.G.K.), and the
   FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) Grants
   2010/51609-7 (to L.F.T.), 04/15856-9 (to E.G.K.). The NIH AIDS Research
   and Reference Reagent Program, Division of AIDS, NIAID, NIH, provided
   the complete HIV-1 Gag Consensus subtype B 15-mer peptide set.
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Daucher M, 2008, J VIROL, V82, P4102, DOI 10.1128/JVI.02212-07
   Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002
   Engram JC, 2009, J IMMUNOL, V183, P706, DOI 10.4049/jimmunol.0803746
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Gray CM, 2009, J VIROL, V83, P470, DOI 10.1128/JVI.01678-08
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Honeyborne I, 2007, J VIROL, V81, P3667, DOI 10.1128/JVI.02689-06
   Huang SH, 2008, J IMMUNOL, V181, P8103, DOI 10.4049/jimmunol.181.11.8103
   Jin X, 2002, J VIROL, V76, P12603, DOI 10.1128/JVI.76.24.12603-12610.2002
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Koup RA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009015
   Kunwar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064405
   Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001
   Liepe J, 2014, BIOMOLECULES, V4, P585, DOI 10.3390/biom4020585
   Liu JY, 2006, J VIROL, V80, P11991, DOI 10.1128/JVI.01348-06
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Murakoshi H, 2015, J VIROL, V89, P5330, DOI 10.1128/JVI.00020-15
   Natarajan K, 1999, Rev Immunogenet, V1, P32
   Perez CL, 2013, AIDS RES HUM RETROV, V29, P602, DOI [10.1089/aid.2012.0171, 10.1089/AID.2012.0171]
   Peut V, 2007, J VIROL, V81, P13125, DOI 10.1128/JVI.01408-07
   Rolland M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001424
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Shalekoff S, 2008, JAIDS-J ACQ IMM DEF, V48, P245, DOI 10.1097/QAI.0b013e31816fdc77
   Sunshine J, 2014, J VIROL, V88, P1354, DOI 10.1128/JVI.02361-13
   Turk G, 2008, J VIROL, V82, P2853, DOI 10.1128/JVI.02260-07
   Wang YYE, 2009, J VIROL, V83, P1845, DOI 10.1128/JVI.01061-08
NR 37
TC 1
Z9 1
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2017
VL 33
IS 8
SI SI
BP 832
EP 842
DI 10.1089/aid.2016.0168
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FD0DN
UT WOS:000407210100012
PM 28594230
OA Green Published
DA 2020-11-26
ER

PT J
AU Aliota, MT
   Bassit, L
   Bradrick, SS
   Cox, B
   Garcia-Blanco, MA
   Gavegnano, C
   Friedrich, TC
   Golos, TG
   Griffin, DE
   Haddow, AD
   Kallas, EG
   Kitron, U
   Lecuit, M
   Magnani, DM
   Marrs, C
   Mercer, N
   McSweegan, E
   Ng, LFP
   O'Connor, DH
   Osorio, JE
   Ribeiro, GS
   Ricciardi, M
   Rossi, SL
   Saade, G
   Schinazi, RF
   Schott-Lerner, GO
   Shan, C
   Shi, PY
   Watkins, DI
   Vasilakis, N
   Weaver, SC
AF Aliota, Matthew T.
   Bassit, Leda
   Bradrick, Shelton S.
   Cox, Bryan
   Garcia-Blanco, Mariano A.
   Gavegnano, Christina
   Friedrich, Thomas C.
   Golos, Thaddeus G.
   Griffin, Diane E.
   Haddow, Andrew D.
   Kallas, Esper G.
   Kitron, Uriel
   Lecuit, Marc
   Magnani, Diogo M.
   Marrs, Caroline
   Mercer, Natalia
   McSweegan, Edward
   Ng, Lisa F. P.
   O'Connor, David H.
   Osorio, Jorge E.
   Ribeiro, Guilherme S.
   Ricciardi, Michael
   Rossi, Shannan L.
   Saade, George
   Schinazi, Raymond F.
   Schott-Lerner, Geraldine O.
   Shan, Chao
   Shi, Pei-Yong
   Watkins, David I.
   Vasilakis, Nikos
   Weaver, Scott C.
TI Zika in the Americas, year 2: What have we learned? What gaps remain? A
   report from the Global Virus Network
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Zika virus; Arbovirus; Congenital manifestations; Maternal-fetal
   transmission; Antiviral therapy; Vaccines
ID GUILLAIN-BARRE-SYNDROME; MALE SEXUAL TRANSMISSION; UNITED-STATES; CELL
   TROPISM; PROLONGED DETECTION; NEURAL PROGENITORS; CEREBRAL ORGANOIDS;
   BORNE TRANSMISSION; INTERIM GUIDANCE; REPRODUCTIVE AGE
AB In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic. (C) 2017 Published by Elsevier B.V.
C1 [Griffin, Diane E.; Haddow, Andrew D.; Kallas, Esper G.; Lecuit, Marc; Mercer, Natalia; McSweegan, Edward; Ng, Lisa F. P.; Osorio, Jorge E.; Schinazi, Raymond F.; Watkins, David I.; Weaver, Scott C.] Global Virus Network, 725 West Lombard St, Baltimore, MD 21201 USA.
   [Aliota, Matthew T.; Friedrich, Thomas C.; Osorio, Jorge E.] Univ Wisconsin Madison, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Bassit, Leda; Cox, Bryan; Gavegnano, Christina; Schinazi, Raymond F.] Emory Univ, Ctr AIDS Res, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
   [Bradrick, Shelton S.; Garcia-Blanco, Mariano A.; Schott-Lerner, Geraldine O.; Shan, Chao; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Friedrich, Thomas C.; Golos, Thaddeus G.; O'Connor, David H.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.
   [Golos, Thaddeus G.] Univ Wisconsin Madison, Dept Comparat Biosci, Madison, WI 53706 USA.
   [Golos, Thaddeus G.] Univ Wisconsin Madison, Dept Obstet & Gynecol, Madison, NJ 53706 USA.
   [Griffin, Diane E.] Johns Hopkins Bloomberg Sch Publ Hlth, Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   [Haddow, Andrew D.] US Army, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kitron, Uriel] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA.
   [Lecuit, Marc] Inst Pasteur, Biol Infect Unit, Paris, France.
   [Lecuit, Marc] INSERM, Unit 1117, Paris, France.
   [Lecuit, Marc] Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Inst Imagine, Sorbonne Paris Cite,Div Infect Dis & Trop Med, Paris, France.
   [Magnani, Diogo M.; Ricciardi, Michael; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33101 USA.
   [Marrs, Caroline; Saade, George] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.
   [Ng, Lisa F. P.] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [O'Connor, David H.] Univ Wisconsin Madison, Dept Pathol & Lab Med, Madison, WI 53706 USA.
   [Ribeiro, Guilherme S.] Univ Fed Bahia, Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Ribeiro, Guilherme S.] Univ Fed Bahia, Inst Sailde Colet, Salvador, BA, Brazil.
   [Rossi, Shannan L.; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Vasilakis, Nikos] Univ Texas Med Branch, Inst Human Infect & Immun, Dept Pathol, Galveston, TX 77555 USA.
RP Weaver, SC (corresponding author), Global Virus Network, 725 West Lombard St, Baltimore, MD 21201 USA.; Weaver, SC (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
EM sweaver@utmb.edu
RI Lecuit, Marc/M-4126-2019; Haddow, Andrew D/C-5902-2008; Vasilakis,
   Nikos/ABE-7318-2020; Ribeiro, Guilherme/B-6624-2008; Lecuit,
   Marc/J-4073-2013
OI Lecuit, Marc/0000-0002-4491-1063; Haddow, Andrew D/0000-0002-8957-2608;
   Ribeiro, Guilherme/0000-0002-6798-2059; Lecuit,
   Marc/0000-0002-4491-1063; Kallas, Esper/0000-0003-2026-6925; Ng,
   Lisa/0000-0003-4071-5222; Garcia-Blanco, Mariano/0000-0001-8538-1997;
   Magnani, Diogo/0000-0002-1773-2406; Aliota, Matthew/0000-0002-6902-9149
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01NS087539-S1,
   R21AI129607, R24AI120942, R01A1121452, R01 AI07157-01A1,
   R01AI116382-01A1S1, U01AI115577, P51 OD011106]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI107157, R01AI116382, R21AI129607,
   R01AI121452, R01AI107157, R24AI120942, R24AI120942, R01AI116382,
   R01AI116382, U01AI115577, R01AI116382, U01AI115577, R01AI121452,
   R21AI129607, R24AI120942, R01AI107157, R01AI121452, R01AI121452,
   U01AI115577, R01AI116382, R01AI121452, U01AI115577, R24AI120942,
   R01AI107157, R24AI120942, R24AI120942] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS087539, R01NS087539, R01NS087539, R01NS087539, R01NS087539,
   R01NS087539] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR,
   NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106] Funding Source: NIH RePORTER
FX Work from the authors' laboratories was funded by in part by U.S.
   National Institutes of Health grants: R01NS087539-S1 (to DEG),
   R21AI129607 (to RFS), and R24AI120942, R01A1121452 (to SCW) R01
   AI07157-01A1 (to TGG), R01AI116382-01A1S1 (to DHO), U01AI115577 (to NV)
   and P51 OD011106 (to the WNPRC).
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Akoua-Koffi C, 2001, B SOC PATHOL EXOT, V94, P227
   Alera MT, 2015, EMERG INFECT DIS, V21, P722, DOI 10.3201/eid2104.141707
   Ali S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005135
   Aliota M. T., 2016, PLOS NEGLECT TROP D, V10, DOI DOI 10.1371/JOURNAL.PNTD.0004750
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005168
   Aliota MT, 2016, EMERG INFECT DIS, V22, P1857, DOI 10.3201/eid2210.161082
   Althouse BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005055
   Amraoui F, 2016, EURO SURVEILL, V21
   [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P2588, DOI [10.1001/jama.2016.19328, 10.1001/jama.2016.18655]
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P553, DOI 10.1590/0037-8682-0245-2016
   Azmi SA, 2015, J VECTOR DIS, V52, P252
   Barba-Spaeth G, 2016, NATURE, V539, DOI 10.1038/nature19780
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Barouch DH, 2017, IMMUNITY, V46, P176, DOI 10.1016/j.immuni.2017.02.005
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   BEARCROFT WGC, 1957, J PATHOL BACTERIOL, V74, P295, DOI 10.1002/path.1700740207
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Berthet N, 2014, VECTOR-BORNE ZOONOT, V14, P862, DOI 10.1089/vbz.2014.1607
   Besnard M, 2016, EUROSURVEILLANCE, V21, P22, DOI 10.2807/1560-7917.ES.2016.21.13.30181
   Besnard M., 2014, EURO SURVEILL, V19
   Boccolini D, 2016, EURO SURVEILL, V21
   Bondarenko GI, 2007, J IMMUNOL, V179, P8042, DOI 10.4049/jimmunol.179.12.8042
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brault JB, 2016, EBIOMEDICINE, V10, P71, DOI 10.1016/j.ebiom.2016.07.018
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Buathong R, 2015, AM J TROP MED HYG, V93, P380, DOI 10.4269/ajtmh.15-0022
   Buechler CR, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00392-16
   BULMER JN, 1984, CLIN EXP IMMUNOL, V57, P393
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Carter AM, 2011, BEST PRACT RES CL OB, V25, P249, DOI 10.1016/j.bpobgyn.2010.10.010
   Cavalcanti MG, 2017, INT J INFECT DIS, V57, P70, DOI 10.1016/j.ijid.2017.01.042
   Chen JC, 2016, INT J INFECT DIS, V51, P139, DOI 10.1016/j.ijid.2016.07.015
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Chimelli L, 2017, ACTA NEUROPATHOL
   Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543
   Chua A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005269
   Coffey LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171148
   CORNET M, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P47
   CORNET M, 1979, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V17, P149
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   Cox Bryan D., 2015, Antiviral Chemistry & Chemotherapy, V24, P118, DOI 10.1177/2040206616653873
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   Cunha MS, 2016, GENOME ANNOUNC, V4
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Daffis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000607
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Carvalho GC, 2014, J VECTOR ECOL, V39, P146, DOI 10.1111/j.1948-7134.2014.12081.x
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   do Rosario MS, 2016, AM J TROP MED HYG, V95, P1157, DOI 10.4269/ajtmh.16-0306
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   DRAPER C C, 1965, West Afr Med J, V14, P16
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056
   Duong V, 2017, EMERG INFECT DIS, V23, P296, DOI 10.3201/eid2302.161432
   El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296
   Enders AC, 2007, PLACENTA, V28, P794, DOI 10.1016/j.placenta.2006.11.001
   Enders AC, 2001, PLACENTA, V22, P284, DOI 10.1053/plac.2001.0626
   EYROLLEGUIGNOT D, 2016, LANCET, V387, P2125, DOI DOI 10.1016/50140-6736(16)00651-6.PUBMED
   FAGBAMI AH, 1979, J HYG-CAMBRIDGE, V83, P213, DOI 10.1017/S0022172400025997
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   FDA, 2017, ZIK VIR EM US AUTH
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Fields BN, 2007, FIELDS VIROLOGY, Vxix, P3091
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Freitas B de Paula, 2016, JAMA OPHTHALMOL
   Froeschl G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2123-9
   Gabriel E, 2017, CELL STEM CELL, V20, P397, DOI 10.1016/j.stem.2016.12.005
   Galel SA, 2017, TRANSFUSION
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gavegnano Christina, 2017, Pathog Immun, V2, P199, DOI 10.20411/pai.v2i2.190
   Godoy AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14764
   Goebel S, 2016, J VIROL METHODS, V238, P13, DOI 10.1016/j.jviromet.2016.09.015
   Golos TG, 2010, INT J DEV BIOL, V54, P431, DOI 10.1387/ijdb.082797tg
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Guerbois M, 2016, J INFECT DIS
   Gulland A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4812
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Guo XX, 2014, J AM MOSQUITO CONTR, V30, P309, DOI 10.2987/14-6439R.1
   Haddow A. D., 2017, EMERG INFECT DIS
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Haddow AD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005083
   Haddow AD, 2016, B WORLD HEALTH ORGAN, V94, P711, DOI 10.2471/BLT.16.181503
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hall-Mendelin S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004959
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hamer DH, 2017, ANN INTERN MED, V166, P99, DOI 10.7326/M16-1842
   Hanley K. A., 2013, INFECT GENET EVOL J
   Hanley Kathryn A., 2017, AM TROP MED HYG
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224
   Herrera B. B., 2017, J INFECT DIS
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Huang YJS, 2016, VECTOR-BORNE ZOONOT, V16, P673, DOI 10.1089/vbz.2016.2058
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Jurado KA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88461
   Katz LM, 2017, ARCH PATHOL LAB MED, V141, P85, DOI 10.5858/arpa.2016-0430-RA
   Kincaid E, 2016, NAT MED, V22, P824, DOI 10.1038/nm0816-824
   Koide F, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02028
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Ledermann JP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003188
   Li C, 2016, CELL STEM CELL, V19, P672, DOI 10.1016/j.stem.2016.10.017
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Li MI, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001792
   Li XF, 2016, EBIOMEDICINE, V12, P170, DOI 10.1016/j.ebiom.2016.09.022
   Li Y, 2017, CELL STEM CELL, V20, P385, DOI 10.1016/j.stem.2016.11.017
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Liu Y, 2017, NATURE
   Louis GMB, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.032
   Lozier M, 2016, MMWR-MORBID MORTAL W, V65, P1219, DOI 10.15585/mmwr.mm6544a4
   Ma WQ, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.009
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Magnani D. M., 2017, PLOS NEGLEC IN PRESS
   Makhluf H, 2016, EXPERT OPIN DRUG DIS, V11, P921, DOI 10.1080/17460441.2016.1212013
   Mann A, 2011, NAT MED, V17, P394, DOI 10.1038/nm0411-394a
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P894, DOI 10.1016/S1473-3099(16)30153-0
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Maurer-Stroh S., 2016, EURO SURVEILL, V21
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i212
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Meaney-Delman D, 2016, MMWR-MORBID MORTAL W, V65, P211, DOI 10.15585/mmwr.mm6508e1
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Molaei G, 2007, AM J TROP MED HYG, V77, P73
   Moreira J., 2017, CLIN MICROBIOL INFEC
   Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Muller W.J., 2016, JAMA
   Munoz-Jordan JL, 2010, VIRUSES-BASEL, V2, P676, DOI 10.3390/v2020676
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EURO SURVEILL, V19
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nguyen SM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006378
   Nicastri E., 2016, EURO SURVEILL, V21
   Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   OLSON JG, 1981, T ROY SOC TROP MED H, V75, P389, DOI 10.1016/0035-9203(81)90100-0
   Olson KE, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P315
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Pacheco O, 2016, N ENGL J MED
   Pagani I, 2017, SCI REP-UK, V7, DOI 10.1038/srep44286
   PAHO, 2017, REG ZIK EP UPD AM 10
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Pardi N., 2017, NATURE
   Parke DW, 2016, OPHTHALMOLOGY, V123, P2432, DOI 10.1016/j.ophtha.2016.06.039
   Paz-Bailey G., 2017, N ENGL J MED
   Perkins TA, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.51
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P315, DOI 10.15585/mmwr.mm6512e2
   Petersen L.R., 2016, N ENGL J MED
   Plourde AR, 2016, EMERG INFECT DIS, V22, P1185, DOI 10.3201/eid2207.151990
   Qian XY, 2016, CELL, V165, P1238, DOI 10.1016/j.cell.2016.04.032
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Ragan IK, 2017, VECTOR-BORNE ZOONOT, V17, P161, DOI 10.1089/vbz.2016.2099
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Richner JM, 2017, CELL
   Ritchie S, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P281
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Roundy CM, 2017, EMERG INFECT DIS, V23, P625, DOI 10.3201/eid2304.161484
   Salchuddin AR, 2017, ASIAN PAC J TROP MED, V10, P201, DOI 10.1016/j.apjtm.2017.03.002
   Salje H, 2016, J INFECT DIS, V213, P604, DOI 10.1093/infdis/jiv470
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shan C, 2017, EBIOMEDICINE, V17, P157, DOI 10.1016/j.ebiom.2017.03.006
   Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004
   Shan C, 2016, ACS INFECT DIS, V2, P170, DOI 10.1021/acsinfecdis.6b00030
   Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114
   Simoni MK, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12613
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   SMFM, 2015, AM J OBSTET GYNECOL
   SMITHBURN KC, 1954, AM J HYG, V59, P157, DOI 10.1093/oxfordjournals.aje.a119630
   Souza BSF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39775
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE
   Strafela P, 2017, ARCH PATHOL LAB MED, V141, P73, DOI 10.5858/arpa.2016-0341-SA
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010
   van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898
   Vasilakis N, 2017, CURR OPIN VIROL, V22, P30, DOI 10.1016/j.coviro.2016.11.007
   Vasquez AM, 2016, MMWR-MORBID MORTAL W, V65, P375, DOI 10.15585/mmwr.mm6514e1
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Vermillion MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14575
   Villar J, 2013, BJOG-INT J OBSTET GY, V120, P9, DOI 10.1111/1471-0528.12047
   Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193
   Walker T, 2016, ARBOVIRUSES: MOLECULAR BIOLOGY, EVOLUTION AND CONTROL, P291
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Weger-Lucarelli J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005101
   Weisblum Y, 2017, J VIROL, V91, DOI [10.1128/jvi.01905-16, 10.1128/JVI.01905-16]
   Wells MF, 2016, CELL STEM CELL, V19, P703, DOI 10.1016/j.stem.2016.11.011
   WHO, 2016, INT GUID UPD PREGN M
   WHO, 2016, ZIK SIT REP 6 OCT 20
   WHO, 2017, GUID INF FEED AR ZIK
   Wikan N, 2016, ASIAN PAC J TROP MED, V9, P136, DOI 10.1016/j.apjtm.2016.01.017
   Wildman DE, 2006, P NATL ACAD SCI USA, V103, P3203, DOI 10.1073/pnas.0511344103
   Williamson P. C., 2017, TRANSFUSION
   Wolfe ND, 2001, AM J TROP MED HYG, V64, P310, DOI 10.4269/ajtmh.2001.64.310
   Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   Xie XP, 2017, MBIO, V8, DOI [10.1128/mBio.02134-16, 10.1128/mbio.02134-16]
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang YJ, 2017, EBIOMEDICINE, V17, P145, DOI 10.1016/j.ebiom.2017.02.003
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Zambrano H, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12630
   Zhang B., 2017, NAT MED
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 260
TC 58
Z9 58
U1 0
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2017
VL 144
BP 223
EP 246
DI 10.1016/j.antiviral.2017.06.001
PG 24
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA FD3DH
UT WOS:000407413200023
PM 28595824
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Grinsztejn, B
   Hoagland, B
   Moreira, R
   Kallas, E
   Madruga, J
   Leite, I
   de Boni, R
   Anderson, P
   Liu, A
   Luz, P
   Veloso, V
AF Grinsztejn, B.
   Hoagland, B.
   Moreira, R.
   Kallas, E.
   Madruga, J.
   Leite, I.
   de Boni, R.
   Anderson, P.
   Liu, A.
   Luz, P.
   Veloso, V.
CA PrEP Brasil Study Grp
TI High level of retention and adherence at Week 48 for MSM and TGW
   enrolled in the PrEP Brasil demonstration study
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Grinsztejn, B.; Hoagland, B.; Moreira, R.; de Boni, R.; Luz, P.; Veloso, V.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Kallas, E.; Madruga, J.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Leite, I.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Anderson, P.] Univ Colorado, Anschutz Med Campus, Denver, CO 80202 USA.
   [Liu, A.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
EM gbeatriz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2017
VL 20
SU 5
MA TUPD
BP 125
EP 125
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FB8ZQ
UT WOS:000406429800231
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Rosen, BC
   Ricciardi, MJ
   Pedreno-Lopez, N
   Gutman, MJ
   Bailey, VK
   Maxwell, HS
   Domingues, A
   Gonzalez-Nieto, L
   Avelino-Silva, VI
   Trindade, M
   Nogueira, J
   Oliveira, CS
   Maestri, A
   Felix, AC
   Levi, JE
   Nogueira, ML
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Rosen, Brandon C.
   Ricciardi, Michael J.
   Pedreno-Lopez, Nuria
   Gutman, Martin J.
   Bailey, Varian K.
   Maxwell, Helen S.
   Domingues, Aline
   Gonzalez-Nieto, Lucas
   Avelino-Silva, Vivian I.
   Trindade, Mateus
   Nogueira, Juliana
   Oliveira, Consuelo S.
   Maestri, Alvino
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Nogueira, Mauricio L.
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI A human inferred germline antibody binds to an immunodominant epitope
   and neutralizes Zika virus
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MEMORY B-CELLS; DENGUE VIRUS; INTERIM GUIDELINES; UNITED-STATES;
   MONOCLONAL-ANTIBODIES; SOMATIC HYPERMUTATION; PREGNANT-WOMEN; HIV-1
   VACCINE; INFECTION; RESPONSES
AB The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut(50) similar to 2 mu g/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting.
C1 [Magnani, Diogo M.; Rosen, Brandon C.; Ricciardi, Michael J.; Pedreno-Lopez, Nuria; Gutman, Martin J.; Bailey, Varian K.; Maxwell, Helen S.; Domingues, Aline; Gonzalez-Nieto, Lucas; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.; Trindade, Mateus] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
   [Trindade, Mateus] Univ Sao Paulo, Sch Med, Neurol Dept, Sao Paulo, SP, Brazil.
   [Nogueira, Juliana] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Oliveira, Consuelo S.] Inst Evandro Chagas, Belem, Para, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, SP, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.
EM dwatkins@med.miami.edu
RI Martins, Mauricio/AAU-9226-2020; amsalu, ribka/G-8780-2019; Whitehead,
   Stephen/AAG-2787-2019; Terrassani Silveira, Cassia/M-8057-2017;
   Nogueira, Mauricio L/B-7599-2012; Avelino-Silva, Vivian I/L-2640-2013
OI Martins, Mauricio/0000-0001-8336-216X; Terrassani Silveira,
   Cassia/0000-0002-0932-7769; Nogueira, Mauricio L/0000-0003-1102-2419;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Kallas,
   Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05]; Wallace H. Coulter
   Center for Translational Research at University of Miami; Miami Clinical
   and Translational Science Institute (CTSI); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891] Funding Source: NIH RePORTER
FX This work was supported by the NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami
   [http://www.miami.edu/index.php/u innovation/about_us/whcc/], and the
   Miami Clinical and Translational Science Institute (CTSI) [http://
   miamictsi.org].The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davidson E, 2014, IMMUNOLOGY, V143, P13, DOI 10.1111/imm.12323
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Paula Freitas B, 2016, JAMA OPHTHALMOL
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6983
   Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fields BN, 2007, FIELDS VIROLOGY, Vxix, P3091
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Honein MA, 2016, JAMA J AM MED ASS
   Huzly D, 2016, EURO SURVEILL, V21
   Kalinke U, 2000, P NATL ACAD SCI USA, V97, P10126, DOI 10.1073/pnas.97.18.10126
   Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0
   Kato M, 2015, J VIROL, V89, P1468, DOI 10.1128/JVI.02293-14
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1180
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mor G, 2016, AM J REPROD IMMUNOL, V75, P421, DOI 10.1111/aji.12505
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Oster AM, 2016, MMWR-MORBID MORTAL W, V65, P120, DOI 10.15585/mmwr.mm6505e1
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sukupolvi-Petty S, 2010, J VIROL, V84, P9227, DOI 10.1128/JVI.01087-10
   Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716
   Thornburg NJ, 2016, J CLIN INVEST, V126, P1482, DOI 10.1172/JCI85317
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
NR 72
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005655
DI 10.1371/journal.pntd.0005655
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700038
PM 28604797
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Truong, HHM
   Mehrotra, M
   Montoya, O
   Lama, JR
   Guanira, JV
   Casapia, M
   Veloso, VG
   Buchbinder, SP
   Mayer, KH
   Chariyalertsak, S
   Schechter, M
   Bekker, LG
   Kallas, EG
   Grant, RM
AF Truong, Hong-Ha M.
   Mehrotra, Megha
   Montoya, Orlando
   Lama, Javier R.
   Guanira, Juan V.
   Casapia, Martin
   Veloso, Valdilea G.
   Buchbinder, Susan P.
   Mayer, Kenneth H.
   Chariyalertsak, Suwat
   Schechter, Mauro
   Bekker, Linda-Gail
   Kallas, Esper G.
   Grant, Robert M.
TI International Sexual Partnerships May Be Shaped by Sexual Histories and
   Socioeconomic Status
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID RISK BEHAVIOR; MEN; TRAVEL; PREVENTION; THERAPY; GAY
AB Exchange sex and higher education were associated with an increased likelihood of international sexual partnerships (ISPs). Exchange sex and older age were associated with an increased likelihood of condomless sex in ISPs. Educational and socioeconomic factors may create unbalanced power dynamics that influence exchange sex and condomless sex in ISPs.
C1 [Truong, Hong-Ha M.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Truong, Hong-Ha M.; Mehrotra, Megha; Grant, Robert M.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
   [Montoya, Orlando] Fdn Ecuatoriana Equidad, Quito Mainland, Ecuador.
   [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Guanira, Juan V.] Invest Med Salud, Lima, Peru.
   [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru.
   [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Buchbinder, Susan P.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
   [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Chiang Mai, Thailand.
   [Schechter, Mauro] Praca Onze, Rio De Janeiro, Brazil.
   [Bekker, Linda-Gail] Univ Cape Town, Cape Town, South Africa.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
RP Truong, HHM (corresponding author), Univ Calif San Francisco, Dept Med, 550 16th St,3rd Floor, San Francisco, CA 94158 USA.
EM Hong-Ha.Truong@ucsf.edu
RI Schechter, Mauro/AAG-7445-2020; Bekker, Linda-Gail/AAZ-8929-2020
OI Grant, Robert/0000-0002-0851-7085; BEKKER,
   LINDA-GAIL/0000-0002-0755-4386; Kallas, Esper/0000-0003-2026-6925
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01 AI64002, R01 MH080657]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, U01AI064002, R01AI118575, R01AI118575, UM1AI069476,
   UM1AI069476, UM1AI069476, U01AI064002, U01AI064002, R01AI118575,
   R01AI118575, UM1AI069476, U01AI064002, U01AI064002, U01AI064002,
   UM1AI069476, UM1AI069476, R01AI118575, U01AI064002, UM1AI069476,
   R01AI118575, U01AI064002, U01AI064002, UM1AI069476] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [R01MH080657, R01MH080657,
   R01MH080657, R01MH080657, R01MH080657, R01MH080657] Funding Source: NIH
   RePORTER
FX NIH U01 AI64002 (PI: Robert M. Grant). NIH R01 MH080657 (PI: Hong-Ha M.
   Truong).
CR Benotsch EG, 2006, SEX TRANSM DIS, V33, P706, DOI 10.1097/01.olq.0000218862.34644.0e
   Benotsch EG, 2011, J COMMUN HEALTH, V36, P398, DOI 10.1007/s10900-010-9321-y
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Darrow WW, 2005, J URBAN HEALTH, V82, P601, DOI 10.1093/jurban/jti122
   Fenton KA, 2005, INFECT DIS CLIN N AM, V19, P311, DOI 10.1016/j.idc.2005.04.004
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Kaufman MR, 2009, J HOMOSEXUAL, V56, P1134, DOI 10.1080/00918360903275534
   Kubicek K, 2015, J INTERPERS VIOLENCE, V30, P83, DOI 10.1177/0886260514532527
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mercer CH, 2007, SEX TRANSM INFECT, V83, P517, DOI 10.1136/sti.2007.026377
   Miller LC, 1995, GENDER POWER COMMUNI, P163
   Nagaraj S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-181
   Salazar X, 2005, CULT HEALTH SEX, V7, P375, DOI 10.1080/13691050500100849
   Truong HHM, 2016, SEX TRANSM DIS, V43, P459, DOI 10.1097/OLQ.0000000000000464
   Truong HHM, 2015, SEX TRANSM INFECT, V91, P220, DOI 10.1136/sextrans-2014-051660
   Truong HHM, 2008, J TRAVEL MED, V15, P454, DOI 10.1111/j.1708-8305.2008.00245.x
   UNAIDS, 2014, 90 90 90 AMB TREATM
   Vivancos R, 2010, INT J INFECT DIS, V14, pE842, DOI 10.1016/j.ijid.2010.02.2251
NR 19
TC 0
Z9 0
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD MAY
PY 2017
VL 44
IS 5
BP 306
EP 309
DI 10.1097/OLQ.0000000000000601
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA ES5PP
UT WOS:000399594000010
PM 28407648
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Hoagland, B
   De Boni, RB
   Moreira, RI
   Madruga, JV
   Kallas, EG
   Goulart, SP
   Cerqueira, N
   Torres, TS
   Luz, PM
   Fernandes, NM
   Liu, AY
   Grinsztejn, B
   Veloso, VG
AF Hoagland, Brenda
   De Boni, Raquel B.
   Moreira, Ronaldo I.
   Madruga, Jose Valdez
   Kallas, Esper G.
   Goulart, Silvia Pereira
   Cerqueira, Natalia
   Torres, Thiago S.
   Luz, Paula M.
   Fernandes, Nilo Martinez
   Liu, Albert Y.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
CA PrEP Brasil Study Team
TI Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among
   Men Who Have Sex with Men and Transgender Women in Brazil
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Pre-exposure prophylaxis; HIV prevention; MSM; Transvestite; Transgender
   women; Awareness; Willingness
ID ANTIRETROVIRAL PROPHYLAXIS; HIV-INFECTION; HETEROSEXUAL MEN; BISEXUAL
   MEN; CONDOM USE; HIGH-RISK; PREVENTION; GAY; MSM; EPIDEMIOLOGY
AB Antiretroviral pre-exposure prophylaxis (PrEP) is recommended to prevent HIV infection among high-risk men who have sex with men (MSM) though not available in Brazil where the HIV epidemic persists unabated in this group. This cross-sectional study describes PrEP awareness and willingness and associated factors among MSM and transvestite/transgender women (trans women) pre-screened for the PrEP Brasil study. Awareness was reported by 61.3 % of the participants and was associated with age, education, site, study period and prior HIV testing. Most participants (82.1 %) were willing to use PrEP, which was associated with site, study period, number of male condomless anal sexual partners and anal sex with HIV positive/unknown partners. PrEP information is need among young and less educated individuals. Willingness to use PrEP was high and future studies should be conducted to confirm PrEP acceptability and the characteristics of the population who chose to adopt this intervention.
C1 [Hoagland, Brenda; De Boni, Raquel B.; Moreira, Ronaldo I.; Torres, Thiago S.; Luz, Paula M.; Fernandes, Nilo Martinez; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fundacao Oswaldo Cruz INI FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Madruga, Jose Valdez; Goulart, Silvia Pereira] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil.
   [Kallas, Esper G.; Cerqueira, Natalia] Univ Sao Paulo, Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
RP Hoagland, B (corresponding author), Fundacao Oswaldo Cruz INI FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM brenda.hoagland@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; TORRES, THIAGO
   SILVA/0000-0002-2557-601X; Luz, Paula/0000-0001-9746-719X; Kallas,
   Esper/0000-0003-2026-6925
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq) [PROEP 402004/2012-4, Universal 45931/2014-0]; FAPERJ
   (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de
   Janeiro)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/110.261/2017, 2012/51743]; SVS-MS
   (Secretaria de Vigilancia em Saude do Ministerio da Saude) [281/2013];
   Departamento de HIV/AIDS e Hepatites Virais-Ministerio da Saude
   [01/2013, BRA/K27]
FX This study was funded by CNPq (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico-Grant PROEP 402004/2012-4; Grant Universal
   45931/2014-0), FAPERJ (Fundacao Carlos Chagas de Amparo a Pesquisa do
   Estado do Rio de Janeiro-Grant E-26/110.261/2017; Grant 2012/51743),
   SVS-MS (Secretaria de Vigilancia em Saude do Ministerio da Saude-Grant
   281/2013) and Departamento de HIV/AIDS e Hepatites Virais-Ministerio da
   Saude (Grant 01/2013 projeto BRA/K27). The funders had no hole in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aghaizu A, 2013, SEX TRANSM INFECT, V89, P207, DOI 10.1136/sextrans-2012-050648
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173
   Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
   Bavinton BR, 2015, VIRAL LOAD AWARENESS, P141
   Bil JP, 2015, AIDS, V29, P955, DOI 10.1097/QAD.0000000000000639
   Blumenthal J, 2015, AIDS BEHAV, V19, P802, DOI 10.1007/s10461-015-0996-z
   Brooks RA, 2012, AIDS PATIENT CARE ST, V26, P87, DOI 10.1089/apc.2011.0283
   Calabrese SK, 2015, AM J PUBLIC HEALTH, V105, P1960, DOI 10.2105/AJPH.2015.302816
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   De Boni R, 2014, CURR OPIN HIV AIDS, V9, P192, DOI 10.1097/COH.0000000000000031
   Departamento de DST Aids e Hepatites Virais, 2015, B EPI DEMIOLOGICO AI
   Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Escudero DJ, 2015, AIDS CARE, V27, P637, DOI 10.1080/09540121.2014.986051
   Golub SA, 2014, AIDS BEHAV, V18, P1686, DOI 10.1007/s10461-014-0770-7
   Grant RM, 2016, CURR OPIN HIV AIDS, V11, P3, DOI 10.1097/COH.0000000000000216
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Hojilla JC, 2016, AIDS BEHAV, V20, P1461, DOI 10.1007/s10461-015-1055-5
   Holt M, 2012, SEX TRANSM INFECT, V88, P258, DOI 10.1136/sextrans-2011-050312
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Krakower DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033119
   Kurtz SP, 2016, LGBT HEALTH, DOI [10.1089/lgbt.2015.0069, DOI 10.1089/LGBT.2015.0069.]
   Lebouche B, 2016, HIV MED, V17, P152, DOI 10.1111/hiv.12286
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Martins TA, 2013, AIDS CARE, V25, P606, DOI 10.1080/09540121.2012.726342
   Mascena MADS, 2015, AIDS BEHAV, V19, P1589
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Mugwanya KK, 2013, LANCET INFECT DIS, V13, P1021, DOI 10.1016/S1473-3099(13)70226-3
   Saude M., 2013, PROTOCOLO CLIN DIRET
   Silva DS, 2015, AIDS BEHAV, DOI [10.1007/s10461-015-1235-3, DOI 10.1007/S10461-015-1235-3.]
   Sineath R Craig, 2013, J Int Assoc Provid AIDS Care, V12, P227, DOI 10.1177/2325957413488184
   Smith DK, 2015, SEX TRANSM DIS, V42, P88, DOI 10.1097/OLQ.0000000000000238
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Ware NC, 2012, JAIDS-J ACQ IMM DEF, V59, P463, DOI 10.1097/QAI.0b013e31824a060b
   Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288
   Yang DZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054495, 10.1371/journal.pone.0059020]
   Young I, 2014, REV RES ACCEPTABILIT, P195
   Zhou F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032329
NR 46
TC 39
Z9 39
U1 1
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD MAY
PY 2017
VL 21
IS 5
BP 1278
EP 1287
DI 10.1007/s10461-016-1516-5
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA ER9JL
UT WOS:000399142400006
PM 27531461
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kailas, EG
   Kalil, J
   Passero, LFD
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan Pereira
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kailas, Esper G.
   Kalil, Jorge
   Passero, Luiz Felipe D.
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI p16(INK4a) Expression and Immunologic Aging in Chronic HIV Infection
   (vol 11, e0166759, 2016)
SO PLOS ONE
LA English
DT Correction
RI Hunt, Peter W./P-2976-2017; KALIL, JORGE/C-8029-2012; Nixon,
   Douglas/AAU-5734-2020; Cunha-Neto, Edecio/B-4157-2009
OI Hunt, Peter W./0000-0002-4571-4870; KALIL, JORGE/0000-0001-8415-4274;
   Nixon, Douglas/0000-0002-2801-1786; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Kallas, Esper/0000-0003-2026-6925
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH RePORTER;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30 AI027763] Funding Source: Medline
CR PEREIRARIBEIRO S, 2016, PLOS ONE, V11
   Ribeiro SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166759
NR 2
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2017
VL 12
IS 4
AR e0176509
DI 10.1371/journal.pone.0176509
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES9KM
UT WOS:000399875900134
PM 28426830
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Greenspun, BC
   Costa, EAS
   Segurado, AC
   Kallas, EG
   Nixon, DF
   Leal, FE
AF Paquin-Proulx, Dominic
   Greenspun, Benjamin C.
   Costa, Emanuela A. S.
   Segurado, Aluisio C.
   Kallas, Esper G.
   Nixon, Douglas F.
   Leal, Fabio E.
TI MAIT cells are reduced in frequency and functionally impaired in human T
   lymphotropic virus type 1 infection: Potential clinical implications
SO PLOS ONE
LA English
DT Article
ID I-ASSOCIATED MYELOPATHY; HTLV-I; PROVIRAL LOAD; CYTOKINE EXPRESSION;
   INTERFERON-GAMMA; LEUKEMIA-VIRUS; HIV-INFECTION; TUBERCULOSIS;
   METABOLITES; ACTIVATION
AB HTLV-1 infection is associated with several inflammatory disorders, including the neurode-generative condition HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is unclear why a minority of infected subjects develop HAM/TSP. The cellular immune response has been implicated in the development of inflammatory alterations in these patients; however the pathogenic mechanisms for disease progression remain unclear. Furthermore, HTLV-1-infected individuals have an increase incidence of Mycobacterium tuberculosis (Mtb) infection, suggesting that immunological defect are associated with HTLV-1 infection. Evidence suggests an important role for Mucosal-associated invariant T (MAIT) cells in the early control of Mtb infection. Chronic viral infections like HIV and HCV have been associated with decreased frequency and functionality of MAIT cells. We hypothesized that HTLV-1 infection is associated with similar perturbations in MAIT cells. We investigated MAIT cell frequency, phenotype, and function by flow cytometry in a cohort of 10 asymptomatic and 10 HAM/TSP HTLV-1 infected patients. We found that MAIT cells from HTLV-1-infected subjects were reduced and showed high co-expression of the activation markers CD38 and HLA-DR but normal levels of CCR6 and CD127. MAIT cells had a lower expression of the transcription factor PLZF in HAM/TSP patients. Unlike Tax-specific CD8+T cells, which are hyperfunctional, MAIT cells from HTLV-1-infected subjects had a poor IFN gamma response following antigen stimulation. MAIT cell perturbations in HTLV-1 infection were not associated with HTLV-1 proviral load and MAIT cells were not infected by HTLV-1 in vivo. Rather, MAIT cells loss was associated with immune activation. Overall, our results do not support a role for MAIT cells in HAM/TSP pathogenesis but reduced numbers of MAIT cells, together with their poor functionality, could contribute to the increased susceptibility of HTLV-1-infected individuals to other infectious agents.
C1 [Paquin-Proulx, Dominic; Greenspun, Benjamin C.; Nixon, Douglas F.; Leal, Fabio E.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Costa, Emanuela A. S.; Segurado, Aluisio C.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM dpaquin_proulx@gwu.edu
RI Segurado, Aluisio C/K-2229-2012; Nixon, Douglas/AAU-5734-2020
OI Segurado, Aluisio C/0000-0002-6311-8036; Nixon,
   Douglas/0000-0002-2801-1786; Paquin Proulx, Dominic/0000-0003-1407-3414;
   Kallas, Esper/0000-0003-2026-6925
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI117970]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); NHLBIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI);
   NIDAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA); NIMHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH); NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA);
   FICUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC);
   NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS); NIDDKUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); OAR;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970] Funding Source: NIH
   RePORTER
FX This research has been facilitated by the services and resources
   provided by the District of Columbia Center for AIDS Research, an NIH
   funded program (AI117970), which is supported by the following NIH
   Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD,
   NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0
   Azakami K, 2009, BLOOD, V114, P3208, DOI 10.1182/blood-2009-02-203042
   Barathan M, 2016, EUR J CLIN INVEST, V46, P170, DOI 10.1111/eci.12581
   Bastos MD, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-199
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Brito-Melo GEA, 2007, CLIN EXP IMMUNOL, V147, P35, DOI 10.1111/j.1365-2249.2006.03252.x
   Cho YN, 2014, J IMMUNOL, V193, P3891, DOI 10.4049/jimmunol.1302701
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1
   Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR
   Dorhoi A, 2014, EUR J IMMUNOL, V44, P2380, DOI 10.1002/eji.201344219
   Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339
   Fernandez CS, 2015, IMMUNOL CELL BIOL, V93, P177, DOI 10.1038/icb.2014.91
   Furuya T, 1999, J NEUROIMMUNOL, V95, P185, DOI 10.1016/S0165-5728(98)00263-X
   Garlet GP, 2010, CLIN INFECT DIS, V50, pE11, DOI 10.1086/649871
   Gerart S, 2013, BLOOD, V121, P614, DOI 10.1182/blood-2012-09-456095
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407
   Goon PKC, 2004, J IMMUNOL, V172, P1735, DOI 10.4049/jimmunol.172.3.1735
   Greene JM, 2016, MUCOSAL IMMUNOL
   Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568
   Hengst J, 2016, EUR J IMMUNOL
   Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Koay HF, 2016, NAT IMMUNOL
   Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71
   MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943
   MORGAN OS, 1989, LANCET, V2, P1184
   Nakamura H, 1997, ANN RHEUM DIS, V56, P167, DOI 10.1136/ard.56.3.167
   Ndhlovu LC, 2009, CLIN EXP IMMUNOL, V158, P294, DOI 10.1111/j.1365-2249.2009.04019.x
   Ndhlovu LC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001030
   NISHIOKA K, 1989, LANCET, V1, P441
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Grassi MFR, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1428-z
   Rocha MC, 2012, TISSUE ANTIGENS, V80, P143, DOI 10.1111/j.1399-0039.2012.01887.x
   Saeidi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124659
   Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545
   Salou M, 2016, CLIN IMMUNOL, V166, P1, DOI 10.1016/j.clim.2016.03.014
   Tattermusch S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002480
   Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433
   Treiner E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00503
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
   Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1
NR 50
TC 14
Z9 14
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2017
VL 12
IS 4
AR e0175345
DI 10.1371/journal.pone.0175345
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES2QB
UT WOS:000399371900161
PM 28384290
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hoagland, B
   Moreira, RI
   De Boni, RB
   Kallas, EG
   Madruga, JV
   Vasconcelos, R
   Goulart, S
   Torres, TS
   Marins, LMS
   Anderson, PL
   Luz, PM
   Leite, ID
   Liu, AY
   Veloso, VG
   Grinsztejn, B
AF Hoagland, Brenda
   Moreira, Ronaldo I.
   De Boni, Raquel B.
   Kallas, Esper G.
   Madruga, Jose Valdez
   Vasconcelos, Ricardo
   Goulart, Silvia
   Torres, Thiago S.
   Marins, Luana M. S.
   Anderson, Peter L.
   Luz, Paula M.
   Leite, Iuri da Costa
   Liu, Albert Y.
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI High pre-exposure prophylaxis uptake and early adherence among men who
   have sex with men and transgender women at risk for HIV Infection: the
   PrEP Brasil demonstration project
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE Pre-exposure prophylaxis; HIV prevention; MSM; transgender women; PrEP
   uptake; PrEP adherence; DRUG Levels
ID TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE; VALIDITY; BEHAVIOR; MSM
AB Introduction: The efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income settings with concentrated epidemics among men who have sex with men (MSM) and transgender women (TGW).
   Methods: PrEP Brasil is a prospective, multicentre, open-label demonstration project assessing PrEP delivery in the context of the Brazilian Public Health System. HIV-uninfected MSM and TGW in 3 referral centres in Rio de Janeiro and Sao Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP. Concentrations of tenofovir diphosphate in dried blood spot samples (DBS) at week 4 after enrolment (early adherence) were measured. Predictors of drug levels were assessed using ordinal logistic regression models considering the DBS drug level as a 3 level variable (<350 fmol/punch, >= 350-699 fmol/punch and >= 700 fmol/punch).
   Results: 1,270 individuals were assessed for participation; n = 738 were potentially eligible and n = 450 were offered PrEP (PrEP uptake was 60.9%). Eligible but not enrolled individuals were younger, had lower HIV risk perception and had lower PrEP awareness. At week 4, 424 participants (of the 450 enrolled) had DBS TFV-DP concentrations, 94.1% in the protective range (>= 350 fmol/punch, consistent with >= 2 pills per week), and 78% were in the highly protective range (>= 700 fmol/punch, >= 4 pills per week). Participants with >= 12 years of schooling had 1.9 times the odds (95% CI 1.10-3.29) of a higher versus lower drug level than participants with <12 years of schooling. Condomless receptive anal intercourse in the prior 3 months was also associated with higher drug levels (adjusted OR = 1.78; 95% CI 1.08-2.94).
   Conclusions: The high uptake and early adherence indicate that PrEP for high-risk MSM and TGW can be successfully delivered in the context of the Brazilian Public Health System. Interventions to address disparities on PrEP awareness and HIV risk perception among the younger and less educated are urgently needed in order to maximize the impact of this prevention strategy on the reduction of HIV infection among MSM and TGW in Brazil.
C1 [Hoagland, Brenda; Moreira, Ronaldo I.; De Boni, Raquel B.; Torres, Thiago S.; Marins, Luana M. S.; Luz, Paula M.; Leite, Iuri da Costa; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Kallas, Esper G.; Vasconcelos, Ricardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Madruga, Jose Valdez; Goulart, Silvia] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Anderson, Peter L.] Univ Colorado Denver, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
RP Grinsztejn, B (corresponding author), INI FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM gbeatriz@ini.fiocruz.br
RI DE BONI, RAQUEL BRANDINI/D-4212-2013; Vasconcelos,
   Ricardo/AAL-4634-2020; TORRES, THIAGO SILVA/D-6548-2014
OI DE BONI, RAQUEL BRANDINI/0000-0002-2455-5997; Vasconcelos,
   Ricardo/0000-0002-9753-0563; TORRES, THIAGO SILVA/0000-0002-2557-601X;
   Luz, Paula/0000-0001-9746-719X; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health [01/2013 BRA/K57]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [402004/2012-4,
   454931/2014-0]; SVS [281/2013]; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/110.261/2014]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2012/51743-0]; National Council of Technological and
   Scientific DevelopmentNational Council for Scientific and Technological
   Development (CNPq); FAPERJ (Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); FAPESP
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP); NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX The study was sponsored by the Brazilian Ministry of Health (#01/2013
   BRA/K57), CNPq (#402004/2012-4, #454931/2014-0) SVS (#281/2013), FAPERJ
   (#E-26/110.261/2014) and FAPESP (#2012/51743-0). PML and BG acknowledge
   funding from the National Council of Technological and Scientific
   Development and the FAPERJ (Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro. EGK acknowledges funding from
   FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo).
CR Allison P. D., 1999, LOGISTIC REGRESSION
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2015, TECHN UPD PREEXP PRO
   [Anonymous], 2015, PROT CLIN DIR TER MA
   Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158560
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Blaschke TF, 2012, ANNU REV PHARMACOL, V52, P275, DOI 10.1146/annurev-pharmtox-011711-113247
   CARLINI EA, 2006, LEVANTAMENTO DOMICIL
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   CDC UPH, 2014, PREEXP PROPH PREV HI
   Cohen SE, 2015, JAIDS-J ACQ IMM DEF, V68, P439, DOI 10.1097/QAI.0000000000000479
   Costa AB, 2015, ARCH SEX BEHAV, V44, P521, DOI 10.1007/s10508-014-0386-z
   Cottrell ML, 2016, J INFECT DIS, V214, P55, DOI 10.1093/infdis/jiw077
   Departamento de DST Aids e Hepatites Virais, 2015, B EP AIDS DST
   Costa EMF, 2014, ARQ BRAS ENDOCRINOL, V58, P188, DOI 10.1590/0004-2730000003091
   Glidden DV, 2015, PREP ENGAGEMENT HIV
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hembree WC, 2009, J CLIN ENDOCR METAB, V94, P3132, DOI 10.1210/jc.2009-0345
   Hoagland B, 2015, AWARENESS WILLINGNES
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   IBGE-I [ISTITUTO BRAS I LEI RO DE GEOGRAFIA E ESTATiSTICA, 2010, CENS DEM 2010 ED DES
   Kerr LRFS, 2013, AIDS, V27, P427, DOI 10.1097/QAD.0b013e32835ad504
   Koblin BA, 2006, AIDS CARE, V18, P961, DOI 10.1080/09540120500467182
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C
   Laranjeira R, 2010, REV BRAS PSIQUIATR, V32, P231, DOI 10.1590/S1516-44462009005000012
   Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683
   Luz PM, 2016, COST EFFECTIVENESS H
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786
   National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2004, NIAAA COUNC APPR DEF
   Osorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216, DOI 10.1111/j.1744-6163.2009.00224.x
   Ostrow DG, 2009, JAIDS-J ACQ IMM DEF, V51, P349, DOI 10.1097/QAI.0b013e3181a24b20
   Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z
   Sander PM, 2013, AIDS, V27, P815, DOI 10.1097/QAD.0b013e32835cff4b
   Schackman BR, 2012, CURR OPIN HIV AIDS, V7, P587, DOI 10.1097/COH.0b013e3283582c8b
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   U.S. Department of Health and Human Services, 2009, DIV AIDS TABL GRAD S
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
   Woolf SE, 2009, AIDS BEHAV, V13, P757, DOI 10.1007/s10461-007-9354-0
   Woolf-King SE, 2013, J URBAN HEALTH, V90, P948, DOI 10.1007/s11524-013-9820-0
   WPATH, 2012, STAND CAR HLTH TRANS
   Zheng JH, 2016, J PHARMACEUT BIOMED, V122, P16, DOI 10.1016/j.jpba.2016.01.038
NR 46
TC 42
Z9 42
U1 0
U2 6
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD APR 6
PY 2017
VL 20
AR 21472
DI 10.7448/IAS.20.1.21472
PG 14
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EU4XM
UT WOS:000401035000001
PM 28418232
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Jogeda, EL
   Huik, K
   Pauskar, M
   Kallas, E
   Karki, T
   Jarlais, DD
   Uuskula, A
   Lutsar, I
   Avi, R
AF Jogeda, Ene-Ly
   Huik, Kristi
   Pauskar, Merit
   Kallas, Eveli
   Karki, Tonis
   Jarlais, Don Des
   Uuskula, Anneli
   Lutsar, Irja
   Avi, Radko
TI Prevalence and Genotypes of GBV-C and Its Associations With HIV
   Infection Among Persons Who Inject Drugs in Eastern Europe
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HGV; viremia; seropositivity; IDU
ID HEPATITIS-G VIRUS; ANTIBODIES; EPIDEMIOLOGY; GLYCOPROTEIN; INHIBITION;
   RNA; HBV; HCV
AB We aimed to determine the rate of GBV-C viremia, seropositivity, and genotypes among people who inject drugs (PWID) and healthy volunteers in Estonia and to evaluate associations between GBV-C and sociodemographic factors, intravenous drug use, co-infections. The study included 345 Caucasian PWID and 118 healthy volunteers. The presence of GBV-C RNA (viremia) was determined by reverse transcriptase-nested PCR in 50 long terminal repeat. PCR products were sequenced and genotyped by phylogenetic analysis. GBV-C seropositivity was determined by ELISA. One third of PWID (114/345) and 6% (7/118) of healthy volunteers (OR = 7.8, 95% CI = 3.5-20.5, P < 0.001) were GBV-C viremic. In PWID group, 79% of sequences belonged to subtype 2a, 19% to subtype 2b, and two remained unclassified. In healthy volunteers, six out of seven sequences belonged to subtype 2a and one to subtype 2b. We found HIV + PWID to have two times increased odds of being GBV-C viremic compared to HIV - PWID (62% vs. 38%; OR = 2.13, 95% CI = 1.34-3.36, P = 0.001). In addition, odds of being GBV-C viremic decreased with increasing age (OR = 0.94, 95% CI = 0.90-0.98, P = 0.001). HIV positivity remained associated with GBV-C viremia in multivariate analysis after adjustment for age (OR = 2.23, 95% CI = 1.39-3.58, P = 0.001). GBV-C seropositivity was similar among PWID and healthy volunteers (2.3% vs. 1.7%, respectively; OR = 1.4, 95% CI = 0.3-13.5, P = 1). In an Eastern European country we demonstrated that GBV-C viremia is common among PWID, but uncommon among healthy volunteers, and GBV-C seropositivity is infrequent among both groups. Similarly to other European countries and USA, GBV-C 2a is the most common genotype in Estonia. (C) 2016 Wiley Periodicals, Inc.
C1 [Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Lutsar, Irja; Avi, Radko] Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, Fac Med, Ravila 19, EE-50411 Tartu, Estonia.
   [Uuskula, Anneli] Univ Tartu, Inst Family Med & Publ Hlth, Dept Epidemiol & Biostat, Fac Med, Tartu, Estonia.
   [Jarlais, Don Des] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
RP Jogeda, EL (corresponding author), Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, Fac Med, Ravila 19, EE-50411 Tartu, Estonia.
EM ene-ly.jogeda@ut.ee
RI Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Kallas, Esper/0000-0003-2026-6925;
   Avi, Radko/0000-0002-9640-8427
FU Estonian Ministry of Education and ResearchMinistry of Education and
   Research, Estonia [SF0180004s12, IUT34-24, IUT34-17]; Estonian Science
   Foundation [ETF8856, ETF8415]; European Regional Development
   FundEuropean Union (EU); Archimedes Foundation; National Institute of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01DA003574]; NATIONAL INSTITUTE ON
   DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574] Funding Source: NIH RePORTER
FX Grant sponsor: Basic Financing and the Target Financing of Estonian
   Ministry of Education and Research; Grant number: SF0180004s12; Grant
   sponsor: Institutional Research Funding of Estonian Ministry of
   Education and Research; Grant numbers: IUT34-24; IUT34-17; Grant
   sponsor: Estonian Science Foundation; Grant numbers: ETF8856; ETF8415;
   Grant sponsor: European Regional Development Fund; Grant sponsor:
   Archimedes Foundation; Grant sponsor: National Institute of Health;
   Grant number: R01DA003574
CR Adojaan M, 2005, JAIDS-J ACQ IMM DEF, V39, P598
   Aitken CK, 2004, J INFECT DIS, V190, P1586, DOI 10.1086/424678
   Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
   Anastassopoulou CG, 1998, J MED VIROL, V56, P246, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;246::AID-JMV12&gt;3.0.CO;2-C
   Bhattarai N, 2012, TRENDS MICROBIOL, V20, P124, DOI 10.1016/j.tim.2012.01.004
   Christensen PB, 2003, J MED VIROL, V70, P156, DOI 10.1002/jmv.10359
   Devereux H, 1998, J MED VIROL, V56, P316, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;316::AID-JMV5&gt;3.0.CO;2-K
   Dille BJ, 1997, J INFECT DIS, V175, P458, DOI 10.1093/infdis/175.2.458
   Dmitriev P. N., 2010, Voprosy Virusologii, V55, P23
   Ernst D, 2014, HIV MED, V15, P245, DOI 10.1111/hiv.12094
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   Guilera M, 1998, GUT, V42, P107, DOI 10.1136/gut.42.1.107
   Huik K, 2010, J INFECT DIS, V201, P730, DOI 10.1086/650491
   Jung S, 2007, AIDS, V21, P645, DOI 10.1097/QAD.0b013e32803277c7
   Kallas E, 2015, INFECT GENET EVOL, V30, P175, DOI 10.1016/j.meegid.2014.12.023
   Kisiel E, 2013, INFECT GENET EVOL, V19, P195, DOI 10.1016/j.meegid.2013.07.010
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Malekinejad M, 2008, AIDS BEHAV, V12, pS105, DOI 10.1007/s10461-008-9421-1
   Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301
   Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
   Muerhoff AS, 2003, J MED VIROL, V70, P141, DOI 10.1002/jmv.10375
   Ramezani A, 2014, AIDS CARE, V26, P1122, DOI 10.1080/09540121.2014.882485
   Reshetnyak VI, 2008, WORLD J GASTROENTERO, V14, P4725, DOI 10.3748/wjg.14.4725
   Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352
   Sathar MA, 2000, INT J EXP PATHOL, V81, P305, DOI 10.1111/j.1365-2613.2000.00166.x
   Schwarze-Zander C, 2012, EXPERT REV ANTI-INFE, V10, P563, DOI [10.1586/ERI.12.37, 10.1586/eri.12.37]
   Tacke M, 1997, LANCET, V349, P318, DOI 10.1016/S0140-6736(96)06461-6
   Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245
   UNAIDS Report on the Global AIDS Epidemic, 2012, UNAIDS REP GLOB AIDS
   Valinciute A, 2013, J ANTIVIR ANTIRETROV, V5, P132
   Wachtler M, 2000, INFECTION, V28, P297, DOI 10.1007/s150100070022
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Zetterberg V, 2004, AIDS RES HUM RETROV, V20, P1148, DOI 10.1089/aid.2004.20.1148
NR 34
TC 10
Z9 10
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD APR
PY 2017
VL 89
IS 4
BP 632
EP 638
DI 10.1002/jmv.24683
PG 7
WC Virology
SC Virology
GA EK4KH
UT WOS:000393895000009
PM 27603233
DA 2020-11-26
ER

PT J
AU Schlusser, KE
   Pilcher, C
   Kallas, EG
   Santos, BR
   Deeks, SG
   Facente, S
   Keating, SM
   Busch, MP
   Murphy, G
   Welte, A
   Quinn, T
   Eshleman, SH
   Laeyendecker, O
AF Schlusser, Katherine E.
   Pilcher, Christopher
   Kallas, Esper G.
   Santos, Breno R.
   Deeks, Steven G.
   Facente, Shelley
   Keating, Sheila M.
   Busch, Michael P.
   Murphy, Gary
   Welte, Alex
   Quinn, Thomas
   Eshleman, Susan H.
   Laeyendecker, Oliver
TI Comparison of cross-sectional HIV incidence assay results from dried
   blood spots and plasma
SO PLOS ONE
LA English
DT Article
ID BED-ENZYME-IMMUNOASSAY; TYPE-1 SEROCONVERSION; CHALLENGES
AB Background
   Assays have been developed for cross-sectional HIV incidence estimation using plasma samples. Large scale surveillance programs are planned using dried blood spot (DBS) specimens for incidence assessment. However, limited information exists on the performance of HIV cross-sectional incidence assays using DBS.
   Methods
   The assays evaluated were: Maxim HIV-1 Limiting Antigen Avidity EIA (LAg-Avidity), Sedia HIV-1 BED-Capture EIA (BED-CEIA), and CDC modified BioRad HIV-1/2 Plus O Aviditybased Assay (CDC-BioRad Avidity) using pre-determined cutoff values. 100 matched HIV-1 positive plasma and DBS samples, with known duration of infection, from the Consortium for the Evaluation and Performance of HIV Incidence Assays repository were tested. All assays were run in duplicate. To examine the degree of variability within and between results for each sample type, both categorical and continuous results were analyzed. Associations were assessed with Bland Altman, R-2 values and Cohen's kappa coefficient (kappa).
   Results
   Intra-assay variability using the same sample type was similar for all assays (R-2 0.96 to 1.00). The R-2 values comparing DBS and plasma results for LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity were 0.96, 0.94, and 0.84, respectively. The concordance and. values between DBS and plasma for all three assays were > 87% and > 0.64, respectively. The Bland-Altman analysis showed significant differences between plasma and DBS samples. For all three assays, a higher number of samples were classified as recent infections using DBS samples.
   Conclusions
   DBS and plasma sample results were highly correlated. However, when compared to plasma, each assay performed somewhat differently in DBS at the lower and higher ends of the dynamic range. DBS samples were more likely to be classified as recently infected by all three assays, which may lead to overestimation of incidence in surveys using performance criteria derived for plasma samples.
C1 [Schlusser, Katherine E.; Quinn, Thomas; Laeyendecker, Oliver] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Pilcher, Christopher; Deeks, Steven G.; Facente, Shelley; Keating, Sheila M.; Busch, Michael P.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kallas, Esper G.] Grp Hosp Conceicao, Porto Alegre, RS, Brazil.
   [Keating, Sheila M.; Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
   [Murphy, Gary] Publ Hlth England, London, England.
   [Welte, Alex] Univ Stellenbosch, South African DST NRF Ctr Excellence Epidemiol Mo, Stellenbosch, South Africa.
   [Quinn, Thomas; Laeyendecker, Oliver] NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Baltimore, MD USA.
   [Eshleman, Susan H.] Johns Hopkins Univ Sch Med, Dept Pathol, Baltimore, MD USA.
RP Laeyendecker, O (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.; Laeyendecker, O (corresponding author), NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Baltimore, MD USA.
EM olaeyen1@jhmi.edu
RI Facente, Shelley/M-1147-2019
OI Facente, Shelley N./0000-0002-7266-352X; Deeks,
   Steven/0000-0001-6371-747X; Keating, Sheila/0000-0002-8324-3694; Kallas,
   Esper/0000-0003-2026-6925
FU Division of Intramural Research, National Institute of Allergy and
   Infectious Diseases (NIAID), NIH; HIV Prevention Trials Network (HPTN) -
   NIAID, National Institutes of Child Health and Human Development
   (NICH/HD), National Institute on Drug Abuse, National Institute of
   Mental Health; Office of AIDS ResearchUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA; Office of
   NIH, DHHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UM1 AI1068613, R01 AI095068,
   R34MH096606]; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation [OPP1017716]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P01 AI071713, R01
   HD074511, P30 AI027763, R24 AI067039]; Brazilian Ministry of Health,
   Brazilian Program [914/BRA/3014-UNESCO]; Sao Paulo City Health
   Department [2004-0.168.922-7]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI095068, ZIAAI000361,
   R01AI095068, UM1AI068613, UM1AI068613, ZIAAI000361, UM1AI068613,
   UM1AI068613, UM1AI068613, ZIAAI000361, ZIAAI000361, UM1AI068613,
   UM1AI068613, R01AI095068, R01AI095068, ZIAAI000361, UM1AI068613,
   UM1AI068613, ZIAAI000361, R01AI095068, R01AI095068, ZIAAI000361,
   UM1AI068613, R01AI095068, ZIAAI000361, UM1AI068613, ZIAAI000361,
   R01AI095068, ZIAAI000361, UM1AI068613] Funding Source: NIH RePORTER
FX This study was supported in part by the Division of Intramural Research,
   National Institute of Allergy and Infectious Diseases (NIAID), NIH.
   Other support was provided by the HIV Prevention Trials Network (HPTN)
   sponsored by the NIAID, National Institutes of Child Health and Human
   Development (NICH/HD), National Institute on Drug Abuse, National
   Institute of Mental Health, and Office of AIDS Research, of the NIH,
   DHHS, UM1 AI1068613 (Eshleman), R01 AI095068 (Eshleman) and R34MH096606
   (Pilcher). Funding for this project was also provided by the Bill and
   Melinda Gates Foundation (grant OPP1017716). The AM PLIAR and Options
   Cohorts received funding from the NIH (grants P01 AI071713 and R01
   HD074511). The SCOPE study also received funding from the NIH (grants
   P30 AI027763 and R24 AI067039). The Sao Paulo Cohort acknowledges
   funding by the Brazilian Ministry of Health, Brazilian Program for STD
   and AIDS (grant 914/BRA/3014-UNESCO) and the Sao Paulo City Health
   Department (grant 2004-0.168.922-7). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Barin F, 2005, J CLIN MICROBIOL, V43, P4441, DOI 10.1128/JCM.43.9.4441-4447.2005
   Brookmeyer R, 2010, EPIDEMIOL REV, V32, P26, DOI 10.1093/epirev/mxq002
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Dobbs T, 2004, J CLIN MICROBIOL, V42, P2623, DOI 10.1128/JCM.42.6.2623-2628.2004
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Laeyendecker O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068349
   Lakshmi V, 2009, J MED MICROBIOL, V58, P312, DOI 10.1099/jmm.0.005249-0
   Longosz AF, 2014, AIDS, V28, P1227, DOI 10.1097/QAD.0000000000000221
   Mastro Timothy D, 2010, J HIV AIDS Surveill Epidemiol, V2, P1
   Mei JV, 2001, J NUTR, V131, p1631S
   O'Mara M, 2011, BIOANALYSIS, V3, P2335, DOI [10.4155/bio.11.220, 10.4155/BIO.11.220]
   Owen M., MODIFIED BIORAD HIV
   Parekh BS, 2011, AIDS RES HUM RETROV, V27, P265, DOI 10.1089/aid.2010.0159
   Rottinghaus EK, 2014, 21 C RETR OPP INF BO
   Wei XR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159266
   Wei XR, 2010, AIDS RES HUM RETROV, V26, P61, DOI 10.1089/aid.2009.0133
   Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525
   World Health Organisation (WHO), 2013, WHO MAN HIV DRUG RES
NR 19
TC 10
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 23
PY 2017
VL 12
IS 2
AR e0172283
DI 10.1371/journal.pone.0172283
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL5SX
UT WOS:000394682400033
PM 28231277
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Piza, FMD
   Correa, TD
   Marra, AR
   Guerra, JCC
   Rodrigues, RD
   Villarinho, AAR
   de Aranda, VF
   Shiramizo, SCPL
   de Lima, MRD
   Kallas, EG
   Cavalcanti, AB
AF de Toledo Piza, Felipe Maia
   Correa, Thiago Domingos
   Marra, Alexandre Rodrigues
   Campos Guerra, Joao Carlos
   Rodrigues, Roseny dos Reis
   Rocco Villarinho, Andrea Aparecida
   de Aranda, Valdir Fernandes
   Pereira Lima Shiramizo, Sandra Christina
   de Jesus de Lima, Maria Roza
   Kallas, Esper Georges
   Cavalcanti, Alexandre Biasi
TI Thromboelastometry analysis of thrombocytopenic dengue patients: a
   cross-sectional study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HEMORRHAGIC-FEVER; COAGULATION; MANAGEMENT; PREDICTORS; FIBRINOGEN
AB Background: Dengue virus infection (DVI) is a prevalent and potentially fatal viral disease associated with coagulopathy. So far, the coagulation profile of DVI patients with thrombocytopenia has not been assessed through a viscoelastic test such as rotational thromboelastometry. We aimed to describe the prevalence and characteristics of coagulation abnormalities in dengue fever outpatients with thrombocytopenia, addressed by both rotational thromboelastometry and conventional coagulation tests.
   Methods: This was a cross-sectional study conducted between April 6th and May 5th 2015 in Sao Paulo, Brazil during a dengue outbreak. Thromboelastometry (ROTEM r) and the conventional coagulation tests prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time (TT), platelet count and fibrinogen levels were performed in 53 patients with DVI and thrombocytopenia.
   Results: Despite a median interquartile range (IQR) platelet count of 77 (63-88) x 109/L in DVI patients, conventional coagulation tests and plasma fibrinogen levels were within the normal range. Subjects demonstrated hypocoagulability in 71.7% (38/53) in INTEM and 54.7% (29/53) in EXTEM DVI patients. FIBTEM analyses detected only 5.7% (3/53) with hypocoagulability among this population. The median (IQR) clotting time (CT), clot formation time (CFT) and maximum clot firmness (MCF) on INTEM were, respectively, 177 (160-207) sec, 144 (108-178) sec and 48 (42-52) mm. On EXTEM, median (IQR) CT, CFT and MCF were, respectively, 69 (65-78) sec, 148 (126-198) sec and 49 (44-55) mm. Median (IQR) MCF on FIBTEM was 15 (13-18) mm.
   Conclusion: Thromboelastometry impairment is highly prevalent in DVI patients with thrombocytopenia, particularly in INTEM and EXTEM analyses, while standard coagulation tests are normal in this setting. Clinical implications remain to be established.
C1 [de Toledo Piza, Felipe Maia; Correa, Thiago Domingos; Marra, Alexandre Rodrigues; Campos Guerra, Joao Carlos; Rodrigues, Roseny dos Reis; Rocco Villarinho, Andrea Aparecida; de Aranda, Valdir Fernandes; Pereira Lima Shiramizo, Sandra Christina; de Jesus de Lima, Maria Roza] Hosp Israelita Albert Einstein, Dept Intens Care Med, Av Albert Einstein,627-701,5 Ander, BR-05651901 Sao Paulo, Brazil.
   [Rodrigues, Roseny dos Reis; Kallas, Esper Georges; Cavalcanti, Alexandre Biasi] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, Brazil.
RP Piza, FMD (corresponding author), Hosp Israelita Albert Einstein, Dept Intens Care Med, Av Albert Einstein,627-701,5 Ander, BR-05651901 Sao Paulo, Brazil.
EM felipe.piza@einstein.br
RI Shiramizo, Sandra/O-3359-2017; Cavalcanti, Alexandre/K-5529-2013
OI Shiramizo, Sandra/0000-0002-8735-4930; Cavalcanti,
   Alexandre/0000-0003-2798-6263; Kallas, Esper/0000-0003-2026-6925;
   Domingos Correa, Thiago/0000-0001-9546-3910
CR Diaz-Quijano FA, 2008, INVEST CLIN, V49, P111
   Diaz-Quijano FA, 2010, J CLIN VIROL, V49, P11, DOI 10.1016/j.jcv.2010.06.011
   Brummel-Ziedins KE, 2014, CURR OPIN HEMATOL, V21, P395, DOI 10.1097/MOH.0000000000000074
   Chen RB, 2011, VIRUSES-BASEL, V3, P1562, DOI 10.3390/v3091562
   Chua M N, 1993, Southeast Asian J Trop Med Public Health, V24 Suppl 1, P141
   Chuang YC, 2013, J FORMOS MED ASSOC, V112, P12, DOI 10.1016/j.jfma.2012.10.013
   de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842
   Favaloro EJ, 2011, THROMB RES, V127, pS13, DOI 10.1016/S0049-3848(10)70148-1
   Fries D, 2010, BRIT J ANAESTH, V105, P116, DOI 10.1093/bja/aeq161
   Funahara Y, 1983, Bibl Haematol, P201
   Ganter MT, 2008, ANESTH ANALG, V106, P1366, DOI 10.1213/ane.0b013e318168b367
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Ho TS, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-75
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hunt BJ, 2014, NEW ENGL J MED, V370, P847, DOI 10.1056/NEJMra1208626
   Karon BS, 2014, CLIN CHIM ACTA, V436, P143, DOI 10.1016/j.cca.2014.05.013
   Kozek-Langenecker SA, 2015, CURR OPIN CRIT CARE, V21, P285, DOI 10.1097/MCC.0000000000000219
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Levy JH, 2010, ANESTH ANALG, V110, P354, DOI 10.1213/ANE.0b013e3181c84ba5
   Mallett SV, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12909
   Mallett SV, 2015, ANAESTHESIA S1, V70, pe25
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   McMichael MA, 2011, VET CLIN PATH, V40, P140, DOI 10.1111/j.1939-165X.2011.00302.x
   Neff AT, 2014, HEMATOL-AM SOC HEMAT, P536, DOI 10.1182/asheducation-2014.1.536
   Nimmannitya S., 1999, P INT C HEM
   Orsi FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-350
   Pea L, 2001, CLIN INFECT DIS, V33, P1611, DOI 10.1086/323013
   Perry DJ, 2010, BRIT J HAEMATOL, V150, P501, DOI 10.1111/j.1365-2141.2010.08223.x
   Reikvam H, 2009, TRANSFUS APHER SCI, V40, P119, DOI 10.1016/j.transci.2009.01.019
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Saner FH, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0706-7
   Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948
   Singhi S, 2007, J PEDIAT-BRAZIL, V83, pS22, DOI 10.1590/S0021-75572007000300004
   Sniecinski RM, 2011, J THORAC CARDIOV SUR, V142, P662, DOI 10.1016/j.jtcvs.2011.03.015
   Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208
   Stensballe J, 2014, CURR OPIN ANESTHESIO, V27, P212, DOI 10.1097/ACO.0000000000000051
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Vickers IE, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0164-9
   Whiting D, 2014, AM J HEMATOL, V89, P228, DOI 10.1002/ajh.23599
   Wills BA, 2002, CLIN INFECT DIS, V35, P277, DOI 10.1086/341410
   Zammarchi L, 2015, EUROSURVEILLANCE, V20, P14
NR 42
TC 4
Z9 4
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 19
PY 2017
VL 17
AR 89
DI 10.1186/s12879-017-2204-4
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA EP4JP
UT WOS:000397347100003
PM 28103832
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Miyaji, KT
   Avelino-Silva, VI
   Simoes, M
   Freire, MD
   de Medeiros, CR
   Braga, PE
   Neves, MAA
   Lopes, MH
   Kallas, EG
   Sartori, AMC
AF Miyaji, Karina Takesaki
   Avelino-Silva, Vivian Iida
   Simoes, Marisol
   Freire, Marcos da Silva
   de Medeiros, Carlos Roberto
   Braga, Patricia Emilia
   Acala Neves, Maria Angelica
   Lopes, Marta Heloisa
   Kallas, Esper Georges
   Christovam Sartori, Ana Marli
TI Prevalence and titers of yellow fever virus neutralizing antibodies in
   previously vaccinated adults
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Elderly; Immunization; Neutralizing antibody; Seroprevalence; Yellow
   fever vaccine
ID 17D; IMMUNOSENESCENCE; IMMUNOGENICITY
AB Introduction: The World Health Organization (WHO) recommends one single dose of the Yellow Fever (YF) vaccine based on studies of antibody persistency in healthy adults. We assessed the prevalence and titers of YF virus neutralizing antibodies in previously vaccinated persons aged >= 60 years, in comparison to younger adults. We also evaluated the correlation between antibody titers and the time since vaccination among participants who received one vaccine dose, and the seropositivity among participants vaccinated prior to or within the past 10 years. Methods: previously vaccinated healthy persons aged >= 18 years were included. YF virus neutralizing antibody titers were determined by means of the 50% Plaque Reduction Neutralization Test. Results: 46 persons aged >= 60 years and 48 persons aged 18 to 59 years were enrolled. There was no significant difference in the prevalence of YF virus neutralizing antibodies between the two groups (p = 0.263). However, titers were significantly lower in the elderly (p = 0.022). There was no correlation between YF virus neutralizing antibody titers and the time since vaccination. There was no significant difference in seropositivity among participants vaccinated prior to or within the past 10 years. Conclusions: the clinical relevance of the observed difference in YF virus neutralizing antibody titers between the two groups is not clear.
C1 [Miyaji, Karina Takesaki; Avelino-Silva, Vivian Iida; Lopes, Marta Heloisa; Christovam Sartori, Ana Marli] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Av Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
   [Simoes, Marisol; Freire, Marcos da Silva] Fundacao Oswaldo Cruz, Lab Tecnol Virol Biomanguinhos, Rio De Janeiro, RJ, Brazil.
   [de Medeiros, Carlos Roberto] Hosp Vital Brazil, Inst Butantan, Sao Paulo, SP, Brazil.
   [Braga, Patricia Emilia] Univ Sao Paulo, Dept Med Prevent, Fac Med, Sao Paulo, SP, Brazil.
   [Acala Neves, Maria Angelica; Kallas, Esper Georges] Univ Sao Paulo, Div Imunol Clin & Alergia, Fac Med, Sao Paulo, SP, Brazil.
RP Miyaji, KT (corresponding author), Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Av Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
EM karinamiyaji@gmail.com
RI Braga, Patricia/B-7806-2018; Sartori, Ana Marli Christovam/I-6663-2012;
   Lopes, Marta H/J-3285-2012; Avelino-Silva, Vivian I/L-2640-2013; Miyaji,
   Karina T/B-1319-2016; Medeiros, Carlos Roberto de/F-6513-2015
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Miyaji, Karina T/0000-0003-2653-3975; Lopes,
   Marta Heloisa/0000-0001-5236-6248; Kallas, Esper/0000-0003-2026-6925
CR [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   Brasil. Ministerio da Saude, REC VAC FEBR AM AP D
   Brasil. Ministerio da Saude, 2014, ASP EP FEBR AM SILV, V45, P1
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Coulange Bodilis H, 2011, Bull Soc Pathol Exot, V104, P260, DOI 10.1007/s13149-011-0135-7
   Gómez Sergio Y, 2008, Rev. salud pública, V10, P796
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904
   Mascheretti M, 2013, REV SAUDE PUBL, V47, DOI 10.1590/S0034-8910.2013047004341
   Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Monath TP, 2013, VACCINES, P870
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Roukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
NR 19
TC 9
Z9 9
U1 0
U2 4
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2017
VL 59
AR e2
DI 10.1590/S1678-9946201759002
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA ER3ZT
UT WOS:000398739500002
PM 28380113
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Grifoni, A
   Pham, J
   O'Rourke, PH
   Peters, B
   de Silva, AD
   Ricciardi, MJ
   Silveira, CG
   Maestri, A
   de Oliveira-Pinto, LM
   Damasco, PV
   Collins, M
   de Silva, AM
   Diehl, SA
   Durbin, AP
   Cerpas, C
   Balmaseda, A
   Kuan, G
   Coloma, J
   Harris, E
   Crowe, JE
   Stone, M
   Norris, PJ
   Busch, M
   Vivanco-Cid, H
   Graham, B
   Ledgerwood, JE
   Watkins, DI
   Kallas, EG
   Sette, A
   Weiskopf, D
AF Grifoni, Alba
   Pham, John
   O'Rourke, Patrick H.
   Peters, Bjoern
   de Silva, Aruna D.
   Ricciardi, Michael J.
   Silveira, Cassia G.
   Maestri, Alvino
   de Oliveira-Pinto, Luzia M.
   Damasco, Paulo Vieira
   Collins, Mathew
   de Silva, Aravinda M.
   Diehl, Sean A.
   Durbin, Anna P.
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kuan, Guillermina
   Coloma, Josefina
   Harris, Eva
   Crowe, James E., Jr.
   Stone, Mars
   Norris, Phillip J.
   Busch, Michael
   Vivanco-Cid, Hector
   Graham, Barney
   Ledgerwood, Julie E.
   Watkins, David I.
   Kallas, Esper G.
   Sette, Alessandro
   Weiskopf, Daniela
TI PRIOR DENGUE VIRUS EXPOSE SHAPES T CELL IMMUNITY TO ZIKA VIRUS IN HUMANS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Grifoni, Alba; Pham, John; O'Rourke, Patrick H.; Peters, Bjoern; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Ricciardi, Michael J.; Watkins, David I.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Silveira, Cassia G.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [de Oliveira-Pinto, Luzia M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Fed Univ State Rio de Janeiro UNIRIO, Rio De Janeiro, Brazil.
   [Collins, Mathew; de Silva, Aravinda M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Diehl, Sean A.] Univ Vermont, Coll Med, Burlington, VT USA.
   [Diehl, Sean A.] Univ Vermont, Vaccine Testing Ctr, Burlington, VT USA.
   [Durbin, Anna P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Kuan, Guillermina] Minist Hlth, Hlth Ctr Socrates Flores Vivas, Managua, Nicaragua.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Stone, Mars; Norris, Phillip J.; Busch, Michael] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Xalapa, Veracruz, Mexico.
   [Graham, Barney; Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RI Diehl, Sean/AAE-2779-2020; Crowe, James E./B-5549-2009; Graham, Barney
   S./AAC-5898-2019; /AAD-2097-2020
OI Diehl, Sean/0000-0001-9700-235X; Crowe, James E./0000-0002-0049-1079;
   Graham, Barney S./0000-0001-8112-0853; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1332
BP 414
EP 414
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215204048
DA 2020-11-26
ER

PT J
AU Keating, SM
   Kassanjee, R
   Lebedeva, M
   Facente, SN
   MacArthur, JC
   Grebe, E
   Murphy, G
   Welte, A
   Martin, JN
   Little, S
   Price, MA
   Kallas, EG
   Busch, MP
   Pilcher, CD
AF Keating, Sheila M.
   Kassanjee, Reshma
   Lebedeva, Mila
   Facente, Shelley N.
   MacArthur, Jeffrey C.
   Grebe, Eduard
   Murphy, Gary
   Welte, Alex
   Martin, Jeffrey N.
   Little, Susan
   Price, Matthew A.
   Kallas, Esper G.
   Busch, Michael P.
   Pilcher, Christopher D.
CA Consortium Evaluation Performance
TI Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in
   Detecting "Recent" HIV Infection and Calculating Population Incidence
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT Conference on Retrovirology and Opportunistic Infections
CY MAR 04, 2014
CL Boston, MA
DE rapid turn-around time; recent HIV infection; HIV incidence
ID CONFIRMATORY ASSAY; SEX; SEROCONVERSION; INTERVENTION; PREVALENCE;
   PREVENTION; SPECIMENS; MEN
AB Objective: HIV seroconversion biomarkers are being used in cross-sectional studies for HIV incidence estimation. Bio-Rad Geenius HIV-1/2 Supplemental Assay is an immunochromatographic single-use assay that measures antibodies (Ab) against multiple HIV-1/2 antigens. The objective of this study was to determine whether the Geenius assay could additionally be used for recency estimation.
   Design: This assay was developed for HIV-1/2 confirmation; however, quantitative data acquired give information on increasing concentration and diversity of antibody responses over time during seroconversion. A quantitative threshold of recent HIV infection was proposed to determine "recent" or "nonrecent" HIV infection; performance using this cutoff was evaluated.
   Methods: We tested 2500 highly characterized specimens from research subjects in the United States, Brazil, and Africa with well-defined durations of HIV infection. Regression and frequency estimation were used to estimate assay properties relevant to HIV incidence measurement: mean duration of recent infection (MDRI), false-recent rate, and assay reproducibility and robustness.
   Results: Using the manufacturer's proposed cutoff index of 1.5 to identify "recent" infection, the assay has an estimated false-recent rate of 4.1% (95% CI: 2.2 to 7.0) and MDRI of 179 days (155 to 201) in specimens from treatment-naive subjects, presenting performance challenges similar to other incidence assays. Lower index cutoffs associated with lower MDRI gave a lower rate of false-recent results.
   Conclusions: These data suggest that with additional interpretive analysis of the band intensities using an algorithm and cutoff, the Geenius HIV-1/2 Supplemental Assay can be used to identify recent HIV infection in addition to confirming the presence of HIV-1 and HIV-2 antibodies.
C1 [Keating, Sheila M.; Lebedeva, Mila; MacArthur, Jeffrey C.; Busch, Michael P.] Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
   [Keating, Sheila M.; Facente, Shelley N.; Martin, Jeffrey N.; Price, Matthew A.; Busch, Michael P.; Pilcher, Christopher D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Kassanjee, Reshma; Grebe, Eduard; Welte, Alex] Univ Stellenbosch, South African DST NRF Ctr Excellence Epidemiol Mo, Stellenbosch, South Africa.
   [Kassanjee, Reshma] Univ Cape Town, Dept Stat Sci, Cape Town, South Africa.
   [Murphy, Gary] Publ Hlth England, London, England.
   [Little, Susan] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Price, Matthew A.] Int AIDS Vaccine Initiat IAVI, Dept Med Affairs, New York, NY USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Keating, SM (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
EM SKeating@bloodsystems.org
RI Little, Susan/AAA-6116-2019; Facente, Shelley/M-1147-2019
OI Kassanjee, Reshma/0000-0002-1200-8726; Grebe,
   Eduard/0000-0001-7046-7245; Kallas, Esper/0000-0003-2026-6925; Price,
   Matt/0000-0002-2918-1373; Keating, Sheila/0000-0002-8324-3694; Facente,
   Shelley N./0000-0002-7266-352X
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R01HD074511,
   R01HD074511, R01HD074511, R01HD074511, R01HD074511] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046, M01RR000046, M01RR000046,
   M01RR000046, M01RR000046, M01RR000046] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI071713, P01AI071713, P30AI027763, P30AI027763, P01AI074621,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, R24AI106039, P30AI027763, P01AI071713,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P01AI074621, R24AI106039, P30AI027763, P30AI027763, P30AI027763,
   U01AI043638, P30AI027763, P30AI027763, P01AI074621, P01AI074621,
   P30AI027763, P01AI071713, P30AI027763, P01AI074621, P01AI071713,
   R24AI067039, P30AI027763, R24AI067039, P30AI027763, R24AI106039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, R24AI067039, P30AI027763,
   P01AI074621, P30AI027763, P01AI071713, P30AI027763, P01AI071713,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, U01AI043638,
   P01AI071713, U01AI043638, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P01AI074621, R24AI067039, P01AI071713, P01AI071713, P01AI074621,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   P01AI071713, P01AI074621, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI043638, R24AI067039, P30AI027763, P30AI027763,
   P01AI071713, R24AI067039, R24AI067039, P30AI027763, R24AI106039,
   P01AI074621, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, U01AI043638, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P01AI074621, P30AI027763, P01AI074621, P30AI027763,
   P30AI027763, P01AI074621, P30AI027763, R24AI067039, U01AI043638,
   P30AI027763, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, R24AI106039, P30AI027763, R24AI106039,
   P30AI027763, R24AI067039, P30AI027763, P01AI074621, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI043638,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, R24AI106039,
   P30AI027763, P01AI074621, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI074621, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI043638, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P01AI074621, P30AI027763, P01AI074621, P30AI027763, P01AI074621,
   P30AI027763, P30AI027763, R24AI067039, P30AI027763, P30AI027763,
   R24AI067039, P01AI074621, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P01AI071713, P01AI071713, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, U01AI043638, P01AI071713,
   U01AI043638, P01AI071713, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U01AI043638, P30AI027763, P30AI027763,
   P30AI027763, U01AI043638, P01AI071713, R24AI067039, P30AI027763,
   U01AI043638, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI043638, R24AI106039, P01AI074621, P30AI027763,
   P30AI027763, P01AI074621, P30AI027763] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01MH100974, R01MH068686,
   R01MH068686, R34MH096606, R01MH068686, R34MH096606, R01MH100974,
   R01MH068686, R01MH068686, R01MH068686, R01MH100974, R34MH096606,
   R01MH100974, R01MH100974] Funding Source: NIH RePORTER; NCRR NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01 RR000046] Funding Source: Medline; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R24 AI106039, P30 AI027763, U01 AI043638,
   P01 AI071713, R24 AI067039, P01 AI074621] Funding Source: Medline; NICHD
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R01 HD074511]
   Funding Source: Medline; NIMH NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01 MH068686, L30 MH072430, R01
   MH100974, R34 MH096606] Funding Source: Medline
CR Aghaizu A, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.2.20673
   Ananworanich J, 2015, JAIDS-J ACQ IMM DEF, V68, P481, DOI 10.1097/QAI.0000000000000502
   Ananworanich J, 2015, CURR OPIN HIV AIDS, V10, P1, DOI 10.1097/COH.0000000000000125
   [Anonymous], 2009, GUIDELINES USING HIV
   [Anonymous], 2012, HIV SURVEILLANCE SUP, P17
   Bellan SE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001801
   Branson BM, 1999, J ACQ IMMUN DEF SYND, V55, pS102
   Cardenas AM, 2013, J CLIN VIROL, V58, pE97, DOI 10.1016/j.jcv.2013.08.021
   Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Eshleman SH, 2013, J INFECT DIS, V207, P223, DOI 10.1093/infdis/jis658
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Gokengin D, 2014, INT J STD AIDS, V25, P695, DOI 10.1177/0956462414531244
   Grijsen ML, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001196
   Hallen AH, 2014, CLIN VACCINE IMMUNOL, V21, P1192, DOI 10.1128/CVI.00153-14
   Hammett TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043141
   Hollingsworth TD, 2015, J INFECT DIS, V211, P1757, DOI 10.1093/infdis/jiu831
   Incidence Assay Critical Path Working G, 2011, PLOS MED, V8
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Laeyendecker O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078818
   Laeyendecker O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068349
   Le Vu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039872
   Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038
   Lissouba P, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-253
   Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
   Montesinos I, 2014, J CLIN VIROL, V60, P399, DOI 10.1016/j.jcv.2014.04.025
   Mor O, 2014, J CLIN MICROBIOL, V52, P2677, DOI 10.1128/JCM.01184-14
   Pilcher CD, 2005, NEW ENGL J MED, V352, P1873, DOI 10.1056/NEJMoa042291
   Reza-Paul S, 2008, AIDS, V22, pS91, DOI 10.1097/01.aids.0000343767.08197.18
   Rosenberg NE, 2015, CURR OPIN HIV AIDS, V10, P61, DOI 10.1097/COH.0000000000000121
   Schupbach J, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-88
   Schuetz A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004543
   Selik R.M., 2014, REVISED SURVEILLANCE
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
NR 34
TC 11
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 15
PY 2016
VL 73
IS 5
BP 581
EP 588
DI 10.1097/QAI.0000000000001146
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA ED7LF
UT WOS:000389045300016
PM 27509247
OA Green Published, Green Accepted
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Miyaji, KT
   Hunt, PW
   Huang, Y
   Simoes, M
   Lima, SB
   Freire, MS
   Caiaffa, HH
   Hong, MA
   Costa, DA
   Dias, JZC
   Cerqueira, NB
   Nishiya, AS
   Sabino, EC
   Sartori, AM
   Kallas, EG
AF Avelino-Silva, Vivian I.
   Miyaji, Karina T.
   Hunt, Peter W.
   Huang, Yong
   Simoes, Marisol
   Lima, Sheila B.
   Freire, Marcos S.
   Caiaffa-Filho, Helio H.
   Hong, Marisa A.
   Costa, Dayane Alves
   Dias, Juliana Zanatta C.
   Cerqueira, Natalia B.
   Nishiya, Anna Shoko
   Sabino, Ester Cerdeira
   Sartori, Ana M.
   Kallas, Esper G.
TI CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity
   in HIV-Infected Patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; TRYPTOPHAN CATABOLISM; C
   INFECTION; MORTALITY; IMMUNIZATION; EVENTS; NORMALIZATION; INFLAMMATION;
   INDIVIDUALS
AB Background
   HIV-infected individuals have deficient responses to Yellow Fever vaccine (YFV) and may be at higher risk for adverse events (AE). Chronic immune activation-characterized by low CD4/CD8 ratio or high indoleamine 2,3-dioxygenase-1 (IDO) activity D may influence vaccine response in this population.
   Methods
   We prospectively assessed AE, viremia by the YFV virus and YF-specific neutralizing antibodies (NAb) in HIV-infected (CD4>350) and -uninfected adults through 1 year after vaccination. The effect of HIV status on initial antibody response to YFV was measured during the first 3 months following vaccination, while the effect on persistence of antibody response was measured one year following vaccination. We explored CD4/CD8 ratio, IDO activity (plasma kynurenine/tryptophan [KT] ratio) and viremia by Human Pegivirus as potential predictors of NAb response to YFV among HIV-infected participants with linear mixed models.
   Results
   12 HIV-infected and 45-uninfected participants were included in the final analysis. HIV was not significantly associated with AE, YFV viremia or NAb titers through the first 3 months following vaccination. However, HIV-infected participants had 0.32 times the NAb titers observed for HIV-uninfected participants at 1 year following YFV (95% CI 0.13 to 0.83, p = 0.021), independent of sex, age and prior vaccination. In HIV-infected participants, each 10% increase in CD4/CD8 ratio predicted a mean 21% higher post-baseline YFV Nab titer (p = 0.024). Similarly, each 10% increase in KT ratio predicted a mean 21% lower post-baseline YFV Nab titer (p = 0.009). Viremia by Human Pegivirus was not significantly associated with NAb titers.
   Conclusions
   HIV infection appears to decrease the durability of NAb responses to YFV, an effect that may be predicted by lower CD4/CD8 ratio or higher KT ratio.
C1 [Avelino-Silva, Vivian I.; Miyaji, Karina T.; Sabino, Ester Cerdeira; Sartori, Ana M.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Hunt, Peter W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Huang, Yong] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Simoes, Marisol; Lima, Sheila B.; Freire, Marcos S.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Caiaffa-Filho, Helio H.; Hong, Marisa A.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Caiaffa-Filho, Helio H.] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 3, Sao Paulo, Brazil.
   [Hong, Marisa A.; Costa, Dayane Alves; Dias, Juliana Zanatta C.; Cerqueira, Natalia B.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nishiya, Anna Shoko; Sabino, Ester Cerdeira] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.; Avelino-Silva, VI (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM viviansilva87@gmail.com
RI Hunt, Peter W./P-2976-2017; Sabino, Ester Cerdeira/F-7750-2010;
   Avelino-Silva, Vivian I/L-2640-2013; Sartori, Ana Marli
   Christovam/I-6663-2012; Caiaffa-Filho, Helio H/H-6982-2012
OI Hunt, Peter W./0000-0002-4571-4870; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Sartori, Ana Marli
   Christovam/0000-0003-3777-0757; Caiaffa-Filho, Helio
   H/0000-0001-6048-4527; Kallas, Esper/0000-0003-2026-6925; Barbosa de
   Lima, Sheila Maria/0000-0001-9234-1678
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes),
   Ministry of Education, BrazilCAPES; Fundacao de Amparo a Pesquisa do
   Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/05246-8]; NIH/NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [1R01AI110271-01A1];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI110271, R01AI110271, R01AI110271, R01AI110271, R01AI110271]
   Funding Source: NIH RePORTER
FX This study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (Capes), Ministry of Education, Brazil; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (2013/05246-8); and NIH/NIAID
   1R01AI110271-01A1. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Avelino-Silva VI, 2013, BONE MARROW TRANSPL, V48, P1008, DOI 10.1038/bmt.2012.277
   Avelino-Silva VI, 2015, J ACQ IMMUN DEF SYND, p[71, 189]
   Barte H, 2014, COCHRANE DB SYST REV, V1
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Bhattarai N, 2012, J INFECT DIS, V206, P1469, DOI 10.1093/infdis/jis515
   Boyer J RL., 2015, C RETR OPP DIS SEATT
   Byakwaga H, 2014, J INFECT DIS, V210, P383, DOI 10.1093/infdis/jiu115
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Gaardbo JC, 2015, JAIDS-J ACQ IMM DEF, V70, P228, DOI 10.1097/QAI.0000000000000758
   GOUJON C, 1995, 4 INT C TRAV MED AC
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Huang Y, 2013, BIOANALYSIS, V5, P1397, DOI [10.4155/BIO.13.74, 10.4155/bio.13.74]
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Martins RD, 2015, HUM VACC IMMUNOTHER, V11, P2183, DOI 10.1080/21645515.2015.1022700
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5
   Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429
   Okulicz JF, 2015, JAMA INTERN MED, V175, P88, DOI 10.1001/jamainternmed.2014.4010
   Pacanowski J, 2012, JAIDS-J ACQ IMM DEF, V59, P360, DOI 10.1097/QAI.0b013e318249de59
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Pistone T, 2010, CURR HIV RES, V8, P461, DOI 10.2174/157016210793499277
   Richardson K, 2011, AIDS, V25, P595, DOI 10.1097/QAD.0b013e32834411a8
   Schouten J, 2014, CROSS SECTIONAL COM
   Selvan SR, 2015, CURR CANC DRUG TARGE
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sibailly TS, 1997, PEDIATR INFECT DIS J, V16, P1177, DOI 10.1097/00006454-199712000-00015
   Sidibe M, 2012, T ROY SOC TROP MED H, V106, P437, DOI 10.1016/j.trstmh.2012.04.002
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Staples JE, 2015, MMWR-MORBID MORTAL W, V64, P647
   Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDS, 2014, DIV AIDS DAIDS TABL
   Veit O, 2009, CLIN INFECT DIS, V48, P659, DOI 10.1086/597006
   Weinberg A, 2006, J INFECT DIS, V193, P302, DOI 10.1086/498979
NR 43
TC 11
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2016
VL 10
IS 12
AR e0005219
DI 10.1371/journal.pntd.0005219
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EI0IX
UT WOS:000392158100070
PM 27941965
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kallas, EG
   Kalil, J
   Passero, LFD
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan Pereira
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kallas, Esper G.
   Kalil, Jorge
   Passero, Luiz Felipe D.
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI p16(INK4a) Expression and Immunologic Aging in Chronic HIV Infection
SO PLOS ONE
LA English
DT Article
ID IMMUNOSENESCENCE; MECHANISMS; SENESCENCE
AB Chronic HIV infection is characterized by increased immune activation and immunosenescence. p16(INK4a) (p16) is a member of the cyclin-dependent kinase antagonist family that inhibits cellular proliferation, and its protein expression increases during normal chronological aging. However, some infectious diseases can increase the expression of this anti-proliferative protein, potentially accelerating immunological aging and dysfunction. In order to investigate the immunological aging in HIV patients, p16 protein expression was evaluated by flow cytometry, in T cell subsets in a cohort of chronically HIV-infected patients on and off ART as well as age-matched healthy controls. Results showed that untreated HIV-infected subjects exhibited increased per-cell p16 protein expression that was discordant with chronological aging. ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment, but not in CD8 T cells, which can be an indicative of an irreversible activation/exhaustion status on these cells. Additionally, the frequency of activated CD4+ and CD8+ T cells was positively correlated with p16 expression in CD4+ and CD8+ T cells in untreated subjects. In contrast to healthy controls, untreated HIV-infected individuals had increased p16 levels within the effector memory (T-EM) subset, indicating a possible role for this marker in impaired clonal expansion during antiviral effector function. Taken together, these data demonstrate that chronic HIV infection is associated with elevated expression of the cellular aging marker p16 in T cells. ART restored normal p16 levels in the CD4+ T cell compartment, indicating that use of therapy can be of fundamental importance to normal cell cycling and maintaining immune homeostasis.
C1 [Ribeiro, Susan Pereira; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] INCT, Iii, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Milush, Jeffrey M.; SenGupta, Devi] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Inst, Sao Paulo, SP, Brazil.
   [Passero, Luiz Felipe D.] Sao Paulo State Univ Julio de Mesquite Filho, Sao Vicent Unit, Paulista Coastal Campus, Sao Paulo, Brazil.
   [Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco Gen Hosp, HIV AIDS Div, San Francisco, CA USA.
   [Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
RP Ribeiro, SP (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil.; Ribeiro, SP (corresponding author), INCT, Iii, Sao Paulo, Brazil.; Ribeiro, SP (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
EM Susan.pereiraribeiro@case.edu
RI Hunt, Peter W./P-2976-2017; Nixon, Douglas/AAU-5734-2020; Cunha-Neto,
   Edecio/B-4157-2009; KALIL, JORGE/C-8029-2012; Passero,
   Felipe/B-9549-2012
OI Hunt, Peter W./0000-0002-4571-4870; Nixon, Douglas/0000-0002-2801-1786;
   Cunha-Neto, Edecio/0000-0002-3699-3345; KALIL,
   JORGE/0000-0001-8415-4274; Passero, Felipe/0000-0002-5986-6381; Deeks,
   Steven/0000-0001-6371-747X; Ribeiro, Susan/0000-0002-3127-3138; Kallas,
   Esper/0000-0003-2026-6925
FU Delaney AIDS Research Enterprise (DARE) [AI096109]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K24 AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR
   [P30 AI027763]; UCSF Clinical and Translational Research Institute
   Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention
   Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24
   AI067039]; NIH NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K08 A120071]; Brazilian
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq); Sao Paulo
   State Research Funding Agency (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/05845-0/EGK/DFN]; CNPq/CAPESNational Council for Scientific and
   Technological Development (CNPq)CAPES [056/2012]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, K24AI069994,
   K24AI069994, U19AI096109, U19AI096109, P30AI027763, U19AI096109,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, K24AI069994,
   U19AI096109, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   U19AI096109, P30AI027763, K24AI069994, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   R24AI067039, P30AI027763, R24AI067039, P30AI027763, R24AI067039,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   U19AI096109, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, U19AI096109, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   U19AI096109, P30AI027763, P30AI027763, K24AI069994, U19AI096109,
   P30AI027763, P30AI027763, R24AI067039, P30AI027763, P30AI027763,
   R24AI067039, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, K24AI069994, P30AI027763, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   R24AI067039, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, K24AI069994, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   R24AI067039, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, R24AI067039, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH RePORTER
FX This work was supported by the Delaney AIDS Research Enterprise (DARE;
   AI096109), NIAID (K24 AI069994), the UCSF/Gladstone Institute of
   Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and
   Translational Research Institute Clinical Research Center (UL1
   RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the
   CFAR Network of Integrated Systems (R24 AI067039). DS was supported by
   NIH NIAID K08 A120071. This research was supported by the Brazilian
   Council for Scientific and Technological Development (CNPq) and the Sao
   Paulo State Research Funding Agency (FAPESP). Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (2010/05845-0/EGK/DFN), CNPq/CAPES
   056/2012 (DFN). ECN and JK are recipients of productivity awards from
   the Brazilian Council for Scientific and Technological Development
   (CNPq). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aberg Judith A, 2012, Top Antivir Med, V20, P101
   Appay V, 2007, EXP GERONTOL, V42, P432, DOI 10.1016/j.exger.2006.12.003
   Chinula L, 2016, CURR OPIN HIV AIDS
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Dock JN, 2011, AGING DIS, V2, P382
   Liu Y, 2009, CURR OPIN IMMUNOL, V21, P431, DOI 10.1016/j.coi.2009.05.011
   Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327
   Migliaccio M, 2006, J IMMUNOL, V176, P2173, DOI 10.4049/jimmunol.176.4.2173
   Migliaccio M, 2005, J IMMUNOL, V174, P3335, DOI 10.4049/jimmunol.174.6.3335
   Nasi M, 2014, IMMUNOL LETT, V162, P329, DOI 10.1016/j.imlet.2014.06.012
   Nelson JAE, 2012, AGING CELL, V11, P916, DOI 10.1111/j.1474-9726.2012.00856.x
NR 11
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2016
VL 11
IS 11
AR e0166759
DI 10.1371/journal.pone.0166759
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC7WC
UT WOS:000388350300102
PM 27861555
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kallas, E
   Huik, K
   Turk, S
   Pauskar, M
   Jogeda, EL
   Sunina, M
   Karki, T
   Jarlais, DD
   Uuskula, A
   Avi, R
   Lutsar, I
AF Kallas, Eveli
   Huik, Kristi
   Turk, Silver
   Pauskar, Merit
   Jogeda, Ene-Ly
   Sunina, Marina
   Karki, Tonis
   Jarlais, Don Des
   Uuskula, Anneli
   Avi, Radko
   Lutsar, Irja
TI T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and
   Intravenous Drug Use
SO VIRAL IMMUNOLOGY
LA English
DT Article
ID HEPATITIS-C-VIRUS; SYSTEMIC IMMUNE ACTIVATION; B-VIRUS; IMMUNOLOGICAL
   PROFILE; HIV; INFECTION; INDIVIDUALS; LYMPHOCYTES; CD4; EXPRESSION
AB Intravenous drug use (IDU) is one of the most important transmission routes for blood borne viruses, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). These infections alter the subset distributions of T cells; however, knowledge of such effects during HIV, HBV, and or HCV coinfection is limited. Therefore, we aimed to evaluate any associations between T cell distribution and the presence of HIV, HBV, and HCV coinfections among persons who inject drugs (PWID). Blood samples from 88 Caucasian PWID (mean age 30; 82% male) and 47 age-matched subjects negative for all three infections (mean age of 29; 83% male) were analyzed. The T cell markers CD3, CD4, CD8, CD45RA, CCR7, HLA-DR, and CCR5 were assessed using flow cytometry. Of the PWID, 40% were HIV+HBV+HCV+,20% HBV+HCV+, 19% HCV+, and 13% negative for all three infections. The HIV+HBV+HCV+PWID had lower percentages of CD4(+) and higher percentages of CD8(+) cells compared to triple negative PWID (p < 0.001 in all cases). The only difference between HBV+HCV+ with triple negative PWID was the lower CD4+ cell percentages among the former (52.1% and 58.6%, p = 0.021). Triple negative PWID had higher immune activation and number of CCR5(+) cells compared to the controls. We suggest that the altered T cell subset distribution among PWID is mainly triggered by HIV infection and or IDU, while HBV and or HCV seropositivity has minimal additional effects on CD4+ cell distribution.
C1 [Kallas, Eveli; Huik, Kristi; Turk, Silver; Pauskar, Merit; Jogeda, Ene-Ly; Karki, Tonis; Avi, Radko; Lutsar, Irja] Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, Fac Med, Ravila 19, EE-50411 Tartu, Estonia.
   [Sunina, Marina] Univ Tartu, Inst Biomed & Translat Med, Dept Immunol, Fac Med, Tartu, Estonia.
   [Jarlais, Don Des] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Uuskula, Anneli] Univ Tartu, Inst Family Med & Publ Hlth, Fac Med, Tartu, Estonia.
RP Kallas, E (corresponding author), Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, Fac Med, Ravila 19, EE-50411 Tartu, Estonia.
EM eveli.kallas@ut.ee
RI Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Kallas, Esper/0000-0003-2026-6925;
   Avi, Radko/0000-0002-9640-8427
FU European Union through the European Regional Development FundEuropean
   Union (EU); Estonian Science Foundation [8415, 8856]; Estonian Ministry
   of Education and ResearchMinistry of Education and Research, Estonia
   [SF0180004s12, IUT34-17]; US National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01 DA003574]
FX The authors thank all the study participants, the team from the
   nongovernmental organization "Convictus," Kristina Marsh for
   coordinating the study, and Karolin Toompere for suggestions regarding
   the statistical analysis. Financial support: This work was supported by
   the European Union through the European Regional Development Fund,
   Estonian Science Foundation (grants 8415 and 8856); Basic Financing and
   Target Financing of the Estonian Ministry of Education and Research
   (SF0180004s12) through institutional research grant No. IUT34-17; and
   grant R01 DA003574 from the US National Institutes of Health.
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Asabe S, 2009, J VIROL, V83, P9652, DOI 10.1128/JVI.00867-09
   BAYER BM, 1990, NEUROPHARMACOLOGY, V29, P369, DOI 10.1016/0028-3908(90)90096-A
   Biasin M, 2000, J INFECT DIS, V182, P1365, DOI 10.1086/315873
   Carotenuto P, 2011, VIRAL IMMUNOL, V24, P27, DOI 10.1089/vim.2010.0067
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Chang JJ, 2005, J VIROL, V79, P3038, DOI 10.1128/JVI.79.5.3038-3051.2005
   Dichamp I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096907
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Gras L, 2015, JAIDS-J ACQ IMM DEF, V68, P536, DOI 10.1097/QAI.0000000000000514
   He XS, 1999, P NATL ACAD SCI USA, V96, P5692, DOI 10.1073/pnas.96.10.5692
   Hodowanec AC, 2013, JAIDS-J ACQ IMM DEF, V64, P232, DOI 10.1097/QAI.0b013e31829c6de0
   Huik K, 2013, INFECT GENET EVOL, V20, P78, DOI 10.1016/j.meegid.2013.08.008
   Kallas E, 2016, MED MICROBIOL IMMUN, V205, P231, DOI 10.1007/s00430-015-0444-8
   Laisaar KT, 2011, AIDS RES HUM RETROV, V27, P841, DOI [10.1089/aid.2010.0223, 10.1089/AID.2010.0223]
   Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751
   Malekinejad M, 2008, AIDS BEHAV, V12, pS105, DOI 10.1007/s10461-008-9421-1
   Osburn WO, 2010, GASTROENTEROLOGY, V138, P315, DOI 10.1053/j.gastro.2009.09.017
   Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998
   Rallon NI, 2011, JAIDS-J ACQ IMM DEF, V57, P1, DOI 10.1097/QAI.0b013e31821024e7
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Sandberg JK, 2010, VIRULENCE, V1, P177, DOI 10.4161/viru.1.3.11206
   Steele AD, 2003, VIROLOGY, V309, P99, DOI 10.1016/S0042-6822(03)00015-1
   Suy A, 2007, J INFECT DIS, V196, P1191, DOI 10.1086/521193
   Tran HK, 2006, AIDS RES HUM RETROV, V22, P255, DOI 10.1089/aid.2006.22.255
   Urbani S, 2002, J VIROL, V76, P12423, DOI 10.1128/JVI.76.24.12423-12434.2002
   Urbani S, 2005, HEPATOLOGY, V41, P826, DOI 10.1002/hep.20614
   Uuskula A, 2006, J INFECT DIS, V193, P455, DOI 10.1086/499436
   Vickerman P, 2013, DRUG ALCOHOL DEPEN, V132, P172, DOI 10.1016/j.drugalcdep.2013.01.020
   Vorobjov S, 2012, J SUBST ABUSE TREAT, V42, P413, DOI 10.1016/j.jsat.2011.09.014
   Wang JB, 2002, J INFECT DIS, V185, P885, DOI 10.1086/339522
   Wang X, 2011, J NEUROIMMUNE PHARM, V6, P477, DOI 10.1007/s11481-011-9296-1
   Wiessing L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103345
   Yang OO, 2002, AIDS RES HUM RETROV, V18, P1051, DOI 10.1089/08892220260235416
NR 35
TC 6
Z9 9
U1 2
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
PD OCT
PY 2016
VL 29
IS 8
BP 464
EP 470
DI 10.1089/vim.2016.0057
PG 7
WC Immunology; Virology
SC Immunology; Virology
GA DY8PC
UT WOS:000385391300004
PM 27564643
OA Green Published
DA 2020-11-26
ER

PT J
AU Goncalves-Lopes, RM
   Lima, NF
   Carvalho, KI
   Scopel, KKG
   Kallas, EG
   Ferreira, MU
AF Goncalves-Lopes, Raquel M.
   Lima, Nathalia F.
   Carvalho, Karina I.
   Scopel, Kezia K. G.
   Kallas, Esper G.
   Ferreira, Marcelo U.
TI Surface expression of inhibitory (CTLA-4) and stimulatory (OX40)
   receptors by CD4(+) regulatory T cell subsets circulating in human
   malaria
SO MICROBES AND INFECTION
LA English
DT Article
DE Human malaria; Immunoregulation; Treg cells; CTLA-4; OX-40
ID PLASMODIUM-FALCIPARUM MALARIA; DENDRITIC CELLS; VIVAX MALARIA; IN-VITRO;
   EFFECTOR; INDUCTION; IMMUNITY; IMMUNOSUPPRESSION; DIFFERENTIATION;
   QUESTIONS
AB Several CD4(+) T cell subtypes contribute to immune homeostasis in malaria, but the markers that define the main suppressive T cell subsets induced by this infection remain largely unknown. Here we provide a detailed phenotypic characterization of immunoregulatory CD4(+) T cell populations in uncomplicated human malaria. We found an increased proportion of CD4(+) T cells expressing CTLA-4, OX40, GITR, TNFRII, and CD69 in acute-phase single-species infections with Plasmodium vivax, Plasmodium falciparum, or both. Such an increase was not proportional to parasite density in P. vivax infections, and did not persist after parasite clearance. Significantly, less than 10% of CD4(+) T cells expressing these regulatory molecules had the classical T regulatory (Treg) phenotype (CD4(+)CD25(+)CD127(-)FoxP3(+)). Two major Treg cell subpopulations, which together accounted for 19-23% of all Treg cells circulating in malaria patients, expressed surface receptors with opposing regulatory functions, either CTLA-4 or OX40. OX40(+) Treg cells outnumbered their CTLA-4(+) counterparts (1.8:1) during acute P. vivax infection, while a more balanced ratio (1.3:1) was observed following parasite clearance These data reveal new players in the complex CD4(+) Treg cell network that maintains immune homeostasis in malaria and suggest potential targets for therapeutic interventions to improve parasite-specific effector immune responses. (C) 2016 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Goncalves-Lopes, Raquel M.; Lima, Nathalia F.; Ferreira, Marcelo U.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Av Prof Lineu Prestes 1374,Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
   [Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
   [Carvalho, Karina I.] Albert Einstein Hosp, Av Albert Einstein 627, BR-05652000 Sao Paulo, SP, Brazil.
   [Scopel, Kezia K. G.] Univ Fed Juiz de Fora, Inst Biol Sci, Dept Parasitol Microbiol & Immunol, Av Lourenco Kelmer, BR-36036900 Juiz De Fora, MG, Brazil.
RP Ferreira, MU (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Av Prof Lineu Prestes 1374,Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
EM muferrei@usp.br
RI Ferreira, Marcelo U/G-8289-2011; Carvalho, Karina IL/J-6789-2012
OI Ferreira, Marcelo U/0000-0002-5293-9090; Carvalho, Karina
   IL/0000-0002-7763-8139; Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/52146-0];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [470315/2012-1]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [U19 AI089681]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681,
   U19AI089681, U19AI089681, U19AI089681, U19AI089681, U19AI089681] Funding
   Source: NIH RePORTER
FX This research was supported by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP; grant 2010/52146-0 to MUF and doctoral
   scholarships to RMG-L and NFL); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; grant 470315/2012-1 to MUF and senior
   research scholarships to EGK and MUF); and the National Institutes of
   Health (grant U19 AI089681 to Joseph M. Vinetz, University of
   California, San Diego).
CR Baecher-Allan C, 2006, J IMMUNOL, V176, P4622, DOI 10.4049/jimmunol.176.8.4622
   Barbosa S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003109
   Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527
   Boyle MJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005041
   Braga EM, 2002, AM J TROP MED HYG, V66, P299, DOI 10.4269/ajtmh.2002.66.299
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Bueno LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009623
   Butler NS, 2012, NAT IMMUNOL, V13, P188, DOI 10.1038/ni.2180
   Chen X, 2011, IMMUNOLOGY, V133, P426, DOI 10.1111/j.1365-2567.2011.03460.x
   Corse E, 2012, J IMMUNOL, V189, P1123, DOI 10.4049/jimmunol.1200695
   Costa PAC, 2015, J INFECT DIS, V212, P1999, DOI 10.1093/infdis/jiv306
   Croft M, 2014, SEMIN IMMUNOL, V26, P183, DOI 10.1016/j.smim.2014.02.005
   Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243
   Finney OC, 2010, TRENDS IMMUNOL, V31, P63, DOI 10.1016/j.it.2009.12.002
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Gandhi R, 2010, J IMMUNOL, V184, P4620, DOI 10.4049/jimmunol.0903329
   Goncalves RM, 2010, INFECT IMMUN, V78, P4763, DOI 10.1128/IAI.00578-10
   Gonzalez-Amaro R, 2013, TRENDS MOL MED, V19, P625, DOI 10.1016/j.molmed.2013.07.006
   GOONEWARDENE R, 1990, EUR J IMMUNOL, V20, P1387, DOI 10.1002/eji.1830200626
   Hafalla JCR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002504
   Han YM, 2009, J IMMUNOL, V182, P111, DOI 10.4049/jimmunol.182.1.111
   Hansen DS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000771
   HO M, 1986, J INFECT DIS, V153, P763, DOI 10.1093/infdis/153.4.763
   Intlekofer AM, 2013, J LEUKOCYTE BIOL, V94, P25, DOI 10.1189/jlb.1212621
   Jangpatarapongsa K, 2008, EUR J IMMUNOL, V38, P2697, DOI 10.1002/eji.200838186
   Jangpatarapongsa K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045971
   Karimi S, 2015, IMMUNOLOGY, V144, P186, DOI 10.1111/imm.12387
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Leal FE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002028
   Minigo G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000402
   Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818
   Oakley MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006793
   Redmond WL, 2014, CANCER IMMUNOL RES, V2, P142, DOI 10.1158/2326-6066.CIR-13-0031-T
   RILEY EM, 1988, CLIN EXP IMMUNOL, V73, P17
   Ruby CE, 2009, J IMMUNOL, V183, P4853, DOI 10.4049/jimmunol.0901112
   Schlotmann T, 2000, J INFECT DIS, V182, P367, DOI 10.1086/315690
   Scholzen A, 2010, TRENDS PARASITOL, V26, P16, DOI 10.1016/j.pt.2009.10.004
   Schuler PJ, 2012, EUR J IMMUNOL, V42, P1876, DOI 10.1002/eji.201142347
   Steiner K, 1999, CLIN EXP IMMUNOL, V115, P451
   Takeda I, 2004, J IMMUNOL, V172, P3580, DOI 10.4049/jimmunol.172.6.3580
   Torres KJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-108
   TROYEBLOMBERG M, 1984, CLIN EXP IMMUNOL, V58, P380
   Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959
   Walker LSK, 2015, TRENDS IMMUNOL, V36, P63, DOI 10.1016/j.it.2014.12.001
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Wang CJ, 2012, J IMMUNOL, V189, P1118, DOI 10.4049/jimmunol.1200972
   Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062
   Zander RA, 2015, CELL HOST MICROBE, V17, P628, DOI 10.1016/j.chom.2015.03.007
   zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10
NR 50
TC 9
Z9 9
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD OCT
PY 2016
VL 18
IS 10
BP 639
EP 648
DI 10.1016/j.micinf.2016.06.003
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EA2IA
UT WOS:000386414800007
PM 27320393
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Kassanjee, R
   Pilcher, CD
   Busch, MP
   Murphy, G
   Facente, SN
   Keating, SM
   Mckinney, E
   Marson, K
   Price, MA
   Martin, JN
   Little, SJ
   Hecht, FM
   Kallas, EG
   Welte, A
AF Kassanjee, Reshma
   Pilcher, Christopher D.
   Busch, Michael P.
   Murphy, Gary
   Facente, Shelley N.
   Keating, Sheila M.
   Mckinney, Elaine
   Marson, Kara
   Price, Matthew A.
   Martin, Jeffrey N.
   Little, Susan J.
   Hecht, Frederick M.
   Kallas, Esper G.
   Welte, Alex
CA CEPHIA
TI Viral load criteria and threshold optimization to improve HIV incidence
   assay characteristics
SO AIDS
LA English
DT Article
DE biomarkers; HIV; incidence assays; incidence estimation; optimization;
   recent infection; viral load
ID RECENT INFECTION; SEROCONVERSION; ANTIBODIES; SPECIMENS
AB Objective: Assays for classifying HIV infections as 'recent' or 'nonrecent' for incidence surveillance fail to simultaneously achieve large mean durations of 'recent' infection (MDRIs) and low 'false-recent' rates (FRRs), particularly in virally suppressed persons. The potential for optimizing recent infection testing algorithms (RITAs), by introducing viral load criteria and tuning thresholds used todichotomize quantitativemeasures, is explored.
   Design: The Consortium for the Evaluation and Performance of HIV Incidence Assays characterized over 2000 possible RITAs constructed from seven assays (Limiting Antigen, BED, Less-sensitive Vitros, Vitros Avidity, BioRad Avidity, Architect Avidity, and Geenius) applied to 2500 diverse specimens.
   Methods: MDRIs were estimated using regression, and FRRs as observed 'recent' proportions, in various specimen sets. Context-specific FRRs were estimated for hypothetical scenarios. FRRs were made directly comparable by constructing RITAs with the same MDRI through the tuning of thresholds. RITA utility was summarized by the precision of incidence estimation.
   Results: All assays produce high FRRs among treated patients and elite controllers (10-80%). Viral load testing reduces FRRs, but diminishes MDRIs. Context-specific FRRs vary substantially by scenario - BioRad Avidity and Limiting Antigen provided the lowest FRRs and highest incidence precision in scenarios considered.
   Conclusion: The introduction of a low viral load threshold provides crucial improvements in RITAs. However, it does not eliminate nonzero FRRs, and MDRIs must be consistently estimated. The tuning of thresholds is essential for comparing and optimizing the use of assays. The translation of directly measured FRRs into context-specific FRRs critically affects their magnitudes and our understanding of the utility of assays. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Kassanjee, Reshma; Welte, Alex] Univ Stellenbosch, South African DST NRF Ctr Excellence Epidemiol Mo, Stellenbosch, South Africa.
   [Kassanjee, Reshma] Univ Cape Town, Dept Stat Sci, Cape Town, South Africa.
   [Pilcher, Christopher D.; Facente, Shelley N.; Marson, Kara; Price, Matthew A.; Martin, Jeffrey N.; Hecht, Frederick M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Busch, Michael P.; Keating, Sheila M.] Blood Syst Res Inst, San Francisco, CA USA.
   [Murphy, Gary; Mckinney, Elaine] Publ Hlth England, London, England.
   [Price, Matthew A.] Dept Med Affairs, IAVI, New York, NY USA.
   [Little, Susan J.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Kassanjee, R (corresponding author), Univ Cape Town, Dept Stat Sci, ZA-7701 Rondebosch, South Africa.
EM reshma.kassanjee@uct.ac.za
RI Facente, Shelley/M-1147-2019; Little, Susan/AAA-6116-2019
OI Facente, Shelley N./0000-0002-7266-352X; Hecht,
   Frederick/0000-0002-5782-1171; Price, Matt/0000-0002-2918-1373; Keating,
   Sheila/0000-0002-8324-3694; Kassanjee, Reshma/0000-0002-1200-8726;
   Kallas, Esper/0000-0003-2026-6925
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1017716]; Bill & Melinda Gates FoundationBill & Melinda Gates
   FoundationCGIAR; Ministry of Foreign Affairs of Denmark; Irish AidCGIAR;
   Ministry of Finance of Japan; Ministry of Foreign Affairs of the
   Netherlands; Norwegian Agency for Development Cooperation (NORAD)CGIAR;
   United Kingdom Department for International Development (DFID); United
   States Agency for International Development (USAID)United States Agency
   for International Development (USAID)CGIAR; USAIDUnited States Agency
   for International Development (USAID); OPEC Fund for International
   Development (OFID); National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [AI43638, AI74621, AI106039, MH100974, IA036214]; California HIV-1
   Research Program (CHRP) [RN07-SD-702]; Brazilian Ministry of Health;
   Brazilian Program for STD and AIDS [914/BRA/3014-UNESCO]; Sao Paulo City
   Health Department [2004-0.168.922-7]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [P30
   AI027763, R24 AI067039, P01 AI071713, R01 HD074511]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R01HD074511, R01HD074511,
   R01HD074511, R01HD074511, R01HD074511] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI036214, P30AI036214, P30AI036214, P30AI027763, P30AI036214,
   P01AI071713, P01AI071713, P30AI036214, P30AI036214, P30AI027763,
   P01AI074621, P30AI027763, P30AI036214, P30AI036214, R24AI067039,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P01AI071713,
   P01AI074621, P01AI074621, P30AI036214, P30AI027763, P30AI027763,
   P30AI036214, P30AI036214, P30AI036214, U01AI043638, P30AI036214,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, P30AI036214,
   P30AI036214, P30AI027763, P30AI027763, P30AI027763, R24AI067039,
   P30AI036214, P30AI027763, P30AI027763, P30AI027763, P30AI036214,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P01AI074621, P30AI036214, P30AI036214, P30AI027763, P30AI036214,
   P01AI071713, P01AI071713, P30AI027763, P30AI036214, R24AI106039,
   P30AI036214, P30AI036214, P30AI027763, P01AI071713, P30AI036214,
   R24AI106039, P30AI036214, P30AI027763, P30AI036214, P30AI036214,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, U01AI043638,
   P30AI036214, P01AI071713, P30AI027763, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P01AI074621, P30AI036214,
   P30AI027763, P30AI036214, P01AI071713, P01AI071713, P30AI027763,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   P30AI027763, P30AI036214, P01AI071713, P30AI036214, P01AI074621,
   P30AI036214, R24AI106039, P30AI036214, P30AI036214, P01AI074621,
   P30AI036214, P30AI027763, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, P01AI074621, P30AI036214,
   P30AI036214, P30AI036214, R24AI067039, P30AI027763, P30AI036214,
   P30AI027763, P30AI036214, P30AI036214, P30AI036214, P30AI036214,
   P01AI071713, P01AI071713, P30AI027763, P30AI036214, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, P30AI036214,
   P01AI074621, P30AI036214, P30AI027763, P30AI036214, P01AI074621,
   P30AI027763, P30AI036214, P30AI027763, U01AI043638, P30AI027763,
   P30AI036214, R24AI067039, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI027763, P30AI036214, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI074621,
   P30AI036214, P30AI027763, P30AI036214, P30AI027763, R24AI106039,
   P30AI036214, P01AI074621, P30AI027763, P30AI027763, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, P30AI027763,
   P01AI071713, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   R24AI106039, P30AI036214, P30AI036214, P30AI027763, R24AI106039,
   P30AI036214, P30AI027763, P30AI036214, P01AI071713, P30AI027763,
   P30AI036214, P30AI027763, P30AI036214, P30AI027763, P30AI036214,
   P30AI027763, P30AI036214, P30AI036214, P30AI027763, P01AI071713,
   P01AI074621, P30AI027763, P01AI071713, P30AI027763, P30AI036214,
   P30AI036214, P01AI074621, P30AI036214, P30AI036214, P01AI071713,
   P30AI027763, P30AI027763, P01AI071713, R24AI067039, P01AI074621,
   U01AI043638, P30AI027763, P30AI036214, P01AI071713, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, P30AI036214,
   P30AI027763, P30AI027763, P30AI036214, P30AI036214, P01AI074621,
   P30AI036214, U01AI043638, P30AI027763, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI036214, P30AI036214, P01AI074621, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   P30AI036214, R24AI067039, P01AI071713, P30AI036214, P30AI036214,
   P01AI074621, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   P30AI027763, P30AI036214, P30AI027763, P01AI074621, P30AI027763,
   R24AI067039, P01AI074621, P30AI027763, P30AI036214, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, P30AI027763, P30AI036214,
   P01AI071713, P30AI036214, P01AI071713, P30AI036214, P30AI027763,
   P30AI036214, P01AI071713, P30AI027763, R24AI067039, P30AI036214,
   P30AI036214, R24AI106039, P30AI027763, P30AI027763, P30AI027763,
   P30AI036214, P30AI036214, U01AI043638, P30AI036214, P30AI027763,
   U01AI043638, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   P30AI036214, P30AI027763, P30AI036214, P01AI074621, P30AI036214,
   P30AI036214, P30AI027763, P30AI036214, P30AI036214, P30AI036214,
   P30AI036214, P30AI027763, P30AI027763, P30AI036214, P30AI027763,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, R24AI067039,
   R24AI067039, P30AI036214, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI036214, P30AI036214, P01AI074621, P30AI027763,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, P30AI036214,
   P30AI027763, P30AI036214, U01AI043638, U01AI043638, P30AI036214,
   P30AI027763, P30AI027763, P01AI071713, R24AI106039, R24AI106039,
   P30AI027763, P30AI036214, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, U01AI043638, P30AI027763, P30AI036214, P30AI027763,
   P30AI036214, U01AI043638, P01AI071713, P30AI036214, P30AI027763,
   P30AI036214, P30AI027763, P30AI027763, P30AI027763, P30AI036214,
   P30AI027763, P30AI036214, P30AI036214, P30AI036214, P30AI027763,
   P30AI036214, P30AI036214, P30AI027763, P30AI027763, P30AI036214,
   P30AI027763, P30AI036214, P01AI071713, P30AI036214, P30AI027763,
   P30AI027763, P01AI074621, P01AI074621, P30AI027763, P01AI074621,
   R24AI067039, P30AI027763, P30AI036214, P30AI027763, P30AI027763,
   P30AI027763, P30AI036214, P30AI027763, U01AI043638, P30AI036214,
   P30AI036214, P30AI027763, P30AI027763, P30AI027763, P30AI036214,
   P30AI036214, P30AI027763, P30AI036214, P30AI036214, P30AI027763,
   P30AI027763, P30AI027763, P30AI036214, P30AI036214, P30AI036214,
   P30AI027763, P30AI036214, R24AI067039, P30AI036214, R24AI067039,
   P30AI027763, P01AI071713, P30AI027763, U01AI043638, P30AI036214,
   P30AI027763, P30AI027763, P30AI027763, P30AI036214, P30AI036214,
   P30AI027763, R24AI067039, P30AI036214, P01AI071713, P30AI027763,
   P30AI027763, P01AI071713, P30AI036214, P30AI036214, R24AI067039,
   P30AI036214, P30AI036214, P01AI074621, P30AI027763, P30AI036214,
   P30AI036214, P30AI036214, P30AI036214, R24AI067039, P01AI071713,
   P30AI036214, P30AI036214, P30AI027763, P30AI027763, P30AI036214,
   P30AI036214, P30AI036214, P30AI027763, U01AI043638, P30AI036214,
   P30AI027763, R24AI067039, P30AI036214, P30AI036214, P30AI027763,
   P30AI036214, P30AI036214, P30AI027763, P30AI036214, P30AI027763,
   P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R34MH096606, R01MH100974, R01MH100974, R34MH096606, R34MH096606,
   R01MH100974, R01MH100974, R01MH100974] Funding Source: NIH RePORTER
FX G.M., A.W., M.P.B., and C.P.D. conceived the study design and sourced
   funding. R.K. and A.W. led the consolidation of data; and the data
   analysis design, implementation, and interpretation. C.D.P., S.N.F.,
   S.J.L., M.A.P., J.N.M., E.G.K., and F.M.H. led on specimen acquisition
   and related data collection. G.M., M.P.B., S.M.K., and E.M. led on assay
   performance and quality, and assay results reporting. R.K. drafted and
   edited the article and supplementary material. All authors assisted in
   the interpretation of findings, provided input and suggestions for
   analysis, contributed to and reviewed the article. Funding for this
   project was provided by the Bill and Melinda Gates Foundation (grant
   OPP1017716).; IAVI's work is made possible by generous support from many
   donors including: the Bill & Melinda Gates Foundation; the Ministry of
   Foreign Affairs of Denmark; Irish Aid; the Ministry of Finance of Japan;
   the Ministry of Foreign Affairs of the Netherlands; the Norwegian Agency
   for Development Cooperation (NORAD); the United Kingdom Department for
   International Development (DFID); and the United States Agency for
   International Development (USAID). The full list of IAVI donors is
   available at www.iavi.org. This report is made possible by the generous
   support of the American people through USAID. The contents are the
   responsibility of the International AIDS Vaccine Initiative and do not
   necessarily reflect the views of USAID or the United States Government.
   Funding was also provided by the OPEC Fund for International Development
   (OFID), a development finance institution of the OPEC Member States,
   established to provide financial support for socioeconomic development,
   particularly for low-income countries.; The San Diego Primary Infection
   Cohort acknowledges funding by the National Institutes of Health (NIH,
   grants AI43638, AI74621, AI106039, MH100974, and IA036214), and the
   California HIV-1 Research Program (CHRP, grant RN07-SD-702).; The Sao
   Paulo Cohort acknowledges funding by the Brazilian Ministry of Health,
   Brazilian Program for STD and AIDS (grant 914/BRA/3014-UNESCO) and the
   Sao Paulo City Health Department (grant 2004-0.168.922-7).; The SCOPE
   Study received funding from the NIH (grants P30 AI027763 and R24
   AI067039).; The AMPLIAR and Options Cohorts also received funding from
   the NIH (grants P01 AI071713 and R01 HD074511).
CR Abbott Laboratories, 2014, ARCHITECT HIV AG AB
   Atun R, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001045
   BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
   Brookmeyer R, 2013, AM J EPIDEMIOL, V177, P264, DOI 10.1093/aje/kws436
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Hargrove J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029736
   Hargrove JW, 2008, AIDS, V22, P511, DOI 10.1097/QAD.0b013e3282f2a960
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Instructions For Use, 2014, INSTRUCTIONS FOR USE
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Kaplan EH, 1999, OPER RES, V47, P29, DOI 10.1287/opre.47.1.29
   Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
   Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/aid.2013.0113, 10.1089/AID.2013.0113]
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Keating SM, 2012, J CLIN MICROBIOL, V50, P3968, DOI 10.1128/JCM.01454-12
   Laeyendecker O, 2012, AIDS RES HUM RETROV, V28, P816, DOI [10.1089/aid.2011.0258, 10.1089/AID.2011.0258]
   Laeyendecker O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068349
   Longosz AF, 2014, AIDS, V28, P1227, DOI 10.1097/QAD.0000000000000221
   Masciotra S, 2010, 17 C RETR OPP INF SA
   Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
   Mastro Timothy D, 2010, J HIV AIDS Surveill Epidemiol, V2, P1
   McDougal JS, 2006, AIDS RES HUM RETROV, V22, P945, DOI 10.1089/aid.2006.22.945
   McWalter TA, 2010, J MATH BIOL, V60, P687, DOI 10.1007/s00285-009-0282-7
   Montesinos I, 2014, J CLIN VIROL, V60, P399, DOI 10.1016/j.jcv.2014.04.025
   Murphy G, 2008, EUROSURVEILLANCE, V13, P4
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Sedia Biosciences Corporation, 2014, SED HIV 1 LAG AV EIA
   Sedia Biosciences Corporation, 2014, SED BED HIV 1 INC EI
   Suligoi B, 2011, J CLIN MICROBIOL, V49, P2610, DOI 10.1128/JCM.02115-10
   Welte A, 2010, EUROSURVEILLANCE, V15, P18
NR 32
TC 33
Z9 34
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 24
PY 2016
VL 30
IS 15
BP 2361
EP 2371
DI 10.1097/QAD.0000000000001209
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DW4FK
UT WOS:000383597700013
PM 27454561
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Jogeda, EL
   Avi, R
   Pauskar, M
   Kallas, E
   Karki, T
   Jarlais, DD
   Uuskula, A
   Lutsar, I
   Huik, K
AF Jogeda, Ene-Ly
   Avi, Radko
   Pauskar, Merit
   Kallas, Eveli
   Karki, Tonis
   Jarlais, Don Des
   Uuskula, Anneli
   Lutsar, Irja
   Huik, Kristi
TI Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug
   users in Eastern Europe
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HTLV-1/2; HIV; Co-infection; Blood-borne infection
ID HTLV-2 INFECTION; HEPATITIS-C; HIV; PREVALENCE; ESTONIA; INJECTION;
   DISEASE; EPIDEMIOLOGY; PROGRESSION; RESISTANCE
AB Background: In Europe, human T-lymphotropic virus (HTLV) type 2 mainly occurs among intravenous drug users (IDUs) with prevalence up to 15% and HTLV-1 among general population with prevalence <1%. However, there is no data regarding the prevalence of HTLV-1 or HTLV-2 in Eastern European IDUs population where HIV prevalence is relatively high. We aimed to determine the prevalence and genotypes of HTLV-1/HTLV-2 among IDUs and healthy volunteers in Estonia.
   Methods: The study included 345 IDUs and 138 healthy volunteers. The presence of HTLV-1/HTLV-2 was determined by nested PCR; positive and negative controls were used in every PCR run.
   Results: The analysed IDUs resembled the IDUs of HIV epidemic in Estonia: mainly male (79%) with median age of 30 years (interquartile range [IQR] 25-34), and prolonged duration of intravenous drug usage (11 years; IQR 7-14). The prevalence exposure to blood-borne viral infections was high - 50% were HIV positive, 88% hepatitis C positive, 67% hepatitis B positive. Of IDUs, 64% reported receptive needle sharing in the past and 18% at least once a month during last six months. None of the IDUs carried HTLV-1 but there was a case of HTLV-2 (prevalence 0.3%; 95% CI 0.1-1.6). All healthy volunteers were HTLV-1 and HTLV-2 PCR negative.
   Conclusion: This is the first study investigating the prevalence of HTLV-1/HTLV-2 among high risk population and healthy volunteers in Eastern European region. Our results suggest that despite otherwidely spread blood-borne infections (e.g. HIV, HBV, HCV) HTLV-1 and HTLV-2 are rare among IDUs in Estonia. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Jogeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Lutsar, Irja; Huik, Kristi] Univ Tartu, Dept Microbiol, Fac Med, EE-50111 Tartu, Estonia.
   [Uuskula, Anneli] Univ Tartu, Fac Med, Inst Family Med & Publ Hlth, EE-50111 Tartu, Estonia.
   [Jarlais, Don Des] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Jogeda, EL (corresponding author), Univ Tartu, Dept Microbiol, Fac Med, EE-50111 Tartu, Estonia.
EM ene-ly.jogeda@ut.ee
RI Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Kallas, Esper/0000-0003-2026-6925;
   Avi, Radko/0000-0002-9640-8427
FU Target Financing of Estonian Ministry of Education and Research
   [SF0180004s12, IUT34-24, IUT34-17]; Estonian Science Foundation
   [ETF8856, ETF8415]; European Union through the European Regional
   Development FundEuropean Union (EU); National Institute of Health
   (USA)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01AI0832035]; NATIONAL INSTITUTE ON
   DRUG ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [P30DA011041, P30DA011041, P30DA011041, R01DA003574, R01DA003574,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, R01DA003574,
   R01DA003574, R01DA003574, P30DA011041, P30DA011041, R01DA003574,
   P30DA011041, R01DA003574, R01DA003574, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, R01DA003574, R01DA003574, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, R01DA003574,
   P30DA011041, P30DA011041, P30DA011041, R01DA003574, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, R01DA003574, P30DA011041,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, R01DA003574, P30DA011041, P30DA011041, R01DA003574,
   R01DA003574, P30DA011041, P30DA011041, R01DA003574, R01DA003574,
   P30DA011041, P30DA011041, R01DA003574, P30DA011041, P30DA011041,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, R01DA003574, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, R01DA003574, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, R01DA003574, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, R01DA003574,
   P30DA011041, P30DA011041, R01DA003574, P30DA011041, P30DA011041,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, R01DA003574, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, R01DA003574, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, P30DA011041, P30DA011041, P30DA011041, R01DA003574,
   R01DA003574, P30DA011041, P30DA011041, P30DA011041, R01DA003574,
   R01DA003574, P30DA011041, P30DA011041, R01DA003574, P30DA011041,
   P30DA011041, R01DA003574, P30DA011041, P30DA011041, P30DA011041,
   P30DA011041, R01DA003574, P30DA011041, P30DA011041, P30DA011041] Funding
   Source: NIH RePORTER
FX the Basic Financing and the Target Financing of Estonian Ministry of
   Education and Research (grant SF0180004s12, IUT34-24, and IUT34-17);
   Estonian Science Foundation (grants ETF8856 and ETF8415); European Union
   through the European Regional Development Fund, and the National
   Institute of Health (USA) grant R01AI0832035.
CR Adojaan M, 2005, JAIDS-J ACQ IMM DEF, V39, P598
   Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126
   Avi R, 2014, AIDS RES HUM RETROV, V30, P278, DOI [10.1089/aid.2012.0357, 10.1089/AID.2012.0357]
   Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   BUSCH MP, 1994, BLOOD, V83, P1143
   Casoli C, 2007, AIDS REV, V9, P140
   de la Fuente L, 2006, J CLIN VIROL, V35, P244, DOI 10.1016/j.jcv.2005.06.006
   Dumchev KV, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-23
   ECDC, 2015, GEOGR DISTR AR HIGH
   Egan JF, 1999, AIDS RES HUM RETROV, V15, P699, DOI 10.1089/088922299310782
   Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
   Giuliani M, 2000, SEX TRANSM DIS, V27, P87, DOI 10.1097/00007435-200002000-00006
   HENRARD DR, 1995, J CLIN MICROBIOL, V33, P1735, DOI 10.1128/JCM.33.7.1735-1738.1995
   Huik K, 2013, INFECT GENET EVOL, V20, P78, DOI 10.1016/j.meegid.2013.08.008
   Huik K, 2010, J INFECT DIS, V201, P730, DOI 10.1086/650491
   Malm K, 2012, SCAND J INFECT DIS, V44, P852, DOI 10.3109/00365548.2012.689847
   Moens B, 2009, J CLIN MICROBIOL, V47, P3682, DOI 10.1128/JCM.00781-09
   Morimoto Helena Kaminami, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P225, DOI 10.1590/S0036-46652007000400006
   Nicolas D, 2015, EXPERT REV ANTI-INFE, V13, P947, DOI 10.1586/14787210.2015.1056157
   Rhodes T, 2006, ADDICTION, V101, P252, DOI 10.1111/j.1360-0443.2006.01317.x
   Roucoux DF, 2004, AIDS REV, V6, P144
   Taylor GP, 2005, JAIDS-J ACQ IMM DEF, V38, P104, DOI 10.1097/00126334-200501010-00018
   UNAIDS, 2003, GLOB RESP HIV AIDS E
   Uuskula A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-517
   Uuskula A, 2007, INT J STD AIDS, V18, P41, DOI 10.1258/095646207779949907
   van Tienen C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001690
NR 26
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 83
EP 85
DI 10.1016/j.meegid.2016.05.022
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100012
PM 27223634
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Barsotti, NS
   Santos, BAN
   Marinho, AKBB
   Kokron, CM
   Carvalho, KI
   Barros, MT
   Kalil, J
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Barsotti, Nathalia Silveira
   Santos, Bianca A. N.
   Marinho, Ana Karolina B. B.
   Kokron, Cristina M.
   Carvalho, Karina I.
   Barros, Myrthes T.
   Kalil, Jorge
   Nixon, Douglas F.
   Kallas, Esper G.
TI Inversion of the V delta 1 to V delta 2 gamma delta T cell ratio in CVID
   is not restored by IVIg and is associated with immune activation and
   exhaustion
SO MEDICINE
LA English
DT Article
DE CVID; gamma delta T cells; immune activation; IVIg; PD-1; V delta 1; V
   delta 2
ID COMMON VARIABLE IMMUNODEFICIENCY; MICROBIAL TRANSLOCATION; B-CELLS;
   DEFICIENCY; RECEPTOR; PATIENT; MEMORY
AB Common variable immunodeficiency (CVID) is defined by low levels of IgG and IgA, but perturbations in T cells are also commonly found. However, there is limited information on gamma delta T cells in CVID patients. Newly diagnosed CVID patients (n=15) were enrolled before and after intravenous IgG (IVIg) replacement therapy. Cryopreserved peripheral blood mononuclear cells were then used to study gamma delta T cells and CVID patients were compared to healthy controls (n=22). The frequency and absolute count of V delta 1 gamma delta T cells was found to be increased in CVID (median 0.60% vs 2.64%, P<0.01 and 7.5 vs 39, P<0.01 respectively), while they were decreased for V delta 2 gamma delta T cells (median, 2.36% vs 0.74%, P<0.01 and 37.8 vs 13.9, P<0.01 respectively) resulting in an inversion of the V delta 1 to V delta 2 ratio (0.24 vs 1.4, P<0.001). Markers of immune activation were elevated on all subsets of gamma delta T cells, and HLA-DR expression was associated with an expansion of V delta 1 gamma delta T cells (r=0.73, P=0.003). Elevated PD-1 expression was found only on V delta 2 gamma delta T cells (median 1.15% vs 3.08%, P<0.001) and was associated with the decrease of V delta 2 gamma delta T cells (r=-0.67, P=0.007). IVIg had no effect on the frequency of V delta 1 and V delta 2 gamma delta T cells or HLA-DR expression, but alleviated CD38 expression on V delta 1 gamma delta T cells (median MFI 965 vs 736, P<0.05). These findings suggest that immunological perturbations of gamma delta T cells are a general feature associated with CVID and are only partially reversed by IVIg therapy.
C1 [Paquin-Proulx, Dominic; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
   [Barsotti, Nathalia Silveira; Santos, Bianca A. N.; Marinho, Ana Karolina B. B.; Kokron, Cristina M.; Barros, Myrthes T.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Carvalho, Karina I.] Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
EM dpaquin_proulx@gwu.edu
RI Kokron, Cristina M/D-3140-2012; Carvalho, Karina IL/J-6789-2012; KALIL,
   JORGE/C-8029-2012; Nixon, Douglas/AAU-5734-2020; Marinho, Ana
   Karolina/C-8395-2017
OI Kokron, Cristina M/0000-0002-9080-0305; Carvalho, Karina
   IL/0000-0002-7763-8139; KALIL, JORGE/0000-0001-8415-4274; Nixon,
   Douglas/0000-0002-2801-1786; Marinho, Ana Karolina/0000-0001-9369-8222;
   Paquin Proulx, Dominic/0000-0003-1407-3414; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of Health grant of the District of Columbia Center
   for AIDS Research [P30AI087714, P30AI117970]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/15856-9/EGK, 2010/05845-0/EGK/DFN];
   CNPq/CAPESNational Council for Scientific and Technological Development
   (CNPq)CAPES [056/2012]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970, P30AI117970,
   P30AI117970, P30AI117970, P30AI117970, P30AI117970] Funding Source: NIH
   RePORTER
FX This work was partially supported by the National Institutes of Health
   grant of the District of Columbia Center for AIDS Research (P30AI087714
   and P30AI117970), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (04/15856-9/EGK and 2010/05845-0/EGK/DFN), CNPq/CAPES 056/2012 (DFN).
CR Adams EJ, 2015, CELL IMMUNOL, V296, P31, DOI 10.1016/j.cellimm.2015.04.008
   Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531
   Barsotti NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151761
   Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Capitani N, 2012, INT J IMMUNOPATH PH, V25, P811, DOI 10.1177/039463201202500332
   Capitani N, 2010, J ALLERGY CLIN IMMUN, V126, P671, DOI 10.1016/j.jaci.2010.05.033
   Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052
   DEPAOLI P, 1991, CLIN EXP IMMUNOL, V83, P187, DOI 10.1111/j.1365-2249.1991.tb05612.x
   Duraisingham SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100324
   Fulcher DA, 2009, CLIN EXP IMMUNOL, V157, P365, DOI 10.1111/j.1365-2249.2009.03973.x
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003
   Harris LD, 2010, BLOOD, V116, P4148, DOI 10.1182/blood-2010-05-283549
   Hart M, 2007, J IMMUNOL, V178, P8212, DOI 10.4049/jimmunol.178.12.8212
   Katial RI, 1997, J CLIN IMMUNOL, V17, P34, DOI 10.1023/A:1027384311897
   Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0
   Muto M, 2015, CANCER IMMUNOL IMMUN, V64, P941, DOI 10.1007/s00262-015-1700-x
   Paquin-Proulx D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00637
   Paquin-Proulx D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075199
   Paquin-Proulx D, 2013, BLOOD, V121, P4963, DOI 10.1182/blood-2013-04-499442
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687
   Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039
   Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945
   Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033
   Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383
   Tyler CJ, 2015, CELL IMMUNOL, V296, P10, DOI 10.1016/j.cellimm.2015.01.008
   van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020
   Viallard JF, 2002, CLIN INFECT DIS, V35, pE134, DOI 10.1086/344469
   Vlkova M, 2015, CLIN IMMUNOL, V160, P292, DOI 10.1016/j.clim.2015.06.013
   Wallace M, 1997, MOL MED, V3, P60, DOI 10.1007/BF03401668
   Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394
NR 36
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL
PY 2016
VL 95
IS 30
AR e4304
DI 10.1097/MD.0000000000004304
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS4RO
UT WOS:000380768900043
PM 27472706
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kallas, EG
   O'Connor, DH
AF Kallas, Esper G.
   O'Connor, David H.
TI Real-Time Sharing of Zika Virus Data in an Interconnected World
SO JAMA PEDIATRICS
LA English
DT Editorial Material
C1 [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53711 USA.
   [O'Connor, David H.] Wisconsin Natl Primate Res Ctr, Madison, WI USA.
RP O'Connor, DH (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, 555 Sci Dr, Madison, WI 53711 USA.
EM doconnor@primate.wisc.edu
OI Kallas, Esper/0000-0003-2026-6925
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI116382] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI116382, R01AI116382, R01AI116382, R01AI116382, R01AI116382]
   Funding Source: NIH RePORTER
CR Athavaley A, ZIKA VIRUS TRENDING
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332
   Francis DP, 2012, J PUBLIC HEALTH POL, V33, P290, DOI 10.1057/jphp.2012.14
   Google Trends, WORLD SEARCH ZIK VIR
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Nelson EK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-71
   Wellcome Trust, DAT SHAR PUBL HLTH E
NR 10
TC 5
Z9 5
U1 0
U2 55
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD JUL
PY 2016
VL 170
IS 7
BP 633
EP 634
DI 10.1001/jamapediatrics.2016.0857
PG 2
WC Pediatrics
SC Pediatrics
GA DQ2OK
UT WOS:000379041800003
PM 27031608
OA Bronze
DA 2020-11-26
ER

PT J
AU O'Connor, DH
   Osorio, JE
   Tanuri, A
   Kallas, EG
AF O'Connor, David H.
   Osorio, Jorge E.
   Tanuri, Amilcar
   Kallas, Esper G.
TI Forging Collaborative Relationships in Brazil: From AIDS to ZIKV
SO CELL
LA English
DT Editorial Material
AB The Zika virus (ZIKV) outbreak has stimulated collaborations between Brazilians, researchers from other South American countries, and scientists from around the world. The Brazilian response to the HIV/AIDS epidemic demonstrates capabilities that can be applied to the study of ZIKV and provides lessons for developing effective international infectious disease research collaborations.
C1 [O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA.
   [Osorio, Jorge E.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53705 USA.
   [Tanuri, Amilcar] Univ Fed Rio de Janeiro, Dept Genet, BR-2194190 Rio De Janeiro, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-01246903 Sao Paulo, Brazil.
RP O'Connor, DH (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA.; Kallas, EG (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.; Kallas, EG (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-01246903 Sao Paulo, Brazil.
EM dhoconno@wisc.edu; esper.kallas@usp.br
OI Kallas, Esper/0000-0003-2026-6925
CR Butler Declan, 2016, Nature, V531, P153, DOI 10.1038/nature.2016.19502
   Central Intelligence Agency, 2016, WORLD FACTBOOK
   Gao GF, 2014, SCIENCE, V346, P666, DOI 10.1126/science.346.6209.666
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Merson MH, 2014, NEW ENGL J MED, V370, P1676, DOI 10.1056/NEJMp1401124
   Murray CJL, 2014, LANCET, V384, P1005, DOI 10.1016/S0140-6736(14)60844-8
   Office of the United Nations Special Envoy on Ebola, 2016, RES RES 5
   Scimago Journal & Country Rank, 2016, COUNTR RANK
   Sistema Unico de Saude, 2016, PORT DA SAUD
   The World Bank, 2016, WORLD DEV IND REPR H
   World Bank, 2016, COUNTR LEND GROUPS
   World Bank, 2016, RES DEV EXP GDP
   World Health Organization, 2016, SIT REP ZIK VIR DIS
   World Health Organization, 2016, WORLD HLTH ORG COUNT
NR 14
TC 1
Z9 1
U1 0
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUN 30
PY 2016
VL 166
IS 1
BP 2
EP 4
DI 10.1016/j.cell.2016.06.023
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DR9ZH
UT WOS:000380254400002
PM 27368092
OA Bronze
DA 2020-11-26
ER

PT J
AU Kuebler, PJ
   Shaw, BI
   Leadabrand, KS
   Mehrotra, ML
   Grant, RM
   Kallas, EG
   Nixon, DF
AF Kuebler, Peter J.
   Shaw, Brian I.
   Leadabrand, Kaitlyn S.
   Mehrotra, Megha L.
   Grant, Robert M.
   Kallas, Esper G.
   Nixon, Douglas F.
TI HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the
   Global iPrEx Chemoprophylaxis Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HESN; polyfunctionality; T cell; CD8(+); vaccine
ID IMMUNE-CORRELATES ANALYSIS; RHESUS-MONKEYS; DOUBLE-BLIND; VACCINE;
   PROTECTION; EFFICACY; WORKERS
AB Association of HIV-1-specific T-cell responses to infection risk in seronegative individuals is controversial. We quantified and phenotypically characterized gp120-specific T-cell responses in HIV-1 exposed, but uninfected subjects enrolled in the global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial. IFN gamma ELISpot responses were detected in 24% of subjects irrespective of infection outcome. HIV-1 gp120 envelope-specific T-cell responses were more uniformly IFN-gamma+TNF-alpha+Mip-1 beta+ in persistently seronegative subjects relative to subjects who later seroconverted (median frequency of 76.5% and 66.5%, respectively). IFNg responses targeted the V2 loop for subjects who remained seronegative. HIV-1 gp120 envelope V2 loop-specific CD8(+) T-cell responses may help to protect against HIV-1 acquisition.
C1 [Kuebler, Peter J.; Shaw, Brian I.; Leadabrand, Kaitlyn S.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
   [Mehrotra, Megha L.; Grant, Robert M.] Gladstone Inst, San Francisco, CA USA.
   [Grant, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
RP Kuebler, PJ (corresponding author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
EM peter.kuebler@gmx.com
RI Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Grant, Robert/0000-0002-0851-7085;
   Kallas, Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI62333, AI64002,
   AI087131, RR024131]; District of Columbia Center for AIDS Research
   [P30AI087714, P30AI117970]; Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation; J. David Gladstone InstitutesUniversity of
   California System; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/EGK, 2010/05845-0/EGK/DFN]; CNPq/CAPESNational Council for
   Scientific and Technological Development (CNPq)CAPES [056/2012]; Peter
   and Shelagh Godsoe Family Foundation through the AIDS Research Institute
   at UCSF; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714, P30AI087714, P30AI087714, P30AI087714, P30AI087714,
   P30AI087714] Funding Source: NIH RePORTER
FX This work was partially supported by the National Institutes of Health
   Grants AI62333, AI64002 and AI087131, RR024131, the District of Columbia
   Center for AIDS Research, (P30AI087714 and P30AI117970), the Bill and
   Melinda Gates Foundation, the J. David Gladstone Institutes, Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/EGK and
   2010/05845-0/EGK/DFN), CNPq/CAPES 056/2012 (DFN), and the Peter and
   Shelagh Godsoe Family Foundation through the AIDS Research Institute at
   UCSF (PJK and DFN).
CR Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   de Souza MS, 2012, J IMMUNOL, V188, P5166, DOI 10.4049/jimmunol.1102756
   Fowke KR, 2000, IMMUNOL CELL BIOL, V78, P586, DOI 10.1046/j.1440-1711.2000.00944.x
   Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Kuebler PJ, 2015, P NATL ACAD SCI USA, V112, P8379, DOI 10.1073/pnas.1501443112
   Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187
   PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133
   Ritchie AJ, 2011, J VIROL, V85, P3507, DOI 10.1128/JVI.02444-10
   Tomescu C, 2011, CLIN EXP IMMUNOL, V164, P158, DOI 10.1111/j.1365-2249.2011.04379.x
NR 14
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2016
VL 72
IS 2
BP 184
EP 188
DI 10.1097/QAI.0000000000000923
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DO8UI
UT WOS:000378059300019
PM 26674373
OA Green Published
DA 2020-11-26
ER

PT J
AU Kallas, E
   Huik, K
   Turk, S
   Pauskar, M
   Jogeda, EL
   Sunina, M
   Karki, T
   Des Jarlais, D
   Uuskula, A
   Avi, R
   Lutsar, I
AF Kallas, Eveli
   Huik, Kristi
   Turk, Silver
   Pauskar, Merit
   Jogeda, Ene-Ly
   Sunina, Marina
   Karki, Tonis
   Des Jarlais, Don
   Uuskula, Anneli
   Avi, Radko
   Lutsar, Irja
TI Differences in T cell distribution and CCR5 expression in HIV-positive
   and HIV-exposed seronegative persons who inject drugs
SO MEDICAL MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
DE Opiates; T cell subset; IDU; Immunological profile; HIV susceptibility;
   Inflammation
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SYSTEMIC IMMUNE ACTIVATION; UNINFECTED
   INDIVIDUALS; IMMUNOLOGICAL PROFILE; CORECEPTORS CXCR4; CD45RO ISOFORMS;
   SEX WORKERS; INFECTION; USERS; RISK
AB Some individuals remain uninfected despite repeated exposure to HIV. This protection against HIV has been partly associated with altered T cell subset distributions and CCR5 expression levels. However, the majority of studies have been conducted in sexually exposed subjects. We aimed to assess whether HIV infection and intravenous drug use were associated with differences in CCR5 expression, immune activation on the CD4+ and CD8+ T cells and T cell distribution among Caucasian persons who inject drugs (PWIDs). Analyses of the data from 41 HIV-positive PWIDs, 47 HIV-exposed seronegative PWIDs (ESNs) and 47 age- and gender-matched HIV-negative non-drug users are presented. Of all of the study subjects, 111 (82 %) were male, and the median age was 29 years. T cell phenotyping was performed in peripheral blood mononuclear cells with multicolour flow cytometry using anti-CD3, CD4, CD8, CD45RA, CD45RO, HLA-DR and CCR5 antibodies. The ESNs exhibited greater levels of immune activation and higher percentages of CD4+ CD45RA+RO+ and CD8+ CD45RA+RO+ cells compared to the controls but not the HIV-positive people. The CCR5 expression on the CD4+ T cell subsets in the ESNs was lower than that in the controls but similar to that the HIV positives. The percentages of CCR5+ T cells were similar in all study groups and in most of the studied cell populations. Intravenous drug use was similarly associated with differences in T cell subset distributions and CCR5 expression among both the HIV-positive and HIV-negative PWIDs compared with the controls.
C1 [Kallas, Eveli; Huik, Kristi; Turk, Silver; Pauskar, Merit; Jogeda, Ene-Ly; Karki, Tonis; Avi, Radko; Lutsar, Irja] Univ Tartu, Dept Microbiol, Ravila 19, EE-50411 Tartu, Estonia.
   [Sunina, Marina] Univ Tartu, Inst Biomed & Translat Med, Dept Immunol, Ulikooli 18, EE-50090 Tartu, Estonia.
   [Des Jarlais, Don] Beth Israel Deaconess Med Ctr, Baron Edmond Rothschild Chem Dependency Inst, New York, NY 10003 USA.
   [Uuskula, Anneli] Univ Tartu, Dept Publ Hlth, Ulikooli 18, EE-50090 Tartu, Estonia.
RP Kallas, E (corresponding author), Univ Tartu, Dept Microbiol, Ravila 19, EE-50411 Tartu, Estonia.
EM eveli.kallas@ut.ee
RI Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Avi, Radko/0000-0002-9640-8427;
   Kallas, Esper/0000-0003-2026-6925
FU European Union through the European Regional Development FundEuropean
   Union (EU); Estonian Science Foundation [8415, 8856]; Basic Financing
   and Target Financing of the Estonian Ministry of Education and Research
   [SF0180004s12, SF0180060s09]; US National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 DA003574]
FX We thank the study participants, the teams from the non-governmental
   organization "Convictus", Kristina Marsh for coordinating the study and
   Karolin Toompere for suggestions regarding the statistical analyses. The
   work was supported by the European Union through the European Regional
   Development Fund, the Estonian Science Foundation (Grants 8415 and
   8856), the Basic Financing and Target Financing of the Estonian Ministry
   of Education and Research (SF0180004s12 and SF0180060s09), and the grant
   R01 DA003574 from the US National Institutes of Health. The funders had
   no role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Avi R, 2014, AIDS RES HUM RETROV, V30, P278, DOI [10.1089/aid.2012.0357, 10.1089/AID.2012.0357]
   Biasin M, 2000, J INFECT DIS, V182, P1365, DOI 10.1086/315873
   Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925
   Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Gijsbers EF, 2012, FUTURE VIROL, V7, P63, DOI 10.2217/FVL.11.134
   Gornalusse GG, 2015, P NATL ACAD SCI USA, V112, pE4762, DOI 10.1073/pnas.1423228112
   Hamann D, 1996, BLOOD, V88, P3513, DOI 10.1182/blood.V88.9.3513.bloodjournal8893513
   Hladik F, 2005, J VIROL, V79, P11677, DOI 10.1128/JVI.79.18.11677-11684.2005
   Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971
   Huik K, 2013, INFECT GENET EVOL, V20, P78, DOI 10.1016/j.meegid.2013.08.008
   Huik K, 2010, J INFECT DIS, V201, P730, DOI 10.1086/650491
   Husman AD, 1999, J IMMUNOL, V163, P4597
   Jennes W, 2003, J INFECT DIS, V187, P206, DOI 10.1086/346049
   Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714
   Killian MS, 2004, AIDS, V18, P161, DOI 10.1097/00002030-200401230-00004
   Laisaar KT, 2011, AIDS RES HUM RETROV, V27, P841, DOI [10.1089/aid.2010.0223, 10.1089/AID.2010.0223]
   Li Y, 2002, J INFECT DIS, V185, P118, DOI 10.1086/338011
   Lichtner M, 2015, J INFECT DIS, V211, P178, DOI 10.1093/infdis/jiu417
   Lo Caputo S, 2003, AIDS, V17, P531, DOI 10.1097/00002030-200303070-00008
   Loeuillet C, 2008, PLOS BIOL, V6, P319, DOI 10.1371/journal.pbio.0060032
   Makedonas G, 2002, AIDS, V16, P1595, DOI 10.1097/00002030-200208160-00004
   Malekinejad M, 2008, AIDS BEHAV, V12, pS105, DOI 10.1007/s10461-008-9421-1
   Messele T, 2001, AIDS RES HUM RETROV, V17, P433, DOI 10.1089/088922201750102526
   Najera O, 2001, CLIN EXP IMMUNOL, V126, P461, DOI 10.1046/j.1365-2249.2001.01694.x
   Ostrowski MA, 1998, J IMMUNOL, V161, P3195
   Palacios-Martinez M, 2012, OPEN J IMMUNOL, V2, P202
   Parikh N, 2012, CURR HIV RES, V10, P557, DOI 10.2174/157016212803306023
   Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000
   Prentice HA, 2014, GENES IMMUN, V15, P275, DOI 10.1038/gene.2014.16
   Rentenaar RJ, 2000, J CLIN INVEST, V105, P541, DOI 10.1172/JCI8229
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   Roy S, 2011, J NEUROIMMUNE PHARM, V6, P442, DOI 10.1007/s11481-011-9292-5
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Shalekoff S, 2001, CLIN DIAGN LAB IMMUN, V8, P432, DOI 10.1128/CDLI.8.2.432-436.2001
   Shearer G, 2010, J INFECT DIS, V202, pS329, DOI 10.1086/655974
   Steele AD, 2003, VIROLOGY, V309, P99, DOI 10.1016/S0042-6822(03)00015-1
   Suy A, 2007, J INFECT DIS, V196, P1191, DOI 10.1086/521193
   Thomas SM, 2006, AIDS, V20, P1879, DOI 10.1097/01.aids.0000244207.49123.ff
   Tran HK, 2006, AIDS RES HUM RETROV, V22, P255, DOI 10.1089/aid.2006.22.255
   Uuskula A, 2007, INT J STD AIDS, V18, P41, DOI 10.1258/095646207779949907
   Wang X, 2011, J NEUROIMMUNE PHARM, V6, P477, DOI 10.1007/s11481-011-9296-1
   Wang X, 2011, AM J PATHOL, V178, P41, DOI 10.1016/j.ajpath.2010.11.042
   Yang OO, 2002, AIDS RES HUM RETROV, V18, P1051, DOI 10.1089/08892220260235416
   Zapata W, 2013, AIDS RES HUM RETROV, V29, P1594, DOI [10.1089/aid.2012.0299, 10.1089/AID.2012.0299]
NR 45
TC 5
Z9 5
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0300-8584
EI 1432-1831
J9 MED MICROBIOL IMMUN
JI Med. Microbiol. Immunol.
PD JUN
PY 2016
VL 205
IS 3
BP 231
EP 239
DI 10.1007/s00430-015-0444-8
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA DM3QR
UT WOS:000376261700004
PM 26696529
DA 2020-11-26
ER

PT J
AU Rocha, JA
   Ribeiro, SP
   Franca, CM
   Coelho, O
   Alves, G
   Lacchini, S
   Kallas, EG
   Irigoyen, MC
   Consolim-Colombo, FM
AF Rocha, Juraci Aparecida
   Ribeiro, Susan Pereira
   Franca, Cristiane Miranda
   Coelho, Otavio
   Alves, Gisele
   Lacchini, Silvia
   Kallas, Esper Georges
   Irigoyen, Maria Claudia
   Consolim-Colombo, Fernanda M.
TI Increase in cholinergic modulation with pyridostigmine induces
   anti-inflammatory cell recruitment soon after acute myocardial
   infarction in rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; NICOTINIC ACETYLCHOLINE-RECEPTOR;
   HEART-RATE-VARIABILITY; BAROREFLEX SENSITIVITY; INFLAMMATORY RESPONSE;
   AUTONOMIC FUNCTION; STIMULATION; LYMPHOCYTES; DYSFUNCTION; INHIBITION
C1 [Rocha, Juraci Aparecida; Irigoyen, Maria Claudia; Consolim-Colombo, Fernanda M.] Univ Sao Paulo, Sch Med, Hypertens Unit, Heart Inst InCor, Sao Paulo, Brazil.
   [Ribeiro, Susan Pereira; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Lab Clin Inununol & Allergy, Div Med, Sao Paulo, Brazil.
   [Franca, Cristiane Miranda; Coelho, Otavio; Alves, Gisele; Consolim-Colombo, Fernanda M.] Univ Nove de Julho, Sao Paulo, Brazil.
   [Lacchini, Silvia] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil.
RP Consolim-Colombo, FM (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Ave Dr Eneas de Carvalho Aguiar, BR-44054039 Sao Paulo, Brazil.
EM fernanda.consolim@incor.com.br
RI Colombo, Fernanda MC/C-6911-2018; IRIGOYEN, MARIA CLAUDIA C/N-6880-2014;
   Rocha, JA/I-3443-2014; Lacchini, Silvia/H-8592-2014; Rocha, Juraci
   Aparecida/X-7491-2018
OI Colombo, Fernanda MC/0000-0003-3220-019X; IRIGOYEN, MARIA CLAUDIA
   C/0000-0003-2097-3662; Rocha, JA/0000-0003-3813-4437; Lacchini,
   Silvia/0000-0002-7937-8473; Rocha, Juraci Aparecida/0000-0003-3813-4437;
   Kallas, Esper/0000-0003-2026-6925; Franca,
   Cristiane/0000-0002-9285-4622; Rizzi Coelho, Otavio/0000-0002-9822-2685
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Fundacao Zerbini; National Council for Scientific
   and Technological DevelopmentNational Council for Scientific and
   Technological Development (CNPq)
FX This study was supported by Sao Paulo Research Foundation, Fundacao
   Zerbini, and National Council for Scientific and Technological
   Development.
CR Abbate A, 2004, CIRCULATION, V110, P46, DOI 10.1161/01.CIR.0000133316.92316.81
   Akinci SB, 2005, WORLD J SURG, V29, P1483, DOI 10.1007/s00268-005-0073-2
   ANTONICA A, 1994, J AUTONOM NERV SYST, V48, P187, DOI 10.1016/0165-1838(94)90047-7
   Anzai T, 2013, CIRC J, V77, P580, DOI 10.1253/circj.CJ-13-0013
   Azevedo PS, 2012, MED SCI MONITOR, V18, pBR253, DOI 10.12659/MSM.883202
   Borovikova LV, 2000, NATURE, V405, P458
   Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204
   de La Fuente RN, 2013, CLIN EXP PHARMACOL P, V40, P610, DOI 10.1111/1440-1681.12121
   Durand MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104476
   Frangogiannis NG, 2008, PHARMACOL RES, V58, P88, DOI 10.1016/j.phrs.2008.06.007
   Harel-Adar T, 2011, P NATL ACAD SCI USA, V108, P1827, DOI 10.1073/pnas.1015623108
   Hofer S, 2008, CRIT CARE MED, V36, P404, DOI 10.1097/01.CCM.0B013E31816208B3
   Hofmann U, 2012, CIRCULATION, V125, P1652, DOI 10.1161/CIRCULATIONAHA.111.044164
   Hu ZP, 2007, J HUAZHONG U SCI-MED, V27, P524, DOI 10.1007/s11596-007-0512-4
   Kain V, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0444-7
   Kox M, 2011, BRIT J ANAESTH, V107, P559, DOI 10.1093/bja/aer202
   La Rovere MT, 1998, LANCET, V351, P478
   Lataro RM, 2013, AM J PHYSIOL-REG I, V305, pR908, DOI 10.1152/ajpregu.00102.2013
   Leib C, 2013, TRENDS CARDIOVAS MED, V23, P46, DOI 10.1016/j.tcm.2012.08.010
   Lewis EF, 2003, J AM COLL CARDIOL, V42, P1446, DOI 10.1016/S0735-1097(03)01057-X
   Lu Y, 2014, J CARDIOVASC PHARM, V63, P412, DOI 10.1097/FJC.0000000000000062
   Mostarda C, 2011, J CARD FAIL, V17, P519, DOI 10.1016/j.cardfail.2011.02.007
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Olofsson PS, 2012, IMMUNOL REV, V248, P188, DOI 10.1111/j.1600-065X.2012.01138.x
   Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382
   Ribeiro SP, 2014, J VIROL, V88, P13836, DOI 10.1128/JVI.01948-14
   Rodrigues B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/702473
   Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x
   Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985
   Soares PPDA, 2004, AUTON NEUROSCI-BASIC, V113, P24, DOI 10.1016/j.autneu.2004.05.002
   Tang TT, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0232-6
   Tang TT, 2010, CELL PHYSIOL BIOCHEM, V25, P451, DOI 10.1159/000303050
   Thomas C, 2013, CLIN EXP PHARMACOL P, V40, P597, DOI 10.1111/1440-1681.12146
   Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104
   van der Laan AM, 2012, HEART, V98, P1384, DOI 10.1136/heartjnl-2012-301623
   Varda-Bloom N, 2000, J MOL CELL CARDIOL, V32, P2141, DOI 10.1006/jmcc.2000.1261
   Wang DW, 2010, J PHARMACOL EXP THER, V335, P553, DOI 10.1124/jpet.110.169961
   Weirather J, 2014, CIRC RES, V115, P55, DOI 10.1161/CIRCRESAHA.115.303895
   Xiong J, 2010, CHINESE MED J-PEKING, V123, P2720, DOI 10.3760/cma.j.issn.0366-6999.2010.19.019
   Yan XX, 2013, J MOL CELL CARDIOL, V62, P24, DOI 10.1016/j.yjmcc.2013.04.023
   Yu JG, 2013, EUR HEART J, V34, P2412, DOI 10.1093/eurheartj/ehr299
   Zhang XJ, 2002, CELL DEATH DIFFER, V9, P790, DOI 10.1038/sj.cdd.4401034
NR 42
TC 16
Z9 18
U1 0
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD APR 15
PY 2016
VL 310
IS 8
BP R697
EP R706
DI 10.1152/ajpregu.00328.2015
PG 10
WC Physiology
SC Physiology
GA DJ3JH
UT WOS:000374100500004
PM 26791829
OA Green Published
DA 2020-11-26
ER

PT J
AU Avi, R
   Pauskar, M
   Karki, T
   Kallas, E
   Jogeda, EL
   Margus, T
   Huik, K
   Lutsar, I
AF Avi, Radko
   Pauskar, Merit
   Karki, Tonis
   Kallas, Eveli
   Jogeda, Ene-Ly
   Margus, Tonu
   Huik, Kristi
   Lutsar, Irja
TI Prevalence of Drug Resistance Mutations in HAART Patients Infected With
   HIV-1 CRF06_cpx in Estonia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE CRF06_cpx; drug resistance; subtype specific pathways; monophyletic;
   injecting drug use
ID ANTIRETROVIRAL THERAPY; NAIVE PATIENTS; COMBINATION THERAPY; INITIAL
   TREATMENT; DIDANOSINE; EFAVIRENZ; ZIDOVUDINE; LAMIVUDINE; SUBTYPE;
   TYPE-1
AB HIV-1 drug resistance mutations (DRMs) and substitutions were assessed after the failure of the first line non-nucleoside reverse transcriptase inhibitors (NNRTIs) + 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) treatment regimens (efavirenz [EFV] + lamivudine[3TC] + zidovudine [ZDV] vs. EFV + 3TC + didanosine[ddI]) among the HIV-1 CRF06_cpx infected subjects in Estonia. HIV-1 genomic RNA was sequenced; DRMs and amino acid substitutions were compared in 44 treatment naive and 45 first-line NNRTI+2 NRTI treatment failed patients consisting of EFV+3TC+ZDV (n = 17) and EFV+3TC+ ddI (n = 21) therapy failed sub-populations. At least one DRM was found in 78% of treatment experienced patients. The most common NRTI mutations were M184V (80%), L74V (31%), L74I (17%), K219E (9%), and M184I (9%), NNRTI mutations were K103N (83%), P225H (14%), L100I (11%), and Y188L (11%), reflecting generally the similar pattern of DRMs to that seen in treatment failed subtype B viruses. Sub-population analysis revealed that EFV+3TC+ddI failed patients had more DRMs compared to EFV+3TC+ZDV failed patients, especially the ddI DRM L74IV and several additional NNRTI DRMs. Additionally, CRF06_cpx specific mutation E179V and substitutions R32K, K122E, and V200AE were also detected in treatment experienced population. After the failure of the first-line EFV+3TC+ddI therapy HIV-1 CRF06_cpx viruses develop additional NRTI and NNRTI mutations compared to EFV+3 TC+ZDV regimen. Therefore the usage of EFV +3TC+ddI in this subtype decreases the options for next regimens containing abacavir, and NNRTI class agents. (C) 2015 Wiley Periodicals, Inc.
C1 [Avi, Radko; Pauskar, Merit; Karki, Tonis; Kallas, Eveli; Jogeda, Ene-Ly; Huik, Kristi; Lutsar, Irja] Univ Tartu, Fac Med, Dept Microbiol, Ravila 19, EE-50111 Tartu, Estonia.
   [Margus, Tonu] Univ Tartu, Dept Mol & Cell Biol, Ulikooli 18, EE-50090 Tartu, Estonia.
RP Avi, R; Lutsar, I (corresponding author), Univ Tartu, Fac Med, Dept Microbiol, Ravila 19, EE-50111 Tartu, Estonia.
EM radko.avi@gmail.com; irja.lutsar@ut.ee
OI Avi, Radko/0000-0002-9640-8427; Kallas, Esper/0000-0003-2026-6925;
   Margus, Tonu/0000-0003-4966-1291
FU European Regional Development FundEuropean Union (EU); Estonian Science
   Foundation [8004, 8415, 8856]; Estonian Ministry of Education and
   ResearchMinistry of Education and Research, Estonia [SF0180004s12]
FX Grant sponsor: European Regional Development Fund; Estonian Science
   Foundation; Grant numbers: 8004; 8415; 8856; Grant sponsor: Basic
   Financing and the Target Financing of Estonian Ministry of Education and
   Research; Grant numbers: SF0180004s12
CR Adojaan M, 2005, JAIDS-J ACQ IMM DEF, V39, P598
   Aulicino PC, 2010, ANTIVIR THER, V15, P641, DOI 10.3851/IMP1571
   Avi R, 2011, SCAND J INFECT DIS, V43, P122, DOI 10.3109/00365548.2010.526956
   Avi R, 2009, J MED VIROL, V81, P953, DOI 10.1002/jmv.21482
   Berenguer J, 2008, CLIN INFECT DIS, V47, P1083, DOI 10.1086/592114
   Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/00002030-200301030-00001
   Crespo M, 2009, J ANTIMICROB CHEMOTH, V63, P189, DOI 10.1093/jac/dkn450
   Geretti AM, 2009, CLIN INFECT DIS, V48, P1296, DOI 10.1086/598502
   Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112
   Laisaar KT, 2011, AIDS RES HUM RETROV, V27, P841, DOI [10.1089/aid.2010.0223, 10.1089/AID.2010.0223]
   Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008
   Laurent C, 2011, TROP MED INT HEALTH, V16, P217, DOI 10.1111/j.1365-3156.2010.02690.x
   Lessells RJ, 2012, CURR OPIN VIROL, V2, P636, DOI 10.1016/j.coviro.2012.08.006
   Maggiolo F, 2003, ANTIVIR THER, V8, P339
   Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109
   Naganawa S, 2002, AIDS RES HUM RETROV, V18, P1145, DOI 10.1089/088922202320567897
   Nielsen C, 1996, AIDS, V10, P625, DOI 10.1097/00002030-199606000-00008
   Novitsky V, 2007, AIDS RES HUM RETROV, V23, P868, DOI 10.1089/aid.2006.0298
   Saag MS, 2004, JAMA-J AM MED ASSOC, V292, P180, DOI 10.1001/jama.292.2.180
   Sanchez-Conde M, 2007, AIDS RES HUM RETROV, V23, P1237, DOI 10.1089/aid.2006.0029
   Santos J, 2005, HIV CLIN TRIALS, V6, P320, DOI 10.1310/1XAE-BB0W-QN5R-AJGJ
   Scherrer AU, 2011, CLIN INFECT DIS, V53, P1143, DOI 10.1093/cid/cir669
   Seyler C, 2003, ANTIVIR THER, V8, P385
   Shafer RW, 2008, AIDS REV, V10, P67
   SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tebit DM, 2008, JAIDS-J ACQ IMM DEF, V49, P17, DOI 10.1097/QAI.0b013e318182d2bc
   van de Vijver DAMC, 2010, ACTA DERMATOVEN ALP, V19, P3
   van de Vijver DA, 2006, JAIDS-J ACQ IMM DEF, V41, P352, DOI 10.1097/01.qai.0000209899.05126.e4
   Wirden M, 2009, AIDS, V23, P95, DOI 10.1097/QAD.0b013e328319bc91
NR 31
TC 2
Z9 2
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2016
VL 88
IS 3
BP 448
EP 454
DI 10.1002/jmv.24361
PG 7
WC Virology
SC Virology
GA DC4II
UT WOS:000369184000012
PM 26291050
DA 2020-11-26
ER

PT J
AU Kuebler, PJ
   Mehrotra, ML
   Shaw, BI
   Leadabrand, KS
   Milush, JM
   York, VA
   Defechereux, P
   Grant, RM
   Kallas, EG
   Nixon, DF
AF Kuebler, Peter J.
   Mehrotra, Megha L.
   Shaw, Brian I.
   Leadabrand, Kaitlyn S.
   Milush, Jeffrey M.
   York, Vanessa A.
   Defechereux, Patricia
   Grant, Robert M.
   Kallas, Esper G.
   Nixon, Douglas F.
TI Persistent HIV Type 1 Seronegative Status Is Associated With Lower
   CD8(+) T-Cell Activation
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; T-cell activation; HESN; infection risk
ID IMMUNE ACTIVATION; INFECTION; SUSCEPTIBILITY; PREDICTS; WOMEN; SEX
AB We leveraged data from the Preexposure Prophylaxis Initiative (iPrEx), a global trial of preexposure chemoprophylaxis against human immunodeficiency virus type 1 (HIV-1) infection, to compare T-cell activation between those who remained negative for HIV-1 and those who became infected during the trial. The frequency of CD38(+)HLA-DR(+)CD8(+)T cells was greater in those who seroconverted, relative to the frequency in those who remained uninfected (1.30% vs 0.82%, respectively; P = .005). This translated to an odds ratio of 4.26 (95% confidence interval, 1.54-11.78) for the association between CD8(+)T-cell activation and infection with HIV-1. T-cell activation may be a biomarker for elevated HIV-1 infection risk.
C1 [Kuebler, Peter J.; Shaw, Brian I.; Leadabrand, Kaitlyn S.; Milush, Jeffrey M.; York, Vanessa A.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
   [Grant, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Mehrotra, Megha L.; Defechereux, Patricia; Grant, Robert M.] Gladstone Inst, Gladstone Inst Virol & Immunol, San Francisco, CA USA.
   [Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Kuebler, PJ (corresponding author), Univ Calif San Francisco, San Francisco, CA 94110 USA.
EM peter.kuebler@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Kallas, Esper/0000-0003-2026-6925;
   Grant, Robert/0000-0002-0851-7085
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI62333, AI64002,
   AI087131, RR024131]; Bill and Melinda Gates FoundationBill & Melinda
   Gates Foundation; J. David Gladstone InstitutesUniversity of California
   System; Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/15856-9/EGK,
   2010/05845-0/EGK/DFN]; CNPq/CAPESNational Council for Scientific and
   Technological Development (CNPq)CAPES [056/2012]; Peter and Shelagh
   Godsoe Family Foundation, through the AIDS Research Institute at
   University of California-San Francisco; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI062333, R01AI062333, U01AI064002,
   R01AI062333, U01AI064002, R01AI062333, R21AI087131, R21AI087131,
   U01AI064002, R21AI087131, R01AI062333, R01AI062333, U01AI064002,
   R01AI062333, U01AI064002, U01AI064002, U01AI064002, U01AI064002,
   U01AI064002, R01AI062333] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (grants
   AI62333, AI64002, AI087131, and RR024131), the Bill and Melinda Gates
   Foundation, the J. David Gladstone Institutes, Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (04/15856-9/EGK and
   2010/05845-0/EGK/DFN), CNPq/CAPES (grant 056/2012 to D. F. N.), and the
   Peter and Shelagh Godsoe Family Foundation, through the AIDS Research
   Institute at University of California-San Francisco (to P. J. K. and D.
   F. N.).
CR Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Biasin M, 2000, J INFECT DIS, V182, P1365, DOI 10.1086/315873
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Jennes W, 2003, J INFECT DIS, V187, P206, DOI 10.1086/346049
   Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117
   Lawn SD, 2001, CLIN MICROBIOL REV, V14, P753, DOI 10.1128/CMR.14.4.753-777.2001
   Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Mahnke YD, 2013, AIDS, V27, P697, DOI 10.1097/QAD.0b013e32835ce2e9
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   van Asten L, 2004, AIDS, V18, P1885, DOI 10.1097/00002030-200409240-00004
NR 15
TC 6
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 15
PY 2016
VL 213
IS 4
BP 569
EP 573
DI 10.1093/infdis/jiv425
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DG9XS
UT WOS:000372437700011
PM 26310308
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Miyaji, KT
   Mathias, A
   Costa, DA
   Dias, JZD
   Lima, SB
   Simoes, M
   Freire, MS
   Caiaffa, HH
   Hong, MA
   Lopes, MH
   Sartori, AM
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Miyaji, Karina Takesaki
   Mathias, Augusto
   Costa, Dayane Alves
   de Carvalho Dias, Juliana Zanatta
   Lima, Sheila Barbosa
   Simoes, Marisol
   Freire, Marcos S.
   Caiaffa-Filho, Helio H.
   Hong, Marisa A.
   Lopes, Marta H.
   Sartori, Ana M.
   Kallas, Esper G.
TI CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in
   Virologically Suppressed HIV-Infected Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE yellow fever vaccine; yellow fever neutralizing antibodies; HIV; CD4(+);
   CD8(+) ratio; immune activation
ID GB-VIRUS-C; T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY;
   IMMUNOFLUORESCENCE ASSAY; PNEUMOCOCCAL CONJUGATE; NEUTRALIZATION TEST;
   IMMUNE ACTIVATION; IGG ANTIBODIES; IMMUNOGENICITY; SAFETY
AB Background:Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population.Methods:We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded.Results:Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log(10)mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants.Conclusions:ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART.
C1 [Avelino-Silva, Vivian Iida; Miyaji, Karina Takesaki; Lopes, Marta H.; Sartori, Ana M.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Mathias, Augusto; Costa, Dayane Alves; de Carvalho Dias, Juliana Zanatta; Hong, Marisa A.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Lima, Sheila Barbosa; Simoes, Marisol; Freire, Marcos S.] Fundacao Oswaldo Cruz Biomanguinhos, Rio De Janeiro, Brazil.
   [Caiaffa-Filho, Helio H.; Hong, Marisa A.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Caiaffa-Filho, Helio H.] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 3, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Av Dr Eneas Carvalho Aguiar 470,Sala 06, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Lopes, Marta H/J-3285-2012; Sartori, Ana Marli Christovam/I-6663-2012;
   Avelino-Silva, Vivian I/L-2640-2013; Mathias, Augusto/C-3247-2017;
   Caiaffa-Filho, Helio H/H-6982-2012; Miyaji, Karina T/B-1319-2016
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Caiaffa-Filho, Helio H/0000-0001-6048-4527;
   Miyaji, Karina T/0000-0003-2653-3975; Kallas, Esper/0000-0003-2026-6925;
   Mathias, Augusto/0000-0002-5896-9223; Barbosa de Lima, Sheila
   Maria/0000-0001-9234-1678; Lopes, Marta Heloisa/0000-0001-5236-6248
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (Capes)CAPES; Ministry of Education, Brazil; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2013/05246-8]
FX This study has been partially funded by Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (Capes), Ministry of Education, Brazil, and
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant Number
   2013/05246-8).
CR Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   Bamford A, 2014, AIDS, V28, P2033, DOI 10.1097/QAD.0000000000000385
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Bhattarai N, 2012, J INFECT DIS, V206, P1469, DOI 10.1093/infdis/jis515
   Boyer JRL, 2015, C RETR OPP DIS FEBR
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Chen S, 2015, OBES RES CLIN PRACT, V9, P35, DOI 10.1016/j.orcp.2013.12.006
   Control. NIfBSa, 2008, WHO REF REAG 1 INT R
   Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054
   Crum-Cianflone NF, 2011, J INFECT DIS, V203, P1815, DOI 10.1093/infdis/jir180
   Dobler G, 1997, Wien Med Wochenschr, V147, P463
   Ernst D, 2014, HIV MED, V15, P245, DOI 10.1111/hiv.12094
   Goujon C, 1995, 4 INT C TRAV MED APR
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Lopes VB, 2013, VACCINE, V31, P1040, DOI 10.1016/j.vaccine.2012.12.047
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   Ministerio da Saude-Secretaria de Vigilancia em Saude-Departamento de DST, 2014, B EP HIV AIDS
   Miraglia JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027214
   Monath TP, 2002, AM J TROP MED HYG, V66, P533, DOI 10.4269/ajtmh.2002.66.533
   Monath TP, 2008, VACCINES, P1748
   Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5
   Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Niedrig M, 2008, CLIN VACCINE IMMUNOL, V15, P177, DOI 10.1128/CVI.00078-07
   Okulicz JF, 2015, JAMA INTERN MED, V175, P88, DOI 10.1001/jamainternmed.2014.4010
   Pacanowski J, 2012, JAIDS-J ACQ IMM DEF, V59, P360, DOI 10.1097/QAI.0b013e318249de59
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Pfister M, 2005, AM J TROP MED HYG, V72, P339, DOI 10.4269/ajtmh.2005.72.339
   Pistone T, 2010, CURR HIV RES, V8, P461, DOI 10.2174/157016210793499277
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Richardson K, 2011, AIDS, V25, P595, DOI 10.1097/QAD.0b013e32834411a8
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Rydze RT, 2012, ANTIVIR THER, V17, P1271, DOI 10.3851/IMP2309
   Sahni H, 2014, J MED VIROL, V86, P426, DOI 10.1002/jmv.23845
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sibailly TS, 1997, PEDIATR INFECT DIS J, V16, P1177, DOI 10.1097/00006454-199712000-00015
   Sidibe M, 2012, T ROY SOC TROP MED H, V106, P437, DOI 10.1016/j.trstmh.2012.04.002
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Vahidnia F, 2012, CLIN INFECT DIS, V55, P1012, DOI 10.1093/cid/cis589
   Veit O, 2009, CLIN INFECT DIS, V48, P659, DOI 10.1086/597006
   Weinberg A, 2006, J INFECT DIS, V193, P302, DOI 10.1086/498979
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
NR 57
TC 8
Z9 8
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2016
VL 71
IS 2
BP 189
EP 195
DI 10.1097/QAI.0000000000000845
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DB8YU
UT WOS:000368803900009
PM 26361176
OA Green Published
DA 2020-11-26
ER

PT J
AU Kuebler, P
   Mehrotra, M
   McConnell, J
   Holditch, S
   Shaw, B
   Tarosso, L
   Leadabrand, K
   Milush, J
   York, V
   Raposo, RAS
   Cheng, R
   Eriksson, E
   McMahan, V
   Glidden, D
   Shiboski, S
   Grant, R
   Kallas, E
   Nixon, D
AF Kuebler, Peter
   Mehrotra, Megha
   McConnell, Jeff
   Holditch, Sara
   Shaw, Brian
   Tarosso, Leandro
   Leadabrand, Kaitlyn
   Milush, Jeffrey
   York, Vanessa
   Raposo, Rui Andre Saraiva
   Cheng, Rex
   Eriksson, Emily
   McMahan, Vanessa
   Glidden, David
   Shiboski, Stephen
   Grant, Robert
   Kallas, Esper
   Nixon, Douglas
TI Cellular Immune correlates Analysis of an HIV-1 Pre-exposure Prophylaxis
   Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 17th Annual International Meeting of the Institute-of-Human-Virology at
   the University-of-Maryland-School-of-Medicine
CY SEP 27-30, 2015
CL Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD
HO Univ Maryland, Sch Med, Inst Human Virol
C1 [Kuebler, Peter; Leadabrand, Kaitlyn; Milush, Jeffrey; York, Vanessa; Cheng, Rex; Eriksson, Emily; Glidden, David; Shiboski, Stephen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Mehrotra, Megha; McConnell, Jeff; Holditch, Sara; Shaw, Brian; McMahan, Vanessa; Grant, Robert] Gladstone Inst, San Francisco, CA USA.
   [Tarosso, Leandro; Kallas, Esper] Univ Sao Paulo, Sao Paulo, Brazil.
   [Raposo, Rui Andre Saraiva; Nixon, Douglas] George Washington Univ, Washington, DC 20052 USA.
RI Glidden, David/AAD-4730-2020
OI Glidden, David/0000-0001-5888-1419
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JAN
PY 2016
VL 71
SU 1
MA D-106
BP 54
EP 54
DI 10.1097/01.qai.0000479554.52108.29
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EQ9HZ
UT WOS:000398396800041
DA 2020-11-26
ER

PT J
AU Araujo, JAP
   Mesquita, D
   Cruvinel, WD
   Salmazi, KI
   Kallas, EG
   Andrade, LEC
AF Pereira Araujo, Julio Antonio
   Mesquita, Danilo, Jr.
   Cruvinel, Wilson de Melo
   Salmazi, Karina Inacio
   Kallas, Esper Georges
   Coelho Andrade, Luis Eduardo
TI Th17 cells and CD4(+) multifunctional T cells in patients with systemic
   lupus erythematosus
SO REVISTA BRASILEIRA DE REUMATOLOGIA
LA Portuguese
DT Article
DE Systemic lupus erythematosus; T lymphocytes; Th17; Multifunctional T
   cells
ID DISEASE-ACTIVITY; IL-17; CYTOKINE; PROFILES; SUBSETS; BALANCE; IL-23
AB Introduction/Objective: Recent evidence suggests that abnormalities involving Th17 lymphocytes are associated with the pathophysiology of systemic lupus erythematosus (SLE). In addition, multifunctional T cells (MFT), i.e., those producing multiple cytokines simultaneously, are present in the inflammatory milieu and may be implicated in the autoimmune process observed in SLE. In the present study, we aimed to characterize the functional status of CD4(+) T cells in SLE by simultaneously determining the concentration of IL-2, IFN-gamma and IL-17 in lymphocyte cultures under exogenous and self-antigenic stimuli.
   Patients and methods: Eighteen patients with active disease, 18 with inactive disease, and 14 healthy controls had functional status of CD4(+) T cells analyzed.
   Results: We found that SLE patients presented a decreased number of total CD4(+) cells, an increased number of activated T cells, and an increased frequency of Th17 cells compared to healthy controls (HC). MFT cells had increased frequency in SLE patients and there was an increased frequency of tri-functional MFT in patients with active SLE compared with those with inactive SLE. Interestingly, MTF cells produced larger amounts of IFN gamma than mono-functional T cells in patients and controls.
   Conclusion: Taken together these data indicate the participation of recently activated Th17 cells and MTF cells in the SLE pathophysiology. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Pereira Araujo, Julio Antonio; Mesquita, Danilo, Jr.; Cruvinel, Wilson de Melo; Coelho Andrade, Luis Eduardo] Univ Fed Sao Paulo Unifesp, Dept Reumatol, Sao Paulo, SP, Brazil.
   [Cruvinel, Wilson de Melo] Pontificia Univ Catolica Goias PUC GO, Dept Biomed, Goiania, Go, Brazil.
   [Salmazi, Karina Inacio; Kallas, Esper Georges] Univ Sao Paulo, Dept Imunol Clin & Alergia, Sao Paulo, SP, Brazil.
RP Andrade, LEC (corresponding author), Univ Fed Sao Paulo Unifesp, Dept Reumatol, Sao Paulo, SP, Brazil.
EM luis.andrade@unifesp.br
RI Carvalho, Karina IL/J-6789-2012; Andrade, Luis Eduardo C/D-1245-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Andrade, Luis Eduardo
   C/0000-0001-8742-9931; Araujo, Julio/0000-0001-6706-2589; Kallas,
   Esper/0000-0003-2026-6925
CR Balanescu P, 2010, Rom J Intern Med, V48, P255
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Chattopadhyay PK, 2006, NAT MED, V12, P972, DOI 10.1038/nm1371
   Cook RJ, 2000, J RHEUMATOL, V27, P1892
   Crispin JC, 2010, CURR OPIN RHEUMATOL, V22, P499, DOI 10.1097/BOR.0b013e32833c62b0
   De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372
   Dong GF, 2003, CHINESE MED J-PEKING, V116, P543
   Garrett-Sinha LA, 2008, CURR OPIN RHEUMATOL, V20, P519
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Henriques A, 2010, CELL IMMUNOL, V264, P97, DOI 10.1016/j.cellimm.2010.05.004
   Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
   Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107
   Kallas EG, 1999, J INFECT DIS, V179, P1124, DOI 10.1086/314702
   Lubberts E, 2008, CYTOKINE, V41, P84, DOI 10.1016/j.cyto.2007.09.014
   Ma JL, 2010, CLIN RHEUMATOL, V29, P1251, DOI 10.1007/s10067-010-1510-7
   Mesquita D, 2011, SCAND J RHEUMATOL, V40, P41, DOI 10.3109/03009742.2010.489229
   Mok MY, 2010, J RHEUMATOL, V37, P2046, DOI 10.3899/jrheum.100293
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Nakayamada S, 2012, CURR OPIN IMMUNOL, V24, P297, DOI 10.1016/j.coi.2012.01.014
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Prado C, 2011, RHEUMATOLOGY, V50, P1794, DOI 10.1093/rheumatology/ker227
   Shah K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2964
   Shin MS, 2011, CURR OPIN RHEUMATOL, V23, P444, DOI 10.1097/BOR.0b013e328349a255
   Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x
   Wong CK, 2008, CLIN IMMUNOL, V127, P385, DOI 10.1016/j.clim.2008.01.019
   Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703
   Wouters CHP, 2004, BRIT J DERMATOL, V150, P693, DOI 10.1111/j.0007-0963.2004.05883.x
   Yang J, 2011, RHEUMATOLOGY, V50, P1366, DOI 10.1093/rheumatology/ker116
   Yu JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P170, DOI 10.2741/2667
NR 31
TC 6
Z9 8
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0482-5004
J9 REV BRAS REUMATOL
JI Rev. Bras. Reumatol.
PD JAN-FEB
PY 2016
VL 56
IS 1
BP 28
EP 36
DI 10.1016/j.rbr.2015.08.008
PG 9
WC Rheumatology
SC Rheumatology
GA DK4NN
UT WOS:000374895300006
PM 27267331
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Freire, MD
   Rocha, V
   Rodrigues, CA
   Novis, YS
   Sabino, EC
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Freire, Marcos da Silva
   Rocha, Vanderson
   Rodrigues, Celso Arrais
   Novis, Yana Sarkis
   Sabino, Ester C.
   Kallas, Esper Georges
TI Persistence of Yellow Fever vaccine-induced antibodies after cord blood
   stem cell transplant
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE cord blood stem cell transplant; immunosuppression; vaccine; yellow
   fever
ID INFECTION; IMMUNITY; VIREMIA
AB We report the case of a cord blood haematopoietic stem cell transplant recipient who was vaccinated for Yellow Fever (YF) 7days before initiating chemotherapy and had persistent YF antibodies more than 3years after vaccination. Since the stem cell donor was never exposed to wild YF or to the YF vaccine, and our patient was not exposed to YF or revaccinated, this finding strongly suggests the persistence of recipient immunity. We briefly discuss potential consequences of incomplete elimination of recipient's leukocytes following existing haematopoietic cancer treatments.
C1 [Avelino-Silva, Vivian Iida; Sabino, Ester C.; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Rocha, Vanderson; Rodrigues, Celso Arrais; Novis, Yana Sarkis; Kallas, Esper Georges] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Freire, Marcos da Silva] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Sabino, Ester C.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Ave Dr Eneas de Carvalho Aguiar 470,Sala 6, BR-05403000 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; Sabino, Ester Cerdeira/F-7750-2010;
   Avelino-Silva, Vivian I/L-2640-2013
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Avelino-Silva VI, 2013, BONE MARROW TRANSPL, V48, P1008, DOI 10.1038/bmt.2012.277
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150
   Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP., 2008, YELLOW FEVER VACCINE, P1748
   Parkkali T, 1997, BONE MARROW TRANSPL, V19, P933, DOI 10.1038/sj.bmt.1700768
   Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Spoulou V, 2004, BONE MARROW TRANSPL, V33, P1187, DOI 10.1038/sj.bmt.1704476
NR 11
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PY 2016
VL 12
IS 4
BP 937
EP 938
DI 10.1080/21645515.2015.1112475
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA DN5RW
UT WOS:000377129200025
PM 26618995
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Yamamoto, ES
   Campos, BLS
   Jesus, JA
   Laurenti, MD
   Ribeiro, SP
   Kallas, EG
   Rafael-Fernandes, M
   Santos-Gomes, G
   Silva, MS
   Sessa, DP
   Lago, JHG
   Levy, D
   Passero, LFD
AF Yamamoto, Eduardo S.
   Campos, Bruno L. S.
   Jesus, Jessica A.
   Laurenti, Marcia D.
   Ribeiro, Susan P.
   Kallas, Esper G.
   Rafael-Fernandes, Mariana
   Santos-Gomes, Gabriela
   Silva, Marcelo S.
   Sessa, Deborah P.
   Lago, Joao H. G.
   Levy, Debora
   Passero, Luiz F. D.
TI The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is
   Related to Programed Cell Death and Presents Therapeutic Potential in
   Experimental Cutaneous Leishmaniasis
SO PLOS ONE
LA English
DT Article
ID VISCERAL LEISHMANIASIS; OLEANOLIC ACID; AMPHOTERICIN-B; IN-VITRO;
   ANTILEISHMANIAL ACTIVITY; DONOVANI PROMASTIGOTES; VIANNIA SHAWI;
   APOPTOSIS; DERIVATIVES; ACTIVATION
AB Among neglected tropical diseases, leishmaniasis is one of the most important ones, affecting more than 12 million people worldwide. The available treatments are not well tolerated, and present diverse side effects, justifying the search for new therapeutic compounds. In the present study, the activity of ursolic acid (UA) and oleanolic acid (OA) were assayed in experimental cutaneous leishmaniasis (in vitro and in vivo). Promastigote forms of L. amazonensis were incubated with OA and UA for 24h, and effective concentration 50% (EC50) was estimated. Ultraestructural alterations in Leishmania amazonensis promastigotes after UA treatment were evaluated by transmission electron microscopy, and the possible mode of action was assayed through Annexin V and propidium iodide staining, caspase 3/7 activity, DNA fragmentation and transmembrane mitochondrial potential. The UA potential was evaluated in intracellular amastigotes, and its therapeutic potential was evaluated in L. amazonensis infected BALB/c mice. UA eliminated L. amazonensis promastigotes with an EC50 of 6.4 mu g/mL, comparable with miltefosine, while OA presented only a marginal effect on promastigote forms at 100 mu g/mL. The possible mechanism by which promastigotes were eliminated by UA was programmed cell death, independent of caspase 3/7, but it was highly dependent on mitochondria activity. UA was not toxic for peritoneal macrophages from BALB/c mice, and it was able to eliminate intracellular amastigotes, associated with nitric oxide (NO) production. OA did not eliminate amastigotes nor trigger NO. L. amazonensis infected BALB/c mice submitted to UA treatment presented lesser lesion size and parasitism compared to control. This study showed, for the first time, that UA eliminate promastigote forms through a mechanism associated with programed cell death, and importantly, was effective in vivo. Therefore, UA can be considered an interesting candidate for future tests as a prototype drug for the treatment of cutaneous leishmaniasis.
C1 [Yamamoto, Eduardo S.; Campos, Bruno L. S.; Jesus, Jessica A.; Laurenti, Marcia D.; Passero, Luiz F. D.] Univ Sao Paulo, Lab Pathol Infect Dis LIM50, Dept Pathol, Sch Med, BR-01246903 Sao Paulo, SP, Brazil.
   [Ribeiro, Susan P.; Kallas, Esper G.] Univ Sao Paulo, Lab Clin Immunol & Allergy LIM60, Sch Med, BR-01246903 Sao Paulo, SP, Brazil.
   [Rafael-Fernandes, Mariana; Santos-Gomes, Gabriela; Silva, Marcelo S.] Univ Nova Lisboa, Global Hlth & Trop Med, IHMT, P-1349008 Lisbon, Portugal.
   [Sessa, Deborah P.; Lago, Joao H. G.] Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, BR-09920000 Diadema, SP, Brazil.
   [Levy, Debora] Univ Sao Paulo, Lab Genet & Mol Hematol LIM31, Sch Med, BR-01246903 Sao Paulo, SP, Brazil.
   [Ribeiro, Susan P.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
RP Passero, LFD (corresponding author), Univ Sao Paulo, Lab Pathol Infect Dis LIM50, Dept Pathol, Sch Med, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM felipepassero@yahoo.com.br
RI Lago, Joao/W-5238-2019; Santos-Gomes, Gabriela/I-2391-2012;
   Santos-Gomes, G/J-2367-2019; Passero, Luiz Felipe/B-9549-2012; Laurenti,
   Marcia Dalastra/C-4734-2012; Levy, Debora/G-8208-2014
OI Lago, Joao/0000-0002-1193-8374; Santos-Gomes, G/0000-0001-9264-3887;
   Passero, Luiz Felipe/0000-0002-5986-6381; Kallas,
   Esper/0000-0003-2026-6925; Yamamoto, Eduardo/0000-0003-2375-6081;
   Rafael-Fernandes, Mariana/0000-0002-5214-7667; Levy,
   Debora/0000-0001-7492-997X; Laurenti, Marcia
   Dalastra/0000-0002-1080-2440
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2012/03903-9, 2013/16297-2]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, grants: 2012/03903-9 and 2013/16297-2. URL:
   http://fapesp.br/en/.
CR Alvarado HL, 2015, COLLOID SURFACE B, V130, P40, DOI 10.1016/j.colsurfb.2015.03.062
   Ashutosh, 2007, J MED MICROBIOL, V56, P143, DOI 10.1099/jmm.0.46841-0
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Begum S, 2014, CHEM BIODIVERS, V11, P709, DOI 10.1002/cbdv.201300151
   BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/j.1469-8137.1994.tb02968.x
   Bero J, 2011, J ETHNOPHARMACOL, V137, P998, DOI 10.1016/j.jep.2011.07.022
   Both DM, 2002, ARCH DERMATOL RES, V293, P569, DOI 10.1007/s00403-001-0272-0
   Camargos HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104429
   Campos BLS, 2015, PARASITE IMMUNOL, V37, P407, DOI 10.1111/pim.12206
   Carneiro MB, 2015, IFN GAMMA DEPENDENT
   Chattopadhyay A, 2011, BIOCHEM BIOPH RES CO, V416, P7, DOI 10.1016/j.bbrc.2011.11.023
   da Luz RAI, 2011, J ANTIMICROB CHEMOTH, V66, P350, DOI 10.1093/jac/dkq444
   da Silva AA, 2009, FITOTERAPIA, V80, P478, DOI 10.1016/j.fitote.2009.06.007
   Das M, 2001, J CELL SCI, V114, P2461
   Das R, 2008, APOPTOSIS, V13, P867, DOI 10.1007/s10495-008-0224-7
   Decuypere S, 2005, ANTIMICROB AGENTS CH, V49, P4616, DOI 10.1128/AAC.49.11.4616-4621.2005
   Demicheli C, 2008, CHEM COMMUN, P4828, DOI 10.1039/b809186b
   Passero LFD, 2014, CURR CLIN PHARMACOL, V9, P187, DOI 10.2174/1574884709999140606161413
   Passero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
   Dutta A, 2007, J MED MICROBIOL, V56, P1196, DOI 10.1099/jmm.0.47114-0
   Serna ME, 2015, PARASITOL INT, V64, P295, DOI 10.1016/j.parint.2015.03.005
   Franca F, 1996, Rev Soc Bras Med Trop, V29, P229, DOI 10.1590/S0037-86821996000300002
   Freitas-Junior LH, 2012, INT J PARASITOL-DRUG, V2, P11, DOI 10.1016/j.ijpddr.2012.01.003
   Gachet MS, 2010, J ETHNOPHARMACOL, V128, P184, DOI 10.1016/j.jep.2010.01.007
   Germonprez N, 2005, J MED CHEM, V48, P32, DOI 10.1021/jm031150y
   Giovannini C, 2002, FEBS LETT, V523, P200, DOI 10.1016/S0014-5793(02)02972-1
   Gnoatto SCB, 2008, J ENZYM INHIB MED CH, V23, P604, DOI 10.1080/14756360802204870 
   Hill RA, 2012, NAT PROD REP, V29, P780, DOI 10.1039/c2np20027a
   Jesus J. A., 2015, EVID-BASED COMPL ALT, V2015, DOI DOI 10.1155/2015/62047225793002
   Johann S, 2012, MED MYCOL, V50, P843, DOI 10.3109/13693786.2012.678903
   Kontogianni VG, 2009, ANAL CHIM ACTA, V635, P188, DOI 10.1016/j.aca.2009.01.021
   Laniado-Laborin R, 2009, REV IBEROAM MICOL, V26, P223, DOI 10.1016/j.riam.2009.06.003
   Laurenti MD, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/134236
   Lin XR, 2014, FOOD FUNCT, V5, P1175, DOI 10.1039/c3fo60720h
   Liu J, 1995, J ETHNOPHARMACOL, V49, P57, DOI 10.1016/0378-8741(95)90032-2
   Machado M, 2012, EXP PARASITOL, V130, P223, DOI 10.1016/j.exppara.2011.12.012
   Maes L, 2004, ANTIMICROB AGENTS CH, V48, P2056, DOI 10.1128/AAC.48.6.2056-2060.2004
   Mehta A, 2004, J BIOL CHEM, V279, P11798, DOI 10.1074/jbc.M309341200
   Neto RLM, 2011, EXP PARASITOL, V127, P215, DOI 10.1016/j.exppara.2010.07.020
   Nam H, 2013, FOOD CHEM TOXICOL, V62, P579, DOI 10.1016/j.fct.2013.09.024
   Oldfield E, 2012, ANGEW CHEM INT EDIT, V51, P1124, DOI 10.1002/anie.201103110
   Ovesna Z, 2006, MUTAT RES-FUND MOL M, V600, P131, DOI 10.1016/j.mrfmmm.2006.03.008
   Passero LFD, 2015, PARASITOL INT, V64, P32, DOI 10.1016/j.parint.2015.01.006
   Passero LFD, 2011, PARASITOL RES, V108, P529, DOI 10.1007/s00436-010-2091-8
   Rath S, 2003, QUIM NOVA, V26, P550, DOI 10.1590/S0100-40422003000400018
   Rego FD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122038
   Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6
   Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8
   Santos DO, 2008, PARASITOL RES, V103, P1, DOI 10.1007/s00436-008-0943-2
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Seebacher W, 2003, MAGN RESON CHEM, V41, P636, DOI 10.1002/mrc.1214
   Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200
   Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121
   Tan N, 2002, PHYTOCHEMISTRY, V61, P881, DOI 10.1016/S0031-9422(02)00361-8
   Thakur CP, 1999, T ROY SOC TROP MED H, V93, P319, DOI 10.1016/S0035-9203(99)90037-8
   Torrado JJ, 2008, J PHARM SCI-US, V97, P2405, DOI 10.1002/jps.21179
   Torres-Santos EC, 2004, PHYTOMEDICINE, V11, P114, DOI 10.1078/0944-7113-00381
   Wang X, 2013, CARCINOGENESIS, V34, P1323, DOI 10.1093/carcin/bgt058
   Yamamoto ES, 2014, PARASITOL RES, V113, P333, DOI 10.1007/s00436-013-3659-x
   Yang L, 2010, CANCER LETT, V298, P128, DOI 10.1016/j.canlet.2010.06.010
   You HJ, 2001, FEBS LETT, V509, P156, DOI 10.1016/S0014-5793(01)03161-1
   Zeng JW, 2015, MOL MED REP, V12, P1997, DOI 10.3892/mmr.2015.3666
NR 62
TC 26
Z9 26
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2015
VL 10
IS 12
AR e0144946
DI 10.1371/journal.pone.0144946
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY9JH
UT WOS:000366722700076
PM 26674781
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Weiskopf, D
   Cerpas, C
   Angelo, MA
   Bangs, DJ
   Sidney, J
   Paul, S
   Peters, B
   Sanches, FP
   Silvera, CGT
   Costa, PR
   Kallas, EG
   Gresh, L
   de Silva, AD
   Balmaseda, A
   Harris, E
   Sette, A
AF Weiskopf, Daniela
   Cerpas, Cristhiam
   Angelo, Michael A.
   Bangs, Derek J.
   Sidney, John
   Paul, Sinu
   Peters, Bjoern
   Sanches, Francoise P.
   Silvera, Cassia G. T.
   Costa, Priscilla R.
   Kallas, Esper G.
   Gresh, Lionel
   de Silva, Aruna D.
   Balmaseda, Angel
   Harris, Eva
   Sette, Alessandro
TI Human CD8(+) T-Cell Responses Against the 4 Dengue Virus Serotypes Are
   Associated With Distinct Patterns of Protein Targets
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE dengue virus; serotype specific; CD8(+) T cells; Nicaragua; Sri Lanka;
   Brazil
ID CLASS-I SUPERTYPES; SECONDARY INFECTION; PROTECTIVE ROLE; VACCINE;
   INHIBITION; NICARAGUA; EPIDEMIC; EFFICACY
AB Background. All 4 dengue virus (DENV) serotypes are now simultaneously circulating worldwide and responsible for up to 400 million human infections each year. Previous studies of CD8(+) T-cell responses in HLA-transgenic mice and human vaccinees demonstrated that the hierarchy of immunodominance among structural versus nonstructural proteins differs as a function of the infecting serotype. This led to the hypothesis that there are intrinsic differences in the serotype-specific reactivity of CD8+ T-cell responses.
   Methods. We tested this hypothesis by analyzing serotype-specific CD8(+) T-cell reactivity in naturally infected human donors from Sri Lanka and Nicaragua, using ex vivo interferon.-specific enzyme-linked immunosorbent spot assays.
   Results. Remarkably similar and clear serotype-specific patterns of immunodominance in both cohorts were identified. Pooling of epitopes that accounted for 90% of the interferon. response in both cohorts resulted in a global epitope pool. Its reactivity was confirmed in naturally infected donors from Brazil, demonstrating its global applicability.
   Conclusions. This study provides new insight into differential serotype-specific immunogenicity of DENV proteins. It further provides a potentially valuable tool for future investigations of CD8+ T-cell responses in the typically small sample volumes available from patients with acute fever and children without requiring prior knowledge of either infecting DENV serotype or HLA type.
C1 [Weiskopf, Daniela; Angelo, Michael A.; Bangs, Derek J.; Sidney, John; Paul, Sinu; Peters, Bjoern; de Silva, Aruna D.; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Ctr Nacl Diagnost & Referencia, Lab Nacl Virol, Minist Salud, Mexico City, DF, Mexico.
   [Gresh, Lionel] Sustainable Sci Inst, Managua, Nicaragua.
   [Sanches, Francoise P.; Silvera, Cassia G. T.; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy LIM 60, BR-05508 Sao Paulo, Brazil.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
RP Weiskopf, D (corresponding author), La Jolla Inst Allergy & Immunol, 9420 Athena Cir, La Jolla, CA 92037 USA.
EM daniela@lji.org
OI Weiskopf, Daniela/0000-0003-2968-7371; Gresh,
   Lionel/0000-0002-2333-1748; Kallas, Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900042C,
   HHSN27220140045C]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq) [458713/2014 7]; Brazilian Ministry of Science, Technology, and
   Innovation; Fundo Nacional de Saude, Brazilian Ministry of Health
   [777588/2012]
FX This work was supported by the National Institutes of Health
   (contractsHHSN272200900042C and HHSN27220140045C to A. S.); the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (grant 458713/2014
   7 to E. G. K.); and the Brazilian Ministry of Science, Technology, and
   Innovation and the Fundo Nacional de Saude (grant 777588/2012),
   Brazilian Ministry of Health.
CR Balmaseda A, 2010, J INFECT DIS, V201, P5, DOI 10.1086/648592
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   KOURI G, 1991, REV I MED TROP, V33, P365, DOI 10.1590/S0036-46651991000500005
   Mateo R, 2013, J VIROL, V87, P1312, DOI 10.1128/JVI.02177-12
   Mattia K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027252
   Montoya M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002357
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Weiskopf D, 2011, J IMMUNOL, V187, P4268, DOI 10.4049/jimmunol.1101970
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zompi S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001568
NR 30
TC 69
Z9 69
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2015
VL 212
IS 11
BP 1743
EP 1751
DI 10.1093/infdis/jiv289
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DB7BN
UT WOS:000368669500009
PM 25980035
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Deutsch, MB
   Glidden, DV
   Sevelius, J
   Keatley, J
   McMahan, V
   Guanira, J
   Kallas, EG
   Chariyalertsak, S
   Grant, RM
AF Deutsch, Madeline B.
   Glidden, David V.
   Sevelius, Jae
   Keatley, Joanne
   McMahan, Vanessa
   Guanira, Juan
   Kallas, Esper G.
   Chariyalertsak, Suwat
   Grant, Robert M.
CA IPrEx Investigators
TI HIV pre-exposure prophylaxis in transgender women: a subgroup analysis
   of the iPrEx trial
SO LANCET HIV
LA English
DT Article
ID DISOPROXIL FUMARATE; RISK; PREVENTION; TENOFOVIR; SEX; PHARMACOKINETICS;
   CONTRACEPTIVES; FACILITATORS; COLLECTION; INFECTION
AB Background Pre-exposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sexual acquisition of HIV in groups at high risk such as transgender women. We used data from the iPrEx study to assess PrEP efficacy, effectiveness, and adherence in transgender women.
   Methods The iPrEx trial was a randomised controlled trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in men who have sex with men (MSM) and transgender women, followed by an open-label extension. Drug concentrations were measured in blood by liquid chromatography and tandem mass spectroscopy. We did unplanned exploratory analyses to investigate differences in PrEP outcomes among transgender women and between transgender women and MSM.
   Findings Of the 2499 participants enrolled in the randomised controlled trial, 29 (1%) identified as women, 296 (12%) identified as trans, 14 (1%) identified as men but reported use of feminising hormones, such that 339 (14%) reported one or more characteristics and are classified as transgender women for the purpose of this study. Compared with MSM, transgender women more frequently reported transactional sex, receptive anal intercourse without a condom, or more than five partners in the past 3 months. Among transgender women, there were 11 HIV infections in the PrEP group and ten in the placebo group (hazard ratio 1.1, 95% CI 0.5-2.7). In the PrEP group, drug was detected in none of the transgender women at the seroconversion visit, six (18%) of 33 seronegative transgender women (p= 0 .31), and 58 (52%) of 111 seronegative MSM (p< 0.0001). PrEP use was not linked to behavioural indicators of HIV risk among transgender women, whereas MSM at highest risk were more adherent.
   Interpretation PrEP seems to be effective in preventing HIV acquisition in transgender women when taken, but there seem to be barriers to adherence, particularly among those at the most risk. Studies of PrEP use in transgender women populations should be designed and tailored specifically for this population, rather than adapted from or subsumed into studies of MSM.
C1 [Deutsch, Madeline B.; Glidden, David V.; Sevelius, Jae; Keatley, Joanne; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94115 USA.
   [McMahan, Vanessa; Grant, Robert M.] Gladstone Inst, San Francisco, CA USA.
   [Guanira, Juan] INMENSA, Lima, Peru.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Chariyalertsak, Suwat] Chiang Mai Univ, RIHES, Chiang Mai 50000, Thailand.
   [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA.
RP Grant, RM (corresponding author), Gladstone UCSF, 1650 Owens St, San Francisco, CA 94158 USA.
EM Madeline.Deutsch@ucsf.edu; Robert.Grant@ucsf.edu
RI Trajman, Anete/C-7679-2016; Sevelius, Jae/AAG-2404-2020; Glidden,
   David/AAD-4730-2020
OI Trajman, Anete/0000-0002-4000-4984; Grant, Robert/0000-0002-0851-7085;
   Guanira, Juan/0000-0002-2746-3086; BEKKER,
   LINDA-GAIL/0000-0002-0755-4386; Glidden, David/0000-0001-5888-1419;
   Amico, K Rivet/0000-0002-4458-6934; Kallas, Esper/0000-0003-2026-6925
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; Bill & Melinda
   Gates FoundationBill & Melinda Gates Foundation; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI118575,
   R01AI062333, UM1AI069399, R01AI062333, U01AI064002, U01AI064002,
   R01AI062333, R01AI062333, U01AI064002, UM1AI069399, U01AI064002,
   R01AI118575, U01AI064002, UM1AI069399, U01AI064002, UM1AI069399,
   R01AI062333, U01AI064002, UM1AI069399, R01AI062333, UM1AI069399,
   R01AI062333, R01AI118575, UM1AI069399, U01AI064002, R01AI118575,
   U01AI064002, R01AI118575, R01AI118575, R01AI062333, UM1AI069399] Funding
   Source: NIH RePORTER
FX US National Institutes of Health and the Bill & Melinda Gates
   Foundation.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Cahill S, 2014, LGBT HEALTH, V1, P157, DOI 10.1089/lgbt.2014.0033
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Centers for Disease Control and Prevention, 2012, HIV TEST CDC FUND SI
   Conron KJ, 2012, AM J PUBLIC HEALTH, V102, P118, DOI 10.2105/AJPH.2011.300315
   Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158
   Deutsch MB, 2014, J ASSOC NURSE AIDS C, V25, P657, DOI 10.1016/j.jana.2014.04.001
   Escudero DJ, 2015, AIDS CARE, V27, P637, DOI 10.1080/09540121.2014.986051
   Golub SA, 2014, AIDS BEHAV, V18, P1686, DOI 10.1007/s10461-014-0770-7
   Golub SA, 2013, AIDS PATIENT CARE ST, V27, P248, DOI 10.1089/apc.2012.0419
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hayer-Zillgen M, 2002, BRIT J PHARMACOL, V136, P829, DOI 10.1038/sj.bjp.0704785
   Heffron R, 2014, AIDS, V28, P2771, DOI 10.1097/QAD.0000000000000493
   Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X
   Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018
   Herbst JH, 2008, AIDS BEHAV, V12, P1, DOI 10.1007/s10461-007-9299-3
   Kearney BP, 2009, PHARMACOTHERAPY, V29, P924, DOI 10.1592/phco.29.8.924
   Kuba S, 2013, INT MULTICULTURALISM, P109
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Melendez RM, 2009, J ASSOC NURSE AIDS C, V20, P387, DOI 10.1016/j.jana.2009.06.002
   Minuesa G, 2009, J PHARMACOL EXP THER, V329, P252, DOI 10.1124/jpet.108.146225
   Murnane PM, 2014, AIDS, V28, P1825, DOI 10.1097/QAD.0000000000000290
   Operario D, 2010, JAIDS-J ACQ IMM DEF, V55, pS91, DOI 10.1097/QAI.0b013e3181fbc9ec
   Poteat T, 2015, LANCET, V385, P274, DOI 10.1016/S0140-6736(14)60833-3
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Sevelius J, 2015, 10 INT C HIV TREATM
   Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8
   Sevelius JM, 2013, SEX ROLES, V68, P675, DOI 10.1007/s11199-012-0216-5
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Stanczyk FZ, 2013, CONTRACEPTION, V87, P706, DOI 10.1016/j.contraception.2012.12.011
   USPHS-CDC, PREEXP PROPH PREV HI
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   WHO, 2012, WHO GUID PREEXP OR P
NR 36
TC 122
Z9 122
U1 2
U2 23
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD DEC
PY 2015
VL 2
IS 12
BP E512
EP E519
DI 10.1016/S2352-3018(15)00206-4
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DB1IZ
UT WOS:000368263200007
PM 26614965
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Carpenter, C
   Sidney, J
   Kolla, R
   Nayak, K
   Tomiyama, H
   Tomiyama, C
   Padilla, OA
   Rozot, V
   Ahamed, SF
   Ponte, C
   Rolla, V
   Antas, PR
   Chandele, A
   Kenneth, J
   Laxmi, S
   Makgotlho, E
   Vanini, V
   Ippolito, G
   Kazanova, AS
   Panteleev, AV
   Hanekom, W
   Mayanja-Kizza, H
   Lewinsohn, D
   Saito, M
   McElrath, MJ
   Boom, WH
   Goletti, D
   Gilman, R
   Lyadova, IV
   Scriba, TJ
   Kallas, EG
   Murali-Krishna, K
   Sette, A
   Arlehamn, CSL
AF Carpenter, Chelsea
   Sidney, John
   Kolla, Ravi
   Nayak, Kaustuv
   Tomiyama, Helena
   Tomiyama, Claudia
   Padilla, Oscar A.
   Rozot, Virginie
   Ahamed, Syed F.
   Ponte, Carlos
   Rolla, Valeria
   Antas, Paulo R.
   Chandele, Anmol
   Kenneth, John
   Laxmi, Seetha
   Makgotlho, Edward
   Vanini, Valentina
   Ippolito, Giuseppe
   Kazanova, Alexandra S.
   Panteleev, Alexander V.
   Hanekom, Willem
   Mayanja-Kizza, Harriet
   Lewinsohn, David
   Saito, Mayuko
   McElrath, M. Juliana
   Boom, W. Henry
   Goletti, Delia
   Gilman, Robert
   Lyadova, Irina V.
   Scriba, Thomas J.
   Kallas, Esper G.
   Murali-Krishna, Kaja
   Sette, Alessandro
   Arlehamn, Cecilia S. Lindestam
TI A side-by-side comparison of T cell reactivity to fifty-nine
   Mycobacterium tuberculosis antigens in diverse populations from five
   continents
SO TUBERCULOSIS
LA English
DT Article
DE Tuberculosis; T cell antigen; Vaccine; CD4
ID LATENT TUBERCULOSIS; VACCINE STRAIN; BCG VACCINE; IMMUNOGENICITY;
   PROTECTION; RESPONSES; M72/AS01; MTB72F/AS02A; EPITOPES; IMMUNITY
AB We compared T cell recognition of 59 prevalently recognized Mycobacterium tuberculosis (MTB) antigens in individuals latently infected with MTB (LTBI), and uninfected individuals with previous BCG vaccination, from nine locations and populations with different HLA distribution, MTB exposure rates, and standards of TB care. This comparison revealed similar response magnitudes in diverse LTBI and BCG-vaccinated cohorts and significant correlation between responses in LTBIs from the USA and other locations. Many antigens were uniformly recognized, suggesting suitability for inclusion in vaccines targeting diverse populations. Several antigens were similarly immunodominant in LTBI and BCG cohorts, suggesting applicability for vaccines aimed at boosting BCG responses. The panel of MTB antigens will be valuable for characterizing MTB-specific CD4 T cell responses irrespective of ethnicity, infecting MTB strains and BCG vaccination status. Our results illustrate how a comparative analysis can provide insight into the relative immunogenicity of existing and novel vaccine candidates in LTBIs. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Carpenter, Chelsea; Sidney, John; Kolla, Ravi; Sette, Alessandro; Arlehamn, Cecilia S. Lindestam] La Jolla Inst Allergy & Immunol, Dept Vaccine Discovery, La Jolla, CA 92037 USA.
   [Nayak, Kaustuv; Chandele, Anmol; Murali-Krishna, Kaja] Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr, New Delhi 110067, India.
   [Tomiyama, Helena; Tomiyama, Claudia; Padilla, Oscar A.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Rozot, Virginie; Makgotlho, Edward; Hanekom, Willem; Scriba, Thomas J.] Univ Cape Town, South African TB Vaccine Initiat, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Rozot, Virginie; Makgotlho, Edward; Hanekom, Willem; Scriba, Thomas J.] Univ Cape Town, Dept Pediat & Child Hlth, ZA-7925 Cape Town, South Africa.
   [Ahamed, Syed F.; Kenneth, John] St Johns Natl Acad Sci, St Johns Res Inst, Div Infect Dis, Bangaluru 560034, Karnataka, India.
   [Ponte, Carlos; Rolla, Valeria; Antas, Paulo R.] Fiocruz MS, Inst Oswaldo Cruz, Clin Immunol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Laxmi, Seetha] St Johns Natl Acad Hlth Sci, St Johns Med Coll Hosp, Dept Transfus Med & Immunohematol, Bangaluru 560034, Karnataka, India.
   [Vanini, Valentina; Ippolito, Giuseppe; Goletti, Delia] Natl Inst Infect Dis, Dept Epidemiol & Preclin Res, Translat Res Unit, Rome, Italy.
   [Kazanova, Alexandra S.; Panteleev, Alexander V.; Lyadova, Irina V.] Cent TB Res Inst, Fed State Budgetary Sci Inst, Dept Immunol, Moscow, Russia.
   [Mayanja-Kizza, Harriet] Makerere Univ, Fac Med, Coll Hlth Sci, Dept Med, Kampala, Uganda.
   [Lewinsohn, David] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
   [Saito, Mayuko; Gilman, Robert] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Saito, Mayuko; Gilman, Robert] Univ Peruana Caytano Hereida, Lima, Peru.
   [Saito, Mayuko] Tohoku Univ, Dept Virol, Sendai, Miyagi 980, Japan.
   [McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.
   [Boom, W. Henry] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA.
   [Murali-Krishna, Kaja] Emory Vaccine Ctr, Atlanta, GA 30329 USA.
   [Murali-Krishna, Kaja] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
RP Arlehamn, CSL (corresponding author), La Jolla Inst Allergy & Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.
EM cecilia@lji.org
RI Mayanja-Kizza, Harriet/AAM-5372-2020; Vanini, Valentina/K-4475-2016;
   Scriba, Thomas/AAH-9413-2020; Saito, Mayuko/J-4508-2018; Rozot,
   Virginie/AAR-7789-2020; Kazanova, Alexandra/H-4602-2014; Ippolito,
   Giuseppe/J-7207-2017; ANTAS, PRZ/AAF-6021-2019; goletti,
   delia/AAM-6577-2020; Lyadova, Irina V/T-7806-2017; Lewinsohn,
   David/I-4936-2013
OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Vanini,
   Valentina/0000-0001-8476-964X; Scriba, Thomas/0000-0002-0641-1359;
   Saito, Mayuko/0000-0003-4622-7027; Rozot, Virginie/0000-0001-9757-1501;
   Lyadova, Irina V/0000-0003-3147-5386; Ippolito,
   Giuseppe/0000-0002-1076-2979; Lewinsohn, David/0000-0001-9906-9494;
   Kallas, Esper/0000-0003-2026-6925; Lindestam Arlehamn,
   Cecilia/0000-0001-7302-8002; Hanekom, Willem/0000-0003-3070-6154; Nayak,
   Kaustuv/0000-0002-7898-0294
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900044C,
   HHSN266200700022C/NO1-AI-70022, R37AI052731]; IOC/FIOCRUZ [CNPq research
   fellowship] [PQ-2-Brazil]; Italian Ministry of Health [Ricerca
   Corrente]Ministry of Health, Italy; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation [OPP1066265]; HIV Vaccine
   Trials Network [RAMP scholarship]; Russian Science FoundationRussian
   Science Foundation (RSF) [15-15-00136]; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37AI052731, UM1AI068614,
   R37AI052731, UM1AI068618, UM1AI068618, UM1AI068614, UM1AI068614,
   R37AI052731, UM1AI068618, UM1AI068618, R37AI052731, R37AI052731,
   UM1AI068614, R37AI052731, UM1AI068618, UM1AI068618, UM1AI068618,
   UM1AI068618, UM1AI068614, R37AI052731, R37AI052731, UM1AI068618,
   UM1AI068614, R37AI052731, UM1AI068614, R37AI052731, UM1AI068614,
   UM1AI068614] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health [contract
   HHSN272200900044C to A.S., contract HHSN266200700022C/NO1-AI- 70022 to
   W.H.B, grant R37AI052731 to E.G.K]: the IOC/FIOCRUZ [CNPq research
   fellowship PQ-2-Brazil to P.R.A.]: The Italian Ministry of Health
   [Ricerca Corrente to D.G.], the Bill and Melinda Gates Foundation
   [OPP1066265 to T.J.S.], and the HIV Vaccine Trials Network [RAMP
   scholarship to O.A.P.], the Russian Science Foundation [15-15-00136 to
   I.V.L.]. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   Andersen P, 2007, TRENDS MOL MED, V13, P175, DOI 10.1016/j.molmed.2007.03.004
   Andrews JR, 2012, CLIN INFECT DIS, V54, P784, DOI 10.1093/cid/cir951
   Arlehamn CSL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018465
   Arlehamn CSL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003130
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236
   Behr MA, 1999, VACCINE, V17, P915, DOI 10.1016/S0264-410X(98)00277-1
   Black GF, 2009, CLIN VACCINE IMMUNOL, V16, P1203, DOI 10.1128/CVI.00111-09
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590
   Commandeur S, 2013, J IMMUNOL, V190, P1659, DOI 10.4049/jimmunol.1201593
   COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8
   Copin R, 2014, VACCINE, V32, P5998, DOI 10.1016/j.vaccine.2014.07.113
   Coscolla M, 2014, SEMIN IMMUNOL, V26, P431, DOI 10.1016/j.smim.2014.09.012
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   Day CL, 2013, AM J RESP CRIT CARE, V188, P492, DOI 10.1164/rccm.201208-1385OC
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Gey van Pittius NC, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-95
   Goletti D, 2010, EUR RESPIR J, V36, P135, DOI 10.1183/09031936.00140009
   Gorak-Stolinska P, 2006, VACCINE, V24, P5726, DOI 10.1016/j.vaccine.2006.04.037
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996
   Idoko OT, 2014, TUBERCULOSIS, V94, P564, DOI 10.1016/j.tube.2014.07.001
   Karp CL, 2015, IMMUNOL REV, V264, P363, DOI 10.1111/imr.12270
   Kaufmann SHE, 2000, NAT MED, V6, P955, DOI 10.1038/79631
   Kaufmann SHE, 2013, SEMIN IMMUNOL, V25, P172, DOI 10.1016/j.smim.2013.04.006
   Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5
   Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035
   Lew JM, 2011, TUBERCULOSIS, V91, P1, DOI 10.1016/j.tube.2010.09.008
   Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018
   McKinney DM, 2013, IMMUNOGENETICS, V65, P357, DOI 10.1007/s00251-013-0684-y
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Montoya J, 2013, J CLIN IMMUNOL, V33, P1360, DOI 10.1007/s10875-013-9949-3
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Reed SG, 2009, P NATL ACAD SCI USA, V106, P2301, DOI 10.1073/pnas.0712077106
   Ritz N, 2008, FEMS MICROBIOL REV, V32, P821, DOI 10.1111/j.1574-6976.2008.00118.x
   Schuck SD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005590
   Scriba TJ, 2011, J INFECT DIS, V203, P1832, DOI 10.1093/infdis/jir195
   Shi L, 2004, INFECT IMMUN, V72, P2420, DOI 10.1128/IAI.72.4.2420-2424.2004
   Spertini F, 2013, TUBERCULOSIS, V93, P179, DOI 10.1016/j.tube.2012.10.011
   Sutherland JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074080
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Vijayalakshmi V, 1995, Indian Pediatr, V32, P979
   Von Eschen K, 2009, HUM VACCINES, V5, P475, DOI 10.4161/hv.8570
   Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 50
TC 19
Z9 19
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PD DEC
PY 2015
VL 95
IS 6
BP 713
EP 721
DI 10.1016/j.tube.2015.07.001
PG 9
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA CX3UZ
UT WOS:000365626300012
PM 26277695
OA Green Accepted, Bronze
DA 2020-11-26
ER

PT J
AU Pilcher, CD
   Bisol, CA
   Paganella, MP
   Vallabhaneni, S
   da Motta, LR
   Kato, SK
   Sperhacke, RD
   Kallas, EG
   Hecht, FM
   Diaz, RS
AF Pilcher, Christopher D.
   Bisol, Claudia Alquati
   Paganella, Machline Paim
   Vallabhaneni, Snigdha
   da Motta, Leonardo Rapone
   Kato, Sergio Kakuta
   Sperhacke, Rosa Dea
   Kallas, Esper G.
   Hecht, Frederick M.
   Diaz, Ricardo Sobhie
TI Efficient Identification of HIV Serodiscordant Couples by Existing HIV
   Testing Programs in South Brazil
SO PLOS ONE
LA English
DT Article
ID DISCORDANT COUPLES; TRANSMISSION; PREVENTION; INFECTION
AB Objective
   To examine the feasibility of identifying HIV negative at risk individuals in HIV serodiscordant couples, during voluntary HIV testing in South Brazil.
   Methods
   We surveyed HIV testers at 4 public testing sites in Rio Grande do Sul. We obtained information on risk behaviors and sexual partnerships. HIV testing and testing for recent infection were performed; HIV prevalence and risk behaviors were assessed among subjects who reported having a steady partner who was HIV positive (serodiscordant group) and compared with the general testing population.
   Results
   Among 3100 patients, 490 (15.8%) reported being in a steady relationship with an HIV positive partner. New HIV infections were diagnosed in 23% of the serodiscordant group (vs. 13% in the general population, p = 0.01); among newly positive subjects, recent HIV infections were more frequent (23/86, 26.7%) among testers with positive partners than among the general testing group (52/334; 15.6%; p = 0.016). Less than half of the serodiscordant testers reported having used a condom during the last sexual intercourse with their HIV-positive partner. Participants with inconsistent condom use with steady partner were four times more likely to test positive for HIV compared to those who reported always using condoms with the steady partner (OR: 4.2; 95% CI: 2.3 to 7.5).
   Conclusion
   It is highly feasible to identify large numbers of HIV susceptible individuals who are in HIV serodiscordant relationships in South Brazil testing sites. Condom use within HIV serodiscordant couples is low in this setting, suggesting urgent need for biomedical prevention strategies to reduce HIV transmission.
C1 [Pilcher, Christopher D.; Vallabhaneni, Snigdha; Hecht, Frederick M.] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
   [Bisol, Claudia Alquati; Paganella, Machline Paim; da Motta, Leonardo Rapone; Kato, Sergio Kakuta; Sperhacke, Rosa Dea] Univ Caxias Sul, Ctr Ciencias Biol & Saude, Lab Pesquisa HIV AIDS, Caxias Do Sul, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Diaz, Ricardo Sobhie] Univ Fed Sao Paulo, Paulista Sch Med, Retrovirl Lab, Sao Paulo, Brazil.
RP Pilcher, CD (corresponding author), Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA 94143 USA.
EM Chris.Pilcher@ucsf.edu
RI Motta, Leonardo R./I-8657-2019
OI Motta, Leonardo R./0000-0003-3673-2687; KAKUTA KATO,
   SERGIO/0000-0002-7180-3121; Kallas, Esper/0000-0003-2026-6925; Hecht,
   Frederick/0000-0002-5782-1171
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 MH0686, P01
   AI071713, R03 AI064037]; STD/Aids Department [AB/BRA/03/H34 (TC
   281/07)]; United Nations Office on Drugs and Crime (UNODC)
   [AB/BRA/03/H34 (TC 281/07)]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P01AI071713,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R03AI064037, P01AI071713, P01AI071713, P01AI071713,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P01AI071713,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R03AI064037, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R03AI064037, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P01AI071713,
   P30AI027763, P01AI071713, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, T32MH019105,
   T32MH019105, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, T32MH019105, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, T32MH019105,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, T32MH019105,
   T32MH019105, T32MH019105, P30MH062246, P30MH062246, T32MH019105,
   P30MH062246, T32MH019105, T32MH019105, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, T32MH019105, P30MH062246, P30MH062246, T32MH019105,
   T32MH019105, T32MH019105, P30MH062246, T32MH019105, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, T32MH019105, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, T32MH019105, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   T32MH019105, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH RePORTER
FX Sources of Funding: National Institutes of Health (R01 MH0686 (Pilcher);
   P01 AI071713 (Hecht); and R03 AI064037 (de Souza)). Cooperation Project
   AB/BRA/03/H34 (TC 281/07) between the STD/Aids Department and The United
   Nations Office on Drugs and Crime (UNODC). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Coburn BJ, 2012, AIDS, V26, P1969, DOI 10.1097/QAD.0b013e328357f783
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   de Amorim CM, 2008, CIENC SAUDE COLETIVA, V13, P1859, DOI 10.1590/S1413-81232008000600021
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Ministerio da Saude, 1998, AC DST HIV AIDS DIR
   Parekh BS, 2011, AIDS RES HUM RETROV, V27, P265, DOI 10.1089/aid.2010.0159
   Pilcher CD, 2005, NEW ENGL J MED, V352, P1873, DOI 10.1056/NEJMoa042291
   Reis RK, 2009, REV ESC ENFERM USP, V43, P662, DOI 10.1590/S0080-62342009000300023
   Rosenberg NE, 2013, JAIDS-J ACQ IMM DEF, V62, P226, DOI 10.1097/QAI.0b013e31827971ca
   Valdiserri RO, 2012, PUBLIC HEALTH REP, V127, P563, DOI 10.1177/003335491212700605
   Wawer MJ, 2009, LANCET, V374, P229, DOI 10.1016/S0140-6736(09)60998-3
   Westreich DJ, 2008, J CLIN MICROBIOL, V46, P1785, DOI 10.1128/JCM.00787-07
NR 13
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 12
PY 2015
VL 10
IS 11
AR e0142638
DI 10.1371/journal.pone.0142638
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV7UL
UT WOS:000364480900053
PM 26562436
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Sette, A
   Cerpas, C
   Angelo, MA
   Bangs, DJ
   Sidney, J
   Peters, B
   Kallas, EG
   Gresh, L
   Balmaseda, A
   Harris, E
   Weiskopf, D
AF Sette, Alessandro
   Cerpas, Cristhiam
   Angelo, Michael A.
   Bangs, Derek J.
   Sidney, John
   Peters, Bjoern
   Kallas, Esper G.
   Gresh, Lionel
   Balmaseda, Angel
   Harris, Eva
   Weiskopf, Daniela
TI HUMAN CD8 T CELL RESPONSES AGAINST THE FOUR DENV SEROTYPES ARE
   ASSOCIATED WITH DISTINCT PATTERNS FOR PROTEIN TARGETS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Sette, Alessandro; Angelo, Michael A.; Bangs, Derek J.; Sidney, John; Peters, Bjoern; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Ctr Nacl Diagnost & Referencia, Managua, Nicaragua.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Gresh, Lionel] Sustainable Sci Inst, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Berkeley, CA 94720 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 761
BP 230
EP 230
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844102502
DA 2020-11-26
ER

PT J
AU Whitehead, SS
   Durbin, AP
   Francis, DP
   Precioso, A
   Palacios, R
   Thome, B
   Kallas, EG
   Campos, LM
   Watanaveeradej, V
   Macareo, LR
   Simasathien, S
   Klungthong, C
   Thaisomboonsuk, B
AF Whitehead, Stephen S.
   Durbin, Anna P.
   Francis, Donald P.
   Precioso, Alexander
   Palacios, Ricardo
   Thome, Beatriz
   Kallas, Esper G.
   Campos, Lucia M.
   Watanaveeradej, Veerachia
   Macareo, Louis R.
   Simasathien, Sriluck
   Klungthong, Chonticha
   Thaisomboonsuk, Butsaya
TI SAFETY EVALUATION AND IMMUNOGENICITY OF A SINGLE-DOSE LIVE-ATTENUATED
   TETRAVALENT DENGUE VACCINE IN DENGUE ENDEMIC POPULATIONS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Whitehead, Stephen S.] NIAID, Bethesda, MD 20892 USA.
   [Durbin, Anna P.] Johns Hopkins Univ, Baltimore, MD USA.
   [Francis, Donald P.] Global Solut Infect Dis, San Francisco, CA USA.
   [Precioso, Alexander; Palacios, Ricardo; Thome, Beatriz] Butantan Inst, Sao Paulo, Brazil.
   [Kallas, Esper G.; Campos, Lucia M.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Watanaveeradej, Veerachia; Simasathien, Sriluck] Phramongkutklao Hosp, Bangkok, Thailand.
   [Macareo, Louis R.; Klungthong, Chonticha; Thaisomboonsuk, Butsaya] Armed Forces Res Inst Med Sci, Bangkok, Thailand.
RI Palacios, Ricardo/B-7248-2018; Precioso, Alexander Roberto/A-9712-2013;
   Whitehead, Stephen/AAG-2787-2019
OI Palacios, Ricardo/0000-0002-1410-8579; Precioso, Alexander
   Roberto/0000-0001-8657-9292; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 1221
BP 372
EP 373
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844103216
DA 2020-11-26
ER

PT J
AU Bailey, AL
   Lauck, M
   Mohns, M
   Peterson, EJ
   Beheler, K
   Brunner, KG
   Crosno, K
   Mejia, A
   Mutschler, J
   Gehrke, M
   Greene, J
   Ericsen, AJ
   Weiler, A
   Lehrer-Brey, G
   Friedrich, TC
   Sibley, SD
   Kallas, EG
   Capuano, S
   Rogers, J
   Goldberg, TL
   Simmons, HA
   O'Connor, DH
AF Bailey, Adam L.
   Lauck, Michael
   Mohns, Mariel
   Peterson, Eric J.
   Beheler, Kerry
   Brunner, Kevin G.
   Crosno, Kristin
   Mejia, Andres
   Mutschler, James
   Gehrke, Matthew
   Greene, Justin
   Ericsen, Adam J.
   Weiler, Andrea
   Lehrer-Brey, Gabrielle
   Friedrich, Thomas C.
   Sibley, Samuel D.
   Kallas, Esper G.
   Capuano, Saverio, III
   Rogers, Jeffrey
   Goldberg, Tony L.
   Simmons, Heather A.
   O'Connor, David H.
TI Durable sequence stability and bone marrow tropism in a macaque model of
   human pegivirus infection
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GB-VIRUS-C; HEPATITIS-G VIRUS; C/HEPATITIS-G VIRUS; BLOOD-DONORS; SEXUAL
   TRANSMISSION; DOWN-REGULATION; HIGH PREVALENCE; RNA; ALIGNMENT;
   INDIVIDUALS
AB Human pegivirus (HPgV)-formerly known as GB virus C and hepatitis G virus-is a poorly characterized RNA virus that infects about one-sixth of the global human population and is transmitted frequently in the blood supply. We create an animal model of HPgV infection by infecting macaque monkeys with a new simian pegivirus (SPgV) discovered in wild baboons. Using this model, we provide a high-resolution, longitudinal picture of SPgV viremia where the dose, route, and timing of infection are known. We detail the highly variable acute phase of SPgV infection, showing that the viral load trajectory early in infection is dependent on the infecting dose, whereas the chronic-phase viremic set point is not. We also show that SPgV has an extremely low propensity for accumulating sequence variation, with no consensus-level variants detected during the acute phase of infection and an average of only 1.5 variants generated per 100 infection-days. Finally, we show that SPgV RNA is highly concentrated in only two tissues: spleen and bone marrow, with bone marrow likely producing most of the virus detected in plasma. Together, these results reconcile several paradoxical observations from cross-sectional analyses of HPgV in humans and provide an animal model for studying pegivirus biology.
C1 [Bailey, Adam L.; Lauck, Michael; Mohns, Mariel; Gehrke, Matthew; Greene, Justin; Ericsen, Adam J.; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53711 USA.
   [Bailey, Adam L.; Lauck, Michael; Mohns, Mariel; Peterson, Eric J.; Beheler, Kerry; Brunner, Kevin G.; Crosno, Kristin; Mejia, Andres; Mutschler, James; Gehrke, Matthew; Greene, Justin; Ericsen, Adam J.; Weiler, Andrea; Lehrer-Brey, Gabrielle; Friedrich, Thomas C.; Sibley, Samuel D.; Capuano, Saverio, III; Rogers, Jeffrey; Goldberg, Tony L.; Simmons, Heather A.; O'Connor, David H.] Wisconsin Natl Primate Res Ctr, Madison, WI 53711 USA.
   [Mutschler, James; Weiler, Andrea; Lehrer-Brey, Gabrielle; Friedrich, Thomas C.; Sibley, Samuel D.; Goldberg, Tony L.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53711 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01310911 Sao Paulo, Brazil.
   [Rogers, Jeffrey] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
RP O'Connor, DH (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53711 USA.
EM doconnor@primate.wisc.edu
RI Simmons, Heather/U-6081-2019
OI Kallas, Esper/0000-0003-2026-6925; Friedrich,
   Thomas/0000-0001-9831-6895; o'connor, david/0000-0003-2139-470X
FU NIH as part of joint NIH-National Science Foundation Ecology of
   Infectious Diseases program [TW009237]; UK Economic and Social Research
   CouncilEconomic & Social Research Council (ESRC); Wisconsin Partnership
   Program through Wisconsin Center for Infectious Diseases; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [R01 AI077376, R01 AI084787]; Office of Research
   Infrastructure Programs [P51 RR000167]; Research Facilities Improvement
   ProgramUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [RR15459-01, RR020141-01]; University of Wisconsin's
   Medical Scientist Training Program [T32 GM008692]; National Research
   Service Award through Microbes in Health and Disease training program at
   the University of Wisconsin [T32 AI55397]; National Institute of General
   Medical Sciences of the NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [T32GM081061]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R01TW009237, R01TW009237, R01TW009237, R01TW009237] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR015459, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [T32AI055397, T32AI078985, R01AI084787, R01AI077376,
   R01AI084787, R01AI084787, T32AI055397, T32AI055397, T32AI078985,
   T32AI078985, R01AI077376, T32AI078985, R01AI077376, T32AI078985,
   T32AI055397, R01AI077376, T32AI078985, R01AI084787, R01AI077376,
   T32AI055397, R01AI084787, T32AI078985, T32AI055397, R01AI077376,
   T32AI078985, R01AI077376, R01AI077376, T32AI078985, T32AI078985,
   T32AI055397, T32AI055397, T32AI055397, T32AI055397, T32AI055397,
   T32AI055397, T32AI055397, T32AI055397, T32AI055397, T32AI078985,
   T32AI055397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [T32GM008692, T32GM008692,
   T32GM008692, T32GM081061, T32GM008692, T32GM081061, T32GM081061,
   T32GM008692, T32GM008692, T32GM081061, T32GM008692, T32GM008692,
   T32GM008692, T32GM008692, T32GM008692, T32GM008692, T32GM081061,
   T32GM008692, T32GM008692, T32GM008692, T32GM008692, T32GM081061,
   T32GM081061, T32GM081061, T32GM081061, T32GM008692, T32GM008692,
   T32GM008692, T32GM008692, T32GM081061, T32GM008692, T32GM008692,
   T32GM008692, T32GM008692, T32GM008692, T32GM008692, T32GM008692] Funding
   Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106] Funding Source: NIH RePORTER
FX This work was funded by NIH grant TW009237 as part of the joint
   NIH-National Science Foundation Ecology of Infectious Diseases program
   and the UK Economic and Social Research Council, the Wisconsin
   Partnership Program through the Wisconsin Center for Infectious
   Diseases, and the NIH (R01 AI077376 and R01 AI084787). This publication
   was made possible in part by a grant (P51 RR000167) from the Office of
   Research Infrastructure Programs, a component of the NIH, to the WNPRC,
   University of Wisconsin-Madison. This research was conducted in part at
   a facility constructed with support from Research Facilities Improvement
   Program grants RR15459-01 and RR020141-01. A.L.B. performed this work
   with support from the University of Wisconsin's Medical Scientist
   Training Program (grant T32 GM008692) and a National Research Service
   Award through the Microbes in Health and Disease training program at the
   University of Wisconsin (T32 AI55397). Research reported in this
   publication was supported by the National Institute of General Medical
   Sciences of the NIH under Award Number T32GM081061. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH. The funders of this research
   had no role in the study design, data collection and analysis, decision
   to publish, or preparation of the manuscript.
CR Abascal F, 2010, NUCLEIC ACIDS RES, V38, pW7, DOI 10.1093/nar/gkq291
   Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x
   Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Bailey AL, 2014, J VIROL, V88, P13231, DOI 10.1128/JVI.02203-14
   Bailey AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090714
   Berzsenyi MD, 2011, J HEPATOL, V55, P536, DOI 10.1016/j.jhep.2010.12.021
   Bhattarai N, 2012, TRENDS MICROBIOL, V20, P124, DOI 10.1016/j.tim.2012.01.004
   Bjorkman P, 2001, VOX SANG, V81, P148, DOI 10.1046/j.1423-0410.2001.00098.x
   Bukh J, 1998, J INFECT DIS, V177, P855, DOI 10.1086/515255
   Cheng Y, 2000, J MED VIROL, V60, P28, DOI 10.1002/(SICI)1096-9071(200001)60:1<28::AID-JMV5>3.0.CO;2-S
   Chivero ET, 2014, J GEN VIROL, V95, P1307, DOI 10.1099/vir.0.063016-0
   Evans DT, 2013, CURR OPIN HIV AIDS, V8, P255, DOI 10.1097/COH.0b013e328361cee8
   Feng Y, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.14169
   Fiordalisi G, 1997, J INFECT DIS, V175, P1025, DOI 10.1086/517488
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   George SL, 2003, VIROLOGY, V316, P191, DOI 10.1016/S0042-6822(03)00585-3
   Greene JM, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0066-z
   GUNJI T, 1994, ARCH VIROL, V134, P293, DOI 10.1007/BF01310568
   Jones RC, 2014, SCI ENG ETHICS, V20, P481, DOI 10.1007/s11948-013-9442-7
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Korber B, 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Ladner J. T., 2014, MBIO, V5
   LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381
   Lanteri MC, 2015, J INFECT DIS, V211, P1585, DOI 10.1093/infdis/jiu660
   Laskus T, 1998, J VIROL, V72, P3072, DOI 10.1128/JVI.72.4.3072-3075.1998
   Lauck M, 2015, J VIROL, V89, P2425, DOI 10.1128/JVI.02752-14
   Lauck M, 2013, J VIROL, V87, P688, DOI 10.1128/JVI.02433-12
   Lauck M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019056
   Lefrere JJ, 1999, TRANSFUSION, V39, P83, DOI 10.1046/j.1537-2995.1999.39199116899.x
   Lefrere JJ, 1997, BLOOD, V90, P3776, DOI 10.1182/blood.V90.9.3776
   Li CY, 2006, AIDS, V20, P379, DOI 10.1097/01.aids.0000200536.79360.03
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   Nerurkar VR, 1998, J MED VIROL, V56, P123, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;123::AID-JMV4&gt;3.0.CO;2-A
   Perelman P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001342
   Ren H, 2005, WORLD J GASTROENTERO, V11, P970, DOI 10.3748/wjg.v11.i7.970
   Rogers J., 1989, THESIS
   Scallan MF, 1998, J MED VIROL, V55, P203, DOI 10.1002/(SICI)1096-9071(199807)55:3&lt;203::AID-JMV4&gt;3.0.CO;2-5
   Seifried C, 2004, TRANSFUSION, V44, P268, DOI 10.1111/j.1537-2995.2004.00665.x
   Sibley SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098569
   Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0
   Stapleton J. T., 2014, T AM CLIN CLIMAT ASS, V125, P24
   Stapleton Jack T, 2014, Trans Am Clin Climatol Assoc, V125, P14
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Timofeeva AV, 2001, BIOTECHNIQUES, V30, P22, DOI 10.2144/01301bm02
   Tucker T J, 2001, Clin Lab, V47, P239
   Tucker TJ, 2000, J MED VIROL, V61, P52, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;52::AID-JMV8&gt;3.0.CO;2-L
   Zhang W, 2006, HIV MED, V7, P173, DOI 10.1111/j.1468-1293.2006.00366.x
NR 52
TC 13
Z9 13
U1 0
U2 38
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 16
PY 2015
VL 7
IS 305
AR 305ra144
DI 10.1126/scitranslmed.aab3467
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA CW8EH
UT WOS:000365231800004
PM 26378244
OA Green Accepted, Bronze
DA 2020-11-26
ER

PT J
AU Papotto, PH
   Maeda, S
   Tomimori, J
   Xavier, MB
   Rizzo, LV
   Kallas, EG
   Carvalho, KI
AF Papotto, Pedro Henrique
   Maeda, Solange
   Tomimori, Jane
   Xavier, Marilia Brasil
   Rizzo, Luiz Vicente
   Kallas, Esper Georges
   Carvalho, Karina Inacio
TI New Players in the Same Old Game: Disturbance of Group 2 Innate Lymphoid
   Cells in HIV-1 and Mycobacterium leprae Coinfected Patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID T-CELLS; LEPROSY
AB Leprosy control is achieved through a fine-tuning of T(H)1 and T(H)2 immune response pattern balance. Given the increasing epidemiological overlay of HIV and M. leprae infections, immune response in co-infected patients consists in an important contemporary issue. Here we describe for the first time the innate lymphoid cells compartment in peripheral blood of leprosy and HIV/M. leprae co-infected patients, and show that co-infection increases group 2 innate lymphoid whilst decreasing group 1 innate lymphoid cells frequencies and function.
C1 [Papotto, Pedro Henrique; Rizzo, Luiz Vicente; Carvalho, Karina Inacio] Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa, Sao Paulo, Brazil.
   [Maeda, Solange; Tomimori, Jane] Univ Fed Sao Paulo, Dept Dermatol, Sao Paulo, Brazil.
   [Xavier, Marilia Brasil] Fed Univ Para, Dept Dermatol, BR-66059 Belem, Para, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM60, Sao Paulo, Brazil.
RP Papotto, PH (corresponding author), Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa, Sao Paulo, Brazil.
EM karina.salmazi@einstein.br
RI Rizzo, Luiz Vicente/B-4458-2009; Carvalho, Karina IL/J-6789-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Papotto,
   Pedro/0000-0002-2488-7182; Kallas, Esper/0000-0003-2026-6925
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [52731];
   Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2013/15448-7]
FX This work was funded by US National Institutes of Health grant number
   52731. PHP was recipient of a personal scholarship supported by the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (2013/15448-7). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Carvalho KI, 2008, IMMUNOLOGY, V124, P206, DOI 10.1111/j.1365-2567.2007.02756.x
   Carvalho KI, 2012, IMMUNOLOGY, V136, P96, DOI 10.1111/j.1365-2567.2012.03563.x
   Diefenbach A, 2013, EUR J MICROBIOL IMMU, V3, P143, DOI 10.1556/EuJMI.3.2013.3.1
   Fernandes SM, 2014, J INFECT DIS, V210, P630, DOI 10.1093/infdis/jiu126
   Li HY, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00417
   Lockwood DNJ, 2004, BRIT MED J, V328, P1447, DOI 10.1136/bmj.328.7454.1447
   Martiniuk F, 2012, J DRUGS DERMATOL, V11, P626
   Menezes VM, 2014, T ROY SOC TROP MED H, V108, P63, DOI 10.1093/trstmh/trt113
   Saini C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002338
   Saude Md, 2006, PLAN NAC EL HANS NIV
   Saude Md, 2013, SIT EP
   Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365
   Talhari C, 2010, J INFECT DIS, V202, P345, DOI 10.1086/653839
   Toossi T, 2001, J ACQ IMMUN DEF SYND, V28, P1, DOI 10.1097/00042560-200109010-00001
   Ustianowski AP, 2006, LANCET INFECT DIS, V6, P350, DOI 10.1016/S1473-3099(06)70493-5
   *WHO, 1982, WHO TECH REP SER, V675, P1
   Xu H, 2012, MUCOSAL IMMUNOL, V5, P658, DOI 10.1038/mi.2012.39
NR 17
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2015
VL 9
IS 9
AR e0004030
DI 10.1371/journal.pntd.0004030
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CT7YI
UT WOS:000363031200023
PM 26335023
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Jogeda, EL
   Avi, R
   Pauskar, M
   Kallas, E
   Karki, T
   Jarlais, DD
   Uuskula, A
   Lutsar, I
   Huik, K
AF Jogeda, Ene-Ly
   Avi, Radko
   Pauskar, Merit
   Kallas, Eveli
   Karki, Tonis
   Jarlais, Don Des
   Uuskuela, Anneli
   Lutsar, Irja
   Huik, Kristi
TI HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs)
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Jogeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Lutsar, Irja; Huik, Kristi] Univ Tartu, Dept Microbiol, EE-50090 Tartu, Estonia.
   [Uuskuela, Anneli] Univ Tartu, Dept Publ Hlth, EE-50090 Tartu, Estonia.
   [Jarlais, Don Des] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
EM ene-ly.jogeda@ut.ee
RI Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Kallas, Esper/0000-0003-2026-6925
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 28
PY 2015
VL 12
SU 1
MA P79
DI 10.1186/1742-4690-12-S1-P79
PG 1
WC Virology
SC Virology
GA DA0EC
UT WOS:000367468500120
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-11-26
ER

PT J
AU Campos, BLS
   Silva, TN
   Ribeiro, SP
   Carvalho, KIL
   Kallas, EG
   Laurenti, MD
   Passero, LFD
AF Campos, B. L. S.
   Silva, T. N.
   Ribeiro, S. P.
   Carvalho, K. I. L.
   Kallas, E. G.
   Laurenti, M. D.
   Passero, L. F. D.
TI Analysis of iron superoxide dismutase-encoding DNA vaccine on the
   evolution of the Leishmania amazonensis experimental infection
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE DNA vaccine; immunity; Leishmania (Leishmania) amazonensis; superoxide
   dismutase
ID CELLULAR IMMUNE-RESPONSE; DIFFUSE CUTANEOUS LEISHMANIASIS; L. L.
   AMAZONENSIS; BALB/C MICE; IFN-GAMMA; PARASITIC INFECTIONS;
   TRYPANOSOMA-CRUZI; EXCRETED ANTIGEN; DENDRITIC CELLS; V. BRAZILIENSIS
AB The present work aimed to evaluate the immunogenicity of Leishmania amazonensis iron superoxide dismutase (SOD) -encoding DNA experimental vaccine and the protective properties of this DNA vaccine during infection. The SOD gene was subcloned into the pVAX1 plasmid, and it was used to immunize BALB/c mice. Twenty-one days after the last immunization, mice were sacrificed (immunogenicity studies) or subcutaneously challenged with L. amazonensis (studies of protection), and alterations in cellular and humoral immune responses were evaluated, as well as the course of infection. Mice only immunized with pVAX1-SOD presented increased frequencies of CD4(+) IFN-gamma(+), CD8(+) IFN- gamma(+) and CD8(+) IL-4(+) lymphocytes; moreover, high levels of IgG2a were detected. After challenge, mice that were immunized with pVAX1-SOD had increased frequencies of the CD4(+) IL- 4(+), CD8(+) IFN-gamma(+) and CD8(+) IL-4(+) T lymphocytes. In addition, the lymph node cells produced high amounts of IFN-gamma and IL-4 cytokines. Increased IgG2a was also detected. The pattern of immunity induced by pVAX1-SOD partially protected the BALB/c mice from a challenge with L. amazonensis, as the animals presented reduced parasitism and lesion size when compared to controls. Taken together, these results indicate that leishmanial SOD modulates the lymphocyte response, and that the elevation in IFN-gamma possibly accounted for the decreased skin parasitism observed in immunized animals.
C1 [Campos, B. L. S.; Silva, T. N.; Laurenti, M. D.; Passero, L. F. D.] Univ Sao Paulo, Sch Med, Lab Pathol Infect Dis LIM50, BR-01246000 Sao Paulo, Brazil.
   [Ribeiro, S. P.; Carvalho, K. I. L.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, BR-01246000 Sao Paulo, Brazil.
   [Ribeiro, S. P.; Kallas, E. G.] Inst Invest Immunol Iii INCT, Sao Paulo, Brazil.
RP Passero, LFD (corresponding author), Univ Sao Paulo, Fac Med, Av Dr Arnaldo 455, BR-01246000 Sao Paulo, Brazil.
EM felipepassero@yahoo.com.br
RI Carvalho, Karina IL/J-6789-2012; Passero, Luiz Felipe/B-9549-2012;
   Laurenti, Marcia Dalastra/C-4734-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Passero, Luiz
   Felipe/0000-0002-5986-6381; Kallas, Esper/0000-0003-2026-6925
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/10409-0, 2011/51157-1, 2012/05219-8];
    [HCFMUSP-LIM50]
FX This work was supported by Grant Number 2012/10409-0 and 2011/51157-1
   from the Sao Paulo Research Foundation (FAPESP) and HCFMUSP-LIM50. B. L.
   S. Campos is fellowship of FAPESP (2012/05219-8).
CR Brelaz-de-Castro MCA, 2012, CELL IMMUNOL, V279, P180, DOI 10.1016/j.cellimm.2012.11.006
   Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   Antinori S, 2012, EUR J CLIN MICROBIOL, V31, P109, DOI 10.1007/s10096-011-1276-0
   Aranha FCS, 2005, SCAND J IMMUNOL, V62, P334, DOI 10.1111/j.1365-3083.2005.01681.x
   BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738
   Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7
   de Morais MAB, 2013, ACTA CRYSTALLOGR F, V69, P408, DOI 10.1107/S1744309113003989
   Carvalho AK, 2012, PARASITE IMMUNOL, V34, P395, DOI 10.1111/j.1365-3024.2012.01370.x
   COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2
   Cupolilo SMN, 2003, HISTOL HISTOPATHOL, V18, P1059, DOI 10.14670/HH-18.1059
   Daifalla NS, 2012, EXP PARASITOL, V131, P317, DOI 10.1016/j.exppara.2012.05.002
   Daifalla NS, 2011, EXP PARASITOL, V129, P292, DOI 10.1016/j.exppara.2011.07.001
   Danesh-Bahreini MA, 2011, INT J NANOMED, V6, P835, DOI 10.2147/IJN.S16805
   David CV, 2009, DERMATOL THER, V22, P491, DOI 10.1111/j.1529-8019.2009.01272.x
   Dey R, 2014, J IMMUNOL, V193, P3513, DOI 10.4049/jimmunol.1303145
   Passero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
   Passero LFD, 2010, PARASITOL INT, V59, P159, DOI 10.1016/j.parint.2009.12.010
   FINKELMAN FD, 1988, J IMMUNOL, V140, P1022
   Ganguly S, 2008, J INFECT DIS, V197, P1762, DOI 10.1086/588387
   Genetu A, 2006, EXP PARASITOL, V113, P221, DOI 10.1016/j.exppara.2006.01.010
   Ghosh S, 2003, BIOCHEM J, V369, P447, DOI 10.1042/BJ20021684
   Hernandez-Ruiz J, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000871
   Hurdayal R, 2014, IMMUNOL LETT, V161, P179, DOI 10.1016/j.imlet.2013.12.022
   Iezzi G, 2006, J IMMUNOL, V177, P2131, DOI 10.4049/jimmunol.177.4.2131
   KAWANO Y, 1994, J IMMUNOL, V153, P4948
   Kedzierski L, 2014, PARASITOLOGY, V141, P1544, DOI 10.1017/S003118201400095X
   Khare P, 2014, PARASITOL RES, V113, P851, DOI 10.1007/s00436-013-3716-5
   Laurenti MD, 1996, INT J EXP PATHOL, V77, P15, DOI 10.1046/j.1365-2613.1996.958096.x
   Lazarski CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071949
   Longoni SS, 2011, VECTOR-BORNE ZOONOT, V11, P815, DOI 10.1089/vbz.2010.0125
   Lopez-Cespedes A, 2013, ZOONOSES PUBLIC HLTH, V60, P277, DOI 10.1111/j.1863-2378.2012.01520.x
   Lykens JE, 2010, J IMMUNOL, V184, P877, DOI 10.4049/jimmunol.0902346
   Marin C, 2007, PARASITOL RES, V101, P801, DOI 10.1007/s00436-007-0551-6
   Marin C, 2009, AM J TROP MED HYG, V80, P55, DOI 10.4269/ajtmh.2009.80.55
   Marin C, 2014, T ROY SOC TROP MED H, V108, P165, DOI 10.1093/trstmh/tru001
   MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8
   MUKHERJEE S, 1988, BIOSCIENCE REP, V8, P131, DOI 10.1007/BF01116457
   Munoz-Montesino C, 2004, INFECT IMMUN, V72, P2081, DOI 10.1128/IAI.72.4.2081-2087.2004
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   Nico D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00189
   Palatnik-de-Sousa CB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00069
   Pinheiro RO, 2004, AN ACAD BRAS CIENC, V76, P519, DOI 10.1590/S0001-37652004000300006
   Rodrigues MM, 2003, AN ACAD BRAS CIENC, V75, P443, DOI 10.1590/S0001-37652003000400005
   Rostami MN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000845
   Sad S, 1997, EUR J IMMUNOL, V27, P914, DOI 10.1002/eji.1830270417
   Shalaby KA, 2003, VACCINE, V22, P130, DOI [10.1016/S0264-410X(03)00535-8, 10.1016/s0264-410X(03)00535-8]
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001
   Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078
   Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817
   Todoli F, 2009, VET PARASITOL, V159, P17, DOI 10.1016/j.vetpar.2008.10.010
   Vazquez MI, 2015, CYTOKINE, V74, P318, DOI 10.1016/j.cyto.2015.02.007
   Virgilio FD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/243786
   Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3
NR 54
TC 17
Z9 17
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD AUG
PY 2015
VL 37
IS 8
BP 407
EP 416
DI 10.1111/pim.12206
PG 10
WC Immunology; Parasitology
SC Immunology; Parasitology
GA CN8SY
UT WOS:000358714500003
PM 26040192
DA 2020-11-26
ER

PT J
AU Kuebler, PJ
   Mehrotra, ML
   McConnell, JJ
   Holditch, SJ
   Shaw, BI
   Tarosso, LF
   Leadabrand, KS
   Milush, JM
   York, VA
   Raposo, RAS
   Cheng, RG
   Eriksson, EM
   McMahan, V
   Glidden, DV
   Shiboski, S
   Grant, RM
   Nixon, DF
   Kallas, EG
AF Kuebler, Peter J.
   Mehrotra, Megha L.
   McConnell, J. Jeff
   Holditch, Sara J.
   Shaw, Brian I.
   Tarosso, Leandro F.
   Leadabrand, Kaitlyn S.
   Milush, Jeffrey M.
   York, Vanessa A.
   Raposo, Rui Andre Saraiva
   Cheng, Rex G.
   Eriksson, Emily M.
   McMahan, Vanessa
   Glidden, David V.
   Shiboski, Stephen
   Grant, Robert M.
   Nixon, Douglas F.
   Kallas, Esper G.
TI Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis
   trial
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE HIV-1; T cell; designated HIV-1-exposed seronegative; preexposure
   chemoprophylaxis; vaccine
ID HIGHLY PATHOGENIC SIV; LYMPHOCYTE-RESPONSES; DOUBLE-BLIND; SEX WORKERS;
   T-CELLS; VACCINE; PROTECTION; INDIVIDUALS; PROSTITUTES; INFECTION
AB HIV-1-specific T-cell responses in exposed seronegative subjects suggest that a viral breach of the exposure site is more common than current transmission rates would suggest and that host immunity can extinguish subsequent infection foci. The Preexposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial provided an opportunity to rigorously investigate these responses in a case-control immunology study; 84 preinfection peripheral blood mononuclear cell samples from individuals enrolled in the iPrEx trial who later seroconverted were matched with 480 samples from enrolled subjects who remained seronegative from both the placebo and active treatment arms. T-cell responses to HIV-1 Gag, Protease, Integrase, Reverse Transcriptase, Vif, and Nef antigens were quantified for all subjects in an IFN-gamma enzyme-linked immunospot (ELISpot) assay. IFN-gamma responses varied in magnitude and frequency across subjects. A positive response was more prevalent in those who remained persistently HIV-1-negative for Gag (P = 0.007), Integrase (P < 0.001), Vif (P < 0.001), and Nef (P < 0.001). When correlated with outcomes in the iPrEx trial, Vif- and Integrase-specific T-cell responses were associated with reduced HIV-1 infection risk [hazard ratio (HR) = 0.36, 95% confidence interval (95% CI) = 0.19-0.66 and HR = 0.52, 95% CI = 0.28-0.96, respectively]. Antigen-specific responses were independent of emtricitabine/tenofovir disoproxil fumarate use. IFN-gamma secretion in the ELISpot was confirmed using multiparametric flow cytometry and largely attributed to effector memory CD4+ or CD8+ T cells. Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfected individuals and that these T-cell responses can differentiate individuals according to infection outcomes.
C1 [Kuebler, Peter J.; Holditch, Sara J.; Shaw, Brian I.; Leadabrand, Kaitlyn S.; Milush, Jeffrey M.; York, Vanessa A.; Raposo, Rui Andre Saraiva; Cheng, Rex G.; Eriksson, Emily M.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94110 USA.
   [Mehrotra, Megha L.; McConnell, J. Jeff; McMahan, Vanessa; Grant, Robert M.] Gladstone Inst, Inst Virol & Immunol, San Francisco, CA 94158 USA.
   [Tarosso, Leandro F.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-01246 Sao Paulo, Brazil.
   [Raposo, Rui Andre Saraiva; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
   [Glidden, David V.; Shiboski, Stephen] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
   [Grant, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Kuebler, PJ (corresponding author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94110 USA.
EM peter.kuebler@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020; Glidden, David/AAD-4730-2020
OI Nixon, Douglas/0000-0002-2801-1786; Kallas, Esper/0000-0003-2026-6925;
   Grant, Robert/0000-0002-0851-7085; Eriksson, Emily/0000-0002-7851-973X;
   Raposo, R. Andre/0000-0001-5435-0290; Glidden, David/0000-0001-5888-1419
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI62333, AI64002,
   AI087131, RR024131]; Bill and Melinda Gates FoundationBill & Melinda
   Gates Foundation; J. David Gladstone InstitutesUniversity of California
   System; University of California, San Francisco (UCSF) Academic Senate
   Committee on ResearchUniversity of California System; Peter and Shelagh
   Godsoe Family Foundation through the AIDS Research Institute at UCSF;
   Howard Hughes Medical Institute Medical Fellowship;
   American-Scandinavian Foundation; National Council for Scientific and
   Technological Development, Brazilian Ministry of Science and
   Technology/Coordination for the Improvement of Higher Education,
   Brazilian Ministry of Health [056/2012]; Fundacao de Amparo a Pesquisa
   do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2010/05845-0, 04/15856-9]; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI062333, U01AI064002, R01AI118575,
   U01AI064002, R01AI062333, R01AI118575, R01AI118575, U01AI064002,
   U01AI064002, U01AI064002, R01AI118575, R01AI062333, R21AI087131,
   U01AI064002, R01AI118575, R01AI062333, R01AI062333, U01AI064002,
   U01AI064002, R01AI118575, R21AI087131, R21AI087131, R01AI062333,
   R01AI062333, R01AI062333, U01AI064002] Funding Source: NIH RePORTER
FX We thank David Watkins, Frederick Hecht, Susan Buchbinder, and Teri
   Liegler for critically reviewing this manuscript. We thank Patricia
   Defechereux, Robert Hance, and Jeanny Lee for specimen distribution. We
   thank the Preexposure Prophylaxis Initiative (iPrEx) chemoprophylaxis
   trial participants for providing the samples. We also thank the iPrEx
   Study team and investigators Javier R. Lama, Juan Vicente Guanira,
   Martin Casapia, Orlando Montoya-Herrera, Susan Buchbinder, Valdilea G.
   Veloso, Kenneth H. Mayer, Suwat Chariyalertsak, Mauro Schechter, and
   Linda-Gail Bekker. We thank the NIH AIDS Reagent Program for providing
   the peptides. This work was partially supported by National Institutes
   of Health Grants AI62333, AI64002, AI087131, and RR024131; the Bill and
   Melinda Gates Foundation; the J. David Gladstone Institutes; the
   University of California, San Francisco (UCSF) Academic Senate Committee
   on Research (P.J.K.); the Peter and Shelagh Godsoe Family Foundation
   through the AIDS Research Institute at UCSF (P.J.K. and D.F.N.); a
   Howard Hughes Medical Institute Medical Fellowship (to R.G.C.); a
   fellowship from the American-Scandinavian Foundation (to E.M.E.);
   National Council for Scientific and Technological Development, Brazilian
   Ministry of Science and Technology/Coordination for the Improvement of
   Higher Education, Brazilian Ministry of Health Grant 056/2012 (to
   D.F.N.); and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo Grants
   2010/05845-0 (to D.F.N. and E.G.K.) and 04/15856-9 (to E.G.K.).
CR Addo MM, 2011, J INFECT DIS, V203, P258, DOI 10.1093/infdis/jiq028
   Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917
   Erickson AL, 2008, CLIN VACCINE IMMUNOL, V15, P1745, DOI 10.1128/CVI.00247-08
   Fowke KR, 2000, IMMUNOL CELL BIOL, V78, P586, DOI 10.1046/j.1440-1711.2000.00944.x
   Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Heller T, 2013, J INFECT DIS, V208, P1020, DOI 10.1093/infdis/jit270
   Hertz T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003404
   Hladik F, 2003, J IMMUNOL, V171, P2671, DOI 10.4049/jimmunol.171.5.2671
   Holditch SJ, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00094
   Kaul R, 2004, AIDS, V18, P2087, DOI 10.1097/00002030-200410210-00015
   Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602
   Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433
   Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714
   Kebba A, 2004, J INFECT DIS, V189, P1705, DOI 10.1086/383227
   Kuhn L, 2001, AIDS, V15, P1, DOI 10.1097/00002030-200101050-00003
   Lederman MM, 2010, J INFECT DIS, V202, pS333, DOI 10.1086/655967
   Legrand FA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000102
   Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
   Mori K, 2001, J VIROL, V75, P4023, DOI 10.1128/JVI.75.9.4023-4028.2001
   Mudd PA, 2012, J IMMUNOL, V188, P3364, DOI 10.4049/jimmunol.1102470
   Pattacini L, 2015, J INFECT DIS, V211, P1943, DOI 10.1093/infdis/jiu815
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993
   Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428
   Refsland EW, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004761
   Ritchie AJ, 2011, J VIROL, V85, P3507, DOI 10.1128/JVI.02444-10
   Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314
   ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7
   Shacklett BL, 2002, AIDS RES HUM RETROV, V18, P805, DOI 10.1089/08892220260139558
   Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021
   Tarosso LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011436
   Trama AM, 2014, CELL HOST MICROBE, V16, P215, DOI 10.1016/j.chom.2014.07.003
   Young JM, 2011, AIDS RES HUM RETROV, V27, P737, DOI [10.1089/aid.2010.0313, 10.1089/AID.2010.0313]
NR 42
TC 11
Z9 11
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 7
PY 2015
VL 112
IS 27
BP 8379
EP 8384
DI 10.1073/pnas.1501443112
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CM2QU
UT WOS:000357527600068
PM 26100867
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Cruvinel, WD
   Mesquita, D
   Araujo, JAP
   Samazi, KC
   Kallas, EG
   Cendoroglo, MS
   Andrade, LEC
AF Cruvinel, Wilson de Melo
   Mesquita Junior, Danilo
   Pereira Araujo, Julio Antonio
   Samazi, Karina Carvalho
   Kallas, Esper Georges
   Cendoroglo, Maysa Seabra
   Coelho Andrade, Luis Eduardo
TI Abnormal phenotypic distribution of regulatory and effector T cells in
   octogenarian and nonagenarian women
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE T-lymphocytes; aging; regulators T-lymphocytes
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; AGED MICE; CD4(+)CD25(+); AUTOIMMUNITY;
   BLOOD; INCREASES; FREQUENCY; EXPANSION; IMPACT; FOXP3
AB Introduction: aging is associated with several immunologic changes. Regulatory (Treg) and effector T cells are involved in the pathogenesis of infectious, neoplastic, and autoimmune diseases. Little is known about the effects of aging on the frequency and function of these T cell subpopulations.
   Methods: peripheral blood mononuclear cells (PBMC) were obtained from 26 young (under 44 years old) and 18 elderly (above 80 years old) healthy women. T cell subpopulations were analyzed by flow cytometry.
   Results: elderly individuals had lower frequency of several activated effector T cell phenotypes as compared with young individuals: CD3(+)CD4(+)CD25(+) (3.82 +/- 1.93 versus 9.53 +/- 4.49; p < 0.0001); CD3(+)CD4(+)CD25(+)CD127(+) (2.39 +/- 1.19 versus 7.26 +/- 3.84; p < 0.0001); CD3(+)CD4(+)CD25(+) (0.41 +/- 0.22 versus 1.86 +/- 0.85, p < 0.0001); and CD3(+)CD4(+)CD25(high)CD127(+) (0.06 +/- 0.038 versus 0.94 +/- 0.64, p < 0.0001). Treg (CD3(+)CD4(+)CD25(+)CD127(empty set)Foxp3(+)) presented lower frequency in elderly individuals as compared to young adults (0.34 +/- 0.18 versus 0.76 +/- 0.48; p = 0.0004) and its frequency was inversely correlated with age in the whole group (r = -0.439; p = 0.013). The elderly group showed higher frequency of two undefined CD25(empty set)Foxp3(+) phenotypes: CD3(+)CD4(+)CD25(empty set)Foxp3(+) (15.05 +/- 7.34 versus 1.65 +/- 1.71; p < 0.0001) and CD3(+)CD4(+)CD25(empty set)CD127(empty set)Foxp3(+) (13.0 +/- 5.52 versus 3.51 +/- 2.87; p < 0.0001).
   Conclusions: the altered proportion of different T cell subsets herein documented in healthy elderly women may be relevant to the understanding of the immunologic behavior and disease susceptibility patterns observed in geriatric patients.
C1 [Cruvinel, Wilson de Melo] Pontificia Univ Catolica Goias, Sch Med Pharmaceut & Biomed Sci, Goiania, Go, Brazil.
   [Mesquita Junior, Danilo; Pereira Araujo, Julio Antonio] Univ Fed Sao Paulo, Div Rheumatol, Sao Paulo, SP, Brazil.
   [Samazi, Karina Carvalho; Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Cendoroglo, Maysa Seabra] Univ Fed Sao Paulo, Div Geriatr, Sao Paulo, SP, Brazil.
   [Coelho Andrade, Luis Eduardo] Univ Fed Sao Paulo, Div Rheumatol, Sao Paulo, SP, Brazil.
RP Andrade, LEC (corresponding author), Rua Botucatu 740,3 Andar Vila Clementino, BR-04023900 Sao Paulo, SP, Brazil.
EM luis.andrade@unifesp.br
RI Andrade, Luis Eduardo C/D-1245-2012
OI Andrade, Luis Eduardo C/0000-0001-8742-9931; Araujo,
   Julio/0000-0001-6706-2589; Cendoroglo, Maysa/0000-0003-2548-2619;
   Kallas, Esper/0000-0003-2026-6925
FU FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/51934-0, 07/51349-2]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [476356/2008-3]
FX Fapesp: 06/51934-0, 07/51349-2 and CNPq (#476356/2008-3)
CR Arruvito L, 2007, J IMMUNOL, V178, P2572, DOI 10.4049/jimmunol.178.4.2572
   Bonelli M, 2009, J IMMUNOL, V182, P1689, DOI 10.4049/jimmunol.182.3.1689
   Chougnet CA, 2011, J IMMUNOL, V186, P156, DOI 10.4049/jimmunol.1001505
   Cools N, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/89195
   Fessler J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00231
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gottenberg JE, 2005, J AUTOIMMUN, V24, P235, DOI 10.1016/j.jaut.2005.01.015
   Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x
   Hasler P, 2005, CELL IMMUNOL, V233, P102, DOI 10.1016/j.cellimm.2005.04.012
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Hristov M, 2012, J IMMUNOL METHODS, V381, P9, DOI 10.1016/j.jim.2012.04.003
   Hunder GG, 2000, CLIN EXP RHEUMATOL, V18, pS6
   Hwang KA, 2009, MECH AGEING DEV, V130, P509, DOI 10.1016/j.mad.2009.06.003
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kondelkova Katerina, 2010, Acta Medica (Hradec Kralove), V53, P73
   Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835
   Mesquita D, 2011, SCAND J RHEUMATOL, V40, P41, DOI 10.3109/03009742.2010.489229
   Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446
   Nishioka T, 2006, J IMMUNOL, V176, P6586, DOI 10.4049/jimmunol.176.11.6586
   Prelog M, 2006, AUTOIMMUN REV, V5, P136, DOI 10.1016/j.autrev.2005.09.008
   Raynor J, 2012, CURR OPIN IMMUNOL, V24, P482, DOI 10.1016/j.coi.2012.04.005
   Rosenkranz D, 2007, J NEUROIMMUNOL, V188, P117, DOI 10.1016/j.jneuroim.2007.05.011
   Safinia N, 2010, CURR OPIN ORGAN TRAN, V15, P427, DOI 10.1097/MOT.0b013e32833bfadc
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Santner-Nanan B, 2008, INT IMMUNOL, V20, P375, DOI 10.1093/intimm/dxm151
   Sharma S, 2006, J IMMUNOL, V177, P8348, DOI 10.4049/jimmunol.177.12.8348
   Simone R, 2008, J LEUKOCYTE BIOL, V84, P1454, DOI 10.1189/jlb.0907627
   Steger MM, 1996, LANCET, V348, P762, DOI 10.1016/S0140-6736(05)65680-2
   Trzonkowski P, 2006, CLIN IMMUNOL, V119, P307, DOI 10.1016/j.clim.2006.02.002
   Urban L, 2002, GERONTOLOGY, V48, P179, DOI 10.1159/000052839
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Weksler ME, 2000, J CLIN IMMUNOL, V20, P240, DOI 10.1023/A:1006659401385
   Williams-Bey Y, 2011, MECH AGEING DEV, V132, P163, DOI 10.1016/j.mad.2011.03.001
   Yan Bing, 2009, Open Rheumatol J, V3, P22, DOI 10.2174/1874312900903010022
   Yan Jun, 2010, Immun Ageing, V7, P4, DOI 10.1186/1742-4933-7-4
   Zhao L, 2007, J LEUKOCYTE BIOL, V81, P1386, DOI 10.1189/jlb.0506364
NR 36
TC 0
Z9 0
U1 0
U2 3
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD JUL-AUG
PY 2015
VL 61
IS 4
BP 329
EP 335
DI 10.1590/1806-9282.61.04.329
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CT8SS
UT WOS:000363087400008
PM 26466214
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Hoagland, B
   Veloso, VG
   De Boni, RB
   Madruga, JV
   Kallas, EG
   Fernandes, NM
   Moreira, RI
   Liu, AY
   Grinsztejn, B
AF Hoagland, Brenda
   Veloso, Valdilea G.
   De Boni, Raquel B.
   Madruga, Jose Valdez
   Kallas, Esper G.
   Fernandes, Nilo Martinez
   Moreira, Ronaldo I.
   Liu, Albert Y.
   Grinsztejn, Beatriz
CA PrEP Brasil Study Team
TI Pre-exposure prophylaxis uptake and associated factors among MSM and TGW
   in the PrEP Brasil demonstration project
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Hoagland, Brenda] Fundacao Oswaldo Cruz, IPEC, Rio De Janeiro, Brazil.
   [Veloso, Valdilea G.; De Boni, Raquel B.; Fernandes, Nilo Martinez; Moreira, Ronaldo I.; Grinsztejn, Beatriz] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
   [Madruga, Jose Valdez] CRT, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, BR-09500900 Sao Paulo, Brazil.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
EM beatriz.grinsztejn@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA TUAC0205LB
DI 10.7448/IAS.18.5.20550
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700080
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Choi, JY
   Ho, JHE
   Pasoto, SG
   Bunin, V
   Kim, ST
   Carrasco, S
   Borba, EF
   Goncalves, CR
   Costa, PR
   Kallas, EG
   Bonfa, E
   Craft, J
AF Choi, Jin-Young
   Ho, John Hsi-en
   Pasoto, Sandra G.
   Bunin, Viviane
   Kim, Sang Taek
   Carrasco, Solange
   Borba, Eduardo F.
   Goncalves, Celio R.
   Costa, Priscila R.
   Kallas, Esper G.
   Bonfa, Eloisa
   Craft, Joseph
TI Circulating Follicular Helper-Like T Cells in Systemic Lupus
   Erythematosus
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID CXC CHEMOKINE RECEPTOR-5; B-CELLS; DISEASE-ACTIVITY; TRANSCRIPTION
   FACTOR; GERMINAL-CENTERS; EFFECTOR-MEMORY; I INTERFERONS; EXPRESSION;
   DIFFERENTIATION; IL-21
AB Objective. To assess circulating follicular helper T (Tfh)-like CD4+ T cells in patients with systemic lupus erythematosus (SLE) and determine their relationship to disease activity.
   Methods. Blood samples from patients with SLE, as well as blood samples from patients with Behcet's disease (BD) and healthy individuals as controls, were analyzed. In all samples, circulating Tfh-like cells were enumerated by flow cytometry, using, as markers, expression of CXCR5, inducible T cell costimulator (ICOS), and programmed death 1 (PD-1) protein, as well as secretion of interleukin-21 (IL-21). The frequency of circulating Tfh-like cells was compared to that of circulating plasmablasts (CD19+IgD-CD38+). In addition, the possible association of circulating Tfh-like cells with the SLE Disease Activity Index (SLEDAI) was evaluated.
   Results. The subset of circulating Tfh-like T cells, identified as CXCR5(high)ICOS(high)PD-1(high), was expanded in the blood of SLE patients compared to controls. Circulating Tfh-like cells were found to produce IL-21 and had lower expression of CCR7 as compared to that in circulating CXCR5(high) central memory T cells, thereby enabling their distinction. Expression of PD-1, but not ICOS or CXCR5, was significantly elevated in circulating Tfh-like cells from SLE patients compared to controls. PD-1 expression among CXCR5(high) circulating Tfh-like cells correlated with the SLEDAI, frequency of circulating plasmablasts, and anti-double-stranded DNA antibody positivity, but not with disease duration or past organ injury; rather, this cell profile appeared to be a reflection of current active disease.
   Conclusion. Circulating Tfh-like cells are associated with disease activity in SLE, suggesting that their presence indicates abnormal homeostasis of T cell-B cell collaboration, with a causal relationship that is central to disease pathogenesis. These findings also suggest that circulating Tfh-like cells provide a surrogate for aberrant germinal center activity in SLE, and that their PD-1 expression offers a tool for measuring disease activity and monitoring the response to therapies.
C1 [Choi, Jin-Young; Ho, John Hsi-en; Bunin, Viviane; Kim, Sang Taek; Craft, Joseph] Yale Univ, Sch Med, New Haven, CT USA.
   [Pasoto, Sandra G.; Carrasco, Solange; Borba, Eduardo F.; Goncalves, Celio R.; Costa, Priscila R.; Kallas, Esper G.; Bonfa, Eloisa] Univ Sao Paulo, Hosp Clin, Fac Med, BR-01246903 Sao Paulo, Brazil.
RP Bonfa, E (corresponding author), Univ Sao Paulo, Disciplina Reumatol, Reumatol, Ave Dr Arnaldo,455-3 Andar, BR-01246903 Sao Paulo, Brazil.
EM eloisa.bonfa@hc.fm.usp.br; joseph.craft@yale.edu
RI carrasco, solange/W-7361-2019; Carrasco, Solange/G-5144-2012; Bonfa,
   Eloisa/B-8438-2012; Borba, Eduardo F/D-1741-2012
OI Carrasco, Solange/0000-0003-2469-9744; Bonfa,
   Eloisa/0000-0002-0520-4681; Borba, Eduardo F/0000-0001-6194-5129;
   Kallas, Esper/0000-0003-2026-6925
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/02119-0]; AbbVie; Alliance for Lupus
   Research; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AR-040072, AR-053495, T32-AR-07107];
   Rheumatology Research Foundation (Scientist Development Award); Biogen
   IdecBiogen; Sanofi; Novo NordiskNovo Nordisk; PfizerPfizer; Moderna;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R01AR040072, R01AR040072,
   T32AR007107, P30AR053495, P30AR053495, P30AR053495, T32AR007107,
   T32AR007107, R37AR040072, P30AR053495, P30AR053495, R37AR040072,
   P30AR053495, T32AR007107, T32AR007107, P30AR053495, P30AR053495,
   R37AR040072, R37AR040072, R01AR040072, P30AR053495, T32AR007107,
   R01AR040072, R01AR040072, T32AR007107, P30AR053495, P30AR053495,
   T32AR007107, R01AR040072, P30AR053495, R01AR040072, T32AR007107,
   P30AR053495, P30AR053495, R37AR040072, P30AR053495, P30AR053495,
   T32AR007107, T32AR007107, T32AR007107, P30AR053495, P30AR053495,
   R37AR040072, P30AR053495, P30AR053495, T32AR007107, P30AR053495,
   T32AR007107, P30AR053495, T32AR007107, P30AR053495, P30AR053495,
   R01AR040072, P30AR053495, P30AR053495, P30AR053495, P30AR053495,
   T32AR007107, P30AR053495, T32AR007107, P30AR053495, P30AR053495,
   T32AR007107, R37AR040072, P30AR053495, R01AR040072, T32AR007107,
   P30AR053495, P30AR053495, P30AR053495, R37AR040072, P30AR053495,
   P30AR053495, P30AR053495, T32AR007107, T32AR007107, T32AR007107,
   P30AR053495, R01AR040072, P30AR053495, P30AR053495, P30AR053495,
   P30AR053495, P30AR053495, P30AR053495, R01AR040072, P30AR053495,
   T32AR007107, P30AR053495, R37AR040072, R01AR040072, P30AR053495,
   T32AR007107, T32AR007107, T32AR007107, T32AR007107, T32AR007107,
   T32AR007107, P30AR053495, P30AR053495, T32AR007107, R01AR040072,
   R37AR040072, T32AR007107, P30AR053495, R01AR040072, R01AR040072,
   P30AR053495, P30AR053495, R37AR040072, T32AR007107, P30AR053495,
   P30AR053495, T32AR007107, T32AR007107, R37AR040072, P30AR053495,
   P30AR053495, R37AR040072, P30AR053495, P30AR053495, R37AR040072] Funding
   Source: NIH RePORTER
FX Supported by the Sao Paulo Research Foundation (FAPESP grant
   2011/02119-0 to Dr. Bonfa), AbbVie, the Alliance for Lupus Research, and
   the NIH (grants AR-040072 and AR-053495 to Dr. Craft). Dr. Kim's work
   was supported by the Rheumatology Research Foundation (Scientist
   Development Award) and the NIH (grant T32-AR-07107).; Dr. Craft has
   received consulting fees, speaking fees, and/or honoraria from AbbVie,
   Biogen Idec, Sanofi, Novo Nordisk, Pfizer, and Moderna (less than
   $10,000 each).
CR Anolik J, 2004, CURR OPIN RHEUMATOL, V16, P505, DOI 10.1097/01.bor.0000133660.52599.f6
   Arce E, 2001, J IMMUNOL, V167, P2361, DOI 10.4049/jimmunol.167.4.2361
   Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100
   Bengtsson AA, 2000, LUPUS, V9, P664, DOI 10.1191/096120300674499064
   Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191
   Bentebibel SE, 2011, P NATL ACAD SCI USA, V108, pE488, DOI 10.1073/pnas.1100898108
   Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545
   Burmeister Y, 2008, J IMMUNOL, V180, P774, DOI 10.4049/jimmunol.180.2.774
   Cappione A, 2005, J CLIN INVEST, V115, P3205, DOI 10.1172/JCI24179
   Chang A, 2011, J IMMUNOL, V186, P1849, DOI 10.4049/jimmunol.1001983
   Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828
   Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023
   Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58
   Dorner T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3433
   Dorner T, 2004, LUPUS, V13, P283, DOI 10.1191/0961203304lu1014oa
   Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867
   Ferreiros-Vidal I, 2007, GENES IMMUN, V8, P138, DOI 10.1038/sj.gene.6364370
   Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x
   Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877
   Grammer AC, 2003, J CLIN INVEST, V112, P1506, DOI 10.1172/JCI200319301
   Hale JS, 2013, IMMUNITY, V38, P805, DOI 10.1016/j.immuni.2013.02.020
   Haymaker C, 2012, ONCOIMMUNOLOGY, V1, P735, DOI 10.4161/onci.20823
   He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007
   Jacobi AM, 2008, ARTHRITIS RHEUM-US, V58, P1762, DOI 10.1002/art.23498
   Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870
   Kasagi S, 2010, J IMMUNOL, V184, P2337, DOI 10.4049/jimmunol.0901652
   Kawamoto M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1928
   Kirou KA, 2005, ARTHRITIS RHEUM-US, V52, P1491, DOI 10.1002/art.21031
   Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1
   Le Coz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075319
   Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738
   Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886
   Liu JL, 2009, J EUR ACAD DERMATOL, V23, P425, DOI 10.1111/j.1468-3083.2009.03087.x
   Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031
   Luzina IG, 2001, J LEUKOCYTE BIOL, V70, P578
   Mendes D, 2009, J AUTOIMMUN, V32, P178, DOI 10.1016/j.jaut.2009.02.011
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676
   Odegard JM, 2008, J EXP MED, V205, P2873, DOI 10.1084/jem.20080840
   Pepper M, 2011, IMMUNITY, V35, P583, DOI 10.1016/j.immuni.2011.09.009
   Petri M, 2007, ANN RHEUM DIS, V66, P61, DOI 10.1136/ard.2007.078477
   Ray JP, 2014, IMMUNITY, V40, P367, DOI 10.1016/j.immuni.2014.02.005
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553
   Shah K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2964
   SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150
   SILMAN AJ, 1990, LANCET, V335, P1078
   Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Terawaki S, 2011, J IMMUNOL, V186, P2772, DOI 10.4049/jimmunol.1003208
   Terrier B, 2012, J RHEUMATOL, V39, P1819, DOI 10.3899/jrheum.120468
   Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637
   Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555
   Watanabe T, 2010, J VIRAL HEPATITIS, V17, P453, DOI 10.1111/j.1365-2893.2010.01313.x
   Weinstein JS, 2014, J IMMUNOL, V192, P3166, DOI 10.4049/jimmunol.1302617
   William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924
   Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002
   Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777
NR 58
TC 133
Z9 141
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD APR
PY 2015
VL 67
IS 4
BP 988
EP 999
DI 10.1002/art.39020
PG 12
WC Rheumatology
SC Rheumatology
GA CE5AJ
UT WOS:000351841800018
PM 25581113
OA Green Published, Bronze, Green Accepted
DA 2020-11-26
ER

PT J
AU Kallas, E
   Huik, K
   Pauskar, M
   Jogeda, EL
   Karki, T
   Des Jarlais, D
   Uuskula, A
   Avi, R
   Lutsar, I
AF Kallas, Eveli
   Huik, Kristi
   Pauskar, Merit
   Jogeda, Ene-Ly
   Karki, Tonis
   Des Jarlais, Don
   Uuskuela, Anneli
   Avi, Radko
   Lutsar, Irja
TI Influence of interleukin 10 polymorphisms-592 and-1082 to the HIV, HBV
   and HCV serostatus among intravenous drug users
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE IL-10; IDU; Genetic factors; Inflammation; Co-infection; HIV
   susceptibility
ID CHRONIC HEPATITIS-B; SINGLE-NUCLEOTIDE POLYMORPHISMS; PROMOTER
   POLYMORPHISMS; GENE; ASSOCIATION; PROGRESSION; HAPLOTYPES; INFECTION;
   IL-10; CELLS
AB Background: Interleukin 10 (IL-10) is a multifunctional cytokine produced by macrophages, monocytes, and T-helper cells. Two polymorphisms at positions -592 and -1082 have been associated with HIV susceptibility. However, their associations with susceptibility to HIV and its co-infections among intravenous drug users (IDUs) are largely unknown.
   Methods: A total of 345 IDUs were recruited. Of the 173 HIV negative IDUs, 20 were classified as highly exposed HIV seronegative subjects (HESNs). A control group consisted of 496 blood donors; all HIV, HCV, and HBV negative. The IL-10-592C/A and -1082A/G were determined using TaqMan allelic discrimination assay.
   Results: Of the IDUs, 50% were HIV positive, 89% HCV positive, 67% HBV positive and 41% had triple infection. IL-10-592C allele and -1082A allele were the most common and the -1082AG/-592CC was the most common genotype pair. All HESNs exhibited -1082A allele as compared to 81.4% of the HIV positive IDUs and 79% of donors (p = 0.029 and p = 0.019, respectively). None of HESNs had GG/CC genotype pair compared with 18.6% of HIV positive IDUs and 21.0% of donors (p = 0.029 and p = 0.019, respectively). The possession of -592AC and genotype pair AG/AC were associated with the decreased odds of HBV infection (OR = 0.28; 95% CI 0.09-0.87; p = 0.028 and OR = 0.19; 95% CI 0.06-0.61; p = 0.052, respectively).
   Conclusions: The presence of low producing IL-10-1082A and -592A alleles and their containing genetic variants protect highly exposed IDUs against acquisition of HIV and HBV infections. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Kallas, Eveli; Huik, Kristi; Pauskar, Merit; Jogeda, Ene-Ly; Karki, Tonis; Avi, Radko; Lutsar, Irja] Univ Tartu, Dept Microbiol, Fac Med, EE-50411 Tartu, Estonia.
   [Des Jarlais, Don] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
   [Uuskuela, Anneli] Univ Tartu, Fac Med, Dept Publ Hlth, EE-50411 Tartu, Estonia.
RP Kallas, E (corresponding author), Univ Tartu, Dept Microbiol, Ravila 19, EE-50411 Tartu, Estonia.
EM eveli.kallas@ut.ee
RI lutsar, irja/H-3177-2015; Uuskula, Anneli/H-3303-2015
OI Uuskula, Anneli/0000-0002-4036-3856; Avi, Radko/0000-0002-9640-8427;
   Kallas, Esper/0000-0003-2026-6925
FU European Union through the European Regional Development Fund, Estonian
   Science Foundation [8415, 8856]; Basic Financing and the Target
   Financing of Estonian Ministry of Education and Research [SF0180004s12,
   SF0180060s09]; US National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01
   DA003574]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574, R01DA003574, R01DA003574, R01DA003574, R01DA003574,
   R01DA003574] Funding Source: NIH RePORTER
FX The work was supported by European Union through the European Regional
   Development Fund, Estonian Science Foundation (grants 8415 and 8856);
   Basic Financing and the Target Financing of Estonian Ministry of
   Education and Research (SF0180004s12 and SF0180060s09); and grant R01
   DA003574 from the US National Institutes of Health.
CR Adojaan M, 2005, JAIDS-J ACQ IMM DEF, V39, P598
   Avi R, 2011, SCAND J INFECT DIS, V43, P122, DOI 10.3109/00365548.2010.526956
   BARCELLINI W, 1995, AIDS, V9, P691, DOI 10.1097/00002030-199507000-00004
   Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296
   Cheong JY, 2006, J GASTROEN HEPATOL, V21, P1163, DOI 10.1111/j.1440-1746.2006.04304.x
   Clerici M, 1996, BLOOD, V88, P574, DOI 10.1182/blood.V88.2.574.bloodjournal882574
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
   De La Vega FM, 2002, BIOTECHNIQUES, P48
   de Saint-Vis B, 1998, J IMMUNOL, V160, P1666
   Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207
   Eskdale J, 1999, GENES IMMUN, V1, P151, DOI 10.1038/sj.gene.6363656
   Gao QJ, 2009, WORLD J GASTROENTERO, V15, P5610, DOI 10.3748/wjg.15.5610
   Hulk K., 2013, INFECT GENET EVOL
   Juffermans NP, 2000, BLOOD, V96, P2649
   Laisaar KT, 2011, AIDS RES HUM RETROV, V27, P841, DOI [10.1089/aid.2010.0223, 10.1089/AID.2010.0223]
   Lazarus R, 2002, GENOMICS, V80, P223, DOI 10.1006/geno.2002.6820
   Levy JA, 2007, HIV AND THE PATHOGENESIS OF AIDS, 3RD EDITION, P1
   Malekinejad M, 2008, AIDS BEHAV, V12, pS105, DOI 10.1007/s10461-008-9421-1
   MCELRATH K, 1994, AM J PUBLIC HEALTH, V84, P1965, DOI 10.2105/AJPH.84.12.1965
   Miyazoe S, 2002, AM J GASTROENTEROL, V97, P2086, DOI 10.1111/j.1572-0241.2002.05926.x
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Naicker DD, 2012, CLIN INFECT DIS, V54, P294, DOI 10.1093/cid/cir811
   Naicker DD, 2009, J INFECT DIS, V200, P448, DOI 10.1086/600072
   Oleksyk TK, 2009, GENES IMMUN, V10, P309, DOI 10.1038/gene.2009.9
   Paat Gerli, 2009, Central European Journal of Public Health, V17, P108
   Peng XM, 2006, LIVER INT, V26, P326, DOI 10.1111/j.1478-3231.2005.01241.x
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Reuss E, 2002, GENES IMMUN, V3, P407, DOI 10.1038/sj.gene.6363920
   Rodriguez S, 2009, AM J EPIDEMIOL, V169, P505, DOI 10.1093/aje/kwn359
   Shin HD, 2000, P NATL ACAD SCI USA, V97, P14467, DOI 10.1073/pnas.97.26.14467
   Shrestha S, 2006, J INFECT DIS, V193, P16, DOI 10.1086/498532
   Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   UNAIDS, 2013, AIDS BY NUMB
   Uuskula Anneli, 2002, International Journal of Infectious Diseases, V6, P23, DOI 10.1016/S1201-9712(02)90131-1
   Wang CB, 2004, JAIDS-J ACQ IMM DEF, V35, P446, DOI 10.1097/00126334-200404150-00002
   Wilson EB, 2011, CURR TOP MICROBIOL, V350, P39, DOI 10.1007/82_2010_96
NR 37
TC 7
Z9 7
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD MAR
PY 2015
VL 30
BP 175
EP 180
DI 10.1016/j.meegid.2014.12.023
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA CC7CN
UT WOS:000350525400024
PM 25542814
DA 2020-11-26
ER

PT J
AU de Matos, AM
   Carvalho, KI
   Rosa, DS
   Villas-Boas, LS
   da Silva, WC
   Rodrigues, CLDL
   Oliveira, OMNPF
   Levi, JE
   Araujo, ESA
   Pannuti, CS
   Luna, EJA
   Kallas, EG
AF de Matos, Andreia Manso
   Carvalho, Karina Inacio
   Rosa, Daniela Santoro
   Villas-Boas, Lucy Santos
   da Silva, Wanessa Cardoso
   de Lima Rodrigues, Celia Luiza
   Peel Furtado Oliveira, Olimpia Massae Nakasone
   Levi, Jose Eduardo
   Affonso Araujo, Evaldo Stanislau
   Pannuti, Claudio Sergio
   Albuquerque Luna, Expedito Jose
   Kallas, Esper George
TI CD8+T Lymphocyte Expansion, Proliferation and Activation in Dengue Fever
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CD8(+) T-CELLS; HEMORRHAGIC-FEVER; VIRAL-INFECTIONS; VIRUS-INFECTION;
   MEMORY; SUBSETS; RESPONSES; DISEASE; DIFFERENTIATION; PATHOGENESIS
AB Dengue fever induces a robust immune response, including massive T cell activation. The level of T cell activation may, however, be associated with more severe disease. In this study, we explored the level of CD8+ T lymphocyte activation in the first six days after onset of symptoms during a DENV2 outbreak in early 2010 on the coast of Sao Paulo State, Brazil. Using flow cytometry we detected a progressive increase in the percentage of CD8+ T cells in 74 dengue fever cases. Peripheral blood mononuclear cells from 30 cases were thawed and evaluated using expanded phenotyping. The expansion of the CD8+ T cells was coupled with increased Ki67 expression. Cell activation was observed later in the course of disease, as determined by the expression of the activation markers CD38 and HLA-DR. This increased CD8+ T lymphocyte activation was observed in all memory subsets, but was more pronounced in the effector memory subset, as defined by higher CD38 expression. Our results show that most CD8+ T cell subsets are expanded during DENV2 infection and that the effector memory subset is the predominantly affected sub population.
C1 [de Matos, Andreia Manso; Carvalho, Karina Inacio; Rosa, Daniela Santoro; Kallas, Esper George] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Carvalho, Karina Inacio] Albert Einstein Hosp, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro] Fed Univ Sao Paulo UNIFESP, Div Immunol, Sao Paulo, Brazil.
   [Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; de Lima Rodrigues, Celia Luiza; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; de Lima Rodrigues, Celia Luiza; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Peel Furtado Oliveira, Olimpia Massae Nakasone; Affonso Araujo, Evaldo Stanislau] Hosp Ana Costa, Sao Paulo, Brazil.
   [Affonso Araujo, Evaldo Stanislau] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 47, Sao Paulo, Brazil.
RP de Matos, AM (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Luna, Expedito J A/B-7948-2012; Carvalho, Karina IL/J-6789-2012; Rosa,
   Daniela S/D-2190-2012; Silva, Wanessa/C-7837-2012
OI Luna, Expedito J A/0000-0002-1145-9672; Carvalho, Karina
   IL/0000-0002-7763-8139; Rosa, Daniela S/0000-0003-4536-891X; Kallas,
   Esper/0000-0003-2026-6925
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq)National Council for Scientific
   and Technological Development (CNPq) [476088/2009-7]; CNPqNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior, Brazilian Ministry of
   Education
FX The present work was supported by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry of Science
   and Technology (CNPq, grant #476088/2009-7 to EGK). AMM and EGK's
   scholarships were supported by CNPq. KIC's scholarship was supported by
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior,
   Brazilian Ministry of Education. URL of CNPq: URL www.cnpq.br; URL of
   CAPES: www.capes.gov.br The funders had no role in study design, data
   collection and analysis, decision to publish; or preparation of the
   manuscript.
CR Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   CORLEY RB, 1985, P NATL ACAD SCI USA, V82, P516, DOI 10.1073/pnas.82.2.516
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Friberg H, 2011, IMMUNOL CELL BIOL, V89, P122, DOI 10.1038/icb.2010.61
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   Goncalves RM, 2010, INFECT IMMUN, V78, P4763, DOI 10.1128/IAI.00578-10
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Lai YL, 2007, J CLIN MICROBIOL, V45, P935, DOI 10.1128/JCM.01258-06
   Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010
   Levi JE, 2007, J CLIN MICROBIOL, V45, P1893, DOI 10.1128/JCM.00065-07
   Liu CC, 2002, J MED VIROL, V68, P241, DOI 10.1002/jmv.10198
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Mathew A, 1999, J IMMUNOL, V162, P5609
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   McMichael AJ, 2000, PHILOS T R SOC B, V355, P363, DOI 10.1098/rstb.2000.0575
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   PAHO, 2008, NUMB REP CAS DENG DE
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SARASOMBATH S, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P649
   Schmid ML, 1999, BRIT MED J, V318, P1076, DOI 10.1136/bmj.318.7190.1076a
   Tomiyama H, 2002, J IMMUNOL, V168, P5538, DOI 10.4049/jimmunol.168.11.5538
   Villar L, 2014, NEW ENGL J MED, DOI [10. 1056/ NEJMsr1414226, DOI 10.1056/NEJMSR1414226]
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Zielinski CE, 2011, IMMUNOL REV, V240, P40, DOI 10.1111/j.1600-065X.2010.01000.x
NR 38
TC 16
Z9 16
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2015
VL 9
IS 2
AR e0003520
DI 10.1371/journal.pntd.0003520
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CD3PW
UT WOS:000350992500048
PM 25675375
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Guanira, JV
   Leigler, T
   Kallas, E
   Schechter, M
   Sharma, U
   Glidden, D
   Grant, RM
AF Guanira, Juan V.
   Leigler, Teri
   Kallas, Esper
   Schechter, Mauro
   Sharma, Usha
   Glidden, David
   Grant, Robert M.
CA IPrEx Study Team
TI Streamlining HIV Testing for HIV Preexposure Prophylaxis
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PERFORMANCE; PREVENTION
AB HIV-testing algorithms for preexposure prophylaxis (PrEP) should be optimized to minimize the risk of drug resistance, the time off PrEP required to evaluate false-positive screening results, and costs and to expedite the start of therapy for those confirmed to be infected. HIV rapid tests (RTs) for anti-HIV antibodies provide results in less than 1 h and can be conducted by nonlicensed staff at the point of care. In many regions, Western blot (WB) testing is required to confirm reactive RT results. WB testing, however, causes delays in diagnosis and adds expense. The iPrEx study evaluated the safety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men and transgender women who have sex with men: HIV infection was assessed with two RTs plus WB confirmation, followed by HIV-1 plasma viral load testing. During the iPrEx study, there were 51,260 HIV status evaluations among 2,499 volunteers using RTs: 142 (0.28%) had concordant positive results (100% were eventually confirmed) and 19 (0.04%) had discordant results among 14 participants; 11 were eventually determined to be HIV infected. A streamlined approach using only one RT to screen and a second RT to confirm (without WB) would have had nearly the same accuracy. Discrepant RT results are best evaluated with nucleic acid testing, which would also increase sensitivity.
C1 [Guanira, Juan V.] Invest Med Salud, Lima, Peru.
   [Leigler, Teri; Glidden, David; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Grant, Robert M.] Gladstone Inst, San Francisco, CA USA.
   [Kallas, Esper] Univ Sao Paulo, Sao Paulo, Brazil.
   [Schechter, Mauro] Praca Onze, Rio De Janeiro, Brazil.
   [Sharma, Usha] NIAID, NIH, Bethesda, MD 20892 USA.
RP Guanira, JV (corresponding author), Invest Med Salud, Lima, Peru.
EM jguanira@inmensa.org
RI Glidden, David/AAD-4730-2020; Schechter, Mauro/AAG-7445-2020
OI Kallas, Esper/0000-0003-2026-6925; Glidden, David/0000-0001-5888-1419;
   Grant, Robert/0000-0002-0851-7085; Guanira, Juan/0000-0002-2746-3086
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [4U01 AI064002];
   Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [48162]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI064002, U01AI064002, U01AI064002, U01AI064002,
   U01AI064002, U01AI064002, U01AI064002, U01AI064002, U01AI064002] Funding
   Source: NIH RePORTER
FX The iPrEx study was sponsored by the U.S. National Institutes of Health
   under grant number 4U01 AI064002 and cofunded by the Bill and Melinda
   Gates Foundation under grant number 48162.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   APHL and CDC, 2009, HIV TEST ALG STAT RE
   Baral S, 2013, AIDS BEHAV, V17, pS60, DOI 10.1007/s10461-012-0202-5
   Bekker LG, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007435
   Branson BM, 2007, CLIN INFECT DIS, V45, pS221, DOI 10.1086/522541
   Cadoff E, 2007, 2007 HIV DIAGN C ORL
   Chavez P, 2011, J CLIN VIROL, V52, pS51, DOI 10.1016/j.jcv.2011.09.010
   Delaney K, 2007, 2007 HIV DIAGN C ORL
   Delaney KP, 2011, CLIN INFECT DIS, V52, P257, DOI 10.1093/cid/ciq068
   FDA, 2013, FDA APPR 1 DIAGN ASS
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Gomez GB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001323
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Haukoos JS, 2007, ACAD EMERG MED, V14, P1149, DOI 10.1111/j.1553-2712.2007.tb02335.x
   Martin EG, 2011, J CLIN VIROL, V52, pS11, DOI 10.1016/j.jcv.2011.09.014
   Murphy G, 2011, J CLIN VIROL, V52, pS71, DOI 10.1016/j.jcv.2011.09.027
   Piatek AS, 2010, 2010 HIV DIAGN C ORL
   Pilcher CD, 2008, ANN INTERN MED, V149, P204, DOI 10.7326/0003-4819-149-3-200808050-00011
   Rosenberg NE, 2012, J INFECT DIS, V205, P528, DOI 10.1093/infdis/jir789
   Rurangirwa J, 2008, 136 AM PUBL HLTH ASS
   Schackman BR, 2012, CURR OPIN HIV AIDS, V7, P587, DOI 10.1097/COH.0b013e3283582c8b
   Smith D. K., 2012, Morbidity and Mortality Weekly Report, V61, P586
NR 22
TC 9
Z9 9
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JAN
PY 2015
VL 53
IS 1
BP 179
EP 183
DI 10.1128/JCM.01540-14
PG 5
WC Microbiology
SC Microbiology
GA AW8HM
UT WOS:000346502200027
PM 25378570
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Milagres, LG
   Costa, PR
   Silva, GP
   Carvalho, KI
   Pereira-Manfro, WF
   Ferreira, B
   Barreto, DM
   Frota, ACC
   Hofer, CB
   Kallas, EG
AF Milagres, Lucimar G.
   Costa, Priscilla R.
   Silva, Giselle P.
   Carvalho, Karina I.
   Pereira-Manfro, Wania F.
   Ferreira, Bianca
   Barreto, Daniella M.
   Frota, Ana Cristina C.
   Hofer, Cristina B.
   Kallas, Esper G.
TI Subsets of Memory CD4(+) T Cell and Bactericidal Antibody Response to
   Neisseria meningitidis Serogroup C after Immunization of HIV-Infected
   Children and Adolescents
SO PLoS One
LA English
DT Article
ID VACCINE; ACTIVATION; DISEASE; MARKER
AB Meningococcal disease is endemic in Brazil, with periodic outbreaks and case fatality rates reach as high as 18 to 20% of cases. Conjugate vaccines against meningococci are immunogenic in healthy children. However, we have previously shown a poor bactericidal antibody response to a Men C conjugate vaccine in Brazilian HIV-infected children and adolescents after a single vaccine administration. The goal of the present work was to investigate associations between bactericidal antibody response induced by MenC vaccine and the frequency and activation profile (expression of CD38, HLA-DR and CCR5 molecules) of total CD4(+) memory T cell sub-populations in HIV-1-infected children and adolescents. Responders to vaccination against MenC had a predominance (about 44%) of CD4(+) T-INTERMEDIATE subset followed by T-TRANSITIONAL memory subset (23 to 26%). Importantly, CD4(+) T-INT frequency was positively associated with bactericidal antibody response induced by vaccination. The positive correlation persisted despite the observation that the frequency T-INT CD38(+)HLA-DR+ was higher in responders. In contrast, CD4(+) T-CENTRAL MEMORY (T-CM) subset negatively correlated with bactericidal antibodies. In conclusion, these data indicate that less differentiated CD+ T cells, like TCM may be constantly differentiating into intermediate and later differentiated CD4(+) T cell subsets. These include CD4 T-INT subset which showed a positive association with bactericidal antibodies.
C1 [Milagres, Lucimar G.; Silva, Giselle P.; Pereira-Manfro, Wania F.] Univ Estado Rio De Janeiro, Dept Microbiol Immunol & Parasitol, Rio De Janeiro, RJ, Brazil.
   [Costa, Priscilla R.; Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Hofer, Cristina B.] Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Rio De Janeiro, RJ, Brazil.
   [Ferreira, Bianca; Barreto, Daniella M.; Frota, Ana Cristina C.; Hofer, Cristina B.] Univ Fed Rio de Janeiro, Sch Med, Dept Prevent Med, Rio De Janeiro, RJ, Brazil.
RP Milagres, LG (corresponding author), Univ Estado Rio De Janeiro, Dept Microbiol Immunol & Parasitol, Rio De Janeiro, RJ, Brazil.
EM lucimar@uerj.br
RI Manfro, Wania FP/M-5882-2013; Carvalho, Karina IL/J-6789-2012; Frota,
   Ana Cristina/L-3644-2018
OI Carvalho, Karina IL/0000-0002-7763-8139; Frota, Ana
   Cristina/0000-0002-2825-4374; Kallas, Esper/0000-0003-2026-6925; Manfro,
   Wania/0000-0003-0166-8144
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [573879/2008-7, 552497/2011-8]; Fundacao de Amparo a Pesquisa do Estado
   do Rio de JaneiroCarlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ) [E-26/112.645/2012]; Fundacao de
   Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2009/54055-5]; Fogarty Institute of the
   National Institutes of Health [5R01TW008397]; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel SuperiorCAPES; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [R01TW008397,
   R01TW008397, R01TW008397, R01TW008397, R01TW008397] Funding Source: NIH
   RePORTER
FX This work was funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico, grants (#573879/2008-7 to EGK and #552497/2011-8 (Edital
   Casadinho) to LGM and EGK); Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (#E-26/112.645/2012 to LGM); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (#2009/54055-5 to EGK); Fogarty
   Institute of the National Institutes of Health under award number
   5R01TW008397 to CBH. PRC received scholarship support from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico. GSP received
   scholarship support from Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Barnett LG, 2014, J IMMUNOL, V192, P3607, DOI 10.4049/jimmunol.1301284
   Borrow R, 2013, VACCINE, V31, P4477, DOI 10.1016/j.vaccine.2013.07.083
   Breton G, 2013, J IMMUNOL, V191, P2194, DOI 10.4049/jimmunol.1200646
   Burgers WA, 2009, J IMMUNOL, V182, P4751, DOI 10.4049/jimmunol.0803801
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567
   Frota AC, PED INFECT IN PRESS
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156, DOI 10.1128/CDLI.4.2.156-167.1997
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, MAN CTR REF IM ESP A
   Safadi MAP, 2012, J PEDIAT-BRAZIL, V88, P195, DOI 10.2223/JPED.2167
   Pallikkuth S, 2012, BLOOD, V120, P985, DOI 10.1182/blood-2011-12-396648
   Rosignoli G, 2007, AIDS, V21, P1379, DOI 10.1097/QAD.0b013e3281de7296
   Safadi MAP, 2013, EPIDEMIOL INFECT, V141, P447, DOI 10.1017/S0950268812001689
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Yue FY, 2004, J IMMUNOL, V172, P2476, DOI 10.4049/jimmunol.172.4.2476
NR 17
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 22
PY 2014
VL 9
IS 12
AR e115887
DI 10.1371/journal.pone.0115887
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA3ZY
UT WOS:000348845100114
PM 25532028
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Liu, A
   Glidden, DV
   Anderson, PL
   Amico, KR
   McMahan, V
   Mehrotra, M
   Lama, JR
   MacRae, J
   Hinojosa, JC
   Montoya, O
   Veloso, VG
   Schechter, M
   Kallas, EG
   Chariyalerstak, S
   Bekker, LG
   Mayer, K
   Buchbinder, S
   Grant, R
AF Liu, Albert
   Glidden, David V.
   Anderson, Peter L.
   Amico, K. Rivet
   McMahan, Vanessa
   Mehrotra, Megha
   Lama, Javier R.
   MacRae, John
   Carlos Hinojosa, Juan
   Montoya, Orlando
   Veloso, Valdilea G.
   Schechter, Mauro
   Kallas, Esper G.
   Chariyalerstak, Suwat
   Bekker, Linda-Gail
   Mayer, Kenneth
   Buchbinder, Susan
   Grant, Robert
CA IPrEx Study Team
TI Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender
   Women in the Global iPrEx Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE pre-exposure prophylaxis; drug detection; emtricitabine/tenofovir;
   adherence; men who have sex with men
ID HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL PROPHYLAXIS; TENOFOVIR
   DIPHOSPHATE; ADHERENCE; TRIAL; EMTRICITABINE; PREVENTION; MEN;
   PHARMACOKINETICS; MEDICATIONS
AB Background: Adherence to pre-exposure prophylaxis (PrEP) is critical for efficacy. Antiretroviral concentrations are an objective measure of PrEP use and correlate with efficacy. Understanding patterns and correlates of drug detection can identify populations at risk for non-adherence and inform design of PrEP adherence interventions.
   Methods: Blood antiretroviral concentrations were assessed among active arm participants in iPrEx, a randomized placebo-controlled trial of emtricitabine/tenofovir in men who have sex with men and transgender women in 6 countries. We evaluated rates and correlates of drug detection among a random sample of 470 participants at week 8 and a longitudinal cohort of 303 participants through 72 weeks of follow-up.
   Results: Overall, 55% of participants (95% confidence interval: 49 to 60) tested at week 8 had drug detected. Drug detection was associated with older age and varied by study site. In longitudinal analysis, 31% never had drug detected, 30% always had drug detected, and 39% had an inconsistent pattern. Overall detection rates declined over time. Drug detection at some or all visits was associated with older age, indices of sexual risk, including condom-less receptive anal sex, and responding "don't know" to a question about belief of PrEP efficacy (0-10 scale).
   Conclusions: Distinct patterns of study product use were identified, with a significant proportion demonstrating no drug detection at any visit. Research literacy may explain greater drug detection among populations having greater research experience, such as older men who have sex with men in the United States. Greater drug detection among those reporting highest risk sexual practices is expected to increase the impact and cost-effectiveness of PrEP.
C1 [Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
   [Liu, Albert; Buchbinder, Susan; Grant, Robert] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Glidden, David V.; Buchbinder, Susan] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Anderson, Peter L.] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO USA.
   [Amico, K. Rivet] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
   [McMahan, Vanessa; Mehrotra, Megha; Grant, Robert] Gladstone Inst, San Francisco, CA USA.
   [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [MacRae, John] Invest Med Salud, Lima, Peru.
   [Carlos Hinojosa, Juan] Asociac Civil Selva Amazon, Iquitos, Peru.
   [Montoya, Orlando] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador.
   [Veloso, Valdilea G.] Inst Pesquisa Clin Evandro Chagas IPEC FIOCRUZ, Rio De Janeiro, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Chariyalerstak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Chariyalerstak, Suwat] Chiang Mai Univ, Fac Med, Chiang Mai 50000, Thailand.
   [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Mayer, Kenneth] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Mayer, Kenneth] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
RP Liu, A (corresponding author), San Francisco Dept Publ Hlth, 25 Van Ness Ave,Suite 100, San Francisco, CA 94102 USA.
EM albert.liu@sfdph.org
RI Glidden, David/AAD-4730-2020; Bekker, Linda-Gail/AAZ-8929-2020;
   /AAE-4700-2020; Schechter, Mauro/AAG-7445-2020
OI Grant, Robert/0000-0002-0851-7085; Amico, K Rivet/0000-0002-4458-6934;
   BEKKER, LINDA-GAIL/0000-0002-0755-4386; Kallas,
   Esper/0000-0003-2026-6925; Glidden, David/0000-0001-5888-1419
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIAID UO1 AI064002,
   U01 AI084735, RO1 AI062333, NIMH R01 MH095628]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation; Gilead SciencesGilead
   Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI062333, UM1AI069476, U01AI064002, U01AI064002,
   U01AI064002, R01AI062333, UM1AI069476, UM1AI069496, R01AI062333,
   UM1AI069476, UM1AI069496, UM1AI069476, UM1AI069496, UM1AI069496,
   UM1AI069496, R01AI062333, U01AI084735, UM1AI069476, UM1AI069476,
   R01AI062333, U01AI064002, UM1AI069496, R01AI062333, UM1AI069476,
   U01AI064002, R01AI062333, U01AI064002, UM1AI069496, U01AI084735,
   U01AI064002, U01AI084735, U01AI084735, U01AI064002, R01AI062333,
   U01AI064002, UM1AI069476, UM1AI069496] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, R01MH095628, P30MH062246, R01MH095628,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, R01MH095628,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, R01MH095628, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, R01MH095628, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246] Funding Source: NIH RePORTER
FX Supported by funds from the National Institutes of Health (NIAID UO1
   AI064002, U01 AI084735 and RO1 AI062333; NIMH R01 MH095628), and the
   Bill and Melinda Gates Foundation. Study drug was supplied by Gilead
   Sciences, which also provided funding to support some staff travel to
   annual investigator meetings and the creation of a video regarding
   participant experience.
CR Agresti A., 2007, INTRO CATEGORICAL DA
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Balaji AB, 2013, AIDS, V27, P269, DOI 10.1097/QAD.0b013e32835ad489
   Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66
   Beyrer C, 2013, AIDS, V27, P2665, DOI 10.1097/01.aids.0000432449.30239.fe
   Blaschke TF, 2012, ANNU REV PHARMACOL, V52, P275, DOI 10.1146/annurev-pharmtox-011711-113247
   Blum MR, 2007, J CLIN PHARMACOL, V47, P751, DOI 10.1177/0091270007300951
   Bushman LR, 2011, J PHARMACEUT BIOMED, V56, P390, DOI 10.1016/j.jpba.2011.05.039
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Clare C, 2013, GYNECOL OBSTET, P3
   Dai JY, 2013, AM J EPIDEMIOL, V177, P256, DOI 10.1093/aje/kws324
   Delahunty T, 2009, J CHROMATOGR B, V877, P1907, DOI 10.1016/j.jchromb.2009.05.029
   Gallagher T, 2014, LGBT HEALTH, V1, P218, DOI 10.1089/lgbt.2013.0046
   Gilmore HJ, 2013, AIDS PATIENT CARE ST, V27, P560, DOI 10.1089/apc.2013.0116
   Goicochea P, 2009, 15 C RETR OPP INF MO, pY162
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Haberer JE, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001511
   Hawkins T, 2005, JAIDS-J ACQ IMM DEF, V39, P406, DOI 10.1097/01.qai.0000167155.44980.e8
   Hendrix CW, 2013, CELL, V155, P515, DOI 10.1016/j.cell.2013.09.030
   Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081
   Hyre Amanda D, 2007, J Clin Hypertens (Greenwich), V9, P179, DOI 10.1111/j.1524-6175.2007.06372.x
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Koenig LJ, 2013, AM J PREV MED, V44, pS91, DOI 10.1016/j.amepre.2012.09.047
   Lewey J, 2013, AM HEART J, V165, P665, DOI 10.1016/j.ahj.2013.02.011
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Marrazzo J, 2013, C RETR OPP INF MARCH
   Muchomba FM, 2012, JAIDS-J ACQ IMM DEF, V61, P490, DOI 10.1097/QAI.0b013e31826f9962
   Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e
   Naderi SH, 2012, AM J MED, V125, P882, DOI 10.1016/j.amjmed.2011.12.013
   Pilote L, 1996, ARCH INTERN MED, V156, P161, DOI 10.1001/archinte.156.2.161
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Wheelock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054288
   Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7
NR 36
TC 42
Z9 42
U1 0
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 5
PY 2014
VL 67
IS 5
BP 528
EP 537
DI 10.1097/QAI.0000000000000351
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT2NW
UT WOS:000344772300015
PM 25230290
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Dracxler, RC
   Oh, C
   Kalmbach, K
   Wang, F
   Liu, L
   Kallas, EG
   Giret, MTM
   Seth-Smith, ML
   Antunes, D
   Keefe, DL
   Abrao, MS
AF Dracxler, Roberta C.
   Oh, C.
   Kalmbach, K.
   Wang, F.
   Liu, L.
   Kallas, E. G.
   Giret, M. T. M.
   Seth-Smith, M. L.
   Antunes, D.
   Keefe, D. L.
   Abrao, M. S.
TI Peripheral Blood Telomere Content Is Greater in Patients With
   Endometriosis Than in Controls
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE endometriosis; telomere; telomerase
ID DEEPLY INFILTRATING ENDOMETRIOSIS; PERITONEAL ENDOMETRIOSIS; OVARIAN
   ENDOMETRIOSIS; STEM-CELLS; CANCER; EXPRESSION; WOMEN; PATHOGENESIS;
   APOPTOSIS; ETIOLOGY
AB The etiology of endometriosis remains poorly understood but circulating stem cells may contribute. Telomeres shorten with cell divisions and age. Stem cells attempt to compensate for telomere attrition through the action of telomerase. Since circulating stem cells may contribute to endometriosis, we compared telomere content in lymphocytes of patients with and without endometriosis.
   Methods: Observational study comparing peripheral lymphocytes telomere content, measured by quantitative polymerase chain reaction, in patients with (n = 86) and without endometriosis (n = 21).
   Findings: Patients with endometriosis had longer telomeres than that of matched, endometriosis-free controls (telomere to single copy gene ratio [T/S ratio] of 1.62 vs 1.34, respectively, P = .00002). Patients with endometriosis were 8.1-fold more likely to have long telomeres. (odds ratio = 8.1, 95% confidence interval: 1.28-51.57, P = .0264).
   Interpretation: Longer telomeres could be consistent with a stem cell origin of endometriosis.
C1 [Dracxler, Roberta C.; Oh, C.; Kalmbach, K.; Wang, F.; Liu, L.; Seth-Smith, M. L.; Antunes, D.; Keefe, D. L.] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10009 USA.
   [Dracxler, Roberta C.; Abrao, M. S.] Univ Sao Paulo, Sch Med, Endometriosis Dept, Sao Paulo, Brazil.
   [Kallas, E. G.; Giret, M. T. M.] Univ Sao Paulo, Sch Med, Dept Immunol, Sao Paulo, Brazil.
RP Dracxler, RC (corresponding author), NYU, Sch Med, Dept Obstet & Gynecol, 450 E 20th St,Apt 6D, New York, NY 10009 USA.
EM roberta_dracxler@yahoo.com.br
RI Abrao, Mauricio S/L-3387-2017
OI Abrao, Mauricio S/0000-0003-1320-3010; Kallas, Esper/0000-0003-2026-6925
FU Obstetrics and Gynecology Department of New York University, New York,
   NY; Endometriosis Department of the Medical School of Sao Paulo
   University, Sao Paulo, SP, Brazil; Immunology Department of the Medical
   School of Sao Paulo University, Sao Paulo, SP, Brazil
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: Obstetrics
   and Gynecology Department of New York University, New York, NY;
   Endometriosis Department of the Medical School of Sao Paulo University,
   Sao Paulo, SP, Brazil; Immunology Department of the Medical School of
   Sao Paulo University, Sao Paulo, SP, Brazil.
CR Abrao MS, 2006, FERTIL STERIL, V86, P543, DOI 10.1016/j.fertnstert.2006.02.102
   Bayne S, 2005, MOL CELL ENDOCRINOL, V240, P11, DOI 10.1016/j.mce.2005.05.009
   Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7
   Calado RT, 2009, BLOOD, V114, P2236, DOI 10.1182/blood-2008-09-178871
   Canis M, 1997, FERTIL STERIL, V67, P817
   Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370
   Chapron C, 2006, HUM REPROD, V21, P1839, DOI 10.1093/humrep/del079
   Erzen M, 1998, EUR J GYNAECOL ONCOL, V19, P553
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   HALME J, 1984, OBSTET GYNECOL, V64, P151
   Hapangama DK, 2008, HUM REPROD, V23, P1511, DOI 10.1093/humrep/den172
   Harada T, 2001, FERTIL STERIL, V76, P1, DOI 10.1016/S0015-0282(01)01816-7
   Harada T, 2004, HUM REPROD UPDATE, V10, P29, DOI 10.1093/humupd/dmh007
   Jimbo H, 1997, INT J GYNECOL OBSTET, V59, P245, DOI 10.1016/S0020-7292(97)00238-5
   Kim CM, 2007, HUM REPROD, V22, P843, DOI 10.1093/humrep/del425
   Lapp T, 2000, AM FAM PHYSICIAN, V62, P1431
   Figueira PGM, 2011, ANN NY ACAD SCI, V1221, P10, DOI 10.1111/j.1749-6632.2011.05969.x
   Meresman GF, 2000, FERTIL STERIL, V74, P760, DOI 10.1016/S0015-0282(00)01522-3
   METZGER DA, 1989, OBSTET GYN CLIN N AM, V16, P1
   Nisolle M, 1997, FERTIL STERIL, V68, P585, DOI 10.1016/S0015-0282(97)00191-X
   O'Callaghan NJ, 2011, BIOL PROCED ONLINE, V13, DOI 10.1186/1480-9222-13-3
   Prescott J, 2012, MUTAT RES-FUND MOL M, V730, P75, DOI 10.1016/j.mrfmmm.2011.06.009
   Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X
   Sasson IE, 2008, ANN NY ACAD SCI, V1127, P106, DOI 10.1196/annals.1434.014
   Starzinski Powitz A, 1999, MOL MED TODAY, V5, P304
   Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4
   Vercellini P, 1997, OBSTET GYNECOL, V90, P264, DOI 10.1016/S0029-7844(97)00235-4
   von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2
   Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3
   Wright WE, 1996, DEV GENET, V18, P173
NR 30
TC 9
Z9 9
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD DEC
PY 2014
VL 21
IS 12
BP 1465
EP 1471
DI 10.1177/1933719114527353
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA AT8YK
UT WOS:000345214700004
PM 24675987
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Milush, JM
   Cunha-Neto, E
   Kallas, EG
   Kalil, J
   Somsouk, M
   Hunt, PW
   Deeks, SG
   Nixon, DF
   SenGupta, D
AF Ribeiro, Susan P.
   Milush, Jeffrey M.
   Cunha-Neto, Edecio
   Kallas, Esper G.
   Kalil, Jorge
   Somsouk, Ma
   Hunt, Peter W.
   Deeks, Steven G.
   Nixon, Douglas F.
   SenGupta, Devi
TI The CD8(+) Memory Stem T Cell (T-SCM) Subset Is Associated with Improved
   Prognosis in Chronic HIV-1 Infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRUS TYPE-1 INFECTION; CD4(+); LYMPHOCYTES; ACTIVATION
AB Memory stem T cells (T-SCM) constitute a long-lived, self-renewing lymphocyte population essential for the maintenance of functional immunity. The hallmarks of HIV-1 pathogenesis are CD4(+) T cell depletion and abnormal cellular activation. We investigated the impact of HIV-1 infection on the T-SCM compartment, as well as any protective role these cells may have in disease progression, by characterizing this subset in a cohort of 113 subjects with various degrees of viral control on and off highly active antiretroviral therapy (HAART). We observed that the frequency of CD8(+) T-SCM was decreased in all individuals with chronic, untreated HIV-1 infection and that HAART had a restorative effect on this subset. In contrast, natural controllers of HIV-1 had the highest absolute number of CD4(+) T-SCM cells among all of the infected groups. The frequency of CD4(+) T-SCM predicted higher CD8(+) T-SCM frequencies, consistent with a role for the CD4(+) subset in helping to maintain CD8(+) memory T cells. In addition, T-SCM appeared to be progenitors for effector T cells (TEM), as these two compartments were inversely correlated. Increased frequencies of CD8(+) T-SCM predicted lower viral loads, higher CD4(+) counts, and less CD8(+) T cell activation. Finally, we found that T-SCM express the mucosal homing integrin alpha(4)beta(7) and can be identified in gut-associated lymphoid tissue (GALT). The frequency of mucosal CD4(+) T-SCM was inversely correlated with that in the blood, potentially reflecting the ability of these self-renewing cells to migrate to a crucial site of ongoing viral replication and CD4(+) T cell depletion.
   IMPORTANCE
   HIV-1 infection leads to profound impairment of the immune system. T-SCM constitute a recently identified lymphocyte subset with stem cell-like qualities, including the ability to generate other memory T cell subtypes, and are therefore likely to play an important role in controlling viral infection. We investigated the relationship between the size of the CD8(+) T-SCM compartment and HIV-1 disease progression in a cohort of chronically infected individuals. Our results suggest that HAART restores a normal frequency of CD8(+) T-SCM and that the natural preservation of this subset in the setting of untreated HIV-1 infection is associated with improved viral control and immunity. Therefore, the CD8(+) T-SCM population may represent a correlate of protection in chronic HIV-1 infection that is directly relevant to the design of T cell-based vaccines, adoptive immunotherapy approaches, or the pharmacologic induction of T-SCM.
C1 [Ribeiro, Susan P.; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, LIM60, Lab Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Ribeiro, Susan P.; Cunha-Neto, Edecio; Kallas, Esper G.; Kalil, Jorge] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Milush, Jeffrey M.; SenGupta, Devi] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Cunha-Neto, Edecio; Kalil, Jorge] Univ Sao Paulo, Sch Med, Inst Heart, Immunol Lab, Sao Paulo, Brazil.
   [Kalil, Jorge] Butantan Inst, Sao Paulo, Brazil.
   [Somsouk, Ma] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA.
   [Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA.
   [Nixon, Douglas F.] George Washington Univ, Dept microbiol Immunol & Trop Med, Washington, DC USA.
RP SenGupta, D (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM devi.sengupta@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020; KALIL, JORGE/C-8029-2012; Cunha-Neto,
   Edecio/B-4157-2009; Hunt, Peter W./P-2976-2017
OI Nixon, Douglas/0000-0002-2801-1786; KALIL, JORGE/0000-0001-8415-4274;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Hunt, Peter
   W./0000-0002-4571-4870; Kallas, Esper/0000-0003-2026-6925; Deeks,
   Steven/0000-0001-6371-747X
FU Delaney AIDS Research Enterprise (DARE) [AI096109]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K24 AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR
   [P30 AI027763]; UCSF Clinical and Translational Research Institute
   Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention
   Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24
   AI067039]; NIH NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [K23 CA157929]; NIH NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [K08
   A120071]; Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Sao Paulo State Research Funding Agency (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2010/05845-0/EGK]; CNPq/CAPESNational Council for
   Scientific and Technological Development (CNPq)CAPES [056/2012];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [K23CA157929, K23CA157929, K23CA157929, K23CA157929]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000004, UL1TR000004,
   UL1TR000004, UL1TR000004, UL1TR000004, UL1TR000004, UL1TR000004] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI027763, P30AI027763, R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, K24AI069994, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, U19AI096109, U19AI096109, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   U19AI096109, R24AI067039, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U19AI096109, K24AI069994, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, P30AI027763, K24AI069994, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   U19AI096109, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, K24AI069994, P30AI027763,
   P30AI027763, U19AI096109, P30AI027763, R24AI067039, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U19AI096109, U19AI096109, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, U19AI096109, U19AI096109,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, U19AI096109, P30AI027763,
   K24AI069994, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, U19AI096109, U19AI096109, R24AI067039, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U19AI096109, R24AI067039,
   P30AI027763, P30AI027763, U19AI096109, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, K24AI069994, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   P30AI027763, U19AI096109, U19AI096109, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U19AI096109,
   U19AI096109, U19AI096109, R24AI067039, U19AI096109, P30AI027763,
   P30AI027763, P30AI027763, R24AI067039, U19AI096109, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding
   Source: NIH RePORTER
FX This work was supported by the Delaney AIDS Research Enterprise (DARE;
   AI096109), NIAID (K24 AI069994), the UCSF/Gladstone Institute of
   Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and
   Translational Research Institute Clinical Research Center (UL1
   RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the
   CFAR Network of Integrated Systems (R24 AI067039). M.S. was supported by
   NIH NCI K23 CA157929. D.S. was supported by NIH NIAID K08 A120071. This
   research was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) and the Sao Paulo State Research
   Funding Agency (FAPESP) and by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (2010/05845-0/EGK) (D.F.N.) and CNPq/CAPES 056/2012
   (D.F.N.). E.C.-N. and J.K. are recipients of productivity awards from
   the Brazilian Council for Scientific and Technological Development
   (CNPq).
CR Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Emu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085613
   Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446
   Ghiglione Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104235
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Grelli S, 2003, ANN NY ACAD SCI, V1010, P560, DOI 10.1196/annals.1299.104
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Klatt NR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004345
   Klatt NR, 2013, TRENDS MICROBIOL, V21, P6, DOI 10.1016/j.tim.2012.09.001
   Koelsch KK, 2008, J INFECT DIS, V197, P411, DOI 10.1086/525283
   Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327
   Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Tabler CO, 2014, J VIROL, V88, P4976, DOI 10.1128/JVI.00324-14
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
NR 18
TC 25
Z9 29
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2014
VL 88
IS 23
BP 13836
EP 13844
DI 10.1128/JVI.01948-14
PG 9
WC Virology
SC Virology
GA AT3CI
UT WOS:000344812800027
PM 25253339
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU van de Weg, CAM
   Huits, RMHG
   Pannuti, CS
   Brouns, RM
   van den Berg, RWA
   van den Ham, HJ
   Martina, BEE
   Osterhaus, ADME
   Netea, MG
   Meijers, JCM
   van Gorp, ECM
   Kallas, EG
AF van de Weg, Cornelia A. M.
   Huits, Ralph M. H. G.
   Pannuti, Claudio S.
   Brouns, Rosalba M.
   van den Berg, Riemsdijk W. A.
   van den Ham, Henk-Jan
   Martina, Byron E. E.
   Osterhaus, Albert D. M. E.
   Netea, Mihai G.
   Meijers, Joost C. M.
   van Gorp, Eric C. M.
   Kallas, Esper G.
TI Hyperferritinaemia in Dengue Virus Infected Patients Is Associated with
   Immune Activation and Coagulation Disturbances
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INFLAMMATORY CYTOKINES; HEMORRHAGIC-FEVER; PATHOGENESIS; FERRITIN;
   CHILDREN; DISEASE; FIBRINOLYSIS; BRADYKININ; ILLNESS; CELLS
AB Background: During a dengue outbreak on the Caribbean island Aruba, highly elevated levels of ferritin were detected in dengue virus infected patients. Ferritin is an acute-phase reactant and hyperferritinaemia is a hallmark of diseases caused by extensive immune activation, such as haemophagocytic lymphohistiocytosis. The aim of this study was to investigate whether hyperferritinaemia in dengue patients was associated with clinical markers of extensive immune activation and coagulation disturbances.
   Methodology/Principal Findings: Levels of ferritin, standard laboratory markers, sIL-2R, IL-18 and coagulation and fibrinolytic markers were determined in samples from patients with uncomplicated dengue in Aruba. Levels of ferritin were significantly increased in dengue patients compared to patients with other febrile illnesses. Moreover, levels of ferritin associated significantly with the occurrence of viraemia. Hyperferritinaemia was also significantly associated with thrombocytopenia, elevated liver enzymes and coagulation disturbances. The results were validated in a cohort of dengue virus infected patients in Brazil. In this cohort levels of ferritin and cytokine profiles were determined. Increased levels of ferritin in dengue virus infected patients in Brazil were associated with disease severity and a pro-inflammatory cytokine profile.
   Conclusions/Significance: Altogether, we provide evidence that ferritin can be used as a clinical marker to discriminate between dengue and other febrile illnesses. The occurrence of hyperferritinaemia in dengue virus infected patients is indicative for highly active disease resulting in immune activation and coagulation disturbances. Therefore, we recommend that patients with hyperferritinaemia are monitored carefully.
C1 [van de Weg, Cornelia A. M.; van den Ham, Henk-Jan; Martina, Byron E. E.; Osterhaus, Albert D. M. E.; van Gorp, Eric C. M.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Huits, Ralph M. H. G.] Dr Horacio E Oduber Hosp, Emergency Dept, Oranjestad, Aruba, Iceland.
   [Huits, Ralph M. H. G.] Dr Horacio E Oduber Hosp, Dept Internal Med, Oranjestad, Aruba, Iceland.
   [Pannuti, Claudio S.] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Pannuti, Claudio S.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Brouns, Rosalba M.; van den Berg, Riemsdijk W. A.] Landslaboratorium, Oranjestad, Aruba, Iceland.
   [Netea, Mihai G.] Radboud Univ Nijmegen, Dept Expt Internal Med, Nijmegen, Netherlands.
   [Meijers, Joost C. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
   [Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
RP van de Weg, CAM (corresponding author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
EM e.vangorp@erasmusmc.nl
RI Brouns, Raf/E-1044-2013; Meijers, J.C.M./S-5981-2019; Netea,
   Mihai/N-5155-2014; Huits, Ralph/I-8361-2019
OI Brouns, Raf/0000-0001-6540-5699; Meijers, J.C.M./0000-0002-4198-6780;
   Huits, Ralph/0000-0001-8803-9468; Kallas, Esper/0000-0003-2026-6925; van
   den Ham, Henk-Jan/0000-0001-8582-5404
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq)National Council for Scientific
   and Technological Development (CNPq) [476088/2009-7, 301339/2009-0];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of EducationCAPES; Virgo consortium - Dutch
   government [FES0908]; Netherlands Genomics Initiative (NGI)
   [050-060-452]; ERCEuropean Research Council (ERC) [310371]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazilian Ministry of Science and Technology
   (CNPq, grant #476088/2009-7 to EGK and 301339/2009-0 to CSP). KIC's
   scholarship was supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education.
   Moreover, this study was supported by the Virgo consortium, funded by
   the Dutch government project number FES0908, and by the Netherlands
   Genomics Initiative (NGI) project number 050-060-452. MGN was supported
   by an ERC Consolidator Grant (no 310371). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anez G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/678645
   BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381
   Chaiyaratana Wathanee, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P832
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Dumoulin A, 2008, J CLIN MICROBIOL, V46, P3104, DOI 10.1128/JCM.01294-08
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   FAHMY M, 1993, BIOCHEM J, V296, P175, DOI 10.1042/bj2960175
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Ludwiczek S, 2003, BLOOD, V101, P4148, DOI 10.1182/blood-2002-08-2459
   Maeda H, 1996, IMMUNOPHARMACOLOGY, V33, P222, DOI 10.1016/0162-3109(96)00063-X
   Mairuhu ATA, 2003, LANCET INFECT DIS, V3, P33, DOI 10.1016/S1473-3099(03)00487-0
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Mentor NA, 1997, ACTA VIROL, V41, P175
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Parthasarathy N, 2002, BIOCHEM J, V365, P279, DOI 10.1042/BJ20011637
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Sadon N, 2008, J VIROL METHODS, V153, P1, DOI 10.1016/j.jviromet.2008.06.023
   Sung JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046292
   Tan LH, 2012, J CLIN VIROL, V55, P79, DOI 10.1016/j.jcv.2012.06.005
   Torrentes-Carvalho A, 2014, IMMUNOBIOLOGY, V219, P329, DOI 10.1016/j.imbio.2013.11.002
   Tran TN, 1997, BLOOD, V90, P4979, DOI 10.1182/blood.V90.12.4979.4979_4979_4986
   Usmani GN, 2013, BRIT J HAEMATOL, V161, P609, DOI 10.1111/bjh.12293
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
   van Gorp ECM, 2002, J MED VIROL, V67, P549, DOI 10.1002/jmv.10137
   Weiss G, 2005, BEST PRACT RES CL HA, V18, P183, DOI 10.1016/j.beha.2004.09.001
   Wills BA, 2002, CLIN INFECT DIS, V35, P277, DOI 10.1086/341410
   World Health Organization, 2009, DENG HEM FEV DIAGN T
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
NR 39
TC 23
Z9 24
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2014
VL 8
IS 10
AR e3214
DI 10.1371/journal.pntd.0003214
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AS9WJ
UT WOS:000344589000032
PM 25299654
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Kassanjee, R
   Pilcher, CD
   Keating, SM
   Facente, SN
   McKinney, E
   Price, MA
   Martin, JN
   Little, S
   Hecht, FM
   Kallas, EG
   Welte, A
   Busch, MP
   Murphy, G
AF Kassanjee, Reshma
   Pilcher, Christopher D.
   Keating, Sheila M.
   Facente, Shelley N.
   McKinney, Elaine
   Price, Matthew A.
   Martin, Jeffrey N.
   Little, Susan
   Hecht, Frederick M.
   Kallas, Esper G.
   Welte, Alex
   Busch, Michael P.
   Murphy, Gary
CA CEPHIA
TI Independent assessment of candidate HIV incidence assays on specimens in
   the CEPHIA repository
SO AIDS
LA English
DT Article
DE biomarkers; HIV; incidence assays; incidence estimation; recent
   infection
ID INFECTION; SEROCONVERSION; DIAGNOSIS; RATES
AB Objective: Cross-sectional HIV incidence surveillance, using assays that distinguish `recent' from `nonrecent' infections, has been hampered by inadequate performance and characterization of incidence assays. In this study, the Consortium for the Evaluation and Performance of HIV Incidence Assays presents results of the first independent evaluation of five incidence assays (BED, Limiting Antigen Avidity, Less-sensitive Vitros, Vitros Avidity and BioRad Avidity).
   Design: A large repository of diverse specimens from HIV-positive patients was established, multiple assays were run on 2500 selected specimens, and data were analyzed to estimate assay characteristics relevant for incidence surveillance.
   Methods: The mean duration of recent infection (MDRI, average time `recent' while infected for less than some time cut-off T) was estimated from longitudinal data on seroconverters by regression. The false-recent rate (FRR, probability of testing `recent' when infected for longer than T) was explored by measuring the proportions of `recent' results in various subsets of patients.
   Results: Assays continue to fail to attain the simultaneously large MDRI and small FRR demanded by existing performance guidelines. All assays produce high FRRs amongst virally suppressed patients (>40%), including elite controllers and treated patients.
   Conclusions: Results from this first independent evaluation provide valuable information about the current performance of assays, and suggest the need for further optimization. Variation of `recent'/`nonrecent' thresholds and the use of multiple antibody-maturation assays, as well as other biomarkers, can now be explored, using the rich data generated by the Consortium for the Evaluation and Performance of HIV Incidence Assays. Consistently high FRRs amongst those virally suppressed suggest that viral load will be a particularly valuable supplementary marker.
   Video abstract: http://links.lww.com/QAD/A569 (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Kassanjee, Reshma; Welte, Alex] Univ Stellenbosch, South African DST NRF Ctr Excellence Epidemiol Mo, ZA-7600 Stellenbosch, South Africa.
   [Kassanjee, Reshma] Univ Witwatersrand, Sch Computat & Appl Math, Johannesburg, South Africa.
   [Pilcher, Christopher D.; Facente, Shelley N.; Price, Matthew A.; Martin, Jeffrey N.; Hecht, Frederick M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Keating, Sheila M.; Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
   [McKinney, Elaine; Murphy, Gary] Publ Hlth England, London, England.
   [Price, Matthew A.] IAVI, Dept Med Affairs, New York, NY USA.
   [Little, Susan] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Kassanjee, R (corresponding author), Univ Stellenbosch, South African DST NRF Ctr Excellence Epidemiol Mo, ZA-7600 Stellenbosch, South Africa.
EM rkassanjee@sun.ac.za
RI Little, Susan/AAA-6116-2019; Facente, Shelley/M-1147-2019
OI Kallas, Esper/0000-0003-2026-6925; Facente, Shelley
   N./0000-0002-7266-352X; Keating, Sheila/0000-0002-8324-3694; Kassanjee,
   Reshma/0000-0002-1200-8726; Hecht, Frederick/0000-0002-5782-1171; Price,
   Matt/0000-0002-2918-1373
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [OPP1017716]; Bill & Melinda Gates FoundationBill & Melinda Gates
   FoundationCGIAR; Ministry of Foreign Affairs of Denmark; Irish AidCGIAR;
   Ministry of Finance of Japan; Ministry of Foreign Affairs of the
   Netherlands; Norwegian Agency for Development Cooperation (NORAD)CGIAR;
   United Kingdom Department for International Development (DFID); United
   States Agency for International Development (USAID)United States Agency
   for International Development (USAID)CGIAR; OPEC Fund for International
   Development (OFID), a development finance institution of the OPEC Member
   States; National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI43638, AI74621, AI106039]; California HIV-1 Research Program(CHRP)
   [RN07-SD-702]; Brazilian Ministry of Health; Brazilian Program for STD
   and AIDS [914/BRA/3014-UNESCO]; Sao Paulo City Health Department
   [2004-0.168.922-7]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30 AI027763, R24
   AI067039, P01 A1071713, R34 MH096606, R01 HD074511]; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R01HD074511, R01HD074511,
   R01HD074511, R01HD074511, R01HD074511] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI071713, P30AI027763, P30AI027763, P30AI027763, U01AI043638,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, R24AI106039, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P01AI074621, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, R24AI067039, U01AI043638, P30AI027763,
   P01AI071713, R24AI106039, R24AI067039, P01AI071713, P30AI027763,
   P30AI027763, P01AI074621, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P01AI074621, R24AI106039,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, R24AI106039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P01AI074621, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI074621, P01AI074621,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI074621, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P01AI074621, P01AI074621,
   P01AI071713, P30AI027763, P01AI074621, P30AI027763, P01AI074621,
   R24AI067039, P30AI027763, P01AI074621, P30AI027763, U01AI043638,
   R24AI067039, U01AI043638, P01AI074621, P30AI027763, P01AI071713,
   R24AI106039, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   U01AI043638, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, U01AI043638,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R24AI067039, P30AI027763, R24AI067039, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, U01AI043638, P30AI027763, P30AI027763, R24AI067039,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P30AI027763, R24AI106039,
   P30AI027763, P30AI027763, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, R24AI067039, P30AI027763, P01AI071713, P30AI027763,
   R24AI067039, P30AI027763, P30AI027763, P01AI071713, R24AI067039,
   P01AI071713, P01AI074621, P01AI074621, P01AI071713, P30AI027763,
   U01AI043638, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   U01AI043638, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P01AI071713, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI043638, P30AI027763, P01AI074621, P30AI027763,
   P01AI071713, P30AI027763, P01AI074621, U01AI043638, R24AI106039,
   P30AI027763, P01AI071713, P01AI074621, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI074621, P30AI027763, P01AI074621,
   P30AI027763, R24AI067039, P30AI027763, U01AI043638, P01AI074621,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   U01AI043638, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, R24AI067039, P01AI074621,
   P01AI074621, P30AI027763, R24AI067039, P01AI071713, P01AI074621,
   U01AI043638, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01MH100974, R01MH100974, R34MH096606, R01MH100974, R01MH100974,
   R01MH100974, R34MH096606, R34MH096606] Funding Source: NIH RePORTER
FX G.M., A.W., C.D.P. and M.P.B. conceived the study design and sourced
   funding. R.K. and A.W. led the data analysis. C.D.P., S.N.F., S.L.,
   M.A.P., J.N.M., E.G.K. and F.M.H. led on specimen acquisition and
   related data collection. G.M., M.P.B., S.M.K. and E.M. led on assay
   performance and quality, and assay results reporting. R.K. drafted the
   paper and all authors assisted in the interpretation of findings,
   provided input and suggestions for analysis, and critically reviewed the
   draft and the final submitted version. Funding for this project was
   provided by the Bill & Melinda Gates Foundation (grant OPP1017716).;
   IAVI's work is made possible by generous support from many donors
   including: the Bill & Melinda Gates Foundation; the Ministry of Foreign
   Affairs of Denmark; Irish Aid; the Ministry of Finance of Japan; the
   Ministry of Foreign Affairs of the Netherlands; the Norwegian Agency for
   Development Cooperation (NORAD); the United Kingdom Department for
   International Development (DFID); and the United States Agency for
   International Development (USAID). The full list of IAVI donors is
   available at www.iavi.org. This report is made possible by the generous
   support of the American people through USAID. The contents are the
   responsibility of the International AIDS Vaccine Initiative and do not
   necessarily reflect the views of USAID or the United States Government.
   Funding was also provided by the OPEC Fund for International Development
   (OFID), a development finance institution of the OPEC Member States,
   established to provide financial support for socioeconomic development,
   particularly for low-income countries.; The San Diego Primary Infection
   Cohort acknowledges funding by the National Institutes of Health (NIH,
   grants AI43638, AI74621 and AI106039), and the California HIV-1 Research
   Program(CHRP, grant RN07-SD-702).; The Sao Paulo Cohort acknowledges
   funding by the Brazilian Ministry of Health, Brazilian Program for STD
   and AIDS (grant 914/BRA/3014-UNESCO) and the Sao Paulo City Health
   Department (grant 2004-0.168.922-7).; The SCOPE study received funding
   from the NIH (grants P30 AI027763 and R24 AI067039).; The AMPLIAR and
   Options Cohorts also received funding from the NIH (grants P01 A1071713,
   R34 MH096606 and R01 HD074511).
CR Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469
   Atun R, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001045
   Bill & Melinda Gates Foundation Letters of Inquiry (LOI), NEW BIOM HIV INC MEA
   Bollinger RC, 1997, JAMA-J AM MED ASSOC, V278, P2085, DOI 10.1001/jama.278.23.2085
   Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
   Brookmeyer R, 2013, AM J EPIDEMIOL, V177, P264, DOI 10.1093/aje/kws436
   Costa PR, 2014, 2014 C RETR OPP INF
   Curtis KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064201
   Daar ES, 2001, ANN INTERN MED, V134, P25, DOI 10.7326/0003-4819-134-1-200101020-00010
   Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
   Efron B., 1993, MONOGRAPHS STAT APPL, V57
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
   Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jain V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015510
   Kassanjee R, 2013, 20 C RETR OPP INF AT
   Kassanjee R, 2013, SAT SESS 20 C RETR O
   Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/aid.2013.0113, 10.1089/AID.2013.0113]
   Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
   Keating SM, 2012, J CLIN MICROBIOL, V50, P3968, DOI 10.1128/JCM.01454-12
   Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640
   Laeyendecker O, 2013, J INFECT DIS, V207, P232, DOI 10.1093/infdis/jis659
   Le Vu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039872
   Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038
   Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014
   Masciotra S, 2010, 17 C RETR OPP INF SA
   Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
   Mastro Timothy D, 2010, J HIV AIDS Surveill Epidemiol, V2, P1
   Mehrotra DV, 2003, BIOMETRICS, V59, P441, DOI 10.1111/1541-0420.00051
   Morris SR, 2010, ANN INTERN MED, V152, P778, DOI 10.7326/0003-4819-152-12-201006150-00005
   Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services, GUIDELINES USE ANTIR
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713
   Powers KA, 2007, AIDS, V21, P2237, DOI 10.1097/QAD.0b013e3282f08b4d
   Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030
   Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001
   Sedia Biosciences Corporation, 2012, SED HIV 1 LAG AV EIA
   Sedia Biosciences Corporation, 2013, SED BED HIV 1 INC EI
   Sedia Biosciences Corporation, 2013, SED HIV 1 LAG AV EIA
   South African Department of Health, S AFR ANT TREATM GUI
   UNAIDS-WHO, 2011, US ASS REC INF EST H
   Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525
   WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472
NR 44
TC 84
Z9 85
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT
PY 2014
VL 28
IS 16
BP 2439
EP 2449
DI 10.1097/QAD.0000000000000429
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AR0YW
UT WOS:000343304000012
PM 25144218
OA Green Published
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Oliveira, Ana Karolina B.
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI Invariant natural killer T cells in patients with common variable
   immunodeficiency
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID DEFICIENCY
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
   [Santos, Bianca A. N.; Toledo-Barros, Myrthes; Oliveira, Ana Karolina B.; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Carvalho, Karina I.] Hosp Albert Einstein, Sao Paulo, Brazil.
RP Paquin-Proulx, D (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
EM dominic.paquin-proulx@ki.se
RI Kokron, Cristina M/D-3140-2012; KALIL, JORGE/C-8029-2012; Marinho, Ana
   Karolina/C-8395-2017; Carvalho, Karina IL/J-6789-2012
OI Kokron, Cristina M/0000-0002-9080-0305; KALIL,
   JORGE/0000-0001-8415-4274; Marinho, Ana Karolina/0000-0001-9369-8222;
   Carvalho, Karina IL/0000-0002-7763-8139; Sandberg,
   Johan/0000-0002-6275-0750; Moll, Markus/0000-0003-4592-3063; Kallas,
   Esper/0000-0003-2026-6925; Paquin Proulx, Dominic/0000-0003-1407-3414
CR Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Fulcher DA, 2009, CLIN EXP IMMUNOL, V157, P365, DOI 10.1111/j.1365-2249.2009.03973.x
   Gao YF, 2014, J ALLERGY CLIN IMMUN, V133, P1420, DOI 10.1016/j.jaci.2013.10.059
   Paquin-Proulx D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075199
   Paquin-Proulx D, 2013, BLOOD, V121, P4963, DOI 10.1182/blood-2013-04-499442
NR 5
TC 3
Z9 3
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD OCT
PY 2014
VL 134
IS 4
BP 989
EP 990
DI 10.1016/j.jaci.2014.06.039
PG 2
WC Allergy; Immunology
SC Allergy; Immunology
GA AQ9GC
UT WOS:000343155700038
PM 25159463
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Francelino, HS
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Francelino, Hilario Sousa
   Kallas, Esper Georges
TI YELLOW FEVER PREVENTION STRATEGIES AWARENESS AMONG HIV-INFECTED PATIENTS
   IN SAO PAULO, BRAZIL
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE HIV; AIDS; Yellow Fever; Vaccine; Questionnaire
ID RISK PERCEPTION; ATTITUDES; KNOWLEDGE; COMMUNICATION; TRAVELERS;
   DISEASES; AIRPORT
AB Introduction: Vaccination is the main preventive strategy against Yellow Fever (YF), which is a public health concern in Brazil. However, HIV-infected patients might have insufficient knowledge regarding YF, YF prevention, and vaccines in general. Methods: In this questionnaire-based study, data from 158 HIV-infected individuals were addressed in three distinct outpatient clinics in Sao Paulo. Information was collected on demographic and clinical characteristics, as well as patients' knowledge of vaccines, YF and YF preventive strategies. In addition, individual YF vaccine recommendations and vaccine status were investigated. Results: Although most participants adequately ascertain the vaccine as the main prevention strategy against YF, few participants were aware of the severity and lack of specific treatment for YF. Discrepancy in YF vaccine (patients who should have taken the vaccine, but did not) was observed in 18.8% of participants. Conclusion: YF is an important and preventable public health concern, and these results demonstrate that more information is necessary for the HIV-infected population.
C1 [Avelino-Silva, Vivian Iida; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Francelino, Hilario Sousa; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Discipline Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Kallas,
   Esper/0000-0003-2026-6925
FU CAPES (Ministerio da Educacao - Brazil)CAPES
FX The authors would like to thank Karina Takesaki Miyaji, Ana Marli
   Sartori and Marta Heloisa Lopes for reviewing the original survey and
   providing useful suggestions. The authors would also like to thank
   Tamara Newman Lobato Sousa, Jessica Fernandes Ramos and Fabiana Siroma
   for helping the application of the questionnaires. This study was
   supported by CAPES (Ministerio da Educacao - Brazil).
CR Brasil. Ministerio da Saude, 2008, SIT FEBR AM SILV BRA
   Brasil. Ministerio da Saude, 2009, EM SAUD PUBL IMP NAC
   Hamer DH, 2004, J TRAVEL MED, V11, P23, DOI 10.2310/7060.2004.13577
   Larson H, 2012, DRUG SAFETY, V35, P1053, DOI 10.2165/11635880-000000000-00000
   Lima JTF, 1985, CAD SAUDE PUBLICA, V1, P377
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Reyna VF, 2012, VACCINE, V30, P3790, DOI 10.1016/j.vaccine.2011.11.070
   Toovey S, 2004, J TRAVEL MED, V11, P16, DOI 10.2310/7060.2004.13587
   Van Herck K, 2004, J TRAVEL MED, V11, P3, DOI 10.2310/7060.2004.13609
NR 9
TC 2
Z9 2
U1 0
U2 7
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2014
VL 56
IS 5
BP 417
EP 420
DI 10.1590/S0036-46652014000500008
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AS5TL
UT WOS:000344332300008
PM 25229222
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Grant, RM
   Anderson, PL
   McMahan, V
   Liu, A
   Amico, KR
   Mehrotra, M
   Hosek, S
   Mosquera, C
   Casapia, M
   Montoya, O
   Buchbinder, S
   Veloso, VG
   Mayer, K
   Chariyalertsak, S
   Bekker, LG
   Kallas, EG
   Schechter, M
   Guanira, J
   Bushman, L
   Burns, DN
   Rooney, JF
   Glidden, DV
AF Grant, Robert M.
   Anderson, Peter L.
   McMahan, Vanessa
   Liu, Albert
   Amico, K. Rivet
   Mehrotra, Megha
   Hosek, Sybil
   Mosquera, Carlos
   Casapia, Martin
   Montoya, Orlando
   Buchbinder, Susan
   Veloso, Valdilea G.
   Mayer, Kenneth
   Chariyalertsak, Suwat
   Bekker, Linda-Gail
   Kallas, Esper G.
   Schechter, Mauro
   Guanira, Juan
   Bushman, Lane
   Burns, David N.
   Rooney, James F.
   Glidden, David V.
CA iPrEx Study Team
TI Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence
   in men and transgender women who have sex with men: a cohort study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID RISK COMPENSATION; HETEROSEXUAL MEN; PREVENTION; BEHAVIOR; INFECTION;
   TENOFOVIR; TRIAL; PREP
AB Background The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a cohort of HIV-negative people at risk of infection.
   Methods In our cohort study, men and transgender women who have sex with men previously enrolled in PrEP trials (ATN 082, iPrEx, and US Safety Study) were enrolled in a 72 week open-label extension. We measured drug concentrations in plasma and dried blood spots in seroconverters and a random sample of seronegative participants. We assessed PrEP uptake, adherence, sexual practices, and HIV incidence. Statistical methods induded Poisson models, comparison of proportions, and generalised estimating equations.
   Findings We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP. Uptake was higher among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0.003) and having serological evidence of herpes (612/791 [77%] vs 613/812 [75%] p=0.03). Of those receiving PrEP, HIV incidence was 1.8 infections per 100 person-years, compared with 2-6 infections per 100 person-years in those who concurrently did not choose PrEP (HR 0.51,95% CI 0.26-1.01, adjusted for sexual behaviours), and 3.9 infections per 100 person-years in the placebo group of the previous randomised phase (HR 0.49,95% CI 0.31-0.77). Among those receiving PrEP, HIV incidence was 4.7 infections per 100 person-years if drug was not detected in dried blood spots, 2.3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0.6 per 100 person-years for use of two to three tablets per week, and 0.0 per 100 person-years for use of four or more tablets per week (p<0.0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes.
   Interpretation PrEP uptake was high when made available free of charge by experienced providers. The effect of PrEP is increased by greater uptake and adherence during periods of higher risk. Drug concentrations in dried blood spots are strongly correlated with protective benefit.
C1 [Grant, Robert M.; McMahan, Vanessa; Mehrotra, Megha] Gladstone Inst, San Francisco, CA USA.
   [Grant, Robert M.; Liu, Albert; Buchbinder, Susan; Glidden, David V.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA.
   [Anderson, Peter L.; Bushman, Lane] Univ Colorado, Aurora, CO USA.
   [Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA.
   [Amico, K. Rivet] Univ Connecticut, Storrs, CT USA.
   [Hosek, Sybil] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Mosquera, Carlos; Guanira, Juan] INMENSA, Lima, Peru.
   [Casapia, Martin] ACSA, Iquitos, Peru.
   [Montoya, Orlando] Equidad, Guayaquil, Ecuador.
   [Veloso, Valdilea G.] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
   [Mayer, Kenneth] Fenway Hlth, Boston, MA USA.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Chiang Mai 50000, Thailand.
   [Bekker, Linda-Gail] Desmond Tutu Hlth Fdn, Cape Town, South Africa.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Burns, David N.] NIH, Bethesda, MD 20892 USA.
   [Rooney, James F.] Gilead Sci Inc, Foster City, CA 94404 USA.
RP Grant, RM (corresponding author), 1650 Owens St, San Francisco, CA 94158 USA.
EM rgrant@gladstone.ucsf.edu
RI Schechter, Mauro/AAG-7445-2020; /AAE-4700-2020; Bekker,
   Linda-Gail/AAZ-8929-2020; Glidden, David/AAD-4730-2020
OI Grant, Robert/0000-0002-0851-7085; Guanira, Juan/0000-0002-2746-3086;
   Amico, K Rivet/0000-0002-4458-6934; Kallas, Esper/0000-0003-2026-6925;
   Glidden, David/0000-0001-5888-1419; BEKKER,
   LINDA-GAIL/0000-0002-0755-4386
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI064002, U01AI064002, U01AI064002, U01AI064002, U01AI064002,
   U01AI064002, U01AI064002, U01AI064002, U01AI064002] Funding Source: NIH
   RePORTER
FX US National Institutes of Health.
CR Amico KR, 2012, AIDS BEHAV, V16, P1243, DOI 10.1007/s10461-012-0182-5
   Amico KR, 2014, CLIN INFECT DIS, V59, pS55, DOI 10.1093/cid/ciu266
   Amico KR, 2012, 7 ANN HIV TREATM PRE
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Arnett J. J., 2004, ADOLESCENCE EMERGING
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bushman LR, 2011, J PHARMACEUT BIOMED, V56, P390, DOI 10.1016/j.jpba.2011.05.039
   Casey BJ, 2008, ANN NY ACAD SCI, V1124, P111, DOI 10.1196/annals.1440.010
   Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   CDC, PREEXP PROPH PREV HI
   Donnell D, 2014, JAIDS-J ACQ IMM DEF, V66, P340, DOI 10.1097/QAI.0000000000000172
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   GREENLAND S, 1985, BIOMETRICAL J, V27, P189, DOI 10.1002/bimj.4710270212
   Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33
   Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081
   Krakower D, 2014, AIDS BEHAV, V18, P1712, DOI 10.1007/s10461-014-0839-3
   Krakower DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033119
   Liu A, 2013, PROVIDING DRUG LEVEL
   Liu A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001613
   Liu AY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083736
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   Marcus JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081997
   Marrazzo J. M., 2013, C RETR OPP INF ATL G
   Mimiaga MJ, 2014, AIDS CARE, V26, P684, DOI 10.1080/09540121.2013.845289
   Mugwanya KK, 2013, LANCET INFECT DIS, V13, P1021, DOI 10.1016/S1473-3099(13)70226-3
   Ndase P, 2014, JAIDS-J ACQ IMM DEF, V66, P206, DOI 10.1097/QAI.0000000000000141
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Underhill K, 2013, SOC SCI MED, V94, P115, DOI 10.1016/j.socscimed.2013.03.020
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Zablotska IB, 2013, JAIDS-J ACQ IMM DEF, V62, P334, DOI 10.1097/QAI.0b013e31827e854a
NR 32
TC 585
Z9 590
U1 5
U2 97
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2014
VL 14
IS 9
BP 820
EP 829
DI 10.1016/S1473-3099(14)70847-3
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AO4WS
UT WOS:000341342700025
PM 25065857
OA Green Accepted
DA 2020-11-26
ER

PT J
AU van de Weg, CAM
   Pannuti, CS
   van den Ham, HJ
   de Araujo, ESA
   Boas, LSV
   Felix, AC
   Carvalho, KI
   Levi, JE
   Romano, CM
   Centrone, CC
   Rodrigues, CLD
   Luna, E
   van Gorp, ECM
   Osterhaus, ADME
   Kallas, EG
   Martina, BEE
AF van de Weg, Cornella A. M.
   Pannuti, Claudio S.
   van den Ham, Henk-Jan
   de Araujo, Evaldo S. A.
   Boas, Lucy S. V.
   Felix, Alvina C.
   Carvalho, Karina I.
   Levi, Jose E.
   Romano, Camila M.
   Centrone, Cristiane C.
   de Lima Rodrigues, Celia L.
   Luna, Expedito
   van Gorp, Eric C. M.
   Osterhaus, Albert D. M. E.
   Kallas, Esper G.
   Martina, Byron E. E.
TI Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers
   for plasma leakage in patients with acute dengue virus infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Dengue virus; Plasma leakage; Vascular permeability; Angiopoietin-2;
   Soluble VEGFR-2
ID TIE-2 LIGAND ANGIOPOIETIN-2; CELL-ADHESION MOLECULES; ENDOTHELIAL-CELLS;
   HEMORRHAGIC-FEVER; SHOCK SYNDROME; ACTIVATION; CHILDREN;
   METALLOPROTEINASES; PERMEABILITY; ASSOCIATION
AB Background: Endothelial cell dysfunction is believed to play an important role in the pathogenesis of plasma leakage in patients with acute dengue virus (DENV) infection. Several factors, produced by activated endothelial cells, have been associated with plasma leakage or severe disease in patients with infectious diseases.
   Objectives: The aim of this study was to investigate which of these markers could serve as a surrogate marker for the occurrence of plasma leakage in patients with acute DENV infection.
   Study design: A case-control study was performed in patients with acute DENV infection in Santos, Brazil. Plasma leakage was detected with X-ray and/or ultrasound examination at admission. Serum levels of soluble endoglin, endothelin-1, angiopoietin-2, VEGF, soluble VEGFR-2, MMP-2, MMP-9, TIMP-1 and TIMP2 were determined using commercially available ELISAs.
   Results: Increased levels of angiopoietin-2, endothelin-1 and MMP-2 and decreased levels of soluble VEGFR2 were significantly associated with the occurrence of plasma leakage. An unsupervised cluster analysis confirmed that angiopoietin-2 and soluble VEGFR-2 were strongly associated with clinical apparent vascular leakage.
   Conclusion: Angiopoietin-2 and soluble VEGFR-2 can serve as surrogate markers for the occurrence of plasma leakage in patients with acute DENV infection. (C) 2014 Elsevier B.V. All rights reserved.
C1 [van de Weg, Cornella A. M.; van den Ham, Henk-Jan; van Gorp, Eric C. M.; Osterhaus, Albert D. M. E.; Martina, Byron E. E.] Erasmus MC, Dept Virosci, NL-3000 CA Rotterdam, Netherlands.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, BR-05403000 Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.] Hosp Ana Costa, Dept Infect Dis, BR-11075400 Campo Grande, Santos, Brazil.
   [Carvalho, Karina I.] Hosp Albert Einstein, BR-05652000 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, BR-05403000 Sao Paulo, Brazil.
RP Martina, BEE (corresponding author), Erasmus MC, Dept Virosci, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM b.martina@erasmusmc.nl
RI Luna, Expedito J A/B-7948-2012; Romano, Camila M/C-8185-2013; Carvalho,
   Karina IL/J-6789-2012; Romano, Camila/ABC-2883-2020
OI Luna, Expedito J A/0000-0002-1145-9672; Carvalho, Karina
   IL/0000-0002-7763-8139; Romano, Camila/0000-0003-4550-1987; van den Ham,
   Henk-Jan/0000-0001-8582-5404; Centrone, Cristiane/0000-0002-7452-5163;
   Kallas, Esper/0000-0003-2026-6925
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq)National Council for Scientific
   and Technological Development (CNPq) [476088/2009-7, 301339/2009-0];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of EducationCAPES; European Union Seventh Framework
   Programme (FP7) under SILVEREuropean Union (EU) [260644]; Dutch
   government [FES0908]; Netherlands Genomics Initiative (NGI)
   [050-060-452]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazilian Ministry of Science and Technology
   (CNPq, grant #476088/2009-7 to EGK and 301339/2009-0 to CSP). KIC's
   scholarship was supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education.; The
   research leading to these results has also received funding from the
   European Union Seventh Framework Programme (FP7/2007-2013) under SILVER
   grant agreement no. 260644.; Moreover, this study was supported by the
   Virgo consortium funded by the Dutch government, project number FES0908,
   and by the Netherlands Genomics Initiative (NGI) project number
   050-060-452.
CR Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5
   Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557
   Bethell DB, 2001, CLIN INFECT DIS, V32, P243, DOI 10.1086/318453
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Cardier JE, 2006, ENDOTHELIUM-J ENDOTH, V13, P335, DOI 10.1080/10623320600972135
   Dalrymple NA, 2012, ADV VIROL, V2012, DOI 10.1155/2012/840654
   Dalrymple NA, 2012, J VIROL, V86, P6408, DOI 10.1128/JVI.00213-12
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Dewi BE, 2008, J GEN VIROL, V89, P642, DOI 10.1099/vir.0.83356-0
   Dietmann A, 2009, J INFECT DIS, V200, P1842, DOI 10.1086/648476
   Dietmann A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-253
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Furuta T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001505
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Kelley JF, 2012, VIROLOGY, V422, P326, DOI 10.1016/j.virol.2011.10.030
   Khongphatthanayothin A, 2003, INTENS CARE MED, V29, P570, DOI 10.1007/s00134-003-1671-9
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kubelka CF, 2010, J INFECTION, V61, P501, DOI 10.1016/j.jinf.2010.09.020
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   Luplertlop N, 2008, JPN J INFECT DIS, V61, P298
   Michels M, 2012, AM J TROP MED HYG, V87, P943, DOI 10.4269/ajtmh.2012.12-0020
   Nachman RL, 2008, NEW ENGL J MED, V359, P1261, DOI 10.1056/NEJMra0800887
   Neufeld G, 1999, FASEB J, V13, P9
   Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412
   Ong SP, 2013, MED MICROBIOL IMMUN, V202, P437, DOI 10.1007/s00430-013-0310-5
   Lam PK, 2013, CLIN INFECT DIS, V57, P1577, DOI 10.1093/cid/cit594
   PITTET JF, 1991, ANN SURG, V213, P261, DOI 10.1097/00000658-199103000-00014
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Romano CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070318
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Seet RCS, 2009, INT J INFECT DIS, V13, pE248, DOI 10.1016/j.ijid.2008.11.028
   Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
   Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   The TD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001679
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
   van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   World Health Organization, 2009, DENG HEM FEV DIAGN T
   YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056
NR 47
TC 27
Z9 28
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2014
VL 60
IS 4
BP 328
EP 335
DI 10.1016/j.jcv.2014.05.001
PG 8
WC Virology
SC Virology
GA AO5AS
UT WOS:000341353200002
PM 24928471
DA 2020-11-26
ER

PT J
AU Mesquita, D
   Cruvinel, WM
   Araujo, JAP
   Salmazi, KC
   Kallas, EG
   Andrade, LEC
AF Mesquita Junior, D.
   Cruvinel, W. M.
   Araujo, J. A. P.
   Salmazi, K. C.
   Kallas, E. G.
   Andrade, L. E. C.
TI Imbalanced expression of functional surface molecules in regulatory and
   effector T cells in systemic lupus erythematosus
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Systemic lupus erythematosus; T lymphocytes; Regulatory T cells;
   Effector T cells
ID SUPPRESSIVE FUNCTION; AUTOIMMUNE-DISEASE; PERIPHERAL-BLOOD; FOXP3;
   NUMBER; LIGAND; HYPEREXPRESSION; POPULATION; CD127; CD40
AB Regulatory T (TREG) cells play an important role in maintaining immune tolerance and avoiding autoimmunity. We analyzed the expression of membrane molecules in TREG and effector T cells in systemic lupus erythematosus (SLE). TREG and effector T cells were analyzed for the expression of CTLA-4, PD1, CD28, CD95, GITR, HLA-DR, OX40, CD40L, and CD45RO in 26 patients with active disease, 31 with inactive disease, and 26 healthy controls. TREG cells were defined as CD25(+/high)CD127 (circle divide/low)FoxP3(+), and effector T cells were defined as CD25(+) CD127(+) FoxP3(circle divide). The ratio of TREG to effector T cells expressing GITR, PD1, HLA-DR, OX40, CD40L, and CD45RO was determined in the three groups. The frequency of TREG cells was similar in patients with SLE and controls. However, SLE patients had a decreased frequency of CTLA-4(+)TREG and CD28(+) TREG cells and an increased frequency of CD40L(+)TREG cells. There was a decrease in the TREG/effector-T ratio for GITR(+), HLA-DR+, OX40(+), and CD45RO(+) cells, and an increased ratio of TREG/ effector-T CD40L(+) cells in patients with SLE. In addition, CD40L(+)TREG cell frequency correlated with the SLE disease activity index (P=0.0163). In conclusion, our findings showed several abnormalities in the expression of functionally critical surface molecules in TREG and effector T cells in SLE that may be relevant to the pathogenesis of this disease.
C1 [Mesquita Junior, D.; Cruvinel, W. M.; Araujo, J. A. P.; Andrade, L. E. C.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Med, Disciplina Reumatol, Sao Paulo, Brazil.
   [Cruvinel, W. M.] Univ Catolica Goias, Dept Biomed, Goiania, Go, Brazil.
   [Salmazi, K. C.; Kallas, E. G.] Univ Sao Paulo, Fac Med, Dept Clin Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
RP Andrade, LEC (corresponding author), Univ Fed Sao Paulo, EPM, Dept Med, Disciplina Reumatol, BR-04023900 Sao Paulo, Brazil.
EM luis.andrade@unifesp.br
RI Carvalho, Karina IL/J-6789-2012; Andrade, Luis Eduardo C/D-1245-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Andrade, Luis Eduardo
   C/0000-0001-8742-9931; Kallas, Esper/0000-0003-2026-6925; Araujo,
   Julio/0000-0001-6706-2589
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/51349-2]
FX Research supported by FAPESP (#2007/51349-2).
CR Alvarado-Sanchez B, 2006, J AUTOIMMUN, V27, P110, DOI 10.1016/j.jaut.2006.06.005
   Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Boumpas DT, 2003, ARTHRITIS RHEUM-US, V48, P719, DOI 10.1002/art.10856
   Crispin JC, 2003, J AUTOIMMUN, V21, P273, DOI 10.1016/S0896-8411(03)00121-5
   DesaiMehta A, 1996, J CLIN INVEST, V97, P2063, DOI 10.1172/JCI118643
   Devi BS, 1998, J AUTOIMMUN, V11, P471, DOI 10.1006/jaut.1998.0213
   Grammer AC, 2003, J CLIN INVEST, V112, P1506, DOI 10.1172/JCI200319301
   Hartigan-O'Connor DJ, 2007, J IMMUNOL METHODS, V319, P41, DOI 10.1016/j.jim.2006.10.008
   Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428
   Kumanogoh A, 2001, J IMMUNOL, V166, P353, DOI 10.4049/jimmunol.166.1.353
   Lee JH, 2006, IMMUNOLOGY, V117, P280, DOI 10.1111/j.1365-2567.2005.02306.x
   Levings MK, 2006, ADV IMMUNOL, V92, P119, DOI 10.1016/S0065-2776(06)92003-3
   Liu MF, 2004, SCAND J IMMUNOL, V59, P198, DOI 10.1111/j.0300-9475.2004.01370.x
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   Mellor-Pita S, 2006, ANN RHEUM DIS, V65, P553, DOI 10.1136/ard.2005.044974
   Mesquita D, 2011, SCAND J RHEUMATOL, V40, P41, DOI 10.3109/03009742.2010.489229
   Miyara M, 2005, J IMMUNOL, V175, P8392, DOI 10.4049/jimmunol.175.12.8392
   Nocentini G, 2005, EUR J IMMUNOL, V35, P1016, DOI 10.1002/eji.200425818
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   So T, 2007, J IMMUNOL, V179, P1427, DOI 10.4049/jimmunol.179.3.1427
   Suarez A, 2006, ANN RHEUM DIS, V65, P1512, DOI 10.1136/ard.2005.049924
   Suen JL, 2009, IMMUNOLOGY, V127, P196, DOI 10.1111/j.1365-2567.2008.02937.x
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Thewissen M, 2007, J IMMUNOL, V179, P6514, DOI 10.4049/jimmunol.179.10.6514
   Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579
   Venigalla RKC, 2008, ARTHRITIS RHEUM-US, V58, P2120, DOI 10.1002/art.23556
   Vieira QF, 2008, J RHEUMATOL, V35, P1762
   Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4
   von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180
   Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748
   Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479
   Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062
   Yan B, 2008, ARTHRITIS RHEUM-US, V58, P801, DOI 10.1002/art.23268
   Yates J, 2008, CLIN EXP IMMUNOL, V153, P44, DOI 10.1111/j.1365-2249.2008.03665.x
NR 37
TC 7
Z9 8
U1 0
U2 6
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2014
VL 47
IS 8
BP 662
EP 669
DI 10.1590/1414-431X20143483
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA AN3KN
UT WOS:000340486700005
PM 25098715
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Solomon, MM
   Lama, JR
   Glidden, DV
   Mulligan, K
   McMahan, V
   Liu, AY
   Guanira, JV
   Veloso, VG
   Mayer, KH
   Chariyalertsak, S
   Schechter, M
   Bekker, LG
   Kallas, EG
   Burns, DN
   Grant, RM
AF Solomon, Marc M.
   Lama, Javier R.
   Glidden, David V.
   Mulligan, Kathleen
   McMahan, Vanessa
   Liu, Albert Y.
   Vicente Guanira, Juan
   Veloso, Valdilea G.
   Mayer, Kenneth H.
   Chariyalertsak, Suwat
   Schechter, Mauro
   Bekker, Linda-Gail
   Kallas, Esper Georges
   Burns, David N.
   Grant, Robert M.
CA IPrEx Study Team
TI Changes in renal function associated with oral emtricitabine/tenofovir
   disoproxil fumarate use for HIV pre- exposure prophylaxis
SO AIDS
LA English
DT Article
DE chemoprophylaxis; HIV prevention; MSM; pre-exposure prophylaxis; renal;
   side effects; tenofovir
ID GLOMERULAR-FILTRATION-RATE; ANTIRETROVIRAL-NAIVE; TUBULAR DYSFUNCTION;
   INFECTED PATIENTS; KIDNEY-DISEASE; TENOFOVIR DF; SAFETY; THERAPY; RISK;
   NEPHROTOXICITY
AB Objective:Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual acquisition of HIV infection. We sought to evaluate the renal safety of TDF in HIV-uninfected persons.Design and methods:The Iniciativa Profilaxis Pre-Exposicion (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with men (MSM) to receive oral daily TDF coformulated with emtricitabine (FTC/TDF) or placebo. Serum creatinine and phosphorus during randomized treatment and after discontinuation were measured, and creatinine clearance (CrCl) was estimated by the Cockcroft-Gault equation. Indicators of proximal renal tubulopathy (fractional excretion of phosphorus and uric acid, urine protein, and glucose) were measured in a substudy.Results:There was a small but statistically significant decrease in CrCl from baseline in the active arm, compared to placebo, which was first observed at week 4 (mean change: -2.4 vs. -1.1ml/min; P=0.02), persisted through the last on-treatment visit (mean change: +0.3 vs. +1.8ml/min; P=0.02), and resolved after stopping pre-exposure prophylaxis (mean change: -0.1 vs. 0.0ml/min; P=0.83). The effect was confirmed when stratifying by drug detection. The effect of FTC/TDF on CrCl did not vary by race, age, or history of hypertension. There was no difference in serum phosphate trends between the treatment arms. In the substudy, two participants receiving placebo had indicators of tubulopathy.Conclusions:In HIV-seronegative MSM, randomization to FTC/TDF was associated with a very mild nonprogressive decrease in CrCl that was reversible and managed with routine serum creatinine monitoring.
C1 [Solomon, Marc M.; McMahan, Vanessa; Grant, Robert M.] Gladstone Inst, San Francisco, CA USA.
   [Solomon, Marc M.; Glidden, David V.; Mulligan, Kathleen; Liu, Albert Y.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Vicente Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Lama, Javier R.] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Fac Med, Dept Community Med, Chiang Mai 50000, Thailand.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Bekker, Linda-Gail] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05403900 Sao Paulo, Brazil.
   [Kallas, Esper Georges] Inst Invest Imunol, BR-05403900 Sao Paulo, Brazil.
   [Burns, David N.] NIAID, Bethesda, MD 20892 USA.
RP Grant, RM (corresponding author), 1650 Owens St, San Francisco, CA 94158 USA.
EM rgrant@gladstone.ucsf.edu
RI Bekker, Linda-Gail/AAZ-8929-2020; Schechter, Mauro/AAG-7445-2020;
   Glidden, David/AAD-4730-2020
OI BEKKER, LINDA-GAIL/0000-0002-0755-4386; Kallas,
   Esper/0000-0003-2026-6925; Glidden, David/0000-0001-5888-1419; Guanira,
   Juan/0000-0002-2746-3086; Grant, Robert/0000-0002-0851-7085
FU GileadGilead Sciences; Division of Acquired Immunodeficiency Syndrome
   (DAIDS), National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UO1 AI64002]; Bill and Melinda
   Gates FoundationBill & Melinda Gates Foundation; DAIDSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [RO1 AI062333]; J. David Gladstone InstitutesUniversity of California
   System; National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [UL1
   RR024131]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR) [UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, T32AI007641, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, T32AI007641, T32AI007641, U01AI064002, R01AI062333,
   P30AI027763, P30AI027763, P30AI027763, T32AI007641, R01AI062333,
   P30AI027763, T32AI007641, P30AI027763, P30AI027763, U01AI064002,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R01AI062333, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI064002,
   P30AI027763, P30AI027763, P30AI027763, R01AI062333, P30AI027763,
   UM1AI069519, P30AI027763, T32AI007641, UM1AI069519, P30AI027763,
   T32AI007641, T32AI007641, P30AI027763, P30AI027763, P30AI027763,
   T32AI007641, P30AI027763, P30AI027763, P30AI027763, U01AI064002,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   T32AI007641, P30AI027763, P30AI027763, R01AI062333, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, T32AI007641,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI069519, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   T32AI007641, T32AI007641, R01AI062333, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, UM1AI069519, P30AI027763,
   P30AI027763, T32AI007641, UM1AI069519, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, T32AI007641,
   R01AI062333, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R01AI062333, P30AI027763, P30AI027763, UM1AI069519, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, T32AI007641, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   UM1AI069519, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, T32AI007641, P30AI027763, U01AI064002, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, UM1AI069519, P30AI027763, P30AI027763] Funding
   Source: NIH RePORTER
FX Source of funding: K. H. M. and M. S. have received research funding
   from Gilead for unrelated research. For the remaining authors none were
   declared.; The work was supported by the Division of Acquired
   Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, as a cooperative
   agreement (UO1 AI64002, to R. M. G.) and by the Bill and Melinda Gates
   Foundation. Study drugs were donated by Gilead Sciences. Support for
   some specimen handling came from a grant from DAIDS (RO1 AI062333, to R.
   M. G.) and by the J. David Gladstone Institutes. Some infrastructure
   support at the University of California at San Francisco was provided by
   a grant from the National Institutes of Health (UL1 RR024131).
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   [Anonymous], 2004, DIV AIDS TABL GRAD S
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P65
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681
   Dauchy FA, 2011, KIDNEY INT, V80, P302, DOI 10.1038/ki.2011.124
   Diggle P.J., 2002, ANAL LONGITUDINAL DA
   Fux CA, 2007, ANTIVIR THER, V12, P1165
   Fux CA, 2007, AIDS, V21, P1483, DOI 10.1097/QAD.0b013e328216f15b
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gish RG, 2012, CLIN GASTROENTEROL H, V10, P941, DOI 10.1016/j.cgh.2012.04.008
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hall AM, 2009, AM J KIDNEY DIS, V54, P1034, DOI 10.1053/j.ajkd.2009.07.012
   Herlitz LC, 2010, KIDNEY INT, V78, P1171, DOI 10.1038/ki.2010.318
   Horberg M, 2010, JAIDS-J ACQ IMM DEF, V53, P62, DOI 10.1097/QAI.0b013e3181be6be2
   Izzedine H, 2004, AIDS, V18, P1074, DOI 10.1097/00002030-200404300-00019
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karras A, 2003, CLIN INFECT DIS, V36, P1070, DOI 10.1086/368314
   Kinai E, 2009, AIDS RES HUM RETROV, V25, P387, DOI 10.1089/aid.2008.0202
   Labarga P, 2009, AIDS, V23, P689, DOI 10.1097/QAD.0b013e3283262a64
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Mauss S, 2005, AIDS, V19, P93, DOI 10.1097/00002030-200501030-00012
   Mauss S, 2011, J HEPATOL, V55, P1235, DOI 10.1016/j.jhep.2011.03.030
   Peyriere H, 2004, JAIDS-J ACQ IMM DEF, V35, P269, DOI 10.1097/00126334-200403010-00007
   Post FA, 2010, JAIDS-J ACQ IMM DEF, V55, P49, DOI 10.1097/QAI.0b013e3181dd911e
   Ridruejo E, 2012, EXPERT OPIN DRUG SAF, V11, P357, DOI 10.1517/14740338.2012.672972
   Rodriguez-Novoa S, 2010, AIDS, V24, P1064, DOI 10.1097/QAD.0b013e32833202e2
   Rodriguez-Novoa S, 2009, CLIN INFECT DIS, V48, pE108, DOI 10.1086/598507
   Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Tordato F, 2011, HIV MED, V12, P4, DOI 10.1111/j.1468-1293.2010.00855.x
   Vrouenraets SME, 2011, AIDS, V25, P2149, DOI 10.1097/QAD.0b013e32834bba87
   Wever K, 2010, JAIDS-J ACQ IMM DEF, V55, P78, DOI 10.1097/QAI.0b013e3181d05579
   Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468-1293.2009.00716.x
   Zimmermann AE, 2006, CLIN INFECT DIS, V42, P283, DOI 10.1086/499048
NR 38
TC 83
Z9 83
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 27
PY 2014
VL 28
IS 6
BP 851
EP 859
DI 10.1097/QAD.0000000000000156
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AD5MH
UT WOS:000333296600006
PM 24499951
OA Green Published
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Sanabani, SS
   Ribeiro, SP
   Sauer, MM
   Tomiyama, HI
   Sucupira, MC
   Diaz, RS
   Sabino, EC
   Kalil, J
   Kallas, EG
AF Tarosso, Leandro F.
   Sanabani, Sabri S.
   Ribeiro, Susan P.
   Sauer, Mariana M.
   Tomiyama, Helena I.
   Sucupira, Maria C.
   Diaz, Ricardo S.
   Sabino, Ester C.
   Kalil, Jorge
   Kallas, Esper G.
TI Short Communication: HIV Type 1 Subtype BF Leads to Faster CD4(+) T Cell
   Loss Compared to Subtype B
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID DISEASE PROGRESSION; VIRUS TYPE-1; EPIDEMIOLOGY; INFECTION; FREQUENCY
AB Although it has been suggested that biological differences among HIV-1 subtypes exist, their possible influence on disease progression has not been fully revealed. In particular, the increasing emergence of recombinants stresses the need to characterize disease presentation in persons infected by these diverse HIV-1 forms. We explored this issue among 83 Brazilian subjects infected with either HIV-1 subtype B or recombinant subtype BF, all followed since incident infection in a cohort study. Viral subtypes were assigned by full length sequencing of HIV-1 genomes. We observed that the baseline measures for CD4(+) T cells and viral load did not differ between the groups. However, longitudinal analysis revealed that subtype BF was clearly associated with a faster CD4(+) T cell decline compared to infection with subtype B, in spite of a similar plasma HIV-1 load. While subtype B-infected subjects presented a loss of 3.6 CD4(+) T cells/l per month, subtype BF-infected individuals showed a monthly decay of 6.3 CD4(+) T cells/l (p<0.01). The time to reach 350 CD4(+) T cells/l and the time to start antiretroviral treatment were also shorter in subtype BF-infected persons. The elucidation of an accelerated CD4(+) T cell loss associated with subtype BF suggests that this HIV-1 genetic form could be more pathogenic than subtype B.
C1 [Tarosso, Leandro F.; Ribeiro, Susan P.; Sauer, Mariana M.; Tomiyama, Helena I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Sanabani, Sabri S.] Univ Sao Paulo, Sch Med, Hosp Clin, Clin Lab,Dept Pathol,LIM 03, BR-01246903 Sao Paulo, Brazil.
   [Sauer, Mariana M.; Tomiyama, Helena I.] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-01246903 Sao Paulo, Brazil.
RP Tarosso, LF (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Av Dr Arnaldo,455,3 Floor,Room 3209, BR-01246903 Sao Paulo, Brazil.
EM tarosso@usp.br
RI KALIL, JORGE/C-8029-2012; Sabino, Ester Cerdeira/F-7750-2010; Sanabani,
   Sabri Saeed/F-5600-2012; Araripe Sucupira, Maria Cecilia/K-1931-2012
OI KALIL, JORGE/0000-0001-8415-4274; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Sanabani, Sabri Saeed/0000-0002-8876-8262;
   Kallas, Esper/0000-0003-2026-6925; Araripe Sucupira, Maria
   Cecilia/0000-0002-1114-5382
FU Brazilian Program for STD/AIDS-Ministry of Health [914/BRA/3014]; Sao
   Paulo City Health Department [2004-0.168.922-7]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2004/15856-9, 2010/51609-7]
FX We thank all the study participants and the dedicated clinical research
   staff at the collaborating sites. This study was supported by the
   Brazilian Program for STD/AIDS-Ministry of Health (914/BRA/3014 to E. G.
   K.), the Sao Paulo City Health Department (2004-0.168.922-7 to E. G.
   K.), and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (2004/15856-9 to E. G. K. and 2010/51609-7 to L.F.T.).
CR Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682
   Beilke MA, 2004, CLIN INFECT DIS, V39, P256, DOI 10.1086/422146
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Hu DJ, 2005, AIDS, V19, P303
   Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
   KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641
   Leal E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011833
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Martinez-Cajas JL, 2008, AIDS REV, V10, P212
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Secretaria Municipal da Saude do Municipio de SAo Paulo (SMS-SP), 2003, B EP AIDS MUN SAO PA, VVII
   UNAIDS, 2010, GLOB REP UNAIDS REP
NR 18
TC 6
Z9 7
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB 1
PY 2014
VL 30
IS 2
BP 190
EP 194
DI 10.1089/aid.2012.0243
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AA6NI
UT WOS:000331214600013
PM 23906381
DA 2020-11-26
ER

PT J
AU Marcus, JL
   Glidden, DV
   Mayer, KH
   Liu, AY
   Buchbinder, SP
   Amico, KR
   McMahan, V
   Kallas, EG
   Montoya-Herrera, O
   Pilotto, J
   Grant, RM
AF Marcus, Julia L.
   Glidden, David V.
   Mayer, Kenneth H.
   Liu, Albert Y.
   Buchbinder, Susan P.
   Amico, K. Rivet
   McMahan, Vanessa
   Kallas, Esper Georges
   Montoya-Herrera, Orlando
   Pilotto, Jose
   Grant, Robert M.
TI No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral
   HIV Preexposure Prophylaxis
SO PLOS ONE
LA English
DT Article
ID MALE CIRCUMCISION; UNITED-STATES; FOLLOW-UP; BEHAVIOR; INFECTION; MEN;
   PREVENTION; PARTICIPANTS; IMPACT; CHEMOPROPHYLAXIS
AB Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We evaluated potential risk compensation using biomarkers of sexual risk behavior.
   Design and methods: Sexual practices were assessed at baseline and quarterly thereafter; perceived treatment assignment and PrEP efficacy beliefs were assessed at 12 weeks. Among participants with >= 1 follow-up behavioral assessment, sexual behavior, syphilis, and HIV infection were compared by perceived treatment assignment, actual treatment assignment, and perceived PrEP efficacy.
   Results: Overall, acute HIV infection and syphilis decreased during follow-up. Compared with participants believing they were receiving placebo, participants believing they were receiving FTC/TDF reported more receptive anal intercourse partners prior to initiating drug (12.8 vs. 7.7, P = 0.04). Belief in receiving FTC/TDF was not associated with an increase in receptive anal intercourse with no condom (ncRAI) from baseline through follow-up (risk ratio [RR] 0.9, 95% confidence interval [CI]: 0.6-1.4; P = 0.75), nor with a decrease after stopping study drug (RR 0.8, 95% CI: 0.5-1.3; P = 0.46). In the placebo arm, there were trends toward lower HIV incidence among participants believing they were receiving FTC/TDF (incidence rate ratio [IRR] 0.8, 95% CI: 0.4-1.8; P = 0.26) and also believing it was highly effective (IRR 0.5, 95% CI: 0.1-1.7; P = 0.12).
   Conclusions: There was no evidence of sexual risk compensation in iPrEx. Participants believing they were receiving FTC/TDF had more partners prior to initiating drug, suggesting that risk behavior was not a consequence of PrEP use.
C1 [Marcus, Julia L.; McMahan, Vanessa; Grant, Robert M.] Gladstone Inst Virol & Immunol, San Francisco, CA USA.
   [Marcus, Julia L.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Glidden, David V.; Liu, Albert Y.; Buchbinder, Susan P.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Amico, K. Rivet] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Montoya-Herrera, Orlando] Fdn Ecuatoriana Equidad, Guayaquil, Guayas, Ecuador.
   [Pilotto, Jose] Hosp Geral Nova Iguacu, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
RP Grant, RM (corresponding author), Gladstone Inst Virol & Immunol, San Francisco, CA USA.
EM robert.grant@ucsf.edu
RI /AAE-4700-2020; Pilotto, Jose Henrique/AAD-9773-2019; Glidden,
   David/AAD-4730-2020
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Amico, K
   Rivet/0000-0002-4458-6934; Grant, Robert/0000-0002-0851-7085; Glidden,
   David/0000-0001-5888-1419; Kallas, Esper/0000-0003-2026-6925
FU Division of Acquired Immunodeficiency Syndrome, National Institute of
   Allergy and Infectious Diseases, National Institutes of Health [UO1
   AI64002]; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation; Gladstone InstitutesUniversity of California System;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI064002, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI064002, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI064002, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, U01AI064002, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI064002,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U01AI064002, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI064002, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763] Funding Source: NIH RePORTER
FX This study was supported by the Division of Acquired Immunodeficiency
   Syndrome, National Institute of Allergy and Infectious Diseases,
   National Institutes of Health, as a cooperative agreement (UO1 AI64002,
   to Dr. Grant), by the Bill and Melinda Gates Foundation, and by the
   Gladstone Institutes. No individuals employed or contracted by the
   funders (other than the named authors) played any role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams J., 1995, RISK
   Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Autier P, 1998, JNCI-J NATL CANCER I, V90, P1873, DOI 10.1093/jnci/90.24.1873
   Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Baeten JM, 2012, N ENGL J MED
   Bartholow BN, 2005, JAIDS-J ACQ IMM DEF, V39, P90, DOI 10.1097/01.qai.0000143600.41363.78
   Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605
   Chesney MA, 1997, J ACQ IMMUN DEF SYND, V16, P266, DOI 10.1097/00042560-199712010-00007
   Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224
   Denison JA, 2008, AIDS BEHAV, V12, P363, DOI 10.1007/s10461-007-9349-x
   Desai K, 2008, AIDS, V22, P1829, DOI 10.1097/QAD.0b013e32830e00f5
   Eaton Lisa A, 2007, Curr HIV/AIDS Rep, V4, P165, DOI 10.1007/s11904-007-0024-7
   Festinger L, 1957, THEORY COGNITIVE DIS
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Guest G, 2008, SEX TRANSM DIS, V35, P1002, DOI 10.1097/OLQ.0b013e3181812939
   Herbst JH, 2008, AIDS BEHAV, V12, P1, DOI 10.1007/s10461-007-9299-3
   HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419
   Huebner DM, 2001, ANN BEHAV MED, V23, P304, DOI 10.1207/S15324796ABM2304_10
   Kasparian NA, 2009, J BEHAV MED, V32, P406, DOI 10.1007/s10865-009-9219-2
   Kong XR, 2012, AM J EPIDEMIOL, V176, P875, DOI 10.1093/aje/kws179
   Liu AY, 2013, J ACQUIR IMMUNE DEFI
   Marrazzo J, 2013, 20 C RETR OPP INF AT
   Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010
   Mattson CL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002443
   Mustanski BS, 2011, J SEX RES, V48, P218, DOI 10.1080/00224499.2011.558645
   Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027
   Richens J, 2000, LANCET, V355, P400, DOI 10.1016/S0140-6736(99)09109-6
   Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530
   Sarkar NN, 2008, EUR J CONTRACEP REPR, V13, P114, DOI 10.1080/13625180802011302
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3
   Vissers DCJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002077
   Wilde GJS, 2001, TARGET RISK DEALING
NR 39
TC 135
Z9 137
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e81997
DI 10.1371/journal.pone.0081997
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300016
PM 24367497
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Milagres, LG
   Costa, PR
   Santos, BAN
   Silva, GP
   Cruz, AC
   Pereira-Manfro, WF
   Ferreira, B
   Barreto, DM
   Frota, ACC
   Kalil, J
   Hofer, CB
   Kallas, EG
AF Milagres, Lucimar G.
   Costa, Priscilla R.
   Santos, Bianca A. N.
   Silva, Giselle P.
   Cruz, Aline C.
   Pereira-Manfro, Wania F.
   Ferreira, Bianca
   Barreto, Daniella M.
   Frota, Ana Cristina C.
   Kalil, Jorge
   Hofer, Cristina B.
   Kallas, Esper G.
TI CD4(+) T-cell activation impairs serogroup C Neisseria meningitis
   vaccine response in HIV-infected children
SO AIDS
LA English
DT Article
DE bactericidal antibody; CD4(+) T-lymphocyte activation; children; HIV;
   meningococcal vaccine; regulatory T cell; seroconversion
ID MENINGOCOCCAL CONJUGATE VACCINE; IMMUNOGENICITY; SAFETY; DISEASE;
   ANTIGEN; HAART
AB Objective:To investigate the influence of CD4(+) T-cell activation and regulatory populations in HIV-infected children antibody response to vaccination with a conjugate C polysaccharide vaccine.Design:CD4(+) T-cell activation was evaluated by expression of CD38, HLA-DR and CCR5 molecules. Regulatory CD4(+) T cells (T-Reg) were characterized as FoxP3(+)CD127(-)CD25(+) and inducer T cells (T-Ind) as CD4(+)FoxP3(-)CD25(-)CD39(+).Methods:All patients (n=36) were HIV-vertically infected, aged 2-17 years-old and were vaccinated with one vaccine injection. Blood samples were obtained before and after immunization to determine bactericidal antibody titers (SBA), CD4(+) T-cell activation and frequency of T-Reg and T-Ind subsets (multiparametric flow cytometry).Results:Children not-responding (n=18) to MenC vaccine expressed higher frequency of activated CD4(+) T cells (HLA-DR(+)CD38(+)CCR5(+)) than responders (n=18), both before and after vaccination (P<0.05). A significant higher frequency of T-Reg was detected in responders compared with nonresponders (P=0.0001). We also detected an inverse correlation between CD4(+)DR(+)CD38(+)CCR5(+) (P=0.01) or CD4(+)DR(+)CD38(+) (P=0.02) T cells and T-Reg cell frequency after vaccination. CD4(+) T-cell activation negatively correlated (P=0.006) with postvaccination SBA titers but a positive correlation (P=0.0001) was detected between T-Reg cells and SBA. T-Reg and T-Ind subsets were inversely correlated (P=0.04).Conclusion:Our findings suggest that higher CD4(+) T-cell activation leads to poor vaccine response in children living with HIV, which may be associated with a T-Reg/T-Ind disequilibrium.
C1 [Milagres, Lucimar G.; Silva, Giselle P.; Cruz, Aline C.; Pereira-Manfro, Wania F.] Univ Estado Rio De Janeiro, Dept Microbiol Immunol & Parasitol, Rio De Janeiro, Brazil.
   [Costa, Priscilla R.; Santos, Bianca A. N.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Ferreira, Bianca; Barreto, Daniella M.; Frota, Ana Cristina C.; Hofer, Cristina B.] Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Sch Med, Rio De Janeiro, Brazil.
   [Hofer, Cristina B.] Univ Fed Rio de Janeiro, Sch Med, Dept Prevent Med, Rio De Janeiro, Brazil.
RP Milagres, LG (corresponding author), Disciplina Microbiol, Av Prof Manoel de Abreu 444,Terceiro Andar, BR-20550170 Rio De Janeiro, RJ, Brazil.
EM lucimar@uerj.br
RI Frota, Ana Cristina/L-3644-2018; KALIL, JORGE/C-8029-2012; Manfro, Wania
   FP/M-5882-2013
OI Frota, Ana Cristina/0000-0002-2825-4374; KALIL,
   JORGE/0000-0001-8415-4274; Manfro, Wania/0000-0003-0166-8144; Kallas,
   Esper/0000-0003-2026-6925
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [573879/2008-7, 552497/2011-8]; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/112.645/2012]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2009/54055-5]; CNPqNational Council for Scientific
   and Technological Development (CNPq); CAPESCAPES; Fogarty Institute of
   the National Institutes of Health [5R01TW008397]; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R01TW008397, R01TW008397, R01TW008397, R01TW008397, R01TW008397]
   Funding Source: NIH RePORTER
FX This work was funded by CNPq grants (#573879/2008-7 to J.K. and E.G.K.
   and #552497/2011-8 (Edital Casadinho) to L.G.M. and E.G.K.), FAPERJ
   (#E-26/112.645/2012 to L.G.M.) and FAPESP (#2009/54055-5 to E.G.K.).
   P.R.C. and B.N.S. received scholarship support from CNPq; G.S.P. and
   A.C.C. received scholarship support from CAPES. We are also grateful to
   Fogarty Institute of the National Institutes of Health under award
   number 5R01TW008397 to CBH. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3
   Chang Qiuzhi, 2012, Clin Epidemiol, V4, P237, DOI 10.2147/CLEP.S28410
   Cohen C, 2010, AIDS, V24, P1351, DOI 10.1097/QAD.0b013e32833a2520
   COVER/SVS/MS, COORD VIG DOENC TRAN
   De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375
   Balado MDD, 2010, J INFECT DIS, V202, P362, DOI 10.1086/653707
   DICKOVER RE, 1994, J INFECT DIS, V170, P1279, DOI 10.1093/infdis/170.5.1279
   Frota ACC, 2013, 7 IAS C HIV PATH TRE
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Goicoechea M, 2006, J INFECT DIS, V194, P29, DOI 10.1086/504718
   Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924
   Imamichi H, 2012, J INFECT DIS, V205, P1479, DOI 10.1093/infdis/jis238
   Kared H, 2008, AIDS, V22, P2451, DOI 10.1097/QAD.0b013e328319edc0
   Kinter AL, 2007, AIDS RES HUM RETROV, V23, P438, DOI 10.1089/aid.2006.0162
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314
   Lujan-Zilbermann J, 2012, J PEDIATR-US, V161, P676, DOI 10.1016/j.jpeds.2012.04.005
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156, DOI 10.1128/CDLI.4.2.156-167.1997
   Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12
   Ndhlovu LC, 2010, EUR J IMMUNOL, V40, P134, DOI 10.1002/eji.200939258
   Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110
   Obaro SK, 2004, LANCET INFECT DIS, V4, P510, DOI 10.1016/S1473-3099(04)01106-5
   OBRIEN WA, 1995, BLOOD, V86, P1082
   Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Siberry GK, 2012, PEDIATR INFECT DIS J, V31, P47, DOI 10.1097/INF.0b013e318236c67b
   Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903
   Westrop SJ, 2012, MOL MED, V18, P1240, DOI 10.2119/molmed.2012.00206
   Westrop SJ, 2010, J VIRAL ENTRY, V4, P1
   Zaccarelli CA, 2007, CYTOM PART B-CLIN CY, V72B, P14, DOI 10.1002/cyto.b.20152
NR 31
TC 9
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2013
VL 27
IS 17
BP 2697
EP 2705
DI 10.1097/QAD.0000000000000007
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 250HR
UT WOS:000326841800004
PM 24149087
DA 2020-11-26
ER

PT J
AU Malta, FM
   Bruno, FR
   Carvalho, KI
   Nastri, ACSS
   Kalil, J
   Carrilho, FJ
   Kallas, EG
   Pinho, JRR
AF Malta, F. M.
   Bruno, F. R.
   Carvalho, K. I.
   Nastri, A. C. S. S.
   Kalil, J.
   Carrilho, F. J.
   Kallas, E. G.
   Pinho, J. R. R.
TI HCV Viremia Drives an Increment of CD86 Expression by Myeloid Dendritic
   Cells
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE hepatitis C virus; innate immunity; dendritic cell; chronic infection;
   CD86
ID HEPATITIS-C VIRUS; GENETIC-VARIATION; FUNCTIONAL-CAPACITY;
   IMMUNE-RESPONSES; INFECTION; INNATE; IL28B; ASSOCIATION; MATURATION;
   CLEARANCE
AB The host immune response, including innate and adaptive immunity, plays a critical role in determining the outcome of viral infection. Nevertheless, little is known about the exact reasons for the failure of the host immune system in controlling hepatitis C virus (HCV) infection. Impairment of dendritic cells (DCs) function is probably one of the mechanisms responsible for immune evasion of HCV. In this study, the frequency and phenotype of DCs subsets were analyzed in three groups: HCV-infected individuals who developed viral persistence (1), HCV-infected individuals who spontaneously cleared the virus (2) and HCV-seronegative uninfected subjects (3). The results showed that the frequency of DCs subsets was not statistically significant between groups. Plasmacytoid DCs circulating exhibited an immature phenotype characterized by low expression of CD86. On the other hand, CD86 expression in myeloid DCs was significantly higher in chronic infected individuals compared to healthy controls (P=0.037). A positive correlation was observed between CD86(+) myeloid DC (mDC) and HCV viral load (r=0.4121, P=0.0263). These results suggest that HCV did not have an inhibitory effect on mDC maturation and the HCV viremia drives the increase of CD86 expression in mDC. The regulation of DCs maturation and migration lies at the level of intracellular signaling. HCV can activate or block intracellular signaling pathways and alter DC function. In conclusion, the present study suggests that imbalance of DC maturation by the virus represents a mechanism of evasion of the immune system despite the fact that HCV viremia appears to exert a stimulatory effect on cell-surface immune phenotype. J Med. Virol. 85:1919-1924, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Malta, F. M.; Nastri, A. C. S. S.; Carrilho, F. J.; Pinho, J. R. R.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05403000 Sao Paulo, Brazil.
   [Bruno, F. R.; Carvalho, K. I.; Kalil, J.; Kallas, E. G.] Univ Sao Paulo, Clin Immunol & Allergy Branch, Dept Internal Med, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Carvalho, K. I.; Pinho, J. R. R.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nastri, A. C. S. S.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05403000 Sao Paulo, Brazil.
RP Malta, FM (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Eneas Carvalho Aguiar,500-2 Andar IMT II, BR-05403000 Sao Paulo, Brazil.
EM femalta@yahoo.com
RI Carvalho, Karina IL/J-6789-2012; KALIL, JORGE/C-8029-2012; Pinho, Joao
   R. R./G-2850-2012; Malta, Fernanda/B-1316-2013; Carrilho, Flair
   J/I-3046-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; KALIL,
   JORGE/0000-0001-8415-4274; Pinho, Joao R. R./0000-0003-3999-0489; Malta,
   Fernanda/0000-0001-8887-5060; Kallas, Esper/0000-0003-2026-6925
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [09/53.270-0, 09/53.306-4.]; FFM; HC-FMUSP; Alves de Queiroz Family
   Fund; Tropical Medicine Institute of Sao Paulo
FX Grant sponsor: FAPESP; Grant numbers: 09/53.270-0, 09/53.306-4.; Grant
   sponsor: FFM; Grant sponsor: HC-FMUSP; Grant sponsor: Alves de Queiroz
   Family Fund; Grant sponsor: Tropical Medicine Institute of Sao Paulo
CR Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171
   Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barchet W, 2005, SEMIN IMMUNOL, V17, P253, DOI 10.1016/j.smim.2005.05.008
   Barnes E, 2008, J VIRAL HEPATITIS, V15, P219, DOI 10.1111/j.1365-2893.2007.00934.x
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Della Bella S, 2007, IMMUNOLOGY, V121, P283, DOI 10.1111/j.1365-2567.2007.02577.x
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Harrison RJ, 2010, CLIN EXP IMMUNOL, V161, P306, DOI 10.1111/j.1365-2249.2010.04169.x
   Jo J, 2011, J GEN VIROL, V92, P477, DOI 10.1099/vir.0.027987-0
   Kanto T, 2004, J INFECT DIS, V190, P1919, DOI 10.1086/425425
   Kanto T, 1999, J IMMUNOL, V162, P5584
   Landi A, 2011, J VIRAL HEPATITIS, V18, P700, DOI 10.1111/j.1365-2893.2010.01357.x
   LARSEN CP, 1994, J IMMUNOL, V152, P5208
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Longman RS, 2005, J INFECT DIS, V192, P497, DOI 10.1086/431523
   Longman RS, 2004, BLOOD, V103, P1026, DOI 10.1182/blood-2003-04-1339
   Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482
   Pachiadakis I, 2009, CLIN IMMUNOL, V131, P415, DOI 10.1016/j.clim.2009.02.001
   Pachiadakis L, 2005, LANCET INFECT DIS, V5, P296, DOI 10.1016/S1473-3099(05)70114-6
   Piccioli D, 2005, J HEPATOL, V42, P61, DOI 10.1016/j.jhep.2004.09.014
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056
   Rehermann B, 2000, SEMIN LIVER DIS, V20, P127, DOI 10.1055/s-2000-9946
   Rehermann B, 2000, CURR TOP MICROBIOL, V242, P299
   Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133
   Reizis B, 2011, NAT REV IMMUNOL, V11, P558, DOI 10.1038/nri3027
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Ryan EJ, 2011, J VIRAL HEPATITIS, V18, P601, DOI 10.1111/j.1365-2893.2011.01453.x
   Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
   Sun JR, 2001, J VIROL, V75, P11992, DOI 10.1128/JVI.75.24.11992-11998.2001
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006
NR 36
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2013
VL 85
IS 11
BP 1919
EP 1924
DI 10.1002/jmv.23692
PG 6
WC Virology
SC Virology
GA 282UG
UT WOS:000329198500008
PM 23926073
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Rosa, DS
   Ribeiro, SP
   Santana, VC
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Almeida, R. R.
   Rosa, D. S.
   Ribeiro, S. P.
   Santana, V. C.
   Kallas, E. G.
   Sidney, J.
   Sette, A.
   Kalil, J.
   Cunha-Neto, E.
TI Broad and Cross-clade CD4+T-Cell Responses Elicited by a DNA Vaccine
   Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus
   Peptides
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY OCT 07-10, 2013
CL Barcelona, SPAIN
C1 [Almeida, R. R.; Ribeiro, S. P.; Santana, V. C.; Kallas, E. G.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Rosa, D. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Sidney, J.; Sette, A.] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Kalil, J.] Inst Heart, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; KALIL,
   JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP A145
EP A145
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500380
DA 2020-11-26
ER

PT J
AU Janes, H
   Friedrich, DP
   Krambrink, A
   Smith, RJ
   Kallas, EG
   Horton, H
   Casimiro, DR
   Carrington, M
   Geraghty, DE
   Gilbert, PB
   McElrath, MJ
   Frahm, N
AF Janes, Holly
   Friedrich, David P.
   Krambrink, Amy
   Smith, Rebecca J.
   Kallas, Esper G.
   Horton, Helen
   Casimiro, Danilo R.
   Carrington, Mary
   Geraghty, Daniel E.
   Gilbert, Peter B.
   McElrath, M. Juliana
   Frahm, Nicole
TI Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia
   After HIV-1 Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1 vaccine; Step study; Gag-specific T cells; HLA class I alleles
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD; DISCORDANT ASSOCIATIONS;
   GENETIC-DETERMINANTS; LYMPHOCYTE RESPONSE; MEDIATED-IMMUNITY;
   CONTROLLED-TRIAL; RHESUS-MONKEYS; STEP TRIAL; ESCAPE
AB The contribution of host T-cell immunity and HLA class I alleles to the control of human immunodeficiency virus (HIV-1) replication in natural infection is widely recognized. We assessed whether vaccine-induced T-cell immunity, or expression of certain HLA alleles, impacted HIV-1 control after infection in the Step MRKAd5/HIV-1 gag/pol/nef study. Vaccine-induced T cells were associated with reduced plasma viremia, with subjects targeting >= 3 gag peptides presenting with half-log lower mean viral loads than subjects without Gag responses. This effect was stronger in participants infected proximal to vaccination and was independent of our observed association of HLA-B(star)27, -B(star)57 and -B(star)58:01 alleles with lower HIV-1 viremia. These findings support the ability of vaccine-induced T-cell responses to influence postinfection outcome and provide a rationale for the generation of T-cell responses by vaccination to reduce viremia if protection from acquisition is not achieved. Clinical trials identifier: NCT00095576.
C1 [Janes, Holly; Friedrich, David P.; Krambrink, Amy; Smith, Rebecca J.; Geraghty, Daniel E.; Gilbert, Peter B.; McElrath, M. Juliana; Frahm, Nicole] Fred Hutchinson Canc Res Ctr, VIDD, Seattle, WA 98109 USA.
   [Janes, Holly; Friedrich, David P.; Krambrink, Amy; Smith, Rebecca J.; Geraghty, Daniel E.; Gilbert, Peter B.; McElrath, M. Juliana; Frahm, Nicole] Fred Hutchinson Canc Res Ctr, HIV Vaccine Trials Network, Seattle, WA 98109 USA.
   [Janes, Holly; Gilbert, Peter B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [McElrath, M. Juliana; Frahm, Nicole] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [McElrath, M. Juliana] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [McElrath, M. Juliana] Univ Washington, Dept Med, Seattle, WA USA.
   [Horton, Helen] Seattle Biomed Res Inst, Washington, DC USA.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Casimiro, Danilo R.] Merck Res Labs, Upper Gwynedd, PA USA.
   [Carrington, Mary] Frederick Natl Lab Canc Res, Canc & Inflammat Program, SAIC Frederick, Frederick, MD USA.
   [Carrington, Mary] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
RP Frahm, N (corresponding author), Fred Hutchinson Canc Res Ctr, VIDD, 1100 Fairview Ave N,E4-200, Seattle, WA 98109 USA.
EM nfrahm@fhcrc.org
OI Kallas, Esper/0000-0003-2026-6925
FU National Institutes of Health Public Health ServiceUnited States Public
   Health ServiceUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UM1 AI068618,
   AI068635]; Frederick National Laboratory for Cancer Research
   [HHSN261200800001E]; NATIONAL CANCER INSTITUTEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [ZIABC010791, ZIABC010791, ZIABC010791,
   ZIABC010791, ZIABC010791, ZIABC010791, ZIABC010791, ZIABC010791,
   ZIABC010791, ZIABC010791] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI068618, UM1AI068618, UM1AI068614, UM1AI068635, U01AI068635,
   UM1AI068635, UM1AI068618, UM1AI068635, UM1AI068635, UM1AI068618,
   U01AI068635, U01AI068635, UM1AI068614, U01AI068635, UM1AI068635,
   UM1AI068618, U01AI068635, UM1AI068635, UM1AI068618, UM1AI068614,
   UM1AI068618, UM1AI068635, UM1AI068614, UM1AI068614, UM1AI068635,
   UM1AI068614, UM1AI068618, UM1AI068635, UM1AI068618, UM1AI068614,
   UM1AI068614, UM1AI068614] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health Public
   Health Service (grants UM1 AI068618 and AI068635) and the Frederick
   National Laboratory for Cancer Research (contract HHSN261200800001E).
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Brockman MA, 2007, J VIROL, V81, P12608, DOI 10.1128/JVI.01369-07
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Cao JH, 2003, J IMMUNOL, V171, P3837, DOI 10.4049/jimmunol.171.7.3837
   Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Carrington M, 2012, ANNU REV MED, V63, P131, DOI 10.1146/annurev-med-062909-130018
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dinges WL, 2010, J VIROL, V84, P4461, DOI 10.1128/JVI.02438-09
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Fellay J, 2011, J INFECT DIS, V203, P773, DOI 10.1093/infdis/jiq125
   Fitzgerald DW, 2011, J INFECT DIS, V203, P765, DOI 10.1093/infdis/jiq114
   Frahm N, 2006, THEORETICAL BIOL BIO, P3
   Frahm N, 2012, J CLIN INVEST, V122, P359, DOI 10.1172/JCI60202
   Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Horton H, 2007, J IMMUNOL METHODS, V323, P39, DOI 10.1016/j.jim.2007.03.002
   Janes H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043396
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Migueles SA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002002
   Mothe BR, 2003, J VIROL, V77, P2736, DOI 10.1128/JVI.77.4.2736-2740.2003
   O'Brien SJ, 2001, TRENDS MOL MED, V7, P379, DOI 10.1016/S1471-4914(01)02131-1
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Ranasinghe S, 2012, J VIROL, V86, P277, DOI 10.1128/JVI.05577-11
   Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316
   Schmitz J, 1999, SCIENCE, V277, P333
   Schneidewind A, 2007, J VIROL, V81, P12382, DOI 10.1128/JVI.01543-07
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   STEEL CM, 1988, LANCET, V1, P1185
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
   Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006
   Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006
NR 49
TC 49
Z9 50
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2013
VL 208
IS 8
BP 1231
EP 1239
DI 10.1093/infdis/jit322
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 223TJ
UT WOS:000324832800006
PM 23878319
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   de Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Barreto de Oliveira, Ana Karolina
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI IVIg Immune Reconstitution Treatment Alleviates the State of Persistent
   Immune Activation and Suppressed CD4 T Cell Counts in CVID
SO PLOS ONE
LA English
DT Article
ID COMMON VARIABLE IMMUNODEFICIENCY; CD1D-RESTRICTED NKT CELLS; MICROBIAL
   TRANSLOCATION; DENDRITIC CELLS; HIV-INFECTION; DISEASE PROGRESSION;
   REPLACEMENT THERAPY; MECHANISMS; EXPRESSION; FREQUENCY
AB Common variable immunodeficiency (CVID) is characterized by defective B cell function, impaired antibody production, and increased susceptibility to bacterial infections. Here, we addressed the hypothesis that poor antibody-mediated immune control of infections may result in substantial perturbations in the T cell compartment. Newly diagnosed CVID patients were sampled before, and 6-12 months after, initiation of intravenous immunoglobulin (IVIg) therapy. Treatment-naive CVID patients displayed suppressed CD4 T cell counts and myeloid dendritic cell (mDC) levels, as well as high levels of immune activation in CD8 T cells, CD4 T cells, and invariant natural killer T (iNKT) cells. Expression of co-stimulatory receptors CD80 and CD83 was elevated in mDCs and correlated with T cell activation. Levels of both FoxP3+ T regulatory (Treg) cells and iNKT cells were low, whereas soluble CD14 (sCD14), indicative of monocyte activation, was elevated. Importantly, immune reconstitution treatment with IVIg partially restored the CD4 T cell and mDC compartments. Treatment furthermore reduced the levels of CD8 T cell activation and mDC activation, whereas levels of Treg cells and iNKT cells remained low. Thus, primary deficiency in humoral immunity with impaired control of microbial infections is associated with significant pathological changes in cell-mediated immunity. Furthermore, therapeutic enhancement of humoral immunity with IVIg infusions alleviates several of these defects, indicating a relationship between poor antibody-mediated immune control of infections and the occurrence of abnormalities in the T cell and mDC compartments. These findings help our understanding of the immunopathogenesis of primary immunodeficiency, as well as acquired immunodeficiency caused by HIV-1 infection.
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden.
   [Santos, Bianca A. N.; Carvalho, Karina I.; Toledo-Barros, Myrthes; Barreto de Oliveira, Ana Karolina; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Sandberg, JK (corresponding author), Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Med,Dept Med, Stockholm, Sweden.
EM johan.sandberg@ki.se
RI Carvalho, Karina IL/J-6789-2012; KALIL, JORGE/C-8029-2012; Kokron,
   Cristina M/D-3140-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; KALIL,
   JORGE/0000-0001-8415-4274; Kokron, Cristina M/0000-0002-9080-0305;
   Paquin Proulx, Dominic/0000-0003-1407-3414; Moll,
   Markus/0000-0003-4592-3063; Sandberg, Johan/0000-0002-6275-0750; Kallas,
   Esper/0000-0003-2026-6925
FU Swedish Research CouncilSwedish Research Council; Swedish Cancer
   Foundation; Stockholm County CouncilStockholm County Council; Karolinska
   InstitutetKarolinska Institutet; US National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [AI52731]; Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR); Conselho Nacional
   de Pesquisa (CNPq), Brazilian Ministry of Science and TechnologyNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) through the PNPD
   Program, Brazilian Ministry of EducationCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX The study was supported by the Swedish Research Council, the Swedish
   Cancer Foundation, Stockholm County Council, Karolinska Institutet, and
   the US National Institutes of Health grant AI52731. DPP is the recipient
   of a postdoctoral fellowship from the Canadian Institutes of Health
   Research. BANS is the recipient of a master fellowship from the Conselho
   Nacional de Pesquisa (CNPq), Brazilian Ministry of Science and
   Technology. KIC is the recipient of a postdoctoral fellowship from the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   through the PNPD Program, Brazilian Ministry of Education. The group at
   the University of Sao Paulo coordinates one of the Brazilian National
   Institutes of Science and Technology (Instituto de Investigacao em
   Imunologia - iii), funded by the CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aukrust P, 1997, J INFECT DIS, V176, P913, DOI 10.1086/516510
   Ballow M, 2011, CLIN IMMUNOL, V139, P208, DOI 10.1016/j.clim.2011.02.006
   Barbosa RR, 2012, CLIN EXP IMMUNOL, V169, P263, DOI 10.1111/j.1365-2249.2012.04620.x
   Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957
   Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001
   Carvalho KI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012652
   Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Eller MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018779
   Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433
   Genre J, 2009, CLIN IMMUNOL, V132, P215, DOI 10.1016/j.clim.2009.03.519
   GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932
   Gouilleux-Gruart V, 2013, CLIN EXP IMMUNOL, V171, P186, DOI 10.1111/cei.12002
   Grassi F, 1999, AIDS, V13, P759, DOI 10.1097/00002030-199905070-00004
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623
   Kasztalska K, 2011, CLIN DRUG INVEST, V31, P299, DOI 10.2165/11586710-000000000-00000
   Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515
   Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771
   Kaveri SV, 2011, CLIN EXP IMMUNOL, V164, P2, DOI 10.1111/j.1365-2249.2011.04387.x
   Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0
   Klatt NR, 2012, TRENDS MICROBIOL
   Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134
   Litzman J, 2012, CLIN EXP IMMUNOL, V170, P321, DOI 10.1111/j.1365-2249.2012.04655.x
   Melo KM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006269
   Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780
   Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Nordoy I, 1998, CLIN EXP IMMUNOL, V114, P258
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x
   Sandberg JK, 2005, TRENDS IMMUNOL, V26, P347, DOI 10.1016/j.it.2005.05.006
   Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002
   Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848
   Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
   Van Kaer L, 2012, TRENDS IMMUNOL
   Vermeulen JN, 2007, AIDS RES HUM RETROV, V23, P1348, DOI 10.1089/aid.2006.0210
   Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599
NR 46
TC 35
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2013
VL 8
IS 10
AR e75199
DI 10.1371/journal.pone.0075199
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236PJ
UT WOS:000325810900021
PM 24130688
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Romano, CM
   Lauck, M
   Salvador, FS
   Lima, CR
   Villas-Boas, LS
   Araujo, ESA
   Levi, JE
   Pannuti, CS
   O'Connor, D
   Kallas, EG
AF Romano, Camila Malta
   Lauck, Michael
   Salvador, Felipe S.
   Lima, Celia Rodrigues
   Villas-Boas, Lucy S.
   Araujo, Evaldo Stanislau A.
   Levi, Jose Eduardo
   Pannuti, Claudio Sergio
   O'Connor, David
   Kallas, Esper Georges
TI Inter- and Intra-Host Viral Diversity in a Large Seasonal DENV2 Outbreak
SO PLOS ONE
LA English
DT Article
ID DENGUE VIRUS; EVOLUTIONARY DYNAMICS; ARBOVIRUS; SELECTION; PRESSURE;
   PATTERNS; MUTATION; TYPE-2; TIME
AB Background: High genetic diversity at both inter-and intra-host level are hallmarks of RNA viruses due to the error-prone nature of their genome replication. Several groups have evaluated the extent of viral variability using different RNA virus deep sequencing methods. Although much of this effort has been dedicated to pathogens that cause chronic infections in humans, few studies investigated arthropod-borne, acute viral infections. Methods and
   Principal Findings: We deep sequenced the complete genome of ten DENV2 isolates from representative classical and severe cases sampled in a large outbreak in Brazil using two different approaches. Analysis of the consensus genomes confirmed the larger extent of the 2010 epidemic in comparison to a previous epidemic caused by the same viruses in another city two years before (genetic distance = 0.002 and 0.0008 respectively). Analysis of viral populations within the host revealed a high level of conservation. After excluding homopolymer regions of 454/Roche generated sequences, we found 10 to 44 variable sites per genome population at a frequency of >1%, resulting in very low intra-host genetic diversity. While up to 60% of all variable sites at intra-host level were non-synonymous changes, only 10% of inter-host variability resulted from non-synonymous mutations, indicative of purifying selection at the population level.
   Conclusions and Significance: Despite the error-prone nature of RNA-dependent RNA-polymerase, dengue viruses maintain low levels of intra-host variability.
C1 [Romano, Camila Malta; Salvador, Felipe S.; Lima, Celia Rodrigues; Villas-Boas, Lucy S.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Romano, Camila Malta; Salvador, Felipe S.; Lima, Celia Rodrigues; Villas-Boas, Lucy S.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIMHC, Sao Paulo, Brazil.
   [Lauck, Michael; O'Connor, David] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Araujo, Evaldo Stanislau A.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
RP Romano, CM (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM cmromano@usp.br
RI Romano, Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; Kallas, Esper/0000-0003-2026-6925;
   o'connor, david/0000-0003-2139-470X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [10/12313-5]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry
   of Science and Technology (CNPq)National Council for Scientific and
   Technological Development (CNPq) [476088/2009-7]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI077376-04A1]; Research
   Facilities Improvement ProgramUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [RR15459-01, RR020141-01]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [C06RR020141, C06RR020141, C06RR020141,
   C06RR020141, C06RR020141, C06RR020141, C06RR015459] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI077376, R01AI077376, R01AI077376, R01AI077376,
   R01AI077376, R01AI077376, R01AI077376, R01AI077376] Funding Source: NIH
   RePORTER
FX The present work was supported by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP grant #10/12313-5 to CMR) and by the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq, grant #476088/2009-7 to EGK).
   URL of FAPESP: www.fapesp.br; URL of CNPq: www.cnpq.br; URL of
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior:
   www.capes.gov.br. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. This work was also made possible in part by National
   Institutes of Health grant R01 AI077376-04A1. The research was
   conducted, in part, at a facility constructed with support from Research
   Facilities Improvement Program grants RR15459-01 and RR020141-01.
CR Aaskov J, 2006, SCIENCE, V311, P236, DOI 10.1126/science.1115030
   Becker EA, 2012, GENOME BIOL EVOL, V4, P457, DOI 10.1093/gbe/evs029
   Bimber BN, 2010, J VIROL, V84, P12087, DOI 10.1128/JVI.01378-10
   Brackney DE, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000856
   Coffey LL, 2008, P NATL ACAD SCI USA, V105, P6970, DOI 10.1073/pnas.0712130105
   CVE DdZ, 2010, DAD PROV CVE DENG
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Descloux E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000493
   Santos Cecília Luiza Simões dos, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P11, DOI 10.1590/S0036-46652003000100003
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Farci P, 2000, SEMIN LIVER DIS, V20, P103
   Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339
   Gilles A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-245
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hoper D, 2012, J VIROL, V86, P1394, DOI 10.1128/JVI.00797-11
   Holmes EC, 2003, J VIROL, V77, P11296, DOI 10.1128/JVI.77.20.11296-11298.2003
   Kanesa-thasan N, 1998, EMERG INFECT DIS, V4, P299, DOI 10.3201/eid0402.980220
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Lai YL, 2007, J CLIN MICROBIOL, V45, P935, DOI 10.1128/JCM.01258-06
   Lauck M, 2012, J VIROL, V86, P3952, DOI 10.1128/JVI.06627-11
   Li DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019447
   MADDISON WP, 1989, FOLIA PRIMATOL, V53, P190, DOI 10.1159/000156416
   Murcia PR, 2010, J VIROL, V84, P6943, DOI 10.1128/JVI.00112-10
   Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
   Oliveira MF, 2010, EMERG INFECT DIS, V16, P576, DOI 10.3201/eid1603.090996
   PAHO, 2008, NUMB REP CAS DENG DE
   Parameswaran P, 2012, J VIROL
   Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rozera G, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-15
   SABINO E, 1993, AIDS RES HUM RETROV, V9, P1265, DOI 10.1089/aid.1993.9.1265
   Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6
   Suzuki S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019534
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Temporao JG, 2011, EMERG INFECT DIS, V17, P938, DOI 10.3201/eid1705.101681
   Thai KTD, 2012, J VIROL, V86, P835, DOI 10.1128/JVI.05985-11
   VARTANIAN JP, 1992, AIDS, V6, P1095, DOI 10.1097/00002030-199210000-00005
   Vasilakis N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000467
   Wang WK, 2002, VIROLOGY, V303, P181, DOI 10.1006/viro.2002.1635
   Wang WK, 2002, J VIROL, V76, P4662, DOI 10.1128/JVI.76.9.4662-4665.2002
   Weaver SC, 1999, J VIROL, V73, P4316, DOI 10.1128/JVI.73.5.4316-4326.1999
   World Health Organization, 2009, DENG GUID DIAGN TREA, P147
NR 48
TC 27
Z9 27
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2013
VL 8
IS 8
AR e70318
DI 10.1371/journal.pone.0070318
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219XU
UT WOS:000324545800039
PM 23936406
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Leal, FE
   Sabino, EC
   Nishiya, AS
   Freire, MD
   Blumm, F
   Rocha, V
   Rodrigues, CA
   Novis, YS
   Kallas, EG
AF Avelino-Silva, V. I.
   Leal, F. E.
   Sabino, E. C.
   Nishiya, A. S.
   Freire, M. da Silva
   Blumm, F.
   Rocha, V.
   Rodrigues, C. A.
   Novis, Y. S.
   Kallas, E. G.
TI Yellow fever vaccine viremia following ablative BM suppression in AML
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID IMMUNE-RESPONSE; ADVERSE EVENTS; 17D; IMMUNIZATION; CHILDREN; PATIENT;
   BRAZIL; ASSAYS; VIRUS
C1 [Avelino-Silva, V. I.; Leal, F. E.; Sabino, E. C.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, V. I.; Leal, F. E.; Blumm, F.; Rocha, V.; Rodrigues, C. A.; Novis, Y. S.; Kallas, E. G.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Leal, F. E.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Sabino, E. C.; Nishiya, A. S.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Nishiya, A. S.] Univ Fed Sao Paulo, Infect Dis Div DIPA, Sao Paulo, Brazil.
   [Freire, M. da Silva] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Nishiya, Anna/Q-8156-2016; Sabino, Ester Cerdeira/F-7750-2010;
   Avelino-Silva, Vivian I/L-2640-2013; Rocha, Vanderson/AAO-1691-2020
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Bae HG, 2008, J INFECT DIS, V197, P1577, DOI 10.1086/587844
   Centers for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P32
   Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7
   Engel AR, 2006, VACCINE, V24, P2803, DOI 10.1016/j.vaccine.2006.01.009
   Galler R, 2001, VIROLOGY, V290, P309, DOI 10.1006/viro.2001.1168
   Gowda R, 2004, EUR J HAEMATOL, V72, P299, DOI 10.1111/j.1600-0609.2004.00218.x
   Kengsakul Kitisak, 2002, J Med Assoc Thai, V85, P131
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Martin M, 2001, LANCET, V358, P98, DOI 10.1016/S0140-6736(01)05327-2
   Silva JRN, 2011, VACCINE, V29, P6327, DOI 10.1016/j.vaccine.2011.05.019
   National Institute for Biological Standards and Control, 2008, 1 INT REF PREP ANT F
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Pickering LK, 2009, CLIN INFECT DIS, V49, P817, DOI 10.1086/605430
   Pulendran B, 2008, J INFECT DIS, V198, P500, DOI 10.1086/590187
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Thomas RE, 2012, AM J TROP MED HYG, V86, P359, DOI 10.4269/ajtmh.2012.11-0525
   Yax JA, 2009, J TRAVEL MED, V16, P365, DOI 10.1111/j.1708-8305.2009.00336.x
NR 18
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2013
VL 48
IS 7
BP 1008
EP 1009
DI 10.1038/bmt.2012.277
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 176KF
UT WOS:000321302300026
PM 23334273
OA Bronze
DA 2020-11-26
ER

PT J
AU Paquin-Proulx, D
   Santos, BAN
   Carvalho, KI
   Toledo-Barros, M
   de Oliveira, AKB
   Kokron, CM
   Kalil, J
   Moll, M
   Kallas, EG
   Sandberg, JK
AF Paquin-Proulx, Dominic
   Santos, Bianca A. N.
   Carvalho, Karina I.
   Toledo-Barros, Myrthes
   Barreto de Oliveira, Ana Karolina
   Kokron, Cristina M.
   Kalil, Jorge
   Moll, Markus
   Kallas, Esper G.
   Sandberg, Johan K.
TI Dysregulated CD1 profile in myeloid dendritic cells in CVID is
   normalized by IVIg treatment
SO BLOOD
LA English
DT Letter
ID COMMON VARIABLE IMMUNODEFICIENCY; T-CELLS; SUBSETS; DISEASE; BLOOD
C1 [Paquin-Proulx, Dominic; Moll, Markus; Sandberg, Johan K.] Karolinska Univ, Huddinge Hosp, Dept Med, Ctr Infect Med,Karolinska Inst, S-14186 Stockholm, Sweden.
   [Santos, Bianca A. N.; Carvalho, Karina I.; Toledo-Barros, Myrthes; Barreto de Oliveira, Ana Karolina; Kokron, Cristina M.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Sandberg, JK (corresponding author), Karolinska Univ, Huddinge Hosp, Dept Med, Ctr Infect Med,Karolinska Inst, F59, S-14186 Stockholm, Sweden.
EM johan.sandberg@ki.se
RI Kokron, Cristina M/D-3140-2012; Carvalho, Karina IL/J-6789-2012; KALIL,
   JORGE/C-8029-2012
OI Kokron, Cristina M/0000-0002-9080-0305; Carvalho, Karina
   IL/0000-0002-7763-8139; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925; Paquin Proulx, Dominic/0000-0003-1407-3414;
   Moll, Markus/0000-0003-4592-3063; Sandberg, Johan/0000-0002-6275-0750
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052731, R37AI052731, R01AI052731, R01AI052731, R37AI052731,
   R37AI052731, R37AI052731, R37AI052731, R37AI052731, R01AI052731,
   R01AI052731, R37AI052731, R37AI052731, R01AI052731, R37AI052731,
   R37AI052731] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI52731] Funding Source: Medline
CR Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369
   De Libero G, 2012, TRENDS IMMUNOL, V33, P103, DOI 10.1016/j.it.2012.01.005
   Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037
   MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097
   Moody DB, 2006, ADV IMMUNOL, V89, P87, DOI 10.1016/S0065-2776(05)89003-0
   Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X
   Romani N, 2003, APMIS, V111, P725, DOI 10.1034/j.1600-0463.2003.11107805.x
   Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x
   Smed-Sorensen A, 2008, BLOOD, V111, P5037
NR 9
TC 12
Z9 12
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 13
PY 2013
VL 121
IS 24
BP 4963
EP 4964
DI 10.1182/blood-2013-04-499442
PG 2
WC Hematology
SC Hematology
GA 184NB
UT WOS:000321896300025
PM 23766460
OA Green Published
DA 2020-11-26
ER

PT J
AU Borrelli, GM
   Carvalho, KI
   Kallas, EG
   Mechsner, S
   Baracat, EC
   Abrao, MS
AF Borrelli, G. M.
   Carvalho, K. I.
   Kallas, E. G.
   Mechsner, S.
   Baracat, E. C.
   Abrao, M. S.
TI Chemokines in the pathogenesis of endometriosis and infertility
SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Review
DE Chemokines; Endometriosis; Infertility; Pathogenesis
ID MONOCYTE CHEMOTACTIC PROTEIN-1; PERITONEAL-FLUID CONCENTRATIONS; STROMAL
   CELLS; OVARIAN ENDOMETRIOMA; INTERLEUKIN-8 LEVELS; AUTOIMMUNE-DISEASE;
   ENDOTHELIAL-CELLS; RANTES PRODUCTION; PERIPHERAL-BLOOD; AUTOCRINE MANNER
AB Endometriosis is a chronic benign disease that affects women of reproductive age causing abdominal pain and infertility. Its pathogenesis remains obscure despite all the research conducted over the past 100 years. However, there is a consensus among the specialists that the basis of its pathophysiology would be multifactorial. Many publications have demonstrated that chemokines are somehow associated with the development of endometriosis and infertility. In this study, we reviewed all PubMed literature using MeSH terms "chemokines" and "endometriosis" as well as "chemokines" and "female infertility" to establish what we know and what we do not yet know about this relationship. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Borrelli, G. M.; Abrao, M. S.] Univ Sao Paulo, Sch Med, Dept Obstet & Gynecol, BR-05508 Sao Paulo, Brazil.
   [Borrelli, G. M.; Mechsner, S.] Univ Med Berlin, Dept Gynecol, Endometriosis Res Ctr, Berlin, Germany.
   [Carvalho, K. I.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Dept Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
   [Baracat, E. C.] Univ Sao Paulo, Sch Med, Dept Obstet & Gynecol, Div Gynecol, BR-05508 Sao Paulo, Brazil.
RP Borrelli, GM (corresponding author), Univ Sao Paulo, Sch Med, Dept Obstet & Gynecol, BR-05508 Sao Paulo, Brazil.
EM giuborrelli@me.com
RI HCFMUSP, Pos-Graduacao DOG -/F-1162-2013; Carvalho, Karina
   IL/J-6789-2012; Baracat, Edmund C/H-3800-2012; Abrao, Mauricio
   S/L-3387-2017
OI Carvalho, Karina IL/0000-0002-7763-8139; Baracat, Edmund
   C/0000-0003-0111-9030; Abrao, Mauricio S/0000-0003-1320-3010; Kallas,
   Esper/0000-0003-2026-6925
CR Agic A, 2008, REPROD SCI, V15, P906, DOI 10.1177/1933719108318598
   Akoum A, 1996, FERTIL STERIL, V66, P17
   Altman GB, 1999, AM J REPROD IMMUNOL, V42, P168
   Arici A, 1997, FERTIL STERIL, V67, P1065, DOI 10.1016/S0015-0282(97)81440-9
   Arici A, 1996, MOL HUM REPROD, V2, P40, DOI 10.1093/molehr/2.1.40
   Augoulea A, 2012, ARCH GYNECOL OBSTET, V286, P99, DOI 10.1007/s00404-012-2357-8
   Batt RE, 2011, HISTORY OF ENDOMETRIOSIS, pXXIII, DOI 10.1007/978-0-85729-585-9
   Bergqvist A, 2000, GYNECOL OBSTET INVES, V50, P1, DOI 10.1159/000010269
   Bersinger NA, 2008, FERTIL STERIL, V89, P1530, DOI 10.1016/j.fertnstert.2007.05.075
   Cakmak H, 2012, REPROD SCI, V19, P572, DOI 10.1177/1933719111430998
   Carmona F, 2012, J REPROD IMMUNOL, V95, P80, DOI 10.1016/j.jri.2012.06.001
   Chand AL, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-18
   Fang CL, 2009, EUR J OBSTET GYN R B, V143, P55, DOI 10.1016/j.ejogrb.2008.12.001
   Furuya M, 2007, HUM PATHOL, V38, P1676, DOI 10.1016/j.humpath.2007.03.023
   Galleri L, 2009, FERTIL STERIL, V91, P331, DOI 10.1016/j.fertnstert.2007.11.075
   Manero MG, 2010, FERTIL STERIL, V94, P450, DOI 10.1016/j.fertnstert.2009.03.074
   Gazvani MR, 1998, HUM REPROD, V13, P1957, DOI 10.1093/humrep/13.7.1957
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Glace L, 2009, STEROIDS, V74, P1015, DOI 10.1016/j.steroids.2009.07.011
   Gmyrek GB, 2005, EUR J OBSTET GYN R B, V122, P199, DOI 10.1016/j.ejogrb.2005.03.019
   Hirata T, 2011, FERTIL STERIL, V96, P113, DOI 10.1016/j.fertnstert.2011.04.060
   Hirata T, 2010, ENDOCRINOLOGY, V151, P5468, DOI 10.1210/en.2010-0398
   Holoch KJ, 2010, CLIN OBSTET GYNECOL, V53, P429, DOI 10.1097/GRF.0b013e3181db7d71
   Hornung D, 2000, J CLIN ENDOCR METAB, V85, P2604, DOI 10.1210/jc.85.7.2604
   Hornung D, 1997, J CLIN ENDOCR METAB, V82, P1621, DOI 10.1210/jc.82.5.1621
   Hornung D, 2001, MOL HUM REPROD, V7, P163, DOI 10.1093/molehr/7.2.163
   Jones RL, 1997, HUM REPROD, V12, P1300
   Kataranovski Milena, 2004, Vojnosanit Pregl, V61, P359, DOI 10.2298/VSP0404359K
   Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135
   KHORRAM O, 1993, AM J OBSTET GYNECOL, V169, P1545, DOI 10.1016/0002-9378(93)90433-J
   Kim JY, 2009, AM J REPROD IMMUNOL, V62, P128, DOI 10.1111/j.1600-0897.2009.00722.x
   Kitaya K, 2010, MODERN PATHOL, V23, P1136, DOI 10.1038/modpathol.2010.98
   Laudanski P, 2006, Adv Med Sci, V51, P148
   Leach RE, 2012, HUM REPROD, V27, P814, DOI 10.1093/humrep/der436
   Lebovic DI, 2004, J CLIN ENDOCR METAB, V89, P1397, DOI 10.1210/jc.2003-031010
   Lebovic DI, 2001, J CLIN ENDOCR METAB, V86, P4759, DOI 10.1210/jc.86.10.4759
   Lee DH, 2012, J OBSTET GYNAECOL RE, V38, P516, DOI 10.1111/j.1447-0756.2011.01734.x
   Li MQ, 2012, HUM REPROD, V27, P2107, DOI 10.1093/humrep/des132
   Li MQ, 2012, FERTIL STERIL, V97, P919, DOI 10.1016/j.fertnstert.2011.12.049
   Liekens S, 2010, CURR PHARM DESIGN, V16, P3903, DOI 10.2174/138161210794455003
   Lira SA, 2012, IMMUNOL RES, V54, P111, DOI 10.1007/s12026-012-8313-7
   Luk J, 2010, REPROD SCI, V17, P278, DOI 10.1177/1933719109352380
   Malhotra N, 2012, GYNECOL ENDOCRINOL, V28, P224, DOI 10.3109/09513590.2011.593664
   Manabe S, 2011, ARCH GYNECOL OBSTET, V284, P1567, DOI 10.1007/s00404-011-2002-y
   Matarese G, 2003, TRENDS MOL MED, V9, P223, DOI 10.1016/S1471-4914(03)00051-0
   McKinnon B, 2012, FERTIL STERIL, V97, P657, DOI 10.1016/j.fertnstert.2011.12.001
   Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275
   Mulayim N, 2003, AM J OBSTET GYNECOL, V188, P651, DOI 10.1067/mob.2003.135
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Na YJ, 2011, ARCH GYNECOL OBSTET, V283, P1333, DOI 10.1007/s00404-010-1583-1
   Naz RK, 1996, AM J REPROD IMMUNOL, V35, P534
   Nishida M, 2004, J CLIN ENDOCR METAB, V89, P5094, DOI 10.1210/jc.2004-0354
   Nishida Masakazu, 2011, Front Biosci (Schol Ed), V3, P1196
   Noel JC, 2008, FERTIL STERIL, V89, P1069, DOI 10.1016/j.fertnstert.2007.05.011
   Ohata Y, 2008, FERTIL STERIL, V90, P994, DOI 10.1016/j.fertnstert.2007.07.1355
   Pritts EA, 2003, FERTIL STERIL, V80, P415, DOI 10.1016/S0015-0282(03)00600-9
   Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013
   Raman D, 2011, EXP CELL RES, V317, P575, DOI 10.1016/j.yexcr.2011.01.005
   Ribeiro S, 2005, PHARMACOL THERAPEUT, V107, P44, DOI 10.1016/j.pharmthera.2005.01.004
   Ruiz A, 2010, REPROD SCI, V17, P894, DOI 10.1177/1933719110379920
   RYAN IP, 1995, FERTIL STERIL, V63, P929, DOI 10.1016/S0015-0282(16)57506-2
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X
   Sarapik A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/606459
   Shi YL, 2007, FERTIL STERIL, V88, P317, DOI 10.1016/j.fertnstert.2006.11.129
   Shi YL, 2006, HUM REPROD, V21, P870, DOI 10.1093/humrep/dei414
   Shibahara H, 2003, AM J REPROD IMMUNOL, V49, P169, DOI 10.1034/j.1600-0897.2003.01154.x
   Shimoya K, 2005, INT J GYNECOL OBSTET, V91, P36, DOI 10.1016/j.ijgo.2005.06.018
   Spandorfer SD, 2001, J REPROD MED, V46, P806
   Sundqvist J, 2011, FERTIL STERIL, V95, P437, DOI 10.1016/j.fertnstert.2010.07.1060
   Szamatowicz J, 2002, GYNECOL ENDOCRINOL, V16, P137, DOI 10.1080/713603033
   Tao Y, 2011, AM J REPROD IMMUNOL, V65, P403, DOI 10.1111/j.1600-0897.2010.00920.x
   Taub D D, 1994, Ther Immunol, V1, P229
   Ulukus M, 2005, HUM REPROD, V20, P794, DOI 10.1093/humrep/deh675
   Ulukus M, 2009, FERTIL STERIL, V91, P687, DOI 10.1016/j.fertnstert.2007.12.067
   vanAcker FAA, 1996, MEDIAT INFLAMM, V5, P393, DOI 10.1155/S0962935196000567
   Vinader V, 2012, FUTURE MED CHEM, V4, P845, DOI [10.4155/FMC.12.49, 10.4155/fmc.12.49]
   Wang XQ, 2010, J MOL ENDOCRINOL, V45, P291, DOI 10.1677/JME-09-0177
   Wang XL, 2009, J CLIN IMMUNOL, V29, P387, DOI 10.1007/s10875-009-9274-z
   Wang Y, 2010, CELL MOL IMMUNOL, V7, P51, DOI 10.1038/cmi.2009.102
   WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O
   Wieser F, 2009, BIOL REPROD, V81, P371, DOI 10.1095/biolreprod.108.075069
   Xu H, 2006, FERTIL STERIL, V86, P1616, DOI 10.1016/j.fertnstert.2006.05.043
   Zeyneloglu HB, 1998, HUM REPROD, V13, P1194, DOI 10.1093/humrep/13.5.1194
   Zhao D, 2002, J CLIN ENDOCR METAB, V87, P2514, DOI 10.1210/jc.87.6.2514
   Zhao D, 2002, MOL HUM REPROD, V8, P849, DOI 10.1093/molehr/8.9.849
   Zhuo OY, 2010, FERTIL STERIL, V94, P58, DOI 10.1016/j.fertnstert.2009.01.129
NR 87
TC 39
Z9 43
U1 0
U2 39
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-0378
J9 J REPROD IMMUNOL
JI J. Reprod. Immunol.
PD JUN
PY 2013
VL 98
IS 1-2
BP 1
EP 9
DI 10.1016/j.jri.2013.03.003
PG 9
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA 161VD
UT WOS:000320220500001
PM 23622730
DA 2020-11-26
ER

PT J
AU Sanabani, SS
   Pessoa, R
   de Oliveira, ACS
   Martinez, VP
   Giret, MTM
   Succi, RCD
   Carvalho, K
   Tomiyama, CS
   Nixon, DF
   Sabino, EC
   Kallas, EG
AF Sanabani, Sabri Saeed
   Pessoa, Rodrigo
   Soares de Oliveira, Ana Carolina
   Martinez, Vanessa Pouza
   Giret, Maria Teresa Maidana
   de Menezes Succi, Regina Celia
   Carvalho, Karina
   Tomiyama, Claudia Satiko
   Nixon, Douglas F.
   Sabino, Ester Cerdeira
   Kallas, Esper Georges
TI Variability of HIV-1 Genomes among Children and Adolescents from Sao
   Paulo, Brazil
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CIRCULATING RECOMBINANT FORM; SUBTYPE-C;
   VERTICAL TRANSMISSION; DRUG-RESISTANCE; HIV-1-INFECTED CHILDREN;
   MOLECULAR EPIDEMIOLOGY; GENOTYPIC RESISTANCE; SEQUENCE ALIGNMENT; DUAL
   INFECTION
AB Background: Genetic variability is a major feature of the human immunodeficiency virus type 1 (HIV-1) and considered the key factor to frustrating efforts to halt the virus epidemic. In this study, we aimed to investigate the genetic variability of HIV-1 strains among children and adolescents born from 1992 to 2009 in the state of Sao Paulo, Brazil.
   Methodology: Plasma and peripheral blood mononuclear cells (PBMC) were collected from 51 HIV-1-positive children and adolescents on ART followed between September 1992 and July 2009. After extraction, the genetic materials were used in a polymerase chain reaction (PCR) to amplify the viral near full length genomes (NFLGs) from 5 overlapped fragments. NFLGs and partial amplicons were directly sequenced and data were phylogenetically inferred.
   Results: Of the 51 samples studied, the NFLGs and partial fragments of HIV-1 from 42 PBMCs and 25 plasma were successfully subtyped. Results based on proviral DNA revealed that 22 (52.4%) patients were infected with subtype B, 16 (38.1%) were infected with BF1 mosaic variants and 4 (9.5%) were infected with sub-subtype F1. All the BF1 recombinants were unique and distinct from any previously identified unique or circulating recombinant forms in South America. Evidence of dual infections was detected in 3 patients coinfected with the same or distinct HIV-1 subtypes. Ten of the 31 (32.2%) and 12 of the 21 (57.1%) subjects with recovered proviral and plasma, respectively, protease sequences were infected with major mutants resistant to protease inhibitors. The V3 sequences of 14 patients with available sequences from PBMC/or plasma were predicted to be R5-tropic virus except for two patients who harbored an X4 strain.
   Conclusions: The high proportion of HIV-1 BF1 recombinant, coinfection rate and vertical transmission in Brazil merits urgent attention and effective measures to reduce the transmission of HIV among spouses and sex partners.
C1 [Sanabani, Sabri Saeed] Univ Sao Paulo, Sch Med, Clin & Res Lab LIM 03, Sao Paulo, Brazil.
   [Sanabani, Sabri Saeed; Pessoa, Rodrigo; Soares de Oliveira, Ana Carolina; Martinez, Vanessa Pouza; Sabino, Ester Cerdeira] Univ Sao Paulo, Inst Trop Med, Virol Lab LIM HCFMUSP 52, Sao Paulo, Brazil.
   [Giret, Maria Teresa Maidana] Univ Florida, Miller Sch Med, Story Lab 2, Miami, FL USA.
   [de Menezes Succi, Regina Celia] Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat, Sao Paulo, Brazil.
   [Carvalho, Karina; Tomiyama, Claudia Satiko; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA.
RP Sanabani, SS (corresponding author), Univ Sao Paulo, Sch Med, Clin & Res Lab LIM 03, Sao Paulo, Brazil.
EM sabyem_63@yahoo.com
RI Carvalho, Karina IL/J-6789-2012; Nixon, Douglas/AAU-5734-2020; Sabino,
   Ester Cerdeira/F-7750-2010; Sanabani, Sabri Saeed/F-5600-2012; Pessoa,
   Rodrigo/B-7206-2018
OI Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Sabino, Ester Cerdeira/0000-0003-2623-5126;
   Sanabani, Sabri Saeed/0000-0002-8876-8262; Kallas,
   Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/09983-1,
   2009/540055-5, 2009/52381-2, 2010/05845-0 2004/15856-9, 2006/50096-0];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [2571/2009]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [R01
   AI060379]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI060379, R01AI060379, R01AI060379, R01AI060379,
   R01AI060379] Funding Source: NIH RePORTER
FX The study was supported by grants 2011/09983-1, 2009/540055-5,
   2009/52381-2 and 2010/05845-0 2004/15856-9 and 2006/50096-0 from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). The study
   was also partially supported by grant 2571/2009 from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). Additional support
   was provided by grant R01 AI060379 from the National Institutes of
   Health. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Almeida FJ, 2009, J PEDIAT, V85, P104, DOI [10.2223/JPED.1877, 10.1590/S0021-75572009000200004]
   Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200
   ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805
   Aulicino PC, 2011, INFECT GENET EVOL, V11, P349, DOI 10.1016/j.meegid.2010.11.008
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bimber BN, 2010, J VIROL, V84, P12087, DOI 10.1128/JVI.01378-10
   Bitnun A, 2002, CAN MED ASSOC J, V166, P904
   Passaes CPB, 2009, AIDS RES HUM RETROV, V25, P1339, DOI 10.1089/aid.2009.0167
   Brindeiro PA, 2002, J CLIN MICROBIOL, V40, P4512, DOI 10.1128/JCM.40.12.4512-4519.2002
   Bushman FD, 2008, AIDS, V22, P1411, DOI 10.1097/QAD.0b013e3282fc972e
   Chueca N, 2009, J MED VIROL, V81, P763, DOI 10.1002/jmv.21425
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   da Silveira AA, 2012, AIDS RES HUM RETROV, V28, P304, DOI 10.1089/aid.2011.0128
   de Oliveira CM, 2008, ARCH VIROL, V153, P1799, DOI 10.1007/s00705-008-0178-7
   DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995
   Dudley DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036494
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Janini LM, 1998, J INFECT DIS, V177, P227, DOI 10.1086/517360
   Koelsch KK, 2003, AIDS, V17, pF11, DOI 10.1097/00002030-200305020-00001
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado ES, 2004, J CLIN VIROL, V30, P24, DOI 10.1016/j.jcv.2003.08.001
   MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995
   McBurney SP, 2008, EXPERT REV VACCINES, V7, P1405, DOI 10.1586/14760584.7.9.1405
   McGovern RA, 2010, AIDS, V24, P2512, DOI 10.1097/QAD.0b013e32833e6cfb
   Peeters M, 2003, AIDS, V17, P2547, DOI 10.1097/00002030-200312050-00002
   Peters V, 2003, PEDIATRICS, V111, P1186
   Pitt J, 1997, J INFECT DIS, V175, P567, DOI 10.1093/infdis/175.3.567
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Raymond S, 2008, AIDS, V22, pF11, DOI 10.1097/QAD.0b013e32830ebcd4
   Russell ES, 2011, J VIROL, V85, P8253, DOI 10.1128/JVI.00197-11
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Samleerat T, 2008, J INFECT DIS, V198, P868, DOI 10.1086/591251
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Sanabani SS, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-78
   Santos AF, 2006, AIDS, V20, P2011
   Schultz AK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-265
   Skrabal K, 2007, J CLIN MICROBIOL, V45, P279, DOI 10.1128/JCM.01118-06
   de Oliveira ACS, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-223
   Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201
   Spira S, 2003, J ANTIMICROB CHEMOTH, V51, P229, DOI 10.1093/jac/dkg079
   Templeton AR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-54
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2005, AIDS REV, V7, P210
   Verhofstede C, 2003, J VIROL, V77, P3050, DOI 10.1128/JVI.77.5.3050-3057.2003
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   Wiktor S Z, 1997, AIDS, V11 Suppl B, pS79
   WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316
NR 55
TC 15
Z9 15
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2013
VL 8
IS 5
AR e62552
DI 10.1371/journal.pone.0062552
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154EP
UT WOS:000319654700046
PM 23667488
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU van de Weg, CAM
   Pannuti, CS
   de Araujo, ESA
   van den Ham, HJ
   Andeweg, AC
   Boas, LSV
   Felix, AC
   Carvalho, KI
   de Matos, AM
   Levi, JE
   Romano, CM
   Centrone, CC
   Rodrigues, CLD
   Luna, E
   van Gorp, ECM
   Osterhaus, ADME
   Martina, BEE
   Kallas, EG
AF van de Weg, Cornelia A. M.
   Pannuti, Claudio S.
   de Araujo, Evaldo S. A.
   van den Ham, Henk-Jan
   Andeweg, Arno C.
   Boas, Lucy S. V.
   Felix, Alvina C.
   Carvalho, Karina I.
   de Matos, Andreia M.
   Levi, Jose E.
   Romano, Camila M.
   Centrone, Cristiane C.
   de Lima Rodrigues, Celia L.
   Luna, Expedito
   van Gorp, Eric C. M.
   Osterhaus, Albert D. M. E.
   Martina, Byron E. E.
   Kallas, Esper G.
TI Microbial Translocation Is Associated with Extensive Immune Activation
   in Dengue Virus Infected Patients with Severe Disease
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID HEMORRHAGIC-FEVER; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN
   MONOCYTES/MACROPHAGES; CYTOKINE PATTERNS; INTERFERON-GAMMA; PLASMA
   LEAKAGE; SHOCK SYNDROME; SEPTIC SHOCK; TNF-ALPHA; EXPRESSION
AB Background: Severe dengue virus (DENV) disease is associated with extensive immune activation, characterized by a cytokine storm. Previously, elevated lipopolysaccharide (LPS) levels in dengue were found to correlate with clinical disease severity. In the present cross-sectional study we identified markers of microbial translocation and immune activation, which are associated with severe manifestations of DENV infection.
   Methods: Serum samples from DENV-infected patients were collected during the outbreak in 2010 in the State of Sao Paulo, Brazil. Levels of LPS, lipopolysaccharide binding protein (LBP), soluble CD14 (sCD14) and IgM and IgG endotoxin core antibodies were determined by ELISA. Thirty cytokines were quantified using a multiplex luminex system. Patients were classified according to the 2009 WHO classification and the occurrence of plasma leakage/shock and hemorrhage. Moreover, a (non-supervised) cluster analysis based on the expression of the quantified cytokines was applied to identify groups of patients with similar cytokine profiles. Markers of microbial translocation were linked to groups with similar clinical disease severity and clusters with similar cytokine profiles.
   Results: Cluster analysis indicated that LPS levels were significantly increased in patients with a profound pro-inflammatory cytokine profile. LBP and sCD14 showed significantly increased levels in patients with severe disease in the clinical classification and in patients with severe inflammation in the cluster analysis. With both the clinical classification and the cluster analysis, levels of IL-6, IL-8, sIL-2R, MCP-1, RANTES, HGF, G-CSF and EGF were associated with severe disease.
   Conclusions: The present study provides evidence that both microbial translocation and extensive immune activation occur during severe DENV infection and may play an important role in the pathogenesis.
C1 [van de Weg, Cornelia A. M.; van den Ham, Henk-Jan; Andeweg, Arno C.; van Gorp, Eric C. M.; Osterhaus, Albert D. M. E.; Martina, Byron E. E.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.] Hosp Ana Costa, Dept Infect Dis, Santos, Brazil.
   [Carvalho, Karina I.; de Matos, Andreia M.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
RP van de Weg, CAM (corresponding author), Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
EM esper.kallas@usp.br
RI Romano, Camila M/C-8185-2013; Luna, Expedito J A/B-7948-2012; Romano,
   Camila/ABC-2883-2020; Carvalho, Karina IL/J-6789-2012
OI Luna, Expedito J A/0000-0002-1145-9672; Romano,
   Camila/0000-0003-4550-1987; Carvalho, Karina IL/0000-0002-7763-8139;
   Osterhaus, Albert/0000-0002-6074-1172; van den Ham,
   Henk-Jan/0000-0001-8582-5404; Kallas, Esper/0000-0003-2026-6925
FU "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   Brazilian Ministry of Science and Technology'' [CNPq] [476088/2009-7];
   CNPqNational Council for Scientific and Technological Development
   (CNPq); "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior,
   Brazilian Ministry of Education''; "Virgo consortium''; Dutch government
   [FES0908]; Netherlands Genomics Initiative (NGI) [050-060-452]
FX This work was supported by the "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazilian Ministry of Science and Technology''
   [CNPq, project number 476088/2009-7 to EGK]. AMdM and EGK's scholarships
   were supported by "CNPq.'' KIC's scholarship was supported by the
   "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazilian
   Ministry of Education.'' Moreover, this study was also supported by the
   "Virgo consortium,'' funded by the Dutch government [project number
   FES0908] and by the "Netherlands Genomics Initiative (NGI)'' [project
   number 050-060-452]. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Bukh AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021275
   CARUSO C, 1993, MEDIAT INFLAMM, V2, P3, DOI 10.1155/S0962935193000018
   Chen JP, 2006, J IMMUNOL, V177, P3185, DOI 10.4049/jimmunol.177.5.3185
   Chen YC, 1999, J VIROL, V73, P2650, DOI 10.1128/JVI.73.4.2650-2657.1999
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Hofer U, 2009, SEMIN IMMUNOPATHOL, V31, P257, DOI 10.1007/s00281-009-0158-3
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   John CC, 2006, J INFECT DIS, V194, P837, DOI 10.1086/506623
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   LANDMANN R, 1995, J INFECT DIS, V171, P639, DOI 10.1093/infdis/171.3.639
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Murphy K, 2008, JANEWAYS IMMUNOBIOLO, V2008
   Opal SM, 1999, J INFECT DIS, V180, P1584, DOI 10.1086/315093
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Perez AB, 2004, J MED VIROL, V73, P230, DOI 10.1002/jmv.20080
   Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sierra B, 2010, CYTOKINE, V52, P175, DOI 10.1016/j.cyto.2010.06.010
   Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
   Suharti C, 2003, EUR CYTOKINE NETW, V14, P172
   Tang YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012644
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
   Wang WM, 2011, INFLAMMATION, V34, P509, DOI 10.1007/s10753-010-9258-4
   World Health Organization, 2009, DENG HEM FEV DIAGN T
NR 45
TC 41
Z9 42
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2013
VL 7
IS 5
AR e2236
DI 10.1371/journal.pntd.0002236
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 158SW
UT WOS:000319994400038
PM 23717702
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Mahnke, YD
   Song, KM
   Sauer, MM
   Nason, MC
   Giret, MTM
   Carvalho, KI
   Costa, PR
   Roederer, M
   Kallas, EG
AF Mahnke, Yolanda D.
   Song, Kaimei
   Sauer, Mariana M.
   Nason, Martha C.
   Giret, Maria Teresa M.
   Carvalho, Karina I.
   Costa, Priscilla R.
   Roederer, Mario
   Kallas, Esper G.
TI Early immunologic and virologic predictors of clinical HIV-1 disease
   progression
SO AIDS
LA English
DT Article
DE CD38; cell-associated viral load; immunophenotyping; prognosis;
   progression; T-cell activation
ID CD8(+) T-CELLS; VIRAL LOAD; TYPE-1 INFECTION; FOLLOW-UP; SET-POINT;
   CD4(+); RESPONSES; ACTIVATION; SURVIVAL; VIREMIA
AB Objective: To identify early determinants of HIV-1 disease progression, which could potentially enable individualized patient treatment, and provide correlates of progression applicable as reference phenotypes to evaluate breakthrough infections in vaccine development.
   Design: High-throughput technologies were employed to interrogate multiple parameters on cryopreserved, retrospective peripheral blood mononuclear cell (PBMC) samples from 51 individuals from Sao Paulo, Brazil, obtained within 1 year of diagnosing early Clade B HIV-1 infection. Fast Progressors, Slow Progressors, and Controllers were identified based on a 2-year clinical follow-up.
   Methods: Phenotypic and functional T-cell parameters were tested by flow cytometry and qPCR to identify potential early determinants of subsequent HIV-1 disease progression.
   Results: Major differences were observed between Controllers and Progressors, especially in cell-associated viral load (CAVL), the differentiation pattern and CD38 expression of CD8(+) T cells, and the cytokine pattern and activation phenotype of HIV-1-specific CD8(+) T cells. Despite remarkably few other differences between the two Progressor groups, the CAVL had predictive power independent of plasma viral load.
   Conclusion: Analysis of three parameters (% CD38(+)CD8(+) T cells, total CAVL,% CCR5(+) CD8(+) T cells) was sufficient to predict subsequent disease progression (P < 0.001). Use of such prognostic correlates may be crucial when early CD4(+) T-cell counts and plasma viral load levels fail to discriminate among groups with differing subsequent clinical progression. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:697-706
C1 [Mahnke, Yolanda D.; Song, Kaimei; Roederer, Mario] NIAID, ImmunoTechnol Sect, VRC, NIH, Bethesda, MD 20892 USA.
   [Sauer, Mariana M.; Giret, Maria Teresa M.; Carvalho, Karina I.; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nason, Martha C.] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA.
   [Giret, Maria Teresa M.] Univ Florida, Miller Sch Med, Story Lab 2, Miami, FL USA.
RP Mahnke, YD (corresponding author), 40 Convent Dr,Rm 5608, Bethesda, MD 20892 USA.
EM mahnkey@mail.nih.gov
RI Carvalho, Karina IL/J-6789-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Kallas,
   Esper/0000-0003-2026-6925; Mahnke, Yolanda/0000-0002-2727-9887
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2004/15856-9, 2006/50096-0]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [ZIAAI005021, ZIAAI005021,
   ZIAAI005020, ZIAAI005020, ZIAAI005020, ZIAAI005021, ZIAAI005021,
   ZIAAI005020, ZIAAI005021, ZIAAI005020, ZIAAI005020, ZIAAI005020,
   ZIAAI005021, ZIAAI005021, ZIAAI005020, ZIAAI005021, ZIAAI005020,
   ZIAAI005020, ZIAAI005021, ZIAAI005021] Funding Source: NIH RePORTER
FX This work was supported by the Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health; the Brazilian Program for STD and AIDS, Ministry
   of Health (grant number 914/BRA/3014-UNESCO/Kallas); the Sao Paulo City
   Health Department (grant number 2004-0.168.922-7/Kallas); and the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (grant
   numbers 2004/15856-9 and 2006/50096-0). The funding bodies had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Blankson JN, 2008, AIDS, V22, P2398, DOI 10.1097/QAD.0b013e328316c3fb
   Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925
   Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004
   Burgers WA, 2009, J IMMUNOL, V182, P4751, DOI 10.4049/jimmunol.0803801
   Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346
   Catalfamo M, 2011, J IMMUNOL, V186, P2106, DOI 10.4049/jimmunol.1002000
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Chun TW, 2004, P NATL ACAD SCI USA, V101, P2464, DOI 10.1073/pnas.0307328101
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Dinges WL, 2010, J VIROL, V84, P4461, DOI 10.1128/JVI.02438-09
   Ganesan A, 2010, J INFECT DIS, V201, P272, DOI 10.1086/649430
   GIORGI JV, 1994, J INFECT DIS, V170, P775, DOI 10.1093/infdis/170.4.775
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904
   Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365
   Goujard C, 2006, CLIN INFECT DIS, V42, P709, DOI 10.1086/500213
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240
   Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244
   Lazaryan A, 2010, J VIROL, V84, P2610, DOI 10.1128/JVI.01962-09
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Liu ZY, 1996, CYTOMETRY, V26, P1
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341
   RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903
   Scheinberg P, 2009, BLOOD, V114, P5071, DOI 10.1182/blood-2009-04-214684
   Schellens IMM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002745
NR 35
TC 8
Z9 8
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAR 13
PY 2013
VL 27
IS 5
BP 697
EP 706
DI 10.1097/QAD.0b013e32835ce2e9
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 098CY
UT WOS:000315524700003
PM 23211771
DA 2020-11-26
ER

PT J
AU Batista, MD
   Tincati, C
   Milush, JM
   Ho, EL
   Ndhlovu, LC
   York, VA
   Kallas, EG
   Kalil, J
   Keating, SM
   Norris, PJ
   Chang, D
   Unemori, P
   Leslie, KS
   Maurer, T
   Liao, W
   Nixon, DF
AF Batista, Mariana D.
   Tincati, Camilla
   Milush, Jeffrey M.
   Ho, Emily L.
   Ndhlovu, Lishomwa C.
   York, Vanessa A.
   Kallas, Esper G.
   Kalil, Jorge
   Keating, Sheila M.
   Norris, Philip J.
   Chang, David
   Unemori, Patrick
   Leslie, Kieron S.
   Maurer, Toby
   Liao, Wilson
   Nixon, Douglas F.
TI CD57 Expression and Cytokine Production by T Cells in Lesional and
   Unaffected Skin from Patients with Psoriasis
SO PLOS ONE
LA English
DT Article
ID HUMAN KERATINOCYTES; ATOPIC-DERMATITIS; GENE-EXPRESSION; IL-22;
   DIFFERENTIATION; LYMPHOCYTES; IMMUNOPATHOGENESIS; ACTIVATION; IMMUNITY;
   SUBSET
AB Background: The immunopathogenic mechanisms leading to psoriasis remain unresolved. CD57 is a marker of replicative inability and immunosenescence on CD8+ T cells and the proportion of CD57 expressing CD8+ T cells is increased in a number of inflammatory conditions.
   Methodology: We examined the expression of CD57 on T cells in the skin of patients affected with psoriasis, comparing lesional and unaffected skin. We also assessed functionality of the T cells by evaluating the secretion of several inflammatory cytokines (IL-17A, IFN-gamma, IL-2, IL-33, TNF-alpha, IL-21, IL-22, and IL-27), from cell-sorted purified CD4+ and CD8+ T cells isolated from lesional and unaffected skin biopsies of psoriasis patients.
   Principal Findings: We observed that the frequency of CD57+CD4+ and CD57+CD8+ T cells was significantly higher in unaffected skin of psoriasis patients compared to lesional skin. Sorted CD4+ T cells from psoriatic lesional skin produced higher levels of IL-17A, IL-22, and IFN-gamma compared to unaffected skin, while sorted CD8+ T cells from lesional skin produced higher levels of IL-17, IL-22, IFN-gamma, TNF-alpha, and IL-2 compared to unaffected skin.
   Conclusions/Significance: These findings suggest that T cells in unaffected skin from psoriasis patients exhibit a phenotype compatible with replicative inability. As they have a lower replicative capacity, CD57+ T cells are less frequent in lesional tissue due to the high cellular turnover.
C1 [Batista, Mariana D.; Tincati, Camilla; Milush, Jeffrey M.; Ho, Emily L.; Ndhlovu, Lishomwa C.; York, Vanessa A.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Batista, Mariana D.; Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kallas, Esper G.; Kalil, Jorge] Univ Sao Paulo, Inst Invest Imunol, Sao Paulo, Brazil.
   [Keating, Sheila M.; Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Keating, Sheila M.; Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA.
   [Norris, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Chang, David] Calif Pacific Med Ctr, San Francisco, CA USA.
   [Unemori, Patrick; Leslie, Kieron S.; Maurer, Toby; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
RP Batista, MD (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM maridiasbatista@gmail.com
RI KALIL, JORGE/C-8029-2012; n, l/AAX-3992-2020; Nixon,
   Douglas/AAU-5734-2020; TINCATI, CAMILLA/K-4501-2018
OI KALIL, JORGE/0000-0001-8415-4274; Nixon, Douglas/0000-0002-2801-1786;
   Keating, Sheila/0000-0002-8324-3694; Kallas, Esper/0000-0003-2026-6925;
   TINCATI, CAMILLA/0000-0002-3083-2962; Milush, Jeffrey
   M./0000-0002-0773-6411; Ndhlovu, Lishomwa/0000-0001-5427-4187
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI64520,
   5T32HL007185]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas, 2010/05845-0/Kallas]; Peter and Shelagh Godsoe
   Family Foundation; UCSF REAC [37710/521717]; American Academy of
   Neurology Clinical Research Training Fellowship; National Institute of
   Musculoskeletal and Skin DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
   [5K08AR057763]; International AIDS Society; U.S. National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; UW Institute of Translational Health
   Sciences; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [K08AR057763, K08AR057763,
   K08AR057763, K08AR057763, K08AR057763, K08AR057763] Funding Source: NIH
   RePORTER
FX This work was supported in part by the National Institutes of Health
   (grants AI64520), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (04/15856-9/Kallas and 2010/05845-0/Kallas and Nixon), and the Peter and
   Shelagh Godsoe Family Foundation. DN was supported in part by UCSF REAC
   grant no. 37710/521717. ELH was a recipient of the American Academy of
   Neurology Clinical Research Training Fellowship. JMM was supported in
   part by the National Institutes of Health (grant 5T32HL007185). WL was
   supported in part by grants from the National Institute of
   Musculoskeletal and Skin Diseases (5K08AR057763) and the International
   AIDS Society in collaboration with the NIH-funded Centers for AIDS
   Research, U.S. National Institutes of Health, and the UW Institute of
   Translational Health Sciences. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arai K, 1998, CLIN EXP IMMUNOL, V111, P345
   Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Cameron AL, 2002, ARCH DERMATOL RES, V294, P363, DOI 10.1007/s00403-002-0349-4
   Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995
   Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107
   Clark RA, 2011, J INVEST DERMATOL, V131, P283, DOI 10.1038/jid.2010.374
   Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
   Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59
   Evans TG, 1999, AIDS, V13, P1139, DOI 10.1097/00002030-199906180-00019
   Focosi D, 2010, J LEUKOCYTE BIOL, V87, P107, DOI 10.1189/jlb.0809566
   Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173
   Iking-Konert C, 2009, CLIN EXP RHEUMATOL, V27, pS19
   Le Priol Y, 2006, J IMMUNOL, V177, P5145, DOI 10.4049/jimmunol.177.8.5145
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213
   Mak RKH, 2009, ACTAS DERMO-SIFILOGR, V100, P2, DOI 10.1016/S0001-7310(09)73372-1
   Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
   Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x
   Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041
   Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/JLB.0109046, 10.1189/jlb.0109046]
   Palmer BE, 2005, J IMMUNOL, V175, P8415, DOI 10.4049/jimmunol.175.12.8415
   Plant D, 2006, EXP DERMATOL, V15, P900, DOI 10.1111/j.1600-0625.2006.00486.x
   Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108
   Sabat R, 2007, EXP DERMATOL, V16, P779, DOI 10.1111/j.1600-0625.2007.00629.x
   Shibata S, J INVEST DERMATOL, V130, P1034
   Simpson RJ, 2008, BRAIN BEHAV IMMUN, V22, P544, DOI 10.1016/j.bbi.2007.11.002
   Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948
   Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124
   Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280
   Tarazona R, 2000, MECH AGEING DEV, V121, P77
   Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x
   Theoharides TC, P NATL ACAD SCI US, V107, P4448
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503
   Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001
   Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505
NR 37
TC 5
Z9 5
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2013
VL 8
IS 2
AR e52144
DI 10.1371/journal.pone.0052144
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098DA
UT WOS:000315524900002
PM 23468834
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Leal, FE
   Ndhlovu, LC
   Hasenkrug, AM
   Bruno, FR
   Carvalho, KI
   Wynn-Williams, H
   Neto, WK
   Sanabani, SS
   Segurado, AC
   Nixon, DF
   Kallas, EG
AF Leal, Fabio E.
   Ndhlovu, Lishomwa C.
   Hasenkrug, Aaron M.
   Bruno, Fernanda R.
   Carvalho, Karina I.
   Wynn-Williams, Harry
   Neto, Walter K.
   Sanabani, Sabri S.
   Segurado, Aluisio C.
   Nixon, Douglas F.
   Kallas, Esper G.
TI Expansion in CD39(+) CD4(+) Immunoregulatory T Cells and Rarity of Th17
   Cells in HTLV-1 Infected Patients Is Associated with Neurological
   Complications
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; IMMUNOLOGICAL
   SELF-TOLERANCE; PROVIRAL LOAD; PERIPHERAL-BLOOD; GENE-EXPRESSION;
   LYMPHOCYTE-PROLIFERATION; IMMUNE SUPPRESSION; CD4+CD25+T CELLS; DISEASE
   SEVERITY
AB HTLV-1 infection is associated with several inflammatory disorders, including the neurodegenerative condition HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is unclear why a minority of infected subjects develops HAM/TSP. CD4(+) T cells are the main target of infection and play a pivotal role in regulating immunity to HTLV and are hypothesized to participate in the pathogenesis of HAM/TSP. The CD39 ectonucleotidase receptor is expressed on CD4(+) T cells and based on co-expression with CD25, marks T cells with distinct regulatory (CD39(+)CD25(+)) and effector (CD39(+)CD25(-)) function. Here, we investigated the expression of CD39 on CD4(+) T cells from a cohort of HAM/TSP patients, HTLV-1 asymptomatic carriers (AC), and matched uninfected controls. The frequency of CD39(+)CD4(+) T cells was increased in HTLV-1 infected patients, regardless of clinical status. More importantly, the proportion of the immunostimulatory CD39(+)CD25(-) CD4+ T-cell subset was significantly elevated in HAM/TSP patients as compared to AC and phenotypically had lower levels of the immunoinhibitory receptor, PD-1. We saw no difference in the frequency of CD39(+)CD25(+) regulatory (Treg) cells between AC and HAM/TSP patients. However, these cells transition from being anergic to displaying a polyfunctional cytokine response following HTLV-1 infection. CD39(-)CD25(+) T cell subsets predominantly secreted the inflammatory cytokine IL-17. We found that HAM/TSP patients had significantly fewer numbers of IL-17 secreting CD4(+) T cells compared to uninfected controls. Taken together, we show that the expression of CD39 is upregulated on CD4(+) T cells HAM/TSP patients. This upregulation may play a role in the development of the proinflammatory milieu through pathways both distinct and separate among the different CD39 T cell subsets. CD39 upregulation may therefore serve as a surrogate diagnostic marker of progression and could potentially be a target for interventions to reduce the development of HAM/TSP.
C1 [Leal, Fabio E.; Ndhlovu, Lishomwa C.; Hasenkrug, Aaron M.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Leal, Fabio E.; Ndhlovu, Lishomwa C.; Wynn-Williams, Harry] Univ Hawaii, John A Burns Sch Med, Dept Trop Med, Hawaii Ctr AIDS, Honolulu, HI 96822 USA.
   [Leal, Fabio E.; Sanabani, Sabri S.; Segurado, Aluisio C.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Deparment Infect Dis, Sao Paulo, Brazil.
   [Bruno, Fernanda R.; Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Neto, Walter K.] Funcacao Prosangue, Hemoctr Sao Paulo, Mol Biol Lab, Sao Paulo, Brazil.
   [Neto, Walter K.] Univ Fed Sao Paulo, Dept Translat Med, Sao Paulo, Brazil.
RP Leal, FE (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM esper.kallas@usp.br
RI Segurado, Aluisio C/K-2229-2012; Nixon, Douglas/AAU-5734-2020; Carvalho,
   Karina IL/J-6789-2012; n, l/AAX-3992-2020; Sanabani, Sabri
   Saeed/F-5600-2012
OI Segurado, Aluisio C/0000-0002-6311-8036; Nixon,
   Douglas/0000-0002-2801-1786; Carvalho, Karina IL/0000-0002-7763-8139;
   Sanabani, Sabri Saeed/0000-0002-8876-8262; Kallas,
   Esper/0000-0003-2026-6925; Ndhlovu, Lishomwa/0000-0001-5427-4187
FU National Institute of Allergies and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; University of
   CaliforniaUniversity of California System; San Francisco-Gladstone
   Institute of Virology & Immunology Center for AIDS Research [P30
   AI027763]; Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/15856-9/Kallas,
   2010/05845-0/Kallas, 11/12297-2/Sanabani]; John E. Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW00003]; National Center for Research ResourcesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR)
   [5P20RR016467-11]; National Institute of General Medical Sciences from
   the National Institutes of Health [8P20GM103466-11]; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467, P20RR016467, P20RR016467,
   P20RR016467, P20RR016467, P20RR016467] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P20GM103466,
   P20GM103466, P20GM103466, P20GM103466, P20GM103466, P20GM103466,
   P20GM103466, P20GM103466, P20GM103466, P20GM103466, P20GM103466,
   P20GM103466, P20GM103466, P20GM103466, P20GM103466, P20GM103466,
   P20GM103466] Funding Source: NIH RePORTER
FX Support for this work was provided by National Institute of Allergies
   and Infectious Diseases and by funds from the National Institutes of
   Health, University of California, San Francisco-Gladstone Institute of
   Virology & Immunology Center for AIDS Research (P30 AI027763).
   Additional support was provided by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (04/15856-9/Kallas and 2010/05845-0/Kallas and Nixon
   and 11/12297-2/Sanabani), the John E. Fogarty International Center (D43
   TW00003), National Center for Research Resources (5P20RR016467-11) and
   the National Institute of General Medical Sciences (8P20GM103466-11)
   from the National Institutes of Health. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Arisawa K, 2000, INT J CANCER, V85, P319, DOI 10.1002/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B
   Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286
   Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0
   Bellon M, 2010, BLOOD, V115, P2441, DOI 10.1182/blood-2009-08-241117
   Benveniste EN, 1995, FASEB J, V9, P1577
   Best I, 2009, IMMUNOLOGY, V128, pe777, DOI 10.1111/j.1365-2567.2009.03082.x
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527
   Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301
   Carneiro-Proietti AB, 2012, AIDS RES HU IN PRESS
   Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   Dodon MD, 2004, J GEN VIROL, V85, P1921, DOI 10.1099/vir.0.79921-0
   Dwyer KM, 2010, AM J TRANSPLANT, V10, P2410, DOI 10.1111/j.1600-6143.2010.03291.x
   EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769
   El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021
   ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567
   Etoh K, 1997, CANCER RES, V57, P4862
   Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632
   Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Garlet GP, 2010, CLIN INFECT DIS, V50, pE11, DOI 10.1086/649871
   Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002
   GESSAIN A, 1985, LANCET, V2, P407
   Goon PKC, 2004, J IMMUNOL, V172, P1735, DOI 10.4049/jimmunol.172.3.1735
   Grant C, 2008, BLOOD, V111, P5601, DOI 10.1182/blood-2007-11-123430
   Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568
   Hanon E, 2001, BLOOD, V98, P721, DOI 10.1182/blood.V98.3.721
   Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017
   Hartigan-O'Connor DJ, 2007, J EXP MED, V204, P2679, DOI 10.1084/jem.20071068
   Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931
   Hilburn S, 2011, J INFECT DIS, V203, P529, DOI 10.1093/infdis/jiq078
   Hisada M, 2001, INT J CANCER, V91, P497, DOI 10.1002/1097-0215(20010215)91:4&lt;497::AID-IJC1044&gt;3.0.CO;2-A
   Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308
   IANNONE R, 1992, J ACQ IMMUN DEF SYND, V5, P810
   Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107
   Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651
   KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451
   Kubota R, 1998, J IMMUNOL, V161, P482
   Kubota R, 2000, J NEUROIMMUNOL, V102, P208, DOI 10.1016/S0165-5728(99)00175-7
   Lehner T, 2008, IMMUNOLOGY, V123, P40, DOI 10.1111/j.1365-2567.2007.02780.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699
   MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574
   Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71
   Matsuura E, 2010, J NEUROIMMUNE PHARM, V5, P310, DOI 10.1007/s11481-010-9216-9
   Michaelsson J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-41
   MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943
   MORGAN OS, 1989, LANCET, V2, P1184
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Ndhlovu LC, 2008, AIDS, V22, P990, DOI 10.1097/QAD.0b013e3282ff884e
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Ndhlovu LC, 2010, J CLIN IMMUNOL, V30, P681, DOI 10.1007/s10875-010-9432-3
   Ndhlovu LC, 2010, EUR J IMMUNOL, V40, P134, DOI 10.1002/eji.200939258
   NISHIOKA K, 1989, LANCET, V1, P441
   Oh U, 2006, J INFECT DIS, V193, P1557, DOI 10.1086/503874
   Ohsugi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018518
   Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA
   Ormsby CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041021
   Osame, 1990, HUMAN RETROVIROLOGY, P191
   OSAME M, 1986, LANCET, V1, P1031
   Raimondi G, 2006, J IMMUNOL, V176, P2808, DOI 10.4049/jimmunol.176.5.2808
   Read S, 2006, J IMMUNOL, V177, P4376, DOI 10.4049/jimmunol.177.7.4376
   RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990
   Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103
   Stromnes IM, 2008, NAT MED, V14, P337, DOI 10.1038/nm1715
   Tandon R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045733
   Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143
   Toulza F, 2008, BLOOD, V111, P5047, DOI 10.1182/blood-2007-10-118539
   Toulza F, 2010, J IMMUNOL, V185, P183, DOI 10.4049/jimmunol.0903846
   UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010
   Usui T, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-34
   Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Yamano Y, 2005, J CLIN INVEST, V115, P1361, DOI 10.1172/JCI200523913
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yamano Y, 2004, J EXP MED, V199, P1367, DOI 10.1084/jem.20032042
   Yamano Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006517
   Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729
   Ziegler SF, 2007, EUR J IMMUNOL, V37, P21, DOI 10.1002/eji.200636929
NR 85
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2013
VL 7
IS 2
AR e2028
DI 10.1371/journal.pntd.0002028
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 099TM
UT WOS:000315644900006
PM 23409198
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Batista, MD
   Ho, EL
   Kuebler, PJ
   Milush, JM
   Lanier, LL
   Kallas, EG
   York, VA
   Chang, D
   Liao, W
   Unemori, P
   Leslie, KS
   Maurer, T
   Nixon, DF
AF Batista, Mariana D.
   Ho, Emily L.
   Kuebler, Peter J.
   Milush, Jeffrey M.
   Lanier, Lewis L.
   Kallas, Esper G.
   York, Vanessa A.
   Chang, David
   Liao, Wilson
   Unemori, Patrick
   Leslie, Kieron S.
   Maurer, Toby
   Nixon, Douglas F.
TI Skewed distribution of natural killer cells in psoriasis skin lesions
SO EXPERIMENTAL DERMATOLOGY
LA English
DT Article
DE CD57; immunosenescence; natural killer cells; psoriasis
ID CD57 DEFINES; NK CELLS; EXPRESSION; SUBSET; RECEPTORS; EDUCATION
AB Psoriasis is a hyper-proliferative disease of the skin in which immunological mechanisms play a direct pathogenetic role. There have been limited studies of natural killer (NK) cells in psoriasis. The aim of this study was to examine the phenotype of NK cells in skin biopsies and peripheral blood mononuclear cells from patients with psoriasis and healthy controls. CD56+CD16- and CD56+CD16+ NK cells were isolated from lesional skin, unaffected skin and PBMC of psoriasis patients, and normal skin and PBMC from healthy controls. The expression of CD57, NKG2A and NKG2C was assessed by flow cytometry. NK cells in psoriasis skin lesions were skewed in their expression of CD57, a marker of NK cell maturity, with CD57 expression significantly reduced and NKG2A expression increased on NK cells in lesional and unaffected skin compared to controls. These data suggest that in this patient cohort, NK cells could be isolated from psoriasis lesions and exhibit an immature phenotype.
C1 [Batista, Mariana D.; Ho, Emily L.; Kuebler, Peter J.; Milush, Jeffrey M.; York, Vanessa A.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Batista, Mariana D.] Univ Sao Paulo, Div Clin Immunol & Allergy, LIM 60, Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Lanier, Lewis L.] Univ Calif San Francisco, Canc Res Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Inst Invest Imunol, Sao Paulo, Brazil.
   [Chang, David] Calif Pacific Med Ctr, San Francisco, CA USA.
   [Liao, Wilson; Unemori, Patrick; Leslie, Kieron S.; Maurer, Toby] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
RP Batista, MD (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, LIM 60, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM maridiasbatista@gmail.com
RI Nixon, Douglas/AAU-5734-2020; Lanier, Lewis L/E-2139-2014
OI Nixon, Douglas/0000-0002-2801-1786; Lanier, Lewis L/0000-0003-1308-3952;
   Milush, Jeffrey M./0000-0002-0773-6411; Kallas,
   Esper/0000-0003-2026-6925
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [T32 HL007185, 5T32HL007185] Funding Source: Medline;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI068129, AI068129, AI64520, P01
   AI064520] Funding Source: Medline; NIAMS NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS) [5K08AR057763, K08 AR057763] Funding Source: Medline; NIDDK NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [P30 DK063720] Funding Source:
   Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185, T32HL007185,
   T32HL007185, T32HL007185, T32HL007185, T32HL007185] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI068129, R01AI068129, P01AI064520, P01AI064520,
   R01AI068129, P01AI064520, P01AI064520, P01AI064520, R01AI068129,
   P01AI064520, R01AI068129, P01AI064520, P01AI064520, P01AI064520,
   R01AI068129, R01AI068129, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, R01AI068129, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, R01AI068129, P01AI064520, R01AI068129,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   R01AI068129, P01AI064520, P01AI064520, P01AI064520, R01AI068129,
   R01AI068129, P01AI064520, P01AI064520, P01AI064520, R01AI068129,
   P01AI064520, P01AI064520] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [K08AR057763, K08AR057763, K08AR057763,
   K08AR057763, K08AR057763, K08AR057763] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720, P30DK063720, P30DK063720,
   P30DK063720, P30DK063720, P30DK063720] Funding Source: NIH RePORTER
CR Beziat V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011966
   Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509
   Cameron AL, 2003, BRIT J DERMATOL, V149, P160, DOI 10.1046/j.1365-2133.2003.05319.x
   Dunphy S, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/248317
   Hong HS, 2010, J VIROL, V84, P1183, DOI 10.1128/JVI.01675-09
   Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108
   Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301
   Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
   Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031
   Ottaviani C, 2006, EUR J IMMUNOL, V36, P118, DOI 10.1002/eji.200535243
   Sun JC, 2011, IMMUNOL CELL BIOL, V89, P327, DOI 10.1038/icb.2010.162
   Suzuki Y, 2004, J INVEST DERMATOL, V122, P1133, DOI 10.1111/j.0022-202X.2004.22517.x
   Tobin AM, 2011, J INNATE IMMUN, V3, P403, DOI 10.1159/000328011
NR 15
TC 29
Z9 29
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6705
EI 1600-0625
J9 EXP DERMATOL
JI Exp. Dermatol.
PD JAN
PY 2013
VL 22
IS 1
BP 64
EP 66
DI 10.1111/exd.12060
PG 3
WC Dermatology
SC Dermatology
GA 062SC
UT WOS:000312941100014
PM 23278897
OA Bronze, Green Accepted
DA 2020-11-26
ER

PT J
AU da Costa, AC
   Bendit, I
   de Oliveira, ACS
   Kallas, EG
   Sabino, EC
   Sanabani, SS
AF da Costa, A. C.
   Bendit, I.
   de Oliveira, A. C. S.
   Kallas, E. G.
   Sabino, E. C.
   Sanabani, S. S.
TI Investigation of human parvovirus B19 occurrence and genetic variability
   in different leukaemia entities
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Coinfection; genotypes; human parvovirus B19; leukaemia; prevalence
ID ACUTE-LYMPHOBLASTIC-LEUKEMIA; HUMAN ERYTHROVIRUSES; INFECTION;
   IDENTIFICATION; PERSISTENCE; CHILDREN; DNA; RECOMBINATION; DIVERSITY;
   EVOLUTION
AB Human parvovirus B19V (B19V) has been associated with various haematological disorders, but data on its prevalence in leukaemia are scarce. In this cross-sectional study, we investigated patients in Sao Paulo, Brazil with leukaemia to determine the molecular frequency of B19 variants and characterize the viral genetic variability by partial and complete sequencing of the coding of non-structural protein 1 (NS1)/viral capsid proteins 1 and 2 (VP1/VP2). The presence of B19V infections was investigated by PCR amplification of the viral NS1 gene fragment and confirmed by sequencing analysis. The NS1/VP1/VP2 and partially larger gene fragments of the NS1-positive samples were determined by overlapping nested PCR and direct sequencing results. The B19V NS1 was detected in 40 (16%) of 249 bone marrow samples including 12/78 (15.4%) acute lymphoblastic leukaemia, 25/155 (16.1%) acute myeloid leukaemia and 3/16 (18.7%) chronic myeloid leukaemia samples. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 15 (37.5%) with genotype 3b. The phylogenetic analysis of other regions revealed that 12/40 (30%) of the patients with leukaemia were co-infected with genotypes 1a and 3b. In addition, a new B19V intergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a were detected in one patient. Our findings demonstrated a relatively high prevalence of B19V monoinfections and dual infections and provide, for the first time, evidence of inter-genotypic recombination in adults with leukaemia that may contribute to the genetic diversity of B19V and may also be a source of new emerging viral strains with future implications for diagnosis, therapy and efficient vaccine development.
C1 [Sanabani, S. S.] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Bendit, I.] Univ Sao Paulo, Dept Haematol, Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Dept Infect Dis, BR-05403000 Sao Paulo, Brazil.
   [Sanabani, S. S.] Univ Sao Paulo, Clin Lab, Dept Pathol, LIM 03,HC,Sch Med, BR-05403000 Sao Paulo, Brazil.
RP Sanabani, SS (corresponding author), Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, LIM 52 Av Dr Eneas Carvalho de Aguiar 470,2 Andar, BR-05403000 Sao Paulo, Brazil.
EM sabyem_63@yahoo.com
RI da-Costa, Antonio Charlys/G-1548-2010; Bendit, Israel/K-9925-2015;
   Sabino, Ester Cerdeira/F-7750-2010; Sanabani, Sabri Saeed/F-5600-2012;
   Bendit, Israel/F-8621-2015
OI da-Costa, Antonio Charlys/0000-0001-5516-5177; Bendit,
   Israel/0000-0002-4751-1428; Sabino, Ester Cerdeira/0000-0003-2623-5126;
   Sanabani, Sabri Saeed/0000-0002-8876-8262; Kallas,
   Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2010/10949-0]
FX The authors declare that they have no competing interests. This study
   was supported with funding from the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (2010/10949-0).
CR AGBANDJE M, 1994, VIROLOGY, V203, P106, DOI 10.1006/viro.1994.1460
   Candotti D, 2004, J VIROL, V78, P12169, DOI 10.1128/JVI.78.22.12169-12178.2004
   Candotti D, 2006, J INFECT DIS, V194, P608, DOI 10.1086/506450
   Cassinotti P, 1997, J MED VIROL, V53, P229, DOI 10.1002/(SICI)1096-9071(199711)53:3&lt;229::AID-JMV8&gt;3.0.CO;2-A
   Corcioli F, 2008, J MED VIROL, V80, P2005, DOI 10.1002/jmv.21289
   DERENZO A, 1994, HAEMATOLOGICA, V79, P259
   El-Mahallawy HA, 2004, J PEDIAT HEMATOL ONC, V26, P403, DOI 10.1097/00043426-200407000-00001
   Elbaz O, 2001, HEMATOLOGY, V5, P383
   Freitas RB, 2008, J CLIN VIROL, V43, P60, DOI 10.1016/j.jcv.2008.03.033
   Gallinella G, 2003, J CLIN VIROL, V28, P1, DOI 10.1016/S1386-6532(03)00120-3
   Garcia SD, 2011, J CLIN MICROBIOL, V49, P1578, DOI 10.1128/JCM.00077-11
   Gustafsson I, 2010, CLIN INFECT DIS, V50, P1426, DOI 10.1086/652286
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Heegaard ED, 1999, PEDIATR HEMAT ONCOL, V16, P329, DOI 10.1080/088800199277155
   Hokynar K, 2002, VIROLOGY, V302, P224, DOI 10.1006/viro.2002.1673
   Huang Y, 2000, BLOOD CELL MOL DIS, V26, P598, DOI 10.1006/bcmd.2000.0339
   Jitschin R, 2011, CLIN MICROBIOL INFEC, V17, P1336, DOI 10.1111/j.1469-0691.2010.03355.x
   Johansen JN, 1998, VIRUS RES, V53, P215, DOI 10.1016/S0168-1702(97)00151-2
   Keller LW, 2009, ARCH VIROL, V154, P1685, DOI 10.1007/s00705-009-0482-x
   Kerr JR, 2003, J CLIN PATHOL, V56, P873, DOI 10.1136/jcp.56.11.873
   Kishore J, 2011, INDIAN J MED RES, V133, P407
   Lindblom A, 2008, CLIN INFECT DIS, V46, P528, DOI 10.1086/526522
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0
   Nakai H, 2000, J VIROL, V74, P9451, DOI 10.1128/JVI.74.20.9451-9463.2000
   Nguyen QT, 2002, VIROLOGY, V301, P374, DOI 10.1006/viro.2002.1585
   Norja P, 2008, J VIROL, V82, P6427, DOI 10.1128/JVI.00471-08
   Norja P, 2006, P NATL ACAD SCI USA, V103, P7450, DOI 10.1073/pnas.0602259103
   Parsyan A, 2007, J GEN VIROL, V88, P428, DOI 10.1099/vir.0.82496-0
   Rinckel LA, 2009, TRANSFUSION, V49, P1488, DOI 10.1111/j.1537-2995.2009.02160.x
   ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Sanabani S, 2006, J CLIN MICROBIOL, V44, P604, DOI 10.1128/JCM.44.2.604-606.2006
   Savasan S, 2003, BRIT J HAEMATOL, V120, P168, DOI 10.1046/j.1365-2141.2003.03983_3.x
   Schneider B, 2008, J GEN VIROL, V89, P164, DOI 10.1099/vir.0.83053-0
   Serpa Mariana, 2010, BMC Blood Disord, V10, P7, DOI 10.1186/1471-2326-10-7
   Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002
   Shackelton LA, 2006, J VIROL, V80, P3666, DOI 10.1128/JVI.80.7.3666-3669.2006
   SHAW PJ, 1993, CANCER, V72, P945, DOI 10.1002/1097-0142(19930801)72:3<945::AID-CNCR2820720346>3.0.CO;2-H
   Sitar G, 1999, HAEMATOLOGICA, V84, P957
   Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6
   Soliman OE, 2009, J PEDIAT HEMATOL ONC, V31, P173, DOI 10.1097/MPH.0b013e3181983b2d
   Sugiyama H, 1996, LEUKEMIA LYMPHOMA, V21, P49, DOI 10.3109/10428199609067579
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Toan NL, 2006, J GEN VIROL, V87, P2941, DOI 10.1099/vir.0.82037-0
   Vasconcelos GM, 2011, EPIGENETICS-US, V6, P1436, DOI 10.4161/epi.6.12.18464
   Waldman M, 2007, NAT CLIN PRACT NEPHR, V3, P540, DOI 10.1038/ncpneph0609
   Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004
   Yalcin A, 2009, INT J LAB HEMATOL, V31, P407, DOI 10.1111/j.1751-553X.2008.01052.x
   YOTO Y, 1993, ACTA HAEMATOL-BASEL, V90, P8
   Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840
   Zaki MES, 2010, INT J LAB HEMATOL, V32, P159, DOI 10.1111/j.1751-553X.2009.01150.x
   Zhi N, 2006, J VIROL, V80, P5941, DOI 10.1128/JVI.02430-05
NR 53
TC 14
Z9 14
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD JAN
PY 2013
VL 19
IS 1
BP E31
EP E43
DI 10.1111/1469-0691.12058
PG 13
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 085YM
UT WOS:000314650200005
PM 23167493
OA Bronze
DA 2020-11-26
ER

PT J
AU Sanabani, SS
   Nukui, Y
   Pereira, J
   da Costa, AC
   de Oliveira, ACS
   Pessoa, R
   Leal, FE
   Segurado, AC
   Kallas, EG
   Sabino, EC
AF Sanabani, Sabri Saeed
   Nukui, Youko
   Pereira, Juliana
   da Costa, Antonio Charlys
   Soares de Oliveira, Ana Carolina
   Pessoa, Rodrigo
   Leal, Fabio Eudes
   Segurado, Aluisio C.
   Kallas, Esper Georges
   Sabino, Ester Cerdeira
TI Lack of evidence to support the association of a single IL28B genotype
   SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HTLV-1; ILB 28 polymorphisms; HAM/TSP; Proviral load
ID T-CELL LEUKEMIA; VIRUS TYPE-I; TUMOR-NECROSIS-FACTOR; HEPATITIS-C;
   GENETIC-VARIATION; INTERLEUKIN-10 PROMOTER; POLYMORPHISM; TYPE-1; RISK;
   CARRIERS
AB Background: The Interleukin 28B (IL28B) rs12979860 polymorphisms was recently reported to be associated with the human T-cell leukemia virus type 1 (HTLV-1) proviral load (PvL) and the development of the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
   Methods: In an attempt to examine this hypothesis, we assessed the association of the rs12979860 genotypes with HTLV-1 PvL levels and clinical status in 112 unrelated Brazilian subjects (81 HTLV-1 asymptomatic carriers, 24 individuals with HAM/TSP and 7 with Adult T cell Leukemia/Lymphoma (ATLL)).
   Results: All 112 samples were successfully genotyped and their PvLs compared. Neither the homozygote TT nor the heterozygote CT mutations nor the combination genotypes (TT/CT) were associated with a greater PvL. We also observed no significant difference in allele distribution between asymptomatic carriers and patients with HTLV-1 associated HAM/TSP.
   Conclusions: Our study failed to support the previously reported positive association between the IL28B rs12979860 polymorphisms and an increased risk of developing HAM/TSP in the Brazilian population.
C1 [Sanabani, Sabri Saeed; da Costa, Antonio Charlys; Soares de Oliveira, Ana Carolina; Pessoa, Rodrigo] Univ Sao Paulo, Clin Lab, Dept Pathol, LIM 03,HC,Sch Med, Sao Paulo, Brazil.
   [Sanabani, Sabri Saeed] Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Nukui, Youko; Pereira, Juliana] Univ Sao Paulo, Dept Hematol, Sao Paulo, Brazil.
   [Leal, Fabio Eudes; Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [Segurado, Aluisio C.; Sabino, Ester Cerdeira] Univ Sao Paulo, Dept Infect Dis, Sch Med, Sao Paulo, Brazil.
RP Sanabani, SS (corresponding author), Univ Sao Paulo, Clin Lab, Dept Pathol, LIM 03,HC,Sch Med, Sao Paulo, Brazil.
EM sabyem_63@yahoo.com
RI Sabino, Ester Cerdeira/F-7750-2010; PEREIRA, JULIANA/C-2742-2014;
   Complexos, INCT Fluidos/H-9172-2013; Segurado, Aluisio C/K-2229-2012;
   Sanabani, Sabri Saeed/F-5600-2012; da-Costa, Antonio
   Charlys/G-1548-2010; Pessoa, Rodrigo/B-7206-2018
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; PEREIRA,
   JULIANA/0000-0002-0655-2821; Segurado, Aluisio C/0000-0002-6311-8036;
   Sanabani, Sabri Saeed/0000-0002-8876-8262; da-Costa, Antonio
   Charlys/0000-0001-5516-5177; Kallas, Esper/0000-0003-2026-6925
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2010/08550-1, 2011/12297-2]
FX This work was supported by grant 2010/08550-1 and 2011/12297-2 from the
   Sao Paulo Research Foundation (FAPESP).
CR Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   Franchini Genoveffa, 2000, Hematology Am Soc Hematol Educ Program, P409
   Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870
   Gadelha SR, 2008, J MED VIROL, V80, P2141, DOI 10.1002/jmv.21341
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Iwanaga M, 2010, BLOOD, V116, P1211, DOI 10.1182/blood-2009-12-257410
   Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
   Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278
   Jonsson JR, 2008, MOL DIAGN THER, V12, P209, DOI 10.1007/BF03256286
   Kamihira S, 2003, CLIN LAB HAEMATOL, V25, P111, DOI 10.1046/j.1365-2257.2003.00503.x
   Kamihira S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-40
   Koziel MJ, 1999, SEMIN LIVER DIS, V19, P157, DOI 10.1055/s-2007-1007107
   Manns A, 1999, J INFECT DIS, V180, P1487, DOI 10.1086/315088
   Martin MP, 2010, J INFECT DIS, V202, P1749, DOI 10.1086/657146
   Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   Mesnard JM, 2006, BLOOD, V108, P3979, DOI 10.1182/blood-2006-03-007732
   MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nattermann J, 2011, J INFECT DIS, V203, P595, DOI 10.1093/infdis/jiq098
   Neto WK, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-535
   Nishimura M, 2002, HUM IMMUNOL, V63, P696, DOI 10.1016/S0198-8859(02)00419-6
   Nishimura M, 2000, HUM IMMUNOL, V61, P1262, DOI 10.1016/S0198-8859(00)00182-8
   NISHIMURA Y, 1991, TISSUE ANTIGENS, V37, P230, DOI 10.1111/j.1399-0039.1991.tb01877.x
   OSAME M, 1990, HUMAN RETROVIROLOGY : HTLV, P191
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Rallon NI, 2011, AIDS, V25, P269, DOI 10.1097/QAD.0b013e328341b84e
   Rallon NI, 2010, AIDS, V24, pF23, DOI 10.1097/QAD.0b013e3283391d6d
   Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Scagnolari C, 2012, VIRUS RES, V165, P236, DOI 10.1016/j.virusres.2012.02.018
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007
   Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
   Thompson AJ, 2010, GASTROENTEROLOGY, V139, P120, DOI 10.1053/j.gastro.2010.04.013
   Trevino A, 2012, CLIN INFECT DIS, V55, pE1, DOI 10.1093/cid/cis343
   Tsukasaki K, 2001, CANCER RES, V61, P3770
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   Yamaguchi K, 2002, INT J HEMATOL, V76, P240, DOI 10.1007/BF03165123
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
NR 40
TC 13
Z9 13
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 23
PY 2012
VL 12
AR 374
DI 10.1186/1471-2334-12-374
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 078KO
UT WOS:000314097700001
PM 23259930
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Felix, AC
   Romano, CM
   Centrone, CD
   Rodrigues, CL
   Villas-Boas, L
   Araujo, ES
   de Matos, AM
   Carvalho, KI
   Martelli, CMT
   Kallas, EG
   Pannuti, CS
   Levi, JE
AF Felix, Alvina Clara
   Romano, Camila Malta
   Centrone, Cristiane de Campos
   Rodrigues, Celia Lima
   Villas-Boas, Lucy
   Araujo, Evaldo Stanislau
   de Matos, Andreia Manso
   Carvalho, Karina Inacio
   Turchi Martelli, Celina Maria
   Kallas, Esper Georges
   Pannuti, Claudio Sergio
   Levi, Jose Eduardo
TI Low Sensitivity of NS1 Protein Tests Evidenced during a Dengue Type 2
   Virus Outbreak in Santos, Brazil, in 2010
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID HEMORRHAGIC-FEVER; ANTIGEN; DIAGNOSIS; VIREMIA; TRANSFUSION; INFECTIONS;
   BLOOD; ELISA; SPECIFICITY; DISEASE
AB In 2010, a large outbreak of dengue occurred in Santos, Brazil. The detection of the NS1 antigen was used for diagnosis in addition to the detection of IgG, IgM, and RNA. A large number of NS1 false-negative results were obtained. A total of 379 RNA-positive samples were selected for thorough evaluation. NS1 was reactive in 37.7% of cases. Most of the cases were characterized as a secondary infection by dengue 2 virus. Sequencing of NS1 positive and negative isolates did not reveal any mutation that could justify the diagnostic failure. Use of existing NS1 tests in the Brazilian population may present a low negative predictive value, and they should be used with caution, preferentially after performing a validation with samples freshly obtained during the ongoing epidemic.
C1 [Felix, Alvina Clara; Romano, Camila Malta; Centrone, Cristiane de Campos; Rodrigues, Celia Lima; Villas-Boas, Lucy; Araujo, Evaldo Stanislau; Pannuti, Claudio Sergio; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Romano, Camila Malta; Centrone, Cristiane de Campos; Rodrigues, Celia Lima; Villas-Boas, Lucy; Araujo, Evaldo Stanislau; Pannuti, Claudio Sergio; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas Parasitarias LIMHC, Sao Paulo, Brazil.
   [Araujo, Evaldo Stanislau] Hosp Ana Costa, Santos, Brazil.
   [de Matos, Andreia Manso; Carvalho, Karina Inacio; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Turchi Martelli, Celina Maria] Univ Fed Goias, IPTSP, Goiania, Go, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Romano, Camila M/C-8185-2013; Carvalho, Karina IL/J-6789-2012; Romano,
   Camila/ABC-2883-2020; Iats, Inct/K-2300-2013
OI Carvalho, Karina IL/0000-0002-7763-8139; Romano,
   Camila/0000-0003-4550-1987; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688; Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/12313-5]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP grant 2010/12313-5).
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Castro-Jorge LA, 2010, J MED VIROL, V82, P1400, DOI 10.1002/jmv.21814
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Coller BAG, 2011, CURR OPIN IMMUNOL, V23, P391, DOI 10.1016/j.coi.2011.03.005
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Duyen HTL, 2011, J INFECT DIS, V203, P1292, DOI 10.1093/infdis/jir014
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Guzman MG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000811
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Kao Chuan-Liang, 2005, Journal of Microbiology Immunology and Infection, V38, P5
   Koraka P, 2003, J CLIN MICROBIOL, V41, P4154, DOI 10.1128/JCM.41.9.4154-4159.2003
   Levi JE, 2007, J CLIN MICROBIOL, V45, P1893, DOI 10.1128/JCM.00065-07
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Lima MDQ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000738
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Secretaria da Saude do Estado de Sao Paulo, OFF DAT DENG EP STAT
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Stramer SL, 2009, TRANSFUSION, V49, p1S, DOI 10.1111/j.1537-2995.2009.02279.x
   Tambyah PA, 2008, NEW ENGL J MED, V359, P1526, DOI 10.1056/NEJMc0708673
   Teixeira MG, 2012, REV INST MED TROP SP, V54, pS1, DOI 10.1590/S0036-46652012000700002
   Teles FRR, 2005, REV MED VIROL, V15, P287, DOI 10.1002/rmv.461
   WHO, WORLD STAT DENG CAS
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 26
TC 25
Z9 26
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD DEC
PY 2012
VL 19
IS 12
BP 1972
EP 1976
DI 10.1128/CVI.00535-12
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 047NU
UT WOS:000311848400011
PM 23100478
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Ho, HE
   Choi, JY
   Bunin, VM
   Pasoto, SG
   Carrasco, S
   Borba, EF
   Goncalves, CR
   Costa, PR
   Kallas, EG
   Bonfa, E
   Craft, JE
AF Ho, Hsi-en
   Choi, Jin Young
   Bunin, Viviane M.
   Pasoto, Sandra G.
   Carrasco, Solange
   Borba, Eduardo F.
   Goncalves, Celio R.
   Costa, Priscila R.
   Kallas, Esper G.
   Bonfa, Eloisa
   Craft, Joseph E.
TI Altered Circulating Follicular Helper T Cell Phenotype and Subset
   Composition Are Associated with Disease Activity in Patients with
   Systemic Lupus Erythematosus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
   and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Choi, Jin Young; Bunin, Viviane M.; Craft, Joseph E.] Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT USA.
   [Pasoto, Sandra G.; Carrasco, Solange; Borba, Eduardo F.; Goncalves, Celio R.; Bonfa, Eloisa] Univ Sao Paulo, Fac Med, Div Rheumatol, Sao Paulo, Brazil.
   [Costa, Priscila R.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Div Immunol, Sao Paulo, Brazil.
RI carrasco, solange/W-7361-2019
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 2497
BP S1054
EP S1055
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748306007
DA 2020-11-26
ER

PT J
AU de Oliveira, ACS
   de Farias, RP
   da Costa, AC
   Sauer, MM
   Bassichetto, KC
   Oliveira, SMS
   Costa, PR
   Tomiyama, C
   Tomiyama, HTI
   Sabino, EC
   Kallas, EG
   Sanabani, SS
AF Soares de Oliveira, Ana Carolina
   de Farias, Rodrigo Pessoa
   da Costa, Antonio Charlys
   Sauer, Mariana Melillo
   Bassichetto, Katia Cristina
   Santos Oliveira, Solange Maria
   Costa, Priscilla Ramos
   Tomiyama, Claudia
   Iwashita Tomiyama, Helena Tomoko
   Sabino, Ester Cerdeira
   Kallas, Esper Georges
   Sanabani, Sabri Saeed
TI Frequency of subtype B and F1 dual infection in HIV-1 positive,
   Brazilian men who have sex with men
SO VIROLOGY JOURNAL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SAO-PAULO; IN-VIVO; TYPE-1 INFECTION;
   MUTATION-RATE; SUPERINFECTION; COHORT; RECOMBINATION; DIVERSITY;
   IDENTIFICATION
AB Background: Because various HIV vaccination studies are in progress, it is important to understand how often inter- and intra-subtype co/superinfection occurs in different HIV-infected high-risk groups. This knowledge would aid in the development of future prevention programs. In this cross-sectional study, we report the frequency of subtype B and F1 co-infection in a clinical group of 41 recently HIV-1 infected men who have sex with men (MSM) in Sao Paulo, Brazil.
   Methodology: Proviral HIV-1 DNA was isolated from subject's peripheral blood polymorphonuclear leukocytes that were obtained at the time of enrollment. Each subject was known to be infected with a subtype B virus as determined in a previous study. A small fragment of the integrase gene (nucleotide 4255-4478 of HXB2) was amplified by nested polymerase chain reaction (PCR) using subclade F1 specific primers. The PCR results were further confirmed by phylogenetic analysis. Viral load (VL) data were extrapolated from the medical records of each patient.
   Results: For the 41 samples from MSM who were recently infected with subtype B virus, it was possible to detect subclade F1 proviral DNA in five patients, which represents a co-infection rate of 12.2%. In subjects with dual infection, the median VL was 5.3 x 10(4) copies/ML, whereas in MSM that were infected with only subtype B virus the median VL was 3.8 x 10(4) copies/ML (p > 0.8).
   Conclusions: This study indicated that subtype B and F1 co-infection occurs frequently within the HIV-positive MSM population as suggested by large number of BF1 recombinant viruses reported in Brazil. This finding will help us track the epidemic and provide support for the development of immunization strategies against the HIV.
C1 [Sanabani, Sabri Saeed] Univ Sao Paulo, Sch Med, Dept Pathol, Clin Lab,Hosp Clin, Sao Paulo, Brazil.
   [Sanabani, Sabri Saeed] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Soares de Oliveira, Ana Carolina; da Costa, Antonio Charlys] Univ Fed Sao Paulo, Dept Translat Med, Sao Paulo, Brazil.
   [Sauer, Mariana Melillo; Costa, Priscilla Ramos; Tomiyama, Claudia; Iwashita Tomiyama, Helena Tomoko; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Bassichetto, Katia Cristina] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
   [Sabino, Ester Cerdeira] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
RP Sanabani, SS (corresponding author), Univ Sao Paulo, Sch Med, Dept Pathol, Clin Lab,Hosp Clin, LIM 03, Sao Paulo, Brazil.
EM sabyem_63@yahoo.com
RI Pessoa, Rodrigo/B-7206-2018; Sabino, Ester Cerdeira/F-7750-2010;
   da-Costa, Antonio Charlys/G-1548-2010; Sanabani, Sabri Saeed/F-5600-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; da-Costa, Antonio
   Charlys/0000-0001-5516-5177; Sanabani, Sabri Saeed/0000-0002-8876-8262;
   Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Sabino Kallas]
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Sabino & Kallas).
CR Andreani G, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-392
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Arien KK, 2007, NAT REV MICROBIOL, V5, P141, DOI 10.1038/nrmicro1594
   ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805
   Batista MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005613
   Becker-Pergola G, 2000, AIDS RES HUM RETROV, V16, P1099, DOI 10.1089/088922200414938
   Bimber BN, 2010, J VIROL, V84, P12087, DOI 10.1128/JVI.01378-10
   Blish CA, 2008, J VIROL, V82, P12094, DOI 10.1128/JVI.01730-08
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Cheonis Nicholas, 2006, BETA, V18, P36
   Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511
   Cornelissen M, 2012, CLIN INFECT DIS, V54, P539, DOI 10.1093/cid/cir849
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995
   Gerhardt M, 2005, J VIROL, V79, P8249, DOI 10.1128/JVI.79.13.8249-8261.2005
   Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7
   Grobler J, 2004, J INFECT DIS, V190, P1355, DOI 10.1086/423940
   Gunthard HF, 2009, CLIN INFECT DIS, V48, pE117, DOI 10.1086/598987
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Herbinger KH, 2006, AIDS RES HUM RETROV, V22, P599, DOI 10.1089/aid.2006.22.599
   Hoelscher M, 2002, AIDS, V16, P2055, DOI 10.1097/00002030-200210180-00011
   Iversen AKN, 1999, J ACQ IMMUN DEF SYND, V22, P325
   Janini LM, 1996, VIRUS GENES, V13, P69, DOI 10.1007/BF00576981
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kothe D, 2003, JAIDS-J ACQ IMM DEF, V33, P625, DOI 10.1097/00126334-200308150-00012
   Kozaczynska K, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-59
   Liu SL, 2002, J VIROL, V76, P10674, DOI 10.1128/JVI.76.21.10674-10684.2002
   MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995
   Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436
   Naidoo AF, 2009, AIDS RES HUM RETROV, V25, P1225, DOI 10.1089/aid.2009.0095
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Pernas M, 2006, JAIDS-J ACQ IMM DEF, V42, P12, DOI 10.1097/01.qai.0000214810.65292.73
   Piantadosi A, 2007, PLOS PATHOG, V3, P1745, DOI 10.1371/journal.ppat.0030177
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Redd AD, 2012, J INFECT DIS, V206, P267, DOI 10.1093/infdis/jis325
   Sagar M, 2003, J VIROL, V77, P12921, DOI 10.1128/JVI.77.23.12921-12926.2003
   SALA M, 1995, AIDS RES HUM RETROV, V11, P653, DOI 10.1089/aid.1995.11.653
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanabani SS, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-78
   Smith DM, 2006, VIROLOGY, V355, P1, DOI 10.1016/j.virol.2006.08.009
   Ssemwanga D, 2012, AIDS RES HUM RETROV, V28, P357, DOI [10.1089/aid.2011.0024, 10.1089/AID.2011.0024]
   Ssemwanga D, 2011, VIROLOGY, V411, P113, DOI 10.1016/j.virol.2010.12.025
   Takehisa J, 1998, VIROLOGY, V245, P1, DOI 10.1006/viro.1998.9141
   Takehisa J, 1997, J ACQ IMMUN DEF SYND, V14, P81, DOI 10.1097/00042560-199701010-00015
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tarosso LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011436
   Templeton AR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-54
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2001, AIDS, V15, P509, DOI 10.1097/00002030-200103090-00010
   Vandepitte J, 2011, SEX TRANSM DIS, V38, P316, DOI 10.1097/OLQ.0b013e3182099545
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   Yerly S, 2004, AIDS, V18, P1413, DOI 10.1097/01.aids.0000131330.28762.0c
   ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995
NR 54
TC 9
Z9 9
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD SEP 29
PY 2012
VL 9
AR 223
DI 10.1186/1743-422X-9-223
PG 8
WC Virology
SC Virology
GA 037SE
UT WOS:000311126000001
PM 23021203
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tandon, R
   Giret, MTM
   SenGupta, D
   York, VA
   Wiznia, AA
   Rosenberg, MG
   Kallas, EG
   Ndhlovu, LC
   Nixon, DF
AF Tandon, Ravi
   Giret, Maria T. M.
   SenGupta, Devi
   York, Vanessa A.
   Wiznia, Andrew A.
   Rosenberg, Michael G.
   Kallas, Esper G.
   Ndhlovu, Lishomwa C.
   Nixon, Douglas F.
TI Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1
   Infected Children
SO PLOS ONE
LA English
DT Article
ID HIV-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION;
   DISEASE PROGRESSION; REPLICATIVE SENESCENCE; CD38 EXPRESSION;
   VIRUS-INFECTION; UNITED-KINGDOM; RNA LEVELS; CD4(+)
AB As perinatally HIV-1-infected children grow into adolescents and young adults, they are increasingly burdened with the long-term consequences of chronic HIV-1 infection, with long-term morbidity due to inadequate immunity. In progressive HIV-1 infection in horizontally infected adults, inflammation, T cell activation, and perturbed T cell differentiation lead to an "immune exhaustion'', with decline in T cell effector functions. T effector cells develop an increased expression of CD57 and loss of CD28, with an increase in co-inhibitory receptors such as PD-1 and Tim-3. Very little is known about HIV-1 induced T cell dysfunction in vertical infection. In two perinatally antiretroviral drug treated HIV-1-infected groups with median ages of 11.2 yr and 18.5 yr, matched for viral load, we found no difference in the proportion of senescent CD28(-)CD57(+)CD8(+) T cells between the groups. However, the frequency of Tim-3(+)CD8(+) and Tim-3(+)CD4(+) exhausted T cells, but not PD-1(+) T cells, was significantly increased in the adolescents with longer duration of infection compared to the children with shorter duration of HIV-1 infection. PD-1(+)CD8(+) T cells were directly associated with T cell immune activation in children. The frequency of Tim-3(+)CD8(+) T cells positively correlated with HIV-1 plasma viral load in the adolescents but not in the children. These data suggest that Tim-3 upregulation was driven by both HIV-1 viral replication and increased age, whereas PD-1 expression is associated with immune activation. These findings also suggest that the Tim-3 immune exhaustion phenotype rather than PD-1 or senescent cells plays an important role in age-related T cell dysfunction in perinatal HIV-1 infection. Targeting Tim-3 may serve as a novel therapeutic approach to improve immune control of virus replication and mitigate age related T cell exhaustion.
C1 [Tandon, Ravi; Ndhlovu, Lishomwa C.] Univ Hawaii, John A Burns Sch Med, Hawaii Ctr AIDS, Dept Trop Med, Honolulu, HI 96822 USA.
   [SenGupta, Devi; York, Vanessa A.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
   [Giret, Maria T. M.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Wiznia, Andrew A.; Rosenberg, Michael G.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
RP Tandon, R (corresponding author), Univ Hawaii, John A Burns Sch Med, Hawaii Ctr AIDS, Dept Trop Med, Honolulu, HI 96822 USA.
EM rtandon@hawaii.edu
RI n, l/AAX-3992-2020; Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Kallas, Esper/0000-0003-2026-6925;
   Ndhlovu, Lishomwa/0000-0001-5427-4187
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R56AI083112]; National Institutes of Health grantUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [AI60397]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027763, P30AI027763, R56AI083112,
   P30AI027763, P30AI027763, R21AI060397, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R21AI060397,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R56AI083112, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763] Funding Source: NIH
   RePORTER
FX Award Number R56AI083112 from the National Institute of Allergy and
   Infectious Diseases supported this work
   (http://www.niaid.nih.gov/Pages/default.aspx). The project was also
   supported by National Institutes of Health grant
   (AI60397)(http://www.nih.gov/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Addo MM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000321
   Agarwal A, 2007, J CLIN VIROL, V40, P301, DOI 10.1016/j.jcv.2007.08.020
   Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959
   Amaya RA, 2002, PEDIATR INFECT DIS J, V21, P405, DOI 10.1097/00006454-200205000-00011
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Appay V, 2007, EXP GERONTOL, V42, P432, DOI 10.1016/j.exger.2006.12.003
   Baitsch L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030852
   Banerjee P, 2007, J VIROL, V81, P9707, DOI 10.1128/JVI.00887-07
   Barbour JD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004408
   Bengsch B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000947
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Brugnoni D, 1997, CLIN EXP IMMUNOL, V109, P412, DOI 10.1046/j.1365-2249.1997.4871386.x
   Cao W, 2009, JAIDS-J ACQ IMM DEF, V50, P137, DOI 10.1097/QAI.0b013e3181926c28
   Chou FC, 2009, EUR J IMMUNOL, V39, P2403, DOI 10.1002/eji.200839177
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   de Weyer PSV, 2006, BIOCHEM BIOPH RES CO, V351, P571, DOI 10.1016/j.bbrc.2006.10.079
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4
   Effros RB, 2005, IMMUNOL REV, V205, P147, DOI 10.1111/j.0105-2896.2005.00259.x
   Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383
   Gibb DM, 2003, BMJ-BRIT MED J, V327, P1019, DOI 10.1136/bmj.327.7422.1019
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09
   Goulder PJR, 2011, ADV EXP MED BIOL, V719, P25, DOI 10.1007/978-1-4614-0204-6_3
   Harrison L, 2012, AIDS BEHAV
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107
   Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398
   Judd A, 2007, CLIN INFECT DIS, V45, P918, DOI 10.1086/521167
   Kahana SY, 2012, AIDS BEHAV
   Kalayjian RC, 2003, J INFECT DIS, V187, P1924, DOI 10.1086/375372
   Kassu A, 2011, AIDS RES HUM RETROV, V27, P1, DOI 10.1089/aid.2010.0156
   Le Priol Y, 2006, J IMMUNOL, V177, P5145, DOI 10.4049/jimmunol.177.8.5145
   Lee J, 2011, MOL CELL BIOL, V31, P3963, DOI 10.1128/MCB.05297-11
   Legrand FA, 2005, AIDS, V19, P1575, DOI 10.1097/01.aids.0000186816.99993.8e
   Leonard EG, 2003, PEDIATR INFECT DIS J, V22, P77, DOI 10.1097/00006454-200301000-00018
   LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   McElhaney JE, 2009, EXPERT REV VACCINES, V8, P593, DOI [10.1586/erv.09.12, 10.1586/ERV.09.12]
   Mekmullica J, 2009, CLIN INFECT DIS, V48, P338, DOI 10.1086/595885
   Menson EN, 2006, BMJ-BRIT MED J, V332, P1183, DOI 10.1136/bmj.332.7551.1183
   Merino J, 1998, CLIN EXP IMMUNOL, V112, P48
   MJ O, 1994, VERTICALLY ACQUIRED
   Mocroft A, 2010, JAIDS-J ACQ IMM DEF, V55, P262, DOI 10.1097/QAI.0b013e3181e9be6b
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Nikolich-Zugich J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318
   Nociari MM, 1999, J IMMUNOL, V162, P3327
   Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054
   Prendergast A, 2011, AIDS RES HUMAN RETRO
   Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13
   Resino S, 2004, CLIN INFECT DIS, V38, P412, DOI 10.1086/380793
   Romeiro Juliana Ribeiro, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P164, DOI 10.1177/1545109711421642
   Sabin CA, 2008, AIDS, V22, P1463
   SADATSOWTI B, 1991, EUR J IMMUNOL, V21, P737, DOI 10.1002/eji.1830210329
   Sandberg JK, 2003, J IMMUNOL, V170, P4403, DOI 10.4049/jimmunol.170.8.4403
   Shimada Y, 2009, EXP GERONTOL, V44, P517, DOI 10.1016/j.exger.2009.05.003
   Sinclair E, 2008, JAIDS-J ACQ IMM DEF, V47, P544, DOI 10.1097/QAI.0b013e318162754f
   Sutcliffe CG, 2008, LANCET INFECT DIS, V8, P477, DOI 10.1016/S1473-3099(08)70180-4
   Tandon R, 2011, J VIROL, V85, P11526, DOI 10.1128/JVI.05418-11
   Valenzuela HF, 2002, CLIN IMMUNOL, V105, P117, DOI 10.1006/clim.2002.5271
   van Baarle D, 2002, AIDS, V16, P2001, DOI 10.1097/00002030-200210180-00004
   van Baarle D, 2002, TRENDS IMMUNOL, V23, P586, DOI 10.1016/S1471-4906(02)02326-8
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 65
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2012
VL 7
IS 9
AR e45733
DI 10.1371/journal.pone.0045733
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 016YB
UT WOS:000309554700063
PM 23029209
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Almeida, RR
   Rosa, DS
   Ribeiro, SP
   Santana, VC
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Almeida, Rafael Ribeiro
   Rosa, Daniela Santoro
   Ribeiro, Susan Pereira
   Santana, Vinicius Canato
   Kallas, Esper Georges
   Sidney, John
   Sette, Alessandro
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Broad and Cross-Clade CD4(+) T-Cell Responses Elicited by a DNA Vaccine
   Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus
   Peptides
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RHESUS-MONKEYS; IMMUNE-RESPONSES;
   DISCORDANT ASSOCIATIONS; LYMPHOCYTE RESPONSES; SIV REPLICATION;
   PATHOGENIC SIV; VIRAL LOAD; EPITOPES; INFECTION
AB T-cell based vaccine approaches have emerged to counteract HIV-1/AIDS. Broad, polyfunctional and cytotoxic CD4(+) T-cell responses have been associated with control of HIV-1 replication, which supports the inclusion of CD4(+) T-cell epitopes in vaccines. A successful HIV-1 vaccine should also be designed to overcome viral genetic diversity and be able to confer immunity in a high proportion of immunized individuals from a diverse HLA-bearing population. In this study, we rationally designed a multiepitopic DNA vaccine in order to elicit broad and cross-clade CD4(+) T-cell responses against highly conserved and promiscuous peptides from the HIV-1 M-group consensus sequence. We identified 27 conserved, multiple HLA-DR-binding peptides in the HIV-1 M-group consensus sequences of Gag, Pol, Nef, Vif, Vpr, Rev and Vpu using the TEPITOPE algorithm. The peptides bound in vitro to an average of 12 out of the 17 tested HLA-DR molecules and also to several molecules such as HLA-DP, -DQ and murine IA(b) and IA(d). Sixteen out of the 27 peptides were recognized by PBMC from patients infected with different HIV-1 variants and 72% of such patients recognized at least 1 peptide. Immunization with a DNA vaccine (HIVBr27) encoding the identified peptides elicited IFN-gamma secretion against 11 out of the 27 peptides in BALB/c mice; CD4(+) and CD8(+) T-cell proliferation was observed against 8 and 6 peptides, respectively. HIVBr27 immunization elicited cross-clade T-cell responses against several HIV-1 peptide variants. Polyfunctional CD4(+) and CD8(+) T cells, able to simultaneously proliferate and produce IFN-gamma and TNF-alpha, were also observed. This vaccine concept may cope with HIV-1 genetic diversity as well as provide increased population coverage, which are desirable features for an efficacious strategy against HIV-1/AIDS.
C1 [Almeida, Rafael Ribeiro; Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Santana, Vinicius Canato; Kallas, Esper Georges; Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
   [Kalil, Jorge; Cunha-Neto, Edecio] Univ Sao Paulo, InCor, Sch Med, Inst Heart, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro; Ribeiro, Susan Pereira; Kalil, Jorge; Cunha-Neto, Edecio] INCT, Inst Invest Immunol, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro] Univ Fed Sao Paulo, UNIFESP, Div Immunol, Sao Paulo, Brazil.
   [Sidney, John] La Jolla Inst Allergy & Immunol, Ctr Infect Dis Allergy & Asthma Res, La Jolla, CA USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Div Clin Immunol & Allergy,Dept Med, Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; Almeida,
   Rafael/F-8014-2014; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; Almeida, Rafael/0000-0003-3984-7527; KALIL,
   JORGE/0000-0001-8415-4274; Kallas, Esper/0000-0003-2026-6925
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [420166/2005-0]; Sao
   Paulo State Research Funding Agency (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2004/15856-9, 2006/50096-0,
   2008/57881-0]; Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Brazilian Council for Scientific and
   Technological Development - CNPq productivity awards
FX This research was supported by the Brazilian National Research Council
   (CNPq), grant 420166/2005-0; Sao Paulo State Research Funding Agency
   (FAPESP), grants 2004/15856-9, 2006/50096-0 and 2008/57881-0; Brazilian
   Program for STD and AIDS, Ministry of Health
   (914/BRA/3014-UNESCO/Kallas); and the Sao Paulo City Health Department
   (2004-0.168.922-7/Kallas). RRA, SPR and VCS are recipients of Sao Paulo
   State Research Funding Agency (FAPESP) fellowships. EGK, JK and ECN are
   recipients of Brazilian Council for Scientific and Technological
   Development - CNPq productivity awards. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67
   Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Batista MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005613
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   Bian HJ, 2004, METHODS, V34, P468, DOI 10.1016/j.ymeth.2004.06.002
   Bijker MS, 2007, J IMMUNOL, V179, P5033, DOI 10.4049/jimmunol.179.8.5033
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Chevalier MF, 2011, J VIROL, V85, P733, DOI 10.1128/JVI.02030-10
   Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
   de Lalla C, 1999, J IMMUNOL, V163, P1725
   Depil S, 2007, J IMMUNOTHER, V30, P215, DOI 10.1097/01.cji.0000211338.99137.4f
   Depla E, 2008, J VIROL, V82, P435, DOI 10.1128/JVI.01505-07
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Egan MA, 2000, J VIROL, V74, P7485, DOI 10.1128/JVI.74.16.7485-7495.2000
   Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Fuller DH, 2007, VIROLOGY, V364, P245, DOI 10.1016/j.virol.2007.02.024
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gauduin MC, 2006, J EXP MED, V203, P2661, DOI 10.1084/jem.20060134
   Gloster SE, 2004, AIDS, V18, P749, DOI 10.1097/00002030-200403260-00005
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NEW ENGLAND J MED, P366
   Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85
   Ishioka GY, 1999, J IMMUNOL, V162, P3915
   Iwai LK, 2007, CLIN VACCINE IMMUNOL, V14, P474, DOI 10.1128/CVI.00458-06
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Kallas EG, 2004, BRAZ J INFECT DIS, V8, P8
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kovjazin R, 2011, VACCINE, V29, P4676, DOI 10.1016/j.vaccine.2011.04.103
   Lacap PA, 2008, AIDS, V22, P1029, DOI 10.1097/QAD.0b013e3282ffb3db
   Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984
   Liao HX, 2006, VIROLOGY, V353, P268, DOI 10.1016/j.virol.2006.04.043
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Ngumbela KC, 2008, AIDS RES HUM RETROV, V24, P72, DOI 10.1089/aid.2007.0124
   Pettersen FO, 2010, CLIN EXP IMMUNOL, V161, P315, DOI 10.1111/j.1365-2249.2010.04179.x
   Porichis F, 2011, CURR OPIN HIV AIDS, V6, P174, DOI 10.1097/COH.0b013e3283454058
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Ranasinghe S, 2012, J VIROL, V86, P277, DOI 10.1128/JVI.05577-11
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Rolland M, 2007, PLOS PATHOG, V3, P1551, DOI 10.1371/journal.ppat.0030157
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Sa D, 2007, AIDS RES HUM RETROV, V23, P1087, DOI 10.1089/aid.2006.0173
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Samri A, 2006, CLIN VACCINE IMMUNOL, V13, P684, DOI 10.1128/CVI.00387-05
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105
   Schroers R, 2002, CANCER RES, V62, P2600
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Sidney J, 2001, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s31
   Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Suhrbier Andreas, 2002, Expert Rev Vaccines, V1, P207, DOI 10.1586/14760584.1.2.207
   Sui YJ, 2010, P NATL ACAD SCI USA, V107, P9843, DOI 10.1073/pnas.0911932107
   Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
   Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05
   Wilson CC, 2003, J IMMUNOL, V171, P5611, DOI 10.4049/jimmunol.171.10.5611
   Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zheng N, 2009, J VIROL, V83, P7668, DOI 10.1128/JVI.00513-09
NR 72
TC 22
Z9 23
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2012
VL 7
IS 9
AR e45267
DI 10.1371/journal.pone.0045267
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 040HS
UT WOS:000311313900110
PM 23028895
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Anderson, PL
   Glidden, DV
   Liu, A
   Buchbinder, S
   Lama, JR
   Guanira, JV
   McMahan, V
   Bushman, LR
   Casapia, M
   Montoya-Herrera, O
   Veloso, VG
   Mayer, KH
   Chariyalertsak, S
   Schechter, M
   Bekker, LG
   Kallas, EG
   Grant, RM
AF Anderson, Peter L.
   Glidden, David V.
   Liu, Albert
   Buchbinder, Susan
   Lama, Javier R.
   Vicente Guanira, Juan
   McMahan, Vanessa
   Bushman, Lane R.
   Casapia, Martin
   Montoya-Herrera, Orlando
   Veloso, Valdilea G.
   Mayer, Kenneth H.
   Chariyalertsak, Suwat
   Schechter, Mauro
   Bekker, Linda-Gail
   Kallas, Esper Georges
   Grant, Robert M.
CA iPrEx Study Team
TI Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis
   Efficacy in Men Who Have Sex with Men
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HIV PREVENTION; PLASMA
AB Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We evaluated drug concentrations among men who have sex with men in a substudy of the iPrEx trial (1). In this randomized placebo-controlled trial, daily oral doses of emtricitabine/tenofovir disoproxil fumarate were used as pre-exposure prophylaxis (PrEP) in men who have sex with men. Drug was detected less frequently in blood plasma and in viable cryopreserved peripheral blood mononuclear cells (PBMCs) in HIV-infected cases at the visit when HIV was first discovered compared with controls at the matched time point of the study (8% versus 44%; P < 0.001) and in the 90 days before that visit (11% versus 51%; P < 0.001). An intracellular concentration of the active form of tenofovir, tenofovir-diphosphate (TFV-DP), of 16 fmol per million PBMCs was associated with a 90% reduction in HIV acquisition relative to the placebo arm. Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week. Pro-phylactic benefits were observed over a range of doses and drug concentrations, suggesting ways to optimize PrEP regimens for this population.
C1 [Glidden, David V.; Buchbinder, Susan; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Anderson, Peter L.; Bushman, Lane R.] Univ Colorado Denver, Aurora, CO 80045 USA.
   [Liu, Albert; Buchbinder, Susan] San Francisco Dept Publ Hlth, HIV Res Sect, San Francisco, CA 94102 USA.
   [Lama, Javier R.] Invest Med Salud, Lima 14, Peru.
   [Lama, Javier R.; Vicente Guanira, Juan] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [McMahan, Vanessa; Grant, Robert M.] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
   [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Maynas, Peru.
   [Montoya-Herrera, Orlando] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador.
   [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040900 Rio De Janeiro, Brazil.
   [Mayer, Kenneth H.] Brown Univ, Providence, RI 02912 USA.
   [Mayer, Kenneth H.] Fenway Inst, Boston, MA 02215 USA.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50200, Thailand.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Hosp Escola Sao Francisco de Assis, BR-20210030 Rio De Janeiro, Brazil.
   [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Bekker, Linda-Gail] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, Brazil.
   [Kallas, Esper Georges] Inst Invest Imunol, BR-05403900 Sao Paulo, Brazil.
RP Grant, RM (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM robert.grant@ucsf.edu
RI Schechter, Mauro/AAG-7445-2020; Glidden, David/AAD-4730-2020; Veloso,
   Valdilea Goncalves/J-6189-2012; Bekker, Linda-Gail/AAZ-8929-2020;
   Trajman, Anete/C-7679-2016
OI Trajman, Anete/0000-0002-4000-4984; Kallas, Esper/0000-0003-2026-6925;
   BEKKER, LINDA-GAIL/0000-0002-0755-4386; Glidden,
   David/0000-0001-5888-1419; Guanira, Juan/0000-0002-2746-3086; Grant,
   Robert/0000-0002-0851-7085
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21MH085598, UO1 AI084735, RO1
   AI062333, UO1 AI064002, UL1 RR024131]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [U01HD068040, U01HD068040, U01HD068040, U01HD068040,
   U01HD068040] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [U01HD068040] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI064002, U01AI084735, U01AI064002, U01AI084735, R01AI062333,
   U01AI084735, R01AI062333, U01AI064002, U01AI064002, R01AI062333,
   R01AI062333, R01AI062333, R01AI062333, U01AI064002, U01AI064002,
   U01AI064002, U01AI064002, R01AI062333, R01AI062333, U01AI064002,
   U01AI084735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R21MH085598, R21MH085598] Funding Source: NIH RePORTER
FX This study was funded by NIH R21MH085598 (A.L.), UO1 AI084735 (P.L.A.),
   RO1 AI062333 (R.M.G.), UO1 AI064002 (R.M.G.), and UL1 RR024131.
CR Anderson P. L., 2011, 18 C RETR OPP INF BO
   Anderson PL, 2012, 19 C RETR OPP INF SE
   Anton PA, 2011, 18 C RETR OPP INF BO
   Baheti G, 2011, ANTIMICROB AGENTS CH, V55, P5294, DOI 10.1128/AAC.05317-11
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Borroto-Esoda K, 2006, ANTIVIR THER, V11, P377
   Bushman LR, 2011, J PHARMACEUT BIOMED, V56, P390, DOI 10.1016/j.jpba.2011.05.039
   Castillo-Mancilla J., 2012, 19 C RETR OPP INF SE
   Delahunty T, 2009, J CHROMATOGR B, V877, P1907, DOI 10.1016/j.jchromb.2009.05.029
   Donnell D, 2012, 19 C RETR OPP INF SE
   Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391
   Glidden DV, 2004, STAT MED, V23, P369, DOI 10.1002/sim.1599
   Grant R, 2011, 6 IAS C HIV PATH TRE
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Kashuba ADM, 2012, LANCET, V379, P2409, DOI 10.1016/S0140-6736(11)61852-7
   Keller MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016475
   Kiser JJ, 2008, ANTIMICROB AGENTS CH, V52, P631, DOI 10.1128/AAC.00761-07
   LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878
   Liu A., 2010, 17 C RETR OPP INF SA
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174
   PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.1093/biomet/65.1.153
   Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676
   StataCorp, 2011, STAT 12 1
   Thigpen M, 2011, 6 IAS C HIV PATH TRE
   Van Damme L, 2012, 19 C RETR OPP INF SE
NR 26
TC 499
Z9 502
U1 4
U2 58
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 12
PY 2012
VL 4
IS 151
AR 151ra125
DI 10.1126/scitranslmed.3004006
PG 8
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 006FX
UT WOS:000308806000004
PM 22972843
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Janes, H
   Frahm, N
   DeCamp, A
   Rolland, M
   Gabriel, E
   Wolfson, J
   Hertz, T
   Kallas, E
   Goepfert, P
   Friedrich, DP
   Corey, L
   Mullins, JI
   McElrath, MJ
   Gilbert, P
AF Janes, Holly
   Frahm, Nicole
   DeCamp, Allan
   Rolland, Morgane
   Gabriel, Erin
   Wolfson, Julian
   Hertz, Tomer
   Kallas, Esper
   Goepfert, Paul
   Friedrich, David P.
   Corey, Lawrence
   Mullins, James I.
   McElrath, M. Juliana
   Gilbert, Peter
TI MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately
   Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral
   Load
SO PLOS ONE
LA English
DT Article
ID FALSE DISCOVERY RATE; MEDIATED-IMMUNITY; STEP; GAG; EPITOPES; ESCAPE;
   CTL
AB Background: The sieve analysis for the Step trial found evidence that breakthrough HIV-1 sequences for MRKAd5/HIV-1 Gag/Pol/Nef vaccine recipients were more divergent from the vaccine insert than placebo sequences in regions with predicted epitopes. We linked the viral sequence data with immune response and acute viral load data to explore mechanisms for and consequences of the observed sieve effect.
   Methods: Ninety-one male participants (37 placebo and 54 vaccine recipients) were included; viral sequences were obtained at the time of HIV-1 diagnosis. T-cell responses were measured 4 weeks post-second vaccination and at the first or second week post-diagnosis. Acute viral load was obtained at RNA-positive and antibody-negative visits.
   Findings: Vaccine recipients had a greater magnitude of post-infection CD8+ T cell response than placebo recipients (median 1.68% vs 1.18%; p = 0.04) and greater breadth of post-infection response (median 4.5 vs 2; p = 0.06). Viral sequences for vaccine recipients were marginally more divergent from the insert than placebo sequences in regions of Nef targeted by pre-infection immune responses (p = 0.04; Pol p = 0.13; Gag p = 0.89). Magnitude and breadth of pre-infection responses did not correlate with distance of the viral sequence to the insert (p. 0.50). Acute log viral load trended lower in vaccine versus placebo recipients (estimated mean 4.7 vs 5.1) but the difference was not significant (p = 0.27). Neither was acute viral load associated with distance of the viral sequence to the insert (p>0.30).
   Interpretation: Despite evidence of anamnestic responses, the sieve effect was not well explained by available measures of T-cell immunogenicity. Sequence divergence from the vaccine was not significantly associated with acute viral load. While point estimates suggested weak vaccine suppression of viral load, the result was not significant and more viral load data would be needed to detect suppression.
C1 [Janes, Holly; Frahm, Nicole; DeCamp, Allan; Hertz, Tomer; Friedrich, David P.; Corey, Lawrence; McElrath, M. Juliana; Gilbert, Peter] Fred Hutchinson Canc Res Ctr, Div Vaccines & Infect Dis, Seattle, WA 98104 USA.
   [Janes, Holly; Gabriel, Erin; Gilbert, Peter] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Frahm, Nicole] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Rolland, Morgane] US Mil HIV Res Program MHRP, Rockville, MD USA.
   [Wolfson, Julian] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
   [Kallas, Esper] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Goepfert, Paul] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Corey, Lawrence; McElrath, M. Juliana] Univ Washington, Dept Med, Seattle, WA USA.
   [Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
RP Janes, H (corresponding author), Fred Hutchinson Canc Res Ctr, Div Vaccines & Infect Dis, 1124 Columbia St, Seattle, WA 98104 USA.
EM hjanes@fhcrc.org
RI Wolfson, Julian/G-6332-2011; Hertz, Tomer/S-5744-2016; Corey,
   Lawrence/AAE-1796-2020
OI Wolfson, Julian/0000-0002-2032-0875; Hertz, Tomer/0000-0002-0561-1578;
   Corey, Lawrence/0000-0002-2179-2436; Kallas, Esper/0000-0003-2026-6925;
   Gabriel, Erin/0000-0002-0504-8404
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI054165-08, UM1AI068635, UM1AI068618]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI068614,
   U01AI068618, U01AI068614, K25AI087397, R37AI054165, UM1AI068618,
   UM1AI068618, UM1AI068614, UM1AI068635, U01AI068614, UM1AI068614,
   UM1AI068618, UM1AI068635, U01AI068618, U01AI068614, UM1AI068618,
   R37AI054165, U01AI068635, K25AI087397, R37AI054165, R37AI054165,
   U01AI068614, U01AI068635, K25AI087397, R37AI054165, UM1AI068635,
   R37AI054165, UM1AI068614, K25AI087397, UM1AI068614, UM1AI068635,
   UM1AI068614, R37AI054165, UM1AI068618, U01AI068618, UM1AI068635,
   UM1AI068635, U01AI068614, UM1AI068618, U01AI068635, UM1AI068618,
   UM1AI068618, UM1AI068614, UM1AI068618, K25AI087397, UM1AI068635,
   U01AI068614, UM1AI068635, U01AI068618, U01AI068614, R37AI054165,
   R37AI054165, UM1AI068635, R37AI054165, U01AI068618, U01AI068635,
   UM1AI068614, U01AI068635, UM1AI068614] Funding Source: NIH RePORTER
FX This work was supported by grants R37AI054165-08, UM1AI068635, and
   UM1AI068618 from the National Institute of Allergy and Infectious
   Diseases. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institute of Allergy and Infectious Diseases or the National Institutes
   of Health. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   Fitzgerald DW, 2011, J INFECT DIS, V203, P765, DOI 10.1093/infdis/jiq114
   Frahm N, 2012, J CLIN INVE IN PRESS
   Harrer T, 1998, J IMMUNOL, V161, P4875
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Heckerman D, 2007, J COMPUT BIOL, V14, P736, DOI 10.1089/cmb.2007.R013
   Horton H, 2007, J IMMUNOL METHODS, V323, P39, DOI 10.1016/j.jim.2007.03.002
   JOHNSON RP, 1991, J IMMUNOL, V147, P1512
   Li FS, 2006, VACCINE, V24, P6893, DOI 10.1016/j.vaccine.2006.06.009
   Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Nickle DC, 2007, PLOS COMPUT BIOL, V3, P754, DOI 10.1371/journal.pcbi.0030075
   Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316
   Rubin DB, 1987, MULTIPLE IMPUTATION
   Schneidewind A, 2007, J VIROL, V81, P12382, DOI 10.1128/JVI.01543-07
   Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Troyer RM, 2009, PLOS PATHOG IN PRESS
NR 22
TC 25
Z9 26
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 27
PY 2012
VL 7
IS 8
AR e43396
DI 10.1371/journal.pone.0043396
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 995WH
UT WOS:000308044800029
PM 22952672
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Champiat, S
   Raposo, RAS
   Maness, NJ
   Lehman, JL
   Purtell, SE
   Hasenkrug, AM
   Miller, JC
   Dean, H
   Koff, WC
   Hong, MA
   Martin, JN
   Deeks, SG
   Spotts, GE
   Pilcher, CD
   Hecht, FM
   Kallas, EG
   Garrison, KE
   Nixon, DF
AF Champiat, Stephane
   Raposo, Rui Andre Saraiva
   Maness, Nicholas J.
   Lehman, John L.
   Purtell, Sean E.
   Hasenkrug, Aaron M.
   Miller, Jacob C.
   Dean, Hansi
   Koff, Wayne C.
   Hong, Marisa Ailin
   Martin, Jeffrey N.
   Deeks, Steven G.
   Spotts, Gerald E.
   Pilcher, Christopher D.
   Hecht, Fredrick M.
   Kallas, Esper G.
   Garrison, Keith E.
   Nixon, Douglas F.
TI Influence of HAART on Alternative Reading Frame Immune Responses over
   the Course of HIV-1 Infection
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; VIRUS TYPE-1 PROTEASE; VIRAL LOAD; CTL EPITOPES;
   TRANSLATION INITIATION; SELECTION PRESSURE; SUBTYPE-C; LYMPHOCYTES;
   GENE; RNA
AB Background: Translational errors can result in bypassing of the main viral protein reading frames and the production of alternate reading frame (ARF) or cryptic peptides. Within HIV, there are many such ARFs in both sense and the antisense directions of transcription. These ARFs have the potential to generate immunogenic peptides called cryptic epitopes (CE). Both antiretroviral drug therapy and the immune system exert a mutational pressure on HIV-1. Immune pressure exerted by ARF CD8(+) T cells on the virus has already been observed in vitro. HAART has also been described to select HIV-1 variants for drug escape mutations. Since the mutational pressure exerted on one location of the HIV-1 genome can potentially affect the 3 reading frames, we hypothesized that ARF responses would be affected by this drug pressure in vivo.
   Methodology/Principal findings: In this study we identified new ARFs derived from sense and antisense transcription of HIV-1. Many of these ARFs are detectable in circulating viral proteins. They are predominantly found in the HIV-1 env nucleotide region. We measured T cell responses to 199 HIV-1 CE encoded within 13 sense and 34 antisense HIV-1 ARFs. We were able to observe that these ARF responses are more frequent and of greater magnitude in chronically infected individuals compared to acutely infected patients, and in patients on HAART, the breadth of ARF responses increased.
   Conclusions/Significance: These results have implications for vaccine design and unveil the existence of potential new epitopes that could be included as vaccine targets.
C1 [Champiat, Stephane; Raposo, Rui Andre Saraiva; Lehman, John L.; Hasenkrug, Aaron M.; Miller, Jacob C.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Maness, Nicholas J.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Dean, Hansi; Koff, Wayne C.] Int AIDS Vaccine Initiat, New York, NY USA.
   [Hong, Marisa Ailin; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Hong, Marisa Ailin] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Infect Dis, Epidemiol & Prevent Intervent Ctr, San Francisco, CA USA.
   [Deeks, Steven G.; Spotts, Gerald E.; Pilcher, Christopher D.; Hecht, Fredrick M.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA USA.
   [Lehman, John L.; Purtell, Sean E.; Garrison, Keith E.] St Marys Coll Calif, Dept Biol, Moraga, CA USA.
RP Champiat, S (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM douglas.nixon@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020; Champiat, Stephane/O-4780-2014
OI Nixon, Douglas/0000-0002-2801-1786; Champiat,
   Stephane/0000-0002-0741-2118; Hecht, Frederick/0000-0002-5782-1171;
   Raposo, R. Andre/0000-0001-5435-0290; Kallas, Esper/0000-0003-2026-6925
FU International AIDS Vaccine Initiative (IAVI); NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   K24AI069994, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   K24AI069994, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763] Funding Source: NIH RePORTER
FX The study was funded by the International AIDS Vaccine Initiative
   (IAVI), a not for profit organization focused on helping facilitate the
   discovery of an effective AIDS vaccine. Two scientists from IAVI were
   involved in the design, analysis and writing of the paper and are
   included as co-authors. The funders had no role in data collection or
   decision to publish the manuscript.
CR Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781
   Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Altfeld M, 2001, J IMMUNOL, V167, P2743, DOI 10.4049/jimmunol.167.5.2743
   Bansal A, 2010, J EXP MED, V207, P51, DOI 10.1084/jem.20092060
   Berger CT, 2010, J EXP MED, V207, P61, DOI 10.1084/jem.20091808
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   BRUCE AG, 1986, P NATL ACAD SCI USA, V83, P5062, DOI 10.1073/pnas.83.14.5062
   Bullock TNJ, 1996, J EXP MED, V184, P1319, DOI 10.1084/jem.184.4.1319
   Bullock TNJ, 1997, J EXP MED, V186, P1051, DOI 10.1084/jem.186.7.1051
   Cardinaud S, 2004, J EXP MED, V199, P1053, DOI 10.1084/jem.20031869
   FETTEN JV, 1991, J IMMUNOL, V147, P2697
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   Garrison KE, 2009, CLIN VACCINE IMMUNOL, V16, P1369, DOI 10.1128/CVI.00410-08
   Gatanaga H, 2010, AIDS, V24, pF15, DOI 10.1097/QAD.0b013e328337b010
   Goepfert PA, 2008, J EXP MED, V205, P1009, DOI 10.1084/jem.20072457
   Ho O, 2006, J IMMUNOL, V176, P2470, DOI 10.4049/jimmunol.176.4.2470
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   John M, 2005, ANTIVIR THER, V10, P551
   Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Landry S, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-71
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Ludwig LB, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-80
   Mahnke Lisa, 2006, AIDS Res Ther, V3, P21, DOI 10.1186/1742-6405-3-21
   Malarkannan S, 1999, IMMUNITY, V10, P681, DOI 10.1016/S1074-7613(00)80067-9
   Maness NJ, 2007, J EXP MED, V204, P2505, DOI 10.1084/jem.20071261
   Maness NJ, 2010, J IMMUNOL, V184, P67, DOI 10.4049/jimmunol.0903118
   Maness NJ, 2009, J VIROL, V83, P10280, DOI 10.1128/JVI.00138-09
   Manosuthi W, 2010, AIDS, V24, P411, DOI 10.1097/QAD.0b013e3283350eef
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   Mason RA, 2004, J IMMUNOL, V172, P7212, DOI 10.4049/jimmunol.172.11.7212
   Mayrand SM, 1998, IMMUNOL TODAY, V19, P551, DOI 10.1016/S0167-5699(98)01342-5
   McBratney S, 1993, CURR OPIN CELL BIOL, V5, P961, DOI 10.1016/0955-0674(93)90077-4
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Meiklejohn DA, 2004, J IMMUNOL METHODS, V288, P135, DOI 10.1016/j.jim.2004.03.006
   MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994
   Mueller SM, 2007, J VIROL, V81, P2887, DOI 10.1128/JVI.01547-06
   Mueller SM, 2011, JAIDS-J ACQ IMM DEF, V56, P109, DOI 10.1097/QAI.0b013e3181fe946e
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189
   Rimoldi D, 2000, J IMMUNOL, V165, P7253, DOI 10.4049/jimmunol.165.12.7253
   Saeterdal I, 2001, P NATL ACAD SCI USA, V98, P13255, DOI 10.1073/pnas.231326898
   Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000
   Saulquin X, 2002, J EXP MED, V195, P353, DOI 10.1084/jem.20011399
   Schmitt M, 2000, AIDS, V14, P653, DOI 10.1097/00002030-200004140-00004
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Schwab SR, 2004, PLOS BIOL, V2, P1774, DOI 10.1371/journal.pbio.0020366
   Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131
   WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078
   Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002
NR 51
TC 9
Z9 9
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2012
VL 7
IS 6
AR e39311
DI 10.1371/journal.pone.0039311
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 967FO
UT WOS:000305892100043
PM 22768072
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Dudley, DM
   Chin, EN
   Bimber, BN
   Sanabani, SS
   Tarosso, LF
   Costa, PR
   Sauer, MM
   Kallas, EG
   O'Connor, DH
AF Dudley, Dawn M.
   Chin, Emily N.
   Bimber, Benjamin N.
   Sanabani, Sabri S.
   Tarosso, Leandro F.
   Costa, Priscilla R.
   Sauer, Mariana M.
   Kallas, Esper G.
   O'Connor, David H.
TI Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for
   Surveillance of HIV Drug Resistance
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; HIV-1-INFECTED PATIENTS;
   TREATMENT-NAIVE; SCALING-UP; MUTATIONS; PREVALENCE; VARIANTS; CHILDREN;
   FAILURE
AB Background: Great efforts have been made to increase accessibility of HIV antiretroviral therapy (ART) in low and middle-income countries. The threat of wide-scale emergence of drug resistance could severely hamper ART scale-up efforts. Population-based surveillance of transmitted HIV drug resistance ensures the use of appropriate first-line regimens to maximize efficacy of ART programs where drug options are limited. However, traditional HIV genotyping is extremely expensive, providing a cost barrier to wide-scale and frequent HIV drug resistance surveillance.
   Methods/Results: We have developed a low-cost laboratory-scale next-generation sequencing-based genotyping method to monitor drug resistance. We designed primers specifically to amplify protease and reverse transcriptase from Brazilian HIV subtypes and developed a multiplexing scheme using multiplex identifier tags to minimize cost while providing more robust data than traditional genotyping techniques. Using this approach, we characterized drug resistance from plasma in 81 HIV infected individuals collected in Sao Paulo, Brazil. We describe the complexities of analyzing next-generation sequencing data and present a simplified open-source workflow to analyze drug resistance data. From this data, we identified drug resistance mutations in 20% of treatment naive individuals in our cohort, which is similar to frequencies identified using traditional genotyping in Brazilian patient samples.
   Conclusion: The developed ultra-wide sequencing approach described here allows multiplexing of at least 48 patient samples per sequencing run, 4 times more than the current genotyping method. This method is also 4-fold more sensitive (5% minimal detection frequency vs. 20%) at a cost 3-5 x less than the traditional Sanger-based genotyping method. Lastly, by using a benchtop next-generation sequencer (Roche/454 GS Junior), this approach can be more easily implemented in low-resource settings. This data provides proof-of-concept that next-generation HIV drug resistance genotyping is a feasible and low-cost alternative to current genotyping methods and may be particularly beneficial for in-country surveillance of transmitted drug resistance.
C1 [Dudley, Dawn M.; Bimber, Benjamin N.; O'Connor, David H.] Univ Wisconsin Madison, Dept Pathol & Lab Med, Madison, WI USA.
   [Chin, Emily N.] Univ Wisconsin Madison, Dept Cellular & Mol Biol, Madison, WI USA.
   [O'Connor, David H.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI USA.
   [Sanabani, Sabri S.] Univ Sao Paulo, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Tarosso, Leandro F.; Costa, Priscilla R.; Sauer, Mariana M.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Dudley, DM (corresponding author), Univ Wisconsin Madison, Dept Pathol & Lab Med, Madison, WI USA.
EM doconnor@primate.wisc.edu
RI Sanabani, Sabri Saeed/F-5600-2012; Tarosso, Leandro F./H-6267-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; Kallas,
   Esper/0000-0003-2026-6925; o'connor, david/0000-0003-2139-470X
FU National Institutes of Health R01 grantUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [Al077376]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2004/15856-9, 2006/50096-0]; CAPES scholarshipsCAPES; FAPESP
   scholarshipsFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX Work at UW-Madison was supported by a National Institutes of Health R01
   grant Al077376. The study was also supported by grants 2004/15856-9 and
   2006/50096-0 from the Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP). SS and MMS have been supported by CAPES scholarships;
   LFT and PRC have been supported by FAPESP scholarships. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BEBENEK K, 1989, J BIOL CHEM, V264, P16948
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   De Wolf H, 2011, J VIROL METHODS, V175, P129, DOI 10.1016/j.jviromet.2011.04.023
   Delobel P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021655
   Eshleman SH, 2004, J CLIN MICROBIOL, V42, P2711, DOI 10.1128/JCM.42.6.2711-2717.2004
   Ferreira FGF, 2010, AIDS RES HUM RETROV, V26, P229, DOI 10.1089/aid.2009.0146
   Gonsalez CR, 2007, VIRUS RES, V129, P87, DOI 10.1016/j.virusres.2007.06.021
   Ji HZ, 2011, ANTIVIR THER, V16, P871, DOI 10.3851/IMP1839
   Ji HZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009263
   Johnson JA, 2008, PLOS MED, V5, P1112, DOI 10.1371/journal.pmed.0050158
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li JZ, 2012, AIDS, V26, P185, DOI 10.1097/QAD.0b013e32834e9d7d
   Metzner KJ, 2009, CLIN INFECT DIS, V48, P239, DOI 10.1086/595703
   Ndembi N, 2011, AIDS, V25, P905, DOI 10.1097/QAD.0b013e328346260f
   Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Peuchant O, 2008, AIDS, V22, P1417, DOI 10.1097/QAD.0b013e3283034953
   Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602
   Stekler JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028952
   Sungkanuparph S, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-12
   Varghese V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010992
   Varghese V, 2009, JAIDS-J ACQ IMM DEF, V52, P309, DOI 10.1097/QAI.0b013e3181bca669
   Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180
   WHO, 2010, WHO HIVRESNET HIV DR
   WHO UNAIDS UNICEF, 2009, UN ACC SCAL HIV INT
   World Health Organisation [WHO], 2010, UN ACC SCAL PRIOR HI
   World Health Organization, 2010, ANT THER HIV INF AD
NR 31
TC 64
Z9 67
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2012
VL 7
IS 5
AR e36494
DI 10.1371/journal.pone.0036494
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WV
UT WOS:000305349800066
PM 22574170
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Gama, L
   Shirk, EN
   Russell, JN
   Carvalho, KI
   Li, M
   Queen, SE
   Kalil, J
   Zink, MC
   Clements, JE
   Kallas, EG
AF Gama, Lucio
   Shirk, Erin N.
   Russell, Julia N.
   Carvalho, Karina I.
   Li, Ming
   Queen, Suzanne E.
   Kalil, Jorge
   Zink, M. Christine
   Clements, Janice E.
   Kallas, Esper G.
TI Expansion of a subset of CD14(high)CD16(neg)CCR2(low/neg) monocytes
   functionally similar to myeloid-derived suppressor cells during SIV and
   HIV infection
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE macrophages; AIDS
ID SIMIAN IMMUNODEFICIENCY VIRUS; PERIPHERAL-BLOOD MONOCYTES; CHEMOKINE
   RECEPTOR EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DENDRITIC CELLS;
   CC-CHEMOKINE; CHEMOATTRACTANT PROTEIN-1; CEREBROSPINAL-FLUID;
   INFLAMMATORY SITES; PHENOTYPIC CHANGES
AB Monocytes have been categorized in three main subpopulations based on CD14 and CD16 surface expression. Classical monocytes express the CD14(++)CD16(-) CCR2(+) phenotype and migrate to inflammatory sites by quickly responding to CCL2 signaling. Here, we identified and characterized the expansion of a novel monocyte subset during HIV and SIV infection, which were undistinguishable from classical monocytes, based on CD14 and CD16 expression, but expressed significantly lower surface CCR2. Transcriptome analysis of sorted cells demonstrated that the CCR2(low/neg) cells are a distinct subpopulation and express lower levels of inflammatory cytokines and activation markers than their CCR2(high) counterparts. They exhibited impaired phagocytosis and greatly diminished chemotaxis in response to CCL2 and CCL7. In addition, these monocytes are refractory to SIV infection and suppress CD8(+) T cell proliferation in vitro. These cells express higher levels of STAT3 and NOS2, suggesting a phenotype similar to monocytic myeloid-derived cells, which suppress expansion of CD8(+) T cells in vivo. They may reflect an antiproliferative response against the extreme immune activation observed during HIV and SIV infections. In addition, they may suppress antiviral responses and thus, have a role in AIDS pathogenesis. Antiretroviral therapy in infected macaque and human subjects caused this population to decline, suggesting that this atypical phenotype is linked to viral replication. J. Leukoc. Biol. 91: 803-816; 2012.
C1 [Gama, Lucio; Shirk, Erin N.; Russell, Julia N.; Li, Ming; Queen, Suzanne E.; Zink, M. Christine; Clements, Janice E.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21287 USA.
   [Gama, Lucio; Carvalho, Karina I.; Kalil, Jorge; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Gama, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, BRB 831, Baltimore, MD 21287 USA.
EM lucio@jhmi.edu
RI KALIL, JORGE/C-8029-2012; Carvalho, Karina IL/J-6789-2012
OI KALIL, JORGE/0000-0001-8415-4274; Carvalho, Karina
   IL/0000-0002-7763-8139; Gama, Lucio/0000-0001-9511-012X; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [MH070306, NS055648,
   MH085554]; Ministry of HealthMinistry of Health - Turkey
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Brazilian Ministry of Education; Brazilian
   Program for STD and AIDS; NATIONAL INSTITUTE OF MENTAL HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH)
   [P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, R01MH085554, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, R01MH085554, P01MH070306,
   R01MH085554, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, R01MH085554, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   R01MH085554, P01MH070306, P01MH070306, P01MH070306, P01MH070306,
   P01MH070306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS055648,
   R01NS055648, R01NS055648, R01NS055648, R01NS055648] Funding Source: NIH
   RePORTER
FX This study was supported by National Institutes of Health grants
   MH070306, NS055648, and MH085554. This study was partially supported
   with funding from the Brazilian Program for STD and AIDS, Ministry of
   Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo City Health
   Department (2004-0.168.922-7/Kallas), and the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (04/15856-9/Kallas). K.I.C.'s
   scholarship is supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education,
   through the Programa Nacional de Pos Doutorado (PNPD) program. We thank
   Brandon B. Bullock for technical assistance as well as the rest of the
   Retrovirus Laboratory for helpful discussion. Special thanks to Jasmeet
   Sethi and the Microarray Core at the Johns Hopkins School of Medicine
   for help with NanoString data acquisition and Ada Tam for assistance
   with cytometry sorting. Medical Editor Michael E. Linde made substantial
   contributions to the editing of the manuscript. We also thank Daniela S.
   Rosa, Bianca N. Santos, Helena Tomiyama, Priscilla Costa, and Claudia
   Tomiyama at Laboratorio de Investigacao Medica 60, School of Medicine,
   University of Sao Paulo, for valuable support in the sample repository
   constitution and the monocyte experiments.
CR Ancuta P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-403
   Barber SA, 2004, J NEUROVIROL, V10, P15, DOI 10.1080/13550280490268179
   Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459
   Bissel SJ, 2006, J NEUROIMMUNOL, V177, P85, DOI 10.1016/j.jneuroim.2006.04.017
   Burdo TH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000842
   Carter DL, 1999, CYTOMETRY, V37, P41, DOI 10.1002/(SICI)1097-0320(19990901)37:1<41::AID-CYTO5>3.3.CO;2-W
   Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
   Clay CC, 2007, J VIROL, V81, P12040, DOI 10.1128/JVI.00133-07
   Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768
   Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Filipazzi P., 2010, CANCER IMMUNOL IMMUN, V61, P255
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19
   Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48
   Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kamp W, 2001, EUR J CLIN INVEST, V31, P984, DOI 10.1046/j.1365-2362.2001.00895.x
   KAZAZI F, 1989, J GEN VIROL, V70, P2661, DOI 10.1099/0022-1317-70-10-2661
   Kim WK, 2010, J LEUKOCYTE BIOL, V87, P557, DOI 10.1189/jlb.0209082
   Lafferty MK, 2010, BLOOD, V115, P1564, DOI 10.1182/blood-2009-06-226423
   Laforge M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002087
   Lewin SR, 1998, AIDS, V12, P719, DOI 10.1097/00002030-199807000-00008
   Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500
   Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820
   Margulies BJ, 2001, AIDS RES HUM RETROV, V17, P981, DOI 10.1089/088922201750290104
   Merino A, 2011, J IMMUNOL, V186, P1809, DOI 10.4049/jimmunol.1001866
   MIKOVITS JA, 1992, J CLIN INVEST, V90, P1486, DOI 10.1172/JCI116016
   Mizuno K, 2005, CLIN EXP IMMUNOL, V142, P461, DOI 10.1111/j.1365-2005.02932.x
   Nagaraj Srinivas, 2009, Cancer Res, V69, P7503, DOI 10.1158/0008-5472.CAN-09-2152
   Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529
   Otani I, 1998, AIDS RES HUM RETROV, V14, P1181, DOI 10.1089/aid.1998.14.1181
   Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
   Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x
   Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
   Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08
   Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191
   Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
   Takeda S, 2010, DIGEST DIS SCI, V55, P1886, DOI 10.1007/s10620-009-0974-2
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Van Grol J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011733
   Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
   Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011
   Velasco F, 2000, MATH GEOL, V32, P439, DOI 10.1023/A:1007573815959
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078
   Weber C, 2000, J LEUKOCYTE BIOL, V67, P699
   Witwer KW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008129
   Xu LL, 2000, EUR J IMMUNOL, V30, P227, DOI 10.1002/1521-4141(200001)30:1<227::AID-IMMU227>3.0.CO;2-X
   Yachie A, 2003, EXP BIOL MED, V228, P550, DOI 10.1177/15353702-0322805-26
   Yona S, 2010, CURR OPIN HEMATOL, V17, P53, DOI 10.1097/MOH.0b013e3283324f80
   Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
   Zink MC, 1999, J VIROL, V73, P10480, DOI 10.1128/JVI.73.12.10480-10488.1999
   Zink MC, 2001, J INFECT DIS, V184, P1015, DOI 10.1086/323478
NR 67
TC 40
Z9 40
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAY
PY 2012
VL 91
IS 5
BP 803
EP 816
DI 10.1189/jlb.1111579
PG 14
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 939TH
UT WOS:000303837200015
PM 22368280
OA Green Published
DA 2020-11-26
ER

PT J
AU Carvalho, KI
   Bruno, FR
   Snyder-Cappione, JE
   Maeda, SM
   Tomimori, J
   Xavier, MB
   Haslett, PA
   Nixon, DF
   Kallas, EG
AF Carvalho, Karina I.
   Bruno, Fernanda R.
   Snyder-Cappione, Jennifer E.
   Maeda, Solange M.
   Tomimori, Jane
   Xavier, Marilia B.
   Haslett, Patrick A.
   Nixon, Douglas F.
   Kallas, Esper G.
TI Lower numbers of natural killer T cells in HIV-1 and Mycobacterium
   leprae co-infected patients
SO IMMUNOLOGY
LA English
DT Article
DE co-infection; HIV-1; interferon-; leprosy; Mycobacterium leprae; natural
   killer T cell
ID NKT CELLS; LEPROSY; TUBERCULOSIS; INDIVIDUALS; CD1D; ACTIVATION;
   EXPRESS; THYMUS
AB Natural killer T (NKT) cells are a heterogeneous population of lymphocytes that recognize antigens presented by CD1d and have attracted attention because of their potential role linking innate and adaptive immune responses. Peripheral NKT cells display a memory-activated phenotype and can rapidly secrete large amounts of pro-inflammatory cytokines upon antigenic activation. In this study, we evaluated NKT cells in the context of patients co-infected with HIV-1 and Mycobacterium leprae. The volunteers were enrolled into four groups: 22 healthy controls, 23 HIV-1-infected patients, 20 patients with leprosy and 17 patients with leprosy and HIV-1-infection. Flow cytometry and ELISPOT assays were performed on peripheral blood mononuclear cells. We demonstrated that patients co-infected with HIV-1 and M.leprae have significantly lower NKT cell frequencies [median 0.022%, interquartile range (IQR): 0.0070.051] in the peripheral blood when compared with healthy subjects (median 0.077%, IQR: 0.0320.405, P < 0.01) or HIV-1 mono-infected patients (median 0.072%, IQR: 0.0300.160, P < 0.05). Also, more NKT cells from co-infected patients secreted interferon-? after stimulation with DimerX, when compared with leprosy mono-infected patients (P = 0.05). These results suggest that NKT cells are decreased in frequency in HIV-1 and M.leprae co-infected patients compared with HIV-1 mono-infected patients alone, but are at a more activated state. Innate immunity in human subjects is strongly influenced by their spectrum of chronic infections, and in HIV-1-infected subjects, a concurrent mycobacterial infection probably hyper-activates and lowers circulating NKT cell numbers.
C1 [Kallas, Esper G.] Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Snyder-Cappione, Jennifer E.; Nixon, Douglas F.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Maeda, Solange M.; Tomimori, Jane] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Xavier, Marilia B.] Fed Univ Para, BR-66059 Belem, Para, Brazil.
   [Haslett, Patrick A.] Shire Human Genet Therapies, Lexington, MA USA.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Carvalho, Karina IL/J-6789-2012; Nixon, Douglas/AAU-5734-2020
OI Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Snyder-Cappione,
   Jennifer/0000-0002-0941-5582; Kallas, Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-AI52731,
   AI060379]; Fogarty International CenterUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43 TW00003]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/15856-9/Kallas, 2010/05845-0/Kallas]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq); Brazilian
   Ministry of Science and Technology [484230/2011-5]; Brazilian Ministry
   of Science and Technology; New York Community Trust; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI060379, R01AI052731, R01AI052731, R01AI060379,
   R01AI060379, R01AI060379, R01AI052731, R01AI060379, R01AI052731,
   R21AI060379, R01AI052731, R01AI052731] Funding Source: NIH RePORTER
FX This work was partially supported by the National Institutes of Health,
   grants #R01-AI52731 and AI060379 (Nixon), The Fogarty International
   Center, grant #D43 TW00003, Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (04/15856-9/Kallas and 2010/05845-0/Kallas and Nixon),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Brazilian Ministry of Science and Technology (484230/2011-5 by KIC);
   KIC's PhD scholarship has been provided by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazilian Ministry of
   Science and Technology. We are also grateful for support from the Heiser
   Program for Research in Leprosy and Tuberculosis of The New York
   Community Trust.
CR [Anonymous], 2007, RECOMENDACOES TERAPI
   Berzins SP, 2005, EUR J IMMUNOL, V35, P1399, DOI 10.1002/eji.200425958
   Carvalho KI, 2008, IMMUNOLOGY, V124, P206, DOI 10.1111/j.1365-2567.2007.02756.x
   Chattree V, 2008, MOL CELL BIOCHEM, V309, P87, DOI 10.1007/s11010-007-9646-8
   Crowe NY, 2003, J IMMUNOL, V171, P4020, DOI 10.4049/jimmunol.171.8.4020
   FROMMEL D, 1994, LANCET, V344, P165, DOI 10.1016/S0140-6736(94)92760-X
   Gansert JL, 2003, J IMMUNOL, V170, P3154, DOI 10.4049/jimmunol.170.6.3154
   Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7
   Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786
   Hammond KJL, 1999, EUR J IMMUNOL, V29, P3768, DOI 10.1002/(SICI)1521-4141(199911)29:11<3768::AID-IMMU3768>3.0.CO;2-G
   Kamishikiryo J, 2011, J BIOL CHEM, V286, P23823, DOI 10.1074/jbc.M110.214254
   Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Makino M, 2005, CELL IMMUNOL, V233, P53, DOI 10.1016/j.cellimm.2005.04.001
   McNab FW, 2005, J IMMUNOL, V175, P3762, DOI 10.4049/jimmunol.175.6.3762
   Montoya CJ, 2008, CLIN IMMUNOL, V127, P1, DOI 10.1016/j.clim.2007.12.006
   Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712
   Murray RA, 2007, J IMMUNOL, V178, P338, DOI 10.4049/jimmunol.178.1.338
   Ndhlovu LC, 2009, CLIN EXP IMMUNOL, V158, P294, DOI 10.1111/j.1365-2249.2009.04019.x
   OREGE PA, 1993, TUBERCLE LUNG DIS, V74, P377, DOI 10.1016/0962-8479(93)90080-H
   RIDEEY D. S., 1966, International Journal of Leprosy, V34, P255
   SAMPAIO EP, 1995, INFECT IMMUN, V63, P1848, DOI 10.1128/IAI.63.5.1848-1854.1995
   Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101
   Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002
   Saude Md, 2006, PLAN NAC EL HAN NIV
   Sieling PA, 2005, J IMMUNOL, V174, P2637, DOI 10.4049/jimmunol.174.5.2637
   Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567
   Snyder-Cappione JE, 2009, AIDS, V23, P1965, DOI 10.1097/QAD.0b013e32832b5134
   Thedrez A, 2007, BLOOD, V110, P251, DOI 10.1182/blood-2007-01-066217
   Unutmaz D, 2003, MICROBES INFECT, V5, P1041, DOI 10.1016/S1286-4579(03)00185-0
   Ustianowski AP, 2006, LANCET INFECT DIS, V6, P350, DOI 10.1016/S1473-3099(06)70493-5
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
   Van Dommelen SLH, 2004, IMMUNOL CELL BIOL, V82, P332, DOI 10.1111/j.0818-9641.2004.01261.x
   Van Kaer L, 2007, CURR OPIN IMMUNOL, V19, P354, DOI 10.1016/j.coi.2007.03.001
   WHO, 1994, WHO TECH REP SER
   Wilson SB, 2001, CURR OPIN IMMUNOL, V13, P555, DOI 10.1016/S0952-7915(00)00258-2
NR 36
TC 5
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD MAY
PY 2012
VL 136
IS 1
BP 96
EP 102
DI 10.1111/j.1365-2567.2012.03563.x
PG 7
WC Immunology
SC Immunology
GA 920JA
UT WOS:000302399200011
PM 22269018
OA Green Published
DA 2020-11-26
ER

PT J
AU Passero, LFD
   Carvalho, AK
   Bordon, MLAC
   Bonfim-Melo, A
   Carvalho, K
   Kallas, EG
   Santos, BBA
   Toyama, MH
   Paes-Leme, A
   Corbett, CEP
   Laurenti, MD
AF Passero, Luiz Felipe D.
   Carvalho, Ana Kely
   Bordon, Maria L. A. C.
   Bonfim-Melo, Alexis
   Carvalho, Karina
   Kallas, Esper G.
   Santos, Bianca B. A.
   Toyama, Marcos H.
   Paes-Leme, Adriana
   Corbett, Carlos E. P.
   Laurenti, Marcia D.
TI Proteins of Leishmania (Viannia) shawi confer protection associated with
   Th1 immune response and memory generation
SO PARASITES & VECTORS
LA English
DT Article
DE Leishmania (Viannia) shawi; Proteic fraction; Immunization; Cellular
   immune response; Long-term protection
ID T-CELL RESPONSES; EXPERIMENTAL VISCERAL LEISHMANIASIS; CUTANEOUS
   LEISHMANIASIS; INTERFERON-GAMMA; SECRETED ANTIGENS; MAJOR INFECTION;
   MURINE MODEL; DNA VACCINE; BALB/C MICE; CD8(+)
AB Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained.
   Methods: F1 fraction was purified from L. (V.) shawi parasite extract by reverse phase HPLC. BALB/c mice were immunized once a week for two consecutive weeks by subcutaneous routes in the rump, using 25 mu g of F1. After 1 and 16 weeks of last immunization, groups were challenged in the footpad with L. (V.) shawi promastigotes. After 2 months, those same mice were sacrificed and parasite burden, cellular and humoral immune responses were evaluated.
   Results: The F1 fraction induced a high degree of protection associated with an increase in IFN-gamma, a decrease in IL-4, increased cell proliferation and activation of CD8(+)T lymphocytes. Long-term protection was acquired in F1-immunized mice, associated with increased CD4(+) central memory T lymphocytes and activation of both CD4+ and CD8(+) T cells. In addition, F1-immunized groups showed an increase in IgG2a levels.
   Conclusions: The inductor capability of antigens to generate memory lymphocytes that can proliferate and secrete beneficial cytokines upon infection could be an important factor in the development of vaccine candidates against American Tegumentary Leishmaniasis.
C1 [Passero, Luiz Felipe D.; Carvalho, Ana Kely; Bordon, Maria L. A. C.; Corbett, Carlos E. P.; Laurenti, Marcia D.] Univ Sao Paulo, Fac Med, Dept Patol, Lab Patol Molestias Infecciosas LIM 50, Sao Paulo, Brazil.
   [Passero, Luiz Felipe D.; Bonfim-Melo, Alexis; Toyama, Marcos H.] Univ Estadual Paulista, Sao Paulo, Brazil.
   [Carvalho, Karina; Kallas, Esper G.; Santos, Bianca B. A.] Univ Sao Paulo, Div Clin Immunol & Allergy LIM 60, Sao Paulo, Brazil.
   [Paes-Leme, Adriana] CNPEM, Brazilian Biosci Natl Lab, Campinas, SP, Brazil.
   [Passero, Luiz Felipe D.] Univ Sao Paulo, Fac Med, Dept Patol, Lab Patol Molestias Infecciosas LIM 50, BR-01246903 Sao Paulo, SP, Brazil.
RP Passero, LFD (corresponding author), Univ Sao Paulo, Fac Med, Dept Patol, Lab Patol Molestias Infecciosas LIM 50, Sao Paulo, Brazil.
EM felipepassero@yahoo.com.br
RI Leme, Adriana F Paes/C-9679-2012; Corbett, Carlos E P/R-7090-2018;
   Toyama, Marcos H/P-4673-2017; Laurenti, Marcia Dalastra/C-4734-2012;
   Carvalho, Karina IL/J-6789-2012; Bonfim-Melo, Alexis/S-4802-2018;
   Passero, Luiz Felipe/B-9549-2012
OI Leme, Adriana F Paes/0000-0001-7959-147X; Toyama, Marcos
   H/0000-0001-6836-3084; Carvalho, Karina IL/0000-0002-7763-8139;
   Bonfim-Melo, Alexis/0000-0002-7812-7701; Passero, Luiz
   Felipe/0000-0002-5986-6381; Kallas, Esper/0000-0003-2026-6925; Laurenti,
   Marcia Dalastra/0000-0002-1080-2440
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); HCFMUSP-LIM50
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) and HCFMUSP-LIM50. It is part of the doctoral
   thesis of L.F.D. Passero, under a FAPESP fellowship. The authors of the
   present work would like to thank Prof. Dr. Fernando T. Silveira for
   kindly identifying and donating the L. (V.) shawi parasite (strain
   MHOM/BR/96/M15789) and, more importantly, encouraging studies involving
   the present parasite strain.
CR AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4
   Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572
   Baum C, 2003, ACTA HAEMATOL-BASEL, V110, P107, DOI 10.1159/000072459
   Beyrodt CGP, 1997, INFECT IMMUN, V65, P2052, DOI 10.1128/IAI.65.6.2052-2059.1997
   Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166
   Carvalho MDR, 2006, ACTA TROP, V98, P277, DOI 10.1016/j.actatropica.2006.06.001
   COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2
   Colmenares M, 2003, INFECT IMMUN, V71, P3172, DOI 10.1128/IAI.71.6.3172-3182.2003
   Costa RP, 2003, IMMUNOL LETT, V90, P155, DOI 10.1016/j.imlet.2003.09.001
   Crescente JAB, 2009, T ROY SOC TROP MED H, V103, P1250, DOI 10.1016/j.trstmh.2009.06.010
   CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715
   CUPOLILLO E, 1994, AM J TROP MED HYG, V50, P296, DOI 10.4269/ajtmh.1994.50.296
   Dey A, 2008, CLIN VACCINE IMMUNOL, V15, P836, DOI 10.1128/CVI.00433-07
   Dey A, 2009, VACCINE, V27, P5152, DOI 10.1016/j.vaccine.2009.05.100
   Passero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
   Passero LFD, 2010, PARASITOL INT, V59, P159, DOI 10.1016/j.parint.2009.12.010
   Passero LFD, 2009, PARASITOL RES, V105, P1741, DOI 10.1007/s00436-009-1614-7
   do Rosario APF, 2008, J IMMUNOL, V181, P8344
   Gomes-Pereira S, 2004, IMMUNOL LETT, V95, P63, DOI 10.1016/j.imlet.2004.06.005
   GORCZYNSKI RM, 1985, CELL IMMUNOL, V94, P1, DOI 10.1016/0008-8749(85)90080-2
   Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495
   Herath S, 2003, PARASITE IMMUNOL, V25, P559, DOI 10.1111/j.0141-9838.2004.00668.x
   HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Khamesipour A, 2005, VACCINE, V23, P3642, DOI 10.1016/j.vaccine.2005.02.015
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0
   Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
   Masih S, 2011, EXP PARASITOL, V129, P55, DOI 10.1016/j.exppara.2011.05.014
   Mora Ana Mariela, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P243, DOI 10.1590/S0036-46651999000400008
   Morrison B, 2010, CLIN EXP DERMATOL, V35, pe116, DOI 10.1111/j.1365-2230.2009.03737.x
   Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701
   Palatnik-de-Sousa CB, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-197
   Palatnik-De-Sousa CB, 2009, VACCINE, V27, P3505, DOI 10.1016/j.vaccine.2009.03.045
   PALATNIKDESOUSA CB, 1994, BRAZ J MED BIOL RES, V27, P547
   Passero LFD, 2012, ARCH DERMATOL RES, V304, P47, DOI 10.1007/s00403-011-1171-7
   Pessoa S, 1940, REV BIOL HIG, V10, P112
   Pinheiro RO, 2006, VACCINE, V24, P5645
   POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589
   ReyLadino JA, 1997, EXP PARASITOL, V85, P249, DOI 10.1006/expr.1996.4137
   Rhee EG, 2002, J EXP MED, V195, P1565, DOI 10.1084/jem.20020147
   RODRIGUES MM, 1987, INFECT IMMUN, V55, P3142, DOI 10.1128/IAI.55.12.3142-3148.1987
   Ruiz JH, 2007, PARASITE IMMUNOL, V29, P671, DOI 10.1111/j.1365-3024.2007.00991.x
   SHAW JJ, 1991, ANN PARASIT HUM COMP, V66, P243, DOI 10.1051/parasite/1991666243
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018
   Stager S, 2003, NAT MED, V9, P1287, DOI 10.1038/nm933
   STEFANI MMA, 1994, EUR J IMMUNOL, V24, P746, DOI 10.1002/eji.1830240338
   Stober CB, 2006, VACCINE, V24, P2602, DOI 10.1016/j.vaccine.2005.12.012
   Strehl B, 2005, IMMUNOL REV, V207, P19, DOI 10.1111/j.0105-2896.2005.00308.x
   Tabatabaee PA, 2011, EXP PARASITOL, V127, P46, DOI 10.1016/j.exppara.2010.06.033
   Toyama MH, 2006, TOXICON, V47, P47, DOI 10.1016/j.toxicon.2005.09.008
   Travi BL, 1996, J PARASITOL, V82, P454, DOI 10.2307/3284085
   Whitmire JK, 2005, J EXP MED, V201, P1053, DOI 10.1084/jem.20041463
NR 55
TC 4
Z9 4
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD MAR 30
PY 2012
VL 5
AR 64
DI 10.1186/1756-3305-5-64
PG 10
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 934LN
UT WOS:000303445700001
PM 22463817
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Giret, MTM
   Kallas, EG
AF Maidana Giret, Maria Teresa
   Kallas, Esper Georges
TI GBV-C: State of the Art and Future Prospects
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE Human immunodeficiency virus (HIV); GB virus C (GBV-C); Co-infection;
   Activation; Inhibition
AB The GB virus C is a common non-pathogenic virus, member of the Flaviviridae family with worldwide distribution. Favorable clinical course and reduced mortality among HIV-infected patients was demonstrated by several studies with patients co-infected with the GB virus C (GBV-C). This potential benefit of GBV-C has been demonstrated in the pre-HAART and post-HAART eras; however, this effect was not observed in all studies and the discrepancy may be due to changes during the course of HIV infection, characteristic of the cohort, and the degree of therapeutic response. The GBV-C has been found to decrease HIV replication in in vitro models, highlighting the interference of persistent GBV- C viremia. The mechanism of the beneficial effect of GBV- C appears to be mediated by changes in the cellular immune response, and elucidation of putative protective effects of GBV- C in HIV co-infection could potentially identify novel targets for anti-HIV agents.
C1 [Maidana Giret, Maria Teresa; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Av Dr Arnaldo 455,3 Floor, BR-01246903 Sao Paulo, Brazil.
EM maidana.giret@gmail.com; esper.kallas@gmail.com
OI Kallas, Esper/0000-0003-2026-6925
CR Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-345
   Barbosa Ade J., 2009, REV SOC BRAS MED TRO, V42, P591
   Berzsenyi MD, 2011, J HEPATOL
   Blankson JN, 2008, AIDS, V22, P2398, DOI 10.1097/QAD.0b013e328316c3fb
   Boodram B, 2011, J VIRAL HEPATITIS, V18, pe153, DOI 10.1111/j.1365-2893.2010.01350.x
   Branco C, 2010, J MED VIROL, V82, P452, DOI 10.1002/jmv.21703
   Campos AF, 2011, INT J STD AIDS, V22, P209, DOI 10.1258/ijsa.2011.010283
   Compston LI, 2009, J MED VIROL, V81, P1860, DOI 10.1002/jmv.21614
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   Gomara MJ, 2011, CHEM BIOL DRUG DES, V78, P277, DOI 10.1111/j.1747-0285.2011.01143.x
   Gomara MJ, 2010, ANAL BIOCHEM, V396, P51, DOI 10.1016/j.ab.2009.09.011
   Hammad AM, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-36
   Haro I, 2011, BBA-BIOMEMBRANES, V1808, P1567, DOI 10.1016/j.bbamem.2011.02.019
   Hekmat S, 2008, J MED VIROL, V80, P1941, DOI 10.1002/jmv.21314
   Herrera E, 2010, J MED CHEM, V53, P6054, DOI 10.1021/jm100452c
   Herrera E, 2009, J PHYS CHEM B, V113, P7383, DOI 10.1021/jp900707t
   Hofer H, 2011, J VIRAL HEPATITIS, V18, P513, DOI 10.1111/j.1365-2893.2010.01340.x
   Hosseini-Moghaddam SM, 2008, J MED VIROL, V80, P1260, DOI 10.1002/jmv.21161
   Sanchez-Martin MJ, 2011, BBA-BIOMEMBRANES, V1808, P2178, DOI 10.1016/j.bbamem.2011.05.020
   Sanchez-Martin MJ, 2011, J COLLOID INTERF SCI, V360, P124, DOI 10.1016/j.jcis.2011.04.053
   Sanchez-Martin MJ, 2009, ANAL BIOANAL CHEM, V394, P1003, DOI 10.1007/s00216-008-2593-8
   Koedel Y, 2011, J VIROL, V85, P7037, DOI 10.1128/JVI.02366-10
   Lalle E, 2008, INT J IMMUNOPATH PH, V21, P161, DOI 10.1177/039463200802100118
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   McLinden JH, 2008, J INFECT DIS, V198, P860, DOI 10.1086/591254
   Moenkemeyer M, 2008, J MED VIROL, V80, P1933, DOI 10.1002/jmv.21305
   Mohr EL, 2011, J GEN VIROL, V92, P91, DOI 10.1099/vir.0.026088-0
   Mohr EL, 2010, J IMMUNOL, V185, P4496, DOI 10.4049/jimmunol.1001980
   Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
   Neibecker M, 2011, J MED VIROL, V83, P685, DOI 10.1002/jmv.22029
   Nunnari G, 2003, ANN INTERN MED, V139, P26, DOI 10.7326/0003-4819-139-1-200307010-00009
   Perez- Lopez S, 2008, J PHYS CHEM B
   Perez-Lopez S, 2009, BIOPHYS CHEM, V141, P153, DOI 10.1016/j.bpc.2009.01.007
   Ramezani A, 2008, J GASTROINTEST LIVER, V17, P269
   Ramezani A, 2008, INT J INFECT DIS, V12, P57, DOI 10.1016/j.ijid.2007.04.010
   Ruiz V, 2010, J GEN VIROL, V91, P1687, DOI 10.1099/vir.0.019877-0
   Sanchez-Martin MJ, 2011, CHEMPHYSCHEM EUROPEA
   Schwarze-Zander C, 2010, ANTIVIR THER, V15, P745, DOI 10.3851/IMP1602
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Stapleton JT, 2009, AIDS, V23, P605, DOI 10.1097/QAD.0b013e32831f1b00
   Stapleton JT, 2009, AIDS
   Supapol WB, 2008, J INFECT DIS, V197, P1369, DOI 10.1086/587488
   Supapol WB, 2011, J MED VIROL, V83, P33, DOI 10.1002/jmv.21946
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Van der Bij AK, 2005, J INFECT DIS, V191, P678, DOI 10.1086/427559
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Xiang J, 2009, J IMMUNOL, V183, P7860, DOI 10.4049/jimmunol.0902276
   Xiang JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002580
   Yeo AET, 2000, ANN INTERN MED, V132, P959, DOI 10.7326/0003-4819-132-12-200006200-00006
NR 53
TC 20
Z9 21
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD MAR
PY 2012
VL 9
IS 1
BP 26
EP 33
DI 10.1007/s11904-011-0109-1
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA V32TS
UT WOS:000208974100004
PM 22246585
DA 2020-11-26
ER

PT J
AU Sucupira, MCA
   Sanabani, S
   Cortes, RM
   Giret, MTM
   Tomiyama, H
   Sauer, MM
   Sabino, EC
   Janini, LM
   Kallas, EG
   Diaz, RS
AF Araripe Sucupira, Maria Cecilia
   Sanabani, Sabri
   Cortes, Rodrigo M.
   Giret, Maria Teresa M.
   Tomiyama, Helena
   Sauer, Mariana M.
   Sabino, Ester Cerdeira
   Janini, Luiz Mario
   Kallas, Esper Georges
   Diaz, Ricardo Sobhie
TI Faster HIV-1 Disease Progression among Brazilian Individuals Recently
   Infected with CXCR4-Utilizing Strains
SO PLOS ONE
LA English
DT Article
ID VIRUS TYPE-1 SUBTYPES; T-CELL-ACTIVATION; HEPATITIS-G VIRUS;
   ANTIRETROVIRAL THERAPY; GENETIC RESTRICTION; ENZYME-IMMUNOASSAY;
   CORECEPTOR USAGE; PROGNOSTIC VALUE; AIDS; VARIANTS
AB Introduction: Primary HIV infection is usually caused by R5 viruses, and there is an association between the emergence of CCXR4-utilizing strains and faster disease progression. We characterized HIV-1 from a cohort of recently infected individuals in Brazil, predicted the virus's co-receptor use based on the env genotype and attempted to correlate virus profiles with disease progression.
   Methods: A total of 72 recently infected HIV patients were recruited based on the Serologic Testing Algorithm for Recent HIV Seroconversion and were followed every three to four months for up to 78 weeks. The HIV-1 V3 region was characterized by sequencing nine to twelve weeks after enrollment. Disease progression was characterized by CD4+ T-cell count decline to levels consistently below 350 cells/mu L.
   Results: Twelve out of 72 individuals (17%) were predicted to harbor CXCR4-utilizing strains; a baseline CD4,350 was more frequent among these individuals (p = 0.03). Fifty-seven individuals that were predicted to have CCR5-utilizing viruses and 10 individuals having CXCR4-utilizing strains presented with baseline CD4.350; after 78 weeks, 33 individuals with CCR5 strains and one individual with CXCR4 strains had CD4.350 (p = 0.001). There was no association between CD4 decline and demographic characteristics or HIV-1 subtype.
   Conclusions: Our findings confirm the presence of strains with higher in vitro pathogenicity during early HIV infection, suggesting that even among recently infected individuals, rapid progression may be a consequence of the early emergence of CXCR4-utilizing strains. Characterizing the HIV-1 V3 region by sequencing may be useful in predicting disease progression and guiding treatment initiation decisions.
C1 [Araripe Sucupira, Maria Cecilia; Cortes, Rodrigo M.; Tomiyama, Helena; Sauer, Mariana M.; Diaz, Ricardo Sobhie] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Sanabani, Sabri] Fundacao Pro Sangue, Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Giret, Maria Teresa M.; Kallas, Esper Georges] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Sabino, Ester Cerdeira] Univ Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Janini, Luiz Mario] Univ Fed Sao Paulo, Div Microbiol, Sao Paulo, Brazil.
RP Sucupira, MCA (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
EM rsdiaz@catg.com.br
RI Kallas, Esper G/C-9539-2012; Sabino, Ester Cerdeira/F-7750-2010;
   Sanabani, Sabri Saeed/F-5600-2012; Araripe Sucupira, Maria
   Cecilia/K-1931-2012; Diaz, Ricardo/K-3978-2012; Janini, Luiz Mario
   R/E-9700-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Sanabani, Sabri
   Saeed/0000-0002-8876-8262; Araripe Sucupira, Maria
   Cecilia/0000-0002-1114-5382; Janini, Luiz Mario/0000-0002-6186-6284;
   Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS; Ministry of HealthMinistry of Health
   - Turkey [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Diaz]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Brazilian Ministry of Education
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Diaz, Sabino,
   Janini & Kallas; M. C. A. S. was supported by the Programa Nacional de
   Pos Doutorado (PNPD) of the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) T. M. G. was supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of Education. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Accetturi CA, 2000, J ACQ IMMUN DEF SYND, V24, P399, DOI 10.1097/00126334-200008010-00016
   Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Brenner BG, 2008, AIDS, V22, P2509, DOI 10.1097/QAD.0b013e3283121c90
   Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
   Casseb J, 2002, INT J INFECT DIS, V6, P164
   Cavaleiro R, 2007, EUR J IMMUNOL, V37, P3435, DOI 10.1002/eji.200737511
   Cecilia D, 2000, VIROLOGY, V271, P253, DOI 10.1006/viro.2000.0297
   Cimerman S, 2007, AIDS PATIENT CARE ST, V21, P100, DOI 10.1089/apc.2006.0035
   de Mendoza C, 2008, JAIDS-J ACQ IMM DEF, V48, P241, DOI 10.1097/QAI.0b013e3181734f0e
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Diaz RS, 1996, AIDS RES HUM RETROV, V12, P1291, DOI 10.1089/aid.1996.12.1291
   Diaz RS, 1997, AIDS, V11, P415, DOI 10.1097/00002030-199704000-00003
   Diaz RS, 2008, SELECTIVE R IN PRESS
   Easterbrook PJ, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-4
   Frange P, 2009, J ANTIMICROB CHEMOTH, V64, P135, DOI 10.1093/jac/dkp151
   Fusuma EE, 2005, AIDS RES HUM RETROV, V21, P965, DOI 10.1089/aid.2005.21.965
   Hendel H, 1999, J IMMUNOL, V162, P6942
   Huang W, 2009, AIDS RES HUM RETROV, V25, P795, DOI 10.1089/aid.2008.0252
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004
   Kothe D, 2003, JAIDS-J ACQ IMM DEF, V33, P625, DOI 10.1097/00126334-200308150-00012
   Leal E, 2008, RETROVIROLOGY RES TR, V1, P1
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)74227-6
   McGovern RA, 2010, AIDS, V24, P2512, DOI 10.1097/QAD.0b013e32833e6cfb
   Mellors JW, 2007, JAMA-J AM MED ASSOC, V297, P2349, DOI 10.1001/jama.297.21.2349
   Montano MA, 1997, J VIROL, V71, P8657, DOI 10.1128/JVI.71.11.8657-8665.1997
   Munerato Patrícia, 2003, Braz J Infect Dis, V7, P236, DOI 10.1590/S1413-86702003000400002
   Ping LH, 1999, J VIROL, V73, P6271, DOI 10.1128/JVI.73.8.6271-6281.1999
   Raymond S, 2010, AIDS, V24, P2305, DOI 10.1097/QAD.0b013e32833e50bb
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Santoro-Lopes G, 2000, AIDS RES HUM RETROV, V16, P953, DOI 10.1089/08892220050058362
   Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660, DOI 10.1128/JCM.34.11.2660-2664.1996
   Sing T, 2007, ANTIVIR THER, V12, P1097
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tscherning C, 1998, VIROLOGY, V241, P181, DOI 10.1006/viro.1997.8980
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Verhofstede C, 2009, JAIDS-J ACQ IMM DEF, V50, P126, DOI 10.1097/QAI.0b013e31819118fa
   Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06
   Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
NR 49
TC 25
Z9 25
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 26
PY 2012
VL 7
IS 1
AR e30292
DI 10.1371/journal.pone.0030292
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 911FX
UT WOS:000301703800012
PM 22291931
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Arismendi, MI
   Kallas, EG
   dos Santos, BAN
   Carneiro-Sampaio, MMS
   Kayser, C
AF Arismendi, Maria Izabel
   Kallas, Esper Georges
   Natali dos Santos, Bianca Almeida
   Sales Carneiro-Sampaio, Magda Maria
   Kayser, Cristiane
TI Thymopoiesis and regulatory T cells in healthy children and adolescents
SO CLINICS
LA English
DT Article
DE T lymphocytes; Thymus; Foxp3; T-cell Receptor
ID REARRANGEMENT EXCISION CIRCLES; JUVENILE IDIOPATHIC ARTHRITIS;
   IMMUNOLOGICAL SELF-TOLERANCE; RECENT THYMIC EMIGRANTS; PERIPHERAL-BLOOD;
   TRANSPLANTATION; IMMUNODEFICIENCY; QUANTIFICATION; POPULATION;
   IMPAIRMENT
AB OBJECTIVES: The purpose of this study was to investigate the association between T cell receptor excision circle levels in peripheral blood mononuclear cells and regulatory T cells that co-express CD25 and Foxp3 in healthy children and adolescents of different ages.
   MATERIALS AND METHODS: The quantification of signal-joint T-cell receptor excision circle levels in the genomic DNA of peripheral blood mononuclear cells was performed using real-time quantitative PCR. The analysis of CD4, CD8, CD25, and Foxp3 expression was performed using flow cytometry.
   RESULTS: Ninety-five healthy controls (46 females and 49 males) ranging in age from 1 to 18 years were analyzed. The mean T-cell receptor excision circle count in all individuals was 89.095 +/- 36.790 T-cell receptor excision circles per microgram of DNA. There was an inverse correlation between T-cell receptor excision circles counts and age (r = -0.846; p < 0.001) as well as between the proportion of CD4(+)CD25(+)Foxp3(+) T cells and age (r = -0.467; p = 0.04). In addition, we observed a positive correlation between the amount of CD4(+)CD25(+)Foxp3(+) T cells and the amount of T-cell receptor excision circles per microgram of DNA in individuals of all ages (r = -0.529; p = 0.02).
   CONCLUSIONS: In this study, we observed a decrease in the thymic function with age based on the fact that the level of T-cell receptor excision circles in the peripheral blood positively correlated with the proportion of regulatory T cells in healthy children and adolescents. These findings indicate that although T-cell receptor excision circles and regulatory T cells levels decrease with age, homeostasis of the immune system and relative regulatory T cells population levels are maintained in the peripheral blood.
C1 [Arismendi, Maria Izabel; Sales Carneiro-Sampaio, Magda Maria] Univ Sao Paulo, Fac Med, Dept Pediat, Hosp Clin,Inst Crianca, Sao Paulo, Brazil.
   [Kallas, Esper Georges; Natali dos Santos, Bianca Almeida] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia, Sao Paulo, Brazil.
   [Kayser, Cristiane] Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Reumatol, Sao Paulo, Brazil.
RP Arismendi, MI (corresponding author), Univ Sao Paulo, Fac Med, Dept Pediat, Hosp Clin,Inst Crianca, Sao Paulo, Brazil.
EM cristiane.kayser@unifesp.br
RI Sampaio, Magda/AAU-6748-2020; Kayser, Cristiane/Q-1074-2019
OI Sampaio, Magda/0000-0002-1924-4043; Kallas, Esper/0000-0003-2026-6925
FU State of Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2008/58238-4]; Coordination
   for the Improvement of Higher Education Personnel (CAPES)CAPES
FX This study was supported by The State of Sao Paulo Research Foundation
   (FAPESP), grant number 2008/58238-4. Arismendi MI was supported by the
   Coordination for the Improvement of Higher Education Personnel (CAPES).
CR Arellano MV, 2006, J CLIN IMMUNOL, V26, P96, DOI 10.1007/s10875-006-7519-7
   Aspinall R, 2002, SPRINGER SEMIN IMMUN, V24, P87, DOI 10.1007/s00281-001-0098-z
   Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007
   Broers AEC, 2002, EXP HEMATOL, V30, P745, DOI 10.1016/S0301-472X(02)00825-1
   Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012
   Chavan S, 2001, J INFECT DIS, V183, P1445, DOI 10.1086/320197
   de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002
   Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374
   Fomin AF, 2010, THESIS U SAO PAULO S
   Fountoulakis S, 2008, THYROID, V18, P1195, DOI 10.1089/thy.2008.0089
   Fuchizawa T, 2007, CLIN IMMUNOL, V125, P237, DOI 10.1016/j.clim.2007.08.004
   Grindebacke H, 2009, J IMMUNOL, V183, P4360, DOI 10.4049/jimmunol.0901091
   Halnon NJ, 2005, PEDIATR RES, V57, P42, DOI 10.1203/01.PDR.0000147735.19342.DE
   Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549
   Hochberg EP, 2001, BLOOD, V98, P1116, DOI 10.1182/blood.V98.4.1116
   Hogquist KA, 2009, NAT IMMUNOL, V10, P565, DOI 10.1038/ni0609-565
   Horvath D, 2010, CLIN EXP RHEUMATOL, V28, P348
   Klein L, 2009, NAT REV IMMUNOL, V9, P833, DOI 10.1038/nri2669
   Lima K, 2010, CLIN EXP IMMUNOL, V161, P98, DOI 10.1111/j.1365-2249.2010.04152.x
   Markert ML, 2004, BLOOD, V104, P2574, DOI 10.1182/blood-2003-08-2984
   McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Prelog M, 2008, ARTHRITIS RHEUM-US, V58, P2153, DOI 10.1002/art.23599
   Roat E, 2008, REJUV RES, V11, P573, DOI 10.1089/rej.2007.0648
   Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Sodora DL, 2000, EUR J IMMUNOL, V30, P1145, DOI 10.1002/(SICI)1521-4141(200004)30:4<1145::AID-IMMU1145>3.0.CO;2-7
   Steffens CM, 2000, CLIN IMMUNOL, V97, P95, DOI 10.1006/clim.2000.4938
   Talvensarri K, 2002, BLOOD, V99, P1458, DOI 10.1182/blood.V99.4.1458
   Teran R, 2011, CLIN IMMUNOL, V138, P299, DOI 10.1016/j.clim.2010.12.011
   Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028
   Weinreich MA, 2008, J IMMUNOL, V181, P2265, DOI 10.4049/jimmunol.181.4.2265
   Ye P, 2002, J IMMUNOL, V168, P4968, DOI 10.4049/jimmunol.168.10.4968
   Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725
NR 34
TC 4
Z9 4
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 5
BP 425
EP 429
DI 10.6061/clinics/2012(05)04
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 952XB
UT WOS:000304827700004
PM 22666784
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Avelino-Silva, VI
   Leal, FE
   Coelho-Netto, C
   Cotti, GCD
   Souza, RAS
   Azambuja, RL
   Rocha, MD
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Leal, Fabio Eudes
   Coelho-Netto, Caio
   de Castro Cotti, Guilherme Cutait
   Souza, Ricardo A. S.
   Azambuja, Rodrigo Lautert
   Rocha, Manoel de Souza
   Kallas, Esper Georges
TI Sclerosing mesenteritis as an unusual cause of fever of unknown origin:
   a case report and review
SO CLINICS
LA English
DT Article
ID PANNICULITIS
C1 [Avelino-Silva, Vivian Iida; Leal, Fabio Eudes; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Leal, Fabio Eudes; Coelho-Netto, Caio; de Castro Cotti, Guilherme Cutait; Souza, Ricardo A. S.; Azambuja, Rodrigo Lautert; Rocha, Manoel de Souza; Kallas, Esper Georges] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Leal, Fabio Eudes; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Rocha, Manoel de Souza] Univ Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Rocha, Manoel S/C-6478-2013; Avelino-Silva, Vivian I/L-2640-2013
OI Rocha, Manoel S/0000-0002-4503-8374; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Akram S, 2007, CLIN GASTROENTEROL H, V5, P589, DOI 10.1016/j.cgh.2007.02.032
   Arora Manish, 2008, Medscape J Med, V10, P30
   Bateman AC, 2009, HISTOPATHOLOGY, V55, P373, DOI 10.1111/j.1365-2559.2008.03217.x
   Chawla S, 2009, WORLD J GASTROENTERO, V15, P117, DOI 10.3748/wjg.15.117
   Cunha BA, 2007, INFECT DIS CLIN N AM, V21, P867, DOI 10.1016/j.idc.2007.09.002
   Ferrari TCA, 2008, CLINICS, V63, P843, DOI 10.1590/S1807-59322008000600023
   Garcia SR, 2007, AN MED INTERN, V24, P393
   Gu Guo-Li, 2008, Cases J, V1, P242, DOI 10.1186/1757-1626-1-242
   Hemaidan A, 1999, SOUTHERN MED J, V92, P513, DOI 10.1097/00007611-199905000-00013
   Issa I, 2009, WORLD J GASTROENTERO, V15, P3827, DOI 10.3748/wjg.15.3827
   Martinez Odriozola P, 2003, An Med Interna, V20, P254
   Mourad O, 2003, ARCH INTERN MED, V163, P545, DOI 10.1001/archinte.163.5.545
   Nobili C, 2009, GASTROENT RES PRACT, V2009, DOI 10.1155/2009/176793
   OTTO F, 1991, Z GASTROENTEROL, V29, P395
   Papadaki HA, 2000, DIGESTION, V61, P145, DOI 10.1159/000007748
   PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001
   SANS M, 1995, AM J GASTROENTEROL, V90, P1159
NR 17
TC 5
Z9 6
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 3
BP 293
EP 295
DI 10.6061/clinics/2012(03)16
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 919WN
UT WOS:000302362900016
PM 22473414
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Holditch, SJ
   Eriksson, EM
   Tarosso, LF
   Kuebler, PJ
   Kallas, EG
   Nielsen, EK
   Wiznia, AA
   Rosenberg, MG
   Nixon, DF
AF Holditch, Sara J.
   Eriksson, Emily M.
   Tarosso, Leandro F.
   Kuebler, Peter J.
   Kallas, Esper G.
   Nielsen, Erik K.
   Wiznia, Andrew A.
   Rosenberg, Michael G.
   Nixon, Douglas F.
TI Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1
   exposed seronegative infants
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE HIV-1; exposed seronegative; vertically exposed; neonates; T cells
AB Objective: The majority of infants born, in developed countries, to HIV-1 positive women are exposed to the HIV-1 virus in utero or peri/post-partum, but are born uninfected.We, and others, have previously shown HIV-1 specific T cell responses in HIV-1 exposed seronegative (HESN) neonates/infants. Our objective in this study was to examine the rate of decay in their HIV-1 specific T cell response over time from birth. Design: Cross-sectional and longitudinal studies of HIV-1 specific T cell responses in HESN infants were performed. Methods: Peripheral blood mononuclear cells (PBMC) were isolated from 18 HIV-1 DNA PCR negative infants born to HIV-1 infected mothers receiving care at the Jacobi Medical Center, Bronx, NY, USA. PBMC were examined for T cell responses to HIV-1 antigens by interferon-gamma (IFN-gamma) ELISPOT. Results: PBMC from 15 HESN neonates/infants were analyzed. We observed a decay of HIV-1 specific T cell responses from birth at a rate of -0.599 spot forming unit/10(6) cells per day, with a median half-life decay rate of 21.38 weeks (13.39-115.8). Conclusion: Our results support the dynamic nature of T cell immunity in the context of a developing immune system. The disparate rate of decay with studies of adults placed on antiretroviral drugs suggests that antigen specific T cell responses are driven by the natural rate of decay of the T cell sub-populations themselves.
C1 [Holditch, Sara J.; Eriksson, Emily M.; Kuebler, Peter J.; Nixon, Douglas F.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Tarosso, Leandro F.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nielsen, Erik K.; Wiznia, Andrew A.; Rosenberg, Michael G.] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA.
RP Nixon, DF (corresponding author), Dept Expt Med, Bldg 3,Room 601,1001 Potrero Ave, San Francisco, CA 94110 USA.
EM douglas.nixon@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Eriksson, Emily/0000-0002-7851-973X;
   Kallas, Esper/0000-0003-2026-6925
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI87131, AI60379]; NIH/NCRR
   UCSF-CTSIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1 RR024131]; Fundacao de Amparo a Pesquisa do Estado
   de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [04/15856-9/Kallas, 2010/05845-0/Kallas]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazilian Ministry of
   Science and TechnologyNational Council for Scientific and Technological
   Development (CNPq)
FX The CEF pool and HIV-1 peptides were obtained through the AIDS Research
   and Reference Reagent Program, Division of AIDS, NIAID, NIH: (CEF, Gag
   p24, Nef, Vif, integrase, protease, and reverse transcriptase). Sara J.
   Holditch, Emily M. Eriksson, and Douglas F. Nixon designed the research;
   Michael G. Rosenberg, Erik K. Nielsen, and Andrew A. Wiznia provided
   HESN infant specimens and analyzed data. Sara J. Holditch and Leandro F.
   Tarosso conducted the cross-sectional laboratory research; Sara J.
   Holditch conducted the longitudinal laboratory research; Sara J.
   Holditch and Leandro F. Tarosso analyzed the data; Sara J. Holditch and
   Douglas F. Nixon prepared the manuscript. Sara J. Holditch, Emily M.
   Eriksson, Leandro F. Tarosso, Peter J. Kuebler, Esper G. Kallas, Andrew
   A. Wiznia, Michael G. Rosenberg, and Douglas F. Nixon contributed to the
   composition of, and proofed, the manuscript. The authors would like to
   thank Dr. Steve Shiboski, from CTSI for help with statistical analysis,
   members of the Nixon lab for assistance in processing blood samples, and
   Janet-Young of NIAID for helpful discussions. Funding: This work was
   supported by grants from the NIH: AI87131, AI60379, NIH/NCRR UCSF-CTSI
   Grant Number UL1 RR024131, Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (04/15856-9/Kallas and 2010/05845-0/Kallas and Nixon), LET had
   a scholarship supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Brazilian Ministry of Science and
   Technology.
CR ALDHOUS MC, 1994, CLIN EXP IMMUNOL, V97, P61
   Ballan WM, 2007, J IMMUNOL, V179, P3362, DOI 10.4049/jimmunol.179.5.3362
   Casazza JP, 2001, J VIROL, V75, P6508, DOI 10.1128/JVI.75.14.6508-6516.2001
   CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905
   DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296
   John-Stewart GC, 2009, J INFECT DIS, V199, P889, DOI 10.1086/597120
   Kuhn L, 2001, AIDS, V15, P1, DOI 10.1097/00002030-200101050-00003
   Legrand FA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000102
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Miles DJC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002905
   Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511
   Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999
   ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7
   Sabbaj S, 2005, J IMMUNOL, V174, P2951, DOI 10.4049/jimmunol.174.5.2951
   Sabbaj S, 2002, J VIROL, V76, P7365, DOI 10.1128/JVI.76.15.7365-7373.2002
   Sharp ER, 2005, J INFECT DIS, V192, P1772, DOI 10.1086/462423
   van Sighem A, 2008, JAIDS-J ACQ IMM DEF, V48, P104, DOI 10.1097/QAI.0b013e31816a1d4f
   Walter J, 2009, J INFECT DIS, V200, P1498, DOI 10.1086/644603
NR 18
TC 6
Z9 6
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2012
VL 2
DI 10.3389/fimmu.2011.00094
PG 6
WC Immunology
SC Immunology
GA V40TP
UT WOS:000209501200010
PM 22566883
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Sanabani, SS
   Pastena, ERD
   da Costa, AC
   Martinez, VP
   Kleine-Neto, W
   de Oliveira, ACS
   Sauer, MM
   Bassichetto, KC
   Oliveira, SMS
   Tomiyama, HTI
   Sabino, EC
   Kallas, EG
AF Sanabani, Sabri Saeed
   de Souza Pastena, Evelyn Regina
   da Costa, Antonio Charlys
   Martinez, Vanessa Pouza
   Kleine-Neto, Walter
   Soares de Oliveira, Ana Carolina
   Sauer, Mariana Melillo
   Bassichetto, Katia Cristina
   Santos Oliveira, Solange Maria
   Iwashita Tomiyama, Helena Tomoko
   Sabino, Ester Cerdeira
   Kallas, Esper Georges
TI Characterization of Partial and Near Full-Length Genomes of HIV-1
   Strains Sampled from Recently Infected Individuals in Sao Paulo, Brazil
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL DRUG-RESISTANCE; SUBTYPE-B;
   MOLECULAR CHARACTERIZATION; GENETIC DIVERSITY; TYPE-1; PREVALENCE;
   TROPISM; RECOMBINATION; TRANSMISSION
AB Background: Genetic variability is a major feature of human immunodeficiency virus type 1 (HIV-1) and is considered the key factor frustrating efforts to halt the HIV epidemic. A proper understanding of HIV-1 genomic diversity is a fundamental prerequisite for proper epidemiology, genetic diagnosis, and successful drugs and vaccines design. Here, we report on the partial and near full-length genomic (NFLG) variability of HIV-1 isolates from a well-characterized cohort of recently infected patients in Sao Paul, Brazil.
   Methodology: HIV-1 proviral DNA was extracted from the peripheral blood mononuclear cells of 113 participants. The NFLG and partial fragments were determined by overlapping nested PCR and direct sequencing. The data were phylogenetically analyzed.
   Results: Of the 113 samples (90.3% male; median age 31 years; 79.6% homosexual men) studied, 77 (68.1%) NFLGs and 32 (29.3%) partial fragments were successfully subtyped. Of the successfully subtyped sequences, 88 (80.7%) were subtype B sequences, 12 (11%) BF1 recombinants, 3 (2.8%) subtype C sequences, 2 (1.8%) BC recombinants and subclade F1 each, 1 (0.9%) CRF02 AG, and 1 (0.9%) CRF31 BC. Primary drug resistance mutations were observed in 14/101 (13.9%) of samples, with 5.9% being resistant to protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTI) and 4.9% resistant to non-NRTIs. Predictions of viral tropism were determined for 86 individuals. X4 or X4 dual or mixed-tropic viruses (X4/DM) were seen in 26 (30.2%) of subjects. The proportion of X4 viruses in homosexuals was detected in 19/69 (27.5%).
   Conclusions: Our results confirm the existence of various HIV-1 subtypes circulating in Sao Paulo, and indicate that subtype B account for the majority of infections. Antiretroviral (ARV) drug resistance is relatively common among recently infected patients. The proportion of X4 viruses in homosexuals was significantly higher than the proportion seen in other study populations.
C1 [Sanabani, Sabri Saeed; Sauer, Mariana Melillo; Iwashita Tomiyama, Helena Tomoko; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Sanabani, Sabri Saeed; da Costa, Antonio Charlys; Kleine-Neto, Walter; Soares de Oliveira, Ana Carolina] Univ Fed Sao Paulo, Dept Translat Med, Sao Paulo, Brazil.
   [Sanabani, Sabri Saeed; Kleine-Neto, Walter; Sabino, Ester Cerdeira] Fundacao Pro Sangue, Blood Ctr Sau Paulo, Sao Paulo, Brazil.
   [de Souza Pastena, Evelyn Regina; da Costa, Antonio Charlys; Martinez, Vanessa Pouza; Soares de Oliveira, Ana Carolina; Sabino, Ester Cerdeira] Univ Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
   [Bassichetto, Katia Cristina; Santos Oliveira, Solange Maria] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
RP Sanabani, SS (corresponding author), Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM sabyem_63@yahoo.com
RI Sabino, Ester Cerdeira/F-7750-2010; Kallas, Esper G/C-9539-2012;
   da-Costa, Antonio Charlys/G-1548-2010; Sanabani, Sabri Saeed/F-5600-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; da-Costa, Antonio
   Charlys/0000-0001-5516-5177; Sanabani, Sabri Saeed/0000-0002-8876-8262;
   Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/15856-9,
   2006/50096-0]
FX The study was supported by grants 04/15856-9 and 2006/50096-0 from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Batista MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005613
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Passaes CPB, 2009, AIDS RES HUM RETROV, V25, P1339, DOI 10.1089/aid.2009.0167
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brennan CA, 2006, J MED VIROL, V78, pS24, DOI 10.1002/jmv.20603
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Brown BK, 2005, J VIROL, V79, P6089, DOI 10.1128/JVI.79.10.6089-6101.2005
   Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Chueca N, 2009, J MED VIROL, V81, P763, DOI 10.1002/jmv.21425
   Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511
   de Mendoza C, 2007, J ANTIMICROB CHEMOTH, V59, P698, DOI 10.1093/jac/dkm012
   Eshleman SH, 2007, AIDS, V21, P1165, DOI 10.1097/QAD.0b013e32810fd72e
   Essex M, 1999, ADV VIRUS RES, V53, P71, DOI 10.1016/S0065-3527(08)60343-7
   Fernandez-Garcia A, 2009, AIDS RES HUM RETROV, V25, P93, DOI 10.1089/aid.2008.0174
   Frange P, 2009, J ANTIMICROB CHEMOTH, V64, P135, DOI 10.1093/jac/dkp151
   Gao F, 1998, J VIROL, V72, P5680, DOI 10.1128/JVI.72.7.5680-5698.1998
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Han MV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-356
   Hunt PW, 2006, J INFECT DIS, V194, P926, DOI 10.1086/507312
   Kandathil AJ, 2005, INDIAN J MED RES, V121, P333
   Kato S, 2003, AIDS RES HUM RETROV, V19, P1057, DOI 10.1089/088922203322588431
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009
   Kuiken C, 2000, AM J EPIDEMIOL, V152, P814, DOI 10.1093/aje/152.9.814
   Lacerda HR, 2007, MEM I OSWALDO CRUZ, V102, P693, DOI [10.1590/S0074-02762007005000109, 10.1590/S0074-02762007000600006]
   Lehmann C, 2006, J CLIN VIROL, V37, P300, DOI 10.1016/j.jcv.2006.08.008
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   de Souza ACMF, 2008, AIDS RES HUM RETROV, V24, P1521, DOI 10.1089/aid.2008.0089
   Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436
   McGovern RA, 2010, AIDS, V24, P2512, DOI 10.1097/QAD.0b013e32833e6cfb
   Nicastri E, 2003, J MED VIROL, V69, P1, DOI 10.1002/jmv.10269
   Nye TMW, 2006, BIOINFORMATICS, V22, P117, DOI 10.1093/bioinformatics/bti720
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI [10.1172/JCI21540, 10.1172/JCI200421540]
   Plantier JC, 2009, NAT MED, V15, P871, DOI 10.1038/nm.2016
   Raymond S, 2008, AIDS, V22, pF11, DOI 10.1097/QAD.0b013e32830ebcd4
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230
   Sa-Ferreira JA, 2007, TRANSFUSION, V47, P97, DOI 10.1111/j.1537-2995.2007.01069.x
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sanabani SS, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-78
   Saracino A, 2009, J MED VIROL, V81, P2036, DOI 10.1002/jmv.21598
   Schultz AK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-265
   Skrabal K, 2007, J CLIN MICROBIOL, V45, P279, DOI 10.1128/JCM.01118-06
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Worobey M, 2001, MOL BIOL EVOL, V18, P254, DOI 10.1093/oxfordjournals.molbev.a003799
   Zhong P, 2007, AIDS RES HUM RETROV, V23, P847, DOI 10.1089/aid.2006.0196
NR 55
TC 29
Z9 29
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2011
VL 6
IS 10
AR e25869
DI 10.1371/journal.pone.0025869
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 834RQ
UT WOS:000295981600017
PM 22022460
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Champiat, S
   Maness, NJ
   Lehman, J
   Hasenkrug, A
   Miller, J
   Hong, M
   Martin, JN
   Deeks, SG
   Spotts, GE
   Hecht, FM
   Kallas, EG
   Garrison, KE
   Nixon, DF
AF Champiat, S.
   Maness, N. J.
   Lehman, J.
   Hasenkrug, A.
   Miller, J.
   Hong, M.
   Martin, J. N.
   Deeks, S. G.
   Spotts, G. E.
   Hecht, F. M.
   Kallas, E. G.
   Garrison, K. E.
   Nixon, D. F.
TI Influence of HAART on Alternative Reading Frame Immune Responses over
   the Course of HIV-1 Infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Champiat, S.; Hasenkrug, A.; Miller, J.; Martin, J. N.; Deeks, S. G.; Spotts, G. E.; Hecht, F. M.; Nixon, D. F.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Maness, N. J.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.
   [Lehman, J.; Garrison, K. E.] St Marys Coll Calif, Moraga, CA USA.
   [Hong, M.; Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020; Champiat,
   Stephane/O-4780-2014
OI Nixon, Douglas/0000-0002-2801-1786; Champiat,
   Stephane/0000-0002-0741-2118
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A92
EP A93
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500236
DA 2020-11-26
ER

PT J
AU Kuebler, PJ
   Holditch, SJ
   Mcconnell, JJ
   Tarosso, L
   Mehrotra, M
   Shaw, BL
   Andre, RRR
   Rex, CG
   Eriksson, EM
   York, VM
   McMahon, V
   Hance, RJ
   Defechereux, P
   Glidden, DV
   Shiboski, S
   Grant, RM
   Nixon, DF
   Kallas, EG
AF Kuebler, P. J.
   Holditch, S. J.
   Mcconnell, J. J.
   Tarosso, L.
   Mehrotra, M.
   Shaw, B. L.
   Andre, R. R. R.
   Rex, C. G.
   Eriksson, E. M.
   York, V. M.
   McMahon, V.
   Hance, R. J.
   Defechereux, P.
   Glidden, D. V.
   Shiboski, S.
   Grant, R. M.
   Nixon, D. F.
   Kallas, E. G.
TI Immunological Correlates of Protection Against Acquisition of HIV-1
   Infection in the iPrEx Trial
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Mcconnell, J. J.; Mehrotra, M.; McMahon, V.; Hance, R. J.; Defechereux, P.; Glidden, D. V.; Shiboski, S.; Grant, R. M.] Univ Calif San Francisco, JD Gladstone Inst, San Francisco, CA 94143 USA.
   [Tarosso, L.; Kallas, E. G.] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI Nixon, Douglas/AAU-5734-2020; Tarosso, Leandro F./H-6267-2012; Glidden,
   David/AAD-4730-2020; Kallas, Esper G/C-9539-2012
OI Nixon, Douglas/0000-0002-2801-1786; 
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A131
EP A132
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500341
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Almeida, RR
   Rosa, DS
   Mairena, EC
   Kallas, EG
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Almeida, R. R.
   Rosa, D. S.
   Mairena, E. C.
   Kallas, E. G.
   Kalil, J.
   Cunha-Neto, E.
TI DNA Vaccine Encoding HIV CD4 T Cell Epitopes Enhances CD8 T Cell
   Responses Induced by Immunization with DNA Vaccines Encoding Whole Gag
   (p55) and Vif
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Ribeiro, S. P.; Almeida, R. R.; Rosa, D. S.; Mairena, E. C.; Kallas, E. G.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo FMUSP, Fac Med, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Rosa, Daniela S/D-2190-2012; Kallas,
   Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A101
EP A102
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500260
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Vieira, VA
   Kallas, EG
AF Tarosso, L. F.
   Vieira, V. A.
   Kallas, E. G.
TI Conserved HIV-1 p24 epitopes elicit cellular immune responses that
   impact disease outcome
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Tarosso, L. F.; Vieira, V. A.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Tarosso, Leandro F./H-6267-2012; Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A94
EP A94
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500240
DA 2020-11-26
ER

PT J
AU Kanunfre, K
   Lemos, E
   Felix, A
   Kallas, E
   Ferreira, A
AF Kanunfre, K.
   Lemos, E.
   Felix, A.
   Kallas, E.
   Ferreira, A.
TI Western blot method as supplemental tool for syphilis diagnosis and
   suggesting possible clinical phases of the disease in recently HIV
   infected patients
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Kanunfre, K.; Lemos, E.; Felix, A.] Univ Sao Paulo, Inst Trop Med Sao Paulo, BR-05508 Sao Paulo, Brazil.
   [Kallas, E.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, BR-05508 Sao Paulo, Brazil.
   [Ferreira, A.] Univ Sao Paulo, Dept Infect & Parasit Dis, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; de Macedo Lemos, Eliana
   Gertrudes/AAA-4225-2020
OI de Macedo Lemos, Eliana Gertrudes/0000-0002-1119-7748
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2011
VL 16
SU 1
SI SI
BP 159
EP 160
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 828RC
UT WOS:000295519100464
DA 2020-11-26
ER

PT J
AU O'Connor, SL
   Burns, CM
   Friedrich, TC
   Broman, KW
   Kallas, EG
   O'Connor, DH
AF O'Connor, Shelby L.
   Burns, Charles M.
   Friedrich, Thomas C.
   Broman, Karl W.
   Kallas, Esper G.
   O'Connor, David H.
TI CREATION OF GENOME-WIDE CD8+T CELL EPITOPE KNOCKOUT SIV VIRUSES FOR
   MAURITIAN CYNOMOLGUS MACAQUES
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Meeting Abstract
C1 [O'Connor, Shelby L.; Burns, Charles M.; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Friedrich, Thomas C.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Friedrich, Thomas C.; O'Connor, David H.] Wisconsin Natl Primate Res Ctr, Madison, WI USA.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0047-2565
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD AUG
PY 2011
VL 40
IS 4
MA 81
BP 274
EP 274
PG 1
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 795YL
UT WOS:000293015700088
DA 2020-11-26
ER

PT J
AU Jain, V
   Sucupira, MC
   Bacchetti, P
   Hartogensis, W
   Diaz, RS
   Kallas, EG
   Janini, LM
   Liegler, T
   Pilcher, CD
   Grant, RM
   Cortes, R
   Deeks, SG
   Hecht, FM
AF Jain, Vivek
   Sucupira, Maria C.
   Bacchetti, Peter
   Hartogensis, Wendy
   Diaz, Ricardo S.
   Kallas, Esper G.
   Janini, Luiz M.
   Liegler, Teri
   Pilcher, Christopher D.
   Grant, Robert M.
   Cortes, Rodrigo
   Deeks, Steven G.
   Hecht, Frederick M.
TI Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation
   Classes
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INTERVAL-CENSORED-DATA; LONG-TERM
   PERSISTENCE; PRIMARY INFECTION; ANTIRETROVIRAL THERAPY; REPLICATIVE
   FITNESS; GENOTYPING KIT; IN-VITRO; TRANSMISSION; PROTEASE
AB Methods. We studied participants with acute and/or early HIV infection and TDR in 2 cohorts (San Francisco, California, and Sao Paulo, Brazil). We followed baseline mutations longitudinally and compared replacement rates between mutation classes with use of a parametric proportional hazards model.
   Results. Among 75 individuals with 195 TDR mutations, M184V/I became undetectable markedly faster than did nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations (hazard ratio, 77.5; 95% confidence interval [CI], 14.7-408.2; P < .0001), while protease inhibitor and NNRTI replacement rates were similar. Higher plasma HIV-1 RNA level predicted faster mutation replacement, but this was not statistically significant (hazard ratio, 1.71 log(10) copies/mL; 95% CI, .90-3.25 log(10) copies/mL; P = .11). We found substantial person-to-person variability in mutation replacement rates not accounted for by viral load or mutation class (P < .0001).
   Conclusions. The rapid replacement of M184V/I mutations is consistent with known fitness costs. The long-term persistence of NNRTI and protease inhibitor mutations suggests a risk for person-to-person propagation. Host and/or viral factors not accounted for by viral load or mutation class are likely influencing mutation replacement and warrant further study.
C1 [Jain, Vivek; Hartogensis, Wendy; Liegler, Teri; Pilcher, Christopher D.; Deeks, Steven G.; Hecht, Frederick M.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA.
   [Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Grant, Robert M.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
   [Sucupira, Maria C.; Diaz, Ricardo S.; Kallas, Esper G.; Janini, Luiz M.; Cortes, Rodrigo] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Hecht, FM (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, Box 0874, San Francisco, CA 94143 USA.
EM rhecht@php.ucsf.edu
RI Diaz, Ricardo/K-3978-2012; Araripe Sucupira, Maria Cecilia/K-1931-2012;
   Kallas, Esper G/C-9539-2012; Janini, Luiz Mario R/E-9700-2012
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Janini, Luiz
   Mario/0000-0002-6186-6284; Grant, Robert/0000-0002-0851-7085; Kallas,
   Esper/0000-0003-2026-6925; Hecht, Frederick/0000-0002-5782-1171
FU National Institutes of Health/National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32AI060530, PO1AI071713,
   K24AI069994, P30 AI027763, UL1 RR024131]; Brazilian Programfor STD and
   AIDS, Ministry of Health [914/BRA/3014-UNESCO]; Sao Paulo City Health
   Department [2004-0.168.922-7]; Programa Nacional de Pos Doutorado /
   Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES
   [PNPD/CAPES-2496/08]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9, 04/12316-3]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Brazilian Ministry of Science and
   TechnologyNational Council for Scientific and Technological Development
   (CNPq); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   K24AI069994, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, T32AI060530,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, K24AI069994, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P01AI071713, T32AI060530,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, T32AI060530,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, K24AI069994, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P01AI071713, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, T32AI060530, P30AI027763,
   K24AI069994, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   T32AI060530, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, T32AI060530, P30AI027763, P30AI027763, T32AI060530,
   K24AI069994, P30AI027763, T32AI060530, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, K24AI069994, P01AI071713, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, K24AI069994,
   P30AI027763, T32AI060530, T32AI060530, P30AI027763, P30AI027763,
   P01AI071713, P01AI071713, P01AI071713, P01AI071713, P30AI027763,
   K24AI069994, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P01AI071713, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, T32AI060530, P30AI027763, T32AI060530, T32AI060530,
   P01AI071713] Funding Source: NIH RePORTER
FX National Institutes of Health/National Institute of Allergy and
   Infectious Diseases (T32AI060530, PO1AI071713 to FMH, K24AI069994 to
   SGD, and P30 AI027763 and UL1 RR024131 to UCSF), Brazilian Programfor
   STD and AIDS, Ministry of Health (914/BRA/3014-UNESCO to EGK), the Sao
   Paulo City Health Department (2004-0.168.922-7 to EGK), Programa
   Nacional de Pos Doutorado / Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (PNPD/CAPES-2496/08 to MCS), and Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (04/15856-9 to RSD and EGK, and
   04/12316-3 to MCS). RSD and EGK are scholarship recipients from the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Brazilian Ministry of Science and Technology.
CR Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10
   Barbour JD, 2004, AIDS, V18, P1683, DOI 10.1097/01.aids.0000131391.91468.ff
   Bellamy SL, 2004, STAT MED, V23, P3607, DOI 10.1002/sim.1918
   Brenner B, 2004, AIDS, V18, P1653, DOI 10.1097/01.aids.0000131377.28694.04
   Brenner BG, 2002, J VIROL, V76, P1753, DOI 10.1128/JVI.76.4.1753-1761.2002
   Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088
   Brenner BG, 2008, AIDS, V22, P2509, DOI 10.1097/QAD.0b013e3283121c90
   Brown AJL, 1997, P NATL ACAD SCI USA, V94, P1862, DOI 10.1073/pnas.94.5.1862
   Campbell TB, 2005, CLIN INFECT DIS, V41, P236, DOI 10.1086/430709
   Castagna A, 2006, AIDS, V20, P795, DOI 10.1097/01.aids.0000218542.08845.b2
   Chaix ML, 2007, ANTIVIR THER, V12, P1305
   Chaix ML, 2009, AIDS, V23, P717, DOI 10.1097/QAD.0b013e328326ca77
   Chan KCW, 2003, AIDS, V17, P1256, DOI 10.1097/00002030-200305230-00020
   Cong ME, 2007, J VIROL, V81, P3037, DOI 10.1128/JVI.02712-06
   Coovadia A, 2009, CLIN INFECT DIS, V48, P462, DOI 10.1086/596486
   Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997
   de Ronde A, 2001, J VIROL, V75, P595, DOI 10.1128/JVI.75.2.595-602.2001
   Deeks SG, 2005, J INFECT DIS, V192, P1537, DOI 10.1086/496892
   Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000
   Gonzalez LMF, 2004, ANTIMICROB AGENTS CH, V48, P3552, DOI 10.1128/AAC.48.9.3552-3555.2004
   Grant RM, 2003, J CLIN MICROBIOL, V41, P1586, DOI 10.1128/JCM.41.4.1586-1593.2003
   Gupta RK, 2009, LANCET INFECT DIS, V9, P409, DOI 10.1016/S1473-3099(09)70136-7
   Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005
   Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196
   Hurt CB, 2009, ANTIVIR THER, V14, P673
   Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488
   Kuritzkes DR, 2003, J CLIN MICROBIOL, V41, P1594, DOI 10.1128/JCM.41.4.1594-1599.2003
   Little SJ, 2008, J VIROL, V82, P5510, DOI 10.1128/JVI.02579-07
   Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999
   Oette M, 2006, JAIDS-J ACQ IMM DEF, V41, P573, DOI 10.1097/01.qai.0000214805.52723.c1
   Pao D, 2004, JAIDS-J ACQ IMM DEF, V37, P1570, DOI 10.1097/00126334-200412150-00006
   Paredes R, 2009, J VIROL, V83, P2038, DOI 10.1128/JVI.02154-08
   Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004
   Rouzine IM, 1999, P NATL ACAD SCI USA, V96, P10758, DOI 10.1073/pnas.96.19.10758
   Shafer RW, 2007, AIDS, V21, P215, DOI 10.1097/QAD.0b013e328011e691
   Smith DM, 2007, J INFECT DIS, V196, P356, DOI 10.1086/519164
   Sparling YH, 2006, BIOSTATISTICS, V7, P599, DOI 10.1093/biostatistics/kxj028
   Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745
   Toni TA, 2009, ANTIMICROB AGENTS CH, V53, P1670, DOI 10.1128/AAC.01494-08
   van Maarseveen NM, 2007, J INFECT DIS, V195, P399, DOI 10.1086/510533
   Vercauteren J, 2009, J INFECT DIS, V200, P1503, DOI 10.1086/644505
   Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789
   Yerly S, 2007, AIDS, V21, P2223, DOI 10.1097/QAD.0b013e3282f0b685
   Zimmer JM, 2008, JAIDS-J ACQ IMM DEF, V48, P255, DOI 10.1097/QAI.0b013e318174dca6
NR 48
TC 93
Z9 93
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 15
PY 2011
VL 203
IS 8
BP 1174
EP 1181
DI 10.1093/infdis/jiq167
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 745MC
UT WOS:000289168500018
PM 21451005
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Giret, MTM
   Miraglia, JL
   Sucupira, MCA
   Nishiya, A
   Levi, JE
   Diaz, RS
   Sabino, EC
   Kallas, EG
AF Giret, Maria Teresa M.
   Miraglia, Joao Luiz
   Araripe Sucupira, Maria Cecilia
   Nishiya, Anna
   Levi, Jose Eduardo
   Diaz, Ricardo S.
   Sabino, Ester C.
   Kallas, Esper G.
TI Prevalence, Incidence Density, and Genotype Distribution of GB Virus C
   Infection in a Cohort of Recently HIV-1-Infected Subjects in Sao Paulo,
   Brazil
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-G VIRUS; C/HEPATITIS-G-VIRUS; EARLY HIV-1 INFECTION;
   ANTIRETROVIRAL THERAPY; PHYLOGENETIC ANALYSIS; DISEASE PROGRESSION;
   REGION SEQUENCES; NONCODING REGION; BLOOD-DONORS; NO INFLUENCE
AB Background: The results of previous studies elsewhere have indicated that GB virus C (GBV-C) infection is frequent in patients infected with the human immunodeficiency virus type 1 (HIV-1) due to similar transmission routes of both viruses. The aim of this study was to determine the prevalence, incidence density and genotypic characteristics of GBV-C in this population.
   Methodology/Principal Findings: The study population included 233 patients from a cohort primarily comprised of homosexual men recently infected with HIV-1 in Sao Paulo, Brazil. The presence of GBV-C RNA was determined in plasma samples by reverse transcriptase-nested polymerase chain reaction and quantified by real-time PCR. GBV-C genotypes were determined by direct sequencing. HIV viral load, CD4+ T lymphocyte and CD8+ T lymphocyte count were also tested in all patients. The overall prevalence of GBV-C infection was 0.23 (95% CI: 0.18 to 0.29) in the study group. There was no significant difference between patients with and without GBV-C infection and Glycoprotein E2 antibody presence regarding age, sex, HIV-1 viral load, CD4+ and CD8+ T cell counts and treatment with antiretroviral drugs. An inverse correlation was observed between GBV-C and HIV-1 loads at enrollment and after one year. Also, a positive but not significant correlation was observed between GBV-C load and CD4+ T lymphocyte. Phylogenetic analysis of the GBV-C isolates revealed the presence of genotype 1 and genotype 2, these sub classified into subtype 2a and 2b.
   Conclusion/Significance: GBV-C infection is common in recently HIV -1 infected patients in Sao Paulo, Brazil and the predominant genotype is 2b. This study provides the first report of the GBV-C prevalence at the time of diagnosis of HIV-1 and the incidence density of GBV-C infection in one year.
C1 [Giret, Maria Teresa M.; Miraglia, Joao Luiz; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Araripe Sucupira, Maria Cecilia; Diaz, Ricardo S.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Nishiya, Anna; Sabino, Ester C.] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP Giret, MTM (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Kallas, Esper G/C-9539-2012; Miraglia, Joao/H-5294-2013; Araripe
   Sucupira, Maria Cecilia/K-1931-2012; Diaz, Ricardo/K-3978-2012; Sabino,
   Ester Cerdeira/F-7750-2010; Nishiya, Anna/Q-8156-2016
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Kallas, Esper/0000-0003-2026-6925;
   Miraglia, Joao Luiz/0000-0002-4788-6254
FU Ministry of HealthMinistry of Health - Turkey
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Diaz, Sabino Kallas, 05/01072-9/Levi]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of EducationCAPES
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Diaz, Sabino &
   Kallas; and 05/01072-9/Levi). T.M.G. was supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of Education. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
   Barbosa AD, 2009, REV SOC BRAS MED TRO, V42, P591, DOI 10.1590/S0037-86822009000500021
   Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076
   Berzsenyi MD, 2005, J CLIN VIROL, V33, P257, DOI 10.1016/j.jcv.2005.04.002
   Birk M, 2002, AIDS, V16, P2482, DOI 10.1097/00002030-200212060-00017
   Bjorkman P, 2004, AIDS, V18, P877, DOI [10.1097/01.aids.0000125908.52357.4c, 10.1097/00002030-200404090-00005]
   Branco C, 2010, J MED VIROL, V82, P452, DOI 10.1002/jmv.21703
   Brumme ZL, 2002, AIDS, V16, P1929, DOI 10.1097/00002030-200209270-00010
   Compston LI, 2009, J MED VIROL, V81, P1860, DOI 10.1002/jmv.21614
   Gallian P, 1998, J MED VIROL, V56, P310, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;310::AID-JMV4&gt;3.0.CO;2-4
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   Hammad AM, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-36
   Handajani R, 2000, J CLIN MICROBIOL, V38, P662, DOI 10.1128/JCM.38.2.662-668.2000
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Hosseini-Moghaddam SM, 2008, J MED VIROL, V80, P1260, DOI 10.1002/jmv.21161
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Katayama K, 1998, ARCH VIROL, V143, P1063, DOI 10.1007/s007050050356
   Lampe E, 1998, J MED VIROL, V56, P39, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;39::AID-JMV7&gt;3.0.CO;2-O
   Lampe E, 1997, J MED VIROL, V52, P61, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;61::AID-JMV10&gt;3.0.CO;2-3
   Lau DTY, 1999, J INFECT DIS, V180, P1334, DOI 10.1086/315031
   Leao GC, 2007, JPN J CLIN ONCOL, V37, P632, DOI 10.1093/jjco/hym063
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Loureiro CL, 2002, J MED VIROL, V68, P357, DOI 10.1002/jmv.10211
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Maidana Maria Teresa, 2005, Braz J Infect Dis, V9, P122, DOI 10.1590/S1413-86702005000200001
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Massud I, 2002, MEDICINA-BUENOS AIRE, V62, P173
   *MIN SAUD SECR VIG, ANT THER REC HIV INF
   Muerhoff AS, 2006, J MED VIROL, V78, P105, DOI 10.1002/jmv.20510
   Muerhoff AS, 2003, J MED VIROL, V70, P141, DOI 10.1002/jmv.10375
   MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995
   Muerhoff AS, 1996, J HEPATOL, V25, P379, DOI 10.1016/S0168-8278(96)80125-5
   Muerhoff AS, 1997, J VIROL, V71, P6501, DOI 10.1128/JVI.71.9.6501-6508.1997
   Mukaide M, 1997, FEBS LETT, V407, P51, DOI 10.1016/S0014-5793(97)00136-1
   Naito H, 1999, J CLIN MICROBIOL, V37, P1217, DOI 10.1128/JCM.37.4.1217-1220.1999
   Naito H, 2001, J VIROL METHODS, V91, P3, DOI 10.1016/S0166-0934(00)00207-X
   Nishiya Anna S., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P213, DOI 10.1590/S0036-46652003000400007
   Okamoto H, 1997, J GEN VIROL, V78, P737, DOI 10.1099/0022-1317-78-4-737
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
   Pinho J. R. R., 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P243, DOI 10.1590/S0036-46651996000300016
   Pinho Joao Renato Rebello, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P441, DOI 10.1590/S0036-46651996000600010
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   Quiros-Roldan E, 2002, AIDS, V16, P1430, DOI 10.1097/00002030-200207050-00019
   Ramezani A, 2008, J GASTROINTEST LIVER, V17, P269
   Ramezani A, 2008, INT J INFECT DIS, V12, P57, DOI 10.1016/j.ijid.2007.04.010
   Ramos R, 2004, MEM I OSWALDO CRUZ, V99, P639, DOI 10.1590/S0074-02762004000600019
   Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352
   Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
   Ryt-Hansen R, 2006, AIDS RES HUM RETROV, V22, P496, DOI 10.1089/aid.2006.22.496
   Sa D, 2007, AIDS RES HUM RETROV, V23, P1087, DOI 10.1089/aid.2006.0173
   Sathar MA, 2004, CLIN INFECT DIS, V38, P405, DOI 10.1086/381092
   SCHLAUDER GG, 1995, LANCET, V346, P447, DOI 10.1016/S0140-6736(95)92821-9
   Schwarze-Zander C, 2006, J INFECT DIS, V194, P410, DOI 10.1086/505713
   SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Smith DB, 1997, J GEN VIROL, V78, P1533, DOI 10.1099/0022-1317-78-7-1533
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   STAPLETON JT, 2010, J GEN VIROL
   Supapol WB, 2008, J INFECT DIS, V197, P1369, DOI 10.1086/587488
   Supapol WB, 2011, J MED VIROL, V83, P33, DOI 10.1002/jmv.21946
   Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Van der Bij AK, 2005, J INFECT DIS, V191, P678, DOI 10.1086/427559
   Watanabe MAE, 2003, RENAL FAILURE, V25, P67, DOI 10.1081/JDI-120017469
   Weng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000
NR 74
TC 25
Z9 26
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2011
VL 6
IS 4
AR e18407
DI 10.1371/journal.pone.0018407
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 745UD
UT WOS:000289191300021
PM 21483671
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ndhlovu, LC
   Leal, FE
   Hasenkrug, AM
   Jha, AR
   Carvalho, KI
   Eccles-James, IG
   Bruno, FR
   Vieira, RGS
   York, VA
   Chew, GM
   Jones, RB
   Tanaka, Y
   Neto, WK
   Sanabani, SS
   Ostrowski, MA
   Segurado, AC
   Nixon, DF
   Kallas, EG
AF Ndhlovu, Lishomwa C.
   Leal, Fabio E.
   Hasenkrug, Aaron M.
   Jha, Aashish R.
   Carvalho, Karina I.
   Eccles-James, Ijeoma G.
   Bruno, Fernanda R.
   Vieira, Raphaella G. S.
   York, Vanessa A.
   Chew, Glen M.
   Jones, R. Brad
   Tanaka, Yuetsu
   Neto, Walter K.
   Sanabani, Sabri S.
   Ostrowski, Mario A.
   Segurado, Aluisio C.
   Nixon, Douglas F.
   Kallas, Esper G.
TI HTLV-1 Tax Specific CD8+ T Cells Express Low Levels of Tim-3 in HTLV-1
   Infection: Implications for Progression to Neurological Complications
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; SPINAL-CORD LESIONS;
   LEUKEMIA-VIRUS; PROVIRAL LOAD; PERIPHERAL-BLOOD; PD-1 EXPRESSION;
   VIRAL-INFECTION; UP-REGULATION; LYMPHOCYTES
AB The T cell immunoglobulin mucin 3 (Tim-3) receptor is highly expressed on HIV-1-specific T cells, rendering them partially "exhausted'' and unable to contribute to the effective immune mediated control of viral replication. To elucidate novel mechanisms contributing to the HTLV-1 neurological complex and its classic neurological presentation called HAM/TSP (HTLV-1 associated myelopathy/tropical spastic paraparesis), we investigated the expression of the Tim-3 receptor on CD8(+) T cells from a cohort of HTLV-1 seropositive asymptomatic and symptomatic patients. Patients diagnosed with HAM/TSP down-regulated Tim-3 expression on both CD8(+) and CD4(+) T cells compared to asymptomatic patients and HTLV-1 seronegative controls. HTLV-1 Tax-specific, HLA-A*02 restricted CD8(+) T cells among HAM/TSP individuals expressed markedly lower levels of Tim-3. We observed Tax expressing cells in both Tim-3(+) and Tim-3(-) fractions. Taken together, these data indicate that there is a systematic downregulation of Tim-3 levels on T cells in HTLV-1 infection, sustaining a profoundly highly active population of potentially pathogenic T cells that may allow for the development of HTLV-1 complications.
C1 [Ndhlovu, Lishomwa C.; Hasenkrug, Aaron M.; Jha, Aashish R.; Eccles-James, Ijeoma G.; Vieira, Raphaella G. S.; York, Vanessa A.; Chew, Glen M.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   [Leal, Fabio E.; Carvalho, Karina I.; Bruno, Fernanda R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Infect Dis, Sao Paulo, Brazil.
   [Jones, R. Brad; Ostrowski, Mario A.] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Tanaka, Yuetsu] Univ Ryukyus, Dept Immunol, Okinawa, Japan.
   [Neto, Walter K.; Sanabani, Sabri S.] Hemoctr Sao Paulo, Mol Biol Lab, Fundacao Prosangue, Sao Paulo, Brazil.
RP Ndhlovu, LC (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
EM lndhlovu@medsfgh.ucsf.edu
RI Kallas, Esper G/C-9539-2012; Sanabani, Sabri Saeed/F-5600-2012;
   Segurado, Aluisio C/K-2229-2012; Carvalho, Karina IL/J-6789-2012; Nixon,
   Douglas/AAU-5734-2020; n, l/AAX-3992-2020
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; Segurado, Aluisio
   C/0000-0002-6311-8036; Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Jha, Aashish/0000-0003-3227-1086; Ndhlovu,
   Lishomwa/0000-0001-5427-4187; Kallas, Esper/0000-0003-2026-6925
FU National Institutes of Health (NIH), University of California, San
   Francisco-Gladstone Institute of Virology & Immunology CenterUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USAUniversity of California System [P30 AI027763]; STD;
   AIDS, Ministry of Health [914/BRA/3014 - UNESCO/Kallas]; Sao Paulo City
   Health Department [2004-0.168.922-7/Kallas]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/ 15856-9/Kallas, 2010/05845-0/Kallas and
   Nixon]; John E. Fogarty International CenterUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43 TW00003]; National Institute of
   Allergy and Infectious Diseases (LCN)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R56AI083112];
   Montana State Complex Biological Systems Research; Howard Hughes Medical
   InstituteHoward Hughes Medical Institute; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R56AI083112, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R56AI083112, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763] Funding
   Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [221S0001] Funding Source: KAKEN
FX Support for this work was provided by funds from the National Institutes
   of Health (NIH), University of California, San Francisco-Gladstone
   Institute of Virology & Immunology Center for AIDS Research (P30
   AI027763). Additional support was provided by the Brazilian Program for
   STD and AIDS, Ministry of Health (914/BRA/3014 - UNESCO/Kallas), the Sao
   Paulo City Health Department (2004-0.168.922-7/Kallas), Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/ 15856-9/Kallas and
   2010/05845-0/Kallas and Nixon), the John E. Fogarty International Center
   (D43 TW00003). The project described was also supported by Award Number
   R56AI083112 from the National Institute of Allergy and Infectious
   Diseases (LCN). Additional support was provided by the Montana State
   Complex Biological Systems Research Scholars Program, funded by the
   Howard Hughes Medical Institute to AH. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson AC, 2006, CURR OPIN IMMUNOL, V18, P665, DOI 10.1016/j.coi.2006.09.009
   [Anonymous], 1989, REP WHO SCI GROUP HT
   Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Biddison WE, 1997, J IMMUNOL, V159, P2018
   Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567
   Enose-Akahata Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000682
   Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K
   Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383
   GESSAIN A, 1985, LANCET, V2, P407
   Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07
   Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09
   Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568
   Hafler DA, 2008, J EXP MED, V205, P2699, DOI 10.1084/jem.20082429
   Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0
   Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   IANNONE R, 1992, J ACQ IMMUN DEF SYND, V5, P810
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
   Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278
   Jin HT, 2010, P NATL ACAD SCI US
   Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398
   KOENIG S, 1993, J IMMUNOL, V151, P3874
   Kozako T, 2009, LEUKEMIA, V23, P375, DOI 10.1038/leu.2008.272
   Kubota R, 1998, J IMMUNOL, V161, P482
   Kubota R, 2000, J NEUROIMMUNOL, V102, P208, DOI 10.1016/S0165-5728(99)00175-7
   LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1
   Levin MC, 1997, J NEUROVIROL, V3, P126, DOI 10.3109/13550289709015802
   Matsuura E, 2010, J NEUROIMMUNE PHARM, V5, P310, DOI 10.1007/s11481-010-9216-9
   Michaelsson J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-41
   Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932
   Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA
   OSAME M, 1986, LANCET, V1, P1031
   Peng GP, 2008, MOL IMMUNOL, V45, P963, DOI 10.1016/j.molimm.2007.07.038
   Petrovas C, 2007, BLOOD, V110, P928, DOI 10.1182/blood-2007-01-069112
   Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496
   Radziewicz H, 2007, J VIROL, V81, P2545, DOI 10.1128/JVI.02021-06
   Sabouri AH, 2008, BLOOD, V112, P2411, DOI 10.1182/blood-2008-02-140335
   Sakai JA, 2001, BLOOD, V98, P1506, DOI 10.1182/blood.V98.5.1506
   Sehrawat S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000882
   Sehrawat S, 2009, J IMMUNOL, V182, P3191, DOI 10.4049/jimmunol.0803673
   Takamura S, 2010, J IMMUNOL, V184, P4696, DOI 10.4049/jimmunol.0903478
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481
   UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P617, DOI 10.1097/00005072-199411000-00009
   UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010
   Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06
   Vali B, 2010, EUR J IMMUNOL
   Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121
   Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 56
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD APR
PY 2011
VL 5
IS 4
AR e1030
DI 10.1371/journal.pntd.0001030
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 755MY
UT WOS:000289937400005
PM 21541358
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Bastos, DA
   Rodrigues, CA
   Patah, P
   Kallas, EG
   Rocha, V
   Novis, Y
AF Bastos, D. A.
   Rodrigues, C. A.
   Patah, P.
   Kallas, E. G.
   Rocha, V.
   Novis, Y.
TI Pandemic influenza A H1N1/09 virus infection in hematopoietic SCT
   recipient
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID OSELTAMIVIR
C1 [Bastos, D. A.; Rodrigues, C. A.; Patah, P.] Hosp Sirio Libanes, BMT Unit, Sao Paulo, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Rocha, V.] Eurocord St Louis Hosp, Paris, France.
RP Bastos, DA (corresponding author), Hosp Sirio Libanes, BMT Unit, Sao Paulo, Brazil.
EM dabastos@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Casper C, 2010, BLOOD, V115, P1331, DOI 10.1182/blood-2009-11-255455
   Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433
   Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023
   Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810
   Englund J., 2009, Morbidity and Mortality Weekly Report, V58, P893
   JABER S, ANN FR ANESTH REANIM
   Quispe-Laime AM, 2010, INTENS CARE MED, V36, P33, DOI 10.1007/s00134-009-1727-6
   Michaelis M, 2009, INFECTION, V37, P381, DOI 10.1007/s15010-009-9181-5
   2009, BRAZILIAN EPIDEMIOLO
NR 9
TC 2
Z9 2
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAR
PY 2011
VL 46
IS 3
BP 467
EP 468
DI 10.1038/bmt.2010.133
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 732DI
UT WOS:000288164000028
PM 20531285
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Mesquita, D
   Cruvinel, WD
   Araujo, JAP
   Pucci, FVC
   Salmazi, KC
   Kallas, EG
   Andrade, LEC
AF Mesquita, D., Jr.
   Cruvinel, W. de Melo
   Araujo, J. A. P.
   Pucci, F. V. C.
   Salmazi, K. C.
   Kallas, E. G.
   Andrade, L. E. C.
TI Systemic lupus erythematosus exhibits a dynamic and continuum spectrum
   of effector/regulatory T cells
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID PERIPHERAL-BLOOD; SUPPRESSIVE FUNCTION; REGULATORY CELLS; FOXP3
   EXPRESSION; SELF-TOLERANCE; CD4(+)CD25(HIGH); IDENTIFICATION;
   POPULATION; NUMBER; CD127
AB Objective: The identification of regulatory T cells (Treg cells) as CD4(+)CD25(high) cells may be upset by the increased frequency of activated effector T cells (Teff cells) in inflammatory diseases such as systemic lupus erythematosus (SLE). This study aimed to evaluate the frequency of T-cell subsets according to the expression of CD25 and CD127 in active (A-SLE) and inactive SLE (I-SLE).
   Methods: Peripheral blood mononuclear cells (PBMCs) from 26 A-SLE patients (SLE Disease Activity Index (SLEDAI) = 10.17 +/- 3.7), 31 I-SLE patients (SLEDAI = 0), and 26 healthy controls (HC) were analysed by multicolour flow. cytometry.
   Results: CD25(high) cell frequency was increased in A-SLE (5.2 +/- 5.7%) compared to I-SLE (3.4 +/- 3.4%) and HC (1.73 +/- 0.8%) (p < 0.01). However, the percentage of FoxP3(+) cells in the CD25(high) subset was decreased in A-SLE (24.6 +/- 16.4%) compared to I-SLE (33.7 +/- 16) and HC (45 +/- 25.1%) (p < 0.01). This was partly due to the increased frequency of Teff cells (CD25(high)CD127(+)FoxP3(empty set)) in A-SLE (10.7 +/- 7.3%) compared to I-SLE (8.5 +/- 6.5) and HC (6.1 +/- 1.8%) (p = 0.02). Hence the frequency of Treg cells (CD25(+/high)CD127(low/empty set)FoxP3(+)) was equivalent in A-SLE (1.4 +/- 0.8%), I-SLE (1.37 +/- 1.0%), and HC (1.13 +/- 0.59%) (p = 0.42). A-SLE presented an increased frequency of CD25(+)CD127(+)FoxP3(+) and CD25(empty set)FoxP3(+)CD127(low/empty set) T cells, which may represent intermediate phenotypes between Treg and Teff cells.
   Conclusions: The present study has provided data supporting normal Treg cell frequency in A-SLE and I-SLE as well as increased frequency of Teff cells in A-SLE. This scenario reflects a Treg/Teff ratio imbalance that may favour the inflammatory phenotype of the disease. In addition, the increased frequency of T cells with putative intermediate phenotypes may be compatible with a highly dynamic immune system in SLE.
C1 [Mesquita, D., Jr.; Cruvinel, W. de Melo; Araujo, J. A. P.; Andrade, L. E. C.] Univ Fed Sao Paulo, Dept Rheumatol, BR-04023062 Sao Paulo, Brazil.
   [Cruvinel, W. de Melo; Pucci, F. V. C.] Catholic Univ Goias UCG, Dept Biomed, Goiania, Go, Brazil.
   [Salmazi, K. C.; Kallas, E. G.] Univ Sao Paulo, Dept Clin Immunol & Allergy, BR-05508 Sao Paulo, Brazil.
RP Andrade, LEC (corresponding author), Univ Fed Sao Paulo, Dept Rheumatol, Rua Botucatu 740, BR-04023062 Sao Paulo, Brazil.
EM luis.andrade@unifesp.br
RI Carvalho, Karina IL/J-6789-2012; Kallas, Esper G/C-9539-2012; Andrade,
   Luis Eduardo C/D-1245-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Andrade, Luis Eduardo
   C/0000-0001-8742-9931; Kallas, Esper/0000-0003-2026-6925; Araujo,
   Julio/0000-0001-6706-2589
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/51934-0, 07/51349-2]; CNP-qNational Council for Scientific and
   Technological Development (CNPq) [2008-476356/2008-3]
FX This work was funded by grants from FAPESP (06/51934-0; 07/51349-2) and
   CNP-q (2008-476356/2008-3).
CR Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004
   Alvarado-Sanchez B, 2006, J AUTOIMMUN, V27, P110, DOI 10.1016/j.jaut.2006.06.005
   Azab NA, 2008, CLIN IMMUNOL, V127, P151, DOI 10.1016/j.clim.2007.12.010
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245
   Barath S, 2007, LUPUS, V16, P489, DOI 10.1177/0961203307080226
   Barreto M, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-5
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Bonelli M, 2008, ANN RHEUM DIS, V67, P664, DOI 10.1136/ard.2007.074690
   Bonelli M, 2008, INT IMMUNOL, V20, P861, DOI 10.1093/intimm/dxn044
   Bonelli M, 2009, J IMMUNOL, V182, P1689, DOI 10.4049/jimmunol.182.3.1689
   Cao D, 2004, ARTHRITIS RES THER, V6, pS14, DOI 10.1186/ar1084
   Crispin JC, 2003, J AUTOIMMUN, V21, P273, DOI 10.1016/S0896-8411(03)00121-5
   Franz B, 2007, ARTHRITIS RHEUM-US, V56, P1910, DOI 10.1002/art.22699
   Habib HM, 2009, SCAND J RHEUMATOL, V38, P112, DOI 10.1080/03009740802409496
   Hartigan-O'Connor DJ, 2007, J IMMUNOL METHODS, V319, P41, DOI 10.1016/j.jim.2006.10.008
   Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Lee HY, 2008, RHEUMATOLOGY, V47, P789, DOI 10.1093/rheumatology/ken108
   Lin SC, 2007, EUR J CLIN INVEST, V37, P987, DOI 10.1111/j.1365-2362.2007.01882.x
   Liu MF, 2004, SCAND J IMMUNOL, V59, P198, DOI 10.1111/j.0300-9475.2004.01370.x
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Mandapathil M, 2009, J IMMUNOL METHODS, V346, P55, DOI 10.1016/j.jim.2009.05.004
   Mellor-Pita S, 2006, ANN RHEUM DIS, V65, P553, DOI 10.1136/ard.2005.044974
   Miyara M, 2005, J IMMUNOL, V175, P8392, DOI 10.4049/jimmunol.175.12.8392
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Suarez A, 2006, ANN RHEUM DIS, V65, P1512, DOI 10.1136/ard.2005.049924
   Suen JL, 2009, IMMUNOLOGY, V127, P196, DOI 10.1111/j.1365-2567.2008.02937.x
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Tsutsumi Y, 2006, DIABETIC MED, V23, P1145, DOI 10.1111/j.1464-5491.2006.01951.x
   Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579
   Venigalla RKC, 2008, ARTHRITIS RHEUM-US, V58, P2120, DOI 10.1002/art.23556
   Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Yan B, 2008, ARTHRITIS RHEUM-US, V58, P801, DOI 10.1002/art.23268
   Yang J, 2009, ARTHRITIS RHEUM-US, V60, P1472, DOI 10.1002/art.24499
   Yates J, 2008, CLIN EXP IMMUNOL, V153, P44, DOI 10.1111/j.1365-2249.2008.03665.x
   Zhang B, 2008, CLIN EXP IMMUNOL, V153, P182, DOI 10.1111/j.1365-2249.2008.03686.x
   Zhang B, 2008, ANN RHEUM DIS, V67, P1037, DOI 10.1136/ard.2007.083543
   Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774
   Ziegler SF, 2007, EUR J IMMUNOL, V37, P21, DOI 10.1002/eji.200636929
   2008, RHEUMATOLOGY OXFORD, V47, P789
NR 45
TC 21
Z9 22
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-9742
EI 1502-7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PD JAN-FEB
PY 2011
VL 40
IS 1
BP 41
EP 50
DI 10.3109/03009742.2010.489229
PG 10
WC Rheumatology
SC Rheumatology
GA 725LF
UT WOS:000287645500007
PM 20936986
DA 2020-11-26
ER

PT J
AU Grant, RM
   Lama, JR
   Anderson, PL
   McMahan, V
   Liu, AY
   Vargas, L
   Goicochea, P
   Casapia, M
   Guanira-Carranza, JV
   Ramirez-Cardich, ME
   Montoya-Herrera, O
   Fernandez, T
   Veloso, VG
   Buchbinder, SP
   Chariyalertsak, S
   Schechter, M
   Bekker, LG
   Mayer, KH
   Kallas, EG
   Amico, KR
   Mulligan, K
   Bushman, LR
   Hance, RJ
   Ganoza, C
   Defechereux, P
   Postle, B
   Wang, FR
   McConnell, JJ
   Zheng, JH
   Lee, J
   Rooney, JF
   Jaffe, HS
   Martinez, AI
   Burns, DN
   Glidden, DV
AF Grant, Robert M.
   Lama, Javier R.
   Anderson, Peter L.
   McMahan, Vanessa
   Liu, Albert Y.
   Vargas, Lorena
   Goicochea, Pedro
   Casapia, Martin
   Guanira-Carranza, Juan Vicente
   Ramirez-Cardich, Maria E.
   Montoya-Herrera, Orlando
   Fernandez, Telmo
   Veloso, Valdilea G.
   Buchbinder, Susan P.
   Chariyalertsak, Suwat
   Schechter, Mauro
   Bekker, Linda-Gail
   Mayer, Kenneth H.
   Kallas, Esper Georges
   Amico, K. Rivet
   Mulligan, Kathleen
   Bushman, Lane R.
   Hance, Robert J.
   Ganoza, Carmela
   Defechereux, Patricia
   Postle, Brian
   Wang, Furong
   McConnell, J. Jeff
   Zheng, Jia-Hua
   Lee, Jeanny
   Rooney, James F.
   Jaffe, Howard S.
   Martinez, Ana I.
   Burns, David N.
   Glidden, David V.
CA iPrEx Study Team
TI Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with
   Men.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS; MALE CIRCUMCISION; LIMITED
   KNOWLEDGE; HOMOSEXUAL-MEN; INFECTION; TRANSMISSION; RISK; TENOFOVIR;
   MACAQUES; TRIAL
AB Background: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
   Methods: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections.
   Results: The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57).
   Conclusions: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.)
   N Engl J Med 2010;363:2587-99.
C1 [Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, HIV Res Sect, San Francisco, CA USA.
   [Lama, Javier R.; Vargas, Lorena] Invest Med Salud, Lima, Peru.
   [Lama, Javier R.; Guanira-Carranza, Juan Vicente; Ramirez-Cardich, Maria E.; Ganoza, Carmela] Asociac Civil Impacta Salud & Educ, Lima, Peru.
   [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru.
   [Anderson, Peter L.; Bushman, Lane R.; Zheng, Jia-Hua] Univ Colorado, Denver, CO 80202 USA.
   [Montoya-Herrera, Orlando; Fernandez, Telmo] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador.
   [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco de Assis, Projeto Praca Onze, Rio De Janeiro, Brazil.
   [Mayer, Kenneth H.] Brown Univ, Providence, RI 02912 USA.
   [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Inst Invest Imunol, Sao Paulo, Brazil.
   [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
   [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.
   [Bekker, Linda-Gail] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   [Martinez, Ana I.; Burns, David N.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Rooney, James F.; Jaffe, Howard S.] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Postle, Brian] DF Net Res, Seattle, WA USA.
   [Amico, K. Rivet] Appl Hlth Res, Brighton, MI USA.
   [Amico, K. Rivet] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA.
   [Grant, Robert M.; McMahan, Vanessa; Goicochea, Pedro; Hance, Robert J.; Defechereux, Patricia; McConnell, J. Jeff; Lee, Jeanny] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
RP Grant, RM (corresponding author), Univ Calif San Francisco, J David Gladstone Inst, 1650 Owens St, San Francisco, CA 94158 USA.
EM robert.grant@ucsf.edu
RI Mathias, Augusto/C-3247-2017; Trajman, Anete/C-7679-2016; Kallas, Esper
   G/C-9539-2012; Veloso, Valdilea Goncalves/J-6189-2012; Cardoso, Sandra
   W/D-7965-2015; /AAE-4700-2020; Schechter, Mauro/AAG-7445-2020; Glidden,
   David/AAD-4730-2020; Bekker, Linda-Gail/AAZ-8929-2020; KALIL,
   JORGE/C-8029-2012
OI Trajman, Anete/0000-0002-4000-4984; Cardoso, Sandra
   W/0000-0001-5230-0003; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925; Grant, Robert/0000-0002-0851-7085; Popuche,
   Dina/0000-0002-4729-7599; Guanira, Juan/0000-0002-2746-3086; Amico, K
   Rivet/0000-0002-4458-6934; BEKKER, LINDA-GAIL/0000-0002-0755-4386;
   Glidden, David/0000-0001-5888-1419
FU Division of Acquired Immunodeficiency Syndrome (DAIDS), National
   Institute of Allergy and Infectious Diseases, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UO1 AI64002]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation; DAIDSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [UO1
   AI84735, AI062333]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [UL1 RR024131]; GileadGilead Sciences; MerckMerck & Company;
   Bristol-Myers SquibbBristol-Myers Squibb; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131,
   UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131, UL1RR024131] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U01AI064002, U01AI064002, R01AI062333,
   U01AI064002, R01AI062333, U01AI064002, R01AI062333, U01AI064002,
   U01AI064002, U01AI084735, U01AI084735, R01AI062333, U01AI064002,
   R01AI062333, U01AI064002, U01AI084735, R01AI062333, U01AI084735,
   U01AI064002, R01AI062333, R01AI062333] Funding Source: NIH RePORTER
FX Supported by the Division of Acquired Immunodeficiency Syndrome (DAIDS),
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, as a cooperative agreement (UO1 AI64002, to Dr.
   Grant) and by the Bill and Melinda Gates Foundation. Study drugs were
   donated by Gilead Sciences. The pharmacological studies were sponsored
   by a cooperative agreement with DAIDS (UO1 AI84735, to Dr. Anderson).
   Support for some specimen handling came from a grant from DAIDS (RO1
   AI062333, to Dr. Grant) and by the J. David Gladstone Institutes. Some
   infrastructure support at the University of California at San Francisco
   was provided by a grant from the National Institutes of Health (UL1
   RR024131).; Dr. Grant reports receiving support as an advisor to Siemens
   (the manufacturer of TruGene HIV-1 Genotyping Kit); Dr. Mayer reports
   receiving grant support from Gilead, Merck, and Bristol-Myers Squibb;
   Dr. Kallas reports serving on a data and safety monitoring board for
   Merck; Dr. Schechter reports receiving consulting fees and grants from
   Gilead; Drs. Liu and Anderson report receiving donations of study drug
   from Gilead for various PrEP projects; and Drs. Jaffe and Rooney report
   being employees of Gilead Sciences and owning stock in the company. No
   other potential conflict of interest relevant to this article was
   reported. Disclosure forms provided by the authors are available with
   the full text of this article at NEJM.org.
CR Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Auvert B, 2006, PLOS MED, V3, P705, DOI 10.1371/journal.pmed.0030226
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2
   Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2
   Gallant JE, 2008, AIDS, V22, P2155, DOI 10.1097/QAD.0b013e3283112b8e
   Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028
   Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391
   Grant RM, 2005, SCIENCE, V309, P2170, DOI 10.1126/science.1116204
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520
   Hofer CB, 2000, J ACQ IMMUN DEF SYND, V25, P188, DOI 10.1097/00126334-200010010-00014
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4
   Liu A., 2010, 17 C RETR OPP INF SA
   Liu AY, 2008, JAIDS-J ACQ IMM DEF, V47, P241, DOI 10.1097/QAI.0b013e31815e4041
   Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010
   Mayer KH, 2008, JAIDS-J ACQ IMM DEF, V47, P494, DOI 10.1097/QAI.0b013e318162afcb
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27
   Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027
   Roland ME, 2005, CLIN INFECT DIS, V41, P1507, DOI 10.1086/497268
   Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Templeton DJ, 2010, CURR OPIN INFECT DIS, V23, P45, DOI 10.1097/QCO.0b013e328334e54d
   TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197
   UNAIDS, 2007, GOOD PART PRACT GUID
   van Griensven F, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-13
   van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3
   Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781
NR 33
TC 2841
Z9 2889
U1 13
U2 297
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 30
PY 2010
VL 363
IS 27
BP 2587
EP 2599
DI 10.1056/NEJMoa1011205
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 700SD
UT WOS:000285763700004
PM 21091279
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Goncalves, RM
   Salmazi, KC
   Santos, BAN
   Bastos, MS
   Rocha, SC
   Boscardin, SB
   Silber, AM
   Kallas, EG
   Ferreira, MU
   Scopel, KKG
AF Goncalves, Raquel M.
   Salmazi, Karina C.
   Santos, Bianca A. N.
   Bastos, Melissa S.
   Rocha, Sandra C.
   Boscardin, Silvia B.
   Silber, Ariel M.
   Kallas, Esper G.
   Ferreira, Marcelo U.
   Scopel, Kezia K. G.
TI CD4(+) CD25(+) Foxp3(+) Regulatory T Cells, Dendritic Cells, and
   Circulating Cytokines in Uncomplicated Malaria: Do Different Parasite
   Species Elicit Similar Host Responses?
SO INFECTION AND IMMUNITY
LA English
DT Article
ID PLASMODIUM-VIVAX MALARIA; GLOBAL DISTRIBUTION; IN-VITRO; BLOOD;
   FALCIPARUM; CHILDREN; IMMUNITY; CTLA-4; IMMUNOSUPPRESSION; TRANSMISSION
AB Clearing blood-stage malaria parasites without inducing major host pathology requires a finely tuned balance between pro- and anti-inflammatory responses. The interplay between regulatory T (Treg) cells and dendritic cells (DCs) is one of the key determinants of this balance. Although experimental models have revealed various patterns of Treg cell expansion, DC maturation, and cytokine production according to the infecting malaria parasite species, no studies have compared all of these parameters in human infections with Plasmodium falciparum and P. vivax in the same setting of endemicity. Here we show that during uncomplicated acute malaria, both species induced a significant expansion of CD4(+) CD25(+) Foxp3(+) Treg cells expressing the key immunomodulatory molecule CTLA-4 and a significant increase in the proportion of DCs that were plasmacytoid (CD123(+)), with a decrease in the myeloid/plasmacytoid DC ratio. These changes were proportional to parasite loads but correlated neither with the intensity of clinical symptoms nor with circulating cytokine levels. One-third of P. vivax-infected patients, but no P. falciparum-infected subjects, showed impaired maturation of circulating DCs, with low surface expression of CD86. Although vivax malaria patients overall had a less inflammatory cytokine response, with a higher interleukin-10 (IL-10)/tumor necrosis factor alpha (TNF-alpha) ratio, this finding did not translate to milder clinical manifestations than those of falciparum malaria patients. We discuss the potential implications of these findings for species-specific pathogenesis and longlasting protective immunity to malaria.
C1 [Goncalves, Raquel M.; Bastos, Melissa S.; Rocha, Sandra C.; Boscardin, Silvia B.; Silber, Ariel M.; Ferreira, Marcelo U.; Scopel, Kezia K. G.] Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil.
   [Salmazi, Karina C.; Santos, Bianca A. N.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, BR-05508900 Sao Paulo, Brazil.
   [Scopel, Kezia K. G.] Univ Fed Juiz de Fora, Inst Biol Sci, Juiz De Fora, Brazil.
RP Ferreira, MU (corresponding author), Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
EM muferrei@usp.br
RI Silber, Ariel/O-6951-2015; Inbeqmedi, Inct/I-1929-2013; Carvalho, Karina
   IL/J-6789-2012; Ferreira, Marcelo U/G-8289-2011; Kallas, Esper
   G/C-9539-2012; Boscardin, Silvia Beatriz/C-3397-2012; 4,
   INCT/H-4499-2013
OI Silber, Ariel/0000-0003-4528-4732; Carvalho, Karina
   IL/0000-0002-7763-8139; Ferreira, Marcelo U/0000-0002-5293-9090;
   Boscardin, Silvia Beatriz/0000-0002-7845-7110; Rocha,
   Sandra/0000-0003-2978-7671; Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/52771-0,
   08/50645-0]; Conselho Nacional de Desenvolvimento Cientfico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq) [470195/2008-8]
FX This research was supported by Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP; research grants 07/52771-0 and 08/50645-0 to
   M.U.F. and scholarships to R.M.G. and K.K.G.S.) and Conselho Nacional de
   Desenvolvimento Cientfico e Tecnologico (CNPq; research grant
   470195/2008-8 to M.U.F. and scholarships to K.C.S., A.M.S., E.G.K., and
   M.U.F.).
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1
   Braga EM, 2002, AM J TROP MED HYG, V66, P299, DOI 10.4269/ajtmh.2002.66.299
   Breitling LP, 2006, INFECT IMMUN, V74, P5725, DOI 10.1128/IAI.00682-06
   Bueno LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009623
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Casals-Pascual C, 2006, AM J TROP MED HYG, V75, P434, DOI 10.4269/ajtmh.2006.75.434
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   da Silva-Nunes M, 2008, AM J TROP MED HYG, V79, P624, DOI 10.4269/ajtmh.2008.79.624
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   Diallo M, 2008, INT J PARASITOL, V38, P1557, DOI 10.1016/j.ijpara.2008.04.013
   ELHASSAN IM, 1994, AM J TROP MED HYG, V51, P372, DOI 10.4269/ajtmh.1994.51.372
   Finney OC, 2010, TRENDS IMMUNOL, V31, P63, DOI 10.1016/j.it.2009.12.002
   Finney OC, 2010, EUR J IMMUNOL, V40, P47, DOI 10.1002/eji.200939708
   FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698
   Good MF, 2005, ANNU REV IMMUNOL, V23, P69, DOI 10.1146/annurev.immunol.23.021704.115638
   GOONEWARDENE R, 1990, EUR J IMMUNOL, V20, P1387, DOI 10.1002/eji.1830200626
   GREENWOOD BM, 1972, LANCET, V1, P169
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   Jacobs T, 2002, J IMMUNOL, V169, P2323, DOI 10.4049/jimmunol.169.5.2323
   Jago CB, 2004, CLIN EXP IMMUNOL, V136, P463, DOI 10.1111/j.1365-2249.2004.02478.x
   Jangpatarapongsa K, 2008, EUR J IMMUNOL, V38, P2697, DOI 10.1002/eji.200838186
   Kalia S, 2007, DERMATOL THER, V20, P160, DOI 10.1111/j.1529-8019.2007.00131.x
   Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246
   Karunaweera ND, 1998, AM J TROP MED HYG, V58, P204, DOI 10.4269/ajtmh.1998.58.204
   Kassa D, 2006, CLIN VACCINE IMMUNOL, V13, P376, DOI 10.1128/CVI.13.3.376-379.2006
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Langhorne J, 2004, IMMUNOL REV, V201, P35, DOI 10.1111/j.0105-2896.2004.00182.x
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   LOOAREESUWAN S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P44
   McKenzie FE, 2005, J INFECT DIS, V192, P323, DOI 10.1086/431152
   MENDIS KN, 1992, MEM I OSWALDO CRUZ, V87, P51, DOI 10.1590/S0074-02761992000700006
   Minigo G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000402
   Fernandes AAM, 2008, CLIN VACCINE IMMUNOL, V15, P650, DOI 10.1128/CVI.00475-07
   Oderup C, 2006, IMMUNOLOGY, V118, P240, DOI 10.1111/j.1365-2567.2006.02362.x
   Park JW, 2003, ANN TROP MED PARASIT, V97, P339, DOI 10.1179/000349803235002416
   Pichyangkul S, 2004, J IMMUNOL, V172, P4926, DOI 10.4049/jimmunol.172.8.4926
   Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1
   Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x
   Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Schlotmann T, 2000, J INFECT DIS, V182, P367, DOI 10.1086/315690
   Scholzen A, 2010, TRENDS PARASITOL, V26, P16, DOI 10.1016/j.pt.2009.10.004
   Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Steeg C, 2009, J IMMUNOL, V183, P7014, DOI 10.4049/jimmunol.0901422
   Tangpukdee N, 2008, PARASITOL INT, V57, P490, DOI 10.1016/j.parint.2008.06.005
   Urban BC, 2001, BLOOD, V98, P2859, DOI 10.1182/blood.V98.9.2859
   Urban BC, 2006, INFECT IMMUN, V74, P6700, DOI 10.1128/IAI.00861-06
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Win TT, 2002, TROP MED INT HEALTH, V7, P231, DOI 10.1046/j.1365-3156.2002.00857.x
   Wykes MN, 2008, NAT REV MICROBIOL, V6, P864, DOI 10.1038/nrmicro1988
NR 53
TC 57
Z9 57
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD NOV
PY 2010
VL 78
IS 11
BP 4763
EP 4772
DI 10.1128/IAI.00578-10
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 665RB
UT WOS:000283052100035
PM 20713627
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Bimber, BN
   Dudley, DM
   Lauck, M
   Becker, EA
   Chin, EN
   Lank, SM
   Grunenwald, HL
   Caruccio, NC
   Maffitt, M
   Wilson, NA
   Reed, JS
   Sosman, JM
   Tarosso, LF
   Sanabani, S
   Kallas, EG
   Hughes, AL
   O'Connor, DH
AF Bimber, Benjamin N.
   Dudley, Dawn M.
   Lauck, Michael
   Becker, Ericka A.
   Chin, Emily N.
   Lank, Simon M.
   Grunenwald, Haiying L.
   Caruccio, Nicholas C.
   Maffitt, Mark
   Wilson, Nancy A.
   Reed, Jason S.
   Sosman, James M.
   Tarosso, Leandro F.
   Sanabani, Sabri
   Kallas, Esper G.
   Hughes, Austin L.
   O'Connor, David H.
TI Whole-Genome Characterization of Human and Simian Immunodeficiency Virus
   Intrahost Diversity by Ultradeep Pyrosequencing
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; ESCAPE; VARIANTS; HIV-1
AB Rapid evolution and high intrahost sequence diversity are hallmarks of human and simian immunodeficiency virus (HIV/SIV) infection. Minor viral variants have important implications for drug resistance, receptor tropism, and immune evasion. Here, we used ultradeep pyrosequencing to sequence complete HIV/SIV genomes, detecting variants present at a frequency as low as 1%. This approach provides a more complete characterization of the viral population than is possible with conventional methods, revealing low-level drug resistance and detecting previously hidden changes in the viral population. While this work applies pyrosequencing to immunodeficiency viruses, this approach could be applied to virtually any viral pathogen.
C1 [Bimber, Benjamin N.; Becker, Ericka A.; Lank, Simon M.; Wilson, Nancy A.; Reed, Jason S.; O'Connor, David H.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.
   [Dudley, Dawn M.; Lauck, Michael; Chin, Emily N.; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
   [Hughes, Austin L.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
   [Tarosso, Leandro F.; Sanabani, Sabri; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Grunenwald, Haiying L.; Caruccio, Nicholas C.; Maffitt, Mark] Epictr Biotechnol, Madison, WI 53713 USA.
   [Sosman, James M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA.
RP O'Connor, DH (corresponding author), Univ Wisconsin, 555 Sci Dr, Madison, WI 53711 USA.
EM doconnor@primate.wisc.edu
RI Tarosso, Leandro F./H-6267-2012; Kallas, Esper G/C-9539-2012; Sanabani,
   Sabri Saeed/F-5600-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; o'connor,
   david/0000-0003-2139-470X; Kallas, Esper/0000-0003-2026-6925
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R21
   AI068488-02, R21AI073230-02, R01 AI077376, GM-43940]; Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [04/15856-9]; National Center for
   Research Resources (NCRR), NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [P51 RR000167, P40 RR019995]; University of
   Wisconsin-Madison; University of Wisconsin School of Medicine and Public
   Health Medical Education and Research Committee [233KA28]; Research
   Facilities Improvement ProgramUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [RR15459-01, RR020141-01]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P40RR019995, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P40RR019995, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P40RR019995, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P40RR019995, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P40RR019995, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR015459, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P40RR019995,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P40RR019995, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P40RR019995, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI077376, R01AI077376,
   R01AI077376, R21AI073230, R01AI077376, R01AI077376, R21AI068488,
   R21AI073230, R01AI077376, R01AI077376, R21AI068488, R01AI077376] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106, P51OD011106, P51OD011106, P51OD011106, P51OD011106,
   P51OD011106] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) grants
   R21 AI068488-02, R21AI073230-02, and R01 AI077376 and by Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grant 04/15856-9. This
   publication was made possible in part by grants (P51 RR000167 and P40
   RR019995) from the National Center for Research Resources (NCRR), a
   component of the NIH, to the Wisconsin National Primate Research Center
   (WNPRC), University of Wisconsin-Madison. This work was also funded by
   University of Wisconsin School of Medicine and Public Health Medical
   Education and Research Committee/Wisconsin Partnership Program grant
   233KA28. This research was conducted in part at a facility constructed
   with support from Research Facilities Improvement Program grants
   RR15459-01 and RR020141-01. Analysis of data performed by Austin L.
   Hughes was funded in part by grant GM-43940, provided by the NIH.
CR Abegaz WE, 2008, ANTIVIR THER, V13, P89
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Barouch DH, 2004, LANCET, V364, P10, DOI 10.1016/S0140-6736(04)16609-9
   Bimber BN, 2009, J VIROL, V83, P8247, DOI 10.1128/JVI.00897-09
   Borderia AV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010319
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Halvas EK, 2010, J INFECT DIS, V201, P672, DOI 10.1086/650542
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   LI WH, 1978, GENETICS, V90, P349
   Loh L, 2008, AIDS RES HUM RETROV, V24, P1067, DOI 10.1089/aid.2007.0309
   Loh L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040012
   MacLeod IJ, 2010, J CLIN VIROL, V48, P162, DOI 10.1016/j.jcv.2010.03.017
   Peyerl FW, 2005, J CLIN MICROBIOL, V43, P4773, DOI 10.1128/JCM.43.9.4773-4779.2005
   Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736
NR 15
TC 49
Z9 51
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2010
VL 84
IS 22
BP 12087
EP 12092
DI 10.1128/JVI.01378-10
PG 6
WC Virology
SC Virology
GA 670KM
UT WOS:000283420500049
PM 20844037
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Frahm, N
   Janes, H
   Friedrich, DP
   Slichter, C
   Smith, R
   Kallas, E
   Geraghty, D
   Self, S
   McElrath, MJ
AF Frahm, N.
   Janes, H.
   Friedrich, D. P.
   Slichter, C.
   Smith, R.
   Kallas, E.
   Geraghty, D.
   Self, S.
   McElrath, M. J.
TI Beneficial effects of protective HLA class I allele expression and
   breadth of epitope recognition after vaccination on HIV viral load
   post-infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2010
CY SEP 28-OCT 01, 2010
CL Atlanta, GA
C1 [Frahm, N.; Janes, H.; Friedrich, D. P.; Slichter, C.; Smith, R.; Geraghty, D.; Self, S.; McElrath, M. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Kallas, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2010
VL 26
IS 10
BP A115
EP A115
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 665OC
UT WOS:000283044200293
DA 2020-11-26
ER

PT J
AU Carvalho, KI
   Melo, KM
   Bruno, FR
   Snyder-Cappione, JE
   Nixon, DF
   Costa-Carvalho, BT
   Kallas, EG
AF Carvalho, Karina I.
   Melo, Karina M.
   Bruno, Fernanda R.
   Snyder-Cappione, Jennifer E.
   Nixon, Douglas F.
   Costa-Carvalho, Beatriz T.
   Kallas, Esper G.
TI Skewed Distribution of Circulating Activated Natural Killer T (NKT)
   Cells in Patients with Common Variable Immunodeficiency Disorders (CVID)
SO PLOS ONE
LA English
DT Article
ID MEMORY B-CELLS; CHEMOKINE RECEPTOR EXPRESSION; CD1D EXPRESSION; CUTTING
   EDGE; SUBSETS; DEFICIENCY; INFECTION; TRAFFICKING; RESPONSES; CAPACITY
AB Common variable immunodeficiency disorder (CVID) is the commonest cause of primary antibody failure in adults and children, and characterized clinically by recurrent bacterial infections and autoimmune manifestations. Several innate immune defects have been described in CVID, but no study has yet investigated the frequency, phenotype or function of the key regulatory cell population, natural killer T (NKT) cells. We measured the frequencies and subsets of NKT cells in patients with CVID and compared these to healthy controls. Our results show a skewing of NKT cell subsets, with CD4+ NKT cells at higher frequencies, and CD8+ NKT cells at lower frequencies. However, these cells were highly activated and expression CD161. The NKT cells had a higher expression of CCR5 and concomitantly expression of CCR5+CD69+CXCR6 suggesting a compensation of the remaining population of NKT cells for rapid effector action.
C1 [Carvalho, Karina I.; Bruno, Fernanda R.; Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Melo, Karina M.; Costa-Carvalho, Beatriz T.; Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Snyder-Cappione, Jennifer E.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Expt Med, San Francisco, CA USA.
RP Carvalho, KI (corresponding author), Univ Sao Paulo, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Carvalho, Karina IL/J-6789-2012; Kallas, Esper G/C-9539-2012; Nixon,
   Douglas/AAU-5734-2020
OI Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Snyder-Cappione,
   Jennifer/0000-0002-0941-5582; Kallas, Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01-AI52731,
   AI060379]; Fogarty International CenterUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43 TW00003]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brazilian Ministry of
   Science and TechnologyNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI060379, R01AI052731, R21AI060379,
   R01AI060379, R01AI060379, R01AI052731, R01AI052731, R01AI060379,
   R01AI052731, R01AI052731, R01AI060379, R01AI052731] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health, grant
   #R01-AI52731 and AI060379 and The Fogarty International Center, grant
   #D43 TW00003. KIC's Ph.D. scholarship has been provided by the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazilian
   Ministry of Science and Technology. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agematsu K, 2002, CLIN IMMUNOL, V103, P34, DOI 10.1006/clim.2001.5197
   Aspalter RM, 2000, CLIN EXP IMMUNOL, V121, P506, DOI 10.1046/j.1365-2249.2000.01317.x
   Au-Yeung BB, 2007, J IMMUNOL, V179, P111, DOI 10.4049/jimmunol.179.1.111
   Bayry J, 2004, BLOOD, V104, P2441, DOI 10.1182/blood-2004-04-1325
   Berzins SP, 2005, EUR J IMMUNOL, V35, P1399, DOI 10.1002/eji.200425958
   Carnaud C, 1999, J IMMUNOL, V163, P4647
   Chan WL, 2003, IMMUNOL LETT, V85, P159, DOI 10.1016/S0165-2478(02)00223-7
   CHAPEL H, 2008, BLOOD
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Falcone M, 2004, J IMMUNOL, V172, P5908, DOI 10.4049/jimmunol.172.10.5908
   Fulcher DA, 2009, CLIN EXP IMMUNOL, V157, P365, DOI 10.1111/j.1365-2249.2009.03973.x
   Galli G, 2007, P NATL ACAD SCI USA, V104, P3984, DOI 10.1073/pnas.0700191104
   Germanov E, 2008, J IMMUNOL, V181, P81, DOI 10.4049/jimmunol.181.1.81
   Haymore BR, 2008, AUTOIMMUN REV, V7, P309, DOI 10.1016/j.autrev.2007.11.024
   Jiang XF, 2005, J IMMUNOL, V175, P2051, DOI 10.4049/jimmunol.175.4.2051
   Johnston B, 2003, J IMMUNOL, V171, P2960, DOI 10.4049/jimmunol.171.6.2960
   Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902
   Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196
   Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742
   Lang GA, 2008, BLOOD, V111, P2158, DOI 10.1182/blood-2007-10-117309
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Lin YL, 2005, EUR J IMMUNOL, V35, P879, DOI 10.1002/eji.200425495
   Livaditi O, 2007, IMMUNOL LETT, V114, P103, DOI 10.1016/j.imlet.2007.09.006
   Oishi Y, 2001, J RHEUMATOL, V28, P275
   Petri B, 2008, J IMMUNOL, V180, P6439, DOI 10.4049/jimmunol.180.10.6439
   Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Rolf J, 2008, MOL IMMUNOL, V45, P2607, DOI 10.1016/j.molimm.2007.12.022
   Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101
   Sandberg JK, 2003, EUR J IMMUNOL, V33, P588, DOI 10.1002/eji.200323707
   Seino K, 2005, J EXP MED, V202, P1623, DOI 10.1084/jem.20051600
   Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567
   Thomas SY, 2003, J IMMUNOL, V171, P2571, DOI 10.4049/jimmunol.171.5.2571
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
   Viallard JF, 2006, CLIN IMMUNOL, V119, P51, DOI 10.1016/j.clim.2005.11.011
   Vodjgani M, 2007, J INVEST ALLERG CLIN, V17, P321
   Yanagihara Y, 1999, CLIN EXP IMMUNOL, V118, P131
   Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001
NR 38
TC 24
Z9 24
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2010
VL 5
IS 9
AR e12652
DI 10.1371/journal.pone.0012652
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 648IW
UT WOS:000281687200015
PM 20844745
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Romano, CM
   de Matos, AM
   Araujo, ESA
   Villas-Boas, LS
   da Silva, WC
   Oliveira, OMNPF
   Carvalho, KI
   de Souza, ACM
   Rodrigues, CL
   Levi, JE
   Kallas, EG
   Pannuti, CS
AF Romano, Camila Malta
   de Matos, Andreia Manso
   Araujo, Evaldo Stanislau A.
   Villas-Boas, Lucy Santos
   da Silva, Wanessa Cardoso
   Oliveira, Olimpia M. N. P. F.
   Carvalho, Karina I.
   Mamana de Souza, Ana Carolina
   Rodrigues, Celia L.
   Levi, Jose Eduardo
   Kallas, Esper G.
   Pannuti, Claudio Sergio
TI Characterization of Dengue Virus Type 2: New Insights on the 2010
   Brazilian Epidemic
SO PLOS ONE
LA English
DT Article
ID HEMORRHAGIC-FEVER; SEROTYPES; OUTBREAK; AMERICA; STATE
AB Dengue viruses (DENV) serotypes 1, 2, and 3 have been causing yearly outbreaks in Brazil. In this study, we report the reintroduction of DENV2 in the coast of Sao Paulo State. Partial envelope viral genes were sequenced from eighteen patients with dengue fever during the 2010 epidemic. Phylogenetic analysis showed this strain belongs to the American/Asian genotype and was closely related to the virus that circulated in Rio de Janeiro in 2007 and 2008. The phylogeny also showed no clustering by clinical presentation, suggesting that the disease severity could not be explained by distinct variants or genotypes. The time of the most recent common ancestor of American/Asian genotype and the Sao Paulo and Rio de Janeiro (SP/RJ) monophyletic cluster was estimated to be around 40 and 10 years, respectively. Since this virus was first identified in Brazil in 2007, we suggest that it was already circulating in the country before causing the first documented outbreak. This is the first description of the 2010 outbreak in the State of Sao Paulo, Brazil, and should contribute to efforts to control and monitor the spread of DENVs in endemic areas.
C1 [Romano, Camila Malta; Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; Mamana de Souza, Ana Carolina; Rodrigues, Celia L.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, LIMHC, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [de Matos, Andreia Manso; Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Araujo, Evaldo Stanislau A.; Oliveira, Olimpia M. N. P. F.] Hosp Ana Costa, Santos, Brazil.
RP Romano, CM (corresponding author), Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, LIMHC, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM cmromano@usp.br
RI Romano, Camila/ABC-2883-2020; Kallas, Esper G/C-9539-2012; Carvalho,
   Karina IL/J-6789-2012; Pannuti, Claudio/B-7649-2012; Romano, Camila
   M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; Carvalho, Karina
   IL/0000-0002-7763-8139; Kallas, Esper/0000-0003-2026-6925
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Ni-vel Superior, Brazilian Ministry of
   Education; Brazilian Ministry of Science and Technology (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [476088/2009-7]
FX The present work was supported by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry of Science
   and Technology (CNPq, grant #476088/2009-7 to EGK). AMM and EGK's
   scholarships were supported by CNPq. KIC's scholarship was supported by
   the Coordenacao de Aperfeicoamento de Pessoal de Ni-vel Superior,
   Brazilian Ministry of Education. URL of CNPq: URL www.cnpq.br; URL of
   CAPES: www.capes.gov.br. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams B, 2006, P NATL ACAD SCI USA, V103, P14234, DOI 10.1073/pnas.0602768103
   Araujo JMG, 2009, INFECT GENET EVOL, V9, P716, DOI 10.1016/j.meegid.2008.10.005
   Carrington CVF, 2005, J VIROL, V79, P14680, DOI 10.1128/JVI.79.23.14680-14687.2005
   de Melo FL, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000390
   DESOUZA RV, 1995, MEM I OSWALDO CRUZ, V90, P345, DOI 10.1590/S0074-02761995000300006
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Miagostovich MP, 1998, MEM I OSWALDO CRUZ, V93, P625, DOI 10.1590/S0074-02761998000500011
   Mondini A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000448
   NOGUEIRA RMR, 1993, EPIDEMIOL INFECT, V111, P163, DOI 10.1017/S0950268800056788
   Oliveira MF, 2010, EMERG INFECT DIS, V16, P576, DOI 10.3201/eid1603.090996
   PAHO, 2008, NUMB REP CAS DENG DE
   de Figueiredo RMP, 2008, EMERG INFECT DIS, V14, P667, DOI 10.3201/eid1404.071185
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W
   RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vasconcelos Pedro F. Da C., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P253
   Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 29
TC 31
Z9 31
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 28
PY 2010
VL 5
IS 7
AR e11811
DI 10.1371/journal.pone.0011811
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 633QX
UT WOS:000280520100005
PM 20676363
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Tarosso, LF
   Sauer, MM
   Sanabani, S
   Giret, MT
   Tomiyama, HI
   Sidney, J
   Piaskowski, SM
   Diaz, RS
   Sabino, EC
   Sette, A
   Kalil, J
   Watkins, DI
   Kallas, EG
AF Tarosso, Leandro F.
   Sauer, Mariana M.
   Sanabani, Sabri
   Giret, Maria Teresa
   Tomiyama, Helena I.
   Sidney, John
   Piaskowski, Shari M.
   Diaz, Ricardo S.
   Sabino, Ester C.
   Sette, Alessandro
   Kalil-Filho, Jorge
   Watkins, David I.
   Kallas, Esper G.
TI Unexpected Diversity of Cellular Immune Responses against Nef and Vif in
   HIV-1-Infected Patients Who Spontaneously Control Viral Replication
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; HIV-INFECTION; IN-VIVO;
   NONPROGRESSORS; PEPTIDE; VIREMIA; PROTEIN; GENE; HLA
AB Background: HIV-1-infected individuals who spontaneously control viral replication represent an example of successful containment of the AIDS virus. Understanding the anti-viral immune responses in these individuals may help in vaccine design. However, immune responses against HIV-1 are normally analyzed using HIV-1 consensus B 15-mers that overlap by 11 amino acids. Unfortunately, this method may underestimate the real breadth of the cellular immune responses against the autologous sequence of the infecting virus.
   Methodology and Principal Findings: Here we compared cellular immune responses against nef and vif-encoded consensus B 15-mer peptides to responses against HLA class I-predicted minimal optimal epitopes from consensus B and autologous sequences in six patients who have controlled HIV-1 replication. Interestingly, our analysis revealed that three of our patients had broader cellular immune responses against HLA class I-predicted minimal optimal epitopes from either autologous viruses or from the HIV-1 consensus B sequence, when compared to responses against the 15-mer HIV-1 type B consensus peptides.
   Conclusion and Significance: This suggests that the cellular immune responses against HIV-1 in controller patients may be broader than we had previously anticipated.
C1 [Tarosso, Leandro F.; Kalil-Filho, Jorge; Kallas, Esper G.] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
   [Sauer, Mariana M.; Giret, Maria Teresa; Tomiyama, Helena I.; Diaz, Ricardo S.; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Sanabani, Sabri; Sabino, Ester C.] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Piaskowski, Shari M.; Watkins, David I.] Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53706 USA.
RP Tarosso, LF (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Sanabani, Sabri Saeed/F-5600-2012; Sabino, Ester Cerdeira/F-7750-2010;
   Diaz, Ricardo/K-3978-2012; Tarosso, Leandro F./H-6267-2012; Kallas,
   Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R24 RR015371];
   Ministry of HealthMinistry of Health - Turkey [914/BRA/3014-UNESCO]; Sao
   Paulo City Health Department [2004-0.168.922-7]; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [04/15856-9]; Coordenacao de Aperfeicoamento de
   Pessoal de Ni-vel Superior (CAPES), Brazilian Ministry of
   EducationCAPES; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR) [R24RR015371,
   R24RR015371, R24RR015371, R24RR015371, R24RR015371, R24RR015371,
   R24RR015371, R24RR015371, R24RR015371, R24RR015371, R24RR015371,
   R24RR015371, R24RR015371] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI073230, R21AI073230] Funding Source: NIH RePORTER
FX This study was supported by the National Institutes of Health Grant R24
   RR015371 (to D. I. W.), Brazilian Program for STD and AIDS - Ministry of
   Health Grant 914/BRA/3014-UNESCO and the Sao Paulo City Health
   Department Grant 2004-0.168.922-7 (to E. G. K.), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo Grant 04/15856-9 (to E. G. K.,
   E. C. S., and R. S. D.). L. F. T., M. T. M. G., and M. M. S. were
   supported by the Coordenacao de Aperfeicoamento de Pessoal de Ni-vel
   Superior (CAPES), Brazilian Ministry of Education. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. The following reagents were obtained
   through the NIH AIDS Research and Reference Reagent Program, Division of
   AIDS, NIAID, NIH: complete HIV-1 Consensus subtype B peptide sets
   (15-mers overlapping by 11 acids) of Nef (Cat# 5189, Lot# 8) and Vif
   (Cat# 6446, Lot# 7).
CR Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000
   Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996
   Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Harrer T, 1996, J IMMUNOL, V156, P2616
   Hassaine G, 2000, VIROLOGY, V276, P169, DOI 10.1006/viro.2000.0543
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kern F, 2000, EUR J IMMUNOL, V30, P1676, DOI 10.1002/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V
   Kiecker F, 2004, HUM IMMUNOL, V65, P523, DOI 10.1016/j.humimm.2004.02.017
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   KORBER BT, 2005, HIV MOL IMMUNOLOGY 2
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004
   Lum JJ, 2003, J CLIN INVEST, V111, P1547, DOI 10.1172/JCI200316233
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   Miura T, 2008, J VIROL, V82, P8422, DOI 10.1128/JVI.00535-08
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Peters B, 2006, PLOS COMPUT BIOL, V2, P574, DOI 10.1371/journal.pcbi.0020065
   Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Saez-Cirion A, 2007, TRENDS IMMUNOL, V28, P532, DOI 10.1016/j.it.2007.09.002
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999
   SOVA P, 1995, J VIROL, V69, P2557, DOI 10.1128/JVI.69.4.2557-2564.1995
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Walker Bruce D, 2007, Top HIV Med, V15, P134
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006
   You LW, 2007, LECT NOTES COMPUT SC, V4774, P337
   Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254
   Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a
NR 48
TC 10
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2010
VL 5
IS 7
AR e11436
DI 10.1371/journal.pone.0011436
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 619YH
UT WOS:000279465700017
PM 20625436
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Silva, MD
   Bastos, M
   Netto, EM
   Gouvea, NAD
   Torres, AJL
   Kallas, E
   Watkins, DI
   Altfeld, M
   Brites, C
AF Silva, Marcio de Oliveira
   Bastos, Milena
   Netto, Eduardo Martins
   de Lima Gouvea, Nancy Alves
   Leite Torres, Alex Jose
   Kallas, Esper
   Watkins, David I.
   Altfeld, Marcus
   Brites, Carlos
TI Acute HIV infection with rapid progression to AIDS
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; acute infection; progression; AIDS
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HLA
AB Acute HIV infection is rarely recognized as the signs and symptoms are normally unspecific and can persist for days or weeks. The normal HIV course is characterized by a progressive loss of CD4+ cells, which normally leads to severe immunodeficiency after a variable time interval. The mean time from initial infection to development of clinical AIDS is approximately 8-10 years, but it is variable among individuals and depends on a complex interaction between virus and host. Here we describe an extraordinary case of a man who developed Pneumocisits jiroveci pneumonia within one month after sexual exposure to HIV-1, and then presented with 3 consecutive CD4 counts bellow 200 cells/mm(3) within 3 months, with no other opportunistic disease. Although antiretroviral therapy (AZT+3TC+ATZ/r) was started, with full adherence of the patient, and genotyping indicating no primary antiretroviral resistance mutations, he required more than six months to have a CD4 restoration to levels above 200 cells/mm(3) and 10 months to HIV-RNA to become undetectable.
C1 [Silva, Marcio de Oliveira; Bastos, Milena; Netto, Eduardo Martins; Leite Torres, Alex Jose; Brites, Carlos] Univ Fed Bahia, BR-41170290 Salvador, BA, Brazil.
   [de Lima Gouvea, Nancy Alves; Kallas, Esper] Fac Med, Sao Paulo, Brazil.
   [Altfeld, Marcus] Massachusetts Gen Hosp, Infect Dis Unit, Partners AIDS Res Ctr, Boston, MA 02114 USA.
RP Silva, MD (corresponding author), Rua Jorge Simoes 156 Ed San Juan,Apt 302, BR-40415720 Salvador, BA, Brazil.
EM oliveiras_m@yahoo.com.br
RI Netto, Eduardo/D-1432-2013; Torres, Alex JL/Q-6186-2018; Kallas, Esper
   G/C-9539-2012; Altfeld, Marcus/AAE-7306-2019
OI Netto, Eduardo/0000-0003-1691-6761; Altfeld, Marcus/0000-0001-5972-2997;
   Kallas, Esper/0000-0003-2026-6925
CR BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198
   GANGE S, 2005, S CAS RAP PROGR MULT
   Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203
   HARRIGAN R, 16 C RETR OPP INF CR
   ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360
   Magierowska M, 1999, BLOOD, V93, P936, DOI 10.1182/blood.V93.3.936.403k08_936_941
   Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)74227-6
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367
   PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183
   SAHMOUD T, 1993, AIDS, V7, P497, DOI 10.1097/00002030-199304000-00007
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737
   VENTO S, 1993, LANCET, V342, P24, DOI 10.1016/0140-6736(93)91884-O
NR 20
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2010
VL 14
IS 3
BP 291
EP 293
DI 10.1590/S1413-86702010000300016
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 648KU
UT WOS:000281693400016
PM 20835515
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Fomin, AF
   Pastorino, A
   Carneiro-Sampaio, M
   Kayser, C
   Kallas, E
   Jacob, C
AF Fomin, A. F.
   Pastorino, A.
   Carneiro-Sampaio, M.
   Kayser, C.
   Kallas, E.
   Jacob, C.
TI Chronic Mucocutaneous Candidiasis With Possible Autosomal Dominant
   Inheritance Complicated by Type 1 Diabetes
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 1st North American Primary Immune Deficiency National Conference
CY MAY 20-23, 2010
CL Philadelphia, PA
C1 [Fomin, A. F.; Pastorino, A.; Carneiro-Sampaio, M.; Kayser, C.; Kallas, E.; Jacob, C.] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 060, Japan.
   [Fomin, A. F.; Pastorino, A.; Carneiro-Sampaio, M.; Kayser, C.; Kallas, E.; Jacob, C.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAY
PY 2010
VL 135
IS 2
SI SI
MA 55
BP 307
EP 307
PG 1
WC Immunology
SC Immunology
GA 588ZH
UT WOS:000277112900067
DA 2020-11-26
ER

PT J
AU Fomin, AF
   Pastorino, A
   Carneiro-Sampaio, M
   Kayser, C
   Kallas, E
   Jacob, C
AF Fomin, A. F.
   Pastorino, A.
   Carneiro-Sampaio, M.
   Kayser, C.
   Kallas, E.
   Jacob, C.
TI Assessment of Thymic Function in Patients With Digeorge Syndrome
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 1st North American Primary Immune Deficiency National Conference
CY MAY 20-23, 2010
CL Philadelphia, PA
C1 [Fomin, A. F.; Pastorino, A.; Carneiro-Sampaio, M.; Kayser, C.; Kallas, E.; Jacob, C.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAY
PY 2010
VL 135
IS 2
SI SI
MA 54
BP 307
EP 307
PG 1
WC Immunology
SC Immunology
GA 588ZH
UT WOS:000277112900066
DA 2020-11-26
ER

PT J
AU Long, BR
   Erickson, AE
   Chapman, JM
   Barbour, JD
   Vu, BAN
   Ho, EL
   Lanier, LL
   Sauer, MM
   Carvalho, KI
   Nixon, DF
   Kallas, EG
AF Long, Brian R.
   Erickson, Ann E.
   Chapman, Joan M.
   Barbour, Jason D.
   Vu, Bien-Aimee N.
   Ho, Emily L.
   Lanier, Lewis L.
   Sauer, Mariana M.
   Carvalho, Karina I.
   Nixon, Douglas F.
   Kallas, Esper G.
TI Increased number and function of natural killer cells in human
   immunodeficiency virus 1-positive subjects co-infected with herpes
   simplex virus 2
SO IMMUNOLOGY
LA English
DT Article
DE CD107; herpes simplex virus 2; human immunodeficiency virus; killer cell
   immunoglobulin-like receptor; natural killer cells
ID ACUTE HIV-1 INFECTION; NK CELLS; TYPE-2 INFECTION; HSV-2 INFECTION;
   HLA-B; INNATE; WOMEN; ACQUISITION; PROGRESSION; PROTECTION
AB P>Natural killer (NK) cells bridge the interface between innate and adaptive immunity and are implicated in the control of herpes simplex virus 2 (HSV-2) infection. In subjects infected with human immunodeficiency virus 1 (HIV-1), the critical impact of the innate immune response on disease progression has recently come into focus. Higher numbers of NK cells are associated with lower HIV-1 plasma viraemia. Individuals with the compound genotype of killer cell immunoglobulin-like receptor (KIR) 3DS1 and human leucocyte antigen (HLA)-Bw4-80I, or who have alleles of KIR3DL1 that encode proteins highly expressed on the NK cell surface, have a significant delay in disease progression. We studied the effect of HSV-2 co-infection in HIV-1-infected subjects, and show that HSV-2 co-infection results in a pan-lymphocytosis, with elevated absolute numbers of CD4+ and CD8+ T cells, and NK cells. The NK cells in HSV-2 co-infected subjects functioned more efficiently, with an increase in degranulation after in vitro stimulation. The number of NK cells expressing the activating receptors NKp30 and NKp46, and expressing KIR3DL1 or KIR3DS1, was inversely correlated with HIV-1 plasma viral load in subjects mono-infected with HIV-1, but not in subjects co-infected with HSV-2. This suggests that HSV-2 infection mediates changes within the NK cell population that may affect immunity in HIV-1 infection.
C1 [Long, Brian R.; Erickson, Ann E.; Chapman, Joan M.; Vu, Bien-Aimee N.; Ho, Emily L.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, Dept Med, San Francisco, CA 94110 USA.
   [Barbour, Jason D.] Univ Calif San Francisco, Div HIV AIDS, Dept Med, San Francisco Gen Hosp, San Francisco, CA 94110 USA.
   [Lanier, Lewis L.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94110 USA.
   [Lanier, Lewis L.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94110 USA.
   [Sauer, Mariana M.; Carvalho, Karina I.; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Nixon, DF (corresponding author), Univ Calif San Francisco, Div Expt Med, Dept Med, 1001 Potrero Ave,Bldg 3,Room 603, San Francisco, CA 94110 USA.
EM douglas.nixon@ucsf.edu; esper.kallas@gmail.com
RI Nixon, Douglas/AAU-5734-2020; Lanier, Lewis L/E-2139-2014; Carvalho,
   Karina IL/J-6789-2012; Kallas, Esper G/C-9539-2012
OI Nixon, Douglas/0000-0002-2801-1786; Lanier, Lewis L/0000-0003-1308-3952;
   Carvalho, Karina IL/0000-0002-7763-8139; Kallas,
   Esper/0000-0003-2026-6925
FU National Institute of Allergies and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [NIAID AI060379, AI052731, AI064520, AI64520, AI-066917, AI-076014];
   Brazilian Program; Ministry of HealthMinistry of Health - Turkey
   [914/BRA/3014 - UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15 856-9/Kallas]; John E. Fogarty International CenterUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43 TW00003]; AIDS Research
   Institute of the AIDS Biology Program at UCSF; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of EducationCAPES; FOGARTY INTERNATIONAL CENTERUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI060379, R37AI052731, R01AI052731,
   P01AI064520, P01AI064520, P01AI064520, R01AI060379, R37AI052731,
   K01AI066917, P01AI064520, R01AI052731, P01AI064520, K01AI066917,
   P01AI064520, R37AI052731, P01AI064520, P01AI064520, R01AI052731,
   P01AI064520, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, R21AI060379, R01AI060379, K01AI066917, P01AI064520,
   R01AI052731, P01AI064520, P01AI064520, P01AI064520, R37AI052731,
   R01AI060379, P01AI064520, P01AI064520, R37AI052731, R21AI076014,
   R37AI052731, R01AI052731, P01AI064520, R37AI052731, P01AI064520,
   P01AI064520, K01AI066917, P01AI064520, P01AI064520, R37AI052731,
   P01AI064520, P01AI064520, R01AI060379, P01AI064520, P01AI064520,
   R21AI076014, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   P01AI064520, R37AI052731, P01AI064520, P01AI064520, R37AI052731,
   R01AI052731, P01AI064520, K01AI066917] Funding Source: NIH RePORTER
FX Support for this work was provided by the National Institute of
   Allergies and Infectious Diseases (grants NIAID AI060379, AI052731 and
   AI064520 to DFN and AI64520 to LLL). JDB is supported by AI-066917 and
   AI-076014 (NIAID). Additional support was provided by the Brazilian
   Program for STD and AIDS, Ministry of Health (914/BRA/3014 -
   UNESCO/Kallas), the Sao Paulo City Health Department
   (2004-0.168.922-7/Kallas), Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (04/15 856-9/Kallas), the John E. Fogarty International Center
   (D43 TW00003) and the AIDS Research Institute of the AIDS Biology
   Program at UCSF (grant to DFN). MMS and KIC's scholarships were
   supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES), Brazilian Ministry of Education. LLL is an American
   Cancer Society Research Professor. We thank Skip Virgin for helpful
   discussions.
CR Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100
   Alter G, 2004, J IMMUNOL, V173, P5305, DOI 10.4049/jimmunol.173.8.5305
   Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008
   Alter G, 2007, J IMMUNOL, V178, P7658, DOI 10.4049/jimmunol.178.12.7658
   Alter G, 2007, J INFECT DIS, V195, P1452, DOI 10.1086/513878
   Alter G, 2006, CURR MOL MED, V6, P621, DOI 10.2174/156652406778195035
   Ashkar AA, 2003, J VIROL, V77, P10168, DOI 10.1128/JVI.77.18.10168-10171.2003
   Baeten JM, 2008, J INFECT DIS, V198, P1804, DOI 10.1086/593214
   Ballan WM, 2007, J IMMUNOL, V179, P3362, DOI 10.4049/jimmunol.179.5.3362
   Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189
   BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605
   Bruunsgaard H, 1997, SCAND J IMMUNOL, V46, P91, DOI 10.1046/j.1365-3083.1997.d01-98.x
   Carr WH, 2007, J IMMUNOL, V178, P647, DOI 10.4049/jimmunol.178.2.647
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   CHING C, 1979, INFECT IMMUN, V26, P49, DOI 10.1128/IAI.26.1.49-56.1979
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Dalloul A, 2004, J CLIN VIROL, V30, P329, DOI 10.1016/j.jcv.2003.11.014
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7
   Gill N, 2007, EUR J IMMUNOL, V37, P2529, DOI 10.1002/eji.200636997
   Guma M, 2006, BLOOD, V107, P3624, DOI 10.1182/blood-2005-09-3682
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0
   Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222
   Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526
   Long BR, 2008, J VIROL, V82, P4785, DOI 10.1128/JVI.02449-07
   Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102
   Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100
   McMahon MA, 2008, J BIOL CHEM, V283, P31289, DOI 10.1074/jbc.C800188200
   Meier UC, 2005, J VIROL, V79, P12365, DOI 10.1128/JVI.79.19.12365-12374.2005
   Michaelsson J, 2008, J INFECT DIS, V197, P117, DOI 10.1086/524141
   Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607
   Schacker T, 1998, J INFECT DIS, V178, P1616, DOI 10.1086/314486
   Schacker T, 2002, J INFECT DIS, V186, P1718, DOI 10.1086/345771
   Strick LB, 2006, CLIN INFECT DIS, V43, P347, DOI 10.1086/505496
   van Stijn A, 2008, J IMMUNOL, V180, P4550, DOI 10.4049/jimmunol.180.7.4550
   Wright PW, 2003, CLIN INFECT DIS, V36, P207, DOI 10.1086/345440
NR 40
TC 11
Z9 12
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD FEB
PY 2010
VL 129
IS 2
BP 186
EP 196
DI 10.1111/j.1365-2567.2009.03170.x
PG 11
WC Immunology
SC Immunology
GA 541YQ
UT WOS:000273458000005
PM 19824915
OA Green Published
DA 2020-11-26
ER

PT J
AU Mast, TC
   Kierstead, L
   Gupta, SB
   Nikas, AA
   Kallas, EG
   Novitsky, V
   Mbewe, B
   Pitisuttithum, P
   Schechter, M
   Vardas, E
   Wolfe, ND
   Aste-Amezaga, M
   Casimiro, DR
   Coplan, P
   Straus, WL
   Shiver, JW
AF Mast, T. Christopher
   Kierstead, Lisa
   Gupta, Swati B.
   Nikas, Alexander A.
   Kallas, Esper G.
   Novitsky, Vladimir
   Mbewe, Bernard
   Pitisuttithum, Punee
   Schechter, Mauro
   Vardas, Eftyhia
   Wolfe, Nathan D.
   Aste-Amezaga, Miguel
   Casimiro, Danilo R.
   Coplan, Paul
   Straus, Walter L.
   Shiver, John W.
TI International epidemiology of human pre-existing adenovirus (Ad) type-5,
   type-6, type-26 and type-36 neutralizing antibodies: Correlates of high
   Ad5 titers and implications for potential HIV vaccine trials
SO VACCINE
LA English
DT Article
DE Vector; Adenovirus; HIV; Vaccine
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REPLICATION-DEFECTIVE ADENOVIRUS;
   VECTOR-BASED VACCINES; RHESUS-MONKEYS; ANTI-AD5 IMMUNITY;
   HEALTHY-ADULTS; GENE-TRANSFER; IMMUNOGENICITY; INFECTION; RESPONSES
AB Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors Few studies have described the international epidemiology of pre-existing immunity to adenoviruses We enrolled 1904 participants in a cross-sectional serological survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing antibodies (NA) for adenovirus types Ad5, Ad6, Ad26 and Ad36 Clinical trial samples were used to assess NA titers from the US and Europe The proportions of participants that were negative were 14 8%(Ad5), 31 5%(Ad6),41 2%(Ad26) and 53.6% (Ad36) Adenovirus NA titers varied by geographic location and were higher in non-US and non-European settings, especially Thailand In multivariate logistic regression analysis, geographic setting (non-US and non-European settings) was statistically significantly associated with having higher Ad5 titers, participants from Thailand had the highest odds of having high Ad5 titers (adjusted OR = 3 53,95% CI 224,557) Regardless of location. titers of Ad5NA were the highest and Ad36 NA were the lowest Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations (C) 2009 Published by Elsevier Ltd
C1 [Mast, T. Christopher; Kierstead, Lisa; Gupta, Swati B.; Nikas, Alexander A.; Aste-Amezaga, Miguel; Casimiro, Danilo R.; Coplan, Paul; Straus, Walter L.; Shiver, John W.] Merck Res Labs, West Point, PA USA.
   [Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Novitsky, Vladimir] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Mbewe, Bernard] Malawi Coll Med, Blantyre, Malawi.
   [Pitisuttithum, Punee] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil.
   [Vardas, Eftyhia] Univ Witwatersrand, JHB, Perinatal HIV Res Unit, ZA-2050 Wits, South Africa.
   [Wolfe, Nathan D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Mast, TC (corresponding author), Merck & Co Inc, POB 1000,UG1D-60, N Wales, PA 19454 USA.
RI Kallas, Esper G/C-9539-2012; Schechter, Mauro/AAG-7445-2020
OI Coplan, Paul/0000-0002-7078-7780; Kallas, Esper/0000-0003-2026-6925;
   Vardas, Eftyhia/0000-0002-7804-878X
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Aste-Amezaga M, 2004, HUM GENE THER, V15, P293, DOI 10.1089/104303404322886147
   Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149
   Barouch DH, 2004, J IMMUNOL, V172, P6290, DOI 10.4049/jimmunol.172.10.6290
   Barouch DH, 2003, J VIROL, V77, P8729, DOI 10.1128/JVI.77.16.8729-8735.2003
   BAURN SG, 2009, PRINCIPLES PRACTICE
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Capone S, 2006, J VIROL, V80, P1688, DOI 10.1128/JVI.80.4.1688-1699.2006
   Casimiro DR, 2004, J VIROL, V78, P11434, DOI 10.1128/JVI.78.20.11434-11438.2004
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994
   DAMBROSIO E, 1982, J HYG-CAMBRIDGE, V89, P155, DOI 10.1017/S0022172400070650
   Harro CD, 2009, AIDS RES HUM RETROV, V25, P103, DOI 10.1089/aid.2008.0212
   Harvey BG, 2002, HUM GENE THER, V13, P15, DOI 10.1089/10430340152712638
   Havenga M, 2006, J GEN VIROL, V87, P2135, DOI 10.1099/vir.0.81956-0
   Kolavic-Gray SA, 2002, CLIN INFECT DIS, V35, P808, DOI 10.1086/342573
   Kostense S, 2004, AIDS, V18, P1213, DOI 10.1097/00002030-200405210-00019
   Koup RA, 2009, J VIROL, V83, P6318, DOI 10.1128/JVI.00384-09
   Limbach KJ, 2009, PARASITE IMMUNOL, V31, P501, DOI 10.1111/j.1365-3024.2009.01141.x
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Nanda A, 2005, J VIROL, V79, P14161, DOI 10.1128/JVI.79.22.14161-14168.2005
   Nwanegbo E, 2004, CLIN DIAGN LAB IMMUN, V11, P351, DOI 10.1128/CDLI.11.2.351-357.2004
   Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993
   Quirk EK, 2008, CLIN INFECT DIS, V47, P1593, DOI 10.1086/593313
   Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Sester M, 2002, J INFECT DIS, V185, P1379, DOI 10.1086/340502
   Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344
   Slack Catherine, 2007, BMC Med Ethics, V8, P5, DOI 10.1186/1472-6939-8-5
   Sumida SM, 2005, J IMMUNOL, V174, P7179, DOI 10.4049/jimmunol.174.11.7179
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013
   Thorner AR, 2006, J CLIN MICROBIOL, V44, P3781, DOI 10.1128/JCM.01249-06
   Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003
   WADELL G, 1984, MOL BIOL ADNOVIRUSES, V2, P205
   Yang ZY, 2003, J VIROL, V77, P799, DOI 10.1128/JVI.77.1.799-803.2003
NR 36
TC 163
Z9 165
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2010
VL 28
IS 4
BP 950
EP 957
DI 10.1016/j.vaccine.2009.10.145
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 560ZB
UT WOS:000274943300017
PM 19925902
DA 2020-11-26
ER

PT J
AU Sucupira, MCA
   Sanabani, S
   Tomiyama, H
   Sauer, MM
   Sabino, EC
   Janini, LM
   Kallas, EG
   Diaz, RS
AF Sucupira, M. C. A.
   Sanabani, S.
   Tomiyama, H.
   Sauer, M. M.
   Sabino, E. C.
   Janini, L. M.
   Kallas, E. G.
   Diaz, R. S.
TI Faster HIV-1 disease progression among Brazilian recently infected
   individual harbouring CXCR4-using strains
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT Workshop on International HIV and Hepatitis Virus Drug Resistance and
   Curative Strategies
CY JUL 08-12, 2010
CL Dubrovnik, CROATIA
SP Univ California, Sch Med
C1 [Sucupira, M. C. A.; Tomiyama, H.; Sauer, M. M.; Janini, L. M.; Kallas, E. G.; Diaz, R. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Sanabani, S.; Sabino, E. C.] Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Sabino, Ester Cerdeira/F-7750-2010; Janini,
   Luiz Mario R/E-9700-2012; Diaz, Ricardo/K-3978-2012; Sanabani, Sabri
   Saeed/F-5600-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Sanabani, Sabri
   Saeed/0000-0002-8876-8262
NR 0
TC 1
Z9 1
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2010
VL 15
SU 2
BP A163
EP A163
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 722KO
UT WOS:000287431300135
DA 2020-11-26
ER

PT J
AU Sucupira, MCA
   Sanabam, S
   Tomiyama, H
   Sauer, MM
   Sabino, EC
   Jamni, LM
   Kallas, EG
   Diaz, RS
AF Sucupira, M. C. A.
   Sanabam, S.
   Tomiyama, H.
   Sauer, M. M.
   Sabino, E. C.
   Jamni, L. M.
   Kallas, E. G.
   Diaz, R. S.
TI Faster HIV-1 disease progression among Brazilian recently infected
   individual harbouring CXCR4-using strains
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT International HIV and Hepatitis Virus Drug Resistance and Curative
   Strategies Workshop
CY JUN 08-12, 2010
CL Dubrovnik, CROATIA
C1 [Sucupira, M. C. A.; Tomiyama, H.; Sauer, M. M.; Jamni, L. M.; Kallas, E. G.; Diaz, R. S.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Sanabam, S.; Sabino, E. C.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Sabino, Ester Cerdeira/F-7750-2010; Janini,
   Luiz Mario R/E-9700-2012; Diaz, Ricardo/K-3978-2012; Sanabani, Sabri
   Saeed/F-5600-2012
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Sanabani, Sabri
   Saeed/0000-0002-8876-8262
NR 0
TC 1
Z9 1
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2010
VL 15
IS 4
MA 131
BP A163
EP A163
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 629QW
UT WOS:000280215800150
DA 2020-11-26
ER

PT J
AU Biatto, JFP
   Costa, ELV
   Pastore, L
   Kallas, EG
   Deheinzelin, D
   Schettino, G
AF Biatto, Jair F. P.
   Costa, Eduardo L. V.
   Pastore, Laerte
   Kallas, Esper G.
   Deheinzelin, Daniel
   Schettino, Guilherme
TI Prone position ventilation, recruitment maneuver and intravenous
   zanamivir in severe refractory hypoxemia caused by influenza A (H1N1)
SO CLINICS
LA English
DT Letter
C1 [Biatto, Jair F. P.; Costa, Eduardo L. V.; Pastore, Laerte; Kallas, Esper G.; Deheinzelin, Daniel; Schettino, Guilherme] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
RP Biatto, JFP (corresponding author), Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
EM guilherme.schettino@hsl.org.br
RI Kallas, Esper G/C-9539-2012; Costa, Eduardo/K-5841-2012
OI Costa, Eduardo/0000-0002-6941-3626; Kallas, Esper/0000-0003-2026-6925
CR Gordon SM, 2009, CLEV CLIN J MED, V76, P577, DOI 10.3949/ccjm.76a.05009
   HODGSON C, 2009, COCHRANE DB SYST REV, V15
   Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695
   Kidd IM, 2009, LANCET, V374, P1036, DOI 10.1016/S0140-6736(09)61528-2
   Martinez O, 2009, ARCH BRONCONEUMOL, V45, P291, DOI 10.1016/j.arbres.2008.05.010
   Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
   Oczenski W, 2005, CRIT CARE MED, V33, P54, DOI 10.1097/01.CCM.0000149853.47651.F0
   Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252
   Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044
   SMITH TF, 1976, NEW ENGL J MED, V294, P708, DOI 10.1056/NEJM197603252941308
NR 10
TC 5
Z9 6
U1 0
U2 3
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2010
VL 65
IS 11
BP 1211
EP 1213
DI 10.1590/S1807-59322010001100026
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 736JW
UT WOS:000288492000026
PM 21243298
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ndhlovu, LC
   Leal, FE
   Eccles-James, IG
   Jha, AR
   Lanteri, M
   Norris, PJ
   Barbour, JD
   Wachter, DJ
   Andersson, J
   Tasken, K
   Torheim, EA
   Aandahl, EM
   Kallas, EG
   Nixon, DF
AF Ndhlovu, Lishomwa C.
   Leal, Fabio E.
   Eccles-James, Ijeoma G.
   Jha, Aashish R.
   Lanteri, Marion
   Norris, Philip J.
   Barbour, Jason D.
   Wachter, Douglas J.
   Andersson, Jan
   Tasken, Kjetil
   Torheim, Eirik A.
   Aandahl, Einar M.
   Kallas, Esper G.
   Nixon, Douglas F.
TI A novel human CD4(+) T-cell inducer subset with potent immunostimulatory
   properties
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE CD25; CD39; FOXP3; Inducer; Proliferation
ID IMMUNE SUPPRESSION; EXPRESSION; INFECTION; FOXP3; CD39; INHIBITION;
   TOLERANCE; ADENOSINE; PATTERNS
AB The complexity of immunoregulation has focused attention on the CD4(+) T "suppressor" regulatory cell (T-reg), which helps maintain balance between immunity and tolerance. An immunoregulatory T-cell population that upon activation amplifies cellular immune responses was described in murine models more than 30 years ago; however, no study has yet identified a naturally occurring T "inducer" cell type. Here, we report that the ectoenzyme CD39/NTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase 1) helps to delineate a novel population of human "inducer" CD4(+) T cells (T-ind) that significantly increases the proliferation and cytokine production of responder T cells in a dose-dependent manner. Furthermore, this unique T-ind subset produces a distinct repertoire of cytokines in comparison to the other CD4(+) T-cell subsets. We propose that this novel CD4(+) T-cell population counterbalances the suppressive activity of suppressor T-reg in peripheral blood and serves as a calibrator of immunoregulation.
C1 [Ndhlovu, Lishomwa C.; Leal, Fabio E.; Eccles-James, Ijeoma G.; Jha, Aashish R.; Wachter, Douglas J.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94110 USA.
   [Leal, Fabio E.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Lanteri, Marion; Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94110 USA.
   [Barbour, Jason D.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94110 USA.
   [Andersson, Jan] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden.
   [Andersson, Jan] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
   [Tasken, Kjetil; Torheim, Eirik A.; Aandahl, Einar M.] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway.
   [Tasken, Kjetil; Torheim, Eirik A.; Aandahl, Einar M.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway, Oslo, Norway.
RP Ndhlovu, LC (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, 1001 Potrero Ave, San Francisco, CA 94110 USA.
EM lndhlovu@medsfgh.ucsf.edu
RI n, l/AAX-3992-2020; Nixon, Douglas/AAU-5734-2020; Kallas, Esper
   G/C-9539-2012
OI Nixon, Douglas/0000-0002-2801-1786; Ndhlovu,
   Lishomwa/0000-0001-5427-4187; Tasken, Kjetil/0000-0003-2841-4697; Jha,
   Aashish/0000-0003-3227-1086; Aandahl, Einar Martin/0000-0002-0115-8382;
   Kallas, Esper/0000-0003-2026-6925
FU National Institutes of Health, University of California, San
   Francisco-Gladstone Institute of Virology & Immunology CenterUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USAUniversity of California System [P30 AI027763,
   AI060379, AI068498, AI066917, AI042590]; AIDS Research Institute (ARI);
   National Institutes of Health, University of California, Berkeley,
   School of Public Health, Division of Epidemiology, Berkeley,
   CaliforniaUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USAUniversity of California System
   [94720-7360]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI060379, P30AI027763, U01AI042590,
   P30AI027763, R01AI068498, P30AI027763, P30AI027763, P30AI027763,
   K01AI066917, P30AI027763, P30AI027763, P30AI027763, U01AI042590,
   P30AI027763, P30AI027763, R01AI076059, P30AI027763, R01AI068498,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI042590, R01AI068498, P30AI027763, U01AI042590,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R01AI076059, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI042590, P30AI027763,
   R01AI076059, P30AI027763, P30AI027763, K01AI066917, P30AI027763,
   U01AI042590, P30AI027763, R01AI076059, U01AI042590, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U01AI042590, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R01AI060379, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, R01AI076059, R01AI068498, P30AI027763,
   U01AI042590, K01AI066917, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R01AI076059, R01AI076059,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R01AI076059,
   U01AI042590, P30AI027763, P30AI027763, R01AI060379, P30AI027763,
   P30AI027763, K01AI066917, P30AI027763, P30AI027763, R01AI060379,
   P30AI027763, P30AI027763, R21AI060379, P30AI027763, U01AI042590,
   P30AI027763, P30AI027763, U01AI042590, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI042590,
   U01AI042590, P30AI027763, P30AI027763, U01AI042590, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   U01AI042590, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R01AI076059, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, U01AI042590, U01AI042590, P30AI027763, P30AI027763,
   R01AI060379, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   K01AI066917, P30AI027763, U01AI042590, P30AI027763, P30AI027763,
   R01AI076059, R01AI076059, U01AI042590, P30AI027763, U01AI042590,
   U01AI042590, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, U01AI042590, U01AI042590] Funding
   Source: NIH RePORTER
FX This research was supported by funds the National Institutes of Health,
   University of California, San Francisco-Gladstone Institute of Virology
   & Immunology Center for AIDS Research (P30 AI027763), the UCSF AIDS
   Biology Program of the AIDS Research Institute (ARI), NIH grants
   (AI060379, AI068498, AI066917 and AI042590), the Fogarty international
   Center of the National Institutes of Health, University of California,
   Berkeley, School of Public Health, Division of Epidemiology, Berkeley,
   California 94720-7360.
CR Aandahl EM, 2002, J IMMUNOL, V169, P802, DOI 10.4049/jimmunol.169.2.802
   Athanassakis I, 2002, IMMUNOL LETT, V84, P179, DOI 10.1016/S0165-2478(02)00182-7
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181
   Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512
   Enjyoji K, 1999, NAT MED, V5, P1010
   GERSHON RK, 1981, J EXP MED, V153, P1533, DOI 10.1084/jem.153.6.1533
   GREEN DR, 1983, J MOL CELL IMMUNOL, V1, P19
   Grinthal Alison, 2006, Purinergic Signal, V2, P391, DOI 10.1007/s11302-005-5907-8
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   Lehner T, 2008, IMMUNOLOGY, V123, P40, DOI 10.1111/j.1365-2567.2007.02780.x
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Musi E, 2007, ARCH BIOCHEM BIOPHYS, V461, P30, DOI 10.1016/j.abb.2007.02.009
   NABEL G, 1981, P NATL ACAD SCI-BIOL, V78, P1157, DOI 10.1073/pnas.78.2.1157
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Nixon DF, 2005, MICROBES INFECT, V7, P1063, DOI 10.1016/j.micinf.2005.03.026
   Reiner SL, 2009, NAT REV IMMUNOL, V9, P81, DOI 10.1038/nri2490
   ROWE M, 1982, INT J CANCER, V29, P373, DOI 10.1002/ijc.2910290403
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423
   von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806
NR 30
TC 13
Z9 14
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JAN
PY 2010
VL 40
IS 1
BP 134
EP 141
DI 10.1002/eji.200939258
PG 8
WC Immunology
SC Immunology
GA 549IP
UT WOS:000274041800016
PM 19877008
OA Green Accepted, Bronze
DA 2020-11-26
ER

PT J
AU Ndhlovu, LC
   Snyder-Cappione, JE
   Carvalho, KI
   Leal, FE
   Loo, CP
   Bruno, FR
   Jha, AR
   Devita, D
   Hasenkrug, AM
   Barbosa, HMR
   Segurado, AC
   Nixon, DF
   Murphy, EL
   Kallas, EG
AF Ndhlovu, L. C.
   Snyder-Cappione, J. E.
   Carvalho, K. I.
   Leal, F. E.
   Loo, C. P.
   Bruno, F. R.
   Jha, A. R.
   Devita, D.
   Hasenkrug, A. M.
   Barbosa, H. M. R.
   Segurado, A. C.
   Nixon, D. F.
   Murphy, E. L.
   Kallas, E. G.
TI Lower numbers of circulating natural killer T (NK T) cells in
   individuals with human T lymphotropic virus type 1 (HTLV-1) associated
   neurological disease
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CD8; HTLV-1 infection; innate immunity; NK T cells; CD4
ID EXPANSION
AB Human T lymphotropic virus type 1 (HTLV-1) infects 10-20 million people worldwide. The majority of infected individuals are asymptomatic; however, approximately 3% develop the debilitating neurological disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is also currently no cure, vaccine or effective therapy for HTLV-1 infection, and the mechanisms for progression to HAM/TSP remain unclear. NK T cells are an immunoregulatory T cell subset whose frequencies and effector functions are associated critically with immunity against infectious diseases. We hypothesized that NK T cells are associated with HAM/TSP progression. We measured NK T cell frequencies and absolute numbers in individuals with HAM/TSP infection from two cohorts on two continents: Sao Paulo, Brazil and San Francisco, CA, USA, and found significantly lower levels when compared with healthy subjects and/or asymptomatic carriers. Also, the circulating NK T cell compartment in HAM/TSP subjects is comprised of significantly more CD4(+) and fewer CD8(+) cells than healthy controls. These findings suggest that lower numbers of circulating NK T cells and enrichment of the CD4(+) NK T subset are associated with HTLV-1 disease progression.
C1 [Ndhlovu, L. C.; Snyder-Cappione, J. E.; Loo, C. P.; Jha, A. R.; Hasenkrug, A. M.; Nixon, D. F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94110 USA.
   [Murphy, E. L.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94110 USA.
   [Murphy, E. L.] Blood Syst Res Inst, San Francisco, CA USA.
   [Carvalho, K. I.; Leal, F. E.; Bruno, F. R.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Segurado, A. C.] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Barbosa, H. M. R.; Kallas, E. G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP Ndhlovu, LC (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94110 USA.
EM lndhlovu@medsfgh.ucsf.edu
RI n, l/AAX-3992-2020; Barbosa, Hugo Marcelo/J-4722-2014; Carvalho, Karina
   IL/J-6789-2012; Kallas, Esper G/C-9539-2012; Nixon,
   Douglas/AAU-5734-2020; Segurado, Aluisio C/K-2229-2012
OI Barbosa, Hugo Marcelo/0000-0002-4854-5996; Carvalho, Karina
   IL/0000-0002-7763-8139; Nixon, Douglas/0000-0002-2801-1786; Segurado,
   Aluisio C/0000-0002-6311-8036; Jha, Aashish/0000-0003-3227-1086; Kallas,
   Esper/0000-0003-2026-6925; Loo, Christopher/0000-0002-5302-8774;
   Ndhlovu, Lishomwa/0000-0001-5427-4187; Snyder-Cappione,
   Jennifer/0000-0002-0941-5582
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI052731]; National Heart Lung and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [2R01-HL-62235];
   AIDS Research Institute of University of California San Francisco;
   Brazilian Program for STD and AIDS; Ministry of HealthMinistry of Health
   - Turkey [914/BRA/3014 -UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas]; John E. Fogarty International CenterUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43 TW00003]; FOGARTY
   INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL062235,
   R01HL062235, R01HL062235, R01HL062235, R01HL062235, R01HL062235,
   R01HL062235, R01HL062235, R01HL062235, R01HL062235] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R37AI052731, R37AI052731, R37AI052731, R37AI052731,
   R37AI052731, R37AI052731, R37AI052731, R37AI052731, R37AI052731,
   R37AI052731] Funding Source: NIH RePORTER
FX The project described was supported by grants R37AI052731 from the
   National Institute of Allergy and Infectious Diseases, 2R01-HL-62235
   from the National Heart Lung and Blood Institute and by funds the AIDS
   Research Institute of University of California San Francisco, the
   Brazilian Program for STD and AIDS, Ministry of Health (914/BRA/3014
   -UNESCO/Kallas), the Sao Paulo City Health Department
   (2004-0.168.922-7/Kallas), Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (04/15856-9/Kallas) and the John E. Fogarty International
   Center (D43 TW00003). The authors would like to thank Dr Johan Sandberg
   for a critical review of the manuscript. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institute of Allergy and Infectious
   Diseases or the National Institutes of Health.
CR Bangham C R, 1993, Curr Opin Neurobiol, V3, P773, DOI 10.1016/0959-4388(93)90152-O
   Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711
   Bricard G, 2009, J IMMUNOL, V182, P5140, DOI 10.4049/jimmunol.0711086
   Brigl M, 2006, J IMMUNOL, V176, P3625, DOI 10.4049/jimmunol.176.6.3625
   Exley MA, 2008, EUR J IMMUNOL, V38, P1756, DOI 10.1002/eji.200737389
   GESSAIN A, 1985, LANCET, V2, P407
   Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786
   Im JS, 2008, CLIN IMMUNOL, V127, P214, DOI 10.1016/j.clim.2007.12.005
   ITOYAMA Y, 1988, NEUROLOGY, V38, P1302, DOI 10.1212/WNL.38.8.1302
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   Kita H, 2002, GASTROENTEROLOGY, V123, P1031, DOI 10.1053/gast.2002.36020
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509
   Li D, 2008, CELL RES, V18, P817, DOI 10.1038/cr.2008.85
   Lucas M, 2003, J VIROL, V77, P2251, DOI 10.1128/JVI.77.3.2251-2257.2003
   Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780
   Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA
   OSAME M, 1986, LANCET, V1, P1031
   Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239
   Sakai JA, 2001, BLOOD, V98, P1506, DOI 10.1182/blood.V98.5.1506
   Sandberg JK, 2003, EUR J IMMUNOL, V33, P588, DOI 10.1002/eji.200323707
   Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002
   Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567
   Snyder-Cappione JE, 2009, AIDS, V23, P1965, DOI 10.1097/QAD.0b013e32832b5134
   Sugawara I, 2002, TUBERCULOSIS, V82, P97, DOI 10.1054/tube.2002.0331
   Unutmaz D, 2003, MICROBES INFECT, V5, P1041, DOI 10.1016/S1286-4579(03)00185-0
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
NR 27
TC 10
Z9 10
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2009
VL 158
IS 3
BP 294
EP 299
DI 10.1111/j.1365-2249.2009.04019.x
PG 6
WC Immunology
SC Immunology
GA 513GS
UT WOS:000271311200006
PM 19778295
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Maidana-Giret, MT
   Silva, TM
   Sauer, MM
   Tomiyama, H
   Levi, JE
   Bassichetto, KC
   Nishiya, A
   Diaz, RS
   Sabino, EC
   Palacios, R
   Kallas, EG
AF Maidana-Giret, Maria Teresa
   Silva, Tania M.
   Sauer, Mariana M.
   Tomiyama, Helena
   Levi, Jose Eduardo
   Bassichetto, Katia C.
   Nishiya, Anna
   Diaz, Ricardo S.
   Sabino, Ester C.
   Palacios, Ricardo
   Kallas, Esper Georges
TI GB virus type C infection modulates T-cell activation independently of
   HIV-1 viral load
SO AIDS
LA English
DT Article
DE activation; CD38; coinfection; GB virus type C; HIV-1; T lymphocyte
ID HEPATITIS-G VIRUS; BLOOD MONONUCLEAR-CELLS; IMMUNE ACTIVATION;
   ANTIRETROVIRAL THERAPY; LYMPHOCYTE ACTIVATION; SET-POINT; COINFECTION;
   RNA; PROGRESSION; INDIVIDUALS
AB Background: Many clinical studies have suggested a beneficial effect of GB virus type C (GBV-C) on the course of HIV-1 infection, but the mechanisms involved in such amelioration are not clear. As recent evidence has implicated cellular activation in HIV-1 pathogenesis, we investigated the effect of GBV-C viremia on T-cell activation in early HIV-1 infection.
   Methods: Forty-eight recently infected HIV-1 patients (23 GBV-C viremic) were evaluated for T-cell counts, expanded immunophenotyping GBV-C RNA detection, and HIV-1 viral load. Nonparametric univariate and multivariate analyses were carried out to identify variables associated with cellular activation, including GBV-C status, HIV-1 viral load, T lymphocyte counts, and CD38 and chemokine (C-C motif) receptor 5 (CCR5) surface expression.
   Finding: We not only confirmed the positive correlation between HIV-1 viral load and the percentage of T cells positive for CD38(+)CD8(+) but also observed that GBV-C viremic patients had a lower percentage of T cells positive for CD38(+)CD4(+), CD38(+)CD8(+), CCR5(+)CD4(+), and CCR5(+)CD8(+) compared with HIV-1-infected patients who were not GBV-C viremic. In regression models, GBV-C RNA(+) status was associated with a reduction in the CD38 on CD4(+) or CD8(+) T cells and CCR5(+) on CD8(+) T cells, independent of the HIV-1 viral load or CD4(+) and CD8(+) T-cell counts. These results were also supported by the lower expression of CD69 and CD25 in GBV-C viremic patients.
   Interpretation: The association between GBV-C replication and lower T-cell activation may be a key mechanism involved in the protection conferred by this virus against HIV-1 disease progression to immunodeficiency in HIV-1-infected patients. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
C1 [Kallas, Esper Georges] Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Maidana-Giret, Maria Teresa; Silva, Tania M.; Sauer, Mariana M.; Tomiyama, Helena; Diaz, Ricardo S.; Palacios, Ricardo; Kallas, Esper Georges] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, BR-01246903 Sao Paulo, Brazil.
   [Bassichetto, Katia C.] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
   [Nishiya, Anna; Sabino, Ester C.] Fundacao Prosangue, Hemoctr, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Palacios, Ricardo/AAN-7606-2020; Diaz, Ricardo/K-3978-2012; Sabino,
   Ester Cerdeira/F-7750-2010; Palacios, Ricardo/B-7248-2018; Nishiya,
   Anna/Q-8156-2016; Kallas, Esper G/C-9539-2012
OI Palacios, Ricardo/0000-0002-1410-8579; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Palacios, Ricardo/0000-0002-1410-8579;
   Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Diaz, 05/01072-9/Levi)]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of EducationCAPES
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Diaz, Sabino &
   Kallas; 05/01072-9/Levi). M.T.M.G. and M.M.S. were supported by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of Education.
CR Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076
   Bisson GP, 2005, AIDS, V19, P1910, DOI 10.1097/01.aids.0000188427.25657.e7
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Chun TW, 2004, P NATL ACAD SCI USA, V101, P2464, DOI 10.1073/pnas.0307328101
   Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Fogeda M, 1999, J VIROL, V73, P4052, DOI 10.1128/JVI.73.5.4052-4061.1999
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255
   Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kao JH, 1998, ARCH VIROL, V143, P797, DOI 10.1007/s007050050331
   Kaufman TM, 2007, AIDS, V21, P1045, DOI 10.1097/QAD.0b013e3280f77412
   LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Lefrere JJ, 1999, J MED VIROL, V59, P32, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;32::AID-JMV6&gt;3.0.CO;2-O
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Nattermann J, 2003, AIDS, V17, P1457, DOI 10.1097/00002030-200307040-00006
   Nunnari G, 2003, ANN INTERN MED, V139, P26, DOI 10.7326/0003-4819-139-1-200307010-00009
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   Reimann KA, 2000, CLIN DIAGN LAB IMMUN, V7, P352, DOI 10.1128/CDLI.7.3.352-359.2000
   Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352
   Rodriguez B, 2003, J INFECT DIS, V187, P504, DOI 10.1086/368206
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004
   Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660, DOI 10.1128/JCM.34.11.2660-2664.1996
   Silvestri G, 2003, J CLIN INVEST, V112, P821, DOI 10.1172/JCI200319799
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Valdez H, 1997, AIDS Clin Rev, P187
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000
NR 46
TC 39
Z9 40
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2009
VL 23
IS 17
BP 2277
EP 2287
DI 10.1097/QAD.0b013e32832d7a11
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 517CF
UT WOS:000271589700005
PM 19773635
DA 2020-11-26
ER

PT J
AU Ndhlovu, LC
   Snyder-Cappione, JE
   Carvalho, KI
   Leal, FE
   Bruno, FR
   Devita, D
   Jha, AR
   Hasenkrug, AK
   Barbosa, HMR
   Segurado, A
   Nixon, DF
   Murphy, EL
   Kallas, EG
AF Ndhlovu, L. C.
   Snyder-Cappione, J. E.
   Carvalho, K., I
   Leal, F. E.
   Bruno, F. R.
   Devita, D.
   Jha, A. R.
   Hasenkrug, A. K.
   Barbosa, H. M. R.
   Segurado, Ac
   Nixon, D. F.
   Murphy, E. L.
   Kallas, E. G.
TI Lower Numbers of Circulating Natural Killer T (NKT) Cells in HTLV-1
   Associated Myelopathy (HAM) Cases Compared to Healthy HTLV-I Carriers
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 14th International Conference on Human Retrovirology HTLV and Related
   Retroviruses
CY JUL 01-04, 2009
CL Salvador, BRAZIL
C1 [Ndhlovu, L. C.; Snyder-Cappione, J. E.; Devita, D.; Jha, A. R.; Hasenkrug, A. K.; Nixon, D. F.; Murphy, E. L.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Carvalho, K., I; Leal, F. E.; Bruno, F. R.; Segurado, Ac; Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Murphy, E. L.] Blood Syst Res Inst, San Francisco, CA USA.
   [Barbosa, H. M. R.; Kallas, E. G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI n, l/AAX-3992-2020; Carvalho, Karina IL/J-6789-2012; Segurado, Aluisio
   C/K-2229-2012; Barbosa, Hugo Marcelo/J-4722-2014; Nixon,
   Douglas/AAU-5734-2020; Kallas, Esper G/C-9539-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Segurado, Aluisio
   C/0000-0002-6311-8036; Barbosa, Hugo Marcelo/0000-0002-4854-5996; Nixon,
   Douglas/0000-0002-2801-1786; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1229
EP 1229
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200094
DA 2020-11-26
ER

PT J
AU Snyder-Cappione, JE
   Loo, CP
   Carvalho, KI
   Kuylenstierna, C
   Deeks, SG
   Hecht, FM
   Rosenberg, MG
   Sandberg, JK
   Kallas, EG
   Nixon, DF
AF Snyder-Cappione, Jennifer E.
   Loo, Christopher P.
   Carvalho, Karina I.
   Kuylenstierna, Carlotta
   Deeks, Steven G.
   Hecht, Frederick M.
   Rosenberg, Michael G.
   Sandberg, Johan K.
   Kallas, Esper G.
   Nixon, Douglas F.
TI Lower cytokine secretion ex vivo by natural killer T cells in
   HIV-infected individuals is associated with higher CD161 expression
SO AIDS
LA English
DT Article
DE CD161; HIV; interferon-gamma; natural killer T; tumor necrosis
   factor-alpha; alpha-galactosyl ceramide
ID INVARIANT NKT CELLS; V-ALPHA-24; SUBSETS; RECEPTOR; DEFINES; THYMUS;
   IL-17
AB Objective: Natural killer T (NKT) cells are efficiently targeted by HIV and severely reduced in numbers in the circulation of infected individuals. The functional capacity of the remaining NKT cells in HIV-infected individuals is poorly characterized. This study measured NKT cell cytokine production directly ex vivo and compared these responses with both the disease status and NKT subset distribution of individual patients.
   Methods: NKT cell frequencies, subsets, and ex-vivo effector functions were measured in the peripheral blood mononuclear cells of HIV-infected patients and healthy controls by flow cytometry. We measured cytokines from NKT cells after stimulation with either a-galactosyl ceramide-loaded CD1d dimers (DimerX-alpha GalCer) or phorbol myristate acetate and ionomycin.
   Results: The frequencies of NKT cells secreting interferon-gamma and tumor necrosis factor-alpha were significantly lower in HIV-infected patients than healthy controls after DimerX-alpha GalCer treatment, but responses were similar after treatment with phorbol myristate acetate and ionomycin. The magnitude of the interferon-gamma response to DimerX-alpha GalCer correlated inversely with the number of years of infection. Both interferon-gamma and tumor necrosis factor-alpha production in response to DimerX-alpha GalCer correlated inversely with CD161 expression.
   Conclusion: The ex-vivo Th1 responses of circulating NKT cells to CD1d-glycolipid complexes are impaired in HIV-infected patients. NKT cell functions may be progressively lost over time in HIV infection, and CD161 is implicated in the regulation of NKT cell responsiveness. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Snyder-Cappione, Jennifer E.; Loo, Christopher P.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, Dept Med, San Francisco, CA 94110 USA.
   [Carvalho, Karina I.; Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Kuylenstierna, Carlotta; Sandberg, Johan K.] Karolinska Univ Hosp, CIM, Dept Med, Karolinska Inst, Stockholm, Sweden.
   [Deeks, Steven G.; Hecht, Frederick M.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA.
   [Rosenberg, Michael G.] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA.
RP Snyder-Cappione, JE (corresponding author), Univ Calif San Francisco, Div Expt Med, Dept Med, 1001 Potrero Ave,Bldg 3,Room 607, San Francisco, CA 94110 USA.
EM jsnyder-cappione@medsfgh.ucsf.edu
RI Kallas, Esper G/C-9539-2012; Carvalho, Karina IL/J-6789-2012; Nixon,
   Douglas/AAU-5734-2020
OI Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Sandberg, Johan/0000-0002-6275-0750;
   Kallas, Esper/0000-0003-2026-6925; Hecht, Frederick/0000-0002-5782-1171;
   Snyder-Cappione, Jennifer/0000-0002-0941-5582; Loo,
   Christopher/0000-0002-5302-8774
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37-A152731]; Brazilian Program for STD and
   AIDS; Ministry of HealthMinistry of Health - Turkey [914/BRA/3014 -
   UNESCO/Kallas]; Sao Paulo City Health Departmen
   [20040.168.922-7/Kallas]; Fundacao de Arnparo a Pesquisa do Estado de
   Sao Paulo [04/15856-9/Kallas]; John E. Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW00003]; AIDS Research Institute of the AIDS Biology Program;
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Brazilian Ministry of Education; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052731, R01AI052731, R01AI052731, R01AI052731, R01AI052731,
   R01AI052731] Funding Source: NIH RePORTER
FX The present study is supported by grant no. NIAID R37-A152731; the
   Brazilian Program for STD and AIDS, Ministry of Health (914/BRA/3014 -
   UNESCO/Kallas), the Sao Paulo City Health Department
   (20040.168.922-7/Kallas), Fundacao de Arnparo a Pesquisa do Estado de
   Sao Paulo (04/15856-9/Kallas), the John E. Fogarty International Center
   (D43 TW00003), the AIDS Research Institute of the AIDS Biology Program
   at UCSF. K.I.C. was supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education.
CR Benlagha K, 2000, SEMIN IMMUNOL, V12, P537, DOI 10.1006/smim.2000.0276
   Berzins SP, 2005, EUR J IMMUNOL, V35, P1399, DOI 10.1002/eji.200425958
   Chen N, 2006, EUR J IMMUNOL, V36, P278, DOI 10.1002/eji.200535487
   Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105
   de Lalla C, 2004, J IMMUNOL, V173, P1417, DOI 10.4049/jimmunol.173.2.1417
   Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786
   Hage CA, 2005, IMMUNOL LETT, V98, P131, DOI 10.1016/j.imlet.2004.10.025
   Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196
   Kim S, 2008, J CLIN INVEST, V118, P2301, DOI [10.1172/JC133071, 10.1172/JCI33071]
   Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854
   Lee KA, 2008, CELL IMMUNOL, V251, P50, DOI 10.1016/j.cellimm.2008.03.004
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712
   Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507
   Prussin C, 1997, J IMMUNOL, V159, P5862
   Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167
   Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101
   Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002
   Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529
   Takahashi T, 2006, J IMMUNOL, V176, P211, DOI 10.4049/jimmunol.176.1.211
   Unutmaz D, 2003, MICROBES INFECT, V5, P1041, DOI 10.1016/S1286-4579(03)00185-0
   van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490
   Vasan S, 2007, INT IMMUNOL, V19, P943, DOI 10.1093/intimm/dxm055
   Wilson SB, 1998, NATURE, V391, P177
NR 24
TC 31
Z9 31
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 24
PY 2009
VL 23
IS 15
BP 1965
EP 1970
DI 10.1097/QAD.0b013e32832b5134
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 502QP
UT WOS:000270475400004
PM 19590406
DA 2020-11-26
ER

PT J
AU Garrison, KE
   Champiat, S
   York, VA
   Agrawal, AT
   Kallas, EG
   Martin, JN
   Hecht, FM
   Deeks, SG
   Nixon, DF
AF Garrison, Keith E.
   Champiat, Stephane
   York, Vanessa A.
   Agrawal, Ashish T.
   Kallas, Esper G.
   Martin, Jeffrey N.
   Hecht, Frederick M.
   Deeks, Steven G.
   Nixon, Douglas F.
TI Transcriptional Errors in Human Immunodeficiency Virus Type 1 Generate
   Targets for T-Cell Responses
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID INITIATION CODON
AB We measured T-cell responses to human immunodeficiency virus type 1 (HIV-1) cryptic epitopes encoded by regions of the viral genome not normally translated into viral proteins. T-cell responses to cryptic epitopes and to regions normally spliced out of the HIV-1 viral proteins Rev and Tat were detected in HIV-1-infected subjects.
C1 [Garrison, Keith E.; Champiat, Stephane; York, Vanessa A.; Agrawal, Ashish T.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, Dept Med, San Francisco, CA 94110 USA.
   [Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Hecht, Frederick M.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94110 USA.
RP Nixon, DF (corresponding author), Univ Calif San Francisco, Div Expt Med, Dept Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94110 USA.
EM douglas.nixon@ucsf.edu
RI Kallas, Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020; Champiat,
   Stephane/O-4780-2014
OI Nixon, Douglas/0000-0002-2801-1786; Champiat,
   Stephane/0000-0002-0741-2118; Kallas, Esper/0000-0003-2026-6925; Hecht,
   Frederick/0000-0002-5782-1171
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI069994, AI071713];
   UCSF Center [AI027763]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, K24AI069994, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, K24AI069994, P30AI027763, P01AI071713, P30AI027763,
   P01AI071713, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI071713, P30AI027763,
   K24AI069994, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, P30AI027763, K24AI069994,
   P30AI027763, P30AI027763, P01AI071713, P01AI071713, P30AI027763,
   P30AI027763, P30AI027763, P01AI071713, K24AI069994, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, K24AI069994, P01AI071713, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P01AI071713, P01AI071713,
   P30AI027763, P30AI027763, P30AI027763, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI071713, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713,
   P30AI027763, P01AI071713, P30AI027763, K24AI069994, P30AI027763,
   P01AI071713, P30AI027763, P01AI071713, K24AI069994, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI071713, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI071713] Funding
   Source: NIH RePORTER
FX This work was supported in part by the AIDS biology program of the AIDS
   Research Institute, UCSF. Steven G. Deeks and Jeffrey N. Martin are
   supported in part by the National Institutes of Health (grants AI069994
   and AI071713) and the UCSF Center for AIDS Research (grant AI027763).
CR Bullock TNJ, 1996, J EXP MED, V184, P1319, DOI 10.1084/jem.184.4.1319
   Bullock TNJ, 1997, J EXP MED, V186, P1051, DOI 10.1084/jem.186.7.1051
   Cardinaud S, 2004, J EXP MED, V199, P1053, DOI 10.1084/jem.20031869
   Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97
   Ho O, 2006, J IMMUNOL, V176, P2470, DOI 10.4049/jimmunol.176.4.2470
   Kamm B, 2006, BIOREFINERIES - INDUSTRIAL PROCESSES AND PRODUCTS: STATUS QUO AND FUTURE DIRECTIONS, VOL 1, P3
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Korber B, 1998, HUMAN RETROVIRUSES A, VIII, P102
   Maness NJ, 2007, J EXP MED, V204, P2505, DOI 10.1084/jem.20071261
   Meiklejohn DA, 2004, J IMMUNOL METHODS, V288, P135, DOI 10.1016/j.jim.2004.03.006
   Schirmbeck R, 2005, J IMMUNOL, V174, P4647, DOI 10.4049/jimmunol.174.8.4647
   STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994
NR 12
TC 13
Z9 13
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD SEP
PY 2009
VL 16
IS 9
BP 1369
EP 1371
DI 10.1128/CVI.00410-08
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 491LL
UT WOS:000269580200017
PM 19571107
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Melo, KM
   Carvalho, KI
   Bruno, FR
   Ndhlovu, LC
   Ballan, WM
   Nixon, DF
   Kallas, EG
   Costa-Carvalho, BT
AF Melo, Karina M.
   Carvalho, Karina I.
   Bruno, Fernanda R.
   Ndhlovu, Lishomwa C.
   Ballan, Wassim M.
   Nixon, Douglas F.
   Kallas, Esper G.
   Costa-Carvalho, Beatriz T.
TI A Decreased Frequency of Regulatory T Cells in Patients with Common
   Variable Immunodeficiency
SO PLOS ONE
LA English
DT Article
ID INTRAVENOUS IMMUNOGLOBULIN; IMMUNOLOGICAL-TOLERANCE; IMMUNE-DEFICIENCY;
   FOXP3; EXPRESSION; DISEASE; ABNORMALITIES; LYMPHOCYTES; SUBGROUPS;
   MOLECULES
AB Introduction: Common variable immunodeficiency disorder (CVID) is a heterogeneous syndrome, characterized by deficient antibody production and recurrent bacterial infections in addition abnormalities in T cells. CD4(+)CD25(high) regulatory T cells (Treg) are essential modulators of immune responses, including down-modulation of immune response to pathogens, allergens, cancer cells and self-antigens.
   Objective: In this study we set out to investigate the frequency of Treg cells in CVID patients and correlate with their immune activation status.
   Materials and Methods: Sixteen patients (6 males and 10 females) with CVID who had been treated with regular intravenous immunoglobulin and 14 controls were enrolled. Quantitative analyses of peripheral blood mononuclear cells (PBMC) were performed by multiparametric flow cytometry using the following cell markers: CD38, HLA-DR, CCR5 ( immune activation); CD4, CD25, FOXP3, CD127, and OX40 (Treg cells); Ki-67 and IFN-gamma (intracellular cytokine).
   Results: A significantly lower proportion of CD4(+)CD25(high) FOXP3 T cells was observed in CVID patients compared with healthy controls (P<0.05). In addition to a higher proportion of CD8(+) T cells from CVID patients expressing the activation markers, CD38(+) and HLA-DR+ (P<0.05), we observed no significant correlation between Tregs and immune activation.
   Conclusion: Our results demonstrate that a reduction in Treg cells could have impaired immune function in CVID patients.
RP Melo, KM (corresponding author), Univ Fed Sao Paulo, Sao Paulo, Brazil.
EM beacarvalho@terra.com.br
RI n, l/AAX-3992-2020; Carvalho, Karina IL/J-6789-2012; Nixon,
   Douglas/AAU-5734-2020; Kallas, Esper G/C-9539-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Nixon,
   Douglas/0000-0002-2801-1786; Kallas, Esper/0000-0003-2026-6925; Ndhlovu,
   Lishomwa/0000-0001-5427-4187
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R21AI060379, R01AI060379, R01AI060379, R01AI052731,
   R01AI060379, R01AI052731, R01AI060379, R01AI052731, R01AI060379,
   R01AI052731, R01AI052731, R01AI052731] Funding Source: NIH RePORTER; FIC
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [#D43 TW00003, D43 TW000003] Funding Source: Medline; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01-AI52731, AI60379, R01 AI052731, R01
   AI060379, R21 AI060379] Funding Source: Medline
CR Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023
   Blanco-Quiros A, 2006, Allergol Immunopathol (Madr), V34, P263
   Campbell DJ, 2007, NAT REV IMMUNOL, V7, P305, DOI 10.1038/nri2061
   Carbone J, 2006, Allergol Immunopathol (Madr), V34, P131, DOI 10.1157/13091037
   Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545
   Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799
   Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x
   Cunningham-Rundies C, 2007, IMMUNOL RES, V38, P78, DOI 10.1007/s12026-007-0024-0
   Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725
   Cunningham-Rundles C, 2001, Curr Allergy Asthma Rep, V1, P421, DOI 10.1007/s11882-001-0027-1
   de Vries E, 2006, CLIN EXP IMMUNOL, V145, P204, DOI 10.1111/j.1365-2249.2006.03138.x
   Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947
   FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099
   FERRER JM, 1995, CLIN EXP IMMUNOL, V102, P286
   Fevang B, 2007, CLIN EXP IMMUNOL, V147, P521, DOI 10.1111/j.1365-2249.2006.03314.x
   FISCHER MB, 1994, BRIT J HAEMATOL, V88, P520, DOI 10.1111/j.1365-2141.1994.tb05068.x
   Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932
   Glocker E, 2007, CURR OPIN PEDIATR, V19, P685, DOI 10.1097/MOP.0b013e3282f1ddd5
   Haymore BR, 2008, AUTOIMMUN REV, V7, P309, DOI 10.1016/j.autrev.2007.11.024
   Holm AM, 2005, BLOOD, V105, P2887, DOI 10.1182/blood-2004-06-2423
   Kessel A, 2007, J IMMUNOL, V179, P5571, DOI 10.4049/jimmunol.179.8.5571
   Kondratenko I, 1997, CLIN EXP IMMUNOL, V108, P9, DOI 10.1046/j.1365-2249.1997.d01-993.x
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133
   Lopes-da-Silva S, 2008, J CLIN IMMUNOL, V28, pS46, DOI 10.1007/s10875-008-9172-9
   Michaelsson J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-41
   Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281
   Nordoy I, 1998, CLIN EXP IMMUNOL, V114, P258
   North ME, 1998, CLIN EXP IMMUNOL, V111, P70
   Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374
   Pons J, 2006, SCAND J IMMUNOL, V63, P383, DOI 10.1111/j.1365-3083.2006.01753.x
   Pozzi N, 2001, CLIN EXP IMMUNOL, V123, P99, DOI 10.1046/j.1365-2249.2001.01413.x
   Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x
   Salzer U, 2006, SEMIN IMMUNOL, V18, P337, DOI 10.1016/j.smim.2006.07.004
   Serrano D, 2000, CLIN IMMUNOL, V97, P248, DOI 10.1006/clim.2000.4941
   Sewell WAC, 1999, CLIN EXP IMMUNOL, V116, P509
   Taams LS, 2006, IMMUNOLOGY, V118, P1, DOI 10.1111/j.1365-2567.2006.02348.x
   Vialle R, 2006, CLIN ANAT, V19, P51, DOI 10.1002/ca.20148
   Waldmann H, 2006, SEMIN IMMUNOL, V18, P111, DOI 10.1016/j.smim.2006.01.010
   Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544
   Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Yu GP, 2009, CLIN IMMUNOL, V131, P240, DOI 10.1016/j.clim.2008.12.006
   Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001
NR 49
TC 41
Z9 41
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2009
VL 4
IS 7
AR e6269
DI 10.1371/journal.pone.0006269
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 477CF
UT WOS:000268494500002
PM 19649263
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Mesquita, D
   Cruvinel, WM
   Camara, NOS
   Kallas, EG
   Andrade, LEC
AF Mesquita, D., Jr.
   Cruvinel, W. M.
   Camara, N. O. S.
   Kallas, E. G.
   Andrade, L. E. C.
TI Autoimmune diseases in the TH17 era
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Review
DE Autoimmune diseases; Cytokines; TH17 cells; IL-17; IL-22; IL-23
ID IL-17-PRODUCING T-CELLS; GROWTH-FACTOR-BETA; INTERLEUKIN-12/23
   MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS PATIENTS; COLLAGEN-INDUCED
   ARTHRITIS; PROINFLAMMATORY CYTOKINES; CARTILAGE DESTRUCTION;
   INFLAMMATORY CYTOKINE; SYNOVIAL FIBROBLASTS; MULTIPLE-SCLEROSIS
AB A new subtype of CD4(+) T lymphocytes characterized by the production of interleukin 17, i.e., TH17 cells, has been recently described. This novel T cell subset is distinct from type 1 and type 2 T helper cells. The major feature of this subpopulation is to generate significant amounts of pro-inflammatory cytokines, therefore appearing to be critically involved in protection against infection caused by extracellular microorganisms, and in the pathogenesis of autoimmune diseases and allergy. The dynamic balance among subsets of T cells is important for the modulation of several steps of the immune response. Disturbances in this balance may cause a shift from normal immunologic physiology to the development of immune-mediated disorders. In autoimmune diseases, the fine balance between the proportion and degree of activation of the various T lymphocyte subsets can contribute to persistent undesirable inflammatory responses and tissue replacement by fibrosis. This review highlights the importance of TH17 cells in this process by providing an update on the biology of these cells and focusing on their biology and differentiation processes in the context of immune-mediated chronic inflammatory diseases.
C1 [Mesquita, D., Jr.; Cruvinel, W. M.; Andrade, L. E. C.] Univ Fed Sao Paulo, Escola Paulista Med, Div Reumatol, BR-04023069 Sao Paulo, Brazil.
   [Camara, N. O. S.] Univ Sao Paulo, Fac Med, Inst Ciencias Biomed, Dept Imunol, Sao Paulo, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, Fac Med, Dept Clin Med, Sao Paulo, Brazil.
   [Cruvinel, W. M.] Univ Catolica Goias, Dept Biomed, Goiania, Go, Brazil.
RP Andrade, LEC (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Div Reumatol, Rua Botucatu,740, BR-04023069 Sao Paulo, Brazil.
EM luis.andrade@unifesp.br
RI Kallas, Esper G/C-9539-2012; Andrade, Luis Eduardo C/D-1245-2012;
   Camara, Niels OS/G-8336-2011; camara, niels/AAX-3269-2020
OI Andrade, Luis Eduardo C/0000-0001-8742-9931; Camara, Niels
   OS/0000-0001-5436-1248; camara, niels/0000-0001-5436-1248; Kallas,
   Esper/0000-0003-2026-6925
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/51349-2, 2007/07139-3]
FX Research supported by FAPESP (#2007/51349-2 and #2007/07139-3).
CR Aarvak T, 1999, J IMMUNOL, V162, P1246
   Agarwal S, 2008, J RHEUMATOL, V35, P515
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294
   Chen Z, 2007, ARTHRITIS RHEUM-US, V56, P2936, DOI 10.1002/art.22866
   Cho ML, 2004, ARTHRITIS RHEUM-US, V50, P776, DOI 10.1002/art.20106
   Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807
   Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295
   Evans HG, 2007, P NATL ACAD SCI USA, V104, P17034, DOI 10.1073/pnas.0708426104
   Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268
   Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65
   Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017
   He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852
   Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x
   Honorati MC, 2001, RHEUMATOLOGY, V40, P522, DOI 10.1093/rheumatology/40.5.522
   Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552
   Hwang SY, 2005, MOL CELLS, V19, P180
   Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107
   Kasper LH, 2006, CURR MED RES OPIN, V22, P1671, DOI 10.1185/030079906X120931
   Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651
   Kirkham BW, 2006, ARTHRITIS RHEUM, V54, P1122, DOI 10.1002/art.21749
   Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967
   Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566
   Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K
   Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   Loong CC, 2002, J PATHOL, V197, P322, DOI 10.1002/path.1117
   Lubberts E, 2004, ARTHRITIS RHEUM-US, V50, P650, DOI 10.1002/art.20001
   Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402
   Matsumoto K, 2003, SCAND J UROL NEPHROL, V37, P164, DOI 10.1080/00365590310008929
   McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539
   Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Raza K, 2005, ARTHRITIS RES THER, V7, pR784, DOI 10.1186/ar1733
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401
   Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011
   Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285
   Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x
   Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690
   Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017
   van Bezooijen RL, 2002, ANN RHEUM DIS, V61, P870, DOI 10.1136/ard.61.10.870
   Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001
   Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613
   Wendling D, 2007, JOINT BONE SPINE, V74, P304, DOI 10.1016/j.jbspin.2006.11.005
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703
   Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404
   Yu JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P170, DOI 10.2741/2667
   Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023
   Zhang Z, 2006, INFLAMM BOWEL DIS, V12, P382, DOI 10.1097/01.MIB.0000218764.06959.91
   Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832
NR 60
TC 21
Z9 22
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 2009
VL 42
IS 6
BP 476
EP 486
DI 10.1590/S0100-879X2009000600002
PG 11
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 446QI
UT WOS:000266135800017
PM 19448894
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Batista, MD
   Ferreira, S
   Sauer, MM
   Tomiyama, H
   Giret, MTM
   Pannuti, CS
   Diaz, RS
   Sabino, EC
   Kallas, EG
AF Batista, Mariana Dias
   Ferreira, Suzete
   Sauer, Mariana M.
   Tomiyama, Helena
   Maidana Giret, Maria Teresa
   Pannuti, Claudio S.
   Diaz, Ricardo S.
   Sabino, Ester C.
   Kallas, Esper G.
TI High Human Herpesvirus 8 (HHV-8) Prevalence, Clinical Correlates and
   High Incidence among Recently HIV-1-Infected Subjects in Sao Paulo,
   Brazil
SO PLOS ONE
LA English
DT Article
AB Background: Human herpesvirus 8 (HHV-8) is the etiological agent for Kaposi Sarcoma, which occurs especially in HIV-infected subjects. HHV-8 infection and its clinical correlates have not been well characterized in recently HIV-1-infected subjects, especially men who have sex with men (MSM).
   Methodology/Principal Findings: We assessed the HHV-8 seroprevalence, clinical correlates, and incidence after one year of follow-up in a cohort of 228 recently HIV-1-infected individuals, of whom 83.6% were MSM, using indirect immunofluorescence assay. The prevalence of HHV-8 infection at the time of cohort enrollment was 25.9% (59/228). In the univariate model, there were significant associations with male gender, black ethnicity, MSM practice, and previous hepatitis B virus and syphilis infections. In the multivariate model we could still demonstrate association with MSM, hepatitis B, and black ethnicity. No differences in mean CD4+ cell counts or HIV viral load according to HHV-8 status were found. In terms of incidence, there were 23/127 (18.1%) seroconversions in the cohort after 1 year.
   Conclusions: HHV-8 is highly prevalent among recently HIV-1-infected subjects. Correlations with other sexually transmitted infections suggest common transmission routes.
RP Batista, MD (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Sabino, Ester Cerdeira/F-7750-2010; Kallas, Esper G/C-9539-2012; Diaz,
   Ricardo/K-3978-2012; Pannuti, Claudio/B-7649-2012; Ferreira,
   Suzete/K-1626-2016
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Ferreira,
   Suzete/0000-0002-4190-0238; Kallas, Esper/0000-0003-2026-6925
CR Ait-Arkoub Z, 2003, AIDS, V17, P1394, DOI 10.1097/00002030-200306130-00016
   Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423
   Biggar RJ, 2003, J INFECT DIS, V187, P12, DOI 10.1086/345866
   Cannon MJ, 2001, NEW ENGL J MED, V344, P637, DOI 10.1056/NEJM200103013440904
   Caselli E, 2001, J GEN VIROL, V82, P1965, DOI 10.1099/0022-1317-82-8-1965
   Caselli E, 2005, BLOOD, V106, P2790, DOI 10.1182/blood-2005-04-1390
   Caselli E, 2003, J GEN VIROL, V84, P1123, DOI 10.1099/vir.0.18799-0
   Casper C, 2002, J INFECT DIS, V185, P990, DOI 10.1086/339605
   Casper C, 2007, J INFECT DIS, V195, P30, DOI 10.1086/509621
   Caterino-De-Araujo A, 1999, J INFECT DIS, V179, P1591, DOI 10.1086/314789
   Crum NF, 2003, SEX TRANSM DIS, V30, P713, DOI 10.1097/01.OLQ.0000078627.30743.4A
   Diamond C, 2001, SEX TRANSM DIS, V28, P176, DOI 10.1097/00007435-200103000-00010
   Dukers NHTM, 2000, AM J EPIDEMIOL, V151, P213, DOI 10.1093/oxfordjournals.aje.a010195
   ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0
   Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925
   Giuliani M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-143
   Greene JT, 2001, ADV INV AN, V8, P183
   Harris AH, 2002, SUPPORT CARE CANCER, V10, P486, DOI 10.1007/s00520-002-0363-2
   Hyun TS, 2001, J VIROL, V75, P8761, DOI 10.1128/JVI.75.18.8761-8771.2001
   Jacobson LP, 2000, J INFECT DIS, V181, P1940, DOI 10.1086/315503
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0
   Mercader M, 2000, AM J PATHOL, V156, P1961, DOI 10.1016/S0002-9440(10)65069-9
   Nascimento MC, 2007, J CLIN MICROBIOL, V45, P715, DOI 10.1128/JCM.01264-06
   Pierrotti LC, 2005, SEX TRANSM DIS, V32, P57, DOI 10.1097/01.olq.0000148300.33428.6e
   Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018
   Smith NA, 1999, J INFECT DIS, V180, P600, DOI 10.1086/314926
   Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008
   de Souza VAUF, 2007, J MED VIROL, V79, P1562, DOI 10.1002/jmv.20949
   Varthakavi V, 2002, VIROLOGY, V297, P270, DOI 10.1006/viro.2002.1434
   Zago A, 2000, SEX TRANSM DIS, V27, P468, DOI 10.1097/00007435-200009000-00009
   Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06
NR 33
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2009
VL 4
IS 5
AR e5613
DI 10.1371/journal.pone.0005613
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 446ZK
UT WOS:000266161200014
PM 19479040
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Melo, K
   Carvalho, K
   Bruno, F
   Ndhlovu, L
   Nixon, D
   Kallas, E
   Costa-Carvalho, B
AF Melo, K.
   Carvalho, K.
   Bruno, F.
   Ndhlovu, L.
   Nixon, D.
   Kallas, E.
   Costa-Carvalho, B.
TI Decreased frequency of regulatory T cells in common variable
   immunodeficiency patients
SO ALLERGY
LA English
DT Meeting Abstract
CT 28th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 06-10, 2009
CL Warsaw, POLAND
SP European Acad Allergy & Clin Immunol
C1 [Melo, K.; Carvalho, K.; Costa-Carvalho, B.] Univ Fed Sao Paulo, Allergy & Immunol Dept, Sao Paulo, Brazil.
   [Bruno, F.; Kallas, E.] Univ Fed Sao Paulo, Infectol Dept, Sao Paulo, Brazil.
   [Ndhlovu, L.; Nixon, D.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
RI Kallas, Esper G/C-9539-2012; Carvalho, Karina IL/J-6789-2012
OI Carvalho, Karina IL/0000-0002-7763-8139
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0105-4538
J9 ALLERGY
JI Allergy
PY 2009
VL 64
MA 644
BP 259
EP 259
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 447DJ
UT WOS:000266171500622
DA 2020-11-26
ER

PT J
AU Sucpira, MCA
   Sanabani, S
   Cortes, RM
   Janini, LM
   Sabino, EC
   Kallas, EG
   Diaz, RS
AF Sucpira, M. C. A.
   Sanabani, S.
   Cortes, R. M.
   Janini, L. M.
   Sabino, E. C.
   Kallas, E. G.
   Diaz, R. S.
TI Primary antiretroviral resistance among individuals with recent HIV
   infection in the city of Sao Paulo, Brazil: use of full-length genome
   sequencing to evaluate six antiretroviral classes
SO ANTIVIRAL THERAPY
LA English
DT Meeting Abstract
CT 18th International HIV Drug Resistance Workshop
CY JUN 09-13, 2009
CL Ft Myers, FL
C1 [Sucpira, M. C. A.; Cortes, R. M.; Janini, L. M.; Kallas, E. G.; Diaz, R. S.] Univ Fed Sao Paulo, Sao Paulo, SP, Brazil.
   [Sanabani, S.; Sabino, E. C.] Fundacao Pro Sangue, Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
   [Kallas, E. G.] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
RI Janini, Luiz Mario R/E-9700-2012; Diaz, Ricardo/K-3978-2012; Sanabani,
   Sabri Saeed/F-5600-2012; Sabino, Ester Cerdeira/F-7750-2010; Kallas,
   Esper G/C-9539-2012
OI Sanabani, Sabri Saeed/0000-0002-8876-8262; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; 
NR 0
TC 1
Z9 1
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2009
VL 14
IS 4
MA 149
BP A172
EP A172
PG 1
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 471FA
UT WOS:000268039900166
DA 2020-11-26
ER

PT J
AU Carvalho, KI
   Romano, FB
   Matos, AM
   Kallas, EG
AF Carvalho, K. I.
   Romano, F. B.
   Matos, A. M.
   Kallas, E. G.
TI Regulatory T cells and TH-17 cells counterbalance in CD4+T cell
   activation in HIV-1-infected subjects progressing to immunodeficiency
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Carvalho, K. I.; Romano, F. B.; Matos, A. M.; Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Carvalho, Karina IL/J-6789-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Kallas,
   Esper/0000-0003-2026-6925
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P3
DI 10.1186/1742-4690-6-S3-P3
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300056
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Fonseca, S
   Coutinho-Silva, A
   Rodrigues, D
   Marti, L
   Moreira, C
   Segurado, A
   Kallas, E
   Kalil, J
   Cunha-Neto, E
AF Fonseca, S.
   Coutinho-Silva, A.
   Rodrigues, D.
   Marti, L.
   Moreira-Filho, C.
   Segurado, A.
   Kallas, E.
   Kalil, J.
   Cunha-Neto, E.
TI Distinct subsets of memory T lymphocytes from HIV-I-infected subjects
   secrete IFN-gamma and IL-2 in response to novel CD4+T-cell HIV-I
   epitopes
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Fonseca, S.; Coutinho-Silva, A.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil.
   [Marti, L.; Moreira-Filho, C.] USP IPT Butantan, Programa Interunidades Biotecnol, Sao Paulo, Brazil.
   [Rodrigues, D.] Inst Clemente Ferreira, Sao Paulo, Brazil.
   [Segurado, A.] FMUSP, Div Doencas Infeccisoas, Sao Paulo, Brazil.
   [Kallas, E.] FMUSP, Div Imunol Clin & Alergia, Sao Paulo, Brazil.
RI KALIL, JORGE/C-8029-2012; Marti, Luciana/Z-2555-2019; Segurado, Aluisio
   C/K-2229-2012; Cunha-Neto, Edecio/B-4157-2009; Kallas, Esper
   G/C-9539-2012
OI KALIL, JORGE/0000-0001-8415-4274; Marti, Luciana/0000-0002-3890-0827;
   Segurado, Aluisio C/0000-0002-6311-8036; Cunha-Neto,
   Edecio/0000-0002-3699-3345; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P282
DI 10.1186/1742-4690-6-S3-P282
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300333
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Ribeiro, SP
   Almeida, RR
   Rosa, DS
   Kallas, EG
   Kalil, J
   Cunha-Neto, E
AF Ribeiro, S. P.
   Almeida, R. R.
   Rosa, D. S.
   Kallas, E. G.
   Kalil, J.
   Cunha-Neto, E.
TI Priming with a DNA vaccine enconding HIV CD4+T cell epitopes enhances
   responses against subsequent immunization with plasmid encoding Vif
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Ribeiro, S. P.; Almeida, R. R.; Rosa, D. S.; Kallas, E. G.; Kalil, J.; Cunha-Neto, E.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Cunha-Neto, Edecio/B-4157-2009; Kallas, Esper G/C-9539-2012; Rosa,
   Daniela S/D-2190-2012; KALIL, JORGE/C-8029-2012
OI Cunha-Neto, Edecio/0000-0002-3699-3345; Rosa, Daniela
   S/0000-0003-4536-891X; KALIL, JORGE/0000-0001-8415-4274; Kallas,
   Esper/0000-0003-2026-6925
NR 0
TC 0
Z9 0
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P364
DI 10.1186/1742-4690-6-S3-P364
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300415
OA DOAJ Gold
DA 2020-11-26
ER

PT J
AU Melo, K
   Carvalho, K
   Silva, T
   Bruno, FR
   Kallas, EG
   Carvalho, BC
AF Melo, K.
   Carvalho, K.
   Silva, T.
   Bruno, Romano F.
   Kallas, E. G.
   Carvalho, Costa B.
TI Evaluation of regulatory T cells in patients with common variable
   Immunodeficiency
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 13th European-Soc-for-Immunodeficiencies/10th
   Int-Patient-Org-for-Primary-Immunodeficiencies/8th
   Int-Nursing-Group-for-Immunodeficiencies Meeting
CY OCT 16-19, 2008
CL Hertogenbosch, NETHERLANDS
SP European Soc Immunodeficiencies, Int Patient Org Primary Immunodeficiencies, Int Nursing Grp Immunodeficiencies
C1 [Melo, K.; Carvalho, K.; Silva, T.; Bruno, Romano F.; Kallas, E. G.; Carvalho, Costa B.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Carvalho, Karina IL/J-6789-2012
OI Carvalho, Karina IL/0000-0002-7763-8139
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD NOV
PY 2008
VL 154
BP 127
EP 127
PG 1
WC Immunology
SC Immunology
GA 398JD
UT WOS:000262727500238
DA 2020-11-26
ER

PT J
AU James, IGE
   Leal, FE
   Jha, AR
   Spotts, G
   Hecht, FM
   Rosenberg, MG
   Kallas, EG
   Nixon, DF
   Ndhlovu, LC
AF James, I. G. Eccles
   Leal, F. E.
   Jha, A. R.
   Spotts, G.
   Hecht, F. M.
   Rosenberg, M. G.
   Kallas, E. G.
   Nixon, D. F.
   Ndhlovu, L. C.
TI CD39 Defines Functionally Suppressive CD4+CD25+T Cells: Implications for
   Modulating T Cell Responses in HIV-1 Infection
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Spotts, G.; Hecht, F. M.] Univ Calif San Francisco, Posit Hlth Program, San Francisco, CA 94143 USA.
   [Leal, F. E.; Kallas, E. G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Rosenberg, M. G.] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA.
RI Kallas, Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020; n,
   l/AAX-3992-2020
OI Nixon, Douglas/0000-0002-2801-1786; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 123
EP 123
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800315
DA 2020-11-26
ER

PT J
AU Mendes, AVA
   Kallas, EG
   Benard, G
   Pannuti, CS
   Menezes, R
   Dulley, FL
   Evans, TG
   Salomao, R
   Machado, CM
AF Almeida Mendes, Ana Verena
   Kallas, Esper Georges
   Benard, Gil
   Pannuti, Claudio Sergio
   Menezes, Renee
   Dulley, Frederico Luiz
   Evans, Thomas George
   Salomao, Reinaldo
   Machado, Clarisse Martins
TI IMPACT OF CYTOMEGALOVIRUS AND GRAFTS VERSUS HOST DISEASE ON THE DYNAMICS
   OF CD57+CD28-CD8+T CELLS AFTER BONE MARROW TRANSPLANT
SO CLINICS
LA English
DT Article
DE Cytomegalovirus; Graft versus host disease; Bone marrow transplant;
   CD57+lymphocytes; immuno-constitution
ID IFN-GAMMA PRODUCTION; LYMPHOCYTE SUBSET RECONSTITUTION; CYTOTOXIC
   T-LYMPHOCYTES; ALLOGRAFT RECIPIENTS; HEALTHY-INDIVIDUALS;
   FLOW-CYTOMETRY; ALLOGENEIC BMT; EXPANSION; CD57(+); INFECTION
AB OBJECTIVES: The present study aimed to evaluate the dynamics of CD28 and CD57 expression in CD8+ T lymphocytes during cytomegalovirus viremia in bone marrow transplant recipients.
   METHODS: In a prospective study, blood samples were obtained once weekly once from 33 healthy volunteers and weekly from 33 patients. To evaluate the expression of CD57 and CD28 on CD8+ T lymphocytes, flow cytometry analysis was performed on blood samples for four months after bone marrow transplant, together with cytomegalovirus antigenemia assays.
   RESULTS: Compared to cytomegalovirus-seronegative healthy subjects, seropositive healthy subjects demonstrated a higher percentage of CD57+ and a lower percentage of CD28+ cells (p < 0.05). A linear regression model demonstrated a continuous decrease in CD28+ expression and a continuous increase in CD57+ expression after bone marrow transplant. The occurrence of cytomegalovirus antigenemia was associated with a steep drop in the percentage of CD28+ cells (5.94%, p < 0.01) and an increase in CD57+ lymphocytes (5.60%, p < 0.01). This cytomegalovirus-dependent effect was for the most part concentrated in the allogeneic bone marrow transplant patients. The development of acute graft versus host disease, which occurred at an earlier time than antigenemia (day 26 vs. day 56 post-bone marrow transplant), also had an impact on the CD57+ subset, triggering an increase of 4.9% in CD57+ lymphocytes (p < 0.05).
   CONCLUSION: We found continuous relative changes in the CD28+ and CD57+ subsets during the first 120 days post-bone marrow transplant, as part of immune system reconstitution and maturation. A clear correlation was observed between the expansion of the CD57+CD28-CD8+ T lymphocyte subpopulation and the occurrence of graft versus host disease and cytomegalovirus viremia.
C1 [Almeida Mendes, Ana Verena] Univ Sao Paulo, Fac Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Lab Imunol, Escola Med, Sao Paulo, Brazil.
RP Mendes, AVA (corresponding author), Univ Sao Paulo, Fac Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
EM avamendes@gmail.com
RI Salomao, Reinaldo/C-6419-2013; Kallas, Esper G/C-9539-2012; Pannuti,
   Claudio/B-7649-2012; Dulley, Frederico Luiz/H-7063-2013
OI Salomao, Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
FU University of Sao Paulo
FX We thank Marta Anesia Viana, Milena Brunialti, Helena Tomiyama, and Lucy
   Vilas Boas for their continuous support during the laboratory work, as
   well as the nursing staff of the Bone Marrow Transplant Program of The
   Hematology and Hemotherapy Discipline of the University of Sao Paulo for
   helping identify patients and collect specimens during this project.
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Arai K, 1998, CLIN EXP IMMUNOL, V111, P345
   Aubert G, 2001, J INFECT DIS, V184, P955, DOI 10.1086/323354
   Bandres E, 2000, CLIN IMMUNOL, V96, P230, DOI 10.1006/clim.2000.4894
   Bilgrami S, 1999, BONE MARROW TRANSPL, V24, P69, DOI 10.1038/sj.bmt.1701827
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Bronke C, 2005, IMMUNOL LETT, V97, P215, DOI 10.1016/j.imlet.2004.11.004
   DANGEAC AD, 1994, EUR J IMMUNOL, V24, P1503, DOI 10.1002/eji.1830240707
   De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701
   DOLSTRA H, 1995, BRIT J HAEMATOL, V90, P300, DOI 10.1111/j.1365-2141.1995.tb05150.x
   Dolstra H, 1996, BONE MARROW TRANSPL, V18, P339
   Evans TG, 1999, AIDS, V13, P1139, DOI 10.1097/00002030-199906180-00019
   Frassanito MA, 1998, BRIT J HAEMATOL, V100, P469
   GARIN L, 1995, CLIN IMMUNOL IMMUNOP, V77, P139, DOI 10.1006/clin.1995.1137
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303
   GOROCHOV G, 1994, BLOOD, V83, P587
   Hazzan M, 1997, TRANSPLANTATION, V63, P693, DOI 10.1097/00007890-199703150-00014
   Hooper M, 1999, J RHEUMATOL, V26, P1452
   Horiuchi T, 2001, BONE MARROW TRANSPL, V27, P731, DOI 10.1038/sj.bmt.1702859
   HUNTER AE, 1995, J ANTIMICROB CHEMOTH, V36, P119, DOI 10.1093/jac/36.suppl_B.119
   Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8
   Khan N, 2002, J INFECT DIS, V185, P1025, DOI 10.1086/339963
   Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984
   Koike Y, 2002, CLIN EXP IMMUNOL, V130, P162, DOI 10.1046/j.1365-2249.2002.01958.x
   LABALETTE M, 1994, CLIN EXP IMMUNOL, V95, P465
   Lee S, 1997, BONE MARROW TRANSPL, V20, P883, DOI 10.1038/sj.bmt.1700986
   LEGENDRE CM, 1985, J IMMUNOL, V135, P1061
   Lieberman J, 1999, AIDS, V13, P891, DOI 10.1097/00002030-199905280-00004
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Machado CM, 2000, BONE MARROW TRANSPL, V26, P413, DOI 10.1038/sj.bmt.1702526
   Mendes AVA, 2002, ACTA HAEMATOL-BASEL, V107, P187, DOI 10.1159/000058313
   Merino J, 1998, CLIN EXP IMMUNOL, V112, P48
   MORLEY JK, 1995, J IMMUNOL, V154, P6182
   Moss P, 2004, HUM IMMUNOL, V65, P456, DOI 10.1016/j.humimm.2004.02.014
   Ozdemir E, 2002, BLOOD, V100, P3690, DOI 10.1182/blood-2002-05-1387
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   Rowbottom AW, 2000, BRIT J HAEMATOL, V110, P315, DOI 10.1046/j.1365-2141.2000.02107.x
   SULLIVAN KM, 1989, J ALLERGY CLIN IMMUN, V84, P632, DOI 10.1016/0091-6749(89)90202-9
   Sze DMY, 2001, BLOOD, V98, P2817, DOI 10.1182/blood.V98.9.2817
   THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706
   VANDERBIJ W, 1988, J MED VIROL, V25, P179, DOI 10.1002/jmv.1890250208
   WANG EC, 1995, SCAND J INFECT DIS S, V99, pS69
   WANG ECY, 1995, J IMMUNOL, V155, P5046
   Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x
   YABE H, 1990, BONE MARROW TRANSPL, V5, P295
   Yu XZ, 2000, J IMMUNOL, V164, P4564, DOI 10.4049/jimmunol.164.9.4564
NR 49
TC 7
Z9 8
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2008
VL 63
IS 5
BP 667
EP 676
DI 10.1590/S1807-59322008000500016
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 361ZQ
UT WOS:000260168400015
PM 18925328
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Vieira, QF
   Kayser, C
   Kallas, EG
   Andrade, LEC
AF Vieira, Queila F.
   Kayser, Cristiane
   Kallas, Esper G.
   Andrade, Luis Eduardo C.
TI Decreased recent thymus emigrant number is associated with disease
   activity in systemic lupus erythematosus
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE systemic lupus erythematosus; T lymphocyte; thymus; T cell receptor
   excision circle
ID RECEPTOR EXCISION CIRCLES; T-CELL HOMEOSTASIS; RHEUMATOID-ARTHRITIS;
   PERIPHERAL-BLOOD; MICROENVIRONMENTAL ABNORMALITIES; PROLIFERATION;
   SELECTION; MARKERS; MICE; SLE
AB Objective. T cell receptor excision circle (TREC) is produced during T cell maturation within the thymus, and the number of TREC-bearing cells reflects the proportion of recent thymic emigrants in the peripheral lymphocyte pool. We studied TREC levels in peripheral CD4+ and CD8+ lymphocytes in patients with systemic lupus erythematosus (SLE) with quiescent and with active disease and in age- and sex-matched healthy volunteers.
   Methods. TREC levels in peripheral CD4+ and CD8+ lymphocytes were determined in 29 patients with quiescent SLE, in 22 with active disease, and in 31 age- and sex-matched healthy volunteers. The number of TREC/mu g DNA was determined by real-time polymerase chain reaction gauged by a standard curve with known number of TREC-containing plasmids.
   Results. TREC levels in CD4+ and CD8+ cells were lower in patients with active SLE (2.27 +/- 2.05 X 10(4) and 4.14 +/- 4.06 X 10(4) TREC/mu g DNA, respectively) compared to quiescent SLE (5.83 +/- 7.41 X 10(4) and 11.24 +/- 15.06 x 10(4) TREC/mu g DNA; p = 0.03, p = 0.02, respectively). Patients with active SLE had lower TREC levels in CD4+ T cells than controls (2.27 +/- 2.05 X 10(4) vs 5.64 +/- 4.99 X 10(4) TREC/mu p, DNA; p = 0.03), but this difference did not reach statistical significance for CD8+ cells (4.14 +/- 4.06 X 10(4) vs 8.77 +/- 8.78 X 10(4) TREC/mu g DNA; p = 0.1). Patients with quiescent SLE presented TREC levels similar to controls in CD4+ and CD8+ cells (p = 0.49, p = 0.3, respectively).
   Conclusion. Out results reveal decreased TREC levels in the peripheral blood of patients with active but not in patients with quiescent SLE. These data Suggest that TREC levels are affected by disease activity in SLE.
C1 [Vieira, Queila F.; Kayser, Cristiane; Andrade, Luis Eduardo C.] Univ Fed Sao Paulo, Div Rheumatol, BR-04023062 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, BR-04023062 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Fed Sao Paulo, Div Clin Immunol & Allergy, BR-04023062 Sao Paulo, Brazil.
RP Andrade, LEC (corresponding author), Univ Fed Sao Paulo, Div Rheumatol, Rua Botucatu 740,3 Andar, BR-04023062 Sao Paulo, Brazil.
EM luis@retumato.epm.br
RI Kayser, Cristiane/Q-1074-2019; Kallas, Esper G/C-9539-2012; Kayser,
   Cristiane/I-4565-2013; Andrade, Luis Eduardo C/D-1245-2012
OI Andrade, Luis Eduardo C/0000-0001-8742-9931; Kallas,
   Esper/0000-0003-2026-6925
FU State of Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [04/14795-6]; Brazilian Society
   of Rheumatology Research Agency
FX Supported by The State of Sao Paulo Research Foundation (FAPESP grant
   04/14795-6) and partially by the Brazilian Society of Rheumatology
   Research Agency.
CR Berzins SP, 2002, TRENDS MOL MED, V8, P469, DOI 10.1016/S1471-4914(02)02415-2
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Cook RJ, 2000, J RHEUMATOL, V27, P1892
   Crispin JC, 2003, LUPUS, V12, P386, DOI 10.1191/0961203303lu368oa
   Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374
   Fujimaki S, 1968, Acta Med Biol (Niigata), V16, P1
   Han BK, 2005, LUPUS, V14, P598, DOI 10.1191/0961203305lu2171oa
   Hazenberg MD, 2001, J MOL MED, V79, P631, DOI 10.1007/s001090100271
   Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
   Honda M, 2001, CLIN IMMUNOL, V99, P211, DOI 10.1006/clim.2001.5023
   HORWITZ DA, 2002, DUBOIS LUPUS ERYTHEM, P157
   Hug A, 2003, J IMMUNOL, V171, P432, DOI 10.4049/jimmunol.171.1.432
   KAMMER GM, 1990, J LAB CLIN MED, V115, P273
   Kayser C, 2004, LUPUS, V13, P906, DOI 10.1191/0961203304lu2031oa
   Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203
   Kong FK, 2002, J IMMUNOL, V168, P6500, DOI 10.4049/jimmunol.168.12.6500
   Kurosaka D, 2003, LUPUS, V12, P591, DOI 10.1191/0961203303lu426oa
   MACSWEEN RN, 1967, J PATHOL BACTERIOL, V93, P611, DOI 10.1002/path.1700930222
   Mato T, 1997, INT IMMUNOL, V9, P547, DOI 10.1093/intimm/9.4.547
   Ponchel F, 2002, BLOOD, V100, P4550, DOI 10.1182/blood-2002-03-0671
   RIVERO SJ, 1977, ARTHRITIS RHEUM, V20, P1169, DOI 10.1002/art.1780200602
   Rubin RL, 2001, LUPUS, V10, P795, DOI 10.1177/096120330101001106
   Sempowski GD, 2001, J IMMUNOL, V166, P2808, DOI 10.4049/jimmunol.166.4.2808
   SMOLEN JS, 1982, AM J MED, V72, P783, DOI 10.1016/0002-9343(82)90544-7
   Sodora DL, 2000, EUR J IMMUNOL, V30, P1145, DOI 10.1002/(SICI)1521-4141(200004)30:4<1145::AID-IMMU1145>3.0.CO;2-7
   TAKEOKA Y, 1995, J AUTOIMMUN, V8, P145, DOI 10.1006/jaut.1995.0012
   Takeuchi T, 2005, AUTOIMMUNITY, V38, P339, DOI 10.1080/08916930500123983
   Talvensarri K, 2002, BLOOD, V99, P1458, DOI 10.1182/blood.V99.4.1458
   Tanchot C, 1997, J EXP MED, V186, P1099, DOI 10.1084/jem.186.7.1099
   Thewissen M, 2007, CLIN IMMUNOL, V123, P209, DOI 10.1016/j.clim.2007.01.005
   Verschuren MCM, 1997, J IMMUNOL, V158, P1208
   WATANABE Y, 1993, J IMMUNOL, V150, P4702
   Ye P, 2002, J IMMUNOL, V168, P4968, DOI 10.4049/jimmunol.168.10.4968
   Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725
NR 34
TC 10
Z9 10
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD SEP
PY 2008
VL 35
IS 9
BP 1762
EP 1767
PG 6
WC Rheumatology
SC Rheumatology
GA 344CY
UT WOS:000258904500013
PM 18634155
DA 2020-11-26
ER

PT J
AU Giret, MM
   Bermudez-Aza, E
   Gouvea, N
   Gouvea, C
   Tomiyama, H
   Sauer, MM
   Kalil, J
   Watkins, D
   Kallas, E
AF Giret, M. Maidana
   Bermudez-Aza, E.
   Gouvea, N.
   Gouvea, C.
   Tomiyama, H.
   Sauer, M. Melillo
   Kalil, J.
   Watkins, D.
   Kallas, E.
TI The HLA-B*57 allele is highly enriched in Brazilian elite controllers
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 15th International Histocompatibility and Immunogenetics Workshop and
   Conference
CY SEP 13-20, 2008
CL Rio de Janeiro, BRAZIL
C1 [Giret, M. Maidana; Bermudez-Aza, E.; Tomiyama, H.; Sauer, M. Melillo; Kallas, E.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Gouvea, N.; Gouvea, C.; Kalil, J.; Kallas, E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Watkins, D.] Univ Wisconsin, Madison, WI 53706 USA.
RI Kallas, Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD SEP
PY 2008
VL 72
IS 3
BP 274
EP 274
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 337OD
UT WOS:000258444500116
DA 2020-11-26
ER

PT J
AU Claro, S
   Oshiro, MEM
   Freymuller, E
   Katchburian, E
   Kallas, EG
   Cerri, PS
   Ferreira, AT
AF Claro, Sandra
   Miyamoto Oshiro, Maria Etsuko
   Freymuller, Edna
   Katchburian, Eduardo
   Kallas, Esper George
   Cerri, Paulo Sergio
   Ferreira, Alice Teixeira
TI gamma-Radiation induces apoptosis via sarcoplasmatic reticulum in guinea
   pig ileum smooth muscle cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE apoptosis; calcium; caspase 12; ileum; gamma-radiation;
   sarco/endoplasmic reticulum
ID EPITHELIAL TUMOR-CELLS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM;
   IONIZING-RADIATION; CELLULAR-RESPONSE; CA2+ RELEASE; CYCLE ARREST;
   CALCIUM; DEATH; STRESS
AB We investigated the effects of gamma-radiation on cells isolated from the longitudinal smooth muscle layer of the guinea pig ileum, a relatively radioresistant tissue. Single doses (up to 50 Gy) reduced the amount of sarcoplasmatic reticulum and condensed the myofibrils, as shown by electron microscopy 3 days post-irradiation. After that, contractility of smooth muscle strips was reduced. Ca2+ handling was altered after irradiation, as shown in fura-2 loaded cells, with elevated basal intracellular Ca2+, reduced amount of intrareticular Ca2+, and reduced capacitive Ca2+ entry. Radiation also induced apoptosis, judged from flow cytometry of cells loaded with proprium iodide. Electron microscopy showed that radiation caused condensation of chromatin in dense masses around the nuclear envelope, the presence of apoptotic bodies, fragmentation of the nucleus, detachment of cells from their neighbors, and reductions in cell volume. Radiation also caused activation of caspase 12. Apoptosis was reduced by the administration of the caspase inhibitor Z-Val-Ala-Asp-fluoromethyl-ketone methyl ester (Z-VAD-FIVIK) during the 3 day period after irradiation, and by the chelator of intracellular Ca2+, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), from 1 h before until 2 h after irradiation. BAPTA also reduced the effects of radiation on contractility, basal intracellular Ca2+, amount of intrareticular Ca2+, capacitative Ca2+ entry, and apoptosis. In conclusion, the effects of gamma radiation on contractility, Ca2+ handling, and apoptosis appear due to a toxic action of intracellular Ca2+. Ca2+-induced damage to the sarcoplasmatic reticulum seems a key event in impaired Ca2+ handling and apoptosis induced by gamma-radiation. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Claro, Sandra; Miyamoto Oshiro, Maria Etsuko; Ferreira, Alice Teixeira] Univ Fed Sao Paulo, Dept Biophys, EPM, BR-04023062 Sao Paulo, Brazil.
   [Katchburian, Eduardo] Univ Fed Sao Paulo, Ctr Electron Microscopy, EPM, BR-04023062 Sao Paulo, Brazil.
   [Katchburian, Eduardo] Univ Fed Sao Paulo, Dept Morphol, EPM, BR-04023062 Sao Paulo, Brazil.
   [Kallas, Esper George] Univ Fed Sao Paulo, Dept Gene Therapy, EPM, BR-04023062 Sao Paulo, Brazil.
   [Cerri, Paulo Sergio] Univ Sao Paulo, Dept Morphol, Sch Dent, Araraquara, SP, Brazil.
RP Claro, S (corresponding author), Univ Fed Sao Paulo, Dept Biophys, EPM, Rua Botucatu 862 ECB 2 Andar, BR-04023062 Sao Paulo, Brazil.
EM sandra@biofis.epm.br
RI Cerri, Paulo/F-5338-2012; Kallas, Esper G/C-9539-2012; Cerri,
   Paulo/AAC-5797-2019
OI Cerri, Paulo/0000-0001-5756-5828; Cerri, Paulo/0000-0001-5756-5828;
   Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, BrasilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP-99/10261-7];
   Centro de Aperfeicoamento de Pessoal cle Ensino superior, Brazil,
   (Capes)CAPES
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo, Brasil, (FAPESP-99/10261-7) and Centro de
   Aperfeicoamento de Pessoal cle Ensino superior, Brazil, (Capes). We
   thank Chandler Tahan, Patricia Milanez, Marcia Fujie Araguth Tanakai and
   Paulo Cesar Franco for helpful technical support, and Dr. Gus
   Schoorlemmer for critical reading of the manuscript.
CR Attix FH, 1986, INTRO RADIOLOGICAL P, P20
   Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067
   Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094
   BOLTON TB, 1979, PHYSIOL REV, V59, P606
   Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817
   Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301
   Chin TY, 2007, AM J PHYSIOL-CELL PH, V292, pC383, DOI 10.1152/ajpcell.00069.2006
   Chun RL, 2007, INT J BIOCHEM CELL B, V39, P426, DOI 10.1016/j.biocel.2006.09.011
   CLARO S, 1999, ACTA MICROSC, V8, P63
   Claro S, 2007, J PHARMACOL EXP THER, V322, P964, DOI 10.1124/jpet.107.125930
   Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3
   Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218
   Eder V, 2004, INT J RADIAT ONCOL, V60, P1530, DOI 10.1016/j.ijrobp.2004.07.698
   Ferrari D, 2002, CELL CALCIUM, V32, P413, DOI 10.1016/S0143416002002014
   FOOTE RL, 1995, INT J RADIAT ONCOL, V32, P1153, DOI 10.1016/0360-3016(94)00454-S
   FOWLER JF, 1989, BRACHYTHERAPY HDR LD, P121
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812
   HALL EJ, 2000, RADIOBIOLOGY RADIOLO, P343
   HALLAHAN DE, 1994, RADIAT RES, V138, P392, DOI 10.2307/3578688
   Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858
   JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121
   Joseph SK, 2007, APOPTOSIS, V12, P951, DOI 10.1007/s10495-007-0719-7
   KANDASAMY SB, 1992, RADIAT RES, V131, P43, DOI 10.2307/3578314
   KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   KHALIL RA, 1988, J PHARMACOL EXP THER, V244, P537
   Killoran PL, 1999, RADIAT RES, V152, P611, DOI 10.2307/3580256
   Kim HS, 2004, J MOL CELL CARDIOL, V37, P871, DOI 10.1016/j.yjmcc.2004.06.017
   Krantis A, 1996, DIGEST DIS SCI, V41, P2307, DOI 10.1007/BF02100119
   LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569
   Ling YH, 2002, MOL CANCER THER, V1, P841
   Mauro C, 2006, J BIOL CHEM, V281, P2631, DOI 10.1074/jbc.M502181200
   MCGAHON AJ, 1995, END CELL LINE METHOD, P153
   MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032
   Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313
   O'Connell AC, 1998, J CELL PHYSIOL, V177, P264, DOI 10.1002/(SICI)1097-4652(199811)177:2<264::AID-JCP8>3.0.CO;2-L
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   PAREKH AB, 2005, PHYSIOL REV, V85, P767
   Pettersen EO, 2007, INT J RADIAT BIOL, V83, P331, DOI 10.1080/09553000701287791
   Philippe J, 1997, CYTOMETRY, V29, P242, DOI 10.1002/(SICI)1097-0320(19971101)29:3<242::AID-CYTO7>3.3.CO;2-Z
   PUTNEY J W JR, 1991, P251
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   SHIMUTA SI, 1990, J PHARMACOL EXP THER, V253, P1215
   Soler F, 2007, ARCH BIOCHEM BIOPHYS, V466, P194, DOI 10.1016/j.abb.2007.06.022
   Soloviev AI, 2005, AM J PHYSIOL-REG I, V289, pR755, DOI 10.1152/ajpregu.00748.2004
   STORY MD, 1992, INT J RADIAT BIOL, V61, P243, DOI 10.1080/09553009214550871
   Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200
   SZUMIEL I, 1990, INT J RADIAT BIOL, V58, P125, DOI 10.1080/09553009014551481
   THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706
   TODD DG, 1994, CANCER RES, V54, P5224
   Trump BF, 1996, BBA-MOL CELL RES, V1313, P173, DOI 10.1016/0167-4889(96)00086-9
   TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018
   VERBRUGGE I, 2007, ONCOGENE ADV ONLINE, DOI DOI 10.1038/SJ.ONC.1210696
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   YANAGIHARA K, 1995, INT J RADIAT BIOL, V67, P677, DOI 10.1080/09553009514550801
   Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3
   Zhang D, 2007, CELL DEATH DIFFER, V14, P703, DOI 10.1038/sj.cdd.4402072
   Zhu DM, 1998, CLIN CANCER RES, V4, P2967
NR 61
TC 7
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 20
PY 2008
VL 590
IS 1-3
BP 20
EP 28
DI 10.1016/j.ejphar.2008.05.038
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 341KF
UT WOS:000258712500003
PM 18582867
DA 2020-11-26
ER

PT J
AU Ono, E
   dos Santos, AMN
   Succi, RCDM
   Machado, DM
   de Angelis, DSA
   Salomao, R
   Kallas, EG
   de Moraes-Pinto, MI
AF Ono, E.
   dos Santos, A. M. Nunes
   Succi, R. C. de Menezes
   Machado, D. M.
   de Angelis, D. S. A.
   Salomao, R.
   Kallas, E. G.
   de Moraes-Pinto, M. I.
TI Imbalance of naive and memory T lymphocytes with sustained high cellular
   activation during the first year of life from uninfected children born
   to HIV-1-infected mothers on HAART
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE immunophenotyping; highly active antiretroviral therapy; HIV-1;
   immunological stimulation; neonates of HIV-infected mothers
ID HIV-INFECTED CHILDREN; INFANTS BORN; IMMUNODEFICIENCY; RESPONSES;
   EXPOSURE; TYPE-1; WOMEN; DIFFERENTIATION; DISTINCT; RISK
AB The immune consequences of in utero HIV exposure to uninfected children whose mothers were submitted to highly active antiretroviral therapy (HAART) during gestation are not well defined. We evaluated 45 HIV-exposed uninfected (ENI) neonates and 45 healthy unexposed control (CT) neonates. All HIV-infected mothers received HAART during pregnancy, and the viral load at delivery was < 50 copies/mL for 56.8%. Twenty-three ENI neonates were further evaluated after 12 months and compared to 23 unexposed healthy age-matched infants. Immunophenotyping was performed by flow cytometry in cord and peripheral blood. Cord blood lymphocyte numbers did not differ between groups. However, ENI neonates had a lower percentage of naive T cells than CT neonates (CD4+, 76.6 vs 83.1%, P < 0.001; CD8+, 70.9 vs 79.6%, P = 0.003) and higher percentages of central memory T cells than CT neonates (CD4+, 13.9 vs 8.7%, P < 0.001; CD8+, 8.6 vs 4.8%, P = 0.001). CD38 mean fluorescence intensity of T cells was higher in ENI neonates (CD4+, 62.2 vs 52.1, P = 0.007; CD8+, 47.7 vs 35.3, P < 0.001). At 12 months, ENI infants still had higher mean fluorescence intensity of CD38 on T cells (CD4+, 34.2 vs 23.3, P < 0.001; CD8+, 26.8 vs 19.4, P = 0.035). Despite effective maternal virologic control at delivery, HIV-exposed uninfected children were born with lower levels of naive T cells. Immune activation was present at birth and remained until at least 12 months of age, suggesting that in utero exposure to HIV causes subtle immune abnormalities.
C1 [Ono, E.; Succi, R. C. de Menezes; Machado, D. M.; de Moraes-Pinto, M. I.] Univ Fed Sao Paulo, EPM, Dept Pediat, Disciplina Infectol Pediat, BR-040392 Sao Paulo, Brazil.
   [de Angelis, D. S. A.] Univ Fed Sao Paulo, EPM, Dept Pediat, Disciplina Pediat Neonatal, BR-040392 Sao Paulo, Brazil.
   [Salomao, R.; Kallas, E. G.] Univ Fed Sao Paulo, EPM, Dept Med, Disciplina Doencas Infecciosas, BR-040392 Sao Paulo, Brazil.
   [de Angelis, D. S. A.] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP de Moraes-Pinto, MI (corresponding author), Univ Fed Sao Paulo, EPM, Dept Pediat, Disciplina Infectol Pediat, Rua Pedro Toledo 781,9 Andar, BR-040392 Sao Paulo, Brazil.
EM m.isabelmp@uol.com.br
RI Kallas, Esper G/C-9539-2012; Salomao, Reinaldo/C-6419-2013; dos Santos,
   Amelia/H-5986-2013
OI Salomao, Reinaldo/0000-0003-1149-4598; dos Santos,
   Amelia/0000-0002-8407-1556; Kallas, Esper/0000-0003-2026-6925
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [01/11011-6]; CAPESCAPES
FX Research supported by FAPESP (#01/11011-6) and CAPES.
CR ABBAS AK, 2008, CELLULAR MOL IMMUNOL, P298
   ALDHOUS MC, 1994, CLIN EXP IMMUNOL, V97, P61
   Alimonti JB, 2005, J INFECT DIS, V191, P20, DOI 10.1086/425998
   Alter G, 2004, J IMMUNOL, V173, P5305, DOI 10.4049/jimmunol.173.8.5305
   Briand N, 2006, PEDIATR INFECT DIS J, V25, P325, DOI 10.1097/01.inf.0000207398.10466.0d
   Bunders MJ, 2005, ACTA PAEDIATR, V94, P1571, DOI 10.1080/08035250510042951
   CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42
   CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012
   CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8
   Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871
   DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296
   Fowke KR, 2000, IMMUNOL CELL BIOL, V78, P586, DOI 10.1046/j.1440-1711.2000.00944.x
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287
   Giaquinto C, 2004, AIDS, V18, P2009
   Gonzalez I, 2005, REV INVEST CLIN, V57, P498
   Harari A, 2002, BLOOD, V100, P1381, DOI 10.1182/blood-2001-11-0080
   Joseph KS, 1998, NEW ENGL J MED, V339, P1434, DOI 10.1056/NEJM199811123392004
   Kuhn L, 2001, AIDS, V15, P1, DOI 10.1097/00002030-200101050-00003
   Lambert JS, 2005, CLIN DIAGN LAB IMMUN, V12, P622, DOI 10.1128/CDLI.12.5.622-631.2005
   Legrand FA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000102
   Levy JA, 1998, J INFECT DIS, V177, P470, DOI 10.1086/517378
   Lima M, 2004, PEDIATR INFECT DIS J, V23, P604, DOI 10.1097/01.inf.0000128780.79145.5c
   LUZURIAGA K, 1995, J IMMUNOL, V154, P433
   MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766
   Montoya CJ, 2006, CLIN IMMUNOL, V120, P138, DOI 10.1016/j.clim.2006.02.008
   Nielsen SD, 2001, BLOOD, V98, P398, DOI 10.1182/blood.V98.2.398
   Pacheco SE, 2006, J INFECT DIS, V194, P1089, DOI 10.1086/507645
   Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489
   Resino S, 2004, CLIN EXP IMMUNOL, V137, P570, DOI 10.1111/j.1365-2249.2004.02583.x
   Resino S, 2006, JAIDS-J ACQ IMM DEF, V42, P269, DOI 10.1097/01.qai.0000222287.90201.d7
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Schenal M, 2005, AIDS, V19, P653, DOI 10.1097/01.aids.0000166088.85951.25
   Silva AAM, 2001, PAEDIATR PERINAT EP, V15, P257, DOI 10.1046/j.1365-3016.2001.00358.x
   ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789
   *UNAIDS, 2004, UNAIDS0416E
   Van Rie A, 2006, CLIN VACCINE IMMUNOL, V13, P246, DOI 10.1128/CVI.13.2.246-252.2006
   Wasik TJ, 1999, J IMMUNOL, V162, P4355
   Zaccarelli CA, 2007, CYTOM PART B-CLIN CY, V72B, P14, DOI 10.1002/cyto.b.20152
NR 39
TC 45
Z9 46
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2008
VL 41
IS 8
BP 700
EP 708
DI 10.1590/S0100-879X2008000800011
PG 9
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 349LP
UT WOS:000259282600011
PM 18797705
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Michaelsson, J
   Barbosa, HMR
   Jordan, KA
   Chapman, JM
   Brunialti, MKC
   Neto, WK
   Nukui, Y
   Sabino, EC
   Chieia, MA
   Oiliveira, ASB
   Nixon, DF
   Kallas, EG
AF Michaelsson, Jakob
   Barbosa, Hugo Marcelo R.
   Jordan, Kimberley A.
   Chapman, Joan M.
   Brunialti, Milena K. C.
   Neto, Walter Kleine
   Nukui, Youko
   Sabino, Ester C.
   Chieia, Marco Antonio
   Bulle Oiliveira, Acary Souza
   Nixon, Douglas F.
   Kallas, Esper G.
TI The frequency of CD127(low) expressing CD4(+)CD25(high) T regulatory
   cells is inversely correlated with human T lymphotrophic virus type-1
   (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated
   myelopathy/tropical spastic paraparesis
SO BMC IMMUNOLOGY
LA English
DT Article
ID I-ASSOCIATED MYELOPATHY; KAPPA-B SITE; TAX PROTEIN; CYTOKINE PRODUCTION;
   CD4+CD25+T CELLS; GENE-EXPRESSION; SELF-TOLERANCE; INFECTED-CELLS;
   BLOOD-DONORS; ANTIGEN 4
AB Background: CD4(+)CD25(high) regulatory T (T-Reg) cells modulate antigen-specific T cell responses, and can suppress anti-viral immunity. In HTLV-1 infection, a selective decrease in the function of T-Reg cell mediated HTLV-1-tax inhibition of FOXP3 expression has been described. The purpose of this study was to assess the frequency and phenotype of T-Reg cells in HTLV-1 asymptomatic carriers and in HTLV-1-associated neurological disease (HAM/TSP) patients, and to correlate with measures of T cell activation.
   Results: We were able to confirm that HTLV-1 drives activation, spontaneous IFN gamma production, and proliferation of CD4+ T cells. We also observed a significantly lower proportion of CTLA-4(+) T-Reg cells (CD4(+)CD25(high) T cells) in subjects with HAM/TSP patients compared to healthy controls. Ki-67 expression was negatively correlated to the frequency of CTLA-4(+) T-Reg cells in HAM/TSP only, although Ki-67 expression was inversely correlated with the percentage of CD127(low) T-Reg cells in healthy control subjects. Finally, the proportion of CD127(low) T-Reg cells correlated inversely with HTLV-1 proviral load.
   Conclusion: Taken together, the results suggest that T-Reg cells may be subverted in HAM/TSP patients, which could explain the marked cellular activation, spontaneous cytokine production, and proliferation of CD4(+) T cells, in particular those expressing the CD25(high)CD127(low) phenotype. T-Reg cells represent a potential target for therapeutic intervention for patients with HTLV-1-related neurological diseases.
C1 [Barbosa, Hugo Marcelo R.; Brunialti, Milena K. C.; Chieia, Marco Antonio; Bulle Oiliveira, Acary Souza; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Michaelsson, Jakob; Jordan, Kimberley A.; Chapman, Joan M.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA USA.
   [Neto, Walter Kleine; Nukui, Youko; Sabino, Ester C.] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Clin Immunol & Allergy Div, BR-05508 Sao Paulo, Brazil.
   [Michaelsson, Jakob] Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden.
RP Kallas, EG (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
EM Jakob.michaelsson@ki.se; hugomarcelo.barbosa@gmail.com;
   kjordan@gmail.com; joanmchapman@yahoo.com; milena.brunialti@unifesp.br;
   walterkleine@yahoo.com.br; ynukui@terra.com.br; sabinoec@uol.com.br;
   abrela99@hotmail.com; abrela99@hotmail.com; douglas.nixon@ucsf.edu;
   kallas.dmed@epm.br
RI Nixon, Douglas/AAU-5734-2020; Kallas, Esper G/C-9539-2012; Sabino, Ester
   Cerdeira/F-7750-2010; Brunialti, Milena K C/C-4905-2012; Barbosa, Hugo
   Marcelo/J-4722-2014
OI Nixon, Douglas/0000-0002-2801-1786; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Brunialti, Milena K C/0000-0003-2874-520X;
   Barbosa, Hugo Marcelo/0000-0002-4854-5996; Kallas,
   Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/10918-6];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [A141531, A152731, A1060379, A1064520];
   The Fogarty International CenterUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43 TW00003]; Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)CAPES; Brazilian Ministry of
   Education; FOGARTY INTERNATIONAL CENTERUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01AI064520, U01AI041531, P01AI064520,
   P01AI064520, R37AI052731, P01AI064520, R01AI052731, P01AI064520,
   R37AI052731, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   R01AI052731, P01AI064520, U01AI041531, P01AI064520, U01AI041531,
   R01AI060379, R01AI052731, R37AI052731, P01AI064520, P01AI064520,
   P01AI064520, P01AI064520, R37AI052731, U01AI041531, R01AI052731,
   P01AI064520, R37AI052731, R37AI052731, U01AI041531, P01AI064520,
   P01AI064520, P01AI064520, P01AI064520, R01AI060379, R21AI060379,
   P01AI064520, U01AI041531, U01AI041531, P01AI064520, R37AI052731,
   P01AI064520, R01AI060379, P01AI064520, P01AI064520, U01AI041531,
   P01AI064520, R37AI052731, P01AI064520, R01AI060379, R01AI052731,
   U01AI041531, P01AI064520, P01AI064520, P01AI064520, P01AI064520,
   R01AI060379, U01AI041531, P01AI064520, P01AI064520, P01AI064520,
   R37AI052731, R01AI052731, P01AI064520, P01AI064520, P01AI064520,
   R37AI052731] Funding Source: NIH RePORTER
FX We would like to thank Marli Campos, Rosemeire Gabriel, and Perpetua for
   the assistance in blood collection, and Dr. Lishomwa Ndhlovu for helpful
   scientific discussions. We are also grateful to Karina I. Carvalho,
   Helena Tomiyama, and Raphaella Goulart for the continuous laboratory
   support. This work was supported by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), grant #04/10918-6, NIH grants (A141531,
   A152731, A1060379, A1064520), and The Fogarty International Center,
   grant #D43 TW00003. Dr. Barbosa and Ms. Brunialti were supported by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of Education.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245
   BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985
   Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509
   Carneiro-Proietti Anna Bárbara F., 2002, Rev. Soc. Bras. Med. Trop., V35, P499, DOI 10.1590/S0037-86822002000500013
   CRENON I, 1993, ONCOGENE, V8, P867
   Daenke S, 1996, VIROLOGY, V217, P139, DOI 10.1006/viro.1996.0101
   deCarvalho SMF, 1997, J ACQ IMMUN DEF SYND, V15, P238, DOI 10.1097/00042560-199707010-00008
   Dittmer U, 2004, IMMUNITY, V20, P293, DOI 10.1016/S1074-7613(04)00054-8
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0
   Edlich Richard F, 2003, J Long Term Eff Med Implants, V13, P127, DOI 10.1615/JLongTermEffMedImplants.v13.i2.70
   FURUKAWA K, 1994, J CLIN INVEST, V94, P1830, DOI 10.1172/JCI117532
   GalvaoCastro B, 1997, TRANSFUSION, V37, P242, DOI 10.1046/j.1537-2995.1997.37297203532.x
   Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x
   Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335
   Gotuzzo E, 2000, INFECT DIS CLIN N AM, V14, P211, DOI 10.1016/S0891-5520(05)70225-7
   IANNONE R, 1992, J ACQ IMMUN DEF SYND, V5, P810
   Innis MA, 1990, PCR PROTOCOLS GUIDE, pxviii
   JACOBSON S, 1991, J IMMUNOL, V146, P1155
   Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848
   Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278
   KANNAGI M, 1992, J VIROL, V66, P2928, DOI 10.1128/JVI.66.5.2928-2933.1992
   Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999
   Kozako T, 2006, J IMMUNOL, V177, P5718, DOI 10.4049/jimmunol.177.8.5718
   LAHERTY CD, 1993, J BIOL CHEM, V268, P5032
   Lim DG, 2000, J IMMUNOL, V165, P6214, DOI 10.4049/jimmunol.165.11.6214
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Mariner JM, 2001, J IMMUNOL, V166, P2602, DOI 10.4049/jimmunol.166.4.2602
   Michaelsson J, 2006, J IMMUNOL, V176, P5741, DOI 10.4049/jimmunol.176.10.5741
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nixon DF, 2005, MICROBES INFECT, V7, P1063, DOI 10.1016/j.micinf.2005.03.026
   Oh U, 2006, J INFECT DIS, V193, P1557, DOI 10.1086/503874
   Pique C, 1996, J VIROL, V70, P4919, DOI 10.1128/JVI.70.8.4919-4926.1996
   Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295
   Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Segurado AAC, 1997, AM J TROP MED HYG, V57, P142, DOI 10.4269/ajtmh.1997.57.142
   Suvas S, 2003, J EXP MED, V198, P889, DOI 10.1084/jem.20030171
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303
   TANAKA Y, 1990, J IMMUNOL, V144, P4202
   UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503
   Vine AM, 2002, J INFECT DIS, V186, P932, DOI 10.1086/342953
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   WARD SM, 2007, J HEPATOL
   Yamano Y, 2005, J CLIN INVEST, V115, P1361, DOI 10.1172/JCI200523913
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 49
TC 17
Z9 17
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2172
J9 BMC IMMUNOL
JI BMC Immunol.
PD JUL 29
PY 2008
VL 9
AR 41
DI 10.1186/1471-2172-9-41
PG 12
WC Immunology
SC Immunology
GA 340EV
UT WOS:000258629800002
PM 18664281
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Ono, E
   dos Santos, AMN
   Machado, DM
   Succi, RCDM
   Amed, AM
   Salomao, R
   Kallas, EG
   de Moraes-Pinto, MI
AF Ono, Erika
   dos Santos, Amelia M. N.
   Machado, Daisy M.
   Succi, Regina C. de M.
   Amed, Abes M.
   Salomao, Reinaldo
   Kallas, Esper G.
   de Moraes-Pinto, M. Isabel
TI Immunologic features of HIV-1-infected women on HAART at delivery
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article; Proceedings Paper
CT 21st Annual Meeting of the Clinical-Cytometry-Society
CY OCT 08-10, 2006
CL Long Beach, CA
SP Clin Cytometry Soc
DE immunophenotyping; HAART; gestation; HIV
ID HIV-INFECTED PATIENTS; CELL SUBSETS; PREGNANCY; RESPONSES; IMMUNITY
AB Background: The conjoint effect of HIV infection and pregnancy on the immune system of women submitted to the prophylactic antiretroviral therapy presently recommended is still poorly understood.
   Methods: We evaluated 44 HIV-infected women (HIV) and 45 HIV-negative women (CT) at parturition and we compared them to 20 healthy nonpregnant women (NP). Immunophenotyping of lymphocytes was done by four-color flow cytometry.
   Results: All HIV-infected women received HAART during pregnancy and 56.8% had viral load <50 copies/mL at delivery. CD4+T cells/mm(3) were lower in HIV (447) than CT (593) and NP (738) (P < 0.05). CD8+T cells/mm(3) were higher in HIV (799) than CT (384) and NP (395) (P < 0.05). NK cells/mm(3) were lower in HIV (146) than in CT (253) and NP (198) (P < 0.05). CD38 expression on CD4+T and on CD8+T cells was higher in HIV (CD4:12.1; CD8:14.9) than in CT(CD4:9.2; CD8:10.2) and NP(CD4:8.6; CD8:6.0) (P < 0.05). However, CD56 expression on CD8+T cells (a marker of cytolytic effector function) was lower in HIV(7%) than in CT(12%) and NP(9%) (P < 0.05).
   Conclusions: Even with low levels of viremia, HIV-infected women at delivery showed a different immunologic profile from both healthy non-HIV-infected women in the puerperium and nonpregnant women, with lower CD4+T and higher CD8+T cells, high levels of CD38 expression, but low CD56 expression on CD8+T cells and low NK cell numbers. (C) 2008 Clinical Cytometry Society.
C1 [Ono, Erika; Machado, Daisy M.; Succi, Regina C. de M.; de Moraes-Pinto, M. Isabel] Univ Fed Sao Paulo, Div Pediat Infect Dis, Res Lab, BR-04039032 Sao Paulo, Brazil.
   [dos Santos, Amelia M. N.] Univ Fed Sao Paulo, Dept Pediat, Div Neonatol Med, BR-04039032 Sao Paulo, Brazil.
   [Amed, Abes M.] Univ Fed Sao Paulo, Dept Obstet, BR-04039032 Sao Paulo, Brazil.
   [Salomao, Reinaldo; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, BR-04039032 Sao Paulo, Brazil.
RP de Moraes-Pinto, MI (corresponding author), Univ Fed Sao Paulo, Div Pediat Infect Dis, Res Lab, Rua Pedro de Toledo,781-9 Andar, BR-04039032 Sao Paulo, Brazil.
EM m.isabelmp@uol.com.br
RI Salomao, Reinaldo/C-6419-2013; dos Santos, Amelia/H-5986-2013; Kallas,
   Esper G/C-9539-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; dos Santos,
   Amelia/0000-0002-8407-1556; Kallas, Esper/0000-0003-2026-6925; Machado,
   Daisy/0000-0003-1993-6442
CR Abbas AK, 2003, CELLULAR MOL IMMUNOL, P243
   Alter G, 2004, J IMMUNOL, V173, P5305, DOI 10.4049/jimmunol.173.8.5305
   Banda NK, 1997, APOPTOSIS, V2, P61, DOI 10.1023/A:1026439726053
   Benito DM, 2005, JAIDS-J ACQ IMM DEF, V38, P373, DOI 10.1097/01.qai.0000153105.42455.c2
   Blair JM, 2004, OBSTET GYNECOL, V103, P663, DOI 10.1097/01.AOG.0000117083.33239.b5
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Douglas SD, 2001, AIDS RES HUM RETROV, V17, P543, DOI 10.1089/08892220151126643
   Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839
   Fiore S, 2006, J REPROD IMMUNOL, V70, P143, DOI 10.1016/j.jri.2005.12.001
   Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287
   Harari A, 2002, BLOOD, V100, P1381, DOI 10.1182/blood-2001-11-0080
   Juretic E, 2004, AM J REPROD IMMUNOL, V52, P1, DOI 10.1111/j.1600-0897.2004.00175.x
   Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341
   Mikyas Y, 1997, J REPROD IMMUNOL, V33, P157, DOI 10.1016/S0165-0378(97)00018-1
   Muller F, 2002, EUR J CLIN INVEST, V32, P535, DOI 10.1046/j.1365-2362.2002.00995.x
   Paranjape RS, 2005, INDIAN J MED RES, V121, P240
   Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148
   Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2
   Ruiz-Mateos E, 2003, AIDS, V17, P947, DOI 10.1097/00002030-200305020-00002
   Sindhu S, 2006, J MED VIROL, V78, P431, DOI 10.1002/jmv.20558
   Sloand E, 2005, AIDS REV, V7, P187
   Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317
   ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789
   *UNAIDS, 2006, REP GLOB AIDS EP, P8
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   ZON LI, 1987, BRIT J HAEMATOL, V66, P251, DOI 10.1111/j.1365-2141.1987.tb01307.x
NR 31
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4949
EI 1552-4957
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD JUL
PY 2008
VL 74B
IS 4
BP 236
EP 243
DI 10.1002/cyto.b.20418
PG 8
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 315HX
UT WOS:000256870500005
PM 18393385
OA Bronze
DA 2020-11-26
ER

PT J
AU Kallas, E
   Merila, M
   Vals, MA
   Terentjeva, I
   Tensing, S
   Ormisson, A
AF Kallas, E.
   Merila, M.
   Vals, M-A
   Terentjeva, I.
   Tensing, S.
   Ormisson, A.
TI Rehospitalization of the newborns after early discharge from delivery
   hospital
SO ACTA PAEDIATRICA
LA English
DT Meeting Abstract
C1 [Kallas, E.; Ormisson, A.] Univ Tartu, Tartu, Estonia.
   [Merila, M.; Vals, M-A] Tartu Univ Hosp, Childrens Clin, Tartu, Estonia.
   [Terentjeva, I.; Tensing, S.] E Viru Cent Hosp, Tartu, Estonia.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD JUN
PY 2008
VL 97
SU 459
BP 145
EP 145
PG 1
WC Pediatrics
SC Pediatrics
GA 313BO
UT WOS:000256716300309
DA 2020-11-26
ER

PT J
AU Carvalho, KI
   Maeda, S
   Marti, L
   Yamashita, J
   Haslett, PAJ
   Kallas, EG
AF Carvalho, Karina I.
   Maeda, Solange
   Marti, Luciana
   Yamashita, Jane
   Haslett, Patrick A. J.
   Kallas, Esper G.
TI Immune cellular parameters of leprosy and human immunodeficiency virus-1
   co-infected subjects
SO IMMUNOLOGY
LA English
DT Article
DE HIV; leprosy; co-infection; lymphocytes; IL-4
ID RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM-TUBERCULOSIS;
   T-CELLS; CYTOKINE PRODUCTION; HIV-INFECTION; RESPONSES; PROFILES;
   SUBSETS; GAMMA; LYMPHOCYTES
AB Leprosy and human immunodeficiency virus-1 (HIV-1) are examples of human infections where interactions between the pathogen and the host cellular immunity determine the clinical manifestations of disease. Hence, a significant immunopathological interaction between HIV-1 and leprosy might be expected. In the present study we explored several aspects of cellular immunity in patients co-infected with HIV-1 and Mycobacterium leprae. Twenty-eight individuals were studied, comprising four groups: healthy controls, HIV-1 and M. leprae co-infection, HIV-1 mono-infection, and M. leprae mono-infection. Subjects in the mono-infection and co-infection groups were matched as far as possible for bacillary load and HIV disease status, as appropriate. Peripheral blood mononuclear cells (PBMC) were analysed using six- and seven-colour flow cytometry to evaluate T-cell subpopulations and their activation status, dendritic cell (DC) distribution phenotypes and expression of IL-4 by T cells. The co-infected group exhibited lower CD4 : CD8 ratios, higher levels of CD8(+) T-cell activation, increased V delta 1 : V delta 2 T cell ratios and decreased percentages of plasmacytoid DC, compared with HIV-1 mono-infected subjects. Across infected groups, IL-4 production by CD4(+) T lymphocytes was positively correlated with the percentage of effector memory CD4(+) T cells, suggesting antigenically driven differentiation of this population of T cells in both HIV-1 and M. leprae infections. Co-infection with M. leprae may exacerbate the immunopathology of HIV-1 disease. A T helper 2 (Th2) bias in the CD4(+) T-cell response was evident in both HIV-1 infection and leprosy, but no additive effect was apparent in co-infected patients.
C1 [Carvalho, Karina I.; Maeda, Solange; Yamashita, Jane; Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Haslett, Patrick A. J.] Univ Miami, Coral Gables, FL 33124 USA.
   [Marti, Luciana] Albert Einstein Res Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Escola Paulista Med, UNIFESP, Disciplina Doencas Infecciosas & Parasitarias, Lab Imunol, Rua Mirassol 207, BR-04044010 Sao Paulo, SP, Brazil.
EM kallas.dmed@epm.br
RI Marti, Luciana/Z-2555-2019; Kallas, Esper G/C-9539-2012; Carvalho,
   Karina IL/J-6789-2012; Marti, Luciana/E-8242-2010
OI Marti, Luciana/0000-0002-3890-0827; Carvalho, Karina
   IL/0000-0002-7763-8139; Marti, Luciana/0000-0002-3890-0827; Kallas,
   Esper/0000-0003-2026-6925
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI052731, R01AI052731, R01AI052731, R01AI052731,
   R01AI052731, R01AI052731] Funding Source: NIH RePORTER; FIC NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW00003, D43 TW000003] Funding Source: Medline; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 AI052731, R01-AI052731-06] Funding Source: Medline
CR Antas PRZ, 2004, BRAZ J MED BIOL RES, V37, P1119, DOI 10.1590/S0100-879X2004000800003
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782
   BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506
   BARNES PF, 1993, INFECT IMMUN, V61, P197, DOI 10.1128/IAI.61.1.197-203.1993
   BLOOM BR, 1986, J IMMUNOL, V137, pR1
   Couppie P, 2004, ARCH DERMATOL, V140, P997, DOI 10.1001/archderm.140.8.997
   Cunha RMD, 2005, CLIN EXP IMMUNOL, V140, P491, DOI 10.1111/j.1365-2249.2005.02796.x
   Eberl M, 2003, FEBS LETT, V544, P4, DOI 10.1016/S0014-5793(03)00483-6
   FUJITA M, 1993, IMMUNOL LETT, V35, P39, DOI 10.1016/0165-2478(93)90145-R
   Galli G, 1998, EUR J IMMUNOL, V28, P3280, DOI 10.1002/(SICI)1521-4141(199810)28:10<3280::AID-IMMU3280>3.0.CO;2-M
   Goebel FD, 2005, INFECTION, V33, P43, DOI 10.1007/s15010-005-6105-x
   Gormus BJ, 2000, J MED PRIMATOL, V29, P259, DOI 10.1034/j.1600-0684.1999.290319.x
   Hirsch HH, 2004, CLIN INFECT DIS, V38, P1159, DOI 10.1086/383034
   Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863
   Kallas EG, 1999, J INFECT DIS, V179, P1124, DOI 10.1086/314702
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864
   Levy JA, 2003, CLIN IMMUNOL, V108, P167, DOI 10.1016/S1521-6616(03)00178-5
   Lockwood DNJ, 2004, BRIT MED J, V328, P1447, DOI 10.1136/bmj.328.7454.1447
   Meima A, 2004, B WORLD HEALTH ORGAN, V82, P373
   Mitra DK, 1999, INT IMMUNOL, V11, P1801, DOI 10.1093/intimm/11.11.1801
   MODLIN RL, 1994, J INVEST DERMATOL, V102, P828, DOI 10.1111/1523-1747.ep12381958
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Nath I, 2000, IMMUNOL LETT, V75, P69, DOI 10.1016/S0165-2478(00)00271-6
   *ORG WH, 1982, WHO TECHREPSER, V675, P1
   Pereira GAS, 2004, AM J TROP MED HYG, V71, P679, DOI 10.4269/ajtmh.2004.71.679
   Poccia F., 2002, Current Molecular Medicine (Hilversum), V2, P769, DOI 10.2174/1566524023361880
   Poles MA, 2003, J VIROL, V77, P10456, DOI 10.1128/JVI.77.19.10456-10467.2003
   Pulendran B, 2004, IMMUNOL RES, V29, P187, DOI 10.1385/IR:29:1-3:187
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Rodrigues DSS, 2002, CLIN EXP IMMUNOL, V128, P149, DOI 10.1046/j.1365-2249.2002.01809.x
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SAMPAIO EP, 1995, INFECT IMMUN, V63, P1848, DOI 10.1128/IAI.63.5.1848-1854.1995
   SAUDE MD, 2006, RECOMENDACOES TERAPI, P1
   SIELING PA, 1993, J IMMUNOL, V150, P5501
   Sousa AE, 2000, CLIN IMMUNOL, V97, P162, DOI 10.1006/clim.2000.4930
   Stenger S, 1999, CURR OPIN MICROBIOL, V2, P89, DOI 10.1016/S1369-5274(99)80015-0
   Stutz A, 2005, EUR J IMMUNOL, V35, P575, DOI 10.1002/eji.200425056
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x
   Ustianowski AP, 2006, LANCET INFECT DIS, V6, P350, DOI 10.1016/S1473-3099(06)70493-5
   WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542
   YAMAMURA M, 1992, J IMMUNOL, V149, P1470
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
NR 45
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD JUN
PY 2008
VL 124
IS 2
BP 206
EP 214
DI 10.1111/j.1365-2567.2007.02756.x
PG 9
WC Immunology
SC Immunology
GA 301VU
UT WOS:000255924900007
PM 18284466
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Watkins, DI
   Burton, DR
   Kallas, EG
   Moore, JP
   Koff, WC
AF Watkins, David I.
   Burton, Dennis R.
   Kallas, Esper G.
   Moore, John P.
   Koff, Wayne C.
TI Nonhuman primate models and the failure of the Merck HIV-1 vaccine in
   humans
SO NATURE MEDICINE
LA English
DT Article
ID SIMIAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; ANKARA BOOST REGIMEN; I
   DOWN-REGULATION; RHESUS MACAQUES; ANTIVIRAL ACTIVITY; INFECTED-CELLS;
   HETEROSEXUAL TRANSMISSION; ANTIRETROVIRAL THERAPY; SIVMAC239 INFECTION
AB The adenovirus type 5 (Ad5)-based vaccine developed by Merck failed to either prevent HIV-1 infection or suppress viral load in subsequently infected subjects in the STEP human Phase 2b efficacy trial. Analogous vaccines had previously also failed in the simian immunodeficiency virus (SIV) challenge-rhesus macaque model. In contrast, vaccine protection studies that used challenge with a chimeric simian-human immunodeficiency virus (SHIV89.6P) in macaques did not predict the human trial results. Ad5 vector -based vaccines did not protect macaques from infection after SHIV89.6P challenge but did cause a substantial reduction in viral load and a preservation of CD4(+) T cell counts after infection, findings that were not reproduced in the human trials. Although the SIV challenge model is incompletely validated, we propose that its expanded use can help facilitate the prioritization of candidate HIV-1 vaccines, ensuring that resources are focused on the most promising candidates. Vaccine designers must now develop T cell vaccine strategies that reduce viral load after heterologous challenge.
C1 [Watkins, David I.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   [Watkins, David I.] Univ Wisconsin, Dept Pathol & Lab Med, Med Sci Ctr 6152, Madison, WI 53706 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Lab Invest Med 60, BR-02146903 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, BR-04044010 Sao Paulo, Brazil.
   [Moore, John P.] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
   [Koff, Wayne C.] IAVI, New York, NY 10038 USA.
RP Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, 1220 Capitol Court, Madison, WI 53715 USA.
EM watkins@primate.wisc.edu
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [R24RR016038, R24RR016038,
   R24RR015371, R24RR016038, R24RR016038, R24RR015371, R24RR015371,
   R24RR016038, R24RR015371, R24RR016038, R24RR015371, R24RR015371,
   R24RR016038, R24RR016038, R24RR015371, R24RR015371, R24RR015371,
   R24RR015371, R24RR016038, R24RR015371, R24RR016038, R24RR015371,
   R24RR016038, R24RR015371] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI036082, R37AI033292, R01AI052056, R01AI049120, R01AI055332,
   R37AI036082, R01AI052056, U01AI069420, R01AI052056, R01AI045463,
   R01AI049120, R01AI045463, R37AI036082, R37AI036082, R01AI049120,
   R37AI033292, R01AI045463, R37AI036082, R37AI036082, R01AI049120,
   R37AI036082, R01AI045463, R01AI055332, R01AI045463, R37AI036082,
   R37AI033292, R37AI036082, R01AI055332, R37AI036082, R01AI052056,
   R37AI036082, R01AI045463, R01AI045463, R01AI045463, R01AI045463,
   R01AI045463, R01AI049120, R37AI033292, R37AI036082, R37AI036082,
   R01AI045463, U01AI069420, R37AI036082, R37AI033292, R37AI033292,
   R01AI049120, R37AI036082, R37AI036082, R01AI049120, R01AI049120,
   R01AI052056, R01AI052056, R37AI036082, R01AI055332, R37AI036082,
   R01AI045463, R01AI045463, U01AI069420, R37AI033292, R37AI036082,
   R01AI055332, R37AI033292, R37AI033292, U01AI069420, R37AI033292,
   R01AI049120, R37AI036082, R37AI036082] Funding Source: NIH RePORTER;
   NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [R24 RR016038, R24 RR015371] Funding Source: Medline;
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI045463, U01 AI069420, R01 AI049120,
   R37 AI33292, R37 AI36082, R37 AI036082, U01 AI69420, R37 AI033292, R01
   AI45463, R01 AI055332, R01 AI052056] Funding Source: Medline
CR Abdel-Motal UM, 2005, VIROLOGY, V333, P226, DOI 10.1016/j.virol.2004.12.030
   Ali A, 2004, J VIROL, V78, P561, DOI 10.1128/JVI.78.2.561-567.2004
   Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002
   Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005
   Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968
   Allen TM, 2002, J VIROL, V76, P10507, DOI 10.1128/JVI.76.20.10507-10511.2002
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   [Anonymous], 2007, Nature, V449, P390
   Baba TW, 2000, NAT MED, V6, P200
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Bennett MS, 2008, J INFECT DIS, V197, P390, DOI 10.1086/525281
   Bennett MS, 2007, J VIROL, V81, P4973, DOI 10.1128/JVI.02362-06
   Benson J, 1998, J VIROL, V72, P4170, DOI 10.1128/JVI.72.5.4170-4182.1998
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005
   Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2
   Chung C, 2007, J VIROL, V81, P1517, DOI 10.1128/JVI.01780-06
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Excler JL, 2007, AIDS, V21, P2259, DOI 10.1097/QAD.0b013e3282eee70c
   Feinberg MB, 2002, NAT MED, V8, P207, DOI 10.1038/nm0302-207
   Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gray RH, 2003, AIDS, V17, P1941, DOI 10.1097/00002030-200309050-00013
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85
   Hel Z, 2002, J IMMUNOL, V169, P4778, DOI 10.4049/jimmunol.169.9.4778
   Hel Z, 2002, VIROLOGY, V304, P125, DOI 10.1006/viro.2002.1722
   Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999
   Kastenmuller W, 2007, J EXP MED, V204, P2187, DOI 10.1084/jem.20070489
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564
   Lifson JD, 2002, NATURE, V415, P272, DOI 10.1038/415272b
   Loffredo JT, 2005, J VIROL, V79, P14986, DOI 10.1128/JVI.79.23.14986-14991.2005
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   McDermott AB, 2005, J VIROL, V79, P15556, DOI 10.1128/JVI.79.24.15556-15566.2005
   McNeil JG, 2004, SCIENCE, V303, P961, DOI 10.1126/science.1096161
   Nilsson C, 1998, AIDS, V12, P2261, DOI 10.1097/00002030-199817000-00006
   O'Connor DH, 2004, J VIROL, V78, P14012, DOI 10.1128/JVI.78.24.14012-14022.2004
   Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002
   Palmowski MJ, 2002, J IMMUNOL, V168, P4391, DOI 10.4049/jimmunol.168.9.4391
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001
   Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333
   Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Rodriguez F, 2002, J VIROL, V76, P4251, DOI 10.1128/JVI.76.9.4251-4259.2002
   Rollman E, 2007, J IMMUNOL, V179, P4571, DOI 10.4049/jimmunol.179.7.4571
   Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2
   Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Smith CL, 2005, J IMMUNOL, V175, P8431, DOI 10.4049/jimmunol.175.12.8431
   THAKALLAPALLY R, 2000, HIV MOL IMMUNOLOGY 2, P73
   Tomiyama H, 2005, J IMMUNOL, V174, P36, DOI 10.4049/jimmunol.174.1.36
   Valentine LE, 2008, J VIROL, V82, P575, DOI 10.1128/JVI.00275-07
   Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998
   *VAXGEN, 2003, VAXGEN ANN RES ITS P
   Vogel TU, 2003, J VIROL, V77, P13348, DOI 10.1128/JVI.77.24.13348-13360.2003
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   Willis RA, 2006, P NATL ACAD SCI USA, V103, P12063, DOI 10.1073/pnas.0605130103
   Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06
   Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999
   Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996
   Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997
   Yang OO, 2003, TRENDS IMMUNOL, V24, P67, DOI 10.1016/S1471-4906(02)00034-0
   Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005
NR 76
TC 198
Z9 201
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2008
VL 14
IS 6
BP 617
EP 621
DI 10.1038/nm.f.1759
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 309NY
UT WOS:000256468700026
PM 18535579
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Bassichetto, KC
   Bergamaschi, DP
   Oliveira, SM
   Deienno, MCV
   Bortolato, R
   de Rezende, HV
   Arthur, T
   Tomiyama, H
   Watkins, C
   Mesquita, F
   Abbate, MC
   Kallas, EG
AF Bassichetto, Katia Cristina
   Bergamaschi, Denise Pimentel
   Oliveira, Solange Maria
   Verri Deienno, Marylei Casteldelli
   Bortolato, Reginaldo
   de Rezende, Heloiza Vilma
   Arthur, Thais
   Tomiyama, Helena
   Watkins, Colyn
   Mesquita, Fabio
   Abbate, Maria Cristina
   Kallas, Esper Georges
TI Elevated Risk for HIV-1 Infection in Adolescents and Young Adults in Sao
   Paulo, Brazil
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; SENSITIVE ENZYME-IMMUNOASSAY; TESTING
   STRATEGY; MEN; PREVENTION; BEHAVIORS; HIV/AIDS; SANTOS; SEX
AB Background. Recent studies have sought to describe HIV infection and transmission characteristics around the world. Identification of early HIV-1 infection is essential to proper surveillance and description of regional transmission trends. In this study we compare people recently infected (RI) with HIV-1, as defined by Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS), to those with chronic infection. Methodology/Principal Findings. Subjects were identified from 2002-2004 at four testing sites in Sao Paulo. Of 485 HIV-1-positive subjects, 57 (12%) were defined as RI. Of the participants, 165 (34.0%) were aware of their serostatus at the time of HIV-1 testing. This proportion was statistically larger (p<0.001) among the individuals without recent infection (n = 158, 95.8%) compared to 7 individuals (4.2%) with recently acquired HIV-1 infection. In the univariate analysis, RI was more frequent in,25 and >59 years-old age strata (p < 0.001). The majority of study participants were male (78.4%), 25 to 45 years-old (65.8%), white (63.2%), single (61.7%), with family income of four or more times the minimum wage (41.0%), but with an equally distributed educational level. Of those individuals infected with HIV-1, the predominant route of infection was sexual contact (89.4%), with both hetero (47.5%) and homosexual (34.5%) exposure. Regarding sexual activity in these individuals, 43.9% reported possible HIV-1 exposure through a seropositive partner, and 49.4% reported multiple partners, with 47% having 2 to 10 partners and 37.4% 11 or more; 53.4% of infected individuals reported condom use sometimes; 34.2% reported non-injecting, recreational drug use and 23.6% were reactive for syphilis by VDRL. Subjects younger than 25 years of age were most vulnerable according to the multivariate analysis. Conclusions/Significance. In this study, we evaluated RI individuals and discovered that HIV-1 has been spreading among younger individuals in Sao Paulo and preventive approaches should, therefore, target this age stratum.
C1 [Bassichetto, Katia Cristina; Mesquita, Fabio; Abbate, Maria Cristina] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
   [Bergamaschi, Denise Pimentel; Arthur, Thais; Kallas, Esper Georges] Univ Sao Paulo, Dept Allergy & Immunol, Sao Paulo, Brazil.
   [Oliveira, Solange Maria] Henfil Counseling & Testing Ctr, Sao Paulo, Brazil.
   [Verri Deienno, Marylei Casteldelli] Spec Attend Serv STD Aids Camp Eliseos, Sao Paulo, Brazil.
   [Bortolato, Reginaldo] Spec Attend Serv STD Aids Lapa, Sao Paulo, Brazil.
   [de Rezende, Heloiza Vilma] Pirituba Counsel & Test Ctr, Sao Paulo, Brazil.
   [Tomiyama, Helena; Watkins, Colyn; Kallas, Esper Georges] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP Bassichetto, KC (corresponding author), Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
EM kbassichetto@prefeitura.sp.gov.br
RI Bergamaschi, Denise Pimentel/I-7383-2017; Kallas, Esper G/C-9539-2012;
   Mesquita, Fabio/AAZ-7021-2020
OI Bergamaschi, Denise Pimentel/0000-0002-6889-8588; Mesquita,
   Fabio/0000-0002-8297-0224; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS; Ministry of HealthMinistry of Health
   - Turkey [TC282/05, 914/BRA/3014]; Sao Paulo City Health Department
   [2004-0.168.922-7]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9]
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (TC282/05, UNESCO/Bassichetto and
   914/BRA/3014, UNESCO/Kallas), the Sao Paulo City Health Department
   (2004-0.168.922-7/Kallas), and Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (04/15856-9/Kallas).
CR Alves K, 2003, JAIDS-J ACQ IMM DEF, V32, P551, DOI 10.1097/00126334-200304150-00014
   Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   *BRAS MIN SAUD, 2002, B EP AIDS, V15
   *BRAS MIN SAUD SEC, 2002, VIG HIV BRAS NOV DIR
   *BRAS MIN SAUD SEC, 2002, SIST INF CENTR TEST
   *CDCP, 2001, MMWR, V50
   Chawla A, 2007, J CLIN MICROBIOL, V45, P415, DOI 10.1128/JCM.01879-06
   Cooperman NA, 2007, AIDS EDUC PREV, V19, P321, DOI 10.1521/aeap.2007.19.4.321
   da Silva CGM, 2005, AIDS, V19, pS31, DOI 10.1097/01.aids.0000191488.77038.bb
   DEAN AG, 2002, EPI INFO DATABASE ST
   Diaz RS, 1999, AIDS, V13, P1417, DOI 10.1097/00002030-199907300-00024
   Hosmer D. W., 2001, APPL LOGISTIC REGRES
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Jarlais DC, 2005, AM J PUBLIC HEALTH, V95, P1439, DOI 10.2105/AJPH.2003.036517
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kellerman SE, 2002, JAIDS-J ACQ IMM DEF, V31, P202, DOI 10.1097/00126334-200210010-00011
   Oliveira CAD, 2005, J CLIN MICROBIOL, V43, P1439, DOI 10.1128/JCM.43.3.1439-1442.2005
   Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013
   Puchhammer-Stokl E, 2005, J CLIN MICROBIOL, V43, P497, DOI 10.1128/JCM.43.1.497-498.2005
   Rawal BD, 2003, JAIDS-J ACQ IMM DEF, V33, P349, DOI 10.1097/00126334-200307010-00009
   Rosa H, 2006, REV SAUDE PUBL, V40, P220, DOI 10.1590/S0034-89102006000200006
   Schwarcz SK, 2002, J INFECT DIS, V186, P1019, DOI 10.1086/342954
   *SECR MUN SAUD SAO, 2007, B EP AIDS DST HEP B
   Snedecor G.W., 1967, STAT METHODS
   STALL R, 1994, ARCH INTERN MED, V154, P57, DOI 10.1001/archinte.154.1.57
   StataCorp, 2015, STAT STAT SOFTW REL
   Stolte IG, 2004, AIDS, V18, P303, DOI 10.1097/00002030-200401230-00021
   Szwarcwald CL, 2005, AIDS, V19, pS51, DOI 10.1097/01.aids.0000191491.66736.16
NR 28
TC 9
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2008
VL 3
IS 1
AR e1423
DI 10.1371/journal.pone.0001423
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 366GT
UT WOS:000260469400019
PM 18183303
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Abel, L
   Pessoa, M
   Sette, H
   Ferraz, BH
   Moreira, CA
   Marti, L
   Rodrigues, D
   Kallas, E
   Alves, V
AF Abel, Lucia
   Pessoa, Mario
   Sette, Hoel
   Ferraz Neto, Ben Hur
   Moreira Filho, Carlos Alberto
   Marti, Luciana
   Rodrigues, Denise
   Kallas, Esper
   Alves, Venancio
TI Imbalance of the Th1/Th2 immune response in patients with different
   outcome of hepatitis C virus infection
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 05-09, 2008
CL Boston, MA
SP Federat Clinical Immunol Soc
C1 [Abel, Lucia; Pessoa, Mario; Sette, Hoel; Ferraz Neto, Ben Hur; Moreira Filho, Carlos Alberto; Marti, Luciana] Albert Einstein Hosp, IEP, Albert Einstein Res Inst, Sao Paulo, Brazil.
   [Rodrigues, Denise; Kallas, Esper] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Alves, Venancio] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Ferraz-Neto, Ben-Hur/AAH-3969-2020; Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2008
VL 127
SU S
BP S132
EP S133
DI 10.1016/j.clim.2008.03.378
PG 2
WC Immunology
SC Immunology
GA 296HD
UT WOS:000255533200382
DA 2020-11-26
ER

PT J
AU Andreoli, MCC
   Dalboni, MA
   Watanabe, R
   Manfredi, SR
   Canziani, MEF
   Kallas, EG
   Sesso, RC
   Draibe, SA
   Balakrishnan, VS
   Jaber, BL
   Liangos, O
   Cendoroglo, M
AF Andreoli, Maria C. C.
   Dalboni, Maria A.
   Watanabe, Renato
   Manfredi, Silvia R.
   Canziani, Maria E. F.
   Kallas, Esper G.
   Sesso, Ricardo C.
   Draibe, Sergio A.
   Balakrishnan, Vaidyanathapuram S.
   Jaber, Bertrand L.
   Liangos, Orfeas
   Cendoroglo, Miguel
TI Impact of dialyzer membrane on apoptosis and function of
   polymorphonuclear cells and cytokine synthesis by peripheral blood
   mononuclear cells in hemodialysis patients
SO ARTIFICIAL ORGANS
LA English
DT Article
DE apoptosis; biocompatibility; complement; cytokines; hemodialysis;
   polymorphonuclear leukocyte
ID NEUTROPHIL APOPTOSIS; COMPLEMENT; CROSSOVER; UREMIA
AB In an in vivo crossover trial, we compared a cellulosic with a synthetic dialyzer with respect to polymorphonuclear cells (PMN) function and apoptosis, cytokine serum levels and synthesis by peripheral blood mononuclear cells (PBMC), and complement activation. Twenty hemodialysis (HD) patients were assigned in alternate order to HD with cellulose acetate (CA) or polysulfone (PS) dialyzer. After 2 weeks, patients were crossed over to the second dialyzer and treated for another 2 weeks. Apoptosis was assessed by flow cytometry in freshly isolated PMN. Phagocytosis and production of peroxide by PMN were studied by flow cytometry in whole blood. PBMC were isolated from blood samples and incubated for 24 h with or without lipopolysaccharide (LPS). There was no impact of dialyzer biocompatibility on PMN apoptosis and function, cytokine synthesis by PBMC or on their serum levels, serum levels of C3a, and terminal complement complex (TCC). Nevertheless, after HD, serum levels of complement correlated negatively with PMN phagocytosis and peroxide production, and positively with PMN apoptosis and cytokine production by PBMC. Although the results did not show a dialyzer advantage on the immunologic parameters, complement activation may have modulated cell function and apoptosis after HD.
C1 Univ Fed Sao Paulo, Div Nephrol, Dept Med, BR-04038002 Sao Paulo, Brazil.
   Tufts Univ, Sch Med, New England Med Ctr, Div Nephrol,Dept Med, Boston, MA 02111 USA.
RP Andreoli, MCC (corresponding author), Univ Fed Sao Paulo, Div Nephrol, Dept Med, Rua Borges Lagoa 960,4 Andar, BR-04038002 Sao Paulo, Brazil.
EM mclaudia@einstein.br
RI Kallas, Esper G/C-9539-2012; Sesso, Ricardo C C/B-4767-2013; draibe,
   sergio antonio/D-9426-2015; Dalboni, Maria Aparecida/V-6749-2019
OI Dalboni, Maria Aparecida/0000-0002-9282-7181; Kallas,
   Esper/0000-0003-2026-6925; Sesso, Ricardo/0000-0002-1062-0073
CR Cendoroglo M, 1999, J AM SOC NEPHROL, V10, P93
   HASUI M, 1989, J IMMUNOL METHODS, V117, P53, DOI 10.1016/0022-1759(89)90118-X
   HIMMELFARB J, 1993, J AM SOC NEPHROL, V4, P178
   HORL WH, 1985, AM J NEPHROL, V5, P320, DOI 10.1159/000166956
   Jaber BL, 1998, BLOOD PURIFICAT, V16, P325, DOI 10.1159/000014352
   Jaber BL, 2000, KIDNEY INT, V57, P2107, DOI 10.1046/j.1523-1755.2000.00061.x
   KLEMPNER MS, 1990, NEW ENGL J MED, V322, P959, DOI 10.1056/NEJM199004053221404
   Martin-Malo A, 2000, J AM SOC NEPHROL, V11, P936
   METCALF JA, 1986, LAB MANUAL NEUTROPHI
   Rosenkranz AR, 2001, KIDNEY INT, V59, pS216, DOI 10.1046/j.1523-1755.2001.59780216.x
   SCHINDLER R, 1990, KIDNEY INT, V37, P85, DOI 10.1038/ki.1990.12
NR 11
TC 18
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD DEC
PY 2007
VL 31
IS 12
BP 887
EP 892
DI 10.1111/j.1525-1594.2007.00485.x
PG 6
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 234TA
UT WOS:000251185700005
PM 17924987
DA 2020-11-26
ER

PT J
AU Loffredo, JT
   Friedrich, TC
   Leon, EJ
   Stephany, JJ
   Rodrigues, DS
   Spencer, SP
   Bean, AT
   Beal, DR
   Burwitz, BJ
   Rudersdorf, RA
   Wallace, LT
   Piaskowski, SM
   May, GE
   Sidney, J
   Gostick, E
   Wilson, NA
   Price, DA
   Kallas, EG
   Piontkivska, H
   Hughes, AL
   Sette, A
   Watkins, DI
AF Loffredo, John T.
   Friedrich, Thomas C.
   Leon, Enrique J.
   Stephany, Jason J.
   Rodrigues, Denise S.
   Spencer, Sean P.
   Bean, Alex T.
   Beal, Dominic R.
   Burwitz, Benjamin J.
   Rudersdorf, Richard A.
   Wallace, Lyle T.
   Piaskowski, Shari M.
   May, Gemma E.
   Sidney, John
   Gostick, Emma
   Wilson, Nancy A.
   Price, David A.
   Kallas, Esper G.
   Piontkivska, Helen
   Hughes, Austin L.
   Sette, Alessandro
   Watkins, David I.
TI CD8(+) T Cells from SIV Elite Controller Macaques Recognize
   Mamu-B*08-Bound Epitopes and Select for Widespread Viral Variation
SO PLOS ONE
LA English
DT Article
AB Background. It is generally accepted that CD8(+) T cell responses play an important role in control of immunodeficiency virus replication. The association of HLA-B27 and -B57 with control of viremia supports this conclusion. However, specific correlates of viral control in individuals expressing these alleles have been difficult to define. We recently reported that transient in vivo CD8(+) cell depletion in simian immunodeficiency virus (SIV)-infected elite controller (EC) macaques resulted in a brief period of viral recrudescence. SIV replication was rapidly controlled with the reappearance of CD8(+) cells, implicating that these cells actively suppress viral replication in ECs. Methods and Findings. Here we show that three ECs in that study made at least seven robust CD8(+) T cell responses directed against novel epitopes in Vif, Rev, and Nef restricted by the MHC class I molecule Mamu-B*08. Two of these Mamu-B*08-positive animals subsequently lost control of SIV replication. Their breakthrough virus harbored substitutions in multiple Mamu-B*08-restricted epitopes. Indeed, we found evidence for selection pressure mediated by Mamu-B*08-restricted CD8(+) T cells in all of the newly identified epitopes in a cohort of chronically infected macaques. Conclusions. Together, our data suggest that Mamu-B*08-restricted CD8(+) T cell responses effectively control replication of pathogenic SIV(mac)239. All seven regions encoding Mamu-B*08-restricted CD8(+) T cell epitopes also exhibit amino acid replacements typically seen only in the presence of Mamu-B*08, suggesting that the variation we observe is indeed selected by CD8(+) T cell responses. SIVmac239 infection of Indian rhesus macaques expressing Mamu-B*08 may therefore provide an animal model for understanding CD8(+) T cell-mediated control of HIV replication in humans.
C1 [Loffredo, John T.; Friedrich, Thomas C.; Leon, Enrique J.; Stephany, Jason J.; Rodrigues, Denise S.; Spencer, Sean P.; Bean, Alex T.; Beal, Dominic R.; Burwitz, Benjamin J.; Rudersdorf, Richard A.; Wallace, Lyle T.; May, Gemma E.; Wilson, Nancy A.; Watkins, David I.] Univ Wisconsin, WNPRC, Madison, WI 53706 USA.
   [Rodrigues, Denise S.; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Piaskowski, Shari M.; Watkins, David I.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA.
   [Gostick, Emma; Price, David A.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Piontkivska, Helen] Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA.
   [Hughes, Austin L.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.
RP Loffredo, JT (corresponding author), Univ Wisconsin, WNPRC, Madison, WI 53706 USA.
EM loffredo@primate.wisc.edu
RI Price, David A/C-7876-2013; Kallas, Esper G/C-9539-2012
OI Price, David A/0000-0001-9416-2737; Kallas, Esper/0000-0003-2026-6925;
   Friedrich, Thomas/0000-0001-9831-6895; Spencer,
   Sean/0000-0002-7328-5399; Wallace, Lyle/0000-0002-6985-5854
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [HHSN266200400088C, R01 AI049120, R01 AI052056, R24 RR015371, R24
   RR016038, R21 AI068586]; National Center for Research Resources
   (NCRR)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [P51 RR000167]; Japan Health Sciences Foundation
   [GM43940]; Kent State University Research Council; Ohio Board of Regents
   Research Challenge; Research Facilities ImprovementUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR) [RR15459-01,
   RR020141-01]; Medical Research CouncilMedical Research Council UK (MRC)
   [G0501963] Funding Source: researchfish; NATIONAL CENTER FOR RESEARCH
   RESOURCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, R24RR016038, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR016038, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, R24RR015371, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR016038, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, R24RR015371,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, C06RR020141, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR016038, P51RR000167, P51RR000167, C06RR015459, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR016038, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, C06RR020141, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR016038, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, R24RR016038,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, R24RR015371, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, R24RR015371, P51RR000167, P51RR000167,
   R24RR016038, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, R24RR016038,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   R24RR016038, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, R24RR016038,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI052056, R01AI049120,
   R01AI049120, R01AI052056, R01AI049120, R01AI049120, R01AI052056,
   R01AI049120, R21AI068586, R01AI052056, R01AI049120, R01AI049120,
   R01AI052056, R01AI049120, R01AI049120, R01AI052056, R21AI068586] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940, R01GM043940,
   R01GM043940, R01GM043940, R01GM043940, R01GM043940] Funding Source: NIH
   RePORTER
FX This research was supported by National Institutes of Health (NIH)
   contract HHSN266200400088C, NIH grants R01 AI049120, R01 AI052056, R24
   RR015371, and R24 RR016038 to D. I. W. as well as R21 AI068586 to T. C.
   F. Additionally, this publication was made possible in part by grant
   number P51 RR000167 from the National Center for Research Resources
   (NCRR), a component of the NIH, awarded to the WNPRC. This project has
   also been funded in part by a grant from the Japan Health Sciences
   Foundation to D. I. W., NIH grant GM43940 to A. L. H., and support to H.
   P. through the Kent State University Research Council and Ohio Board of
   Regents Research Challenge Grant. D. A. P. is a Medical Research Council
   (UK) Senior Clinical Fellow. This work was conducted in part at a
   facility constructed with support from Research Facilities Improvement
   grant numbers RR15459-01 and RR020141-01 (WNPRC). This publication's
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of NCRR or NIH.
CR Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005
   Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001
   Barassi C, 2004, BLOOD, V104, P2205, DOI 10.1182/blood-2004-06-2134
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102
   BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0
   Borroto R J, 1997, Rev Panam Salud Publica, V1, P3
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Boyson JE, 1996, J IMMUNOL, V156, P4656
   Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Cline AN, 2005, J MED PRIMATOL, V34, P303
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Draenert R, 2004, J EXP MED, V199, P905, DOI 10.1084/jem.20031982
   Dzuris JL, 2000, J IMMUNOL, V164, P283, DOI 10.4049/jimmunol.164.1.283
   Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224
   Evans DT, 2000, J VIROL, V74, P7400, DOI 10.1128/JVI.74.16.7400-7410.2000
   Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004
   Friedrich TC, 2004, J VIROL, V78, P10064, DOI 10.1128/JVI.78.18.10064-10073.2004
   Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585
   Harrer T, 1996, J IMMUNOL, V156, P2616
   Hendel H, 1999, J IMMUNOL, V162, P6942
   Herberts CA, 2006, J IMMUNOL, V176, P2697, DOI 10.4049/jimmunol.176.5.2697
   Horton H, 2006, J IMMUNOL, V177, P7406, DOI 10.4049/jimmunol.177.10.7406
   Hughes AL, 2005, BIOINFORMATICS, V21, P39, DOI 10.1093/bioinformatics/bti1203
   Hughes AL, 2006, CURR GENOMICS, V7, P227, DOI 10.2174/138920206778426942
   Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200
   Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kaizu M, 2007, IMMUNOGENETICS, V59, P693, DOI 10.1007/s00251-007-0233-7
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Keet IPM, 1999, J INFECT DIS, V180, P299, DOI 10.1086/314862
   KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735
   KOENIG WJ, 1995, PLAST RECONSTR SURG, V95, P1
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Kuroda MJ, 1999, J IMMUNOL, V162, P5127
   Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Liu HL, 2004, J INFECT DIS, V190, P1055, DOI 10.1086/423209
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07
   Loffredo JT, 2007, J VIROL, V81, P2624, DOI 10.1128/JVI.01912-06
   Loffredo JT, 2005, J IMMUNOL, V175, P5986, DOI 10.4049/jimmunol.175.9.5986
   Loffredo JT, 2004, J IMMUNOL, V173, P5064, DOI 10.4049/jimmunol.173.8.5064
   Lum JJ, 2003, J CLIN INVEST, V111, P1547, DOI 10.1172/JCI200316233
   Mao HW, 2005, J VIROL, V79, P14887, DOI 10.1128/JVI.79.23.14887-14898.2005
   Marsh SGE, 2000, THE HLA FACTS BOOK
   Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907
   Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Mothe BR, 2002, J IMMUNOL, V169, P210, DOI 10.4049/jimmunol.169.1.210
   Muhl T, 2002, J IMMUNOL, V169, P3438, DOI 10.4049/jimmunol.169.6.3438
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   O'Connor DH, 2003, J VIROL, V77, P9029, DOI 10.1128/JVI.77.16.9029-9040.2003
   O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493
   O'Connor DH, 2004, J VIROL, V78, P14012, DOI 10.1128/JVI.78.24.14012-14022.2004
   Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002
   Pastori C, 2006, BLOOD, V107, P4825, DOI 10.1182/blood-2005-06-2463
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994
   Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000
   Robinson S, 2001, J VIROL, V75, P10179, DOI 10.1128/JVI.75.21.10179-10186.2001
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074
   Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741
   Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002
   Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006
   Zhang ZQ, 2002, J VIROL, V76, P12845, DOI 10.1128/JVI.76.24.12845-12854.2002
NR 82
TC 65
Z9 65
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2007
VL 2
IS 11
AR e1152
DI 10.1371/journal.pone.0001152
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10JA
UT WOS:000207459100001
PM 18000532
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-11-26
ER

PT J
AU Barbour, JD
   Sauer, MM
   Sharp, ER
   Garrison, KE
   Long, BR
   Tomiyama, H
   Bassichetto, KC
   Oliveira, SM
   Abbate, MC
   Nixon, DF
   Kallas, EG
AF Barbour, Jason D.
   Sauer, Mariana M.
   Sharp, Elizabeth R.
   Garrison, Keith E.
   Long, Brian R.
   Tomiyama, Helena
   Bassichetto, Katia C.
   Oliveira, Solange M.
   Abbate, Maria C.
   Nixon, Douglas F.
   Kallas, Esper G.
TI HIV-1/HSV-2 Co-Infected Adults in Early HIV-1 Infection Have Elevated
   CD4+T Cell Counts
SO PLOS ONE
LA English
DT Article
AB Introduction. HIV-1 is often acquired in the presence of pre-existing co-infections, such as Herpes Simplex Virus 2 (HSV-2). We examined the impact of HSV-2 status at the time of HIV-1 acquisition for its impact on subsequent clinical course, and total CD4+ T cell phenotypes. Methods. We assessed the relationship of HSV-1/HSV-2 co-infection status on CD4+ T cell counts and HIV-1 RNA levels over time prior in a cohort of 186 treatment naive adults identified during early HIV-1 infection. We assessed the activation and differentiation state of total CD4+ T cells at study entry by HSV-2 status. Results. Of 186 recently HIV-1 infected persons, 101 (54%) were sero-positive for HSV-2. There was no difference in initial CD8+ T cell count, or differences between the groups for age, gender, or race based on HSV-2 status. Persons with HIV-1/HSV-2 co-infection sustained higher CD4+ T cell counts over time (+69 cells/ul greater (SD = 33.7, p = 0.04) than those with HIV-1 infection alone (Figure 1), after adjustment for HIV-1 RNA levels (-57 cells per 1 log(10) higher HIV-1 RNA, p<0.0001). We did not observe a relationship between HSV-2 infection status with plasma HIV-1 RNA levels over time. HSV-2 acquistion after HIV-1 acquisition had no impact on CD4+ count or viral load. We did not detect differences in CD4+ T cell activation or differentiation state by HSV-2+ status. Discussion. We observed no effect of HSV-2 status on viral load. However, we did observe that treatment naive, recently HIV-1 infected adults co-infected with HSV-2+ at the time of HIV-1 acquisition had higher CD4+ T cell counts over time. If verified in other cohorts, this result poses a striking paradox, and its public health implications are not immediately clear.
C1 [Sauer, Mariana M.; Tomiyama, Helena; Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Barbour, Jason D.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA.
   [Sharp, Elizabeth R.; Garrison, Keith E.; Long, Brian R.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Expt Med, San Francisco, CA USA.
   [Bassichetto, Katia C.; Oliveira, Solange M.; Abbate, Maria C.] Sao Paula City Hlth Syst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
EM kallas.dmed@epm.br
RI Kallas, Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020
OI Nixon, Douglas/0000-0002-2801-1786; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS, Ministry of Health [914/BRA/3014
   UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Kallas]; NIAID/NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI066917/Barbour,
   AI064520/Nixon]; John E. Fogarty International CenterUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43 TW00003]; AIDS Research
   Institute of the AIDS Biology Program at UCSF; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Brazilian
   Ministry of Education; FOGARTY INTERNATIONAL CENTERUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P01AI064520, P01AI064520, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K01AI066917, P30AI027763,
   P01AI064520, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P01AI064520, P30AI027763, P30AI027763,
   K01AI066917, P30AI027763, P01AI064520, P30AI027763, P01AI064520,
   P30AI027763, P30AI027763, K01AI066917, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI064520, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI064520, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P01AI064520, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, K01AI066917, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P01AI064520, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P01AI064520, P30AI027763, P01AI064520, P01AI064520,
   K01AI066917, P30AI027763, P01AI064520, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P01AI064520, P01AI064520,
   P01AI064520, P30AI027763, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P01AI064520, P30AI027763, P30AI027763, P01AI064520, P01AI064520,
   P01AI064520, P30AI027763, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P01AI064520, P30AI027763, P30AI027763, P01AI064520,
   P30AI027763, P30AI027763] Funding Source: NIH RePORTER
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014 UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (04/15856-9/Kallas), the NIAID/NIH
   (AI066917/Barbour), (AI064520/Nixon) the John E. Fogarty International
   Center (D43 TW00003), The AIDS Research Institute of the AIDS Biology
   Program at UCSF. M. M. S. was supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of Education.
CR Barcy S, 2001, J IMMUNOL, V166, P6242, DOI 10.4049/jimmunol.166.10.6242
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Bosnjak L, 2005, J IMMUNOL, V174, P2220, DOI 10.4049/jimmunol.174.4.2220
   Brown EL, 2006, AM J EPIDEMIOL, V164, P733, DOI 10.1093/aje/kwj270
   Cachay ER, 2007, J INFECT DIS, V195, P1270, DOI 10.1086/513568
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Cunningham Anthony L, 2004, J HIV Ther, V9, P9
   FILHO DJ, 2007, AIDS RES HU IN PRESS
   Jones CA, 2003, J VIROL, V77, P11139, DOI 10.1128/JVI.77.20.11139-11149.2003
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Mark KE, 2007, J INFECT DIS, V195, P1324, DOI 10.1086/513276
   Mikloska Z, 2001, J VIROL, V75, P5958, DOI 10.1128/JVI.75.13.5958-5964.2001
   Milligan GN, 1997, VIROLOGY, V229, P259, DOI 10.1006/viro.1997.8441
   MILLIGAN GN, 1995, VIROLOGY, V212, P481, DOI 10.1006/viro.1995.1506
   Milligan GN, 1998, J IMMUNOL, V160, P6093
   Morrow RA, 2003, AM J CLIN PATHOL, V120, P839, DOI [10.1039/AKWHF62YYJ054HA6, 10.1309/AKWHF62YYJ054HA6]
   Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607
   REBBAPRAGADA A, 2006, AIDS 2006 16 INT AID
   Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498
   Schacker T, 2002, J INFECT DIS, V186, P1718, DOI 10.1086/345771
   Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739
   Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915
NR 22
TC 19
Z9 20
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2007
VL 2
IS 10
AR e1080
DI 10.1371/journal.pone.0001080
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10IU
UT WOS:000207458500025
PM 17957262
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Karlsson, AC
   Chapman, JM
   Heiken, BD
   Hoh, R
   Kallas, EG
   Martin, JN
   Hecht, FM
   Deeks, SG
   Nixon, DF
AF Karlsson, A. C.
   Chapman, J. M.
   Heiken, B. D.
   Hoh, R.
   Kallas, E. G.
   Martin, J. N.
   Hecht, F. M.
   Deeks, S. G.
   Nixon, D. F.
TI Antiretroviral drug therapy alters the profile of human immunodeficiency
   virus type 1-specific T-cell responses and shifts the immunodominant
   cytotoxic T-lymphocyte response from gag to pol
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PRIMARY HIV-1 INFECTION; SUBSTANTIAL DIFFERENCES; VIRAL PERSISTENCE;
   IMMUNE-RESPONSES; RESISTANT HIV-1; ESCAPE MUTATION; FITNESS COST;
   EPITOPE; PROTEASE; REPLICATION
AB Antiretroviral drug therapy and cytotoxic T lymphocytes (CTL) both exert selective pressures on human immunodeficiency virus type 1, which influence viral evolution. Compared to chronically infected, antiretroviral-untreated patients, most chronically infected, treated patients with detectable viremia lack a cellular immune response against the Gag 77-85(SL9) epitope but show a new immunodominant response against an epitope in protease PR 76-84. Hence, mutations induced by antiretroviral therapy likely alter the profile of epitopes presented to T cells and thus the direction of the response. The consequences of dual pressures from treatment and CTL need to be considered in monitoring of drug therapy.
C1 Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.
   Karolinska Inst, Swedish Inst Infect Dis Control, S-17182 Solna, Sweden.
   Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.
   San Francisco Gen Hosp, Positive Hlth Program, San Francisco, CA 94110 USA.
   Univ Fed Sao Paulo, Sao Carlos, SP, Brazil.
RP Karlsson, AC (corresponding author), Karolinska Inst, Swedish Inst Infect Dis Control, Dept Virol Immunol & Vaccinol, S-17182 Solna, Sweden.
EM annika.karlsson@smi.ki.se
RI Kallas, Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020; Karlsson,
   Annika/R-2255-2016
OI Nixon, Douglas/0000-0002-2801-1786; Karlsson,
   Annika/0000-0002-2028-8393; Kallas, Esper/0000-0003-2026-6925; Hecht,
   Frederick/0000-0002-5782-1171
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW000003, D43 TW00003] Funding Source: Medline; NCRR NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01
   RR000083, 5-M01 RR00083-37] Funding Source: Medline; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI44595, R01 AI044595, R21 AI055273, AI052745,
   AI055273, P30 AI027763, P30 AI27763, R01 AI052745] Funding Source:
   Medline; NIMH NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [P30 MH062246, P30 MH62246, P30 MH59037] Funding
   Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC) [D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083,
   M01RR000083, M01RR000083, M01RR000083, M01RR000083, M01RR000083] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, R01AI044595, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, R01AI044595, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, R01AI052745, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, R01AI044595, P30AI027763, R01AI044595,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, R01AI052745, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   R01AI044595, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R01AI052745,
   P30AI027763, P30AI027763, R01AI044595, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, R01AI052745,
   P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH059037, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH059037, P30MH059037,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH059037, P30MH059037, P30MH062246,
   P30MH062246, P30MH062246, P30MH059037, P30MH059037, P30MH062246,
   P30MH062246, P30MH059037, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH059037, P30MH059037, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH059037, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH059037, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH059037, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH059037,
   P30MH059037, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH059037, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH059037, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH059037, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH059037, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH059037, P30MH062246, P30MH062246, P30MH059037,
   P30MH059037, P30MH062246, P30MH062246, P30MH062246, P30MH059037,
   P30MH062246, P30MH062246, P30MH059037, P30MH062246, P30MH059037,
   P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246,
   P30MH062246, P30MH062246] Funding Source: NIH RePORTER
CR Alatrakchi N, 2005, AIDS, V19, P25, DOI 10.1097/00002030-200501030-00003
   Ali A, 2004, J VIROL, V78, P561, DOI 10.1128/JVI.78.2.561-567.2004
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Altfeld M, 2005, J VIROL, V79, P5000, DOI 10.1128/JVI.79.8.5000-5005.2005
   Bansal A, 2005, AIDS, V19, P241
   Barbour JD, 2002, J VIROL, V76, P11104, DOI 10.1128/JVI.76.21.11104-11112.2002
   Bergmann CC, 1999, J IMMUNOL, V163, P3379
   Betts MR, 2000, J VIROL, V74, P9144, DOI 10.1128/JVI.74.19.9144-9151.2000
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Dalod M, 1999, J CLIN INVEST, V104, P1431, DOI 10.1172/JCI7162
   Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702
   Deeks SG, 2004, J INFECT DIS, V189, P312, DOI 10.1086/380098
   Deeks SG, 2005, J INFECT DIS, V192, P1537, DOI 10.1086/496892
   Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005
   Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005
   Ferrari G, 2004, J IMMUNOL, V173, P2126, DOI 10.4049/jimmunol.173.3.2126
   Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998
   Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181
   Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005
   Iversen AKN, 2006, NAT IMMUNOL, V7, P179, DOI 10.1038/ni1298
   Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996
   Jamieson BD, 2003, J IMMUNOL, V171, P5372, DOI 10.4049/jimmunol.171.10.5372
   Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003
   Karlsson AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000225
   KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549
   KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3
   Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   Mason RA, 2004, J IMMUNOL, V172, P7212, DOI 10.4049/jimmunol.172.11.7212
   Mason RD, 2005, AIDS, V19, P981, DOI 10.1097/01.aids.0000171415.07034.0d
   Mueller SM, 2007, J VIROL, V81, P2887, DOI 10.1128/JVI.01547-06
   Myint L, 2004, ANTIMICROB AGENTS CH, V48, P444, DOI 10.1128/AAC.48.2.444-452.2004
   Nietfield W, 1995, J Immunol, V154, P2189
   Nixon DF, 2005, LANCET, V365, P1924, DOI 10.1016/S0140-6736(05)66653-6
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Price DA, 2003, J VIROL, V77, P6041, DOI 10.1128/JVI.77.10.6041-6049.2003
   Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000
   Schmitt M, 2000, AIDS, V14, P653, DOI 10.1097/00002030-200004140-00004
   Stratov I, 2005, J VIROL, V79, P7728, DOI 10.1128/JVI.79.12.7728-7737.2005
   van der Most RG, 2003, VIROLOGY, V315, P93, DOI 10.1016/j.virol.2003.07.001
   vanderMost RG, 1996, J IMMUNOL, V157, P5543
   Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003
NR 44
TC 11
Z9 11
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2007
VL 81
IS 20
BP 11543
EP 11548
DI 10.1128/JVI.00779-07
PG 6
WC Virology
SC Virology
GA 218MK
UT WOS:000250019400069
PM 17670829
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Sa, D
   Kallas, EG
   Sanabani, S
   Sabino, E
   Sucupira, MC
   Sanchez-Rosa, AC
   Tescarollo, G
   Tomiyama, H
   Bassichetto, K
   Janini, LM
   Diaz, RS
AF Sa-Filho, Dercy
   Kallas, Esper G.
   Sanabani, Sabri
   Sabino, Ester
   Sucupira, Maria Cecilia
   Sanchez-Rosa, Ana Carolina
   Tescarollo, Graziela
   Tomiyama, Helena
   Bassichetto, Katia
   Janini, Luis Mario
   Diaz, Ricardo Sobhie
TI Characterization of the full-length human immunodeficiency virus-1
   genome from recently infected subjects in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID GP120 ENVELOPE GLYCOPROTEIN; EARLY HIV-1 INFECTION; SAO-PAULO;
   DRUG-RESISTANCE; SUBTYPE-B; TYPE-1; GLYCOSYLATION; DIVERSITY; EVOLUTION;
   SEQUENCES
C1 Univ Fed Sao Paulo, Lab Retrovirol, Sao Paulo, Brazil.
   Fundacao Pro Sangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   Secretaria Municipal Saude Sao Paulo, Coordenacao Municipal DST AIDS, Sao Paulo, Brazil.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, Lab Retrovirol, Rua Pedro de Toledo 78,Vila Clementino, Sao Paulo, Brazil.
EM rsodiaz@terra.com.br
RI Janini, Luiz Mario R/E-9700-2012; Araripe Sucupira, Maria
   Cecilia/K-1931-2012; Diaz, Ricardo/K-3978-2012; Sabino, Ester
   Cerdeira/F-7750-2010; Kallas, Esper G/C-9539-2012; Sanabani, Sabri
   Saeed/F-5600-2012
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Sanabani, Sabri Saeed/0000-0002-8876-8262;
   Kallas, Esper/0000-0003-2026-6925; Janini, Luiz
   Mario/0000-0002-6186-6284
CR Accetturi CA, 2000, J ACQ IMMUN DEF SYND, V24, P399, DOI 10.1097/00126334-200008010-00016
   BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0
   BOTARELLI P, 1991, J IMMUNOL, V147, P3128
   Calazans A, 2005, J INFECT DIS, V191, P1961, DOI 10.1086/430002
   Casseb J, 2004, MEM I OSWALDO CRUZ, V99, P69, DOI 10.1590/S0074-02762004000100012
   Casseb Jorge, 2002, International Journal of Infectious Diseases, V6, P164, DOI 10.1016/S1201-9712(02)90105-0
   Choisy M, 2004, J VIROL, V78, P1962, DOI 10.1128/JVI.78.4.1962-1970.2004
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   Delgado E, 2001, AIDS RES HUM RETROV, V17, P753, DOI 10.1089/088922201750237022
   DILHO DJS, 2005, AIDS RES HUM RETRVIR, V21, P145
   FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513
   Gao Feng, 2004, Expert Rev Vaccines, V3, pS161, DOI 10.1586/14760584.3.4.S161
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Heyndrickx L, 1998, AIDS RES HUM RETROV, V14, P1291, DOI 10.1089/aid.1998.14.1291
   Holguin Africa, 2002, HIV Clin Trials, V3, P403
   Huang XL, 1997, BIOCHEMISTRY-US, V36, P10846, DOI 10.1021/bi9703655
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kantor R, 2004, J CLIN VIROL, V29, P152, DOI 10.1016/S1386-6532(03)00115-X
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Mullins James I, 2004, Expert Rev Vaccines, V3, pS151, DOI 10.1586/14760584.3.4.S151
   Papandreou MJ, 1996, FEBS LETT, V379, P171, DOI 10.1016/0014-5793(95)01505-1
   Pollakis G, 2001, J BIOL CHEM, V276, P13433, DOI 10.1074/jbc.M009779200
   Rawal BD, 2003, JAIDS-J ACQ IMM DEF, V33, P349, DOI 10.1097/00126334-200307010-00009
   Rossini MAA, 2001, BRAZ J MED BIOL RES, V34, P45, DOI 10.1590/S0100-879X2001000100005
   Sa DJ, 2003, J CLIN VIROL, V28, P186, DOI 10.1016/S1386-6532(03)00007-6
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Santoro-Lopes G, 2000, AIDS RES HUM RETROV, V16, P953, DOI 10.1089/08892220050058362
   Sucupira MCA, 2001, ANTIVIR THER, V6, P263
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Yamaguchi Y, 1997, P NATL ACAD SCI USA, V94, P1264, DOI 10.1073/pnas.94.4.1264
   Yamaguchi-Kabata Y, 2000, J VIROL, V74, P4335, DOI 10.1128/JVI.74.9.4335-4350.2000
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
NR 37
TC 5
Z9 5
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2007
VL 23
IS 9
BP 1087
EP 1094
DI 10.1089/aid.2006.0173
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 219BC
UT WOS:000250058700005
PM 17919103
DA 2020-11-26
ER

PT J
AU Hoff, ST
   Abebe, M
   Ravn, P
   Range, N
   Malenganisho, W
   Rodriques, DS
   Kallas, EG
   Soborg, C
   Doherty, TM
   Andersen, P
   Weldingh, K
AF Hoff, Soren T.
   Abebe, Markos
   Ravn, Pernille
   Range, Nyagosya
   Malenganisho, Wabyahe
   Rodriques, Denise S.
   Kallas, Esper G.
   Soborg, Christian
   Doherty, T. Mark
   Andersen, Peter
   Weldingh, Karin
TI Evaluation of Mycobacterium tuberculosis-specific antibody responses in
   populations with different levels of exposure from Tanzania, Ethiopia,
   Brazil, and Denmark
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; SEROLOGICAL MARKERS;
   HUMORAL RESPONSE; CELL EPITOPES; T-CELLS; DIAGNOSIS; INFECTION;
   ANTIGENS; ESAT-6
AB Background. New, simple, and better-performing diagnostic tools are needed for the diagnosis of tuberculosis (TB). Much effort has been invested in developing an antibody-based test for TB, but to date, no such test has performed with sufficient sensitivity and specificity. A key question remaining is the extent to which the disappointing performance of current tests is associated with a high background prevalence of latent TB.
   Methods. We compared Mycobacterium tuberculosis-specific ESAT-6 and CFP-10 antibody responses in a total of 565 human serum samples from M. tuberculosis-uninfected donors and donors with latent infection, as well as samples from patients with active TB. Our study included samples from 4 countries, representing environments with low, intermediate, and high TB incidences.
   Results. We demonstrated significant increases in antibody levels in latently infected contacts, compared with M. tuberculosis-uninfected individuals, and in patients with active TB disease, compared with latently infected contacts. Furthermore, we found a striking increase in the magnitude of the antibody responses in samples obtained from infected Ethiopian individuals (with and without disease), compared with Danish and Brazilian infected individuals; this was presumably the result of higher exposure levels.
   Conclusions. Our study confirms the presence of ESAT-6 and CFP-10 antibodies in patients with TB, and we demonstrate that significant antibody responses are not restricted to active TB disease but can reflect latent infection, particularly in areas with high levels of exposure to M. tuberculosis. This finding is important for the understanding of the poor discriminatory power of current serodiagnostic tests in regions of endemicity, and it may have major implications on the future development of serologic tests.
C1 Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen S, Denmark.
   Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.
   Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark.
   Armauer Hansen Res Inst, Addis Ababa, Ethiopia.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Clemente Ferreira Inst, Sao Paulo, Brazil.
RP Hoff, ST (corresponding author), Statens Serum Inst, Dept Infect Dis Immunol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM Sho@ssi.dk
RI Kallas, Esper G/C-9539-2012
OI Andersen, Peter/0000-0002-5869-2551; Kallas, Esper/0000-0003-2026-6925
CR Al Zahrani K, 2000, AM J RESP CRIT CARE, V162, P1323, DOI 10.1164/ajrccm.162.4.9912115
   Aseffa A, 2005, LEPROSY REV, V76, P147
   Azzurri A, 2006, INT J IMMUNOPATH PH, V19, P199
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195
   Brock I, 2004, J CLIN MICROBIOL, V42, P2379, DOI 10.1128/JCM.42.6.2379-2387.2004
   Brusasca PN, 2001, SCAND J IMMUNOL, V54, P448, DOI 10.1046/j.1365-3083.2001.00975.x
   Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002
   Conde MB, 2004, CLIN DIAGN LAB IMMUN, V11, P94, DOI 10.1128/CDLI.11.1.94-97.2004
   Davidow A, 2005, INFECT IMMUN, V73, P6846, DOI 10.1128/IAI.73.10.6846-6851.2005
   Demissie A, 2004, J IMMUNOL, V172, P6938, DOI 10.4049/jimmunol.172.11.6938
   DINNES J, 2007, HEALTH TECHNOL ASSES, V4, pE202
   Gennaro ML, 2000, CLIN INFECT DIS, V30, pS243, DOI 10.1086/313868
   Gounder C, 2002, J CLIN MICROBIOL, V40, P1989, DOI 10.1128/JCM.40.6.1989-1993.2002
   Greenaway C, 2005, INT J TUBERC LUNG D, V9, P1112
   Haile Y, 2002, MICROBIOL-SGM, V148, P3881, DOI 10.1099/00221287-148-12-3881
   Harboe M, 1998, INFECT IMMUN, V66, P717, DOI 10.1128/IAI.66.2.717-723.1998
   HILL PG, 2001, SCAND J IMMUNOL, V54, P448
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002
   Kassa-Kelembho E, 2006, CLIN VACCINE IMMUNOL, V13, P702, DOI 10.1128/CVI.00194-05
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Maekura R, 2003, J CLIN MICROBIOL, V41, P1322, DOI 10.1128/JCM.41.3.1322-1325.2003
   McConkey SJ, 2002, INT J TUBERC LUNG D, V6, P246
   Mukhopadhyay A, 2006, INT J TUBERC LUNG D, V10, P620
   Okuda Y, 2004, J CLIN MICROBIOL, V42, P1136, DOI 10.1128/JCM.42.3.1136-1141.2004
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Perkins MD, 2003, CHEST, V123, P107, DOI 10.1378/chest.123.1.107
   Range N, 2005, TROP MED INT HEALTH, V10, P826, DOI 10.1111/j.1365-3156.2005.01463.x
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005
   Rogerson BJ, 2006, IMMUNOLOGY, V118, P195, DOI 10.1111/j.1365-2567.2006.02355.x
   ROTHEL JS, 2005, ANTI INFECT THER, V3, P981
   Silva VMC, 2003, INT J TUBERC LUNG D, V7, P478
   Singh KK, 2005, INFECT IMMUN, V73, P5004, DOI 10.1128/IAI.73.8.5004-5014.2005
   Singh KK, 2005, CLIN DIAGN LAB IMMUN, V12, P354, DOI 10.1128/CDLI.12.2.354-358.2005
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202
   Talbot EA, 2004, CLIN INFECT DIS, V39, pE1, DOI 10.1086/421388
   Tiwari RP, 2005, CLIN DIAGN LAB IMMUN, V12, P465, DOI 10.1128/CDLI.12.3.465-473.2005
   Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005
   *WHO, 2004, GLOB TUB CONTR REP
NR 40
TC 50
Z9 50
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2007
VL 45
IS 5
BP 575
EP 582
DI 10.1086/520662
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 197LM
UT WOS:000248557000017
PM 17682991
OA Bronze
DA 2020-11-26
ER

PT J
AU Snyder-Cappione, JE
   Nixon, DF
   Loo, CP
   Chapman, JM
   Meiklejohn, DA
   Melo, FF
   Costa, PR
   Sandberg, JK
   Rodrigues, DS
   Kallas, EG
AF Snyder-Cappione, Jennifer E.
   Nixon, Douglas F.
   Loo, Christopher P.
   Chapman, Joan M.
   Meiklejohn, Duncan A.
   Melo, Fernando F.
   Costa, Priscilla R.
   Sandberg, Johan K.
   Rodrigues, Denise S.
   Kallas, Esper G.
TI Individuals with pulmonary tuberculosis have lower levels of circulating
   CD1d-restricted NKT cells
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID KILLER T-CELLS; RECEPTOR; PATHOGENESIS; METAANALYSIS; SARCOIDOSIS;
   MENINGITIS; ACTIVATION; EXPANSION; DISEASES; ANTIGEN
AB Mycobacterium tuberculosis (MTB) is a leading cause of mortality worldwide from an infectious agent. Natural killer T (NKT) cells recognize mycobacterial antigens and contribute to anti-MTB immunity in mouse models. NKT cells were measured in subjects with pulmonary tuberculosis, MTB-exposed individuals, and healthy controls. NKT cell levels are selectively lower in peripheral blood mononuclear cells from individuals with pulmonary tuberculosis than in both MTB-exposed subjects and healthy control subjects. This apparent loss of NKT cells from the peripheral blood is sustained during the 6 months after the initiation of MTB treatment. These findings indicate that NKT cells may be an important component of antituberculosis immunity.
C1 Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
   Karolinska Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
   Clemente Ferreira Inst, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Nixon, DF (corresponding author), Univ Calif San Francisco, Div Expt Med, Box 1234, San Francisco, CA 94143 USA.
EM douglas.nixon@ucsf.edu
RI Nixon, Douglas/AAU-5734-2020; Kallas, Esper G/C-9539-2012
OI Nixon, Douglas/0000-0002-2801-1786; Snyder-Cappione,
   Jennifer/0000-0002-0941-5582; Sandberg, Johan/0000-0002-6275-0750; Loo,
   Christopher/0000-0002-5302-8774; Kallas, Esper/0000-0003-2026-6925
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43 TW00003] Funding Source: Medline; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI41531, AI52731] Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI041531, U01AI041531, U01AI041531, R01AI052731, U01AI041531,
   R01AI052731, R37AI052731, R01AI052731, R01AI052731, U01AI041531,
   U01AI041531, U01AI041531, R37AI052731, R37AI052731, R37AI052731,
   R01AI052731, R01AI052731, R37AI052731, R37AI052731, U01AI041531,
   R37AI052731, R37AI052731, R37AI052731, R37AI052731, U01AI041531,
   U01AI041531] Funding Source: NIH RePORTER
CR Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141
   Chackerian A, 2002, INFECT IMMUN, V70, P6302, DOI 10.1128/IAI.70.11.6302-6309.2002
   Dieli F, 2003, J IMMUNOL, V171, P1961, DOI 10.4049/jimmunol.171.4.1961
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5
   Erdozain JG, 2006, LUPUS, V15, P232, DOI 10.1191/0961203306lu2289xx
   Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101
   Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594
   Hansen DS, 2004, INT J PARASITOL, V34, P15, DOI 10.1016/j.ijpara.2003.09.007
   Harada M, 2004, INT IMMUNOL, V16, P241, DOI 10.1093/intimm/dxh023
   Ho LP, 2005, LANCET, V365, P1062, DOI 10.1016/S0140-6736(05)71143-0
   Kobayashi S, 2004, INT IMMUNOL, V16, P215, DOI 10.1093/intimm/dxh020
   Kojo S, 2001, ARTHRITIS RHEUM-US, V44, P1127, DOI 10.1002/1529-0131(200105)44:5<1127::AID-ANR194>3.0.CO;2-W
   Lee PT, 2002, J CLIN INVEST, V110, P793, DOI 10.1172/JCI200215832
   Mempel M, 2000, AM J PATHOL, V157, P509, DOI 10.1016/S0002-9440(10)64562-2
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Sandberg JK, 2003, EUR J IMMUNOL, V33, P588, DOI 10.1002/eji.200323707
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Wilson MT, 2003, P NATL ACAD SCI USA, V100, P10913, DOI 10.1073/pnas.1833166100
   World Health Organisation, 2006, TUB FACT SHEET 104
NR 20
TC 45
Z9 49
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2007
VL 195
IS 9
BP 1361
EP 1364
DI 10.1086/513567
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 153AY
UT WOS:000245405300020
PM 17397008
OA Bronze
DA 2020-11-26
ER

PT J
AU Leal, FE
   Cavazzana, CL
   de Andrade, HF
   Galisteo, AJ
   De Mendonca, JS
   Kallas, EG
AF Leal, Fabio Eudes
   Cavazzana, Cinthya Luzia
   de Andrade, Heitor Franco, Jr.
   Galisteo, Andres Jimenez, Jr.
   De Mendonca, Joao Silva
   Kallas, Esper Georges
TI Toxoplasma gondii pneumonia in immunocompetent subjects: case report and
   review
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INDUCIBLE NITRIC-OXIDE; GAMMA-INTERFERON; MACROPHAGE; INFECTION; HOST;
   ACTIVATION; MICE
AB Pulmonary toxoplasmosis is rare in immunocompetent subjects. Here, we describe a 41-year-old previously healthy male patient who presented to the emergency department of a hospital with a life-threatening case of pneumonia due to Toxoplasma gondii infection, which responded to specific therapy. Clinical and image-based findings overlap with those for atypical pneumonias, and toxoplasmosis should be considered in the differential diagnosis-especially if immunoglobulin M-specific antibodies are detected.
C1 Univ Fed Sao Paulo, BR-04044010 Sao Paulo, Brazil.
   Hosp Serv Publ Estadual Sao Paulo, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Fed Sao Paulo, Rua Mirassol 207, BR-04044010 Sao Paulo, Brazil.
EM kallas.dmed@epm.br
RI Kallas, Esper G/C-9539-2012; de Andrade Junior, Heitor
   Franco/AAP-4689-2020; Galisteo, Andres J/F-6639-2012; de Andrade Junior,
   Heitor Franco/F-7082-2012
OI de Andrade Junior, Heitor Franco/0000-0003-4697-4647; Galisteo, Andres
   J/0000-0003-1611-6721; de Andrade Junior, Heitor
   Franco/0000-0003-4697-4647; cavazzana, cinthya/0000-0002-5088-4831;
   Kallas, Esper/0000-0003-2026-6925
CR Andrade RM, 2005, INFECT IMMUN, V73, P3115, DOI 10.1128/IAI.73.5.3115-3123.2005
   Andrade RM, 2003, J IMMUNOL, V171, P6750, DOI 10.4049/jimmunol.171.12.6750
   CANDOLFI E, 1993, J INFECTION, V26, P79, DOI 10.1016/0163-4453(93)96968-V
   Carme B, 2002, J CLIN MICROBIOL, V40, P4037, DOI 10.1128/JCM.40.11.4037-4044.2002
   Coêlho Raquel A.L., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P229, DOI 10.1590/S0036-46652003000400011
   Darde ML, 1998, J CLIN MICROBIOL, V36, P324
   De Salvador-Guillouet Francine, 2006, J Infect, V53, pe47, DOI 10.1016/j.jinf.2005.10.026
   Evans T G, 1991, Semin Respir Infect, V6, P51
   FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158
   Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104
   HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102
   Khan IA, 1996, J IMMUNOL, V156, P636
   MANELL GL, 2005, PRINCIPLES PRACTICE, V2
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595
   MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404
   MURRAY HW, 1979, J EXP MED, V150, P950, DOI 10.1084/jem.150.4.950
   NETO V A, 1969, Revista do Instituto de Medicina Tropical de Sao Paulo, V11, P377
   Pinkerton H, 1941, J AMER MED ASSOC, V116, P807, DOI 10.1001/jama.1941.02820090007002
   Saeij JPJ, 2005, TRENDS PARASITOL, V21, P476, DOI 10.1016/j.pt.2005.08.001
   SchartonKersten TM, 1997, J EXP MED, V185, P1261, DOI 10.1084/jem.185.7.1261
   Spalding SM, 2005, REV SOC BRAS MED TRO, V38, P173, DOI 10.1590/S0037-86822005000200009
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   TOURANI JM, 1985, LANCET, V1, P989
   UBAUSTE CS, 2006, INFECT IMMUN, V74, P1573
   Yap GS, 1998, J IMMUNOL, V160, P1340
NR 26
TC 42
Z9 43
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2007
VL 44
IS 6
BP E62
EP E66
DI 10.1086/511871
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 136RT
UT WOS:000244242500030
PM 17304443
OA Bronze, Green Published
DA 2020-11-26
ER

PT J
AU Loffredo, JT
   Burwitz, BJ
   Rakasz, EG
   Spencer, SP
   Stephany, JJ
   Vela, JPG
   Martin, SR
   Reed, J
   Piaskowski, SM
   Furlott, J
   Weisgrau, KL
   Rodrigues, DS
   Soma, T
   Napoe, G
   Friedrich, TC
   Wilson, NA
   Kallas, EG
   Watkins, DI
AF Loffredo, John T.
   Burwitz, Benjamin J.
   Rakasz, Eva G.
   Spencer, Sean P.
   Stephany, Jason J.
   Vela, Juan Pablo Giraldo
   Martin, Sarah R.
   Reed, Jason
   Piaskowski, Shari M.
   Furlott, Jessica
   Weisgrau, Kim L.
   Rodrigues, Denise S.
   Soma, Taeko
   Napoe, Gnankang
   Friedrich, Thomas C.
   Wilson, Nancy A.
   Kallas, Esper G.
   Watkins, David I.
TI The antiviral efficacy of simian immunodeficiency virus-specific CD8(+)
   T cells is unrelated to epitope specificity and is abrogated by viral
   escape
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CLASS-I ALLELES; HIGH-FREQUENCY; LYMPHOCYTE RESPONSES; EXPRESSION
   KINETICS; DISEASE PROGRESSION; IMMUNE-RESPONSES; SIV REPLICATION;
   DOWN-REGULATION; RHESUS-MONKEYS; HIV-1
AB CD8(+) T lymphocytes appear to play a role in controlling human immunodeficiency virus (HIV) replication, yet routine immunological assays do not measure the antiviral efficacy of these cells. Furthermore, it has been suggested that CD8(+) T cells that recognize epitopes derived from proteins expressed early in the viral replication cycle can be highly efficient. We used a functional in vitro assay to assess the abilities of different epitope-specific CD8(+) T-cell lines to control simian immunodeficiency virus (SIV) replication. We compared the antiviral efficacies of 26 epitope-specific CD8' T-cell lines directed against seven SIN epitopes in Tat, Nef, Gag, Env, and Vif that were restricted by either Mamu-A*01 or Mamu-A*02. Suppression of SIV replication varied depending on the epitope specificities of the CD8(+) T cells and was unrelated to whether the targeted epitope was derived from an early or late viral protein. Tat(28-35)SL8- and Gag(181-189)CM9-specific CD8(+) T-cell lines were consistently superior at suppressing viral replication compared to the other five SIV-specific CD8(+) T-cell lines. We also investigated the impact of viral escape on antiviral efficacy by determining if Tat(28-35)SL8- and Gag(181-189)CM9-specifie CD8(+) T-cell lines could suppress the replication of an escaped virus. Viral escape kabrogated the abilities of Tat(28-35)SL8- and Gag(181-189)gCM9-specific CD8(+) T cells to control viral replication. However, gamma interferon (IFN-gamma) enzyme-linked immunospot and IFN-gamma/tumor necrosis factor alpha intracellular-cytokine-staining assays detected cross-reactive immune responses against the Gag escape variant. Understanding antiviral efficacy and epitope variability, therefore, will be important in selecting candidate epitopes for an HIV vaccine.
C1 Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53715 USA.
   Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP Watkins, DI (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 555 Sci Dr, Madison, WI 53711 USA.
EM watkins@primate.wisc.edu
RI Rakasz, Eva G/H-9197-2019; Kallas, Esper G/C-9539-2012
OI Friedrich, Thomas/0000-0001-9831-6895; Kallas,
   Esper/0000-0003-2026-6925; Spencer, Sean/0000-0002-7328-5399
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [R24 RR 015371, RR 020141-01, P51 RR 000167, C06
   RR015459, C06 RR020141, P51 RR000167, RR 15459-01, R24 RR015371] Funding
   Source: Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI 049120, R01 AI052056,
   R01 AI049120, R01 AI 052056] Funding Source: Medline; NATIONAL CENTER
   FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR015459,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, R24RR015371, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   C06RR020141, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, R24RR015371,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, R24RR015371, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, C06RR020141, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, R24RR015371,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   R24RR015371, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, R24RR015371, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, R24RR015371, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, R24RR015371, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, C06RR020141,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, P51RR000167,
   P51RR000167, P51RR000167, P51RR000167, P51RR000167, R24RR015371,
   P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI052056, R01AI049120,
   R01AI052056, R01AI049120, R01AI052056, R01AI052056, R01AI049120,
   R01AI049120, R01AI049120, R01AI052056, R01AI049120, R01AI049120,
   R01AI049120, R01AI052056, R01AI049120] Funding Source: NIH RePORTER
CR Ali A, 2004, J VIROL, V78, P561, DOI 10.1128/JVI.78.2.561-567.2004
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Borroto R J, 1997, Rev Panam Salud Publica, V1, P3
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005
   Chen ZW, 2001, J IMMUNOL, V166, P4525, DOI 10.4049/jimmunol.166.7.4525
   Chung C, 2007, J VIROL, V81, P1517, DOI 10.1128/JVI.01780-06
   Cline AN, 2005, J MED PRIMATOL, V34, P303
   Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Dong T, 2004, J EXP MED, V200, P1547, DOI 10.1084/jem.20032044
   Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224
   Frahm N, 2006, NAT IMMUNOL, V7, P173, DOI 10.1038/ni1281
   Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998
   Friedrich TC, 2004, J VIROL, V78, P2581, DOI 10.1128/JVI.78.5.2581-2585.2004
   FRIEDRICH TC, IN PRESS J VIROL
   GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167
   Gauduin MC, 1998, J VIROL, V72, P6315, DOI 10.1128/JVI.72.8.6315-6324.1998
   Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005
   GILLESPIE GM, 2002, AIDS, V16, P691
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Iversen AKN, 2006, NAT IMMUNOL, V7, P179, DOI 10.1038/ni1298
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Kawada M, 2006, J VIROL, V80, P1949, DOI 10.1128/JVI.80.4.1949-1958.2006
   KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735
   Killian MS, 2005, AIDS, V19, P887, DOI 10.1097/01.aids.0000171402.00372.c2
   KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989
   KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011
   Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513
   Loffredo JT, 2005, J VIROL, V79, P14986, DOI 10.1128/JVI.79.23.14986-14991.2005
   Loffredo JT, 2005, J IMMUNOL, V175, P5986, DOI 10.4049/jimmunol.175.9.5986
   Loffredo JT, 2004, J IMMUNOL, V173, P5064, DOI 10.4049/jimmunol.173.8.5064
   Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001
   MARTIN AJ, 2001, AUSTR J GUIDANCE COU, V11, P1, DOI DOI 10.1017/S1037291100004301
   Matano T, 2004, J EXP MED, V199, P1709, DOI 10.1084/jem.20040432
   Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   McDermott AB, 2005, J VIROL, V79, P15556, DOI 10.1128/JVI.79.24.15556-15566.2005
   McKinney DM, 2004, J IMMUNOL, V173, P1941, DOI 10.4049/jimmunol.173.3.1941
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Muhl T, 2002, J IMMUNOL, V169, P3438, DOI 10.4049/jimmunol.169.6.3438
   Newberg MH, 2006, J IMMUNOL, V176, P319, DOI 10.4049/jimmunol.176.1.319
   O'Connor DH, 2003, J VIROL, V77, P9029, DOI 10.1128/JVI.77.16.9029-9040.2003
   O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493
   O'Connor DH, 2004, J VIROL, V78, P14012, DOI 10.1128/JVI.78.24.14012-14022.2004
   Peyerl FW, 2004, J VIROL, V78, P13901, DOI 10.1128/JVI.78.24.13901-13910.2004
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7
   Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010
   RANKI A, 1994, ARCH VIROL, V139, P365, DOI 10.1007/BF01310798
   Robinson S, 2001, J VIROL, V75, P10179, DOI 10.1128/JVI.75.21.10179-10186.2001
   SACHA JB, IN PRESS J IMMUNOL
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002
   Tomiyama H, 2005, J IMMUNOL, V174, P36, DOI 10.4049/jimmunol.174.1.36
   TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421
   Turnbull EL, 2006, J IMMUNOL, V176, P6130, DOI 10.4049/jimmunol.176.10.6130
   Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998
   van Baalen CA, 2002, EUR J IMMUNOL, V32, P2644, DOI 10.1002/1521-4141(200209)32:9<2644::AID-IMMU2644>3.0.CO;2-R
   Vogel TU, 2002, J VIROL, V76, P11623, DOI 10.1128/JVI.76.22.11623-11636.2002
   Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05
   Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06
   Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997
   Yang OO, 2003, J IMMUNOL, V171, P3718, DOI 10.4049/jimmunol.171.7.3718
   Yang OO, 2003, TRENDS IMMUNOL, V24, P67, DOI 10.1016/S1471-4906(02)00034-0
   Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006
   Zhang ZQ, 2002, J VIROL, V76, P12845, DOI 10.1128/JVI.76.24.12845-12854.2002
NR 76
TC 60
Z9 61
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAR
PY 2007
VL 81
IS 6
BP 2624
EP 2634
DI 10.1128/JVI.01912-06
PG 11
WC Virology
SC Virology
GA 145FN
UT WOS:000244850800009
PM 17192314
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Zaccarelli, CA
   Ono, E
   Machado, DM
   Brunialti, M
   Succi, RCDM
   Salomao, R
   Kallas, EG
   de Moraes-Pinto, MI
AF Zaccarelli-Filho, Carlos Alberto
   Ono, Erika
   Machado, Daisy Maria
   Brunialti, Milena
   Succi, Regina Celia de Menezes
   Salomao, Reinaldo
   Kallas, Esper Georges
   de Moraes-Pinto, Maria Isabel
TI HIV-1-Infected children on HAART: Immunologic features of three
   different levels of viral suppression
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article
DE HIV-infected children; antiretroviral therapy; immune reconstitution
ID ACTIVE ANTIRETROVIRAL THERAPY; T-CELL SUBSETS; HIV-INFECTION; 1-INFECTED
   CHILDREN; ACTIVATION MARKERS; RESPONSES; ANTIGEN; EXPRESSION; NAIVE; AGE
AB Background: HIV-1-infected children show changes of blood lymphocyte subpopulations. We have, therefore, investigated how highly active anti-retroviral therapy (ART) alter these subsets. Blood samples were taken from 41 HIV-1-infected children on ART who were divided into groups showing good, partial and poor responses to ART on the basis of viral load (VL) measurement in blood. The observations were compared to those seen in 20 uninfected children.
   Methods: The samples were studied using 4-color flow cytometry for "naive", central memory and effector memory cells as well as for CD38 expression as the sign of activation within both the CD4+ and the CD8+ T cell populations. HIV-1 infected children were also evaluated for the presence and the titers of antibodies induced by vaccination against childhood infections in our patients while on HAART.
   Results: Lymphocyte counts were lower in the "poor" viral load responding (VLR) group when compared with partial and good VLRs. Poor VLRs had lower total and naive CD4+ T cell counts. HIV-1-infected children from all three groups had high CD8+ T cell counts. Central memory CD4+ and CD8+ T cell percentages were particularly low in the poor VLR group while in the poor VLR group the percentages of effector memory CD4+ and CD8+ T cells were higher when compared with the control group. Higher cellular activation of CD8+ T cells was observed in HIV-1-infected children, particularly when analyzed for the intensity of CD38 expression in the poor VLR group. CD5 expression on B cells was higher among all HIV-1-infected children. Antibodies to tetanus, diphtheria, measles, rubella, and hepatitis B were present in a large proportion of children but the titers were similarly low for all three groups of HIV-infected children.
   Conclusions: Children with different levels of viral response to HAART present immune phenotype characteristics that tend to place the children with partial and good virological responses into the same group. These children are still moderately deficient in their immune responses but show better recovery than seen with children in the poor VLR group. These observations indicate that the proportions of central memory cells among the CD4+ T cells and the intensity of the expression of CD38 activation antigen on CD8+ T cells provide more informative parameters for monitoring children on HAART than the absolute numbers of CD4+ and CD8+ T cells alone. (c) 2006 Clinical Cytometry Society.
C1 Univ Fed Sao Paulo, Res Lab, Div Pediat Infect Dis, BR-04039032 Sao Paulo, SP, Brazil.
   Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP de Moraes-Pinto, MI (corresponding author), Univ Fed Sao Paulo, Res Lab, Div Pediat Infect Dis, Rua Pedro Toledo 781-9 Andar, BR-04039032 Sao Paulo, SP, Brazil.
EM m.isabelmp@uol.com.br
RI Salomao, Reinaldo/C-6419-2013; Brunialti, Milena K C/C-4905-2012;
   Kallas, Esper G/C-9539-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; Brunialti, Milena K
   C/0000-0003-2874-520X; Kallas, Esper/0000-0003-2026-6925; Machado,
   Daisy/0000-0003-1993-6442
CR Abbas A., 2003, CELLULAR MOL IMMUNOL
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Bonetti TCS, 2004, VACCINE, V22, P3707, DOI 10.1016/j.vaccine.2004.03.023
   CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036
   CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8
   CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   deMoraesPinto MI, 1996, J INFECT DIS, V173, P1077, DOI 10.1093/infdis/173.5.1077
   Elrefaei M, 2004, J IMMUNOL, V173, P2184, DOI 10.4049/jimmunol.173.3.2184
   Essajee SM, 1999, AIDS, V13, P2523, DOI 10.1097/00002030-199912240-00005
   Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839
   GALAZKA A, 1993, WHOEPIGEN9312
   GALAZKA AM, 1993, WHOEPIGEN9313
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   Gibb DM, 2000, LANCET, V355, P1331, DOI 10.1016/S0140-6736(00)02117-6
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   Hainaut M, 2003, PEDIATR INFECT DIS J, V22, P62, DOI 10.1097/00006454-200301000-00016
   Harari A, 2004, EUR J IMMUNOL, V34, P3525, DOI 10.1002/eji.200425324
   Harari A, 2002, BLOOD, V100, P1381, DOI 10.1182/blood-2001-11-0080
   Hepatitis B, 2003, RED BOOK 2003 REPORT, P318
   IBEGBU C, 1994, CLIN IMMUNOL IMMUNOP, V71, P27, DOI 10.1006/clin.1994.1047
   IBEGBU CC, 1992, ANN NY ACAD SCI, V651, P572
   Kaufmann GR, 2000, AIDS, V14, P2643, DOI 10.1097/00002030-200012010-00003
   King DJS, 2001, CLIN EXP IMMUNOL, V125, P447, DOI 10.1046/j.1365-2249.2001.01616.x
   Kristiansen M, 1997, APMIS, V105, P843, DOI 10.1111/j.1699-0463.1997.tb05093.x
   Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002
   Lederman MM, 2000, AIDS, V14, P2635, DOI 10.1097/00002030-200012010-00002
   Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591
   Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4
   Liu ZY, 1996, CYTOMETRY, V26, P1
   McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370
   McFarland RD, 2000, P NATL ACAD SCI USA, V97, P4215, DOI 10.1073/pnas.070061597
   Mezzaroma I, 1999, AIDS, V13, P1187, DOI 10.1097/00002030-199907090-00006
   Newell ML, 2006, J INFECT DIS, V193, P954
   PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046
   Resino S, 2006, CLIN INFECT DIS, V42, P862, DOI 10.1086/500412
   Resino S, 2006, PEDIATR INFECT DIS J, V25, P365, DOI 10.1097/01.inf.0000207419.50016.5e
   Resino S, 2003, CLIN EXP IMMUNOL, V132, P105, DOI 10.1046/j.1365-2249.2003.02116.x
   Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x
   SCHLESINGER M, 1995, PEDIATR RES, V38, P390, DOI 10.1203/00006450-199509000-00020
   Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901
   Sherman GG, 2002, PEDIATR RES, V51, P740, DOI 10.1203/01.PDR.0000017478.64723.79
   Sindhu STAK, 2003, CLIN EXP IMMUNOL, V132, P120, DOI 10.1046/j.1365-2249.2003.02120.x
   Soh CH, 2003, LANCET, V362, P2045, DOI 10.1016/S0140-6736(03)15098-2
   Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502
   [Anonymous], 2001, MMWR Recomm Rep, V50, P1
   van Rossum AMC, 2002, LANCET INFECT DIS, V2, P93, DOI 10.1016/S1473-3099(02)00183-4
   van Rossum AMC, 2001, AIDS, V15, P2267, DOI 10.1097/00002030-200111230-00008
NR 49
TC 21
Z9 21
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4949
EI 1552-4957
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD JAN 15
PY 2007
VL 72B
IS 1
BP 14
EP 21
DI 10.1002/cyto.b.20152
PG 8
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 123UQ
UT WOS:000243322000004
PM 17041945
OA Bronze
DA 2020-11-26
ER

PT J
AU Jamli Abel, LC
   Pessoa, M
   Sette, H
   Moreira, C
   Neto, BHF
   Marti, L
   Rodrigues, D
   Kallas, E
   Alves, V
AF Jamli Abel, Lucia Cristina
   Pessoa, Mario
   Sette, Hoet, Jr.
   Moreira-Filho, Carlos
   Neto, Ben-Hur Ferraz
   Marti, Luciana
   Rodrigues, Denise
   Kallas, Esper
   Alves, Venancio
TI Loss of interferon gamma receptor alpha (IFNGR alpha) in peripheral
   blood mononuclear cells from patients with chronic hepatitis C
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 7th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 07-11, 2007
CL San Diego, CA
SP Federat Clin Immunol Soc
C1 Albert Einstein Hosp, Albert Einstein Res Inst, Sao Paulo, Brazil.
   Albert Einstein Hosp, Albert Einstein Res Inst, IEP, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2007
VL 123
SU S
BP S35
EP S35
DI 10.1016/j.clim.2007.03.277
PG 1
WC Immunology
SC Immunology
GA 177EU
UT WOS:000247137200089
DA 2020-11-26
ER

PT J
AU Legrand, FA
   Nixon, DF
   Loo, CP
   Ono, E
   Chapman, JM
   Miyamoto, M
   Diaz, RS
   Santos, AMN
   Succi, RCM
   Abadi, J
   Rosenberg, MG
   de Moraes-Pinto, MI
   Kallas, EG
AF Legrand, Fatema A.
   Nixon, Douglas F.
   Loo, Christopher P.
   Ono, Erika
   Chapman, Joan M.
   Miyamoto, Maristela
   Diaz, Ricardo S.
   Santos, Amelia M. N.
   Succi, Regina C. M.
   Abadi, Jacob
   Rosenberg, Michael G.
   de Moraes-Pinto, Maria Isabel
   Kallas, Esper G.
TI Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected
   Infants and Neonates Revealed after Regulatory T Cell Removal
SO PLOS ONE
LA English
DT Article
AB Background. In utero transmission of HIV-1 occurs on average in only 3%-15% of HIV-1-exposed neonates born to mothers not on antiretroviral drug therapy. Thus, despite potential exposure, the majority of infants remain uninfected. Weak HIV-1specific T-cell responses have been detected in children exposed to HIV-1, and potentially contribute to protection against infection. We, and others, have recently shown that the removal of CD4(+)CD25(+) T-regulatory (Treg) cells can reveal strong HIV-1 specific T-cell responses in some HIV-1 infected adults. Here, we hypothesized that Treg cells could suppress HIV-1-specific immune responses in young children. Methodology/Principal Findings. We studied two cohorts of children. The first group included HIV-1-exposed-uninfected (EU) as well as unexposed (UNEX) neonates. The second group comprised HIV-1-infected and HIV-1-EU children. We quantified the frequency of Treg cells, T-cell activation, and cell-mediated immune responses. We detected high levels of CD4(+)CD25(+)CD127(-) Treg cells and low levels of CD4(+) and CD8(+) T cell activation in the cord blood of the EU neonates. We observed HIV-1-specific T cell immune responses in all of the children exposed to the virus. These T-cell responses were not seen in the cord blood of control HIV-1 unexposed neonates. Moreover, the depletion of CD4(+)CD25(+) Treg cells from the cord blood of EU newborns strikingly augmented both CD4(+) and CD8(+) HIV-1-specific immune responses. Conclusions/Significance. This study provides new evidence that EU infants can mount strong HIV-1-specific T cell responses, and that in utero CD4(+)CD25(+) T-regulatory cells may be contributing to the lack of vertical transmission by reducing T cell activation.
C1 [Nixon, Douglas F.; Loo, Christopher P.; Chapman, Joan M.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
   [Legrand, Fatema A.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
   [Ono, Erika; Miyamoto, Maristela; Diaz, Ricardo S.; Santos, Amelia M. N.; Succi, Regina C. M.; de Moraes-Pinto, Maria Isabel; Kallas, Esper G.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Abadi, Jacob; Rosenberg, Michael G.] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY USA.
RP Nixon, DF (corresponding author), Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA.
EM douglas.nixon@ucsf.edu
RI Miyamoto, Maristela/B-3834-2013; dos Santos, Amelia/H-5986-2013; Kallas,
   Esper G/C-9539-2012; Nixon, Douglas/AAU-5734-2020; Diaz,
   Ricardo/K-3978-2012
OI dos Santos, Amelia/0000-0002-8407-1556; Nixon,
   Douglas/0000-0002-2801-1786; Loo, Christopher/0000-0002-5302-8774;
   Kallas, Esper/0000-0003-2026-6925
FU Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI060379, AI060407]; John E. Fogarty
   International CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [D43 TW00003]; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [01/11011-6, 04/15317-0]; UC
   President's Postdoctoral; CAPESCAPES; FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003, D43TW000003, D43TW000003, D43TW000003, D43TW000003,
   D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R21AI060407, R01AI060379,
   R01AI060379, R01AI060379, R01AI060379, R01AI060379, R21AI060407,
   R21AI060379] Funding Source: NIH RePORTER
FX This work was supported by the Elizabeth Glaser Pediatric AIDS
   Foundation, the National Institutes of Health (AI060379 and AI060407),
   the John E. Fogarty International Center (D43 TW00003), and FAPESP, a
   Brazilian funding agency (01/11011-6). D. F. N. is an Elizabeth Glaser
   Scientist of the Elizabeth Glaser Pediatric AIDS Foundation. F. A. L. is
   supported by the UC President's Postdoctoral Fellowship. E. O. is
   supported by a CAPES (a Brazilian funding agency) MSc fellowship. M. M.
   is supported by a FAPESP PhD fellowship (04/15317-0).
CR Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   BURCHETT SK, 1992, J INFECT DIS, V165, P813, DOI 10.1093/infdis/165.5.813
   BUSEYNE F, 1993, J IMMUNOL, V150, P3569
   Chakraborty R, 2005, J IMMUNOL, V174, P8191, DOI 10.4049/jimmunol.174.12.8191
   CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905
   CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004
   CONNOR EM, 1994, PEDIATR INFECT DIS J, V13, P440, DOI 10.1097/00006454-199405000-00036
   DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Frenkel LM, 1998, SCIENCE, V280, P1073, DOI 10.1126/science.280.5366.1073
   Gibson L, 2004, J IMMUNOL, V172, P2256, DOI 10.4049/jimmunol.172.4.2256
   Hermann E, 2002, BLOOD, V100, P2153, DOI 10.1182/blood.V100.6.2153.h81802002153_2153_2158
   Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kalams SA, 1999, J VIROL, V73, P6721, DOI 10.1128/JVI.73.8.6721-6728.1999
   Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341
   LIU W, 2006, J EXP MED
   Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005
   Luzuriaga K, 2005, CLIN INFECT DIS, V40, P466
   LUZURIAGA K, 1991, J PEDIATR-US, V119, P230, DOI 10.1016/S0022-3476(05)80732-2
   Luzuriaga Katherine, 2002, AIDS Reviews, V4, P21
   Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.1111/j.1365-2249.2005.02799.x
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Mascart F, 2003, J IMMUNOL, V170, P1504, DOI 10.4049/jimmunol.170.3.1504
   MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766
   McGowan JP, 2000, J ANTIMICROB CHEMOTH, V46, P657, DOI 10.1093/jac/46.5.657
   Michaelsson J, 2006, J IMMUNOL, V176, P5741, DOI 10.4049/jimmunol.176.10.5741
   Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890
   RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995
   ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sandberg JK, 2003, J IMMUNOL, V170, P4403, DOI 10.4049/jimmunol.170.8.4403
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Scott-Algara D, 2001, J INFECT DIS, V183, P1565, DOI 10.1086/320708
   Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x
   Spiegel HML, 2000, J INFECT DIS, V182, P88, DOI 10.1086/315639
   Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766
   Zhang QB, 2002, PEDIATR INFECT DIS J, V21, P209, DOI 10.1097/00006454-200203000-00010
   Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102
   CLIN INFECT DIS, V40, P458
NR 53
TC 110
Z9 110
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2006
VL 1
IS 1
AR e102
DI 10.1371/journal.pone.0000102
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DB
UT WOS:000207443600101
PM 17183635
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Fonseca, SG
   Coutinho-Silva, A
   Fonseca, LAM
   Segurado, AC
   Moraes, SL
   Rodrigues, H
   Hammer, J
   Kallas, EG
   Sidney, J
   Sette, A
   Kalil, J
   Cunha-Neto, E
AF Fonseca, Simone G.
   Coutinho-Silva, Adriana
   Fonseca, Luiz Augusto M.
   Segurado, Aluisio C.
   Moraes, Sandra L.
   Rodrigues, Helcio
   Hammer, Juergen
   Kallas, Esper G.
   Sidney, John
   Sette, Alessandro
   Kalil, Jorge
   Cunha-Neto, Edecio
TI Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1
   whole genome that are frequently recognized by HIV-1 infected patients
SO AIDS
LA English
DT Article
DE HIV-1; CD4+T cell epitopes; HLA binding; vaccine; consensus; conserved
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CLASS-II MOLECULES; ANTIRETROVIRAL
   THERAPY; MYCOBACTERIUM-TUBERCULOSIS; IMMUNODOMINANT EPITOPES; VIRAL
   LOAD; RESPONSES; INFECTION; VIREMIA; INDIVIDUALS
AB Objective: To identify promiscuous and potentially protective human CD4 T-cell epitopes in most conserved regions within the protein-coding genome of HIV-1 clade B consensus sequence.
   Design: We used the TEPITOPE algorithm to screen the most conserved regions of the whole genome of the HIV-1 subtype B consensus sequence to identify promiscuous human CD4 T-cell epitopes in HIV-1. The actual promiscuity of HLA binding of the 18 selected peptides was assessed by binding assays to nine prevalent HLA-DR molecules. Synthetic peptides were tested with interferon-gamma ELISPOT assays on peripheral blood mononuclear cells (PBMC) from 38 HIV-1 infected patients and eight uninfected controls.
   Results: Most peptides bound to multiple HLA-DR molecules. PBMC from 91% of chronically HIV-1 infected patients recognized at least one of the promiscuous peptides, while none of the healthy controls recognized peptides. All 18 peptides were recognized, and each peptide was recognized by at least 18% of patients; 44% of the patients recognized five or more peptides. This response was not associated to particular HLA-DR alleles. Similar responses were obtained in CD8 T-cell-depleted PBMC.
   Conclusion: In silico prediction of promiscuous epitopes led to the identification of naturally immunodominant CD4 T-cell epitopes recognized by PBMC from a significant proportion of a genetically heterogeneous patient population exposed to HIV-1. This combination of CD4 T-cell epitopes-11 of them not described before-may have the potential for inclusion in a vaccine against HIV-1, allowing the immunization of genetically distinct populations. (c) 2006 Lippincott Williams & Wilkins.
C1 Univ Sao Paulo, Sch Med, Heart Inst Incor, Immunol Lab, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Dept Med, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA.
   Univ Fed Sao Paulo, Div Infect & Parasit Dis, Sao Paulo, Brazil.
   La Jolla Inst Allergy & Immunol, San Diego, CA USA.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst Incor, Immunol Lab, Av Dr Eneas Carvalho Aguiar 44,Bloco 2,9 Andar, BR-05403000 Sao Paulo, Brazil.
EM edecunha@gmail.com
RI Kallas, Esper G/C-9539-2012; KALIL, JORGE/C-8029-2012; FONSECA, SIMONE
   GONCALVES/U-9278-2019; Cunha-Neto, Edecio/B-4157-2009; Segurado, Aluisio
   C/K-2229-2012; Fonseca, Luiz Augusto M/F-9344-2012
OI KALIL, JORGE/0000-0001-8415-4274; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Segurado, Aluisio C/0000-0002-6311-8036;
   Kallas, Esper/0000-0003-2026-6925
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01-AI-95362] Funding Source: Medline;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01AI095362, N01AI095362, N01AI095362, N01AI095362] Funding Source: NIH
   RePORTER
CR Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219
   Alatrakchi N, 2005, AIDS, V19, P25, DOI 10.1097/00002030-200501030-00003
   Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003
   BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
   BETTE TM, 2005, 5 MOL IMMUNOLOGY
   Bian HJ, 2003, METHODS, V29, P299, DOI 10.1016/S1046-2023(02)00352-3
   BIGNON JD, 1997, GENETIC DIVERSITY HL, V1, P584
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376
   Caride E, 2001, VIRUS GENES, V23, P193, DOI 10.1023/A:1011812810397
   Cochlovius B, 2000, J IMMUNOL, V165, P4731, DOI 10.4049/jimmunol.165.8.4731
   Consogno G, 2003, BLOOD, V101, P1038, DOI 10.1182/blood-2002-03-0933
   Damico FM, 2005, INVEST OPHTH VIS SCI, V46, P2465, DOI 10.1167/iovs.04-1273
   De Groot AS, 2004, METHODS, V34, P476, DOI 10.1016/j.ymeth.2004.06.003
   De Groot AS, 2005, VACCINE, V23, P2136, DOI 10.1016/j.vaccine.2005.01.097
   de Lalla C, 1999, J IMMUNOL, V163, P1725
   Deeks SG, 2004, J INFECT DIS, V189, P312, DOI 10.1086/380098
   Fonseca CT, 2005, MICROBES INFECT, V7, P204, DOI 10.1016/j.micinf.2004.10.012
   Fonseca CT, 2004, MEM I OSWALDO CRUZ, V99, P63, DOI 10.1590/S0074-02762004000900011
   Fonseca SG, 2005, MICROBES INFECT, V7, P688, DOI 10.1016/j.micinf.2005.01.001
   GOLDBERG AC, 1997, HLA 1997, P330
   GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Heeney JL, 1997, IMMUNOL TODAY, V18, P4, DOI 10.1016/S0167-5699(97)80005-9
   Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874
   McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598
   MEISTER GE, 1995, VACCINE, V13, P581, DOI 10.1016/0264-410X(94)00014-E
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Panigada M, 2002, INFECT IMMUN, V70, P79, DOI 10.1128/IAI.70.1.79-85.2002
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Schroers R, 2003, CLIN CANCER RES, V9, P3260
   Schroers R, 2002, CANCER RES, V62, P2600
   Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101
   SIDNEY J, 1998, CURRENT PROTOCOLS IM
   Smith CJ, 2003, AIDS, V17, P963, DOI 10.1097/00002030-200305020-00004
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   THERTON E, 1989, SOLID PHASE PEPTIDE
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
NR 50
TC 33
Z9 33
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 28
PY 2006
VL 20
IS 18
BP 2263
EP 2273
DI 10.1097/01.aids.0000253353.48331.5f
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 119UM
UT WOS:000243039400002
PM 17117012
DA 2020-11-26
ER

PT J
AU Galante, NZ
   Camara, NOS
   Kallas, EG
   Salomao, R
   Pacheco-Silva, A
   Medina-Pestana, JO
AF Galante, Nelson Zocoler
   Saraiva Camara, Niels Olsen
   Kallas, Esper Georges
   Salomao, Reinaldo
   Pacheco-Silva, Alvaro
   Medina-Pestana, Jose Osmar
TI Noninvasive immune monitoring assessed by flow cytometry and real time
   RT-PCR in urine of renal transplantation recipients
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE acute rejection; immunological monitoring; kidney transplantation; T
   lymphocytes; urine
ID MESSENGER-RNA; ALLOGRAFT-REJECTION; GENE-EXPRESSION; CELLS; LYMPHOCYTES;
   ACTIVATION; DIAGNOSIS; SEDIMENT; TOOL
AB Background: Monitoring recipient's alloreactivity has shown to be critical for limiting overimmunosuppression besides allowing preemptive treatment of acute rejection (AR).
   Methods: Flow cytometry and real time RT-PCR were performed in urine of kidney transplant recipients with AR (n=13) and compared with pyelonephritis(n = 10), chronic allograft nephropathy (n=13), acute tubular necrosis (n= 13) and stable graft function (n= 11). Expression of CD3, CD4, CD8, HLA-DR, Fas-L, ICAM-1 and CD25 were assessed using flow cytometry. mRNA of perform, granzyme B and Fas-L were quantified by real time RT-PCR.
   Results: Frequencies of CD3(+), HLA-DR+, Fas-L+, ICAM-1(+) and CD25(+) cells were significantly higher in AR group (P<0.05). ROC curves showed sensitivity from 70% to 91% and specificity from 30% to 100%, whereas the highest sensitivity and specificity was 91% and 100% respectively, for Fas-L+ cells. Levels of mRNA of perforin, granzyme B and Fas-L were significantly augmented in AR, while the sensitivity and specificity ranged from 85% to 88% and from 55% to 100%, respectively.
   Conclusions: Analyses of immune activation markers by flow cytometry and real time RT-PCR are equally useful for noninvasive monitoring kidney allografts. (C) 2006 Elsevier B.V. All rights reserved.
C1 Univ Fed Sao Paulo, Disciplina Nefrol, Dept Med, Lab Imunol Clin & Expt, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Disciplina Doencas Infecciosas & Parasitarias, Dept Med, Lab Imunol, Sao Paulo, Brazil.
RP Medina-Pestana, JO (corresponding author), Rua Botucatu 740, BR-04023900 Sao Paulo, Brazil.
EM medina@hrim.com.br
RI camara, niels/AAX-3269-2020; Salomao, Reinaldo/C-6419-2013; Camara,
   Niels OS/G-8336-2011; Galante, Nelson Z/F-7865-2010; Kallas, Esper
   G/C-9539-2012; Pacheco-Silva, Alvaro/K-3583-2013
OI camara, niels/0000-0001-5436-1248; Salomao,
   Reinaldo/0000-0003-1149-4598; Camara, Niels OS/0000-0001-5436-1248;
   Galante, Nelson Z/0000-0001-7047-586X; Kallas,
   Esper/0000-0003-2026-6925; Medina Pestana, Jose/0000-0003-3912-2980
CR Chan L, 2001, AM J KIDNEY DIS, V38, pS2, DOI 10.1053/ajkd.2001.28921
   Ding RC, 2003, TRANSPLANTATION, V75, P1307, DOI 10.1097/01.TP.0000064210.92444.B5
   Dugre FJ, 2000, TRANSPLANTATION, V70, P1074, DOI 10.1097/00007890-200010150-00014
   Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901
   HENNY FC, 1986, TRANSPLANTATION, V42, P479, DOI 10.1097/00007890-198611000-00007
   JACKSON AL, 1990, CLIN IMMUNOL IMMUNOP, V54, P126, DOI 10.1016/0090-1229(90)90012-F
   Kotsch K, 2004, TRANSPLANTATION, V77, P1866, DOI 10.1097/01.tp.0000131157.19937.3f
   Li BG, 2001, NEW ENGL J MED, V344, P947, DOI 10.1056/NEJM200103293441301
   Muthukumar T, 2003, TRANSPLANTATION, V75, P1565, DOI 10.1097/01.TP.0000058230.91518.2F
   NANNICOSTA A, 1992, TRANSPLANT INT, V5, pS8
   Roberti I, 1997, TRANSPLANTATION, V64, P731, DOI 10.1097/00007890-199709150-00012
   Roberti I, 2001, TRANSPLANTATION, V71, P1317, DOI 10.1097/00007890-200105150-00024
   Rush D, 1998, J AM SOC NEPHROL, V9, P2129
   Stachowski J, 1998, J IMMUNOL METHODS, V213, P145, DOI 10.1016/S0022-1759(98)00013-1
   Strehlau J, 1997, P NATL ACAD SCI USA, V94, P695, DOI 10.1073/pnas.94.2.695
   Tatapudi RR, 2004, KIDNEY INT, V65, P2390, DOI 10.1111/j.1523-1755.2004.00663.x
   Vasconcellos LM, 1998, TRANSPLANTATION, V66, P562, DOI 10.1097/00007890-199809150-00002
   VONWILLEBRAND E, 1995, TRANSPLANT P, V27, P917
   Yu DS, 1999, UROL INT, V62, P143, DOI 10.1159/000030378
NR 19
TC 20
Z9 25
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0966-3274
EI 1878-5492
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD AUG
PY 2006
VL 16
IS 2
BP 73
EP 80
DI 10.1016/j.trim.2006.03.014
PG 8
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 072NP
UT WOS:000239680400002
PM 16860708
DA 2020-11-26
ER

PT J
AU Schechter, M
   Kallas, EG
AF Schechter, Mauro
   Kallas, Esper Georges
TI HIV/AIDS research in Brazil: the missing piece?
SO FUTURE VIROLOGY
LA English
DT Editorial Material
ID RIO-DE-JANEIRO; AIDS; INFECTION; ACCESS; DRUGS; RISK
C1 Univ Fed Rio de Janeiro, Univ Hosp Clementino Fraga Filho, AIDS, Res Lab, BR-21941 Rio De Janeiro, Brazil.
RP Schechter, M (corresponding author), Univ Fed Rio de Janeiro, Univ Hosp Clementino Fraga Filho, AIDS, Res Lab, Av Brigadeiro Trompowski s-n Ilha do Fundao, BR-21941 Rio De Janeiro, Brazil.
EM maurosch@hucff.ufrj.br
RI Schechter, Mauro/AAG-7445-2020; Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR BOULLE A, 2006, 13 C RETR OPP INF DE
   Chequer P, 2005, AIDS, V19, pS1, DOI 10.1097/01.aids.0000191483.46544.a2
   Cook RL, 2004, SEX TRANSM DIS, V31, P67, DOI 10.1097/01.OLQ.0000105004.85419.17
   Galvao J, 2005, AM J PUBLIC HEALTH, V95, P1110, DOI 10.2105/AJPH.2004.044313
   Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2
   Harrison LH, 1999, J ACQ IMMUN DEF SYND, V21, P408
   *I BRAS GEOG EST, 2006, ESP VID NASC
   *I BRAS GEOG EST, 2006, EST POP
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001
   Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012
   MENON R, 1997, CONFRONTING AIDS
   Oliveira-Cruz V, 2004, TROP MED INT HEALTH, V9, P292, DOI 10.1046/j.1365-3156.2003.01188.x
   Piot P, 2004, SCIENCE, V304, P1909, DOI 10.1126/science.1101137
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641
   *STAT SAO PAUL RES, 2004, FAPESP, V432
   Tuboi SH, 2005, JAIDS-J ACQ IMM DEF, V40, P324, DOI 10.1097/01.qai.0000182627.28595.01
   2005, B EPIDEMIOLOGICO
   2005, PROGRAMA NACL DST, V480
   2005, HUMAN DEV REPORT, V372
NR 19
TC 1
Z9 2
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD JUL
PY 2006
VL 1
IS 4
BP 409
EP 413
DI 10.2217/17460794.1.4.409
PG 5
WC Virology
SC Virology
GA 209ZH
UT WOS:000249426000001
OA Bronze
DA 2020-11-26
ER

PT J
AU Gupta, SB
   Mast, CT
   Wolfe, ND
   Novitsky, V
   Dubey, SA
   Kallas, EG
   Schechter, M
   Mbewe, B
   Vardas, E
   Pitisuttithum, P
   Burke, D
   Freed, D
   Mogg, R
   Coplan, PM
   Condra, JH
   Long, RS
   Anderson, K
   Casimiro, DR
   Shiver, JW
   Straus, WL
AF Gupta, SB
   Mast, CT
   Wolfe, ND
   Novitsky, V
   Dubey, SA
   Kallas, EG
   Schechter, M
   Mbewe, B
   Vardas, E
   Pitisuttithum, P
   Burke, D
   Freed, D
   Mogg, R
   Coplan, PM
   Condra, JH
   Long, RS
   Anderson, K
   Casimiro, DR
   Shiver, JW
   Straus, WL
TI Cross-clade reactivity of HIV-1-specific T-cell responses in
   HIV-1-Infected individuals from Botswana and Cameroon
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; cell-mediated immunity; viral clade
ID GENETIC DIVERSITY; HIV TYPE-1; INFECTIONS
AB An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples.
C1 Merck & Co Inc, Whitehouse Stn, NJ USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   Malawi Coll Med, Blantyre, Malawi.
   Minist Populat & Hlth, Lilongwe, Malawi.
   Univ Witwatersrand, Johannesburg, South Africa.
   Mahidol Univ, Bangkok 10700, Thailand.
   Int Partnership Microbicides, Plymouth Meeting, PA USA.
RP Gupta, SB (corresponding author), Merck Res Labs, POB 4,BL1-7, West Point, PA 19483 USA.
EM swati_gupta@merck.com
RI Schechter, Mauro/AAG-7445-2020; Kallas, Esper G/C-9539-2012
OI Vardas, Eftyhia/0000-0002-7804-878X; Kallas, Esper/0000-0003-2026-6925;
   Coplan, Paul/0000-0002-7078-7780; /0000-0002-5704-8094
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [5 K01 TW000003-05] Funding Source: Medline; FOGARTY INTERNATIONAL
   CENTERUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [K01TW000003, K01TW000003, K01TW000003, K01TW000003, K01TW000003,
   K01TW000003, K01TW000003, K01TW000003] Funding Source: NIH RePORTER
CR Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861
   McMichael A, 2002, VACCINE, V20, P1918, DOI 10.1016/S0264-410X(02)00067-1
   MOGG R, 2003, AIDS VACC C 2003 NEW
   Nabel G, 2002, SCIENCE, V296, P2335, DOI 10.1126/science.296.5577.2335
   Ndembi N, 2004, JAIDS-J ACQ IMM DEF, V37, P1641, DOI 10.1097/00126334-200412150-00019
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013
   *UNAIDS, 2005, AIDS EP UPD
   *VAXG INC, 2005, VAXG ANN IN RES ITS
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   Vogel TU, 2002, J IMMUNOL, V169, P4511, DOI 10.4049/jimmunol.169.8.4511
   Walker BD, 2000, NAT MED, V6, P1094, DOI 10.1038/80415
   Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656
   Yamaguchi J, 2004, AIDS RES HUM RETROV, V20, P944, DOI 10.1089/aid.2004.20.944
NR 14
TC 15
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2006
VL 42
IS 2
BP 135
EP 139
DI 10.1097/01.qai.0000223017.01568.e7
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 047WZ
UT WOS:000237910700001
PM 16760794
DA 2020-11-26
ER

PT J
AU Sardenberg, C
   Suassuna, P
   Andreoli, MCC
   Watanabe, R
   Dalboni, MA
   Manfredi, SR
   dos Santos, OP
   Kallas, EG
   Draibe, SA
   Cendoroglo, M
AF Sardenberg, C
   Suassuna, P
   Andreoli, MCC
   Watanabe, R
   Dalboni, MA
   Manfredi, SR
   dos Santos, OP
   Kallas, EG
   Draibe, SA
   Cendoroglo, M
TI Effects of uraemia and dialysis modality on polymorphonuclear cell
   apoptosis and function
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE apoptosis; dialysis; immune dysfunction; polymorphonuclear cells;
   uraemia
ID NEUTROPHIL APOPTOSIS; HEMODIALYSIS; EXPRESSION; LIGAND
AB Background. Previous studies have reported that incubation of polymorphonuclear cells (PMN) in uraemic plasma or with different haemodialysis membranes and peritoneal dialysis solutions increases apoptosis in this cell type. In addition, PMN harvested from uraemic patients show a reduced ability to generate superoxide in response to stimuli as well as impaired phagocytosis, chemotaxis and degranulation. The aim of the current study was to investigate the effect of uraemia and dialysis modality on apoptosis and function in freshly harvested non-incubated PMN.
   Methods. Polymorphonuclear cells were harvested from 14 chronic haemodialysis (HD) patients, from 14 continuous peritoneal dialysis patients (CAPD), 28 chronic kidney disease (CKD), pre-dialysis patients and from 14 healthy subjects (Controls). In these in vivo experiments, PMN apoptosis was studied by means of flow cytometric analysis of annexin V binding to freshly isolated cells. Polymorphonuclear cell phagocytosis and production of reactive oxygen species by unstimulated or stimulated (S.aureus, fMLP, PMA) cells were also studied by flow cytometry using whole blood.
   Results. We observed increased PMN apoptosis in CKD patients. CAPD and HD patients displayed PMN apoptosis rates similar to controls. In the HD group, PMN exhibited decreased phagocytosis rates. In contrast, phagocytosis rates in PMN from CAPD were not significantly different from controls. In the CKD and HD groups, apoptosis was inversely correlated with respiratory burst activity and phagocytosis.
   Conclusion. Our results suggest that both uraemia and treatment modality may interfere with PMN apoptosis and function. Dialysis appears to normalize the increased PMN apoptosis rates observed in CKD patients.
C1 Univ Fed Sao Paulo, UNIFESP, Dept Med, Div Infect Dis, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, UNIFESP, Div Nephrol, Sao Paulo, Brazil.
RP Sardenberg, C (corresponding author), Univ Fed Sao Paulo, UNIFESP, Div Nephrol, Hosp Rim & Hipertensao, Rua Borges Lagoa 960,4 Andar, BR-04038002 Sao Paulo, Brazil.
EM camilasarden@einstein.br
RI draibe, sergio antonio/D-9426-2015; Kallas, Esper G/C-9539-2012;
   Dalboni, Maria Aparecida/V-6749-2019
OI Dalboni, Maria Aparecida/0000-0002-9282-7181; Suassuna, Paulo
   Giovanni/0000-0002-9123-9564; Kallas, Esper/0000-0003-2026-6925
CR Cendoroglo M, 1999, J AM SOC NEPHROL, V10, P93
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cohen G, 1997, KIDNEY INT, V52, pS79
   Daniels I, 1996, CLIN DIAGN LAB IMMUN, V3, P682, DOI 10.1128/CDLI.3.6.682-688.1996
   DeLeo FR, 2004, APOPTOSIS, V9, P399, DOI 10.1023/B:APPT.0000031448.64969.fa
   Eknoyan G, 2001, AM J KIDNEY DIS, V37, pS5, DOI 10.1016/S0272-6386(01)70004-2
   HASUI M, 1989, J IMMUNOL METHODS, V117, P53, DOI 10.1016/0022-1759(89)90118-X
   Ibs KH, 2003, J NUTR, V133, p1452S, DOI 10.1093/jn/133.5.1452S
   Jaber BL, 2001, KIDNEY INT, V59, pS197, DOI 10.1046/j.1523-1755.2001.59780197.x
   Jaber BL, 2001, J LEUKOCYTE BIOL, V69, P1006
   Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429
   Majewska E, 2003, NEPHROL DIAL TRANSPL, V18, P2582, DOI 10.1093/ndt/gfg441
   METCALF JA, 1986, LAB MANUAL NEUTROPHI
   Omerod MG, 1998, LEUKEMIA, V12, P1013
   Rao M, 2004, KIDNEY INT, V65, P682, DOI 10.1111/j.1523-1755.2004.00429.x
   Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1046/j.1523-1755.2000.00337.x
   WATANABE R, UNPUB EFFECTS UREMIC
   WHYTE MKB, 1993, J IMMUNOL, V150, P5124
   Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067
   Zhang B, 2003, J BIOL CHEM, V278, P28443, DOI 10.1074/jbc.M210727200
NR 20
TC 50
Z9 51
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JAN
PY 2006
VL 21
IS 1
BP 160
EP 165
DI 10.1093/ndt/gfi095
PG 6
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 000BO
UT WOS:000234436100031
PM 16155068
DA 2020-11-26
ER

PT J
AU Fusuma, EE
   Caruso, SC
   Lopez, DF
   Costa, LJ
   Janini, LM
   De Mendonca, JS
   Kallas, EG
   Diaz, RS
AF Fusuma, EE
   Caruso, SC
   Lopez, DF
   Costa, LJ
   Janini, LM
   De Mendonca, JS
   Kallas, EG
   Diaz, RS
TI Duplication of peri-kappa B and NF-kappa B sites of the first human
   immunodeficiency virus type 2 (HIV-2) transmission in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ACTIVATION; ORGANIZATION; INFECTION; ENHANCER; AIDS
AB After the identification of HIV-2 in 1986, most of the cases reported have been concentrated in West Africa. We identified a case of HIV-2 infection in Sao Paulo, Brazil of a 45-year-old female who presented with Pneumocystis carinii pneumonia, with a CD4 count of 22 cells/ml. DNA samples from this patient were subjected to end-point PCR amplification of the LTR region. Clones were sequenced and subjected to phylogenetic analyses. All clones were subtype A related, and four presented an insertion, corresponding to an extra NF-kappa B site. This is the first confirmed case report of an HIV-2-infected subject identified in Brazil whose transmission occurred within the country. Furthermore, the NF-kappa B duplication would potentially be associated with an increase in viral cytopathogenicity. This raises concern for the need for permanent monitoring of the spread of HIV-2 in different areas of the world, even considering its lower rate of transmission and pathogenicity when compared to HIV-1.
C1 Univ Fed Sao Paulo, Paulista Sch Med, Div Infect Dis, Retrovirol Lab, BR-04039032 Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual, Sao Paulo, Brazil.
RP Diaz, RS (corresponding author), Univ Fed Sao Paulo, Paulista Sch Med, Div Infect Dis, Retrovirol Lab, Rua Pedro de Toledo 781,16 Andar, BR-04039032 Sao Paulo, Brazil.
EM rsdiaz@usp.br
RI Kallas, Esper G/C-9539-2012; Costa, Luciana J/B-7878-2013; Diaz,
   Ricardo/K-3978-2012
OI Kallas, Esper/0000-0003-2026-6925
CR BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Carvalho MB, 1996, AIDS, V10, P1135, DOI 10.1097/00002030-199609000-00012
   CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995
   CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000
   MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   Matheron S, 1997, AIDS, V11, P934
   Montano MA, 1997, J VIROL, V71, P8657, DOI 10.1128/JVI.71.11.8657-8665.1997
   PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002
   SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990
   TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
NR 17
TC 7
Z9 7
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2005
VL 21
IS 11
BP 965
EP 970
DI 10.1089/aid.2005.21.965
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 995KO
UT WOS:000234099400011
PM 16386115
DA 2020-11-26
ER

PT J
AU Dorigatti, F
   Brunialti, MKC
   Romero, EC
   Kallas, EG
   Salomao, R
AF Dorigatti, F
   Brunialti, MKC
   Romero, EC
   Kallas, EG
   Salomao, R
TI Leptospira interrogans activation of peripheral blood monocyte
   glycolipoprotein demonstrated in whole blood by the release of IL-6
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE glycolipoprotein; Leptospira interrogans; interleukin-6; monocytes;
   CD45; CD14
ID NECROSIS-FACTOR-ALPHA; ANTIGENS; LIPOPOLYSACCHARIDE; MECHANISM
AB Glycolipoprotein (GLP) from pathogenic serovars of Leptospira has been implicated in the pathogenesis of leptospirosis by its presence in tissues of experimental animals with leptospirosis, the inhibition of the Na,K-ATPase pump activity, and induced production of cytokines. The aims of the present study were to investigate the induction of IL-6 by GLP in peripheral blood mononuclear cells (PBMC) and to demonstrate monocyte stimulation at the cellular level in whole blood from healthy volunteers. PBMC were stimulated with increasing concentrations (5 to 2500 ng/ml) of GLP extracted from the pathogenic L. interrogans serovar Copenhageni, lipopolysaccharide (positive control) or medium (negative control), and supernatants were collected after 6, 20/24, and 48 h, and kept at -80 degrees C until use. Whole blood was diluted 1:1 in RPMI medium and cultivated for 6 h, with medium, GLP and lipopolysaccharide as described above, Monensin was added after the first hour of culture. Supernatant cytokine levels from PBMC were measured by ELISA and intracellular IL-6 was detected in monocytes in whole blood cultures by flow-eytometry. Monocytes were identified in whole blood on the basis of forward versus side scatter parameters and positive reactions with CD45 and CD14 antibodies. GLP (>= 50 ng/ml)-induced IL-6 levels in supernatants were detected after 6-h incubation, reaching a peak after 20/24 h. The percentage of monocytes staining for IL-6 increased with increasing GLP concentration. Thus, our findings show a GLP-induced cellular activation by demonstrating the ability of GLP to induce IL-6 and the occurrence of monocyte activation in whole blood at the cellular level.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Doencas Infecciosas & Parasitarias, Sao Paulo, Brazil.
   Inst Adolpho Lutz, Sao Paulo, Brazil.
RP Salomao, R (corresponding author), R Pedro Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
EM rsalomao-dipa@pesquisa-epm.br
RI Salomao, Reinaldo/C-6419-2013; Romero, Eliete C/H-6976-2012; Brunialti,
   Milena K C/C-4905-2012; Kallas, Esper G/C-9539-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; Romero, Eliete
   C/0000-0002-8635-439X; Brunialti, Milena K C/0000-0003-2874-520X;
   Kallas, Esper/0000-0003-2026-6925
CR ALVES VAF, 1991, EXP PATHOL-JENA, V42, P81, DOI 10.1016/S0232-1513(11)80051-4
   ALVES VAF, 1992, EXP TOXICOL PATHOL, V44, P425, DOI 10.1016/S0940-2993(11)80185-5
   Cinco M, 1996, FEMS MICROBIOL LETT, V138, P211, DOI 10.1111/j.1574-6968.1996.tb08159.x
   Diament D, 2002, INFECT IMMUN, V70, P1677, DOI 10.1128/IAI.70.4.1677-1683.2002
   FAINE S, 1994, LETOSPIRA LEPTOSPIRO
   GALANOS C, 1992, BACTERIAL ENDOTOXIN
   Haake DA, 2000, INFECT IMMUN, V68, P2276, DOI 10.1128/IAI.68.4.2276-2285.2000
   ISOGAI E, 1986, ZBL BAKT-INT J MED M, V261, P53, DOI 10.1016/S0176-6724(86)80062-1
   LOMAR AV, 1997, TRATADO INFECTOLOGIA
   MACEDOSANTOS RT, 1989, REV INST MED TROP SP, V31, P235
   Pereira MM, 1997, EXP TOXICOL PATHOL, V49, P505, DOI 10.1016/S0940-2993(97)80155-8
   Tajiki MH, 1996, CLIN INFECT DIS, V23, P1177, DOI 10.1093/clinids/23.5.1177
   TAJIKI MH, 1997, BRAZ J INFECT DIS, V1, P138
   VINH T, 1986, J GEN MICROBIOL, V132, P111
   Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354
   Wooten RM, 1998, J IMMUNOL, V160, P5485
   YANAGIHARA Y, 1984, MICROBIOL IMMUNOL, V28, P747, DOI 10.1111/j.1348-0421.1984.tb00730.x
   YOUNESIBRAHIM M, 1995, CR ACAD SCI III-VIE, V318, P619
   2000, 208 FUNASA
NR 19
TC 19
Z9 21
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 2005
VL 38
IS 6
BP 909
EP 914
DI 10.1590/S0100-879X2005000600013
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 940EA
UT WOS:000230125300013
PM 15933785
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Cunha, RMD
   Kallas, EG
   Rodrigues, DS
   Burattini, MN
   Salomao, R
AF Cunha, RMD
   Kallas, EG
   Rodrigues, DS
   Burattini, MN
   Salomao, R
TI Interferon-gamma and tumour necrosis factor-alpha production by CD4(+)T
   and CD8(+)T lymphocytes in AIDS patients with tuberculosis
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE AIDS; cytokines; tuberculosis
ID IMMUNODEFICIENCY-VIRUS-INFECTION; BACILLUS-CALMETTE-GUERIN;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; T-CELLS; CYTOKINE
   RESPONSES; IMMUNE ACTIVATION; HIV REPLICATION; IN-VITRO; PROTECTION
AB Tuberculosis (TB) is usually more severe in HIV-infected patients, and the immune derangement found in co-infected patients may differ from that in each isolated disease. Following mitogen stimulation of peripheral blood mononuclear cells (PBMC), interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha production was evaluated in T cells by flow cytometry, and in culture supernatants by enzyme-linked immunosorbent assay (ELISA) in 33 individuals: 11 AIDS patients with tuberculosis, six asymptomatic HIV-1-infected patients, eight patients with tuberculosis and eight healthy controls. The proportion of CD4(+) T lymphocytes expressing IFN-gamma did not differ between the groups, whereas a trend towards increased proportions of TNF-alpha-expression in CD4(+) T cells was observed in the TB compared to the HIV group, while intermediate values were observed in co-infected patients. Detection of IFN-gamma and TNF-alpha in CD8(+) T lymphocytes was higher in TB than in HIV individuals. Co-infected patients presented intermediate values for IFN-gamma, while TNF-alpha detection was similar to that in HIV mono-infection. In conclusion, the proportion of T cells expressing IFN-gamma was relatively preserved in co-infected patients compared to TB patients, while the percentage of T cells expressing TNF-alpha was decreased, mainly in CD8(+) T lymphocytes. However, the marked reduction in T lymphocyte numbers in co-infected patients led to a striking reduction of both cytokines in PBMC supernatants, a finding that is consistent with the impaired response to Mycobacterium tuberculosis.
C1 Univ Fed Sao Paulo, UNIFESP, Div Infect Dis, Immunol Lab, BR-04039032 Sao Paulo, Brazil.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, UNIFESP, Div Infect Dis, Immunol Lab, Rua Pedro de Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
EM rsalomao-dipa@pesquisa.epm.br
RI Kallas, Esper G/C-9539-2012; Burattini, Marcelo N/J-9272-2014; Salomao,
   Reinaldo/C-6419-2013
OI Burattini, Marcelo N/0000-0002-5407-6890; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR BECK JS, 1985, CLIN EXP IMMUNOL, V60, P49
   Cohen O., 1999, FUNDAMENTAL IMMUNOLO, P1455
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Garrait V, 1997, J IMMUNOL, V159, P2824
   Goletti D, 1998, J INFECT DIS, V177, P1332, DOI 10.1086/515276
   Goletti D, 1996, J IMMUNOL, V157, P1271
   Jones BE, 1997, CLIN INFECT DIS, V24, P988, DOI 10.1093/clinids/24.5.988
   KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4
   Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005
   McDyer JF, 1997, J IMMUNOL, V158, P492
   MUTIS T, 1993, EUR J IMMUNOL, V23, P2189, DOI 10.1002/eji.1830230921
   ONWUBALILI JK, 1987, TUBERCLE, V68, P195, DOI 10.1016/0041-3879(87)90055-9
   ORME IM, 1983, J EXP MED, V158, P74, DOI 10.1084/jem.158.1.74
   POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151
   Rodrigues DSS, 2002, CLIN EXP IMMUNOL, V128, P149, DOI 10.1046/j.1365-2249.2002.01809.x
   Rodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010
   SINGHAL M, 1989, TUBERCLE, V70, P171, DOI 10.1016/0041-3879(89)90047-0
   Sousa AO, 1998, J INFECT DIS, V177, P1554, DOI 10.1086/515326
   TAKASHIMA T, 1990, INFECT IMMUN, V58, P3286, DOI 10.1128/IAI.58.10.3286-3292.1990
   Tascon RE, 1998, INFECT IMMUN, V66, P830, DOI 10.1128/IAI.66.2.830-834.1998
   Toossi Z, 1997, J ACQ IMMUN DEF SYND, V15, P325, DOI 10.1097/00042560-199708150-00001
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x
   TURETT GS, 1994, CHEST, V105, P1335, DOI 10.1378/chest.105.5.1335
   Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
   WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542
   Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008
   Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020
   Xing Z, 1998, INFECT IMMUN, V66, P5537, DOI 10.1128/IAI.66.11.5537-5542.1998
   ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611
NR 32
TC 13
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 2005
VL 140
IS 3
BP 491
EP 497
DI 10.1111/j.1365-2249.2005.02796.x
PG 7
WC Immunology
SC Immunology
GA 927UW
UT WOS:000229227000011
PM 15932510
OA Green Published
DA 2020-11-26
ER

PT J
AU Coplan, PM
   Gupta, SB
   Dubey, SA
   Pitisuttithum, P
   Nikas, A
   Mbewe, B
   Vardas, E
   Schechter, M
   Kallas, EG
   Freed, DC
   Fu, TM
   Mast, CT
   Puthavathana, P
   Kublin, J
   Collins, KB
   Chisi, J
   Pendame, R
   Thaler, SJ
   Gray, G
   Mcintyre, J
   Straus, WL
   Condra, JH
   Mehrotra, DV
   Guess, HA
   Emini, EA
   Shiver, JW
AF Coplan, PM
   Gupta, SB
   Dubey, SA
   Pitisuttithum, P
   Nikas, A
   Mbewe, B
   Vardas, E
   Schechter, M
   Kallas, EG
   Freed, DC
   Fu, TM
   Mast, CT
   Puthavathana, P
   Kublin, J
   Collins, KB
   Chisi, J
   Pendame, R
   Thaler, SJ
   Gray, G
   Mcintyre, J
   Straus, WL
   Condra, JH
   Mehrotra, DV
   Guess, HA
   Emini, EA
   Shiver, JW
TI Cross-reactivity of anti-HIV-1 T cell immune responses among the major
   HIV-1 clades in HIV-1-positive individuals from 4 continents
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 14th International AIDS Conference
CY JUL 07-12, 2002
CL BARCELONA, SPAIN
SP Univ N Carolina, Gen Clin Res Ctr, UNC Ctr AIDS Res, Natl Inst Hlth, Swiss Natl AIDS Res Program, Bristol-Myers Squibb Co, Boehringer Ingelheim, GlaxoWellcome Res & Dev, HIV Antiviral Res
ID VIRUS TYPE-1 EPIDEMIC; FALSE DISCOVERY RATE; LYMPHOCYTE RESPONSES;
   AFRICAN; IDENTIFICATION; VACCINES; SUBTYPES; EPITOPE; SPREAD; NEF
AB Background. The genetic diversity of human immunodeficiency virus type 1 (HIV-1) raises the question of whether vaccines that include a component to elicit antiviral T cell immunity based on a single viral genetic clade could provide cellular immune protection against divergent HIV-1 clades. Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades.
   Methods. Cellular immune responses to HIV-1 clades A, B, and C were compared by standardized interferon-gamma enzyme-linked immunospot assays among 250 unvaccinated individuals, infected with diverse HIV-1 clades, from Brazil, Malawi, South Africa, Thailand, and the United States. Cross-clade reactivity was evaluated by use of the ratio of responses to heterologous versus homologous ( infecting) clades of HIV-1.
   Results. Cellular immune responses were predominantly focused on viral Gag and Nef proteins. Cross-clade reactivity of cellular immune responses to HIV-1 clade A, B, and C proteins was substantial for Nef proteins ( ratio, 0.97 [95% confidence interval, 0.89-1.05]) and lower for Gag proteins ( ratio, 0.67 [ 95% confidence interval, 0.62-0.73]). The difference in cross-clade reactivity to Nef and Gag proteins was significant (P < .0001).
   Conclusions. Cross-clade reactivity of cellular immune responses can be substantial but varies by viral protein.
C1 Merck Res Labs, West Point, PA USA.
   Mahidol Univ, Bangkok 10700, Thailand.
   Malawi Coll Med, Blantyre, Malawi.
   Minist Populat & Hlth, Lilongwe, Malawi.
   Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Univ Witwatersrand, Johannesburg, South Africa.
RP Coplan, PM (corresponding author), Int Partnership Microbicides, Clin & Regulatory Affairs, 2997 Runnymede Dr, Plymouth Meeting, PA 19462 USA.
EM pcoplan@ipm-microbicides.org
RI Schechter, Mauro/AAG-7445-2020; Kallas, Esper G/C-9539-2012
OI Vardas, Eftyhia/0000-0002-7804-878X; Kallas, Esper/0000-0003-2026-6925;
   Coplan, Paul/0000-0002-7078-7780
CR Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781
   Auswinporn Somsri, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P346
   Batra M, 2000, AIDS RES HUM RETROV, V16, P973, DOI 10.1089/08892220050058399
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997
   Cao HY, 2000, J INFECT DIS, V182, P1350, DOI 10.1086/315868
   Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997
   Currier JR, 2002, J IMMUNOL METHODS, V260, P157, DOI 10.1016/S0022-1759(01)00535-X
   Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998
   Esparza J, 2000, LANCET, V355, P2061, DOI 10.1016/S0140-6736(00)02360-6
   Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396
   Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996
   Gillespie GMA, 2002, AIDS, V16, P961, DOI 10.1097/00002030-200205030-00002
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   KUIKEN CL, 2000, THEORETICAL BIOL BIO
   Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861
   Mashishi T, 2002, CLIN CHEM LAB MED, V40, P903, DOI 10.1515/CCLM.2002.159
   Mashishi T, 2001, AIDS RES HUM RETROV, V17, P1681, DOI 10.1089/088922201753342103
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   McCormack GP, 2002, J VIROL, V76, P12890, DOI 10.1128/JVI.76.24.12890-12899.2002
   McMichael A, 2002, VACCINE, V20, P1918, DOI 10.1016/S0264-410X(02)00067-1
   Nabel G, 2002, SCIENCE, V296, P2335, DOI 10.1126/science.296.5577.2335
   Novitsky V, 2001, J VIROL, V75, P9210, DOI 10.1128/JVI.75.19.9210-9228.2001
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013
   Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   Scheibenbogen C, 2003, INT J CANCER, V104, P188, DOI 10.1002/ijc.10961
   Tobery TW, 2001, J IMMUNOL METHODS, V254, P59, DOI 10.1016/S0022-1759(01)00397-0
   *UNAIDS, 2004, 2004 REP GLOB AIDS E
   Van Harmelen JH, 1999, AIDS RES HUM RETROV, V15, P395
   vanHarmelen J, 1997, AIDS, V11, P81, DOI 10.1097/00002030-199701000-00012
   Walker BD, 2000, NAT MED, V6, P1094, DOI 10.1038/80415
   Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656
   Wilson SE, 1998, AIDS RES HUM RETROV, V14, P925, DOI 10.1089/aid.1998.14.925
NR 39
TC 67
Z9 69
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2005
VL 191
IS 9
BP 1427
EP 1434
DI 10.1086/428450
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 913CS
UT WOS:000228128800008
PM 15809900
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Galante, NZ
   Ozaki, KS
   Cenedeze, MA
   Kallas, EG
   Salomao, R
   Pacheco-Silva, A
   Camara, NOS
AF Galante, NZ
   Ozaki, KS
   Cenedeze, MA
   Kallas, EG
   Salomao, R
   Pacheco-Silva, A
   Camara, NOS
TI Frequency of V alpha 24(+)V beta 11(+) NKT cells in peripheral blood of
   human kidney transplantation recipients
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 6th International Conference on New Trends in Immunosuppression
CY FEB, 2004
CL Salzburg, AUSTRIA
DE T lymphocytes; kidney transplantation
ID T-CELLS; INDUCTION; PHENOTYPE
AB There are still lacking data supporting a role for natural killer T (NKT) cells in the maintenance of human tissue-specific tolerance. We are interested to study NKT cell frequency in kidney transplant recipients and its correlation with graft function. Peripheral blood T cell receptors (TCR) Valpha24(+)Vbeta11(+) NKT cells were phenotyped according to CD4 and CD8 expression in normal controls (NC), in 10 years rejection-free cadaver kidney allografts maintained with minimal immunosuppression longterm rejection free [LTRF]), in patients with acute rejection (AR) and in patients with acute tubular necrosis (ATN). Results were expressed as percentages of CD4(+)CD8(-) (CD4(+) NKT) or CD4(-)CD8(-) (double negative-DN NKT) Valpha24(+)Vbeta11(+) cells. The percentages of Valpha24(+)Vbeta11(+) cells were 0.09%, 0.14%, 0.02% and 0.09% on gated lymphocytes respectively in AR, ATN, LTRF and NC groups (p=0.263). DN NKT cells were more frequent in NC patients (52.11%) and less present in ATN patients (11.04%). In contrast, CD4(+) NKT (IL-4-producing NKT cells subset) was more frequent in AR (42.86%). and corresponded to almost 3 to 7 folds more what we obtained in the other groups. Although total Valpha24(+)Vbeta11(+) cells did not significantly differ among the groups, the lowest frequency was observed in the LTRF group. In conclusion. we observed that total number of NKT cells did not differ significantly among transplant patients when compared to normal controls, although specific-subsets seem to be more frequent in determined events. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Fed Sao Paulo, Dept Med, Clin & Expt Immunol Lab, Disciplina Nefrol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Immunol Lab, Dept Med, Disciplina Doencas Infecciosas & Parasitarias, Sao Paulo, Brazil.
RP Camara, NOS (corresponding author), Rua Botucatu,740, BR-04023900 Sao Paulo, Brazil.
EM niels@nefro.epm.br
RI camara, niels/AAX-3269-2020; Galante, Nelson Z/F-7865-2010; Kallas,
   Esper G/C-9539-2012; Pacheco-Silva, Alvaro/K-3583-2013; Salomao,
   Reinaldo/C-6419-2013; Camara, Niels OS/G-8336-2011
OI camara, niels/0000-0001-5436-1248; Galante, Nelson
   Z/0000-0001-7047-586X; Salomao, Reinaldo/0000-0003-1149-4598; Camara,
   Niels OS/0000-0001-5436-1248; Kallas, Esper/0000-0003-2026-6925
CR Araki M, 2003, INT IMMUNOL, V15, P279, DOI 10.1093/intimm/dxg029
   BACHETONI A, 1995, CLIN TRANSPLANT, V9, P433
   Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535
   Boyson JE, 2002, P NATL ACAD SCI USA, V99, P13741, DOI 10.1073/pnas.162491699
   Carlson JA, 2000, AM J DERMATOPATH, V22, P7, DOI 10.1097/00000372-200002000-00002
   Jiang SP, 2003, BLOOD, V102, P2180, DOI 10.1182/blood-2003-04-1164
   Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI200213605
   LANIER LL, 1987, J IMMUNOL, V138, P2019
   LANIER LL, 1989, J EXP MED, V169, P2233, DOI 10.1084/jem.169.6.2233
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Loza MJ, 2002, EUR J IMMUNOL, V32, P3453, DOI 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D
   Lucas M, 2003, J VIROL, V77, P2251, DOI 10.1128/JVI.77.3.2251-2257.2003
   Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155
   Seino K, 2001, P NATL ACAD SCI USA, V98, P2577, DOI 10.1073/pnas.041608298
   TAKII Y, 1994, CLIN EXP IMMUNOL, V97, P522
   Vincent MS, 2003, NAT IMMUNOL, V4, P517, DOI 10.1038/ni0603-517
   Wilson SB, 2003, NAT REV IMMUNOL, V3, P211, DOI 10.1038/nri1028
   Wilson SB, 1998, NATURE, V391, P177
NR 18
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN
PY 2005
VL 5
IS 1
BP 53
EP 58
DI 10.1016/j.intimp.2004.09.013
PG 6
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 891XX
UT WOS:000226615400007
PM 15589459
DA 2020-11-26
ER

PT J
AU Chaves, MMS
   Kallas, EG
AF Chaves, MMS
   Kallas, EG
TI Cell cycle distribution of CD4(+) lymphocytes in HIV-1-infected subjects
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article
DE human immunodeficiency virus; lymphocyte; cell cycle; CD4; flow
   cytometry
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; T-LYMPHOCYTES; INDUCED
   APOPTOSIS; VPR; ACTIVATION; PROLIFERATION; INDUCTION; MECHANISM; SIGNALS
AB Background: Apoptosis is one of the possible explanations for the progressive loss of CD4(+) T lymphocytes in infection with the human immunodeficiency virus (HIV), which may interfere with cell cycle distribution. This study evaluated the cell cycle of CD4(+) and CD8(+) lymphocytes in HIV-infected subjects and controls.
   Methods: Two methods to identify lymphocytes for cell cycle analysis were evaluated, magnetic beads and concurrent staining, and both were followed by propidium iodide DNA labeling. The chosen method was used to evaluate the cell cycle of lymphocytes in HIV-1-infected subjects and controls.
   Results: There was no significant difference between the two methods, although a higher variability was observed with the magnetic bead cell separation method. A higher proportion of cells in the S phase was observed in HIV-1 patients (2.69% vs. 1.19%, P = 0.016), coupled with a decrease in G, (96.11% vs. 98.10%, P = 0.005) in CD4(+) lymphocytes, a phenomenon not observed in CD8(+) lymphocytes. No correlation was detected between the different cell cycle phases and T-lymphocyte counts or viral load.
   Conclusions: The present work developed a new approach to evaluate lymphocyte cell cycle distribution, applied in the setting of HIV-1 infection. It may contribute to the understanding of the CD4(+) T-Iymphocytes depletion seen in these patients. (C) 2004 Wiley-Liss, Inc.
C1 Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Fed Sao Paulo, Lab Imunol, Disciplina Doencas Infecciosas & Parasitarias, Escola Paulista Med, Rua Pedro Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
EM kallas.dmed@epm.br
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Alberts B, 2002, MOL BIOL CELL
   Badley AD, 2000, BLOOD, V96, P2951, DOI 10.1182/blood.V96.9.2951.h8002951_2951_2964
   Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999
   Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996
   Blanco J, 1999, AIDS, V13, P909, DOI 10.1097/00002030-199905280-00006
   Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756
   Chowdhury IH, 2003, VIROLOGY, V305, P371, DOI 10.1006/viro.2002.1777
   Gandhi RT, 1998, J EXP MED, V187, P1113, DOI 10.1084/jem.187.7.1113
   Gougeon ML, 1996, J IMMUNOL, V156, P3509
   Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319
   JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995
   Mahalingam M, 1995, CLIN EXP IMMUNOL, V102, P481
   Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997
   Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Noraz N, 1997, AIDS, V11, P1671, DOI 10.1097/00002030-199714000-00003
   OYAIZU N, 1993, BLOOD, V82, P3392
   OYAIZU N, 1995, J CLIN IMMUNOL, V15, P217, DOI 10.1007/BF01540879
   Patki AH, 1999, AIDS, V13, P1177, DOI 10.1097/00002030-199907090-00005
   Patki AH, 1999, CLIN IMMUNOL, V93, P245, DOI 10.1006/clim.1999.4802
   Patki AH, 2000, CLIN IMMUNOL, V97, P241, DOI 10.1006/clim.2000.4940
   Piedimonte G, 1999, AIDS, V13, P1159, DOI 10.1097/00002030-199907090-00003
   ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995
   Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200
   Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839
   Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568
   Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997
   Suzuki S, 2000, MICROBIOL IMMUNOL, V44, P111, DOI 10.1111/j.1348-0421.2000.tb01254.x
   Tamma SML, 1997, CLIN IMMUNOL IMMUNOP, V85, P195, DOI 10.1006/clin.1997.4424
NR 29
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4949
EI 1552-4957
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD NOV
PY 2004
VL 62B
IS 1
BP 46
EP 51
DI 10.1002/cyto.b.20029
PG 6
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 869KW
UT WOS:000224983000005
PM 15476192
DA 2020-11-26
ER

PT J
AU Costa-Carvalho, BT
   Viana, MA
   Brunialti, MKC
   Kallas, EG
   Salomao, R
AF Costa-Carvalho, BT
   Viana, MA
   Brunialti, MKC
   Kallas, EG
   Salomao, R
TI An imbalance of naive and memory/effector subsets and altered expression
   of CD38 on T lymphocytes in two girls with hyper-IgM syndrome
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CD38; cytokines; hyper-IgM; naive/memory cells; T lymphocytes
ID X-LINKED IMMUNODEFICIENCY; CD40 LIGAND; GLYCOPROTEIN; MUTATIONS;
   HYPOGAMMAGLOBULINEMIA; DEFICIENCY; MOLECULE; CHILDREN; ZOSTER; CELLS
AB In this report we evaluated CD4(+) T, CD8(+) T and natural killer (NK) cell counts, the levels of naive/memory subsets within the CD4(+) T lymphocyte population, expression of CD38 on T lymphocytes, and CD4(+) and CD8(+) T cell cytokine production in two girls with hyper-IgM (HIM) syndrome. Both girls developed recurrent infections early in infancy, presenting a wide spectrum of clinical manifestations, with a strikingly different disease severity between them. CD4(+) T cell counts were low in both children (patient 1: 214 cells/mm(3) and patient 2: 392 cells/mm(3)), and the CD4/CD8 T cell ratio was 0.4 for patient 1, the patient with the more severe disease, and 1.4 for patient 2. NK cell numbers were low in patient 1 (60 cells/mm(3)) and borderline (286 cells/mm(3)) with regard to normal levels in patient 2. An imbalance of naive and memory/effector cell subsets was found in both girls, with the percentage of CD45RA(+) 27(+) (naive) CD4(+) T lymphocytes being 5.8 and 12.4 for patients 1 and 2, respectively. Expression of CD38 on the surface of T lymphocytes was low in patient 1. Detection of intracellular interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha in CD4(+) and CD8(+) T lymphocytes upon PMA-Io stimulus was preserved in both children. In conclusion, we found low numbers of CD4(+) T lymphocytes and a dramatic redistribution of naive and memory/effector CD4(+) T lymphocytes in two girls with non-X-linked HIM syndrome. Furthermore, we found low expression of CD38 on T lymphocytes and low numbers of NK cells in the patient with the more severe disease, indicating a possible role for these cells in the pathogenesis of this immunodeficiency.
C1 Univ Fed Sao Paulo, Div Infect Dis, UNIFESP, Immunol Lab, BR-04039032 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Pediat, Div Rheumatol Allergy & Clin Immunol, BR-04039032 Sao Paulo, Brazil.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, UNIFESP, Immunol Lab, Rua Pedro de Toledo N 781,15o Andar, BR-04039032 Sao Paulo, Brazil.
EM rsalomao-dipa@pesquisa.epm.br
RI Kallas, Esper G/C-9539-2012; Salomao, Reinaldo/C-6419-2013; Brunialti,
   Milena K C/C-4905-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; Brunialti, Milena K
   C/0000-0003-2874-520X; Kallas, Esper/0000-0003-2026-6925
CR BEALL GN, 1980, J ALLERGY CLIN IMMUN, V65, P471, DOI 10.1016/0091-6749(80)90242-0
   Bonilla FA, 2001, IMMUNOL ALLERGY CLIN, V21, P65, DOI 10.1016/S0889-8561(05)70193-4
   Brill KJ, 2001, INFECT IMMUN, V69, P1755, DOI 10.1128/IAI.69.3.1755-1765.2001
   BUSCHAM A, 2000, J IMMUNOL, V164, P2871
   CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q
   CALLARD RE, 1994, J IMMUNOL, V153, P3295
   CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3
   Cunningham CK, 1999, J PEDIATR-US, V134, P584, DOI 10.1016/S0022-3476(99)70245-3
   DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0
   ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5
   Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898
   Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151
   FIORILLI M, 1986, CLIN IMMUNOL IMMUNOP, V38, P256, DOI 10.1016/0090-1229(86)90143-1
   GALAMA JMD, 1991, J INFECTION, V23, P175, DOI 10.1016/0163-4453(91)92161-W
   JACKSON DG, 1990, J IMMUNOL, V144, P2811
   Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1
   KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0
   Leiva LE, 1998, J CLIN IMMUNOL, V18, P283, DOI 10.1023/A:1027337923709
   LEVACHER M, 1992, CLIN EXP IMMUNOL, V90, P376
   Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9
   LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8
   MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1
   MARODI L, 1988, EUR J PEDIATR, V148, P215, DOI 10.1007/BF00441406
   McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370
   Minegishi Y, 2000, CLIN IMMUNOL, V97, P203, DOI 10.1006/clim.2000.4956
   MIZUTANI K, 1995, MICROBIOL IMMUNOL, V39, P217, DOI 10.1111/j.1348-0421.1995.tb02192.x
   NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101
   OLIVA A, 1995, J ALLERGY CLIN IMMUN, V96, P403, DOI 10.1016/S0091-6749(95)70060-9
   Quezada A, 2000, J INVEST ALLERG CLIN, V10, P375
   TERADA K, 1993, SCAND J INFECT DIS, V25, P521, DOI 10.3109/00365549309008536
   Uronen H, 2000, CLIN EXP IMMUNOL, V121, P346, DOI 10.1046/j.1365-2249.2000.01307.x
NR 31
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAY
PY 2004
VL 136
IS 2
BP 291
EP 296
DI 10.1111/j.1365-2249.2004.02446.x
PG 6
WC Immunology
SC Immunology
GA 810XI
UT WOS:000220736600015
PM 15086393
OA Green Published
DA 2020-11-26
ER

PT J
AU Galante, NZ
   Camara, NOS
   Kall s, EG
   Salomao, R
   Pacheco-Silva, A
AF Galante, NZ
   Camara, NOS
   Kall s, EG
   Salomao, R
   Pacheco-Silva, A
TI Modulation of peripheral blood T-lymphocytes in kidney transplant
   recipients treated with low dose OKT3 therapy
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE T lymphocytes; OKT3; T-cell activation; kidney transplantation
ID MONOCLONAL-ANTIBODY; ANTIGENIC MODULATION; IMMUNOSUPPRESSION; INDUCTION;
   MECHANISM
AB The immunosuppressive effect of OKT3 depends upon both T cell depletion and antigenic modulation of CD3 complex. To establish the effect of low doses of OKT3 on peripheral T lymphocytes, we analyzed 47 kidney transplant recipients receiving OKT3 for the first time. OKT3 was used as rescue therapy in 39 patients and as part of induction protocols in 8. The mean age of patients was 39 1 10 years, 30 were females and 9 were re-transplants. Half of them (51.1%) received kidney from cadaver donors. Among those receiving OKT3 as rescue therapy, 82% recovered graft function, including patients with severe BANFF-graded rejections. After the first dose of OKT3, it a pronounced T cell depletion was observed followed by an increase in CD4 and CD8 expression in CD3 negative T cells, supporting the idea that T cell modulation was present. In conclusion, low dose OKT3 was effective in treating severe allograft rejection by inducing a sustained TCR/CD3 down modulation without long-lasting T cell depletion. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Fed Sao Paulo, Dept Med, Lab Imunol Clin & Expt, Disciplina Nefrol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Med, Lab Imunol, Disciplina Doencas Infecciosas & Parasitarias, Sao Paulo, Brazil.
RP Pacheco-Silva, A (corresponding author), Univ Fed Sao Paulo, Dept Med, Lab Imunol Clin & Expt, Disciplina Nefrol, Sao Paulo, Brazil.
EM apacheco@nefro.epm.br
RI Galante, Nelson Z/F-7865-2010; camara, niels/AAX-3269-2020; Camara,
   Niels OS/G-8336-2011; Salomao, Reinaldo/C-6419-2013; Pacheco-Silva,
   Alvaro/K-3583-2013
OI Galante, Nelson Z/0000-0001-7047-586X; camara,
   niels/0000-0001-5436-1248; Camara, Niels OS/0000-0001-5436-1248;
   Salomao, Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR ALONSOPULPON L, 1995, J HEART LUNG TRANSPL, V14, P136
   Bhat G, 1997, TRANSPLANT P, V29, p21S, DOI 10.1016/S0041-1345(97)00851-8
   BonnefoyBerard N, 1996, J HEART LUNG TRANSPL, V15, P435
   CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116
   Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000
   CHATENOUD L, 1984, IMMUNOL TODAY, V5, P20, DOI 10.1016/0167-5699(84)90061-6
   GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337
   HIRSCH R, 1988, J IMMUNOL, V140, P3766
   JANSSEN O, 1992, TRANSPLANTATION, V53, P233
   NORMAN DJ, 1991, TRANSPLANT P, V23, P1052
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Starzl TE, 2003, LANCET, V361, P1502, DOI 10.1016/S0140-6736(03)13175-3
   Swanson SJ, 2002, LANCET, V360, P1662, DOI 10.1016/S0140-6736(02)11606-0
   VIGERAL P, 1986, TRANSPLANTATION, V41, P730, DOI 10.1097/00007890-198606000-00013
   WONG JT, 1990, TRANSPLANTATION, V50, P683, DOI 10.1097/00007890-199010000-00030
NR 15
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD JAN 30
PY 2004
VL 91
IS 1
BP 75
EP 77
DI 10.1016/j.imlet.2003.10.008
PG 3
WC Immunology
SC Immunology
GA 774HA
UT WOS:000188972700012
PM 14757373
DA 2020-11-26
ER

PT J
AU Galante, NZ
   Kallas, EG
   Cenedeze, MA
   Salomao, R
   Pacheco-Silva, A
   Camara, NOS
AF Galante, NZ
   Kallas, EG
   Cenedeze, MA
   Salomao, R
   Pacheco-Silva, A
   Camara, NOS
TI Reduced number of V alpha 24(+)V beta 11(+) NKT cells in peripheral
   blood of long term rejection-free recipients of human kidney allografts
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY MAY 14-19, 2004
CL Boston, MA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
C1 Univ Fed Sao Paulo, Hosp Rim & Hipertensao, Disciplina Nefrol, Lab Imunol Clin & Expt, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Disciplina Doencas Infecciosas & Parasitarias, Lab Imunol, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Pacheco-Silva, Alvaro/K-3583-2013; Galante,
   Nelson Z/F-7865-2010; Camara, Niels OS/G-8336-2011; camara,
   niels/AAX-3269-2020
OI Galante, Nelson Z/0000-0001-7047-586X; Camara, Niels
   OS/0000-0001-5436-1248; camara, niels/0000-0001-5436-1248
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2004
VL 4
SU 8
MA 1291
BP 511
EP 511
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 819NT
UT WOS:000221322501287
DA 2020-11-26
ER

PT J
AU Salomao, R
   Brunialti, MK
   Martins, PS
   Fernandes, ML
   Silva, E
   Rigato, O
   Kallas, EG
AF Salomao, R
   Brunialti, MK
   Martins, PS
   Fernandes, ML
   Silva, E
   Rigato, O
   Kallas, EG
TI Effect of recombinant human activated protein C (Drotrecogin Alfa
   Activated - DAA) in the inflammatory response of monocytes and
   neutrophils in whole blood of healthy volunteers (HV)
SO SHOCK
LA English
DT Meeting Abstract
CT 27th Annual Conference on Shock
CY JUN 05-08, 2004
CL Halifax, CANADA
C1 UNIFESP, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PY 2004
VL 21
SU 2
MA 160
BP 54
EP 55
DI 10.1097/00024382-200406002-00160
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 826GC
UT WOS:000221816300160
DA 2020-11-26
ER

PT J
AU Marins, PS
   Kallas, EG
   Cenderoglo, M
   Dalboni, MA
   Blecher, S
   Salomao, R
AF Marins, PS
   Kallas, EG
   Cenderoglo, M
   Dalboni, MA
   Blecher, S
   Salomao, R
TI Increased oxidative metabolism, phagocytosis and apoptosis in human
   neutrophils from septic patients
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 16th Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 05-08, 2003
CL AMSTERDAM, NETHERLANDS
SP European Soc Intens Care Med
C1 Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   Hosp Santa Marcelina, Intens Care Unit, Sao Paulo, Brazil.
RI Dalboni, Maria Aparecida/V-6749-2019; Kallas, Esper G/C-9539-2012
OI Dalboni, Maria Aparecida/0000-0002-9282-7181; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2003
VL 29
MA 102
BP S31
EP S31
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 728ZC
UT WOS:000185745400103
DA 2020-11-26
ER

PT J
AU Freire, ACG
   de Assis, CF
   Frick, AO
   Melo, PD
   Haun, M
   Aoyama, H
   Duran, N
   Sauer, MM
   Kallas, EG
   Ferreira, CV
AF Freire, ACG
   de Assis, CF
   Frick, AO
   Melo, PD
   Haun, M
   Aoyama, H
   Duran, N
   Sauer, MM
   Kallas, EG
   Ferreira, CV
TI Influence of protein phosphatase inhibitors on HL60 cells death
   induction by dehydrocrotonin
SO LEUKEMIA RESEARCH
LA English
DT Article
DE pervanadate; okadaic acid; dehydrocrotonin; HL60; protein phosphatase;
   glutathione; differentiation; apoptosis
ID MYELOID-LEUKEMIA CELLS; BCL-X-L; OKADAIC ACID; INDUCED CYTOTOXICITY;
   OXIDATIVE STRESS; CROTON CAJUCARA; ANNEXIN-V; IN-VITRO; APOPTOSIS;
   DIFFERENTIATION
AB Oxidative stress can be involved in several cellular responses, such as differentiation, apoptosis and necrosis. Dehydrocrotonin (DCTN, diterpene lactone) from Croton cajucara, Brazilian medicinal plant, slightly induced NBT-reducing activity. In presence of protein phosphatase inhibitors significant differentiation of HL60 cells was observed. Flow cytometry analysis demonstrated that apoptosis was induced when the cells were treated with okadaic acid (OKA) and plus trans-dehydrocrotonin (t-DCTN) this effect was two-fold increased. Unlike, when the cells were treated only with t-DCTN, necrosis was observed. On the other hand, the necrosis induced by t-DCTN could be due to oxidative stress, revealed by increase of GSH content. Therefore, this differentiation pathway involves the modulation of protein phosphatases and this inhibition promotes the t-DCTN action on apoptosis induction. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 UNICAMP, Inst Biol, Dept Biochem, BR-13083970 Campinas, SP, Brazil.
   UNICAMP, Inst Chem, Biol Chem Lab, BR-13081970 Campinas, SP, Brazil.
   UNIFESP, EPM, Immunol Lab, Dept Infectoparasitaries Dis, Sao Paulo, Brazil.
RP Ferreira, CV (corresponding author), UNICAMP, Inst Biol, Dept Biochem, CP 6109, BR-13083970 Campinas, SP, Brazil.
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925; Duran, Nelson/0000-0001-8372-5143
CR Benito A, 1997, LEUKEMIA, V11, P940, DOI 10.1038/sj.leu.2400699
   BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283
   BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300-483X(00)00181-5
   Dirsch VM, 2001, CANCER RES, V61, P5817
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   GRESSER MJ, 1990, VANADIUM BIOL SYSTEM, P63
   Harrison S, 1999, GEN PHARMACOL-VASC S, V32, P287, DOI 10.1016/S0306-3623(98)00204-3
   Hiruma-Lima CA, 1999, PLANTA MED, V65, P325, DOI 10.1055/s-1999-13995
   HOMBURG CHE, 1995, BLOOD, V85, P532
   Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843
   Kohroki J, 1998, LEUKEMIA RES, V22, P405, DOI 10.1016/S0145-2126(97)00190-2
   LI YB, 1994, LIFE SCI, V54, P901, DOI 10.1016/0024-3205(94)00626-1
   Maciel MAM, 2000, J ETHNOPHARMACOL, V70, P41, DOI 10.1016/S0378-8741(99)00159-2
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Riordan FA, 1998, FEBS LETT, V435, P195, DOI 10.1016/S0014-5793(98)01070-9
   Schindl A, 1998, J PHOTOCH PHOTOBIO B, V44, P97, DOI 10.1016/S1011-1344(98)00127-4
   Shimizu T, 1999, LEUKEMIA RES, V23, P901, DOI 10.1016/S0145-2126(99)00106-X
   STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463
   STERN A, 1993, BIOCHEM CELL BIOL, V71, P103, DOI 10.1139/o93-018
   Torsoni MA, 1998, BIOCHEM MOL BIOL INT, V46, P147
   Uzunoglu S, 1999, LEUKEMIA RES, V23, P507, DOI 10.1016/S0145-2126(99)00040-5
   VANDRE DD, 1992, J CELL SCI, V101, P79
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wyllie A H, 1980, Int Rev Cytol, V68, P251
   Xu K, 2001, BIOCHEM PHARMACOL, V61, P165, DOI 10.1016/S0006-2952(00)00526-8
   Zhu WH, 1998, LIFE SCI, V63, P265, DOI 10.1016/S0024-3205(98)00270-7
NR 29
TC 19
Z9 20
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
J9 LEUKEMIA RES
JI Leuk. Res.
PD SEP
PY 2003
VL 27
IS 9
BP 823
EP 829
DI 10.1016/S0145-2126(03)00013-4
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 692KB
UT WOS:000183659300009
PM 12804641
DA 2020-11-26
ER

PT J
AU Martins, PS
   Kallas, EG
   Neto, MC
   Dalboni, MA
   Blecher, S
   Salomao, R
AF Martins, PS
   Kallas, EG
   Neto, MC
   Dalboni, MA
   Blecher, S
   Salomao, R
TI Upregulation of reactive oxygen species generation and phagocytosis, and
   increased apoptosis in human neutrophils during severe sepsis and septic
   shock
SO SHOCK
LA English
DT Article
DE oxidative metabolism; flow cytometry; inflammatory response; S. aureus;
   LPS
ID INFLAMMATORY RESPONSE SYNDROME; WHOLE-BLOOD; RESPIRATORY BURST;
   OXIDATIVE BURST; PLASMA; SERUM; INTERLEUKIN-10; EPIDEMIOLOGY;
   EXPRESSION; INHIBITION
AB We evaluated neutrophil activation by measuring its phagocytic ability and oxidative burst activity in 16 patients with sepsis and 16 healthy volunteers. We also focused on neutrophil apoptosis as a regulatory mechanism of the inflammatory response. Neutrophil phagocytosis was evaluated by the detection of propidium iodide (PI)-labeled Staphylococcus aureus added to whole blood. Reactive oxygen species (ROS) formation was quantified by measuring the oxidation of 2',7' dichlorofluorescein diacetate (DCFH-DA) at baseline and after cell stimulation with phorbol myristate acetate (PMA), and bacterial cells (killed S. aureus) or products (lipopolysaccharide [LPS] and N-formyl-methionyl-leucylphenylalanine [FMLP]). Apoptosis was assessed in neutrophils stained with annexin V and Pl. Neutrophil phagocytic ability was increased in patients with sepsis compared with healthy controls (median geometric mean fluorescence intensity [GMFI] was 101.9 and 54.7, respectively; P = 0.05). ROS formation was enhanced in patients with sepsis compared with healthy volunteers at baseline (median GMFI 275.6 and 52.1, respectively; P < 0.001), and after stimulation with S. aureus (median GMFI 2395.8 and 454.9, respectively; P < 0.001), PMA (median GMFI 1120.6 and 307.5, respectively; P = 0.003), FMLP (median GMFl 792.4 and 123.2, respectively; P < 0.001), and LPS (median GMFI 624.8 and 144.8, respectively; P < 0.001). Early neutrophil apoptosis was increased in patients with sepsis compared with healthy volunteers (median 11.3% and 9.1%, respectively; P = 0.03). These data demonstrate that neutrophil function is enhanced in patients with sepsis. Additionally, circulating neutrophils from patients with sepsis presented with increased early apoptosis, which may be consequence of a regulatory mechanism of the inflammatory response.
C1 Univ Fed Sao Paulo, Immunol Lab, Div Infect Dis, Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Div Nephrol, Escola Paulista Med, BR-04039 Sao Paulo, Brazil.
   Santa Marcelina Hosp, Intens Care Unit, Sao Paulo, Brazil.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, Immunol Lab, Div Infect Dis, Escola Paulista Med, Rua Pedro Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Dalboni, Maria Aparecida/V-6749-2019;
   Salomao, Reinaldo/C-6419-2013
OI Dalboni, Maria Aparecida/0000-0002-9282-7181; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035
   BASS DA, 1983, J IMMUNOL, V130, P1910
   Bloomfield GL, 1997, CRIT CARE MED, V25, P584, DOI 10.1097/00003246-199704000-00006
   BOHMER RH, 1992, CYTOMETRY, V13, P525, DOI 10.1002/cyto.990130512
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   CALVANO SE, 1994, ARCH SURG-CHICAGO, V129, P220
   ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341
   Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005
   Faist E, 1998, NEW HORIZ-SCI PRACT, V6, pS97
   Fanning NF, 1999, SHOCK, V11, P167, DOI 10.1097/00024382-199903000-00003
   GALANOS C, 1992, BACTERIAL ENDOTOXIC, V2, P75
   Hack CE, 2001, CRIT CARE MED, V29, pS21, DOI 10.1097/00003246-200107001-00011
   Jimenez MF, 1997, ARCH SURG-CHICAGO, V132, P1263
   KARZAI W, 2000, YB INTENSIVE CARE EM, P41
   Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356
   Kobold ACM, 2000, INTENS CARE MED, V26, P883, DOI 10.1007/s001340051277
   Le Tulzo Y, 2002, SHOCK, V18, P487, DOI 10.1097/00024382-200212000-00001
   MARSHALL JC, 2001, MECH ORGAN DYSFUNCTI, P110
   Papathanassoglou EDE, 2001, CRIT CARE MED, V29, P709, DOI 10.1097/00003246-200104000-00002
   Pascual C, 1998, INTENS CARE MED, V24, P1181, DOI 10.1007/s001340050742
   Power C, 2002, SHOCK, V18, P197, DOI 10.1097/00024382-200209000-00001
   Rigato O, 2003, SHOCK, V19, P113, DOI 10.1097/00024382-200302000-00004
   Rigato O., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P13, DOI 10.2174/1568008013341794
   Salomao R, 2002, J ENDOTOXIN RES, V8, P371, DOI 10.1179/096805102125000704
   Salomao R, 1999, INFECTION, V27, P1, DOI 10.1007/BF02565163
   Savill J, 1997, J LEUKOCYTE BIOL, V61, P375
   Schlichting E, 1996, SCAND J CLIN LAB INV, V56, P167, DOI 10.3109/00365519609088604
   THOMAS EL, 1988, REV INFECT DIS S2, V10, P450
   TOBIAS PS, 1988, J BIOL CHEM, V263, P13479
   TRAUTINGER F, 1991, J LEUKOCYTE BIOL, V49, P449
   TRINKLE LS, 1987, DIAGN CLIN IMMUNOL, V5, P62
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
   Wenisch C, 1999, INFECTION, V27, P183, DOI 10.1007/BF02561525
NR 34
TC 104
Z9 111
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD SEP
PY 2003
VL 20
IS 3
BP 208
EP 212
DI 10.1097/01.shk.0000079425.52617.db
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 713DQ
UT WOS:000184841100002
PM 12923490
OA Green Accepted
DA 2020-11-26
ER

PT J
AU Biasutti, C
   Jorge, MG
   Lima, SH
   Kallas, EG
   Segurado, AC
AF Biasutti, C
   Jorge, MG
   Lima, SH
   Kallas, EG
   Segurado, AC
TI Immunophenotypic evaluation of peripheral CD4+ and CD8+ T lymphocytes in
   asymptomatic carriers of HTLV-I.
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT 11th International Conference on Human Retrovirology: HTLV and Related
   Viruses
CY JUN 09-12, 2003
CL SAN FRANCISCO, CALIFORNIA
C1 Univ Sao Paulo, Sch Med, Virol Lab, Dept Infect Dis, BR-05508 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Immunol Lab, Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Segurado, Aluisio C/K-2229-2012
OI Segurado, Aluisio C/0000-0002-6311-8036
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PY 2003
VL 19
SU S
MA P50
BP S43
EP S43
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 685TU
UT WOS:000183280000126
DA 2020-11-26
ER

PT J
AU Hueb, AC
   Jatene, FB
   Moreira, LFP
   Pomerantzeff, PM
   Kallas, E
   de Oliveira, SA
AF Hueb, AC
   Jatene, FB
   Moreira, LFP
   Pomerantzeff, PM
   Kallas, E
   de Oliveira, SA
TI Ventricular remodeling and mitral valve modifications in dilated
   cardiomyopathy: New insights from anatomic study
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID IN-VITRO; HEART-FAILURE; REGURGITATION; ANNULOPLASTY; RECONSTRUCTION;
   ECHOCARDIOGRAPHY; DETERMINANT; DILATATION; MECHANISMS; ANULUS
AB Objective: The purpose of this study was to analyze the behavior of the mitral valve ring and the left ventricle in dilated cardiomyopathy.
   Methods: We analyzed 68 fixed adult human hearts, divided into 48 hearts with dilated cardiomyopathy of ischemic or idiopathic origin and 20 hearts free of pathologic heart conditions. Digital images of the mitral ring perimeter, attachment of the anterior and posterior leaflets, and fibrous and muscular portions were collected. We also measured the internal perimeter of the left ventricle, the distance from the septum to the anterior and posterior papillary muscles, the distance between the papillary muscles, and the extension of interventricular septum.
   Results: The analysis of the results showed proportional distribution of the ring's fibrous portion (r(2) = 0.98) and muscular portion (r(2) = 0.99) according to the degree of mitral valve dilation. Linear regression revealed that the perimeters of anterior and posterior leaflet attachments (r(2) = 0.96 and r(2) = 0.98, respectively) also had a proportional relation. We did not observe proportionality between the degree of dilation of the mitral ring and the left ventricle. It was observed that dilation of the left ventricle takes place globally in its segments.
   Conclusion: Differently from what was thought, in ischemic or idiopathic dilated cardiomyopathy, dilation of mitral ring is proportional and does not exclusively affect the posterior portion. The degree of left ventricular dilation does not determine the degree of dilation of the mitral ring because they are independent processes. These observations shed new light on the techniques used to correct mitral valve insufficiency in dilated cardiomyopathy.
C1 Univ Sao Paulo, Sch Med, Inst Heart, InCor, Sao Paulo, Brazil.
RP Hueb, AC (corresponding author), Rua Oscar Freire 1707 Apto 22, BR-05409011 Sao Paulo, Brazil.
RI Hueb, Alexandre/E-6804-2013; Jatene, Fabio B/D-1679-2012; Pomerantzeff,
   Pablo M A/L-5525-2016; Moreira, Luiz Felipe Pinho/F-9882-2012
OI Pomerantzeff, Pablo M A/0000-0003-0566-1038; Moreira, Luiz Felipe
   Pinho/0000-0003-0179-4976
CR Bolling SF, 1998, J THORAC CARDIOV SUR, V115, P381, DOI 10.1016/S0022-5223(98)70282-X
   Braile DM, 1990, REV BRAS CIR CARDIOV, V5, P86
   BROCK RC, 1952, BRIT HEART J, V14, P489
   BULKLEY BH, 1975, AM J MED, V59, P457, DOI 10.1016/0002-9343(75)90252-1
   CAMILLERI L, 1995, J CARDIAC SURG, V10, P99
   CARPENTIER A, 1969, PRESSE MED, V77, P251
   CHANDRARATNA PA, 1981, CHEST, V79, P152
   Choo SJ, 1998, J HEART VALVE DIS, V7, P593
   Comin J, 1999, REV ESP CARDIOL, V52, P512, DOI 10.1016/S0300-8932(99)74959-6
   COSGROVE DM, 1995, ANN THORAC SURG, V60, P499, DOI 10.1016/0003-4975(95)00458-W
   DEMARIA R, 1993, SURG RADIOL ANAT, V15, P145, DOI 10.1007/BF01628316
   DURAN CG, 1976, ANN THORAC SURG, V22, P458, DOI 10.1016/S0003-4975(10)64454-2
   Glasson JR, 1996, J THORAC CARDIOV SUR, V111, P574, DOI 10.1016/S0022-5223(96)70309-4
   He SQ, 1997, CIRCULATION, V96, P1826, DOI 10.1161/01.CIR.96.6.1826
   He SQ, 1999, J HEART VALVE DIS, V8, P294
   KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4
   KONO T, 1991, AM J CARDIOL, V68, P355, DOI 10.1016/0002-9149(91)90831-5
   KONO T, 1992, J AM COLL CARDIOL, V20, P1594, DOI 10.1016/0735-1097(92)90455-V
   Kunzelman K S, 1994, J Heart Valve Dis, V3, P491
   OKADA Y, 1995, ANN THORAC SURG, V59, P658, DOI 10.1016/0003-4975(94)01008-0
   Oki T, 1996, CLIN CARDIOL, V19, P639, DOI 10.1002/clc.4960190811
   Otsuji Y, 1997, CIRCULATION, V96, P1999, DOI 10.1161/01.CIR.96.6.1999
   Pellegrini A, 1993, J Heart Valve Dis, V2, P633
   PERLOFF JK, 1972, CIRCULATION, V46, P227, DOI 10.1161/01.CIR.46.2.227
   SALATI M, 1991, EUR J CARDIO-THORAC, V5, P226, DOI 10.1016/1010-7940(91)90168-J
   SIMAO C, 1998, THESIS SAO PAULO U S
   WALMSLEY R, 1978, BRIT HEART J, V40, P351
NR 27
TC 122
Z9 132
U1 0
U2 4
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD DEC
PY 2002
VL 124
IS 6
BP 1216
EP 1224
DI 10.1067/mtc.2002.125342
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 623MC
UT WOS:000179706200024
PM 12447190
DA 2020-11-26
ER

PT J
AU Guarro, J
   Kallas, EG
   Godoy, P
   Karenina, A
   Gene, J
   Stchigel, A
   Colombo, AL
AF Guarro, J
   Kallas, EG
   Godoy, P
   Karenina, A
   Gene, J
   Stchigel, A
   Colombo, AL
TI Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID FISCHERI; PSEUDOFISCHERI; PATIENT
AB We report the first case of infection by Neosartorya hiratsukae, an ascomycete in which the conidial state resembles Aspergillus fumigatus. The fungus caused a brain infection in a Brazilian woman, who died despite itraconazole treatment. Diagnosis was established by direct microscopic examination, computed tomographic scan, and magnetic resonance imaging of the brain, and repeated cultures from the lesions. The in vitro antifungal susceptibility of the isolate is provided.
C1 Univ Rovira & Virgili, Fac Med & Ciencies Salut, Dept Ciencies Med Basiques, Unitat Microbiol, Tarragona 43201, Spain.
   UNIFESP, Escola Paulista Med, Sao Paulo, Brazil.
   Hosp Servidor Publ Etatual, Sao Paulo, Brazil.
RP Guarro, J (corresponding author), Univ Rovira & Virgili, Fac Med & Ciencies Salut, Dept Ciencies Med Basiques, Unitat Microbiol, Carrer Sant Llorenc 21, Tarragona 43201, Spain.
RI Colombo, Arnaldo Lopes/V-4417-2019; Colombo, Arnaldo Lopes/H-4397-2012;
   Stchigel, Alberto/G-1261-2016; Kallas, Esper G/C-9539-2012
OI Stchigel, Alberto/0000-0003-3987-7996; Colombo, Arnaldo
   Lopes/0000-0003-0793-8491; Guarro, Josep/0000-0002-7839-7568
CR Chim CS, 1998, SCAND J INFECT DIS, V30, P190, DOI 10.1080/003655498750003627
   CORIGLIONE G, 1990, EUR J EPIDEMIOL, V6, P382, DOI 10.1007/BF00151712
   De Hoog G.S., 2000, ATLAS CLIN FUNGI
   GERBER J, 1973, AM J CLIN PATHOL, V60, P861
   Gori S, 1998, J MYCOL MED, V8, P105
   Lonial S, 1997, BONE MARROW TRANSPL, V19, P753, DOI 10.1038/sj.bmt.1700715
   National Committee for Clinical Laboratory Standards (NCCLS), 1998, M38P NCCLS
   PADHYE AA, 1994, J CLIN MICROBIOL, V32, P2832, DOI 10.1128/JCM.32.11.2832-2836.1994
   PETERSON SW, 1992, MYCOL RES, V96, P547, DOI 10.1016/S0953-7562(09)80979-9
   Pujol I, 1996, ANTIMICROB AGENTS CH, V40, P2106, DOI 10.1128/AAC.40.9.2106
   Someya Ayako, 1999, Mycoscience, V40, P405, DOI 10.1007/BF02464395
   SUMMERBELL RC, 1992, J CLIN MICROBIOL, V30, P1580, DOI 10.1128/JCM.30.6.1580-1582.1992
   Udagawa S. I., 1991, Transactions of the Mycological Society of Japan, V32, P23
NR 13
TC 41
Z9 44
U1 0
U2 3
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2002
VL 8
IS 9
BP 989
EP 991
DI 10.3201/eid0809.020073
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 588XZ
UT WOS:000177728700021
PM 12194781
OA DOAJ Gold, Green Published
DA 2020-11-26
ER

PT J
AU Galante, NZ
   Kallas, EG
   Salomao, R
   Medina, JOP
   Pacheco-Silva, A
AF Galante, NZ
   Kallas, EG
   Salomao, R
   Medina, JOP
   Pacheco-Silva, A
TI Modulation of peripheral blood T lymphocytes from kidney transplants
   recipients with 2,5 mg/day of OKT3 therapy.
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Meeting Abstract
C1 UNIFESP, Div Nephrol, Sao Paulo, Brazil.
RI Pacheco-Silva, Alvaro/K-3583-2013; Kallas, Esper G/C-9539-2012; Galante,
   Nelson Z/F-7865-2010
OI Galante, Nelson Z/0000-0001-7047-586X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD SEP
PY 2002
VL 13
SU S
BP 566A
EP 566A
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 589KL
UT WOS:000177757502774
DA 2020-11-26
ER

PT J
AU Rodrigues, DSS
   Medeiros, EAS
   Weckx, LY
   Bonnez, W
   Salomao, R
   Kallas, EG
AF Rodrigues, DSS
   Medeiros, EAS
   Weckx, LY
   Bonnez, W
   Salomao, R
   Kallas, EG
TI Immunophenotypic characterization of peripheral T lymphocytes in
   Mycobacterium tuberculosis infection and disease
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Proceedings Paper
CT 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 17-21, 2000
CL TORONTO, CANADA
SP NIH
DE Mycobacterium tuberculosis; tuberculosis; lymphocyte; immunophenotyping
ID ACTIVE PULMONARY TUBERCULOSIS; CELL CLONES; ALPHA-BETA;
   INTERFERON-GAMMA; HIV-INFECTION; CD4(+); IMMUNITY; PROTECTION;
   DEPLETION; BCG
AB The cellular immune response probably plays a pivotal role in determining the clinical outcome after exposure to Mycobacterium tuberculosis. We used multi-parameter flow-cytometry to evaluate the distribution of T-lymphocyte subsets during infection and disease caused by M. tuberculosis. Samples were obtained from 71 volunteers to identify the T CD4(+) and CD8(+) lymphocyte numbers, and the activation plus memory/naive phenotypes, as defined by CD38, HLA-DR, CD45RA and CD27 markers. Subjects were divided into 18 healthy volunteers without detectable reaction to purified protein derivative (PPD-), 18 health care workers with a recent conversion to PPD, 20 patients with active pulmonary tuberculosis (TBC) and 15 patients with treated TBC at 6 months of therapy. By multiple-comparison analyses, the T CD4(+) lymphocyte number of the TBC group was lower than the PPD- group (P < 0.05). Ibis difference was apparently lost after treatment. The higher and the lower number of naive T CD4(+) cells was observed in the PPD- and TB C group, respectively. CD8(+) T lymphocytes were also statistically different among the four groups (P = 0.0002), lower in the TBC group (P < 0.05). CD8(+) T lymphocyte activation was evaluated by the CD38 and HLA-DR surface expression. The percentage distribution of these markers was statistically different between the four groups (P = 0.0055). TBC patients had a higher percentage of CD38(+) cells and mean fluorescence index, suggesting an overall increase of cell activation. These results suggest that peripheral T lymphocytes reflect cellular activation during TBC, along with possible redistribution of naive, memory/effector and late differentiated memory/effector phenotypes in the peripheral blood after infection and disease caused by M. tuberculosis.
C1 Univ Fed Sao Paulo, LKab Imunol, Disciplina Doencas Infecc & Parasitarias, Escola Paulista Med,Infect Dis Discipline, BR-04039032 Sao Paulo, Brazil.
   Univ Rochester, Infect Dis Unit, Rochester, NY 14627 USA.
RP Kallas, EG (corresponding author), Univ Fed Sao Paulo, LKab Imunol, Disciplina Doencas Infecc & Parasitarias, Escola Paulista Med,Infect Dis Discipline, Rue Pedro Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
EM kallas.dmed@epm.br
RI Kallas, Esper G/C-9539-2012; Salomao, Reinaldo/C-6419-2013; Medeiros,
   Eduardo A/B-9825-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; Medeiros, Eduardo
   A/0000-0002-6205-259X; Kallas, Esper/0000-0003-2026-6925; WECKX,
   LILY/0000-0003-4949-3582
CR AINSLIE GM, 1992, THORAX, V47, P513, DOI 10.1136/thx.47.7.513
   Batoni G, 1998, CLIN EXP IMMUNOL, V112, P52
   BECK JS, 1985, CLIN EXP IMMUNOL, V60, P49
   BHATNAGAR R, 1977, AM REV RESPIR DIS, V115, P207
   Das G, 1999, CLIN EXP IMMUNOL, V115, P324, DOI 10.1046/j.1365-2249.1999.00755.x
   DJOMAND G, 1994, AIDS, V8, P843, DOI 10.1097/00002030-199406000-00019
   DSouza CD, 1997, J IMMUNOL, V158, P1217
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Evans TG, 1998, ANTIVIR RES, V39, P163, DOI 10.1016/S0166-3542(98)00035-7
   Feng CG, 2000, J INFECT DIS, V181, P1846, DOI 10.1086/315466
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   Gerosa F, 1999, CLIN IMMUNOL, V92, P224, DOI 10.1006/clim.1999.4752
   Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403
   Jones BE, 1997, CLIN INFECT DIS, V24, P988, DOI 10.1093/clinids/24.5.988
   KAUFMANN SHE, 1994, IMMUNOBIOLOGY, V191, P509, DOI 10.1016/S0171-2985(11)80457-2
   Kony SJ, 2000, J INFECTION, V41, P167, DOI 10.1053/jinf.2000.0721
   Lalvani T, 1998, P NATL ACAD SCI USA, V95, P270, DOI 10.1073/pnas.95.1.270
   LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8
   MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0
   ONWUBALILI JK, 1987, TUBERCLE, V68, P195, DOI 10.1016/0041-3879(87)90055-9
   ORME IM, 1988, J IMMUNOL, V140, P3589
   ORME IM, 1983, J EXP MED, V158, P74, DOI 10.1084/jem.158.1.74
   Ozeki Y, 1997, INFECT IMMUN, V65, P1793, DOI 10.1128/IAI.65.5.1793-1799.1997
   PEAKMAN M, 1994, DIABETOLOGIA, V37, P155, DOI 10.1007/s001250050087
   PEDRAZZINI T, 1986, J IMMUNOL, V136, P1828
   PITHIE AD, 1992, THORAX, V47, P695, DOI 10.1136/thx.47.9.695
   Rojas RE, 1999, INFECT IMMUN, V67, P6461
   ROOK GAW, 1976, CLIN EXP IMMUNOL, V26, P129
   SANTOS MD, 2001, 8 C RETR OPP INF FDN
   Scanga CA, 2000, J EXP MED, V192, P347, DOI 10.1084/jem.192.3.347
   SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404
   SILVA CL, 1994, IMMUNOLOGY, V83, P341
   SINGHAL M, 1989, TUBERCLE, V70, P171, DOI 10.1016/0041-3879(89)90047-0
   Swaminathan S, 1999, CLIN INFECT DIS, V28, P1290, DOI 10.1086/514794
   Tascon RE, 1998, INFECT IMMUN, V66, P830, DOI 10.1128/IAI.66.2.830-834.1998
   TOMKINSON BE, 1987, J IMMUNOL, V139, P3802
   Tsukaguchi K, 1999, CELL IMMUNOL, V194, P12, DOI 10.1006/cimm.1999.1497
   TURETT GS, 1994, CHEST, V105, P1335, DOI 10.1378/chest.105.5.1335
   VANES A, 1984, TRANSPLANTATION, V37, P65
   Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
NR 40
TC 55
Z9 61
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 2002
VL 128
IS 1
BP 149
EP 154
DI 10.1046/j.1365-2249.2002.01809.x
PG 6
WC Immunology
SC Immunology
GA 577UA
UT WOS:000177079300021
PM 11982602
OA Green Published
DA 2020-11-26
ER

PT J
AU Diament, D
   Brunialti, MKC
   Romero, EC
   Kallas, EG
   Salomao, R
AF Diament, D
   Brunialti, MKC
   Romero, EC
   Kallas, EG
   Salomao, R
TI Peripheral blood mononuclear cell activation induced by Leptospira
   interrogans glycolipoprotein
SO INFECTION AND IMMUNITY
LA English
DT Article
ID BORRELIA-BURGDORFERI LIPOPROTEINS; TUMOR-NECROSIS-FACTOR; TOLL-LIKE
   RECEPTOR-2; ACUTE-RENAL-FAILURE; BIOLOGICAL-ACTIVITIES; CYTOKINE
   PRODUCTION; FACTOR-ALPHA; PATHOGENESIS; INFECTION; MONOCYTES
AB Leptospira interrogans glycolipoprotein (GLP) has been implicated in pathological and functional derangement seen in leptospirosis. The goal of this study was to evaluate GLP's ability to induce cellular activation, as assessed by cytokine production and expression of surface activation markers. GLP extracted from either pathogenic L. interrogans serovar Copenhageni or nonpathogenic Leptospira biflexa serovar Patoc (GLPp) was used to stimulate peripheral blood mononuclear cell cultures from healthy donors. Supernatant cytokine levels were measured by enzyme-linked immunosorbent assay. Expression of CD69 and HLA-DR on lymphocytes and monocytes, as well as lipopolysaccharide (LPS) binding, were measured by flow cytometry. At 6 h of incubation, GLP induced a significant rise in tumor necrosis factor alpha levels, which dropped progressively until 72 h of incubation. Interleukin-10 peak levels were obtained at between 24 and 48 h, with sustained levels until 72 h of incubation. The response magnitude was proportional to the GLP dose. CD69 expression on T lymphocytes and monocytes increased significantly, as did HLA-DR expression on monocytes. GLPp induced no CD69 or HLA-DR expression. GLP did not block biotinylated LPS binding to monocytes, suggesting that different pathways are used to induce cell activation. In conclusion, GLP induces cellular activation and may play a major role in the pathogenesis of leptospirosis.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   Inst Adolpho Lutz, Sao Paulo, Brazil.
RP Salomao, R (corresponding author), R Pedro de Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
RI Romero, Eliete C/H-6976-2012; Brunialti, Milena K C/C-4905-2012;
   Diament, Decio/A-5195-2010; Salomao, Reinaldo/C-6419-2013; Kallas, Esper
   G/C-9539-2012
OI Romero, Eliete C/0000-0002-8635-439X; Brunialti, Milena K
   C/0000-0003-2874-520X; Diament, Decio/0000-0003-0147-2061; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR Abdulkader RCRM, 1996, AM J TROP MED HYG, V54, P1
   Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736
   ALVES VAF, 1991, EXP PATHOL-JENA, V42, P81, DOI 10.1016/S0232-1513(11)80051-4
   Barnett JK, 1999, INFECT IMMUN, V67, P853, DOI 10.1128/IAI.67.2.853-861.1999
   BRITO T, 1979, J PATHOL, V128, P177
   BRITO T, 1987, ANN TROP MED PARASIT, V81, P207
   BRODIE C, 1995, J CELL PHYSIOL, V165, P246, DOI 10.1002/jcp.1041650205
   BRUNIALTI MKC, IN PRESS CYTOMETRY
   Casey LC, 2000, CRIT CARE CLIN, V16, P193, DOI 10.1016/S0749-0704(05)70107-X
   Cinco M, 1996, FEMS MICROBIOL LETT, V138, P211, DOI 10.1111/j.1574-6968.1996.tb08159.x
   CINCO M, 1980, ZBL BAKT-INT J MED M, V248, P260, DOI 10.1016/S0174-3031(80)80044-8
   DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999
   DIAMENT D, 1995, R EV SOC BRAS MED TR, V28, P157
   ESTAVOYER JM, 1991, REV INFECT DIS, V13, P1245
   FAINE S., 1994, LEPTOSPIRA LEPTOSPIR
   Foey AD, 1997, BBA-MOL CELL RES, V1355, P43, DOI 10.1016/S0167-4889(96)00116-4
   Galanos C., 1977, INT REV BIOCH BIOCH, V14, P239
   Giambartolomei GH, 1999, INFECT IMMUN, V67, P140, DOI 10.1128/IAI.67.1.140-147.1999
   Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491
   Haake DA, 2000, INFECT IMMUN, V68, P2276, DOI 10.1128/IAI.68.4.2276-2285.2000
   Hirschfeld M, 1999, J IMMUNOL, V163, P2382
   ISOGAI E, 1986, ZBL BAKT-INT J MED M, V261, P53, DOI 10.1016/S0176-6724(86)80062-1
   Kurosawa M, 2000, AM J PHYSIOL-CELL PH, V278, pC500
   Lomar AV, 2000, INFECT DIS CLIN N AM, V14, P23, DOI 10.1016/S0891-5520(05)70216-6
   MACEDOSANTOS RT, 1989, REV INST MED TROP SP, V31, P235
   MAGALDI AJ, 1992, NEPHRON, V62, P332, DOI 10.1159/000187069
   Marakhova I I, 1998, Membr Cell Biol, V12, P363
   Marzio R, 1999, IMMUNOPHARM IMMUNOT, V21, P565, DOI 10.3109/08923979909007126
   NICODEMO AC, 1989, REV I MED TROP, V31, P71, DOI 10.1590/S0036-46651989000200002
   Olej B, 1998, BIOSCIENCE REP, V18, P1, DOI 10.1023/A:1022259832207
   OLEJ B, 1994, INT J IMMUNOPHARMACO, V16, P769, DOI 10.1016/0192-0561(94)90097-3
   ORAVEC C, 1978, NEOPLASMA, V25, P565
   Pereira MM, 1997, EXP TOXICOL PATHOL, V49, P505, DOI 10.1016/S0940-2993(97)80155-8
   RADOLF JD, 1995, J IMMUNOL, V154, P2866
   Salomao R, 1999, INFECTION, V27, P1, DOI 10.1007/BF02565163
   SEGURO AC, 1990, NEPHRON, V55, P146, DOI 10.1159/000185943
   SHIMIZU T, 1987, MICROBIOL IMMUNOL, V31, P727, DOI 10.1111/j.1348-0421.1987.tb03134.x
   Slifka MK, 2000, J MOL MED, V78, P74, DOI 10.1007/s001090000086
   Tajiki MH, 1996, CLIN INFECT DIS, V23, P1177, DOI 10.1093/clinids/23.5.1177
   TAJIKI MH, 1997, BRAZ J INFECT DIS, V1, P138
   van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0
   VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211
   VIHN T, 1986, J GEN MICROBIOL, V132, P111
   VOLINA EG, 1986, J HYG EPID MICROB IM, V2, P163
   Wooten RM, 1998, J IMMUNOL, V160, P5485
   YANAGIHARA Y, 1984, MICROBIOL IMMUNOL, V28, P747, DOI 10.1111/j.1348-0421.1984.tb00730.x
   YOUNESIBRAHIM M, 1995, CR ACAD SCI III-VIE, V318, P619
NR 47
TC 50
Z9 51
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2002
VL 70
IS 4
BP 1677
EP 1683
DI 10.1128/IAI.70.4.1677-1683.2002
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 534FE
UT WOS:000174573200002
PM 11895929
OA Green Published, Bronze
DA 2020-11-26
ER

PT J
AU Brunialti, MKC
   Kallas, EG
   Freudenberg, M
   Galanos, C
   Salomao, R
AF Brunialti, MKC
   Kallas, EG
   Freudenberg, M
   Galanos, C
   Salomao, R
TI Influence of EDTA and heparin on lipopolysaccharide binding and cell
   activation, evaluated at single-cell level in whole blood
SO CYTOMETRY
LA English
DT Article
DE flow cytometry; LPS; whole blood; cell activation; EDTA; heparin;
   intracellular TNF-alpha; CD69; HLA-DR
ID TUMOR-NECROSIS-FACTOR; CYTOKINE RELEASE; HUMAN MONOCYTES; ENDOTOXIN;
   PROTEIN; LPS; ANTICOAGULANTS; MODULATION; EXPRESSION; INFECTIONS
AB Background: The use of whole blood (WB) in studying lipopolysaccharide (LPS)-induced cellular activation preserves the milieu in which LPS-cell interaction occurs in vivo. However, little information is available on using such a system at a single-cell level. We evaluated LPS binding and cell activation in WB by using flow cytometry. The influence of heparin or EDTA as anticoagulants was also addressed. Methods: Blood was obtained from healthy donors in EDTA and/or heparin tubes. Biotinylated LPS (LPSb) was used to evaluate cell binding of LPS in WB. Cells were surface stained with appropriate antibodies and LPSb was detected by adding streptavidin-allophycocyanin (APC). LPS-induced activation was evaluated by the expression of surface activation markers and by the detection of intracellular tumor necrosis factor-alpha (TNF-alpha). Results: LPSb bound promptly to monocytes in EDTA- and heparin-treated blood. In EDTA-treated blood, membrane-bound LPSb decreased after 60 min of incubation, whereas it remained detectable in heparinized blood during the 6 h of incubation. LPS induced TNF-alpha and enhanced the expression of HLA-DR in monocytes, as well as the expression of CD69 in T and B lymphocytes. Induction of both TNF-alpha in monocytes and CD69 in lymphocytes was more efficient in heparinized blood. Conclusion: Detection of membrane-bound LPSb on monocytes differed in EDTA or heparin-treated blood, and cell activation was better obtained in heparinized blood. (C) 2002 Wiley-Liss, Inc.
C1 Univ Fed Sao Paulo, Div Infect Dis, Immunol Lab, Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
   Max Planck Inst Immunbiol, D-7800 Freiburg, Germany.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Immunol Lab, Escola Paulista Med, Rua Pedro Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Brunialti, Milena K C/C-4905-2012; Salomao,
   Reinaldo/C-6419-2013
OI Brunialti, Milena K C/0000-0003-2874-520X; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR Blondin C, 1997, EUR J IMMUNOL, V27, P3303, DOI 10.1002/eji.1830271229
   Eggesbo JB, 1996, CYTOKINE, V8, P152, DOI 10.1006/cyto.1996.0022
   Engstad CS, 1997, THROMB HAEMOSTASIS, V77, P690
   ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341
   FREUDENBERG MA, 1992, BACTERIAL ENDOTOXIC, V2, P275
   Galanos C., 1977, INT REV BIOCH BIOCH, V14, P239
   HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269
   Heinzelmann M, 1998, INFECT IMMUN, V66, P5842, DOI 10.1128/IAI.66.12.5842-5847.1998
   Heinzelmann M, 1999, ANN SURG, V229, P542, DOI 10.1097/00000658-199904000-00014
   Heinzelmann M, 2000, IMMUNOPHARMACOLOGY, V48, P117, DOI 10.1016/S0162-3109(00)00195-8
   Hodge S, 1999, SCAND J IMMUNOL, V49, P548
   LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995
   Lo CJ, 1996, ARCH SURG-CHICAGO, V131, P44
   Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J
   Mitov IG, 1997, INFECTION, V25, P206, DOI 10.1007/BF01713144
   Ogata M, 1997, INFECT IMMUN, V65, P2160, DOI 10.1128/IAI.65.6.2160-2167.1997
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4
   Salomao R, 1999, INFECTION, V27, P1, DOI 10.1007/BF02565163
   Schlichting E, 1996, SCAND J CLIN LAB INV, V56, P167, DOI 10.3109/00365519609088604
   SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637
   West MA, 1996, J TRAUMA, V41, P647, DOI 10.1097/00005373-199610000-00009
NR 22
TC 21
Z9 22
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0196-4763
J9 CYTOMETRY
JI Cytometry
PD FEB 15
PY 2002
VL 50
IS 1
BP 14
EP 18
DI 10.1002/cyto.10049
PG 5
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 523RR
UT WOS:000173969700003
PM 11857593
OA Bronze
DA 2020-11-26
ER

PT J
AU Mendes, AVA
   Benard, G
   Pereira, CB
   Kallas, EG
   Duarte, AJS
   Pannuti, CS
   Dulley, FL
   Machado, CM
AF Mendes, AVA
   Benard, G
   Pereira, CB
   Kallas, EG
   Duarte, AJS
   Pannuti, CS
   Dulley, FL
   Machado, CM
TI Different kinetics in anti-cytomegalovirus immunity reconstitution
   evaluated by lymphocyte proliferation and IFN-gamma production in
   allogeneic and autologous bone marrow transplantation
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE bone marrow transplantation; CD8; cytomegalovirus; IFN-gamma; immune
   reconstitution; lymphoproliferative response
ID BLOOD STEM-CELL; CMV DISEASE; T-CELLS; GANCICLOVIR; RECIPIENTS;
   INFECTION; INTERFERON; FIBROBLASTS; RESPONSES; PARACOCCIDIOIDOMYCOSIS
AB Allogeneic bone marrow transplantation (ALLOBMT) is associated with an increased risk of cytomegalovirus (CMV) morbidity compared to autologous BMT (AUTOBMT). To investigate this, we evaluated AUTOBMT and ALLOBMT patients regarding anti-CMV immune reconstitution at 1 and 4 months after BMT and on the day after first CMV antigenemia detection. Intermittent ganciclovir preemptive therapy was prompted by antigenemia of greater than or equal to2 cells. One month after transplant, AUTOBMT recipients already displayed larger CD8+ T cell numbers than ALLOBMT recipients, but comparably small CD4+ T cell numbers. Most AUTOBMT patients had positive CMV antigen (CMV-Ag)-induced lymphoproliferation (86%) and IFN-gamma secretion (86%), whereas this was infrequently seen in ALLOBMT patients (20 and 10%, respectively). This early AUTOBMT immune reconstitution was associated with a lower frequency of CMV reactivation up to +4 months in AUTOBMT (21%) than ALLOBMT patients (91%). At +4 months, most ALLOBMT recipients had also recovered CMV-Ag immune responses. At first antigenemia detection, all 3 AUTOBMT recipients already displayed anti-CMV immune functions and 2 cleared the infection without therapy, whereas of the 10 ALLOBMT recipients only 1 had positive lymphoproliferation. In the latter group, none had IFN-gamma secretion or cleared the infection without therapy. Thus, differences in anti-CMV immune reconstitution may help to explain the contrasting rates of CMV morbidity between ALLOBMT and AUTOBMT patients. Copyright (C) 2002 S. Karger AG, Basel.
C1 Univ Sao Paulo, Sch Med, Virol Lab, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Clin & Expt Allergy & Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Discipline Infect Dis, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Fundacao Pro Sangue Hemoctr Sao Paulo, Discipline Hematol,BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Dulley, Frederico Luiz/H-7063-2013; Pannuti, Claudio/B-7649-2012;
   Duarte, Alberto J S/D-4382-2012; Benard, Gil/D-9414-2013; Kallas, Esper
   G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Benard G, 1997, J INFECT DIS, V175, P1263, DOI 10.1086/593694
   Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824
   Bilgrami S, 1999, BONE MARROW TRANSPL, V24, P69, DOI 10.1038/sj.bmt.1701827
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   BOLAND GJ, 1992, CLIN EXP IMMUNOL, V88, P506
   BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005
   BOWDEN RA, 1990, TRANSPLANTATION, V50, P38, DOI 10.1097/00007890-199007000-00008
   Bruggeman CA, 1995, SCAND J INFECT DIS, P43
   Dai ZH, 2000, J IMMUNOL, V165, P3031, DOI 10.4049/jimmunol.165.6.3031
   de Vries E, 2000, BONE MARROW TRANSPL, V25, P267, DOI 10.1038/sj.bmt.1702141
   DUNCOMBE AS, 1990, BLOOD, V76, P1046
   EINSELE H, 1995, BLOOD, V86, P2815
   GAST GC, 1985, BLOOD, V6, P428
   Ghanekar SA, 2001, CLIN DIAGN LAB IMMUN, V8, P628, DOI 10.1128/CDLI.8.3.628-631.2001
   GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303
   Gor D, 1998, BONE MARROW TRANSPL, V21, P597, DOI 10.1038/sj.bmt.1701139
   GRUNDY JE, 1993, IMMUNOLOGY, V78, P405
   GRUNDY JE, 1993, IMMUNOLOGY, V78, P413
   Holmberg LA, 1999, BLOOD, V94, P4029, DOI 10.1182/blood.V94.12.4029.424k21_4029_4035
   Humar A, 1999, J INFECT DIS, V179, P484, DOI 10.1086/314602
   Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7
   Krause H, 1997, BONE MARROW TRANSPL, V19, P1111, DOI 10.1038/sj.bmt.1700801
   LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971
   LJUNGMAN P, 1986, BLOOD, V68, P108
   LJUNGMAN P, 1985, TRANSPLANTATION, V40, P515, DOI 10.1097/00007890-198511000-00009
   LJUNGMAN P, 1993, BRIT J HAEMATOL, V83, P118, DOI 10.1111/j.1365-2141.1993.tb04641.x
   Ljungman P, 1996, SCAND J INFECT DIS, P59
   Ljungman P, 1995, SCAND J INFECT DIS, P87
   Machado CM, 2000, BONE MARROW TRANSPL, V26, P413, DOI 10.1038/sj.bmt.1702526
   MEYERS JD, 1980, J INFECT DIS, V142, P816, DOI 10.1093/infdis/142.6.816
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   Podlech J, 1998, J GEN VIROL, V79, P2099, DOI 10.1099/0022-1317-79-9-2099
   QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102
   REUSSER P, 1991, BLOOD, V78, P1373
   Reusser P, 1997, BLOOD, V89, P3873, DOI 10.1182/blood.V89.10.3873.3873_3873_3879
   SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501
   THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706
   Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947
   WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001
NR 39
TC 8
Z9 8
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PY 2002
VL 107
IS 4
BP 187
EP 194
DI 10.1159/000058313
PG 8
WC Hematology
SC Hematology
GA 563MT
UT WOS:000176260000001
PM 12053145
DA 2020-11-26
ER

PT J
AU Caride, E
   Brindeiro, RM
   Kallas, EG
   de Sa, CAM
   Eyer-Silva, WA
   Machado, E
   Tanuri, A
AF Caride, E
   Brindeiro, RM
   Kallas, EG
   de Sa, CAM
   Eyer-Silva, WA
   Machado, E
   Tanuri, A
TI Sexual transmission of HIV-1 isolate showing G -> A hypermutation
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE HIV-1; G -> A hypermutation; protease; reverse transcriptase; HAART;
   CD4+T cells; oligoclonal expansion
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL REPOPULATION; ANTIRETROVIRAL
   THERAPY; REVERSE TRANSCRIPTION; LYMPHOCYTES-T; TYPE-1; INFECTION;
   LATENCY; RECOMBINATION; REPLICATION
AB Retroviral genomes with a high frequency of G --> A mutations are thought to originate during reverse transcription (RT). Here we present a case report of an AIDS patient infected with a subtype F variant where extensive G --> A hypermutation (G --> A Hypm) sequences were found in the protease gene. This patient was failing HAART at the time the hypermutation was found. These sequences were basically encountered in the proviral compartment on two occasions and were persistently absent in the plasma viral population. The patient's viral genotype showed several mutations related to antiretroviral drug resistance in RT (T69N, N184V, T215F, K219Q) and protease (M36I, G48V, I54V, T63L, V82A) genes. The drug regimen was changed and the viral load dropped 0.9 Logs and CD4 count increased by 200 cells/ml. The hypermutation was not found any more in a 1-year follow up. The patient's wife was infected with a similar virus strain and G A Hypm sequences were also detected in the RT gene. This is the first report of sexual transmitted G --> A Hypermutation in HIV-1 and suggest that this phenomenon can be genetically coded by the viral RT molecule. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Fed Rio de Janeiro, Mol Virol Lab, Dept Genet, BR-21944970 Rio De Janeiro, Brazil.
   UFESP, Escola Paulista Med, Sao Paulo, Brazil.
   Hosp Univ Gaffree & Guinle, Rio De Janeiro, Brazil.
   UFRJ, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
RP Tanuri, A (corresponding author), Univ Fed Rio de Janeiro, Mol Virol Lab, Dept Genet, Bloco A,Sala 121,2 Andar, BR-21944970 Rio De Janeiro, Brazil.
RI de Araujo Eyer-Silva, Walter/J-6264-2019; Kallas, Esper G/C-9539-2012
OI Eyer-Silva, Walter de Araujo/0000-0001-6386-666X
CR Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   BORMAN AM, 1995, VIROLOGY, V208, P601, DOI 10.1006/viro.1995.1191
   Brindeiro R, 1999, ANTIMICROB AGENTS CH, V43, P1674, DOI 10.1128/AAC.43.7.1674
   CHIODI F, 1989, VIROLOGY, V173, P178, DOI 10.1016/0042-6822(89)90233-X
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   Collins RH, 1997, EXP HEMATOL, V25, P147
   Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533
   FITZGIBBON JE, 1993, AIDS RES HUM RETROV, V9, P833, DOI 10.1089/aid.1993.9.833
   FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365
   FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K
   GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0
   GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933
   Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865
   HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556
   KUMAR S, 1993, MEGA MOL EVOLUTIONAR
   KUNKEL TA, 1986, J BIOL CHEM, V261, P160
   Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4
   LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991
   Mackall CL, 1997, IMMUNOL TODAY, V18, P245, DOI 10.1016/S0167-5699(97)81664-7
   MARTINEZ MA, 1995, NUCLEIC ACIDS RES, V23, P2573, DOI 10.1093/nar/23.14.2573
   MILLER RA, 1984, J IMMUNOL, V133, P2925
   PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992
   PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024
   POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x
   POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992
   POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7
   ROCHA B, 1983, J IMMUNOL, V131, P2158
   ROCHA BB, 1987, J IMMUNOL, V139, P365
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663
   SHARP PM, 1995, MOL BASIS VIRUS EVOL, P124
   TANURI A, 1999, DEFIC SYNDR HUM RETR, V20, P60
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   TOUGH DF, 1995, STEM CELLS, V13, P242, DOI 10.1002/stem.5530130305
   VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092
   VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991
   WAINHOBSON S, 1995, VIROLOGY, V209, P297, DOI 10.1006/viro.1995.1261
   Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154
NR 40
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JAN
PY 2002
VL 23
IS 3
BP 179
EP 189
DI 10.1016/S1386-6532(01)00218-9
PG 11
WC Virology
SC Virology
GA 511AM
UT WOS:000173240800006
PM 11595597
DA 2020-11-26
ER

PT J
AU Salomao, R
   Brunialti, MKC
   Kallas, EG
   Martins, PS
   Rigato, O
   Freudenberg, M
AF Salomao, R
   Brunialti, MKC
   Kallas, EG
   Martins, PS
   Rigato, O
   Freudenberg, M
TI Lipopolysaccharide-cell interaction and induced cellular activation in
   whole blood of septic patients
SO JOURNAL OF ENDOTOXIN RESEARCH
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; BINDING-PROTEIN; INCREASING PROTEIN;
   DOWN-REGULATION; SEVERE SEPSIS; ENDOTOXIN; HYPERSENSITIVITY; EXPRESSION;
   TOLERANCE; SHOCK
AB We used biotinylated LPS (LPSb) and flow cytometry to study LPS-monocyte interaction and LPS-induced cellular activation in whole blood from septic patients (SP). Expression of surface activation markers was evaluated on monocytes (HLA-DR) and T lymphocytes (CD69 and CD95), and intracellular TNF-alpha on monocytes. Saturating curve and kinetics of LPSb detection on monocytes were similar in SP and healthy volunteers (HV). LPSb bound to monocytes was detected after 5 min of incubation in both groups, with a more pronounced decay in SP. Monocytes from SP had a lower expression of HLA-DR as compared to HV, both constitutive and upon LPS stimulation. The proportion of monocytes producing TNF-alpha after LPS stimulus was higher in HV than SP (mean+/-SD=25.2+/-14.2% and 2.2+/-2.6%, respectively, P<0.001). LPS-induced CD69 on T CD8(+) and CD8(-) lymphocytes was similar for patients and controls. Expression of CD95 on T lymphocytes was higher in SP as compared to HV on T CD8(+) cells (GMFI, mean&PLUSMN;SD=22.3&PLUSMN;14.6 and 8.6&PLUSMN;5.0, respectively, P=0.01) and CD8(-) cells (GMFI, mean&PLUSMN;SD=28.3&PLUSMN;7.7 and 14&PLUSMN;4.3 respectively, P<0.001). Thus, monocytes and lymphocytes seem to respond differently to LPS in septic patients. Monocyte hyporesponsiveness appears not to be related to a decreased binding capacity of LPS, but rather to an impaired signal transduction.
C1 Univ Fed Sao Paulo, UNIFESP, Immunol Lab, Div Infect Dis,Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
   Max Planck Inst Immunbiol, D-7800 Freiburg, Germany.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, UNIFESP, Immunol Lab, Div Infect Dis,Escola Paulista Med, 781 Rue Pedro de Toledo,15o Andar, BR-04039032 Sao Paulo, Brazil.
RI Brunialti, Milena K C/C-4905-2012; Kallas, Esper G/C-9539-2012; Salomao,
   Reinaldo/C-6419-2013
OI Brunialti, Milena K C/0000-0003-2874-520X; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P213
   BARTHOLEYNS J, 1987, INFECT IMMUN, V55, P2230, DOI 10.1128/IAI.55.9.2230-2233.1987
   BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025
   Brunialti MKC, 2002, CYTOMETRY, V50, P14, DOI 10.1002/cyto.10049
   Diament D, 2002, INFECT IMMUN, V70, P1677, DOI 10.1128/IAI.70.4.1677-1683.2002
   Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678
   ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341
   Freudenberg MA, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P719
   GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939
   GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9
   GALANOS C, 1992, BACTERIAL ENDOTOXIC, V2, P75
   Galanos C., 1977, INT REV BIOCH BIOCH, V14, P239
   HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269
   HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351
   Holub M, 2000, CLIN MICROBIOL INFEC, V6, P657, DOI 10.1046/j.1469-0691.2000.00175.x
   Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952
   JOHNSTON CA, 1985, HDB ENDOTOXIN, V2, P359
   KATSCHINSKI T, 1992, INFECT IMMUN, V60, P1994, DOI 10.1128/IAI.60.5.1994-2001.1992
   Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI13139
   MATSUURA M, 1990, INFECT IMMUN, V58, P935, DOI 10.1128/IAI.58.4.935-937.1990
   Mitov IG, 1997, INFECTION, V25, P206, DOI 10.1007/BF01713144
   Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476
   Opal SM, 1999, J INFECT DIS, V180, P1584, DOI 10.1086/315093
   Papathanassoglou EDE, 2001, CRIT CARE MED, V29, P709, DOI 10.1097/00003246-200104000-00002
   Rigato O., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P13, DOI 10.2174/1568008013341794
   Salomao R, 1999, INFECTION, V27, P1, DOI 10.1007/BF02565163
   Schlichting E, 1996, SCAND J CLIN LAB INV, V56, P167, DOI 10.3109/00365519609088604
   Schroeder S, 2001, LANGENBECK ARCH SURG, V386, P42
   SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637
   TOBIAS PS, 1988, J BIOL CHEM, V263, P13479
   vonderMohlen MAM, 1996, J IMMUNOL, V156, P4969
   ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13
   ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001
   Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800
NR 34
TC 15
Z9 17
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA HUDSON RD, LEEDS LS9 7DL, ENGLAND
SN 0968-0519
J9 J ENDOTOXIN RES
JI J. Endoxtin Res.
PY 2002
VL 8
IS 5
BP 371
EP 379
DI 10.1179/096805102125000704
PG 9
WC Biochemistry & Molecular Biology; Immunology; Medicine, Research &
   Experimental; Microbiology
SC Biochemistry & Molecular Biology; Immunology; Research & Experimental
   Medicine; Microbiology
GA 631CU
UT WOS:000180150300009
PM 12537696
DA 2020-11-26
ER

PT J
AU Evans, TG
   Kallas, EG
   Campbell, M
   Andrews, J
   Schwartz, D
   Keefer, M
   Caudrelier, P
AF Evans, TG
   Kallas, EG
   Campbell, M
   Andrews, J
   Schwartz, D
   Keefer, M
   Caudrelier, P
TI Evaluation of canarypox-induced CD8(+) responses following immunization
   by measuring the effector population IFN gamma production
SO IMMUNOLOGY LETTERS
LA English
DT Article; Proceedings Paper
CT 37th Annual Meeting of the Infectious-Diseases-Society-of-America
CY NOV 18-21, 1999
CL PHILADELPHIA, PENNSYLVANIA
SP Infect Dis Soc Amer
DE canarypox-induced CD8(+) responses; effector population; IFN gamma
   production; immunization
ID MEMORY T-CELLS; IMMUNODEFICIENCY-VIRUS; HIV TYPE-1; LYMPHOCYTE
   RESPONSES; BYSTANDER ACTIVATION; CYTOKINE SYNTHESIS; BLOOD-LYMPHOCYTES;
   IMMUNE-RESPONSES; VIRAL-INFECTION; FLOW-CYTOMETRY
AB CD8(+) cytolytic activity is traditionally measured by detecting the release of Cr-51 after incubation of effector cells with HLA-matched, infected, radiolabeled targets. An alternative method to detect CD8+ activity is to measure the production of intracellular interferon gamma (IFN gamma) after antigen-specific stimulation, either by ELISPOT or by flow cytometry. Studies were performed in 19 volunteers enrolled in a phase 1 trial of candidate canarypox HIV-1 vaccines that encoded multiple HIV-1 genes. The vaccines including vCP205 (Env, Gag, and protease), vCP1433 (Env, Gag, protease, and CTL epitope-rich regions of pol and nef) and vCP1452 (equivalent to vCP1433 with additional immunomodulatory genes of vaccinial. PBMCs were stimulated in vitro with vaccinia constructs encoding enu and gag or a lacZ control, and the effecters were cultured for 12-14 days. EBV-transformed B cell lines were infected overnight with the vaccinia vectors, and then incubated with the effector cells for 4 h in the presence of monensin. CD8+ gene-specific activity was determined as a percentage of IFN gamma cells in the CD3(+)CD8(+)CD45RO(+) gate after subtracting both the isotype control and the lacZ control stimulation. CD4 memory IFN gamma production was simultaneously determined in the CD3(+)CD8(-)CD45RO(+) gate. Using these techniques in blinded studies, we found that CD8(+) IFN gamma activity could be measured in the majority of volunteers given four immunizations. Specifically, the responses to the gag gene were control - 0/2; vCP205 - 2/4; vCP1433 - 5/6; vCP1452 - 4/7. Most of the positive responses were detected after the fourth immunization. Flow cytometric techniques hold promise as a surrogate measure of CTL and for ease of phenotyping of the effector population. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Rochester, Sch Med & Dent, Infect Dis Serv, Dept Med, Sacramento, CA 95817 USA.
   Johns Hopkins Univ, Sacramento, CA USA.
   Aventis Pasteur, Lyon, France.
RP Evans, TG (corresponding author), Univ Rochester, Sch Med & Dent, Infect Dis Serv, Dept Med, Suite 500,PSSB 4150 V St, Sacramento, CA 95817 USA.
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044,
   M01RR000044, M01RR000044, M01RR000044, M01RR000044, M01RR000044] Funding
   Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [5 M01 RR00044] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI-05063] Funding Source:
   Medline
CR Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Asanuma H, 2000, J INFECT DIS, V181, P859, DOI 10.1086/315347
   Belshe RB, 1998, AIDS, V12, P2407, DOI 10.1097/00002030-199818000-00009
   Carmichael A, 1996, J VIROL, V70, P8468, DOI 10.1128/JVI.70.12.8468-8476.1996
   Clements-Mann ML, 1998, J INFECT DIS, V177, P1230, DOI 10.1086/515288
   Donahoe SM, 2000, VIROLOGY, V272, P347, DOI 10.1006/viro.2000.0404
   Dyer WB, 1999, J VIROL, V73, P436, DOI 10.1128/JVI.73.1.436-443.1999
   Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895
   Fries LF, 1996, VACCINE, V14, P428, DOI 10.1016/0264-410X(95)00171-V
   Jin X, 2000, J INFECT DIS, V181, P165, DOI 10.1086/315201
   JOHNSON RP, 1991, J IMMUNOL, V147, P1512
   Kallas EG, 1999, J INFECT DIS, V179, P1124, DOI 10.1086/314702
   Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7
   Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8
   Klein MR, 1998, IMMUNOL TODAY, V19, P317, DOI 10.1016/S0167-5699(98)01288-2
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Lalvani A, 1998, CLIN SCI, V95, P531, DOI 10.1042/CS19980201
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   McElrath MJ, 1997, AIDS RES HUM RETROV, V13, P211, DOI 10.1089/aid.1997.13.211
   McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367
   Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7
   Murali-Krishna K, 1998, ADV EXP MED BIOL, V452, P123
   PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408
   RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903
   Salmon-Ceron D, 1999, AIDS RES HUM RETROV, V15, P633, DOI 10.1089/088922299310935
   Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338
   Waldrop SL, 1998, J IMMUNOL, V161, P5284
NR 28
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD MAY 1
PY 2001
VL 77
IS 1
BP 7
EP 15
DI 10.1016/S0165-2478(01)00173-0
PG 9
WC Immunology
SC Immunology
GA 435LF
UT WOS:000168882400004
PM 11348664
DA 2020-11-26
ER

PT J
AU Evans, TG
   McElrath, MJ
   Matthews, T
   Montefiori, D
   Weinhold, K
   Wolff, M
   Keefer, MC
   Kallas, EG
   Corey, L
   Gorse, GJ
   Belshe, R
   Graham, BS
   Spearman, PW
   Schwartz, D
   Mulligan, MJ
   Goepfert, P
   Fast, P
   Berman, P
   Powell, M
   Francis, D
AF Evans, TG
   McElrath, MJ
   Matthews, T
   Montefiori, D
   Weinhold, K
   Wolff, M
   Keefer, MC
   Kallas, EG
   Corey, L
   Gorse, GJ
   Belshe, R
   Graham, BS
   Spearman, PW
   Schwartz, D
   Mulligan, MJ
   Goepfert, P
   Fast, P
   Berman, P
   Powell, M
   Francis, D
CA NIAID AIDS Vaccine Evaluation Grp
TI QS-21 promotes an adjuvant effect allowing for reduced antigen dose
   during HIV-1 envelope subunit immmunization in humans
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 5th Conference on Retroviruses and Opportunistic Infections
CY FEB 01-05, 1998
CL CHICAGO, ILLINOIS
DE QS-21; gp120 HIV-1MN protein; immunization
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE RESPONSES; SAPONIN ADJUVANT;
   IMMUNE-RESPONSES; RECOMBINANT GLYCOPROTEIN-120; NEUTRALIZING ANTIBODIES;
   SERONEGATIVE VOLUNTEERS; CONJUGATE VACCINE; HEPATITIS-B; IMMUNOGENICITY
AB Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 mug), either alone or in combination with aluminum hydroxide (600 mug). At the highest doses of rsgp120 (100, 300, and 600 mug). QS-21 exerted no significant effect on either binding or neutralizing antibody titers. Antibody binding and neutralizing responses fell dramatically when rsgp120, formulated with alum alone, was given at low doses (3 and 30 mug). In contrast, antibody responses similar in titer to those in the high dose antigen groups were induced with the low dose rsgp120 formulated with QS-21. In addition, the lymphocyte proliferation and delayed type hypersensitivity skin testing were superior in the QS-21 recipients compared with the alum recipients at the low antigen doses. Moderate to severe pain was observed in majority of the volunteers receiving QS-21 formulations, and vasovagal episodes and hypertension were not infrequent. Thus, the use of QS-21 may provide a means to reduce the dose of a soluble protein immunogen. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Rochester, Sch Med & Dent, Rochester, NY USA.
   Univ Washington, Sch Med, Seattle, WA USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   EMMES Corp, Potomac, MD USA.
   St Louis VA Med Ctr, St Louis, MO USA.
   St Louis Univ, Sch Med, St Louis, MO USA.
   Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Univ Alabama, Birmingham, AL USA.
   NIAID, Div AIDS, Bethesda, MD 20892 USA.
   VaxGen Corp, San Francisco, CA USA.
RP Evans, TG (corresponding author), Div Infect Dis, PSSB Suite 500,4150 V St, Sacramento, CA 95817 USA.
RI Kallas, Esper G/C-9539-2012; Graham, Barney S./AAC-5898-2019; Corey,
   Lawrence/AAE-1796-2020
OI Graham, Barney S./0000-0001-8112-0853; Corey,
   Lawrence/0000-0002-2179-2436; Kallas, Esper/0000-0003-2026-6925
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01 AI-45212, N01 AI-45211, N01 AI-45209,
   N01 AI-45210, AI-82500, N01 AI-65305, N01 AI-45208] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [N01AI082500, N01AI065305, N01AI045211, N01AI082500,
   N01AI082500, N01AI045211, N01AI045208, N01AI045210, N01AI082500,
   N01AI045211, N01AI045210, N01AI065305, N01AI045210, N01AI045208,
   N01AI045209, N01AI082500, N01AI082500, N01AI045208, N01AI045211,
   N01AI082500, N01AI045210, N01AI045210, N01AI045209, N01AI045209,
   N01AI045208, N01AI082500, N01AI082500, N01AI065305, N01AI065305,
   N01AI045208, N01AI045210, N01AI065305, N01AI045211, N01AI045208,
   N01AI045208, N01AI045211, N01AI045209, N01AI065305, N01AI082500,
   N01AI045208, N01AI045209, N01AI045211, N01AI045209, N01AI045210,
   N01AI045211, N01AI045210, N01AI045210, N01AI045208, N01AI065305,
   N01AI045209, N01AI045209, N01AI045211, N01AI045211, N01AI045210,
   N01AI045209, N01AI045209, N01AI045210, N01AI082500, N01AI045209,
   N01AI045208, N01AI065305] Funding Source: NIH RePORTER
CR Allison A C, 1994, Int J Technol Assess Health Care, V10, P107
   BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475
   BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992
   BRYAN JP, 1992, CLIN INFECT DIS, V14, P697, DOI 10.1093/clinids/14.3.697
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   COUGHLIN RT, 1995, J INFECT DIS, V171, P1049, DOI 10.1093/infdis/171.4.1049
   Dreyer K, 1999, AIDS RES HUM RETROV, V15, P1563, DOI 10.1089/088922299309856
   Dutta JK, 1999, TROP DOCT, V29, P196, DOI 10.1177/004947559902900404
   Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895
   Gahery-Segard H, 2000, J VIROL, V74, P1694, DOI 10.1128/JVI.74.4.1694-1703.2000
   Gorse GJ, 1996, CLIN DIAGN LAB IMMUN, V3, P378, DOI 10.1128/CDLI.3.4.378-386.1996
   Gorse GJ, 1999, AIDS RES HUM RETROV, V15, P115, DOI 10.1089/088922299311547
   GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   HANCOCK GE, 1995, VACCINE, V13, P391, DOI 10.1016/0264-410X(95)98263-A
   HELLING F, 1995, CANCER RES, V55, P2783
   Jacobsen NE, 1996, CARBOHYD RES, V280, P1, DOI 10.1016/0008-6215(95)00278-2
   Kallas EG, 1999, J INFECT DIS, V179, P1124, DOI 10.1086/314702
   Keefer MC, 1997, AIDS RES HUM RETROV, V13, P1163, DOI 10.1089/aid.1997.13.1163
   KEEFER MC, 1991, J INFECT DIS, V163, P448, DOI 10.1093/infdis/163.3.448
   Keefer MC, 1996, AIDS RES HUM RETROV, V12, P683, DOI 10.1089/aid.1996.12.683
   Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475
   KENSIL CR, 1991, J IMMUNOL, V146, P431
   Kensil CR, 1996, CRIT REV THER DRUG, V13, P1
   LIN R, 1995, CLIN INFECT DIS, V21, P1339
   LIPFORD GB, 1994, VACCINE, V12, P73, DOI 10.1016/0264-410X(94)90013-2
   LIVINGSTON PO, 1994, VACCINE, V12, P1275, DOI 10.1016/S0264-410X(94)80052-2
   LIVINGSTON PO, 1995, IMMUNOL REV, V145, P147, DOI 10.1111/j.1600-065X.1995.tb00080.x
   MA JN, 1994, VACCINE, V12, P925, DOI 10.1016/0264-410X(94)90036-1
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340
   Migasena S, 2000, AIDS RES HUM RETROV, V16, P655, DOI 10.1089/088922200308882
   Montefiori David C., 1999, AIDS Research and Human Retroviruses, V15, P689, DOI 10.1089/088922299310773
   Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6
   NEWMAN MJ, 1992, J IMMUNOL, V148, P2357
   NEWMAN MJ, 1994, AIDS RES HUM RETROV, V10, P853, DOI 10.1089/aid.1994.10.853
   NEWMAN MJ, 1992, AIDS RES HUM RETROV, V8, P1413, DOI 10.1089/aid.1992.8.1413
   Newman MJ, 1997, VACCINE, V15, P1001, DOI 10.1016/S0264-410X(96)00293-9
   PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399
   Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508
   POWELL MF, 1995, AIDS RES HUM RETROV, V11, P203, DOI 10.1089/aid.1995.11.203
   POWELL MF, 1994, AIDS RES HUM RETROV, V10, P105
   RIVEY MP, 1991, DICP ANN PHARMAC, V25, P628, DOI 10.1177/106002809102500612
   SCOTT MT, 1985, INT ARCH ALLER A IMM, V77, P409, DOI 10.1159/000233817
   Sjolander A, 1997, CELL IMMUNOL, V177, P69, DOI 10.1006/cimm.1997.1088
   VANCOTT TC, 1995, J IMMUNOL, V155, P4100
   Vogel FR, 1996, ANTIBIOT CHEMOTHER, V48, P84
   WU JY, 1992, J IMMUNOL, V148, P1519
   WU JY, 1994, CELL IMMUNOL, V154, P393, DOI 10.1006/cimm.1994.1086
NR 48
TC 104
Z9 109
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2001
VL 19
IS 15-16
BP 2080
EP 2091
DI 10.1016/S0264-410X(00)00415-1
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 412DF
UT WOS:000167538200029
PM 11228380
DA 2020-11-26
ER

PT J
AU Milan, EP
   Kallas, EG
   Costa, PRD
   da Matta, DA
   Colombo, AL
AF Milan, EP
   Kallas, EG
   Costa, PRD
   da Matta, DA
   Colombo, AL
TI Oral colonization by Candida spp. among AIDS household contacts
SO MYCOSES
LA English
DT Article
DE Candida; candidosis; colonization; AIDS; epidemiology
ID INFECTED PATIENTS; RESISTANCE; MYCOSES
AB This study was designed to investigate the oral yeast colonization rate of household contacts of AIDS patients. Sixty-four AIDS household contacts were sequentially enrolled along with 103 HIV-negative blood bank donors (control group). Samples were obtained by swabbing the oral mucosa. Yeast isolates were identified by classical methods and antifungal susceptibility testing was performed according to NCCLS microbroth assay. Candida spp. was recovered from the oral cavity of 33% of the AIDS household contacts, in contrast with 14% of the control group (P = 0.003 or P = 0.04 after adjusting for oral prosthesis use). Candida albicans was the most frequently isolated species in both groups. All of the isolates were susceptible to fluconazole, itraconazole and ketoconazole. In conclusion, we were able to demonstrate a higher colonization rate in the AIDS household contacts group compared with the control group. No resistant isolates to antifungal drugs was observed. We suggest that the contact with AIDS patients may play a role as a risk factor for developing oral colonization by Candida spp.
C1 Univ Fed Sao Paulo, Escola Paulista Med, UNIFESP, Div Infect Dis, BR-04023062 Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual Francisco Morato Oliv, Infect Dis Unit, Sao Paulo, Brazil.
   Univ Fed Rio Grande Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
RP Colombo, AL (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, UNIFESP, Div Infect Dis, Rua Botucatu 740,Vila Clementino, BR-04023062 Sao Paulo, Brazil.
RI da Matta, Daniel Archimedes/J-4307-2019; Colombo, Arnaldo
   Lopes/H-4397-2012; Colombo, Arnaldo Lopes/V-4417-2019
OI Kallas, Esper/0000-0003-2026-6925
CR BARCHIESI F, 1994, J CLIN MICROBIOL, V32, P2494, DOI 10.1128/JCM.32.10.2494-2500.1994
   CANDIDO RC, 1995, REV ODONIOL UNICID, V7, P27
   CARTLEDGE VD, 1997, AIDS, V12, P1249
   CHALLACOMBE SJ, 1994, ORAL SURG ORAL MED O, V78, P202, DOI 10.1016/0030-4220(94)90148-1
   Datry A., 1992, Journal de Mycologie Medicale, V2, P5
   Dromer F, 1997, AIDS, V11, P1095, DOI 10.1097/00002030-199709000-00003
   DUPONT B, 1994, J MED VET MYCOL, V32, P65
   DUPONT B, 1992, J MED VET MYCOL, V30, P19
   *EP SOFTW, 1994, EP SOFTW VERS 6 0 WO
   Kurtzman C, 1998, YEASTS TAXONOMIC STU
   LYNCH DP, 1994, ORAL SURG ORAL MED O, V78, P189, DOI 10.1016/0030-4220(94)90146-5
   Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219
   MEUNIER F, 1989, EUR J CLIN MICROBIOL, V8, P438, DOI 10.1007/BF01964058
   Milan EP, 1998, DIAGN MICR INFEC DIS, V32, P211, DOI 10.1016/S0732-8893(98)00107-2
   MOONEY MA, 1995, INT J DERMATOL, V34, P759, DOI 10.1111/j.1365-4362.1995.tb04392.x
   National Committee for Clinical Laboratory, 1997, M27A NCCLS
   PARK AW, 1994, NIHON U SCH DENT, V36, P1
   RODRIGUEZTUDELA JL, 1995, J ANTIMICROB CHEMOTH, V35, P793, DOI 10.1093/jac/35.6.793
   SAMARANAYAKE LP, 1992, ORAL SURG ORAL MED O, V73, P171, DOI 10.1016/0030-4220(92)90191-R
   SANGEORZAN JA, 1994, AM J MED, V97, P339, DOI 10.1016/0002-9343(94)90300-X
   Silveira Fernando R. X. Da, 1995, Revista de Microbiologia, V26, P279
   ZEGARELLI DJ, 1993, OTOLARYNG CLIN N AM, V26, P1069
NR 22
TC 4
Z9 4
U1 0
U2 0
PU BLACKWELL WISSENSCHAFTS-VERLAG GMBH
PI BERLIN
PA KURFURSTENDAMM 57, D-10707 BERLIN, GERMANY
SN 0933-7407
J9 MYCOSES
JI Mycoses
PY 2001
VL 44
IS 7-8
BP 273
EP 277
DI 10.1111/j.1439-0507.2001.00652.x
PG 5
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 489HY
UT WOS:000171987000004
PM 11714061
DA 2020-11-26
ER

PT J
AU Santos, SC
   Kinashiro, CA
   Kallas, E
   Cerri, P
   Oshiro, ME
   Ferreira, AT
   Khalil, RA
AF Santos, SC
   Kinashiro, CA
   Kallas, E
   Cerri, P
   Oshiro, ME
   Ferreira, AT
   Khalil, RA
TI gamma-radiation promotes visceral smooth muscle apoptosis via activation
   of alpha- and epsilon-protein kinase
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
RI Cerri, Paulo/F-5338-2012; Cerri, Paulo/AAC-5797-2019; Kallas, Esper
   G/C-9539-2012
OI Cerri, Paulo/0000-0001-5756-5828; Cerri, Paulo/0000-0001-5756-5828; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 15
PY 2000
VL 14
IS 4
BP A582
EP A582
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 294NV
UT WOS:000085918103366
DA 2020-11-26
ER

PT J
AU Hasan, MS
   Kallas, EG
   Thomas, EK
   Looney, J
   Campbell, M
   Evans, TG
AF Hasan, MS
   Kallas, EG
   Thomas, EK
   Looney, J
   Campbell, M
   Evans, TG
TI Effects of interleukin-15 on in vitro human T cell proliferation and
   activation
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; IN-VIVO; IL-15; INFECTION; MIGRATION
AB Interleukin-15 (IL,-15) has been reported to have many activities on T cell populations, including a potential role in improving antigen-specific proliferation in HIV-1 disease. We tested this response in healthy adults by studying the response of T cell populations after stimulation with medium, tetanus, cytomegalovirus (CMV) antigens in cultures from 21 volunteers. IL,-15 caused a dose-dependent increase in medium and antigen-induced proliferation. The expansion was due to CD8>natural killer (NK)>CD4 lymphocytes and memory > naive cells. The IL-15-stimulated CD8 cells had increased levels of the activation markers CD69 and DR. The published CMV-induced expression of CD57 on CD8(+) cells was increased in CMV seronegative and seropositive subjects by IL-15. IL-15 appears to be a stimulator of T cell populations in healthy adults and mag be useful in settings to enhance nonspecific NK activity or antigen-specific CD8 activity.
C1 Univ Rochester, Sch Med & Dent, Rheumatol Unit, Rochester, NY 14642 USA.
   Immunex Corp, Seattle, WA 98101 USA.
   Univ Rochester, Sch Med & Dent, Infect Dis Unit, Rochester, NY 14642 USA.
RP Evans, TG (corresponding author), 601 Elmwood Ave,Room 3-6209, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Agostini C, 1997, BLOOD, V90, P1115, DOI 10.1182/blood.V90.3.1115.1115_1115_1123
   BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935
   Chehimi J, 1997, J IMMUNOL, V158, P5978
   Hooper M, 1999, J RHEUMATOL, V26, P1452
   Jullien D, 1997, J IMMUNOL, V158, P800
   Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7
   Kanai T, 1996, J IMMUNOL, V157, P3681
   Kanegane H, 1996, BLOOD, V88, P230
   Kennedy MK, 1996, J CLIN IMMUNOL, V16, P134, DOI 10.1007/BF01540911
   Khan IA, 1996, J IMMUNOL, V157, P2103
   Lin SJ, 1997, CLIN IMMUNOL IMMUNOP, V82, P163, DOI 10.1006/clin.1996.4298
   McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175
   Oppenheimer-Marks N, 1998, J CLIN INVEST, V101, P1261, DOI 10.1172/JCI1986
   Patki AH, 1996, J CLIN INVEST, V98, P616, DOI 10.1172/JCI118831
   SEDER RA, 1995, J EXP MED, V182, P1067, DOI 10.1084/jem.182.4.1067
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6
NR 17
TC 17
Z9 17
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD FEB
PY 2000
VL 20
IS 2
BP 119
EP 123
DI 10.1089/107999000312513
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 287YU
UT WOS:000085535700001
PM 10714546
DA 2020-11-26
ER

PT J
AU Dreyer, K
   Kallas, EG
   Planelles, V
   Montefiori, D
   McDermott, MP
   Hasan, MS
   Evans, TG
AF Dreyer, K
   Kallas, EG
   Planelles, V
   Montefiori, D
   McDermott, MP
   Hasan, MS
   Evans, TG
TI Primary isolate neutralization by HIV type 1-infected patient sera in
   the era of highly active antiretroviral therapy
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL FUNCTION; ANTIBODY-RESPONSES;
   CORECEPTOR USAGE; INFECTION; AIDS; INDIVIDUALS; SENSITIVITY; DISEASE;
   IMMUNIZATION
AB Sera from highly selected HIV-1-positive patients are known to have the ability to neutralize a diverse array of primary isolates of HIV-1, The human osteosarcoma cell line that expresses CD4 and chemokine receptors (GHOST cells) was adapted to study HIV-1 neutralization in 37 HIV-1-infected individuals who were selected because of slow disease progression or nonprogression. Many of these individuals were receiving combination drug therapy. Molecularly cloned HIV-1 JR-FL and NL4-3 viruses were used as prototypes to define assay conditions. Sera were then tested at a 1:40 dilution against six additional primary isolates, three of which utilized CCR5 and three of which used both CCR5 and CXCR4, The assay was highly reproducible and independent of viral input titer, with a readout at 48 hr equivalent to that at later time points. As previously reported, neutralization sensitivity was entirely independent of coreceptor usage. Only a few sera from slow progressors were able to neutralize a broad array of primary isolates at a 1:40 dilution, and the best clinical predictor of broadly neutralizing antibody for primary isolates was the present use of antiretroviral agents. In further studies it was found that purified antibody accounted for the majority of the measured neutralization. However, experiments with exogenous addition of antiviral agents showed that the use of nucleosides also greatly contributed to the measured neutralization in some patients. Measurement of neutralization of HIV-1 primary isolates by sera from patients receiving antiretroviral therapy must be carried out with some caution.
C1 Univ Rochester, Med Ctr, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
   Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
   Duke Univ, Dept Surg, Durham, NC 27710 USA.
   Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA.
RP Evans, TG (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Med, Box 689,601 Elmwood Ave, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 45208, R21AI4475] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [N01AI045208, N01AI045208, N01AI045208, N01AI045208,
   N01AI045208, N01AI045208, N01AI045208, N01AI045208, N01AI045208,
   N01AI045208] Funding Source: NIH RePORTER
CR ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986
   Auewarakul P, 1996, VIRAL IMMUNOL, V9, P175, DOI 10.1089/vim.1996.9.175
   Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475
   Burton DR, 1997, AIDS, V11, pS87
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005
   Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998
   CLEMENTS JE, 1995, J VIROL, V69, P2737, DOI 10.1128/JVI.69.5.2737-2744.1995
   Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497
   Foresman L, 1998, AIDS RES HUM RETROV, V14, P1035, DOI 10.1089/aid.1998.14.1035
   Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1
   Hioe CE, 1997, INT IMMUNOL, V9, P1281, DOI 10.1093/intimm/9.9.1281
   KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751
   LaCasse RA, 1998, J VIROL, V72, P2491, DOI 10.1128/JVI.72.3.2491-2495.1998
   LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357
   Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4
   Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340
   Montefiori David C., 1999, AIDS Research and Human Retroviruses, V15, P689, DOI 10.1089/088922299310773
   Montefiori DC, 1998, J VIROL, V72, P1886, DOI 10.1128/JVI.72.3.1886-1893.1998
   Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60
   Moog C, 1997, AIDS RES HUM RETROV, V13, P19, DOI 10.1089/aid.1997.13.19
   Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997
   Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233
   OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0
   Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508
   Poignard P, 1996, IMMUNOL TODAY, V17, P239, DOI 10.1016/0167-5699(96)10007-4
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Sattentau QJ, 1996, CURR OPIN IMMUNOL, V8, P540, DOI 10.1016/S0952-7915(96)80044-6
   Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568
   Trkola A, 1998, J VIROL, V72, P1876, DOI 10.1128/JVI.72.3.1876-1885.1998
   VANCOTT TC, 1995, J IMMUNOL, V155, P4100
   WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211
   Zhang YJ, 1997, VIROLOGY, V238, P254, DOI 10.1006/viro.1997.8812
NR 36
TC 33
Z9 33
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 20
PY 1999
VL 15
IS 17
BP 1563
EP 1571
DI 10.1089/088922299309856
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 257LR
UT WOS:000083783800009
PM 10580407
DA 2020-11-26
ER

PT J
AU Zanotto, PMD
   Kallas, EG
   de Souza, RF
   Holmes, EC
AF Zanotto, PMD
   Kallas, EG
   de Souza, RF
   Holmes, EC
TI Genealogical evidence for positive selection in the nef gene of HIV-1
SO GENETICS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; CELL RESPONSES;
   IN-VIVO; DISEASE PROGRESSION; PRIMARY INFECTION; VIRAL POPULATION;
   EVOLUTION; ESCAPE; TYPE-1
AB The pattern and process of evolution in the nef gene of HIV-1 was analyzed within and among patients. Using a maximum likelihood method that allows for variable intensity of selection pressure among codons, strong positive selection was detected in a hemophiliac patient over 30 mo of infection. By reconstructing the process of allele substitution in this patient using parsimony, the synapomorphic amino acid changes separating each time point were found to have high probabilities of being under positive selection, with selective coefficients of at least 3.6%. Positive selection was also detected among 39 nef sequences from HIV-1 subtype B. Tn contrast, multiple pairwise comparisons of nonsynonymous and synonymous substitution rates provided no good evidence for positive selection and sliding window analyses failed to detect most positively selected sites. These findings demonstrate that positive selection is an important determinant of nef gene evolution and that genealogy-based methods outperform pairwise methods in the detection of adaptive evolution. Mapping the locations of positively selected sites may also be of use in identifying targets of the immune response and hence aid vaccine design.
C1 Univ Sao Paulo, Escola Paulista Med, Bioinformat & Retrovirol Lab, BR-05508900 Sao Paulo, Brazil.
   Univ Sao Paulo, Escola Paulista Med, Immunol Lab, DIPA, BR-05508900 Sao Paulo, Brazil.
   Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England.
RP Zanotto, PMD (corresponding author), Univ Sao Paulo, Escola Paulista Med, Bioinformat & Retrovirol Lab, BR-05508900 Sao Paulo, Brazil.
RI de Souza, RF/G-9716-2011; de A. Zanotto, Paolo M./B-9286-2019
OI de Souza, RF/0000-0002-5284-4630; de A. Zanotto, Paolo
   M./0000-0002-8167-0625; Holmes, Edward/0000-0001-9596-3552; Kallas,
   Esper/0000-0003-2026-6925
CR Bennett SRM, 1998, NATURE, V393, P478
   BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0
   Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   Brown AJL, 1997, P NATL ACAD SCI USA, V94, P1862, DOI 10.1073/pnas.94.5.1862
   Brown AJL, 1997, NAT MED, V3, P268
   Crandall KA, 1999, MOL BIOL EVOL, V16, P372, DOI 10.1093/oxfordjournals.molbev.a026118
   da Silva J, 1998, MOL BIOL EVOL, V15, P1259, DOI 10.1093/oxfordjournals.molbev.a025854
   Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998
   Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629
   FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0
   FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270
   FU YX, 1993, GENETICS, V133, P693
   GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725
   Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Holmes EC, 1998, J VIROL, V72, P886
   HUGHES AL, 1988, NATURE, V335, P367
   Karlsson AC, 1998, AIDS, V12, P839, DOI 10.1097/00002030-199808000-00005
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330
   KORBER B, 1997, HUMAN RETROVIRUS AID
   KORBER BTM, 1997, HIV MOL IMMUNOLOGY D
   KUHNER MK, 1995, GENETICS, V140, P1421
   KUMAR S, 1993, MEGA MOL EVOLUTIONAR
   LEVY JA, 1998, HIV PATHOGENESIS AID
   MADDISON WP, 1992, MACCLADE ANAL PHYLOG
   McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2
   McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271
   Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0
   Muse SV, 1996, MOL BIOL EVOL, V13, P105, DOI 10.1093/oxfordjournals.molbev.a025549
   Musey L, 1997, J EXP MED, V185, P293, DOI 10.1084/jem.185.2.293
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   Nei M, 1987, MOL EVOLUTIONARY GEN
   Nielsen R, 1998, GENETICS, V148, P929
   Nielsen R, 1997, J EVOLUTION BIOL, V10, P217, DOI 10.1007/s000360050019
   NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0
   Nowak MA, 1996, SCIENCE, V274, P1008, DOI 10.1126/science.274.5289.1008
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Plikat U, 1997, J VIROL, V71, P4233, DOI 10.1128/JVI.71.6.4233-4240.1997
   Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890
   Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   SATTA Y, 1994, P NATL ACAD SCI USA, V91, P7184, DOI 10.1073/pnas.91.15.7184
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002
   Sharp PM, 1997, NATURE, V385, P111, DOI 10.1038/385111a0
   Temin Howard M., 1993, P219
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wain-Hobson Simon, 1994, P185
   WainHobson S, 1996, TRENDS MICROBIOL, V4, P135, DOI 10.1016/0966-842X(96)10023-8
   Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240
   YANG Z, 1997, PHYLOGENETIC ANAL MA
   Yokoyama S, 1996, ANNU REV ECOL SYST, V27, P543, DOI 10.1146/annurev.ecolsys.27.1.543
   ZANOTTO PMD, 1995, VIROLOGY, V210, P152
NR 57
TC 105
Z9 106
U1 0
U2 1
PU GENETICS
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD NOV
PY 1999
VL 153
IS 3
BP 1077
EP 1089
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 253CR
UT WOS:000083539500002
PM 10545443
DA 2020-11-26
ER

PT J
AU Diaz, RS
   Kallas, EG
   Castelo, A
   Rawal, BD
   Busch, MP
AF Diaz, RS
   Kallas, EG
   Castelo, A
   Rawal, BD
   Busch, MP
TI Use of a new 'less-sensitive enzyme immunoassay' testing strategy to
   identify recently infected persons in a Brazilian prison: estimation of
   incidence and epidemiological tracing
SO AIDS
LA English
DT Letter
C1 Blood Ctr Pacific, San Francisco, CA USA.
   Univ Fed Sao Paulo, Paulista Sch Med, Div Infect Dis, Sao Paulo, Brazil.
   Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
RP Diaz, RS (corresponding author), Blood Ctr Pacific, San Francisco, CA USA.
RI Kallas, Esper G/C-9539-2012; Diaz, Ricardo/K-3978-2012
CR Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
NR 1
TC 18
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JUL 30
PY 1999
VL 13
IS 11
BP 1417
EP 1418
DI 10.1097/00002030-199907300-00024
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 221JD
UT WOS:000081723200023
PM 10449299
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Reynolds, K
   Andrews, J
   Treanor, JJ
   Evans, TG
AF Kallas, EG
   Reynolds, K
   Andrews, J
   Treanor, JJ
   Evans, TG
TI Production of influenza-stimulated tumor necrosis factor-alpha by
   monocytes following acute influenza infection in humans
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID SEPTIC SHOCK; INTERLEUKIN-1; CYTOKINES; SEPSIS
AB Tumor necrosis factor-alpha (TNF-alpha) is often measured in the serum or plasma of patients with severe infections, and marked elevation correlates with poor outcome. The relationship of TNF-alpha to protection from disease is frequently not observed because prospective studies of infectious agents are difficult to perform. We took advantage of a human antiviral influenza challenge study to correlate TNF-alpha production with seroconversion and symptom development. TNF-alpha production was measured by ELISA in the plasma compartment or was measured by intracellular production at the single cell level in the monocyte gated population. Monocyte TNF-alpha was associated with asymptomatic seroconversion, whereas there was no change in the plasma at the times measured. Measurement of TNF-alpha at the single cell level by flow cytometry may allow for better differentiation of the protective role of this cytokine in future studies.
C1 Univ Rochester, Infect Dis Unit, Rochester, NY USA.
RP Evans, TG (corresponding author), Box 689,601 Elmwood Ave, Rochester, NY 14641 USA.
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N0I-AI-45248, N0I-AI-45208] Funding Source:
   Medline
CR Abraham E, 1997, JAMA-J AM MED ASSOC, V277, P1531, DOI 10.1001/jama.277.19.1531
   CONN CA, 1995, AM J PHYSIOL-REG I, V268, pR78
   DOWDLE WA, 1979, DIAGNOSTIC PROCEDURE, P585
   Grau GE, 1997, NAT MED, V3, P1193, DOI 10.1038/nm1197-1193
   GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x
   HINDER F, 1991, PATHOBIOLOGY, V59, P227, DOI 10.1159/000163651
   Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408
   HOUDE M, 1990, CELL IMMUNOL, V129, P104, DOI 10.1016/0008-8749(90)90190-3
   JAKEMAN KJ, 1991, J GEN VIROL, V72, P705, DOI 10.1099/0022-1317-72-3-705
   LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1
   MARKS JD, 1990, AM REV RESPIR DIS, V141, P94, DOI 10.1164/ajrccm/141.1.94
   MOCK DJ, 1987, J CLIN INVEST, V78, P620
   Salomao Reinaldo, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P113, DOI 10.1590/S0036-46651996000200005
   TREANOR JJ, 1998, ORAL GS 4104 PREVENT
   WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859
NR 15
TC 9
Z9 11
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD JUL
PY 1999
VL 19
IS 7
BP 751
EP 755
DI 10.1089/107999099313596
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 224LA
UT WOS:000081899500007
PM 10454345
DA 2020-11-26
ER

PT J
AU Hooper, M
   Kallas, EG
   Coffin, D
   Campbell, D
   Evans, TG
   Looney, RJ
AF Hooper, M
   Kallas, EG
   Coffin, D
   Campbell, D
   Evans, TG
   Looney, RJ
TI Cytomegalovirus seropositivity is associated with the expansion of
   CD4+CD28-and CD8+CD28-T cells in rheumatoid arthritis
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE rheumatoid arthritis; cytomegalovirus; T lymphocytes; CD28; CD57
ID VIRUS CARRIER STATUS; CYTOTOXIC T-LYMPHOCYTES; HEALTHY-INDIVIDUALS;
   SUBSETS; CD4(+); CD4+; CLONOTYPES; REPERTOIRE; ANTIGEN; GENES
AB Objective. Previous researchers have found expansion of CD4+CD28- T cells in patients with rheumatoid arthritis (RA) compared to age matched controls, and have identified expanded clones of autoreactive cells within this population. We examine the association of prior cytomegalovirus (CMV) infection (positive serum anti-CMV IgG) with the percentage of CD3+CD28- T cells and CD8+CD28- T cells in patients with RA.
   Methods. A total of 45 patients (36 women, 9 men), mean age of 59 years, with definite RA were studied.
   Results. In this group 28 patients were seropositive for CMV and 17 seronegative. Seropositive and seronegative subjects did not differ significantly in age, sex, medication use, or severity of disease. Joint count, Health Assessment Questionnaire, pain score, patient global assessment, physician global assessment, and presence of extraarticular disease served to assess disease severity. Expression of CD4/CD28/CD57 and CD8/CD28/CD57 on lymphocytes was determined by 3 color flow cytometry. (CD28 and CD57 are reciprocally related.) CD4+CD28-CD57+ T cells were expanded only in CMV seropositive patients.
   Conclusion. The "carrier" phenotype that has been hypothesized based on a 2 population model for the distribution of CD4+CD28- T cells in RA can be explained by prior infection with CMV.
C1 Univ Rochester, Dept Med, Clin Immunol Rheumatol Unit, Rochester, NY 14642 USA.
RP Looney, RJ (corresponding author), Univ Rochester, Dept Med, Clin Immunol Rheumatol Unit, Box 695,601 Elmwood Ave, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Bessis N, 1998, CLIN EXP IMMUNOL, V111, P391
   BREEDVELD FC, 1995, IMMUNOL REV, V144, P5, DOI 10.1111/j.1600-065X.1995.tb00063.x
   Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395
   CHOREMIPAPADOPOULOU H, 1994, J ACQ IMMUN DEF SYND, V7, P245
   DAMLE NK, 1983, J IMMUNOL, V131, P2296
   Davey MP, 1997, HUM IMMUNOL, V55, P11, DOI 10.1016/S0198-8859(97)00087-6
   Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383
   GonzalezQuintial R, 1996, J CLIN INVEST, V97, P1335, DOI 10.1172/JCI118550
   GRATAMA JW, 1987, CLIN EXP IMMUNOL, V69, P16
   GRATAMA JW, 1989, CLIN EXP IMMUNOL, V77, P245
   GRATAMA JW, 1987, BLOOD, V70, P516
   GRATAMA JW, 1988, CLIN EXP IMMUNOL, V74, P190
   Hazzan M, 1997, TRANSPLANTATION, V63, P693, DOI 10.1097/00007890-199703150-00014
   Ikeda Y, 1996, ARTHRITIS RHEUM, V39, P446, DOI 10.1002/art.1780390312
   Imberti L, 1997, BLOOD, V89, P2822, DOI 10.1182/blood.V89.8.2822
   JEFFERIS R, 1995, BRIT MED BULL, V51, P312, DOI 10.1093/oxfordjournals.bmb.a072963
   JENDRO MC, 1995, ARTHRITIS RHEUM, V38, P1242, DOI 10.1002/art.1780380912
   Kato T, 1997, J IMMUNOL, V159, P5143
   LENKEI R, 1995, CLIN IMMUNOL IMMUNOP, V77, P131, DOI 10.1006/clin.1995.1136
   Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615
   McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367
   Mendelson M, 1996, J GEN VIROL, V77, P3099, DOI 10.1099/0022-1317-77-12-3099
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644
   Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638
   TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301
   Waase I, 1996, ARTHRITIS RHEUM, V39, P904, DOI 10.1002/art.1780390606
   WANG ECY, 1993, CLIN EXP IMMUNOL, V94, P297
   WANG ECY, 1994, EUR J IMMUNOL, V24, P2903, DOI 10.1002/eji.1830241148
   WANG ECY, 1995, J IMMUNOL, V155, P5046
   Wang ECY, 1995, SCAND J INFECT DIS, P69
   WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814
   WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801
NR 33
TC 72
Z9 74
U1 0
U2 2
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUL
PY 1999
VL 26
IS 7
BP 1452
EP 1457
PG 6
WC Rheumatology
SC Rheumatology
GA 212QF
UT WOS:000081227200006
PM 10405929
DA 2020-11-26
ER

PT J
AU Evans, TG
   Kallas, EG
   Luque, AE
   Menegus, M
   McNair, C
   Looney, RJ
AF Evans, TG
   Kallas, EG
   Luque, AE
   Menegus, M
   McNair, C
   Looney, RJ
TI Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is
   related to CMV serostatus
SO AIDS
LA English
DT Letter
ID HEALTHY-INDIVIDUALS; HUMAN CYTOMEGALOVIRUS; ALLOGRAFT RECIPIENTS;
   DOWN-REGULATION; LYMPHOCYTES; ANTIGEN; CD4(+)
C1 Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
   Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
RP Evans, TG (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
CR AUTRAN B, 1991, BLOOD, V77, P2237
   BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004
   Caruso A, 1998, J CLIN INVEST, V101, P137, DOI 10.1172/JCI195
   CHOREMIPAPADOPOULOU H, 1994, J ACQ IMMUN DEF SYND, V7, P245
   DANGEAC AD, 1994, EUR J IMMUNOL, V24, P1503, DOI 10.1002/eji.1830240707
   Hazzan M, 1997, TRANSPLANTATION, V63, P693, DOI 10.1097/00007890-199703150-00014
   LABALETTE M, 1994, CLIN EXP IMMUNOL, V95, P465
   LEGAC E, 1992, BLOOD, V79, P1746
   Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615
   McNerlan SE, 1998, J CLIN IMMUNOL, V18, P31, DOI 10.1023/A:1023283719877
   Mollet L, 1998, INT IMMUNOL, V10, P311, DOI 10.1093/intimm/10.3.311
   SADATSOWTI B, 1994, EUR J IMMUNOL, V24, P2882, DOI 10.1002/eji.1830241145
   VINGERHOETS JH, 1995, CLIN EXP IMMUNOL, V100, P425
   WANG ECY, 1993, CLIN EXP IMMUNOL, V94, P297
   WANG ECY, 1994, EUR J IMMUNOL, V24, P2903, DOI 10.1002/eji.1830241148
   WANG ECY, 1995, J IMMUNOL, V155, P5046
   Wang ECY, 1995, SCAND J INFECT DIS, P69
NR 17
TC 21
Z9 21
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 18
PY 1999
VL 13
IS 9
BP 1139
EP 1141
DI 10.1097/00002030-199906180-00019
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 207GL
UT WOS:000080927900019
PM 10397546
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Gibbons, DC
   Soucier, H
   Fitzgerald, T
   Treanor, JJ
   Evans, TG
AF Kallas, EG
   Gibbons, DC
   Soucier, H
   Fitzgerald, T
   Treanor, JJ
   Evans, TG
TI Detection of intracellular antigen-specific cytokines in human T cell
   populations
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 37th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 28-OCT 02, 1997
CL TORONTO, CANADA
ID FLOW-CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-4; EXPRESSION; IL-4;
   STIMULATION; RESPONSES; IMMUNODEFICIENCY; VOLUNTEERS; INFECTION
AB Determination of antigen-specific cytokine responses of T lymphocytes after vaccination is made difficult by the low frequency of responder cells. In order to detect these responses, the profile of intracellular cytokines was analyzed using flow cytometry after antigenic expansion. Peripheral blood mononuclear cells were stimulated with antigens for 5 days, further expanded with interleukin (IL)-2, and then restimulated on day 10. Cytokine production was detected by intracellular staining with monoclonal antibodies after saponin-based permeabilization. Influenza expansion resulted in specific interferon-gamma (IFN-gamma) production of 6%-20%, with less IL-4 production (0%-2%), Tetanus toroid resulted in even greater production. IL-4 and IFN-gamma were produced mainly by memory cells of the CD45RO(+) phenotype. IFN-gamma production was contributed by both CD4 and CD8 populations. These methods were then applied to a clinical trial of a candidate human immunodeficiency virus type 1 vaccine. Antigen-specific increases in IFN-gamma were measured, which corresponded to antibody production, lymphoproliferation, and skin testing.
C1 Univ Rochester, Sch Med & Dent, Infect Dis Unit, Rochester, NY 14642 USA.
RP Evans, TG (corresponding author), Univ Rochester, Sch Med & Dent, Infect Dis Unit, 601 Elmwood Ave,Box 689, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-45208, AI-45248] Funding Source: Medline
CR ANDERSSON U, 1990, EUR J IMMUNOL, V20, P1591, DOI 10.1002/eji.1830200727
   Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513
   BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D
   Evans TG, 1998, CLIN EXP IMMUNOL, V111, P243
   FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303
   Gibbons DC, 1996, CYTOMETRY, V23, P260
   HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59
   HOLADAY BJ, 1993, J INFECT DIS, V167, P411, DOI 10.1093/infdis/167.2.411
   IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229
   JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4
   JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2
   JUTEL M, 1995, J IMMUNOL, V154, P4187
   Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7
   KALLAS EG, 1998, 5 C RETR OPP INF CHI, P88
   KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LEWIS DB, 1988, P NATL ACAD SCI USA, V85, P9743, DOI 10.1073/pnas.85.24.9743
   LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405
   MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408
   Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X
   Sander B, 1995, IMMUNOLOGY, V86, P512
   SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123
   SZTEIN MB, 1994, J INFECT DIS, V170, P1508, DOI 10.1093/infdis/170.6.1508
   Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x
   URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513
   Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338
   WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
NR 30
TC 28
Z9 30
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY
PY 1999
VL 179
IS 5
BP 1124
EP 1131
DI 10.1086/314702
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 189TQ
UT WOS:000079922600010
PM 10191213
OA Bronze
DA 2020-11-26
ER

PT J
AU Kallas, EG
   Reynolds, K
   Andrews, J
   Fitzgerald, T
   Kasper, M
   Menegus, M
   Evans, TG
AF Kallas, EG
   Reynolds, K
   Andrews, J
   Fitzgerald, T
   Kasper, M
   Menegus, M
   Evans, TG
TI Cytomegalovirus-specific IFN gamma and IL-4 are produced by antigen
   expanded human blood lymphocytes from seropositive volunteers
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE cytokines; cytomegalovirus; interferon gamma; interleukin-4; lymphocytes
ID MARROW TRANSPLANT RECIPIENTS; SINGLE-CELL LEVEL; MEMORY T-CELLS;
   FLOW-CYTOMETRY; INTERFERON-GAMMA; IN-VITRO; CD4+; INTERLEUKIN-4;
   CYTOKINES; IMMUNITY
AB The cytokine responses to cytomegalovirus (CMV) antigen in seropositive and seronegative individuals were measured using a combination of antigenic expansion and intracellular staining. Intracellular IFN gamma and IL-4 were produced in a dose-dependent manner by T cells in response to CMV only in the seropositive population. The potential for individual cells to produce both Th1 and Th2 cytokines simultaneously was clear, as IL-4 was most often produced in those cells with the highest IFN gamma production. The cytokine-specific nature of this response was demonstrated by fluorescence microscopy, which showed granular cytoplasmic staining, and at the mRNA level by ribonuclease protection assays. These methods expand our ability to evaluate the immune response to CMV, and can now be correlated to a number of clinical conditions. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Univ Rochester, Sch Med & Dent, Infect Dis Unit, Rochester, NY 14642 USA.
   Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
RP Evans, TG (corresponding author), Univ Rochester, Sch Med & Dent, Infect Dis Unit, POB 680,601 Elmwood Ave, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N0I-AI-45248, N0I-AI-45208] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [N01AI045208, N01AI045248, N01AI045248, N01AI045208,
   N01AI045248, N01AI045248, N01AI045208, N01AI045248, N01AI045248,
   N01AI045248, N01AI045248, N01AI045248, N01AI045248, N01AI045248,
   N01AI045208, N01AI045248, N01AI045248, N01AI045208, N01AI045248,
   N01AI045208, N01AI045248, N01AI045208, N01AI045248, N01AI045208,
   N01AI045208, N01AI045208, N01AI045248] Funding Source: NIH RePORTER
CR ANDERSSON U, 1990, EUR J IMMUNOL, V20, P1591, DOI 10.1002/eji.1830200727
   Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513
   BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D
   Davignon JL, 1996, J VIROL, V70, P2162, DOI 10.1128/JVI.70.4.2162-2169.1996
   ELSON LH, 1995, J IMMUNOL, V154, P4294
   Evans TG, 1998, CLIN EXP IMMUNOL, V111, P243
   HOLADAY BJ, 1993, J INFECT DIS, V167, P411, DOI 10.1093/infdis/167.2.411
   IHARA T, 1994, LEUKEMIA RES, V18, P485, DOI 10.1016/0145-2126(94)90086-8
   JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4
   JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2
   JUTEL M, 1995, J IMMUNOL, V154, P4187
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LOLLI F, 1993, FEMS IMMUNOL MED MIC, V7, P55, DOI 10.1016/0928-8244(93)90043-4
   MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264
   PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408
   Prussin C, 1997, J CLIN IMMUNOL, V17, P195, DOI 10.1023/A:1027350226435
   SANDER B, 1991, SCAND J IMMUNOL, V33, P287, DOI 10.1111/j.1365-3083.1991.tb01774.x
   SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123
   Sparrelid E, 1997, TRANSPLANTATION, V63, P1782, DOI 10.1097/00007890-199706270-00013
   Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x
   TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6
   Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338
NR 22
TC 18
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD DEC
PY 1998
VL 64
IS 2-3
BP 63
EP 69
DI 10.1016/S0165-2478(98)00080-7
PG 7
WC Immunology
SC Immunology
GA 148XV
UT WOS:000077560400002
PM 9870656
DA 2020-11-26
ER

PT J
AU Milan, EP
   Burattini, MN
   Kallas, EG
   Fischmann, O
   Costa, PRD
   Colombo, AL
AF Milan, EP
   Burattini, MN
   Kallas, EG
   Fischmann, O
   Costa, PRD
   Colombo, AL
TI Azole resistance among oral Candida species isolates from AIDS patients
   under ketoconazole exposure
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
ID HIV-INFECTED PATIENTS; FLUCONAZOLE-RESISTANT; ALBICANS STRAINS;
   DRUG-RESISTANCE; SUSCEPTIBILITY; ITRACONAZOLE; EMERGENCE; GLABRATA;
   THERAPY; YEASTS
AB This is a prospective study designed to investigate species distribution and azole susceptibility profile among Candida spp. isolated from the oral cavities of AIDS patients. One hundred thirty-two AIDS patients sequentially admitted at a teaching tertiary care hospital were enrolled in this study. Samples were obtained by swabbing the oral cavities of the patients. Yeast isolates were identified by classical methods and the antifungal susceptibility profile was further determined according to the NCCLS microbroth assay. Among all patients with prescriptions of systemic antifungal drugs, ketoconazole had been elected to treat 56% of patients. We found 82% of oral yeast carriage, 22% of them harboring non-albicans species. Overall rates of susceptibility dose dependent/resistance to azoles was 16% for itraconazole, 13% for ketoconazole, and 10% for fluconazole with a high agreement rate among the susceptibility profiles of all isolates tested against the triazoles. (C) 1998 Elsevier, Science Inc.
C1 Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Cellular Biol, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual Francisco Moratto de, Sao Paulo, Brazil.
   Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
RP Colombo, AL (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, Rua Botucatu 740,Vila Clementino, BR-04023062 Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Burattini, Marcelo N/J-9272-2014; Colombo,
   Arnaldo Lopes/V-4417-2019; Colombo, Arnaldo Lopes/H-4397-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Colombo, Arnaldo
   Lopes/0000-0003-0793-8491; Kallas, Esper/0000-0003-2026-6925
CR Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1
   Barchiesi F, 1996, ANTIMICROB AGENTS CH, V40, P1317, DOI 10.1128/AAC.40.5.1317
   BARCHIESI F, 1994, J CLIN MICROBIOL, V32, P2494, DOI 10.1128/JCM.32.10.2494-2500.1994
   BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161
   COLOMBO AL, 1995, J ANTIMICROB CHEMOTH, V36, P93, DOI 10.1093/jac/36.1.93
   Dronda F, 1996, EUR J CLIN MICROBIOL, V15, P446, DOI 10.1007/BF01691310
   DUPONT B, 1994, J MED VET MYCOL, V32, P65
   DUPONT B, 1992, J MED VET MYCOL, V30, P19
   EspinelIngroff A, 1997, INFECT DIS CLIN N AM, V11, P929, DOI 10.1016/S0891-5520(05)70398-6
   HITCHCOCK CA, 1993, ANTIMICROB AGENTS CH, V37, P1962, DOI 10.1128/AAC.37.9.1962
   IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K
   JOHNSON EM, 1995, J ANTIMICROB CHEMOTH, V35, P103, DOI 10.1093/jac/35.1.103
   Kreger-van Rij NJW, 1984, YEASTS TAXONOMIC STU
   LEGUENNEC R, 1995, J CLIN MICROBIOL, V33, P2732, DOI 10.1128/JCM.33.10.2732-2737.1995
   LYNCH DP, 1994, ORAL SURG ORAL MED O, V78, P189, DOI 10.1016/0030-4220(94)90146-5
   Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219
   MENESES EA, 1993, C BRAS MICR 17 SANT, P150
   MILLON L, 1994, J CLIN MICROBIOL, V32, P1115, DOI 10.1128/JCM.32.4.1115-1118.1994
   NCCLS, 1997, NCCLS, V17, P1
   PERSONS DA, 1991, NEW ENGL J MED, V325, P1315
   Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235
   RODRIGUEZTUDELA JL, 1995, J ANTIMICROB CHEMOTH, V35, P793, DOI 10.1093/jac/35.6.793
   SANGEORZAN JA, 1994, AM J MED, V97, P339, DOI 10.1016/0002-9343(94)90300-X
   STGERMAIN G, 1995, J ANTIMICROB CHEMOTH, V36, P109, DOI 10.1093/jac/36.1.109
   TAVITIAN A, 1986, GASTROENTEROLOGY, V90, P443, DOI 10.1016/0016-5085(86)90946-7
   Torres-Rodriguez Josep M., 1996, Revista Iberoamericana de Micologia, V13, pS30
   Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1
   VANDEN BOSSCHE H, 1994, J MED VET MYCOL, V32, P189
   VANDERWALT JP, 1971, YEASTS TAXONOMIC STU, P35
   WARNOCK DW, 1988, LANCET, V2, P1310
NR 30
TC 19
Z9 23
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD NOV
PY 1998
VL 32
IS 3
BP 211
EP 216
DI 10.1016/S0732-8893(98)00107-2
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 152PW
UT WOS:000077786800012
PM 9884838
DA 2020-11-26
ER

PT J
AU Looney, RJ
   Hooper, M
   Kallas, EG
   Coffin, D
   Campbell, D
   Evans, TG
AF Looney, RJ
   Hooper, M
   Kallas, EG
   Coffin, D
   Campbell, D
   Evans, TG
TI The potential role of CMV in the expansion of CD4+CD28- T cells in RA.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
C1 Univ Rochester, Rochester, NY 14642 USA.
RI Kallas, Esper G/C-9539-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0004-3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD SEP
PY 1998
VL 41
IS 9
SU S
MA 777
BP S162
EP S162
PG 1
WC Rheumatology
SC Rheumatology
GA 125AQ
UT WOS:000076215600778
DA 2020-11-26
ER

PT J
AU Pannuti, CS
   Kallas, EG
   Muccioli, C
   Roland, RK
   Ferreira, EC
   Bueno, SMHS
   DoCanto, CLM
   Boas, LSV
   Belfort, R
AF Pannuti, CS
   Kallas, EG
   Muccioli, C
   Roland, RK
   Ferreira, EC
   Bueno, SMHS
   DoCanto, CLM
   Boas, LSV
   Belfort, R
TI Cytomegalovirus antigenemia in acquired immunodeficiency syndrome
   patients with untreated cytomegalovirus retinitis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IMMUNE-DEFICIENCY-SYNDROME; INTRAVITREAL GANCICLOVIR; VIRUS RETINITIS;
   AIDS; INFECTION; DISEASE; BLOOD; TRANSPLANTATION; RECIPIENTS; FOSCARNET
AB PURPOSE: To determine the frequency of cytomegalovirus (CMV) viremia in patients with acquired immunodeficiency syndrome (AIDS) and untreated CMV retinitis using conventional cell culture isolation and the sensitive CMV antigenemia assay.
   METHODS: We examined 24 AIDS patients with ophthalmologic diagnosis of untreated CMV retinitis and 24 AIDS patients without present or past retinitis (control patients) from three medical centers between September 1992 and March 1994. Cytomegalovirus antigenemia was detected by an indirect peroxidase staining in 300,000 cytocentrifuged neutrophils, using a mixture of murine monoclonal antibodies directed against the pp65 lower matrix protein of CMV.
   RESULTS: Positive antigenemia was demonstrated in eight (33.3%) of the 24 retinitis patients and in none of the 24 control patients (P <.001). Only two of the eight antigenemia-positive patients had a concurrent positive CMV isolation from blood leukocytes by conventional cell culture assay.
   CONCLUSIONS: These results emphasize the risk of extraocular disease in AIDS patients with CMV retinitis because the virus is often present in peripheral blood leukocytes. The CMV antigenemia assay may be a simple and rapid means of identifying those patients with unilateral retinitis at highest risk of developing CMV retinitis of the fellow eye or of visceral CMV disease if intravitreal injections or implants are used as sole treatment for CMV retinitis.
C1 HOSP SERV PUBL ESTADUAL SAO PAULO, DIV INFECT DIS, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, SCH MED,DEPT INFECT DIS,HOSP CLIN,FAC MED, LAB INVEST MED,INST MED TROP SAO PAULO, SAO PAULO, BRAZIL.
   ESCOLA PAULISTA MED, DEPT OPHTHALMOL, SAO PAULO, BRAZIL.
   SECRETARIA ESTADUAL SAUDE SAO PAULO, CTR REFERENCIA & TREINAMENTO AIDS, SAO PAULO, BRAZIL.
RI Belfort, Rubens/E-2252-2012; Pannuti, Claudio/B-7649-2012; Muccioli,
   Cristina/C-3419-2013; Kallas, Esper G/C-9539-2012
OI Belfort, Rubens/0000-0002-8422-3898; Kallas, Esper/0000-0003-2026-6925
CR *AID RES GROUP, 1992, NEW ENGL J MED, V326, P213
   Bek B, 1996, J CLIN MICROBIOL, V34, P457, DOI 10.1128/JCM.34.2.457-459.1996
   COCHEREAUMASSIN I, 1990, PRESSE MED, V19, P1313
   DIAZLLOPIS M, 1992, AM J OPHTHALMOL, V114, P742, DOI 10.1016/S0002-9394(14)74054-1
   DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002
   GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223
   GERNA G, 1990, AIDS, V4, P1027, DOI 10.1097/00002030-199010000-00014
   HALWACHS G, 1993, TRANSPLANTATION, V56, P338, DOI 10.1097/00007890-199308000-00016
   HENRY K, 1987, AM J OPHTHALMOL, V103, P17, DOI 10.1016/S0002-9394(14)74163-7
   HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604
   JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031
   Jacobson MA, 1995, SCAND J INFECT DIS, P96
   KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2
   KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4
   KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9
   MACGREGOR RR, 1995, J ACQ IMMUN DEF SYND, V10, P324
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   MAZZULLI T, 1993, J CLIN MICROBIOL, V31, P2824, DOI 10.1128/JCM.31.10.2824-2827.1993
   PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665
   PATEL R, 1995, J CLIN MICROBIOL, V33, P2984, DOI 10.1128/JCM.33.11.2984-2986.1995
   PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472
   SALTZMAN RL, 1992, J CLIN INVEST, V90, P1832, DOI 10.1172/JCI116059
   SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557
   The TH, 1995, SCAND J INFECT DIS, P25
   TURCHI MD, 1991, REV I MED TROP, V33, P243, DOI 10.1590/S0036-46651991000400001
   VANDENBERG AP, 1991, J INFECT DIS, V164, P265
   VANDENBERG AP, 1989, TRANSPLANTATION, V48, P991, DOI 10.1097/00007890-198912000-00019
   VANDERBIJ W, 1988, J CLIN MICROBIOL, V26, P2531, DOI 10.1128/JCM.26.12.2531-2535.1988
   YOUNG SH, 1992, MED J AUSTRALIA, V157, P370, DOI 10.5694/j.1326-5377.1992.tb137242.x
NR 30
TC 18
Z9 20
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 1996
VL 122
IS 6
BP 847
EP 852
DI 10.1016/S0002-9394(14)70381-2
PG 6
WC Ophthalmology
SC Ophthalmology
GA VW758
UT WOS:A1996VW75800010
PM 8956639
DA 2020-11-26
ER

EF